

NUVELO INC  
Form S-4/A  
November 24, 2008  
Table of Contents

As filed with the U.S. Securities and Exchange Commission on November 21, 2008

Registration No. 333-154839

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Amendment No. 1 to Form S-4**  
**REGISTRATION STATEMENT**

*UNDER*

*THE SECURITIES ACT OF 1933*

**Nuvelo, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

2835  
(Primary Standard Industrial  
Classification Code Number)  
201 Industrial Road, Suite 310

San Carlos, CA 94070-6211

(650) 517-8000

36-3855489  
(I.R.S. Employer  
Identification No.)

Edgar Filing: NUVELO INC - Form S-4/A

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Ted W. Love**

**Chairman of the Board and Chief Executive Officer**

**Nuvelo, Inc.**

**201 Industrial Road, Suite 310**

**San Carlos, CA 94070-6211**

**(650) 517-8000**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copies to:*

**John M. Geschke, Esq.**

**Richard B. Brewer**

**Alan L. Dye, Esq.**

**Cooley Godward Kronish LLP**

**President and Chief Executive Officer**

**Michael J. Silver, Esq.**

**Five Palo Alto Square**

**ARCA biopharma, Inc.**

**Hogan & Hartson L.L.P.**

**3000 El Camino Real**

**8001 Arista Place, Suite 200**

**555 Thirteenth Street, N.W.**

**Palo Alto, CA 94306**

**Broomfield, CO 80021**

**Washington, D.C. 20004**

**(650) 843-5757**

**(720) 940-2200**

**(202) 637-5600**

Approximate date of commencement of proposed sale of the securities to the public: As soon as practicable after the effectiveness of this registration statement and the satisfaction or waiver of all other conditions under the merger agreement described herein.

If the securities being registered on this form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box. "

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. "

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "small reporting company" in Rule 12b-2 of the Exchange Act.

## Edgar Filing: NUVELO INC - Form S-4/A

Large accelerated filer   
 Non-accelerated filer   
 (do not check if a smaller reporting company)

Accelerated filer   
 Smaller reporting company

### CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price per Share	Proposed Maximum Aggregate Offering Price(2)	Amount of Registration Fee(3)
Common Stock, \$.001 par value	115,000,000	N/A	\$11,639.37	\$0.46

- (1) This registration statement covers the maximum number of shares of common stock, \$0.001 par value per share, of Nuvelo, Inc. ( Nuvelo ) issuable as part of the proposed merger described herein to holders of ARCA biopharma, Inc. s ( ARCA ) common stock, \$0.001 par value per share (including those shares of ARCA common stock issuable upon conversion of ARCA s 6% Convertible Promissory Notes due March 31, 2009), holders of ARCA s Series A preferred stock, \$0.001 par value per share, holders of ARCA s Series B-1 preferred stock, \$0.001 par value per share, holders of ARCA s Series B-2 preferred stock, \$0.001 par value per share, and to holders of ARCA s outstanding options and warrants to acquire ARCA common stock and preferred stock, which options and warrants will be assumed by Nuvelo as part of the merger. All of Nuvelo s common stock covered by this registration statement will be reclassified and combined by a reverse stock split into a lesser amount of Nuvelo s common stock, and the amount of undistributed common stock covered by this registration statement shall be proportionately reduced.
- (2) Estimated solely for the purpose of calculating the registration fee required by Section 6(b) of the Securities Act of 1933, as amended, and computed pursuant to Rule 457(f)(2), based on the par value (\$0.001 per share) of the up to approximately 34,918,121 shares of ARCA common stock and preferred stock to be exchanged in the proposed merger.
- (3) Previously paid.

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.**

**Table of Contents**

**The information in this proxy statement/prospectus/consent solicitation is not complete and may be changed. Nuvelo may not sell its securities pursuant to the proposed transaction until the Registration Statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus/consent solicitation is not an offer to sell these securities and it is not soliciting an offer to buy any securities in any jurisdiction where the offer or sale is not permitted.**

**SUBJECT TO COMPLETION, DATED NOVEMBER 21, 2008**

<b>Nuvelo, Inc.,</b>	<b>ARCA biopharma, Inc.,</b>
<b>a Delaware corporation</b>	<b>a Delaware corporation</b>
<b>Proxy Statement/Prospectus</b>	<b>Consent Solicitation</b>

**For a Special Meeting of Stockholders**

**to be held on January 7, 2009**

**Shares of Common Stock**

We are furnishing this proxy statement/prospectus/consent solicitation to the holders of Nuvelo Inc.'s common stock and to holders of ARCA biopharma, Inc.'s common stock, Series A preferred stock, Series B-1 preferred stock and Series B-2 preferred stock.

Nuvelo is soliciting proxies for use at a special meeting of its stockholders to consider and vote upon (i) a proposal to approve the issuance of Nuvelo common stock pursuant to a merger transaction with ARCA, (ii) a proposal to approve an amendment to Nuvelo's amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo's common stock, (iii) a proposal to approve an amendment to Nuvelo's amended and restated certificate of incorporation to increase the number of authorized shares of Nuvelo common stock to 250 million, and (iv) an adjournment of the special meeting, if necessary, if a quorum is present, to solicit additional parties if there are not sufficient votes in favor of Proposals No. 1 and No. 2.

ARCA is soliciting written consents from its stockholders to consider and vote on a proposal to adopt the merger agreement with Nuvelo and approve the merger and other transactions contemplated thereby.

Pursuant to the merger, ARCA security holders will be entitled to receive shares of Nuvelo common stock representing approximately 67% of the shares of outstanding common stock of the combined company after giving effect to issuance of shares pursuant to ARCA's outstanding options and warrants primarily on a treasury method basis, and without giving effect to any shares issuable pursuant to Nuvelo's outstanding options and warrants. The actual number of shares of Nuvelo common stock to be issued in respect of each share of common stock of ARCA will be determined by dividing an aggregate of 109,009,278 shares of Nuvelo common stock by the number of shares of ARCA common stock outstanding and deemed outstanding pursuant to the formula set forth in the merger agreement and described in this proxy statement/prospectus/consent solicitation under the heading "The Merger."

Nuvelo's common stock is traded on the Nasdaq Global Market under the symbol "NUVO" and on November 21, 2008, the closing sale price of Nuvelo common stock was \$0.27 per share. Following the merger, the combined company is expected to be renamed ARCA biopharma, Inc. and to change its symbol for trading on the Nasdaq Global Market. ARCA has reserved the symbol "ABIO" for this purpose.

**FOR A DISCUSSION OF SIGNIFICANT MATTERS THAT SHOULD BE CONSIDERED IN EVALUATING THE MERGER AND THE PROPOSALS SET FORTH HEREIN, SEE RISK FACTORS BEGINNING ON PAGE 28.**

## Edgar Filing: NUVELO INC - Form S-4/A

This proxy statement/prospectus/consent solicitation is dated \_\_\_\_\_, 2008, and is first being mailed to stockholders of Nuvelo and ARCA on or about November 25, 2008.

This proxy statement/prospectus/consent solicitation incorporates or refers to important business and financial information about Nuvelo and ARCA that is not included in or delivered with this proxy statement/prospectus/consent solicitation. Such information is available without charge to stockholders of Nuvelo and ARCA upon written or oral request at the following addresses: For information concerning Nuvelo, Nuvelo, Inc., Attn: Investor Relations, 201 Industrial Road, Suite 310, San Carlos, CA or by telephone at (650) 517-8000 and for information concerning ARCA, ARCA biopharma, Inc., Attn: General Counsel, 8001 Arista Place, Suite 200, Broomfield, CO 80021 or by telephone at (720) 940-2200. To obtain timely delivery, Nuvelo stockholders must request the information no later than five business days before the date of the special meeting of Nuvelo stockholders, or no later than December 30, 2008, and ARCA stockholders must request the information before delivering their signed written consent, which must be delivered to ARCA no later than November 28, 2008.

**NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE MERGER OR THE NUVELO COMMON STOCK TO BE ISSUED IN THE MERGER OR DETERMINED IF THIS PROXY STATEMENT/PROSPECTUS/CONSENT SOLICITATION IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

---

**Table of Contents**

To the Stockholders of Nuvelo, Inc.:

On September 24, 2008, Nuvelo, Inc., or Nuvelo, and ARCA biopharma, Inc., or ARCA, entered into an agreement and plan of merger and reorganization, which the parties amended on October 28, 2008, and which, as amended, unless otherwise indicated, we refer to as the merger agreement, pursuant to which a wholly-owned subsidiary of Nuvelo, Dawn Acquisition Sub, Inc., or the merger sub, will merge with and into ARCA, with ARCA continuing after the merger as the surviving corporation and a wholly owned subsidiary of Nuvelo. At the effective time of the merger, each share of ARCA capital stock issued and outstanding immediately prior to the merger (other than shares held by any wholly-owned subsidiary of ARCA, or by Nuvelo, merger sub or any other subsidiary of Nuvelo) will be automatically converted into the right to receive that number of shares of Nuvelo common stock as determined pursuant to the exchange ratio described in the merger agreement. In addition, Nuvelo will assume options and warrants to purchase shares of ARCA capital stock.

Following the merger, and subject to adjustment in accordance with the merger agreement, current stockholders of Nuvelo are expected to own approximately 33% of the combined company, and current ARCA stockholders are expected to own approximately 67% of the combined company, after giving effect to the issuance of shares pursuant to ARCA's outstanding options and warrants primarily on a treasury-method basis, and without giving effect to any shares issuable pursuant to Nuvelo's outstanding options and warrants. The actual number of shares of Nuvelo common stock to be issued in respect of each share of capital stock of ARCA will be determined by dividing an aggregate of 109,009,278 shares of Nuvelo common stock by the number of shares of ARCA common stock outstanding and deemed outstanding pursuant to the formula set forth in the merger agreement and described herein under "The Merger Agreement." The exact exchange ratio per share of ARCA's capital stock will depend upon the number of shares of ARCA's capital stock outstanding or issuable pursuant to ARCA's outstanding convertible notes, options and warrants immediately prior to the effective time of the merger and the closing price per share of Nuvelo's common stock for the five consecutive days immediately preceding the effective time of the merger and will not be calculated until that time.

Nuvelo's common stock is traded on the Nasdaq Global Market under the symbol "NUVO" and on November 21, 2008, the closing sale price of Nuvelo common stock was \$0.27 per share. Following the merger, the combined company is expected to be renamed ARCA biopharma, Inc. and to change its symbol for trading on the Nasdaq Global Market. ARCA has reserved the symbol "ABIO" for this purpose.

At Nuvelo's special meeting of stockholders, stockholders of Nuvelo will be asked to approve, among other proposals, the issuance of shares of Nuvelo common stock to the stockholders of ARCA and certain amendments to Nuvelo's certificate of incorporation. The date, time and place of the Nuvelo special meeting are as follows:

January 7, 2009

9:00 a.m., Pacific Standard Time (PST)

Nuvelo, Inc.

201 Industrial Road, Suite 310

San Carlos, CA 94070-6211

This proxy statement/prospectus/consent solicitation provides you with information about Nuvelo, ARCA and the proposed merger. **We encourage you to read carefully the entire proxy statement/prospectus/consent solicitation. In particular, you should carefully consider the matters discussed under Risk Factors beginning on page 28.**

San Carlos, California

November 21, 2008

**Ted W. Love**  
**Chairman of the Board and Chief Executive Officer**

**NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE MERGER OR THE NUVELO COMMON STOCK TO BE ISSUED IN THE MERGER OR DETERMINED IF THIS PROXY STATEMENT/PROSPECTUS/CONSENT SOLICITATION IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

This proxy statement/prospectus/consent solicitation is dated \_\_\_\_\_, 2008, and is first being mailed to stockholders of Nuvelo on or about November 25, 2008.

**Table of Contents**

**NOTICE OF SPECIAL MEETING OF STOCKHOLDERS**

**TO BE HELD ON JANUARY 7, 2009**

To the Stockholders of Nuvelo, Inc.:

A special meeting of stockholders of Nuvelo will be held on January 7, 2009 at 9:00 a.m. PST, at Nuvelo, Inc., 201 Industrial Road, Suite 310, San Carlos, California, for the following purposes:

1. To consider and vote upon a proposal to approve the issuance of Nuvelo common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated September 24, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., as amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., as described in the attached proxy statement/prospectus/consent solicitation. A copy of the Agreement and Plan of Merger and Reorganization is attached as *Annex A* to the accompanying proxy statement/prospectus/consent solicitation and a copy of Amendment No. 1 to Agreement and Plan of Merger and Reorganization is attached as *Annex B* to the accompanying proxy statement/prospectus/consent solicitation.
2. To approve an amendment to Nuvelo's amended and restated certificate of incorporation in order to effect a reverse stock split of the issued and outstanding shares of Nuvelo's common stock. A copy of the amendment to Nuvelo's amended and restated certificate of incorporation to effect the reverse stock split is attached as *Annex E* to the accompanying proxy statement/prospectus/consent solicitation.
3. To approve an amendment to Nuvelo's amended and restated certificate of incorporation in order to increase the number of authorized shares of Nuvelo common stock to 250 million. A copy of the amendment to Nuvelo's amended and restated certificate of incorporation to increase the number of authorized shares of Nuvelo common stock to 250 million is attached as *Annex F* to the accompanying proxy statement/prospectus/consent solicitation.
4. To consider and vote upon an adjournment of the special meeting, if necessary, if a quorum is present, to solicit additional parties if there are not sufficient votes in favor of Proposals No. 1 and No. 2.
5. To transact such other business as may properly come before the special meeting or any adjournment or postponement thereof.

The board of directors of Nuvelo has fixed November 11, 2008 as the record date for the determination of stockholders entitled to notice of, and to vote at, the special meeting and any adjournment or postponement thereof. Only holders of record of shares of Nuvelo common stock at the close of business on the record date are entitled to notice of, and to vote at, the special meeting. At the close of business on the record date, Nuvelo had 53,663,805 shares of common stock outstanding and entitled to vote.

**Your vote is important. The affirmative vote of the holders of a majority of the votes cast in person or by proxy at the Nuvelo special meeting is required for approval of Proposals No. 1 and No. 4 above and the affirmative vote of at least a majority of Nuvelo's issued and outstanding shares of common stock is required for approval of Proposals No. 2 and No. 3 above. Even if you plan to attend the special meeting in person, please sign and return the enclosed proxy and thus ensure that your shares will be represented at the special meeting if you are unable to attend. If you sign, date and mail your proxy card without indicating how you wish to vote, your proxy will be counted as a vote in favor of Proposals No. 1, No. 2, No. 3 and No. 4. If you fail to return your proxy card, the effect will be that your shares will not be counted for purposes of determining whether a quorum is present at the special meeting. You may revoke your proxy in the manner described in this document before it has been voted at the special meeting. If you decide to attend the Nuvelo special meeting, you may withdraw your proxy and vote in person.**

By Order of the Board of Directors,

By:

**Lee Bendekgey**  
Secretary

San Carlos, California



November 21, 2008

**THE NUVELO BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE, AND IN THE BEST INTERESTS OF, NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE NUVELO BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR EACH SUCH PROPOSAL.**

---

**Table of Contents**

To the Stockholders of ARCA biopharma, Inc.:

On September 24, 2008, ARCA biopharma, Inc. and Nuvelo, Inc. entered into an agreement and plan of merger and reorganization, which was amended on October 28, 2008. Under the merger agreement, a wholly-owned subsidiary of Nuvelo, Dawn Acquisition Sub, Inc., will merge with and into ARCA, with ARCA continuing after the merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. At the effective time of the merger, each share of ARCA capital stock issued and outstanding immediately prior to the merger (other than shares held by any wholly-owned subsidiary of ARCA, or by Nuvelo, merger sub or any other subsidiary of Nuvelo) will automatically convert into the right to receive a number of shares of Nuvelo common stock determined according to the exchange ratio described in the merger agreement. In addition, Nuvelo will assume options and warrants to purchase shares of ARCA capital stock.

Following the merger, and subject to adjustment in accordance with the merger agreement, current stockholders of Nuvelo are expected to own approximately 33% of the combined company, and current ARCA stockholders are expected to own approximately 67% of the combined company. These percentages give effect to the issuance of shares pursuant to ARCA's outstanding options and warrants primarily on a treasury-method basis, and do not give effect to any shares issuable pursuant to Nuvelo's outstanding options and warrants. The actual number of shares of Nuvelo common stock to be issued in respect of each share of capital stock of ARCA will be determined by dividing an aggregate of 109,009,278 shares of Nuvelo common stock by the number of shares of ARCA common stock outstanding and deemed outstanding pursuant to the formula set forth in the merger agreement and described herein under "The Merger Agreement." The exact exchange ratio per share of ARCA's capital stock will depend upon the number of shares of ARCA's capital stock outstanding or issuable pursuant to ARCA's outstanding convertible notes, options and warrants immediately prior to the effective time of the merger and the closing price per share of Nuvelo's common stock for the five consecutive days immediately preceding the effective time of the merger and will not be calculated until that time.

Nuvelo's common stock is traded on the Nasdaq Global Market under the symbol "NUVO" and on November 21, 2008, the closing sale price of Nuvelo common stock was \$0.27 per share. Following the merger, the combined company is expected to be renamed ARCA biopharma, Inc. and to change its symbol for trading on the Nasdaq Global Market. ARCA has reserved the symbol "ABIO" for this purpose.

As described in this proxy statement/prospectus/consent solicitation, Nuvelo is holding a special meeting of its stockholders in order to obtain its stockholder approvals necessary to complete the merger. ARCA is soliciting written consents in order to obtain the stockholder approval of ARCA necessary to complete the merger.

This proxy statement/prospectus/consent solicitation provides you with information about Nuvelo, ARCA and the proposed merger. **We encourage you to read carefully the entire proxy statement/prospectus/consent solicitation. In particular, you should carefully consider the matters discussed under Risk Factors beginning on page 28.**

**Richard B. Brewer**  
President and Chief Executive Officer

Broomfield, Colorado

November 21, 2008

**NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE MERGER OR THE NUVELO COMMON STOCK TO BE ISSUED IN THE MERGER OR DETERMINED IF THIS PROXY STATEMENT/PROSPECTUS/CONSENT SOLICITATION IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

This proxy statement/prospectus/consent solicitation is dated \_\_\_\_\_, 2008, and is being first mailed to stockholders of ARCA on or about November 25, 2008.

THIS PROXY STATEMENT/PROSPECTUS/CONSENT SOLICITATION IS NOT AN OFFER TO SELL ANY SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY ANY SECURITIES IN ANY JURISDICTION WHERE THE OFFER OR SALE IS NOT PERMITTED.

**Table of Contents**

**SOLICITATION OF WRITTEN CONSENT IN LIEU OF A MEETING  
OF THE STOCKHOLDERS OF ARCA BIOPHARMA, INC.**

To the Stockholders of ARCA biopharma, Inc.:

The purpose of this solicitation of written consent in lieu of a meeting of ARCA stockholders is to adopt and approve the Agreement and Plan of Merger and Reorganization dated as of September 24, 2008, by and among Nuvelo, Inc., a Delaware corporation, Dawn Acquisition Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Nuvelo, and ARCA, as amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA, and to approve the merger and the transactions contemplated thereby. A copy of the Agreement and Plan of Merger and Reorganization is attached as *Annex A* to the accompanying proxy statement/prospectus/consent solicitation and a copy of Amendment No.1 to Agreement and Plan of Merger and Reorganization is attached as *Annex B* to the accompanying proxy statement/prospectus/consent solicitation. In addition, by consenting to the adoption of the merger agreement and approving the merger and transactions contemplated thereby, each ARCA stockholder is acknowledging that (i) such stockholder's consent to the adoption of the merger agreement and approval of the merger is irrevocable; (ii) such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section 262 of the Delaware General Corporation Law, which we refer to as the DGCL, and that such stockholder has received and read a copy of Section 262 of the DGCL; and (iii) such stockholder is not entitled to appraisal rights with respect to its shares in connection with the merger and that the stockholder hereby waives any rights to receive payment of the fair value of ARCA capital stock under the DGCL.

In accordance with the DGCL, the record date for determination of the holders of ARCA common stock and ARCA preferred stock entitled to vote by written consent shall be the first date on which a signed written consent approving the merger is delivered to ARCA. Only holders of record of shares of ARCA common stock and ARCA preferred stock at the close of business on the record date are entitled to vote by written consent. On November 20, 2008, ARCA had 5,713,818 shares of common stock and 15,677,836 shares of preferred stock, consisting of 9,222,257 shares of Series A preferred stock, 3,688,902 shares of Series B-1 preferred stock and 2,766,677 shares of Series B-2 preferred stock, outstanding and entitled to vote.

**Your consent is important. The affirmative consent of the holders of (a) a majority of the shares of ARCA common stock and ARCA preferred stock, voting together as a single class, with holders of ARCA preferred stock voting on an as-converted basis and (b) a majority of the following ARCA stockholders, who we refer to as the Principal Series Preferred Stockholders : Atlas Venture Fund VII, L.P. and its affiliates, Boulder Ventures IV, L.P. and Boulder Ventures IV (Annex), L.P. and their respective affiliates, Skyline Venture Partners Qualified Purchaser Fund IV, L.P. and its affiliates, and InterWest Partners IX, L.P. and its affiliates is required to approve the proposal. If you fail to return your signed written consent, the effect will be that your shares will counted as votes against the proposal. Once you return your signed written consent, you may not revoke it. As described more fully under the heading Written Consent of ARCA Stockholders below, all written consents to ARCA proposals must be received at ARCA's executive offices no later than November 28, 2008.**

Pursuant to certain voting agreements with ARCA, the holders of approximately 84.97% of ARCA's outstanding capital stock including approximately 92.11% of ARCA's outstanding preferred stock, on an as converted basis, and all of the Principal Series Preferred Stockholders, have agreed to consent to the proposal.

Under the DGCL, holders of ARCA's capital stock who do not execute a written consent to the adoption of the proposal will have the right to seek appraisal of the fair value of their shares as determined by the Delaware Court of Chancery if the merger is completed, but only if they submit a written demand for an appraisal within 20 days after the mailing of notice by ARCA that the merger was approved by written consent of the ARCA stockholders and they comply with the other procedures under the DGCL explained in the accompanying proxy statement/prospectus/consent solicitation. See The Merger Appraisal Rights beginning on page 101 of the accompanying proxy statement/prospectus/consent solicitation.

Your consent is important. Please complete, sign, date and return your consent in the enclosed envelope promptly. Please do not send any ARCA stock certificates at this time. After the merger is completed, you will receive written instructions for receiving your Nuvelo stock certificates.

By Order of ARCA's Board of Directors,

**Richard B. Brewer**  
**President and Chief Executive Officer**

Broomfield, Colorado

November 21, 2008

**THE ARCA BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT THE PROPOSAL OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, ARCA AND ITS STOCKHOLDERS AND HAS APPROVED SUCH PROPOSAL. THE ARCA BOARD OF DIRECTORS RECOMMENDS THAT ARCA STOCKHOLDERS CONSENT TO SUCH PROPOSAL.**

**Table of Contents****TABLE OF CONTENTS**

	<b>Page</b>
<u>QUESTIONS AND ANSWERS ABOUT THE MERGER, THE NUVELO SPECIAL MEETING AND THE ARCA CONSENT SOLICITATION</u>	1
<u>SUMMARY</u>	8
<u>MARKET PRICE AND DIVIDEND INFORMATION</u>	19
<u>SELECTED HISTORICAL FINANCIAL DATA</u>	21
<u>SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA</u>	24
<u>COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA PER SHARE DATA</u>	27
<u>RISK FACTORS</u>	28
<u>Risks Related to the Proposed Merger and Combined Company</u>	28
<u>Risks Related to Nuvelo</u>	36
<u>Risks Related to Nuvelo's Capital Structure and Financial Results and Stock Price Volatility</u>	46
<u>Risks Related to Nuvelo Intellectual Property and Other Legal Matters</u>	53
<u>Risks Related to ARCA's Business</u>	57
<u>FORWARD-LOOKING INFORMATION</u>	71
<u>THE SPECIAL MEETING OF NUVELO STOCKHOLDERS</u>	72
<u>Date, Time and Place</u>	72
<u>Purposes of the Nuvelo Special Meeting</u>	72
<u>Recommendation of the Nuvelo Board of Directors</u>	72
<u>Record Date and Voting Power</u>	73
<u>Voting and Revocation of Proxies</u>	73
<u>Quorum and Required Vote</u>	75
<u>Solicitation of Proxies</u>	75
<u>Other Matters</u>	75
<u>NUVELO PROPOSAL NO. 1 APPROVAL OF ISSUANCE OF SHARES OF NUVELO COMMON STOCK IN THE MERGER</u>	76
<u>THE MERGER</u>	76
<u>General Description of the Merger</u>	76
<u>Background of the Merger</u>	76
<u>Reasons for the Merger</u>	80
<u>Opinion of Nuvelo's Financial Advisor</u>	85
<u>Officers and Directors of the Combined Company Following the Merger</u>	94
<u>Interests of Nuvelo's Executive Officers and Directors in the Merger</u>	94
<u>Interests of ARCA's Executive Officers and Directors in the Merger</u>	97
<u>Stock Options</u>	100
<u>Warrants</u>	100
<u>ARCA Preferred Stock</u>	100
<u>Convertible Promissory Notes and Warrants</u>	101
<u>Regulatory Approvals</u>	101
<u>Appraisal Rights</u>	101
<u>Material U.S. Federal Income Tax Consequences of the Merger</u>	104
<u>Anticipated Accounting Treatment</u>	106
<u>Vote Required; Recommendation of Board of Directors</u>	106
<u>THE MERGER AGREEMENT</u>	107
<u>General</u>	107
<u>Closing of the Merger</u>	107
<u>Merger Consideration</u>	107
<u>Assumption of ARCA Stock Options and Warrants</u>	109
<u>Fractional Shares</u>	109
<u>Exchange of ARCA Stock Certificates</u>	109

**Table of Contents**

	<b>Page</b>
<u>Amended and Restated Certificate of Incorporation of Nuvelo</u>	110
<u>Conditions to the Completion of the Merger</u>	110
<u>Conduct of Business Prior to the Merger</u>	111
<u>Limitation on Soliciting, Discussing or Negotiating Other Acquisition Proposals</u>	114
<u>Change in Recommendation</u>	115
<u>Meeting of Stockholders: Stockholder Consent</u>	116
<u>Other Agreements</u>	116
<u>Representations and Warranties</u>	117
<u>Material Adverse Effect</u>	118
<u>Termination of the Merger Agreement</u>	119
<u>Termination Fees</u>	121
<u>Amendment and Waiver of the Merger Agreement</u>	121
<u>OTHER AGREEMENTS RELATED TO THE MERGER</u>	123
<u>Voting Agreements</u>	123
<u>Note and Warrant Purchase Agreement</u>	125
<u>NUVELO PROPOSAL NO. 2 AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF NUVELO S COMMON STOCK</u>	126
<u>Overview</u>	126
<u>Reasons for the Reverse Stock Split</u>	126
<u>Effects of the Reverse Stock Split</u>	128
<u>Effective Date</u>	129
<u>Payment for Fractional Shares</u>	129
<u>Exchange of Stock Certificates</u>	129
<u>Accounting Consequences</u>	129
<u>Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</u>	129
<u>No Appraisal Rights</u>	131
<u>Vote Required; Recommendation of Board of Directors</u>	132
<u>NUVELO PROPOSAL NO. 3 AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED SHARES OF NUVELO COMMON STOCK</u>	133
<u>Overview</u>	133
<u>Reasons for the Increase in Authorized Shares</u>	133
<u>Effects of the Increase in Authorized Shares</u>	133
<u>Vote Required; Recommendation of Board of Directors</u>	134
<u>NUVELO PROPOSAL NO. 4 APPROVAL OF POSSIBLE ADJOURNMENT OF THE SPECIAL MEETING</u>	135
<u>Overview</u>	135
<u>Vote Required; Recommendation of Board of Directors</u>	135
<u>WRITTEN CONSENT OF ARCA STOCKHOLDERS</u>	136
<u>ARCA PROPOSAL APPROVAL OF THE MERGER, MERGER AGREEMENT AND THE TRANSACTIONS CONTEMPLATED THEREBY</u>	136
<u>Recommendations of ARCA s Board of Directors</u>	136
<u>Record Date and Voting Power</u>	136
<u>Irrevocability of Written Consents</u>	137
<u>Execution and Delivery of Written Consents</u>	137
<u>Required Consent</u>	137
<u>Appraisal Rights</u>	137
<u>INFORMATION ABOUT NUVELO S BUSINESS</u>	138
<u>Overview</u>	138
<u>Nuvelo s Strategy</u>	140
<u>Corporate Information</u>	141

**Table of Contents**

	<b>Page</b>
<u>Research and Development Collaborations</u>	141
<u>Manufacturing</u>	143
<u>Patents and Trade Secrets</u>	143
<u>Competition</u>	144
<u>Government Regulation</u>	144
<u>Human Resources</u>	145
<u>Properties</u>	145
<u>Legal Proceedings</u>	146
<b><u>INFORMATION ABOUT ARCA S BUSINESS</u></b>	148
<u>Overview</u>	148
<u>Market Opportunity</u>	149
<u>ARCA Strategy</u>	150
<u>Gencaro</u>	150
<u>The Gencaro Test</u>	156
<u>Marketing and Sales</u>	156
<u>Competition</u>	157
<u>Other Potential Indications for Gencaro</u>	157
<u>Manufacturing and Product Supply</u>	158
<u>Government Regulation</u>	158
<u>Intellectual Property</u>	163
<u>Employees</u>	164
<u>Facilities</u>	164
<u>Legal Proceedings</u>	164
<b><u>MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR NUVELO</u></b>	165
<u>Overview</u>	165
<u>Results of Operations</u>	167
<u>Liquidity and Capital Resources</u>	172
<u>Selected Quarterly Financial Data (Unaudited)</u>	175
<u>Critical Accounting Policies and Estimates</u>	175
<u>Recent Accounting Pronouncements</u>	180
<u>Off-Balance Sheet Arrangements</u>	180
<u>Indemnifications</u>	181
<b><u>NUVELO QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u></b>	182
<b><u>MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR ARCA</u></b>	183
<u>Overview</u>	183
<u>Critical Accounting Policies and Estimates</u>	184
<u>Results of Operations</u>	189
<u>Liquidity and Capital Resources</u>	191
<u>Recent Accounting Pronouncements</u>	194
<u>Off-Balance Sheet Arrangements</u>	194
<b><u>ARCA QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</u></b>	195
<b><u>ARCA CONTROLS AND PROCEDURES</u></b>	196
<b><u>MANAGEMENT OF THE COMBINED COMPANY AFTER THE MERGER</u></b>	197
<u>Executive Officers and Directors</u>	197
<u>Committees of the Board of Directors</u>	200
<u>Compensation of Directors</u>	201
<b><u>EXECUTIVE COMPENSATION AND OTHER INFORMATION</u></b>	202
<u>ARCA s Compensation Discussion and Analysis</u>	202
<u>Compensation Committee Interlocks and Insider Participation in Compensation Decisions</u>	207

**Table of Contents**

	<b>Page</b>
<u>Summary Compensation Table</u>	207
<u>Grants of Plan-Based Awards</u>	208
<u>Holdings of Previously Awarded Equity</u>	208
<u>Option Exercises and Stock Vested</u>	209
<u>Employment Agreements and Potential Payment Upon Termination or Change of Control</u>	209
<u>Quantification of Termination Payments and Benefits</u>	211
<u>ARCA 2004 Stock Incentive Plan</u>	213
<u>ARCA 401(k) Plan</u>	216
<u>Compensation of Directors</u>	216
<u>Non-Employee Director Compensation</u>	217
<u>RELATED PARTY TRANSACTIONS INVOLVING DIRECTORS AND EXECUTIVE OFFICERS FOLLOWING THE MERGER</u>	219
<u>Nuvelo Transactions</u>	219
<u>ARCA Transactions</u>	219
<u>Procedures for Approval of Related Person Transactions</u>	223
<u>NUVELO SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	224
<u>ARCA SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	226
<u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT FOLLOWING THE MERGER</u>	230
<u>DESCRIPTION OF NUVELO S CAPITAL STOCK</u>	233
<u>Preferred Stock</u>	233
<u>Common Stock</u>	233
<u>Limitation of Liability and Indemnification</u>	233
<u>Additional Information Concerning Nuvelo s Capital Stock</u>	234
<u>COMPARATIVE RIGHTS OF NUVELO STOCKHOLDERS AND ARCA STOCKHOLDERS</u>	236
<u>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</u>	248
<u>LEGAL MATTERS</u>	258
<u>EXPERTS</u>	258
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	259
<u>INDEX TO FINANCIAL STATEMENTS</u>	F-1
<b>ANNEXES:</b>	

- A Agreement and Plan of Merger
- B Amendment No. 1 to Agreement and Plan of Merger and Reorganization
- C Form of Nuvelo Voting Agreement
- D Form of ARCA Voting Agreement
- E Opinion of Jefferies & Company, Inc.
- F Certificate of Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split
- G Certificate of Amendment to the Amended and Restated Certificate of Incorporation to Increase the Authorized Shares of Nuvelo Common Stock
- H Section 262 of the Delaware General Corporation Law



**Table of Contents**

Nuvelo was incorporated as Hyseq, Inc. in Illinois in 1992 and reincorporated in Nevada in 1993. On January 31, 2003, Hyseq merged with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts, and, in connection with the merger, changed its name to Nuvelo, Inc. On March 25, 2004, Nuvelo reincorporated from Nevada to Delaware. Nuvelo's principal executive offices are located at 201 Industrial Road, Suite 310, San Carlos, California 94070.

Nuvelo files its annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 electronically with the Securities and Exchange Commission, or SEC. The public may read or copy any materials Nuvelo files with the SEC at the SEC's Public Reference Rooms at 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is <http://www.sec.gov>.

You may obtain a free copy of Nuvelo's annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports on the day of filing with the SEC on Nuvelo's website, on the Internet at <http://www.nuvelo.com> or by contacting the Investor Relations Department at Nuvelo's corporate office by calling (650) 517-8000 or sending an e-mail message to [ir@nuvelo.com](mailto:ir@nuvelo.com). Information found on Nuvelo's website is not incorporated by reference into this proxy statement/prospectus/consent solicitation.

---

**Table of Contents**

**QUESTIONS AND ANSWERS ABOUT THE MERGER, THE NUVELO SPECIAL MEETING AND THE ARCA CONSENT SOLICITATION**

*The following section provides answers to frequently asked questions about the merger, the effect of the merger on holders of Nuvelo common stock and ARCA common stock and preferred stock, the Nuvelo special meeting and the ARCA consent solicitation. This section, however, only provides summary information. Nuvelo and ARCA urge you to read carefully the remainder of this proxy statement/prospectus/consent solicitation, including the annexes to this proxy statement/prospectus/consent solicitation, because the information in this section does not provide all the information that might be important to you regarding the merger and the other matters being considered at Nuvelo's special meeting and in the ARCA consent solicitation.*

*As used in this proxy statement/prospectus/consent solicitation, references to Nuvelo refer collectively to Nuvelo, Inc. and all of its subsidiaries unless the context requires otherwise and references to ARCA refer to ARCA biopharma, Inc.*

**Q: What is the merger?**

A: Nuvelo, ARCA, and Dawn Acquisition Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Nuvelo, have entered into an Agreement and Plan of Merger dated as of September 24, 2008, as amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, by and among Nuvelo, Dawn Acquisition Sub, Inc. and ARCA, which, as amended, unless otherwise indicated, is referred to in this proxy statement/prospectus/consent solicitation as the merger agreement, that contains the terms and conditions of the proposed business combination of Nuvelo and ARCA. Pursuant to the merger agreement, on the terms and conditions set forth therein, Dawn Acquisition Sub, Inc. will be merged with and into ARCA, with ARCA surviving the merger as a wholly-owned subsidiary of Nuvelo.

**Q: What will ARCA's stockholders receive in the merger?**

A: Nuvelo has agreed to issue, and holders of ARCA capital stock will receive, shares of Nuvelo common stock such that following the consummation of the transactions contemplated by the merger agreement, current stockholders of Nuvelo are expected to own approximately 33% of the common stock of the combined company, and current ARCA stockholders are expected to own or have the right to acquire approximately 67% of the combined company, after giving effect to the shares issuable pursuant to ARCA's outstanding options and warrants, primarily on a treasury method basis, and without giving effect to any shares issuable pursuant to Nuvelo's outstanding options and warrants. Immediately prior to the effective time of the merger, all outstanding shares of ARCA preferred stock will convert automatically into shares of ARCA common stock at the then applicable conversion rate, and the outstanding principal and accrued interest under ARCA's 6% convertible promissory notes dated October 10, 2008 will convert automatically into shares of ARCA common stock at the conversion price stated in the notes. The actual number of shares of Nuvelo common stock to be issued in respect of each share of capital stock of ARCA will be determined by dividing an aggregate of 109,009,278 shares of Nuvelo common stock by the number of shares of ARCA common stock outstanding and deemed outstanding pursuant to the formula set forth in the merger agreement and described herein and under The Merger Agreement. The exact exchange ratio per share of ARCA's capital stock will depend upon the number of shares of ARCA's common stock outstanding or issuable pursuant to the conversion of ARCA's outstanding preferred stock and convertible notes and the exercise of ARCA's outstanding options and warrants immediately prior to the effective time of the merger and the closing price per share of Nuvelo's common stock for the five consecutive days immediately preceding the effective time of the merger and will not be calculated until that time.

**Q: Why are the two companies proposing to merge?**

A: Nuvelo and ARCA believe that the combined company resulting from the merger will have a number of potential advantages, including the increased scale of a larger cardiovascular focused biotechnology company with a near term commercial opportunity represented by ARCA's product candidate, Gencaro, and



---

**Table of Contents**

longer term product development opportunities represented by Nuvelo's product candidate, NU172, more secure capitalization to support product candidates and other significant potential management and business synergies and cost savings that Nuvelo and ARCA believe can be achieved by consolidating the infrastructures of the two companies and allowing management to fully leverage the combined research, development and administrative capabilities across multiple potential product candidates.

**Q: What is the reverse stock split and why is it necessary?**

A: Immediately prior to the effective time of the merger, the outstanding shares of Nuvelo's common stock will be reclassified and combined into a lesser number of shares to be determined by Nuvelo's board of directors prior to the effective time and publicly announced by Nuvelo. The merger constitutes a reverse merger under applicable marketplace rules established by Nasdaq, which requires the combined company to comply with the initial listing standards of the applicable Nasdaq market to continue to be listed on such market following the merger. The Nasdaq Global Select Market's and Nasdaq Global Market's initial listing standards require a company to have, among other things, a \$5.00 per share minimum bid price and the Nasdaq Capital Market's initial listing standards require a company to have, among other things, a \$4.00 per share minimum bid price. Because it is a condition precedent to the merger that Nuvelo's common stock be listed on any of the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market and the current price of Nuvelo common stock is less than the minimum bid prices required by any of these markets, unless the condition is waived, the reverse stock split is necessary to consummate the merger.

**Q: Why am I receiving this proxy statement/prospectus/consent solicitation?**

A: You are receiving this proxy statement/prospectus/consent solicitation because you have been identified as a stockholder of Nuvelo or a stockholder of ARCA. This document serves as a proxy statement of Nuvelo, used to solicit proxies for the special meeting, and consent solicitation for ARCA, used to solicit the written consent of its stockholders, and a prospectus of Nuvelo, used to offer shares of Nuvelo common stock to ARCA stockholders in exchange for shares of ARCA common stock pursuant to the terms of the merger agreement and to offer shares of Nuvelo common stock to holders of warrants and options exercisable into shares of ARCA capital stock, which warrants and options are to be assumed by Nuvelo in the merger. If you are a stockholder of Nuvelo, you are entitled to vote at Nuvelo's special meeting. If you are a stockholder of ARCA, you are entitled to execute a written consent in lieu of a vote at a meeting. This document contains important information about the merger, the shares of Nuvelo common stock to be issued in the merger and the special meeting of Nuvelo stockholders, and you should read it carefully.

**Q: What Nuvelo stockholder approvals are required to consummate the merger?**

A: To consummate the merger, Nuvelo stockholders must approve:

the issuance of shares of Nuvelo common stock in the merger, which requires the affirmative vote of holders of a majority of the votes cast in person or by proxy at the Nuvelo special meeting; and

the amendment to Nuvelo's certificate of incorporation to effect the reverse stock split of the issued and outstanding shares of Nuvelo's common stock, which requires the affirmative vote of holders of a majority of the outstanding shares of Nuvelo common stock as of the record date for the special meeting.

Nuvelo's stockholders are also being asked to approve an amendment to Nuvelo's certificate of incorporation to increase the number of authorized shares of Nuvelo's common stock to 250 million, which requires the affirmative vote of holders of a majority of the outstanding shares of Nuvelo common stock as of the record date for the special meeting. While approval of this proposal is not required to consummate the merger, the Nuvelo board of directors has determined that the proposal is advisable, and in the best interests of, Nuvelo and its stockholders and recommends that you vote for this proposal.

## Edgar Filing: NUVELO INC - Form S-4/A

In connection with the execution of the merger agreement, Ted W. Love and Lee Bendekgey, both officers of Nuvelo, and Mark Perry, a director of Nuvelo, entered into voting agreements with ARCA that provide, among other things, that they will vote in favor of the issuance of Nuvelo common stock pursuant to the

**Table of Contents**

merger agreement and the amendment of Nuvelo's amended and restated certificate of incorporation to effect the reverse stock split and grant to ARCA an irrevocable proxy to vote all of their shares of Nuvelo common stock in favor of such proposals and against any proposal made in opposition to, or in competition with, such proposals.

**Q: What ARCA stockholder approvals are required to consummate the merger?**

A: To consummate the merger, ARCA stockholders must adopt and approve the merger agreement and approve the merger and the transactions contemplated thereby, which requires the approval of the holders of a majority of (i) the shares of ARCA common stock and ARCA preferred stock, voting together as a single class, with holders of ARCA preferred stock voting on an as-converted basis and (ii) the Principal Series Preferred Stockholders.

In connection with the execution of the merger agreement, the holders of approximately 84.97% of ARCA's outstanding common and preferred stock, including approximately 92.11% of ARCA's outstanding preferred stock, on an as converted basis, and all of the Principal Series Preferred Stockholders, have entered into voting agreements with Nuvelo that provide, among other things, that they will vote in favor of the merger and that grant to Nuvelo an irrevocable proxy to vote all of their shares of ARCA common stock and ARCA preferred stock in favor of the merger and against any proposal made in opposition to, or in competition with, the proposed merger. All of these stockholders are executive officers, directors, or entities controlled by such persons, or 5% stockholders, of ARCA, and include the Principal Series Preferred Stockholders.

**Q: What other conditions must be satisfied to consummate the merger?**

A: In addition to Nuvelo and ARCA obtaining stockholder approval, closing conditions include:

conditional approval for the listing of Nuvelo common stock to be issued in the merger on any of the Nasdaq Global Select Market, Nasdaq Global Market or Nasdaq Capital Market;

subject to certain exceptions, the absence of any effects, changes, events or circumstances that singularly or collectively have a material adverse effect on the business, financial condition, operations or results of operations of Nuvelo or ARCA or the ability of Nuvelo or ARCA to consummate the merger or perform their obligations under the merger agreement;

the accuracy of the representations and warranties provided by Nuvelo and ARCA pursuant to the merger agreement except where such inaccuracies do not constitute a material adverse effect;

the performance of the covenants and obligations of Nuvelo and ARCA pursuant to the merger agreement in all material respects;

the delivery of certain certifications and opinions by each party and the termination of certain stockholder and related agreements by ARCA and its stockholders; and

the absence of any injunction or order preventing the consummation of the merger or any legal proceeding in which a governmental body seeks to prohibit or restrain the consummation of the merger or otherwise materially impact the rights or operations of Nuvelo or ARCA following the consummation of the merger.

Nuvelo or ARCA may waive compliance with any closing condition intended for its benefit.

**Q: What are the material U.S. federal income tax consequences of the merger to me?**

A: The merger has been structured to qualify as a tax-free reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended, or the Code, and Nuvelo and ARCA have agreed to use their commercially reasonable efforts in order to obtain the opinion of Nuvelo's counsel, Cooley Godward Kronish LLP, and ARCA's counsel, Hogan & Hartson, LLP, regarding such qualification. Assuming that the merger qualifies as a reorganization, ARCA stockholders will not recognize gain or loss for U.S. federal income tax purposes upon the exchange of shares of ARCA capital stock for shares of Nuvelo common stock, except with respect to cash received in lieu of fractional shares of Nuvelo common stock.

**Table of Contents**

**Q: What risks should I consider in deciding whether to vote in favor of or consent to the proposals?**

A: You should carefully review the section of this proxy statement/prospectus/consent solicitation entitled **Risk Factors** beginning on page 28, which sets forth certain risks and uncertainties related to the merger to which Nuvelo's and ARCA's businesses are and will be subject.

**Q: When do you expect the merger to be consummated?**

A: We anticipate that the merger will occur in the first quarter of 2009 as promptly as practicable after the Nuvelo special meeting and satisfaction or waiver of all closing conditions, but we cannot predict the exact timing.

**Q: Am I entitled to appraisal rights?**

A: Under Delaware General Corporation Law, or the DGCL, holders of Nuvelo common stock are not entitled to appraisal rights in connection with the merger or the proposals described in this proxy statement/prospectus/consent solicitation. Under the DGCL, ARCA stockholders who do not consent to approve the merger and who comply with the procedural requirements of Section 262 of the DGCL may demand payment in cash of the fair value of their shares of ARCA capital stock in lieu of the merger consideration, if any. These rights are commonly known as **dissenters' rights**. If the dissenting stockholder and surviving corporation do not agree on a fair value of the shares, a court of proper jurisdiction will determine the fair value upon the dissenting stockholder's petition, which could be more than, less than or equal to the value of the merger consideration. Dissenting stockholders lose their **dissenters' rights** if they fail to follow all of the procedures required by Section 262 of the DGCL. See **The Merger Appraisal Rights** beginning on page 101 of this proxy statement/prospectus/consent solicitation.

**Q: Should ARCA's and Nuvelo's stockholders send in their stock certificates now?**

A: No. After the merger is consummated, ARCA's stockholders will receive written instructions from the exchange agent for exchanging their certificates representing shares of ARCA capital stock for certificates representing shares of Nuvelo's common stock. ARCA's stockholders will also receive a cash payment for any fractional shares. Nuvelo's stockholders are not required to tender or exchange their certificates as part of the merger, but if Proposal No. 2 to effect a reverse stock split is approved and implemented, Nuvelo's stockholders will be asked by Nuvelo's transfer agent to surrender stock certificates representing pre-reverse stock split shares in exchange for post-reverse stock split shares in accordance with procedures to be set forth in a letter of transmittal.

**Q: Who is paying for this proxy and consent solicitation?**

A: Nuvelo and ARCA are conducting this proxy and consent solicitation and will each bear one-half of the costs of the proxy and consent solicitation, including the preparation, assembly, printing and mailing of this proxy statement/prospectus/consent solicitation, the proxy card and any additional information furnished to stockholders. Nuvelo and ARCA will each bear its own legal expenses. Nuvelo may also reimburse brokerage houses and other custodians, nominees and fiduciaries for their costs of forwarding proxy and solicitation materials to beneficial owners.

**Q: Who can help answer my questions?**



## Edgar Filing: NUVELO INC - Form S-4/A

A: If you are a Nuvelo stockholder and would like additional copies, without charge, of this proxy statement/prospectus/consent solicitation or if you have questions about the proposals described herein, including the procedures for voting your shares, you should contact:  
Nuvelo, Inc.

Attn: Investor Relations

201 Industrial Road, Suite 310

San Carlos, CA 94070-6211

(650) 517-8000

E-mail: [ir@Nuvelo.com](mailto:ir@Nuvelo.com)

**Table of Contents**

If you are an ARCA stockholder and would like additional copies, without charge, of this proxy statement/prospectus/consent solicitation, or if you have questions about the ARCA proposal described herein, including the procedures for voting your shares by written consent, you should contact:

ARCA biopharma, Inc.

Attn: General Counsel, Executive Vice President of Business Development

8001 Arista Place, Suite 200

Broomfield, CO 80021

(720) 940-2200

E-mail: Chris.Ozeroff@arcabiopharma.com

To obtain timely delivery, ARCA stockholders must request the information before delivering their signed written consent, which must be delivered to ARCA no later than November 28, 2008.

**FOR NUVELO STOCKHOLDERS:**

**Q: Who is soliciting my proxy?**

A: The proxy is being solicited of Nuvelo's stockholders by Nuvelo's board of directors.

**Q: As a Nuvelo stockholder, how does Nuvelo's Board of Directors recommend that I vote?**

A: After careful consideration, Nuvelo's board of directors recommends that Nuvelo stockholders vote:

FOR Proposal No. 1 to approve the issuance of shares of Nuvelo common stock in the merger;

FOR Proposal No. 2 to approve the amendment to Nuvelo's amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo's common stock;

FOR Proposal No. 3 to approve the amendment to Nuvelo's amended and restated certificate of incorporation to increase the number of authorized shares of Nuvelo common stock to 250 million; and

FOR Proposal No. 4 to consider and vote upon an adjournment of the special meeting, if necessary, if a quorum is present, to solicit additional parties if there are not sufficient votes in favor of Proposals No. 1 and No. 2.

**Q: What do I need to do now?**

A: We urge you to read this proxy statement/prospectus/consent solicitation carefully, including its annexes, and to consider how the merger affects you.

If your shares of Nuvelo stock are registered directly in your name, you may provide your proxy instructions in four different ways. First, you can mail your signed proxy card in the enclosed return envelope. Alternatively, you can provide your proxy instructions via the toll-free call

## Edgar Filing: NUVELO INC - Form S-4/A

center set up for this purpose at 1-877-816-0836. You can also provide your proxy instructions via the Internet at <http://proxy.georgeson.com>. Finally, you can deliver your completed proxy card in person or by completing a ballot in person at the special meeting. Please provide your proxy instructions only once and as soon as possible so that your shares can be voted at the special meeting of Nuvelo stockholders.

If your Nuvelo shares are held in a brokerage account in street name or by another nominee, your broker will not be able to vote your shares of Nuvelo common stock without instructions from you. You should instruct your broker to vote your shares, following the procedure provided by your broker.

**Q: What happens if I do not return a proxy card or otherwise provide proxy instructions?**

A: If you do not submit a proxy card or vote at the special meeting, your shares will not be counted as present for the purpose of determining the presence of a quorum. Also, not submitting a proxy card or voting at the special meeting will have no effect on the approval of Proposals No. 1 or No. 4 but will have the same effect

## **Table of Contents**

as voting against Proposals No. 2 and No. 3. Broker non-votes will similarly have no effect on the approval of Proposals No. 1 or No. 4, but will have the same effect as voting against Proposals No. 2 and No. 3. If you submit a proxy card and affirmatively elect to abstain from voting, your proxy will be counted as present for the purpose of determining the presence of a quorum but will not be voted at the meeting. As a result, your abstention will have no effect on the approval of Proposals No. 1 or No. 4, but will have the same effect as voting against Proposals No. 2 and No. 3.

### **Q: May I vote in person?**

A: If your shares of Nuvelo common stock are registered directly in your name with Nuvelo's transfer agent you are considered, with respect to those shares, the stockholder of record, and the proxy materials and proxy card are being sent directly to you. If you are a Nuvelo stockholder of record as of November 11, 2008, you may attend the special meeting of Nuvelo stockholders to be held on January 7, 2009 and vote your shares in person, rather than signing and returning your proxy card or otherwise providing proxy instructions. However, we urge you to return your proxy card with your voting instructions in any event, just in case your plans should change.

If your shares of Nuvelo common stock are held in a brokerage account or by another nominee, you are considered the beneficial owner of shares held in street name, and the proxy materials are being forwarded to you together with a voting instruction card. As the beneficial owner, you are also invited to attend the special meeting of Nuvelo stockholders. Since a beneficial owner is not the stockholder of record, you may not vote these shares in person at the special meeting unless you obtain a legal proxy from the broker, trustee or nominee that holds your shares, giving you the right to vote the shares at the meeting.

### **Q: May I change my vote after I have provided proxy instructions?**

A: Any stockholder of record, other than those stockholders who have executed voting agreements, has the right to revoke the proxy any time before its proxy is voted at the special meeting by sending a written notice stating that it would like to revoke the proxy, by submitting new proxy instructions either on a new proxy card, by telephone or via the Internet, or by attending the special meeting and voting in person. Attendance alone at the special meeting will not revoke your proxy. If a Nuvelo stockholder has instructed a broker to vote shares of Nuvelo common stock held in street name, the stockholder must follow directions received from the broker to change those instructions.

### **FOR ARCA STOCKHOLDERS:**

### **Q: Who is soliciting my written consent?**

A: The written consent is being solicited of ARCA stockholders by ARCA's board of directors.

### **Q: As an ARCA stockholder, how does ARCA's Board of Directors recommend that I vote?**

A: After careful consideration, ARCA's board of directors recommends that ARCA stockholders affirmatively consent to adopt and approve the merger agreement and to approve the merger and the transactions contemplated thereby.

### **Q: What do I need to do now?**

A: We urge you to read this proxy statement/prospectus/consent solicitation carefully, including its annexes, and to consider how the merger affects you. Then, please execute and deliver the written consent to ARCA in the enclosed envelope at ARCA biopharma, Inc., Attn: General Counsel, 8001 Arista Place, Suite 200, Broomfield, CO 80021. Please provide your signed written consent as soon as possible and

no later than November 28, 2008.

**Table of Contents**

**Q: What happens if I do not return a written consent?**

A: If you do not return your signed written consent, it will have the same effect as voting against the merger, the merger agreement and the transactions contemplated thereby.

**Q: May I provide my written consent in person?**

A: No. ARCA will not be holding a special meeting. The written consent is provided in lieu of a special meeting.

**Q: May I change or revoke my vote after I have provided a signed written consent?**

A: No. By consenting to the adoption of the merger agreement and approving the merger and transactions contemplated thereby, each ARCA stockholder is acknowledging, among other matters, that such stockholder's consent to the adoption of the merger, the merger agreement and the transactions contemplated thereby is irrevocable. You may not change or revoke your consent once it is provided.

**Table of Contents**

**SUMMARY**

*This summary highlights selected information from this proxy statement/prospectus/consent solicitation. To understand the merger fully, you should read carefully this entire document and the documents to which we refer, including the annexes attached hereto. See *Where You Can Find More Information* on page 259. A copy of the merger agreement is attached as Annex A to the accompanying proxy statement/prospectus/consent solicitation and a copy of the amendment to the merger agreement is attached as Annex B to the accompanying proxy statement/prospectus/consent solicitation. You are encouraged to read the merger agreement as it is the legal document that governs the merger. Page references to this proxy statement/prospectus/consent solicitation have been included in parentheses to direct you to a more detailed description of the topics presented in this summary.*

**The Companies**

**Nuvelo, Inc.**

201 Industrial Road, Suite 310

San Carlos, CA 94070-6211

(650) 517-8000

Nuvelo is a biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor that has completed Phase 1 development for use as a short-acting anticoagulant during medical or surgical procedures, and Phase 1 clinical candidate NU206, a recombinant, secreted protein for the potential treatment of gastrointestinal, or GI, diseases, including cancer therapy induced mucositis and inflammatory bowel disease, in addition to bone disease and wound healing. Nuvelo anticipates initiating a Phase 2 study evaluating NU172 in coronary artery bypass graft patients in the first half of 2009. Nuvelo initiated a Phase 1 single ascending dose trial of NU206 in healthy volunteers in July 2008 and expects data from the trial in the fourth quarter of 2008. Nuvelo also plans to initiate a Phase 1b multiple ascending dose trial in healthy volunteers in the fourth quarter of 2008 or first quarter of 2009. In addition to its NU172 and NU206 development programs, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics.

**ARCA biopharma, Inc.**

8001 Arista Place, Suite 200

Broomfield, CO 80021

(720) 940-2200

ARCA is a privately-held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA is currently developing Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, for the treatment of heart failure and other indications. The U.S. Food and Drug Administration, or FDA, accepted for filing ARCA's New Drug Application, or NDA, for Gencaro in September 2008. The name Gencaro has not yet been approved for use by the FDA. ARCA was originally organized in 2001 as a Colorado corporation and reincorporated to Delaware in 2004.

**Dawn Acquisition Sub, Inc.**

201 Industrial Road, Suite 310

San Carlos, CA 94070-6211

(650) 517-8000

Dawn Acquisition Sub, Inc. is a wholly-owned subsidiary of Nuvelo that was incorporated in Delaware in September 2008. Dawn Acquisition Sub, Inc. does not engage in any operations and exists solely to facilitate the merger.





## **Table of Contents**

### **Summary of the Merger (see page 76)**

If the merger is consummated, ARCA and Dawn Acquisition Sub, Inc. will merge, with ARCA surviving as a wholly-owned subsidiary of Nuvelo. It is anticipated that shortly after the merger Nuvelo will change its name to ARCA biopharma, Inc. A copy of the merger agreement is attached as *Annex A* to this proxy statement/prospectus/consent solicitation and a copy of the amendment to the merger agreement is attached as *Annex B* to this proxy statement/prospectus/consent solicitation. You are encouraged to read the merger agreement in its entirety because it is the legal document that governs the merger.

### **Reasons for the Merger (see page 80)**

#### ***Mutual Reasons for the Merger***

Nuvelo and ARCA believe that the combined company resulting from the merger will have the following potential advantages:

the combined company will be a larger cardiovascular focused biotechnology company with a near term commercial opportunity represented by ARCA's product candidate, Gencaro, and longer term product development opportunities represented by Nuvelo's product candidate, NU 172;

the combined company will be more securely capitalized to commercialize its late stage product candidate and develop its pipeline of longer term product candidates; and

there are significant potential synergies and cost savings that Nuvelo and ARCA believe can be achieved by consolidating the infrastructures of the two companies and allowing management to fully leverage the combined research, development and administrative capabilities across multiple potential product candidates.

Each of the boards of directors of Nuvelo and ARCA also considered other reasons for the merger.

Nuvelo's board of directors considered, among other things:

Nuvelo's limited prospects if it were to remain an independent, standalone company as a result of factors such as the absence of a late-stage product candidate, its declining cash balance, the expenses and fixed costs associated with its operations and its prospects for development and commercialization of Nuvelo's early stage product candidates, particularly given its limited resources;

the opportunity for Nuvelo's stockholders to participate in the potential future value of the combined company;

Nuvelo's board of directors view as to the potential for other third parties to enter into strategic relationships with or acquire Nuvelo on favorable terms, if at all, based on the interest expressed by other third parties during the strategic alternatives review process undertaken by Nuvelo; and

the belief that the merger was more favorable to Nuvelo's stockholders than any other alternative reasonably available to Nuvelo and its stockholders, including the alternative of remaining an independent, standalone company.

ARCA's board of directors considered, among other things:

## Edgar Filing: NUVELO INC - Form S-4/A

ARCA's additional capital requirements, which ARCA anticipates can be met with Nuvelo's available cash, together with ARCA's other cash resources, to fund ARCA's projected operating requirements through the end of 2009, beyond the expected date of FDA approval of Gencaro; and, given market conditions, the benefits of this option over others considered by ARCA to finance its operations, such as an equity offering;

---

## **Table of Contents**

Nuvelo's longer term product development opportunities represented by its product candidate, NU172, that would be complimentary to development efforts undertaken for Gencaro;

ARCA's ability to leverage Nuvelo's other non-cardiovascular candidates and research platforms and its experienced clinical, regulatory and administrative employees as a compliment to ARCA's own employees; and

the merger with Nuvelo will enhance the combined company's access to capital, providing ARCA with a greater range of options than if it continued as a privately-held company.

### **Opinion of Nuvelo's Financial Advisor (see page 85)**

Jefferies & Company, Inc., or Jefferies, served as Nuvelo's financial advisor in connection with the proposed transaction. On September 24, 2008, Jefferies delivered to the board of Nuvelo its oral opinion, subsequently confirmed in writing on such date, to the effect that, as of that date and based upon and subject to the various assumptions made, procedures followed, matters considered and limitations described in its opinion, the Exchange Ratio, representing the amount of shares of Nuvelo common stock to be exchanged for ARCA capital stock in the merger pursuant to the terms of the merger agreement, was fair, from a financial point of view, to Nuvelo.

**Jefferies' opinion was provided for the use and benefit of the Nuvelo board in its consideration of the proposed transaction. Jefferies' opinion did not address the relative merits of the proposed transaction as compared to any alternative transaction or opportunity that might be available to Nuvelo, nor did it address the underlying business decision by Nuvelo to engage in the proposed transaction or the terms of the merger agreement or the documents referred to therein. Furthermore, Jefferies' opinion did not constitute a recommendation as to how any holder of Nuvelo common stock should vote on the proposed transaction or any matter related thereto. The full text of Jefferies' written opinion, dated September 24, 2008, is attached as *Annex E* to this proxy statement/prospectus/consent solicitation and is incorporated into this proxy statement/prospectus/consent solicitation by reference. Nuvelo urges its stockholders to read carefully Jefferies' entire opinion. See the section captioned "The Merger Opinion of Nuvelo's Financial Advisor" beginning on page 85.**

### **Overview of the Merger Agreement**

#### ***Merger Consideration (see page 107)***

At the effective time of the merger, each share of ARCA capital stock not held by Nuvelo, or any subsidiary of Nuvelo, shall be converted into a right to receive a number of shares of Nuvelo common stock equal to the Exchange Ratio. The Exchange Ratio is determined immediately prior to the effective time of the merger by dividing 109,009,278 by the number of shares of ARCA common stock outstanding and deemed to be outstanding pursuant to a formula set forth in the merger agreement.

Pursuant to the terms of the merger agreement, ARCA and Nuvelo have agreed upon a methodology to determine the shares of ARCA common stock outstanding and deemed outstanding which is dependent on the number of shares of ARCA capital stock outstanding and issuable upon the conversion of ARCA's outstanding preferred stock and convertible notes and the exercise of ARCA's outstanding options and warrants as well as the average closing price of Nuvelo's common stock for the five trading days preceding the date the merger is consummated. For illustration purposes, assuming the merger closed on November 19, 2008, and based on the respective capitalizations of Nuvelo and ARCA on November 19, 2008, the Exchange Ratio would have been 3.3395 per share of ARCA capital stock. Nuvelo and ARCA have used this assumed Exchange Ratio of 3.3395 elsewhere in this proxy statement/prospectus/consent solicitation to reflect, for illustration purposes, the effect of

## **Table of Contents**

the merger. The Exchange Ratio will be recalculated for the actual closing date of the merger using updated information.

Immediately after the merger, based on the Exchange Ratio, existing ARCA stockholders will own approximately 67% of the common stock of the combined company and Nuvelo stockholders will own approximately 33% of the common stock of the combined company, after giving effect to the issuance of shares of ARCA capital stock issuable upon exercise of options and warrants outstanding immediately prior to the effective time, primarily on a treasury stock basis, and without giving effect to options and warrants to purchase Nuvelo common stock outstanding immediately prior to the effective time.

The Exchange Ratio is subject to proportionate adjustment to account for the effect of the reverse stock split of Nuvelo's issued and outstanding common stock.

### ***Conditions to Completion of Merger (see page 110)***

Each party's obligation to complete the merger is subject to a number of conditions, which may be waived by the applicable party, and that include, among others, and subject to specified exceptions, the following:

stockholders of ARCA must have approved the merger and adopted the merger agreement, and stockholders of Nuvelo must have approved the issuance of Nuvelo common stock in the merger and the amendment to the certificate of incorporation of Nuvelo to effect the reverse stock split;

no temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Merger shall have been issued by any court of competent jurisdiction or other governmental body and remain in effect, and there shall not be any legal requirement enacted or deemed applicable to the merger that makes consummation of the merger illegal;

the initial listing application on any of the Nasdaq Global Select Market, Nasdaq Global Market or Nasdaq Capital Market shall have been conditionally approved, and the shares of Nuvelo common stock to be issued in the merger shall be conditionally approved for listing on any of such markets, both subject only to the completion of the closing and completion by Nuvelo of any reverse stock split required by Nasdaq; and

since the signing of the merger agreement, there shall not have occurred and be continuing any material adverse effect for either party.

### ***Limitation on Soliciting, Discussing or Negotiating Other Acquisition Proposals (see page 114)***

Pursuant to the merger agreement, each of Nuvelo and ARCA agreed that, except as described below, they will not, during the pre-closing period, directly or indirectly:

solicit, initiate, knowingly encourage, induce or facilitate the making, submission or announcement of any acquisition proposal or acquisition inquiry, each as defined in the merger agreement and explained in this proxy statement/prospectus/consent solicitation, or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry;

furnish any nonpublic information regarding ARCA or Nuvelo, as the case may be, or any of its subsidiaries, to any person in connection with or in response to an acquisition proposal or acquisition inquiry;

engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry;

approve, endorse or recommend any acquisition proposal or acquisition inquiry; or

**Table of Contents**

enter into any letter of intent or similar document or any contract contemplating or otherwise relating to any acquisition transaction. Notwithstanding the foregoing, prior to obtaining the consent of their stockholders, either party may furnish information regarding such party to, and may enter into discussions or negotiations with, any third party in response to a bona fide written acquisition proposal made or received after the date of the merger agreement, which such party's board of directors determines in good faith, after consultation with a nationally recognized independent financial advisor and its outside legal counsel, constitutes or is reasonably likely to result in a superior offer, (as defined in the merger agreement and explained in this proxy statement/prospectus/consent solicitation), if:

neither such party nor any representative of such party has breached the no solicitation provisions of the merger agreement described above;

such party gives the other party at least two business days' prior notice of the identity of the third party and of their intention to furnish information to, or enter into discussions or negotiations with, such third party before furnishing any information or entering into discussions or negotiations with such person, and such party receives from the third party an executed confidentiality agreement; and

at least two business days' prior to the furnishing of any information to a third party, the other party furnishes the same information to the other party to the extent not previously furnished.

***Termination of the Merger Agreement (see page 119)***

The merger agreement may be terminated prior to the effective time of the merger (whether before or after adoption of the merger agreement by ARCA's stockholders and whether before or after approval of the issuance of Nuvelo common stock in the merger by Nuvelo's stockholders):

by mutual written consent of Nuvelo and ARCA, duly authorized by their respective boards of directors;

subject to certain limitations, by either Nuvelo or ARCA if the merger shall not have been consummated by February 28, 2009;

by either Nuvelo or ARCA if a court of competent jurisdiction or other governmental body shall have issued a final and nonappealable order, or shall have taken any other final and nonappealable action, having the effect of permanently restraining, enjoining or otherwise prohibiting the consummation of the merger;

by either Nuvelo or ARCA if Nuvelo's stockholders fail to approve the issuance of the Nuvelo common stock pursuant to the merger agreement at the special meeting;

subject to certain limitations, by either party in the event of any inaccuracy of representations and warranties of the other party having a material adverse effect or a material breach by the other party of its obligations or covenants under the merger agreement;

subject to certain conditions, by Nuvelo immediately prior to entering into a definitive agreement with respect to a superior offer; or

subject to certain conditions, by ARCA immediately prior to entering into a definitive agreement with respect to a superior offer.



---

**Table of Contents**

***Termination Fees and Expenses (see page 121)***

Nuvelo must pay ARCA a nonrefundable fee of \$947,112 and reimburse ARCA for up to \$500,000 in actual out of pocket legal, accounting and investment advisory fees paid or payable in connection with the transactions contemplated by the merger agreement if:

the merger agreement is terminated by Nuvelo immediately prior to Nuvelo entering into a definitive agreement with respect to a transaction that constitutes a superior offer; or

the merger agreement is terminated by Nuvelo or ARCA if the stockholders of Nuvelo do not approve the issuance of Nuvelo common stock at the Nuvelo special meeting of stockholders, and all of the following conditions are met:

prior to the Nuvelo special meeting of stockholders, an acquisition proposal with respect to Nuvelo has been publicly made and not withdrawn;

within nine months of such termination, Nuvelo enters into a definitive agreement to consummate an acquisition transaction with a party other than ARCA; and

such acquisition transaction is consummated pursuant to such definitive agreement.

ARCA must pay Nuvelo a nonrefundable fee of \$1,922,924 and reimburse Nuvelo for up to \$500,000 in actual out of pocket legal, accounting and investment advisory fees paid or payable in connection with the transactions contemplated by the merger agreement if the merger agreement is terminated by ARCA immediately prior to ARCA entering into a definitive agreement with respect to a transaction that constitutes a superior offer.

***Voting Agreements (see page 123)***

In order to induce Nuvelo to enter into the merger agreement, several ARCA stockholders entered into voting agreements with and granted irrevocable proxies in favor of Nuvelo pursuant to which, among other things, each of these stockholders agreed, solely in its capacity as a stockholder, to vote all of its shares of ARCA capital stock and other ARCA securities in favor of the merger, the execution and delivery by ARCA of the merger agreement and the adoption and approval of the merger agreement and the terms thereof, in favor of each of the other actions contemplated by the merger agreement and in favor of any action in furtherance of any of the foregoing, and against, among other things, any proposal made in opposition to, or in competition with, the merger.

As of October 31, 2008, the stockholders of ARCA that entered into voting agreements collectively owned 3,553,635 shares of common stock and 16,785,136 shares of preferred stock of ARCA, on an as converted basis, representing approximately 84.97% of the outstanding capital stock of ARCA, including approximately 92.11% of ARCA's outstanding preferred stock, on an as converted basis, of ARCA. All of these stockholders are executive officers, directors, or entities controlled by such persons, or 5% stockholders, of ARCA, and include all of the Principal Series Preferred Stockholders.

Under these voting agreements executed by ARCA stockholders, subject to certain exceptions, such stockholders also have agreed not to sell or transfer ARCA capital stock and securities held by them, or any voting rights with respect thereto, until the earlier of the termination of the merger agreement or the completion of the merger. To the extent that any such sale or transfer is permitted pursuant to the exceptions included in the voting agreement, each person to which any shares of ARCA capital stock or securities are so sold or transferred must agree in writing to be bound by the terms and provisions of the voting agreement.

In addition, in order to induce ARCA to enter into the merger agreement, several Nuvelo stockholders entered into voting agreements with and granted irrevocable proxies in favor of ARCA pursuant to which, among





**Table of Contents**

other things, each of these stockholders agreed, solely in his capacity as a stockholder, to vote all of his shares of Nuvelo common stock in favor of issuance of the shares of Nuvelo common stock in the merger and in favor of the amendment to Nuvelo's amended and restated certificate of incorporation to effect the reverse stock split, and against, among other things, any proposal made in opposition to, or in competition with, the merger.

These Nuvelo stockholders also granted ARCA an irrevocable proxy to their respective shares in accordance with the voting agreement. These Nuvelo stockholders may vote their shares of Nuvelo common stock on all other matters not referred to in such proxy.

As of November 11, 2008, the stockholders of Nuvelo that entered into voting agreements owned in the aggregate number of shares of Nuvelo common stock representing approximately 0.29% of the outstanding Nuvelo common stock.

**Management of the Combined Company After the Merger (see page 197)**

Following the merger, the executive management team of the combined company is expected to be composed of the following individuals:

<b>Name</b>	<b>Position in the Combined Company</b>	<b>Current Position</b>
Richard B. Brewer	Chief Executive Officer	ARCA, President and CEO and Director
Michael R. Bristow, M.D., Ph.D.	Chief Science and Medical Officer	ARCA, Chairman and Chief Science and Medical Officer
Joseph L. Turner	Chief Financial Officer	ARCA, expected to join ARCA as its Chief Financial Officer prior to the closing of the proposed merger
Christopher Ozeroff	Executive Vice President of Business Development and General Counsel	ARCA, Executive Vice President of Business Development and General Counsel
Randall St. Laurent	Executive Vice President of Commercial Operations	ARCA, Executive Vice President of Commercial Operations

Following the merger, Lee Bendekgey, Nuvelo's Sr. Vice President, Chief Financial Officer and General Counsel, will serve as the combined company's Principal Accounting Officer on a transitional basis, but will not be an executive officer of the combined company.

**Table of Contents**

**The Board of Directors Following the Merger (see page 197)**

Following the merger, the board of directors of the combined company will be as follows:

<b>Name</b>	<b>Current Affiliation</b>
Richard B. Brewer	ARCA, President and CEO and Director
Michael R. Bristow, M.D., Ph.D.	ARCA, Chairman and Chief Science and Medical Officer
Jean-François Formela, MD	Atlas Venture, Partner, and ARCA Director
J. William Freytag, Ph.D.	Freytag Holdings LLC, President, and ARCA Director
Ted W. Love, M.D.	Nuvelo, Chairman and CEO
Mary K. Pendergast	Pendergast Consulting, President, and Nuvelo Director
Burton E. Sobel, M.D.	University of Vermont and Fletcher Allen Health Care, Professor of Medicine and Biochemistry and Director of Cardiovascular Center, and Nuvelo Director
John L. Zabriskie, Ph.D.	Puretech Ventures, LLC, Co-Founder and Director, and ARCA Director
David G. Lowe, Ph.D.	Skyline Ventures, Managing Director, and ARCA Director
Linda Graiss, M.D.	InterWest Management Partners IX, LLC, Venture Member, InterWest Partners IX, LP, General Partner, and ARCA Director

**Interests of Nuvelo's Executive Officers and Directors (see page 94)**

In considering the recommendation of the Nuvelo board of directors with respect to issuing shares of Nuvelo common stock as contemplated by the merger agreement, Nuvelo stockholders should be aware that certain members of the board of directors and executive officers of Nuvelo have interests in the merger that are different from, or in addition to, their interests as Nuvelo stockholders. These interests present a conflict of interest. The Nuvelo board of directors was aware of these conflicts of interest during its deliberations on the merits of the merger and in making its decision in approving the merger, the merger agreement, the amendments to Nuvelo's certificate of incorporation and the related transactions.

**Interests of ARCA's Executive Officers and Directors (see page 97)**

In considering the recommendation of the ARCA board of directors with respect to approving the adoption of the merger agreement, ARCA stockholders should be aware that certain members of the board of directors and executive officers of ARCA have interests in the merger that are different from, or in addition to, their interests as ARCA stockholders. These interests present a conflict of interest. The ARCA board of directors was aware of these conflicts of interest during its deliberations on the merits of the merger and in making its decision in approving the merger, the merger agreement and the transactions contemplated thereby.

---

**Table of Contents****Stock Options and Warrants (see page 100)**

Each option and warrant to purchase ARCA capital stock outstanding at the effective time of the merger shall be assumed by Nuvelo to the extent not previously exercised. Each such option or warrant shall be converted into a option or warrant, as applicable, to acquire that number of shares of Nuvelo common stock equal to the product obtained by multiplying (i) the number of shares of ARCA capital stock (on an as converted basis) subject to such option or warrant by (ii) the Exchange Ratio, rounded down to the nearest whole share of Nuvelo common stock. Each such option or warrant shall have a purchase price per share of Nuvelo common stock equal to the quotient obtained by dividing (x) the per share purchase price of ARCA capital stock (as adjusted for the conversion of such capital stock into common stock, as applicable) subject to such option or warrant by (y) the Exchange Ratio rounded up to the nearest whole cent. Each such option or warrant shall otherwise be subject to the same terms and conditions (including as to vesting and exercisability) as were applicable under the respective option or warrant to purchase ARCA capital stock immediately prior to the effective time of the merger. Subject to ARCA stockholder approval, prior to the effective time of the merger, ARCA plans to amend its 2004 Stock Incentive Plan, or the ARCA Plan, to increase the number of shares of ARCA common stock reserved and available for awards under the ARCA Plan by up to 2,000,000 shares to a maximum of 8,356,550. ARCA anticipates granting additional option awards prior to the effective time of the merger. Shares of ARCA common stock reserved for awards but not covered by awards made prior to the effective time of the merger will not be assumed by Nuvelo, and after such effective time, no further awards can be made under the ARCA Plan.

**Conversion of Convertible Notes (see page 125)**

As agreed to in the merger agreement, ARCA entered into a Note and Warrant Purchase Agreement dated September 24, 2008, as amended on October 10, 2008 with certain holders of ARCA preferred stock pursuant to which ARCA sold, for an aggregate consideration of \$8.75 million, its 6% Convertible Promissory Notes due March 31, 2009, or the Notes, and warrants, or the Warrants, to purchase a number of shares of ARCA's common stock as determined pursuant to the Warrants. The outstanding principal and accrued interest on the Notes will convert into that number of shares of ARCA common stock immediately prior to the closing of the merger equal to the amount of unpaid principal and interest due as of the date of conversion divided by the conversion price. The conversion price is equal to the lesser of: (i) \$3.253 or (ii) the product of (a) the average closing price of Nuvelo common stock on the Nasdaq Global Market for the five consecutive trading days immediately preceding (but not including) the date the merger is consummated and (b) the Exchange Ratio; provided, however that in no event will the conversion price be less than \$1.6265. The number of shares of ARCA common stock subject to the Warrants issued in the convertible bridge note financing is calculated by dividing (i) 20% of the sum of the principal amount of each Note plus the consideration paid for the associated Warrants by (ii) the conversion price for the Notes. The Warrants have an exercise price equal to the conversion price and have a five-year exercise period. Assuming the lowest conversion price possible under the Notes, the Warrants will be exercisable for an aggregate of 1,075,933 shares of ARCA common stock.

**Conversion of Preferred Stock (see page 100)**

In accordance with the Series A Preferred Stock Purchase Agreement, the Series B Preferred Stock Purchase Agreement and the Supplemental Agreement to Series B Preferred Stock Purchase Agreement, ARCA issued shares of its preferred stock to certain investors. Each share of Series A preferred stock will convert immediately prior to the merger into one share of ARCA common stock. Each share of Series B-1 and Series B-2 preferred stock will convert immediately prior to the merger into a number of shares of ARCA common stock equal to the original issue price for such share divided by the then effective conversion price for the Series B-1 or Series B-2 share, as applicable. The issuance of the notes and warrants under the Note and Warrant Purchase Agreement results in adjustments to the conversion prices for the Series B-1 and Series B-2 preferred stock in accordance with the anti-dilution provisions in ARCA's amended and restated certificate of incorporation, as amended,

---

## **Table of Contents**

which we refer to as the Restated Certificate. The amount of the adjustments depends on the actual conversion price for the notes, which will not be determined until the closing of the merger. See *Agreements Related to the Merger Note and Warrant Purchase Agreement*. However, in no event will the conversion price for the notes be less than \$1.6265 and in no event will the adjusted conversion prices for the Series B-1 and Series B-2 preferred stock be less than \$2.00, as set forth in ARCA's Restated Certificate.

### **Material U.S. Federal Income Tax Consequences of the Merger (see page 104)**

The merger has been structured to qualify as a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended, or the Code, and it is a closing condition to the merger that Nuvelo and ARCA receive opinions of their respective counsel regarding such qualification. There will be no U.S. federal income tax consequences to Nuvelo stockholders as a result of the merger. Assuming that the merger qualifies as a reorganization, ARCA stockholders will not recognize gain or loss for U.S. federal income tax purposes upon the exchange of shares of ARCA capital stock for shares of Nuvelo common stock, except with respect to cash received in lieu of fractional shares of Nuvelo common stock. Tax matters are highly complex, and the tax consequences of the merger to a particular ARCA stockholder will depend in part on such stockholder's circumstances. Accordingly, you are urged to consult your own tax advisor for a full understanding of the tax consequences of the merger to you, including the applicability and effect of federal, state, local and foreign income and other tax laws.

### **Risk Factors (see page 28)**

Both Nuvelo and ARCA are subject to various risks associated with their businesses and their industries, and the combined company will also be subject to those and other risks. In addition, the merger poses a number of risks to each company and its stockholders, including the following risks:

Some of Nuvelo's and ARCA's officers and directors have interests in the merger that may be different from yours and influence them to support or approve the merger.

The merger may be completed even though material adverse changes may result from the announcement of the merger, economic or industry-wide changes and other causes.

Nuvelo's and ARCA's stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger.

Negative perceptions regarding the pending merger may harm either Nuvelo's or ARCA's business and employee relationships.

### **Regulatory Approvals (see page 101)**

As of the date of this proxy statement/prospectus/consent solicitation, neither Nuvelo nor ARCA is required to obtain approvals or clearances from any antitrust regulatory authorities in the United States or other countries to consummate the merger. In the United States, Nuvelo must comply with applicable federal and state securities laws and Nasdaq rules and regulations in connection with the issuance of shares of Nuvelo common stock in the merger and the filing of this proxy statement/prospectus/consent solicitation. Nuvelo has filed an initial listing application with the Nasdaq Global Market pursuant to Nasdaq's reverse merger rules to effect the initial listing of Nuvelo's common stock issuable in connection with the merger.

### **Anticipated Accounting Treatment (see page 106)**

The merger will be treated by Nuvelo as a reverse merger and will be accounted for as a business combination using the acquisition method of accounting in accordance with U.S. generally accepted accounting principles. For accounting purposes, ARCA is considered to be acquiring Nuvelo in this transaction.



**Table of Contents**

**Appraisal Rights (see page 101)**

Nuvelo's stockholders are not entitled to appraisal rights in connection with the merger or any of the proposals to be voted on at the special meeting.

ARCA's stockholders are entitled to appraisal rights if they do not consent to the adoption of the merger agreement and they comply with the conditions established by Section 262 of the DCGL.

**Comparison of Stockholder's Rights (see page 236)**

Both Nuvelo and ARCA are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the merger is completed, ARCA's stockholders will become stockholders of Nuvelo, and their rights will be governed by the DCGL, the certificate of incorporation and the bylaws of Nuvelo, as they may be amended. The rights of Nuvelo's stockholders contained in the certificate of incorporation and bylaws of Nuvelo differ from the rights of ARCA's stockholders under the certificate of incorporation and bylaws of ARCA.

**Table of Contents****MARKET PRICE AND DIVIDEND INFORMATION****Nuvelo**

Nuvelo's common stock is listed on the Nasdaq Global Market under the symbol NUVO. Prior to July 2006, Nuvelo's common stock traded on the Nasdaq National Market, the predecessor to the Nasdaq Global Market. The following table sets forth, for the periods indicated, the high and low per share sales prices for Nuvelo's common stock as reported on Nasdaq.

**Nuvelo Common Stock**

	High	Low
<b>Year Ended December 31, 2006</b>		
First Quarter	\$ 18.71	\$ 8.16
Second Quarter	18.20	14.15
Third Quarter	20.98	15.13
Fourth Quarter	20.37	3.35
<b>Year Ended December 31, 2007</b>		
First Quarter	\$ 4.12	\$ 3.04
Second Quarter	6.63	2.55
Third Quarter	3.03	1.52
Fourth Quarter	2.70	1.26
<b>Year Ended December 31, 2008</b>		
First Quarter	\$ 1.88	\$ 0.55
Second Quarter	0.97	0.55
Third Quarter	0.75	0.34
Fourth Quarter (through November 21, 2008)	0.47	0.21

On September 24, 2008, the last day prior to the public announcement of the merger, the closing price per share of Nuvelo's common stock as reported on the Nasdaq Global Market was \$0.40, for an aggregate market value of Nuvelo of approximately \$21.5 million. Accordingly, if the merger had been consummated on that day, the value attributable to the shares of Nuvelo's common stock issued or issuable to holders of ARCA's outstanding common stock, preferred stock, options, warrants and convertible notes in connection with the merger would have been approximately \$43.6 million, based on approximately 109 million shares of Nuvelo's common stock issued or issuable in the merger, multiplied by \$0.40.

On November 21, 2008, the last practicable date before the printing of this proxy statement/prospectus/consent solicitation, the closing price per share of Nuvelo's common stock as reported on the Nasdaq Global Market was \$0.27, for an aggregate market value of Nuvelo of approximately \$14,489,227. Accordingly, if the merger had been consummated on that day, the value attributable to the shares of Nuvelo's common stock issued to holders of ARCA's common stock, preferred stock, options, warrants and convertible notes in connection with the merger would have been approximately \$30,373,967, based on approximately 112,496,177 shares of Nuvelo's common stock issued or issuable in the merger multiplied by \$0.27.

Because the market price of Nuvelo's common stock is subject to fluctuation, the market value of the shares of Nuvelo's common stock that holders of ARCA's common stock, preferred stock, options, warrants and convertible notes will be entitled to receive in the merger may increase or decrease.

Shares of Nuvelo common stock are currently listed on the Nasdaq Global Market under the symbol NUVO. Following the merger, the combined company is expected to be renamed ARCA biopharma, Inc. and to change its symbol for trading on the Nasdaq Global Market. ARCA has reserved the symbol ABIO for this purpose.



**Table of Contents**

Nuvelo has never declared or paid cash dividends on its capital stock. Nuvelo currently intends to retain earnings, if any, to finance the growth and development of its business, and does not expect to pay any cash dividends to its stockholders in the foreseeable future. Payment of future dividends, if any, will be at the discretion of Nuvelo's board of directors.

As of the record date of November 11, 2008, there were approximately 190 holders of record of Nuvelo common stock.

**ARCA**

ARCA is a privately-held company and its shares are not publicly traded.

ARCA has never declared or paid any cash dividends on its capital stock nor does it intend to do so in the foreseeable future.

As of November 20, 2008, there were approximately 53 holders of record of ARCA common stock and preferred stock.

**Table of Contents****SELECTED HISTORICAL FINANCIAL DATA****Nuvelo Selected Historical Consolidated Financial Data**

The statements of operations data for the years ended December 31, 2007, 2006 and 2005 and the balance sheet data as of December 31, 2007 and 2006 are derived from Nuvelo's audited consolidated financial statements, which are included in this proxy statement/prospectus/consent solicitation beginning on page F-15. The statements of operations data for the nine months ended September 30, 2008 and 2007 and the balance sheet data as of September 30, 2008 are derived from Nuvelo's unaudited consolidated financial statements, which are included in this proxy statement/prospectus/consent solicitation beginning on page F-2. The unaudited financial data as of September 30, 2008 and for the nine months ended September 30, 2008 and 2007 include all adjustments (consisting only of normal recurring adjustments) that Nuvelo considers necessary for a fair presentation of the financial position and operating results for the periods presented. The statements of operations data for the years ended December 31, 2004 and 2003 and the balance sheet data as of December 31, 2005, 2004 and 2003 are derived from Nuvelo's audited consolidated financial statements, which are not included in this proxy statement/prospectus/consent solicitation. Historical results are not necessarily indicative of future results, and results for any interim period are not necessarily indicative of results to be expected for a full fiscal year. The following selected historical consolidated financial data should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations for Nuvelo and Nuvelo's consolidated financial statements and related notes thereto included in this proxy statement/prospectus/consent solicitation.

	Nine Months Ended		Year Ended December 31,				
	September 30, 2008 (Unaudited)	2007	2007	2006	2005	2004	2003
(In thousands, except per share amounts)							
<b>Statement of Operations Data:</b>							
Contract revenues	\$ 15,188	\$ 46,798	\$ 46,861	\$ 3,888	\$ 545	\$ 195	\$ 1,024
Operating expenses:							
Research and development	24,555	33,452	42,654	89,370	57,778	39,970	30,014
General and administrative	11,359	16,843	20,762	30,632	15,805	8,869	16,294
Restructuring	2,470	2,336	2,336				
Facility exit charges	1,472			24,460			
Impairment of goodwill	4,671						
Total operating expenses	44,527	52,631	65,752	144,462	73,583	48,839	46,308
Operating loss	(29,339)	(5,833)	(18,891)	(140,574)	(73,038)	(48,644)	(45,284)
Interest and other income	2,186	5,269	6,693	8,385	2,431	1,063	458
Interest expense	(4)	(101)	(103)	(588)	(1,004)	(1,361)	(1,403)
Loss from continuing operations	(27,157)	(665)	(12,301)	(132,777)	(71,611)	(48,942)	(46,229)
Discontinued operations, including loss on disposal						(3,547)	(3,958)
Loss before cumulative effect of change in accounting principle	(27,157)	(665)	(12,301)	(132,777)	(71,611)	(52,489)	(50,187)
Cumulative effect of change in accounting principle				2,224			
Net loss	\$ (27,157)	\$ (665)	\$ (12,301)	\$ (130,553)	\$ (71,611)	\$ (52,489)	\$ (50,187)
Basic and diluted net loss per share:							
Loss from continuing operations	\$ (0.51)	\$ (0.01)	\$ (0.23)	\$ (2.58)	\$ (1.73)	\$ (1.59)	\$ (2.20)
Discontinued operations						(0.11)	(0.19)
Cumulative effect of change in accounting principle				0.04			
Basic and diluted net loss per share	\$ (0.51)	\$ (0.01)	\$ (0.23)	\$ (2.54)	\$ (1.73)	\$ (1.70)	\$ (2.38)

Edgar Filing: NUVELO INC - Form S-4/A

Weighted average shares used in computing basic and diluted net loss per share	53,536	53,310	53,333	51,451	41,279	30,874	21,054
--	--------	--------	--------	--------	--------	--------	--------

**Table of Contents**

	September 30, 2008 (Unaudited)	2007	2006	December 31, 2005	2004	2003
(In thousands)						
<b>Balance Sheet Data:</b>						
Cash and cash equivalents, marketable securities and restricted cash	\$ 65,132	\$ 103,567	\$ 153,126	\$ 70,336	\$ 50,625	\$ 34,189
Working capital	46,572	81,799	122,496	49,582	45,261	25,772
Total assets	75,399	120,683	184,405	108,046	79,264	57,809
Bank loans			1,492	3,032	2,600	
Notes payable				4,000	4,000	6,600
Related party line of credit			2,292	5,042	7,792	10,542
Other non-current liabilities	16,339	34,837	70,598	11,315	1,992	6,631
Accumulated deficit	(497,670)	(470,513)	(458,212)	(327,659)	(256,048)	(203,559)
Total stockholders' equity	44,715	67,659	69,843	56,764	45,589	22,701
<b>ARCA Selected Historical Financial Data</b>						

The statements of operations data for the years ended December 31, 2007, 2006 and 2005 and the balance sheet data as of December 31, 2007 and 2006 were derived from ARCA's audited financial statements which are included in this proxy statement/prospectus/consent solicitation beginning on page F-45. The statements of operations data for the years ended December 31, 2004 and 2003 and the balance sheet data as of December 31, 2005, 2004 and 2003 were derived from both ARCA's audited and unaudited financial statements which are not included in this proxy statement/prospectus/consent solicitation. The statement of operations data for the nine months ended September 30, 2008 and 2007 and for the period from inception, December 17, 2001, through September 30, 2008, and the balance sheet data as of September 30, 2008 were derived from ARCA's unaudited financial statements which are included in this proxy statement/prospectus/consent solicitation beginning on page F-45.

The unaudited pro forma basic and diluted weighted average shares outstanding and net loss per common share data for the year ended December 31, 2007 and for the nine-month period ended September 30, 2008 reflect the mandatory conversion, upon the consummation of the proposed merger, of all outstanding shares of preferred stock at their respective conversion rates then in effect into shares of ARCA common stock, as if the conversion had occurred on January 1, 2007 or the date of issuance, if later.

Historical results are not necessarily indicative of future results and results for any interim periods are not necessarily indicative of results for a full fiscal year.

**Table of Contents**

The following selected historical financial data should be read in conjunction with ARCA's Management's Discussion and Analysis of Financial Condition and Results of Operations for ARCA and ARCA's financial statements and related notes thereto included in this proxy statement/prospectus/consent solicitation. ARCA is considered to be a development stage company for financial reporting purposes.

	Nine Months Ended September 30,		Year Ended December 31,					Period from December 17, 2001 (date of inception) to September 30, 2008
	2008 (Unaudited)	2007 (Unaudited)	2007	2006	2005	2004	2003 (Unaudited)	(Unaudited)
<b>Statement of operations data:</b>								
Operating expenses:								
Research and development	\$ 8,363	\$ 7,270	\$ 10,244	\$ 3,978	\$ 846	\$ 60	\$	\$ 23,491
General and administrative	6,037	3,332	4,210	1,545	569	444	134	12,971
Loss from operations	(14,400)	(10,602)	(14,454)	(5,523)	(1,415)	(504)	(134)	(36,462)
Other income (expense), net	144	355	460	282	(44)	(7)	18	885
Net loss	\$ (14,256)	\$ (10,247)	\$ (13,994)	\$ (5,241)	\$ (1,459)	\$ (511)	\$ (116)	\$ (35,577)
Less: Accretion of redeemable convertible preferred stock	(42)	(25)	(37)	(17)				(97)
Net loss attributable to common stockholders	\$ (14,298)	\$ (10,272)	\$ (14,031)	\$ (5,258)	\$ (1,459)	\$ (511)	\$ (116)	\$ (35,674)
Basic and diluted net loss attributable to common stockholders per share	\$ (3.29)	\$ (2.73)	\$ (3.71)	\$ (1.62)	\$ (1.16)	\$ (1.88)	\$ (1.24)	
Weighted average shares outstanding basic and diluted	4,343	3,769	3,781	3,247	1,258	272	93	
Pro forma basic and diluted net loss attributable to common stockholders per share (unaudited)	\$ (0.71)		\$ (0.92)					
Pro forma weighted average shares outstanding basic and diluted (unaudited)	20,020		15,189					

	As of September 30,		As of December 31,				
	2008 (Unaudited)	2007	2006	2005	2004	2003 (Unaudited)	
<b>Balance sheet data:</b>							
Cash and cash equivalents	\$ 5,457	\$ 15,862	\$ 9,712	\$ 373	\$ 251	\$ 8	
Working capital	840	12,986	9,010	(745)	(678)	(115)	
Total assets	7,528	16,204	9,941	452	322	8	
Total liabilities	8,492	3,084	766	1,130	941	123	
Redeemable convertible preferred stock	32,851	32,809	14,919				
Accumulated deficit	(35,577)	(21,321)	(7,327)	(2,086)	(627)	(116)	
Total stockholders' deficit	(33,815)	(19,689)	(5,744)	(678)	(619)	(115)	

---

**Table of Contents****SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA**

*The following unaudited pro forma financial data should be read in conjunction with the historical financial statements and the accompanying notes of ARCA and Nuvelo, and the respective Management's Discussion and Analysis of Financial Condition and Results of Operations for Nuvelo, and Management's Discussion and Analysis of Financial Condition and Results of Operations for ARCA, which are included elsewhere in this proxy statement/prospectus/consent solicitation, and the other information contained in this proxy statement/prospectus/consent solicitation. See Where You Can Find More Information beginning on page 259 and the financial statements of Nuvelo and ARCA beginning on pages F-2 and F-44, respectively. The following information does not give effect to the reverse stock split of Nuvelo common stock described in Nuvelo Proposal No. 2.*

The following selected unaudited pro forma condensed combined financial information presents the effect of the merger of Nuvelo and ARCA pursuant to the merger agreement. For accounting purposes, ARCA is considered to be acquiring Nuvelo in the merger. The following unaudited pro forma condensed combined balance sheet data assume that the merger took place on September 30, 2008, and combine the ARCA historical balance sheet at September 30, 2008 with the Nuvelo historical condensed consolidated balance sheet at September 30, 2008 and \$8.75 million of notes payable issued by ARCA in October 2008, which convert into common stock upon the closing of the proposed merger. The unaudited pro forma condensed combined statement of operations data assume that the merger took place as of January 1, 2007, and combine the historical results of Nuvelo and ARCA for the nine months ended September 30, 2008 and the year ended December 31, 2007. The ARCA balance sheet information was derived from its unaudited balance sheet as of September 30, 2008 included herein. The Nuvelo balance sheet information was derived from its unaudited condensed consolidated balance sheet included in its Form 10-Q for the quarterly period ended September 30, 2008 and also included herein. The historical results of ARCA were derived from its unaudited statement of operations for the nine months ended September 30, 2008 and its audited statement of operations for the year ended December 31, 2007 included herein. The historical results of Nuvelo were derived from its unaudited condensed consolidated statement of operations for the nine months ended September 30, 2008 included in its Form 10-Q for the quarterly period ended September 30, 2008, and its audited consolidated statement of operations included in its Annual Report on Form 10-K for the year ended December 31, 2007, which are also included herein.

The selected unaudited pro forma condensed combined financial data are presented for illustrative purposes only and are not necessarily indicative of the combined financial position or results of operations of future periods or the results that actually would have been realized had the entities been a single entity during these periods. The selected unaudited pro forma condensed combined financial data as of and for the nine months ended September 30, 2008 and for the year ended December 31, 2007 are derived from the unaudited pro forma condensed combined financial information appearing elsewhere in this proxy statement/prospectus/consent solicitation, and should be read in conjunction with that information. In the selected unaudited pro forma condensed combined financial data included in the proxy statement/prospectus/consent solicitation filed on October 30, 2008, the proposed merger transaction was presented as a business combination using the purchase method of accounting in accordance with Statement of Financial Accounting Standards No. 141, *Business Combinations*, as the transaction was assumed to be consummated on or before December 31, 2008. The stockholders' meeting and consummation of the transaction is now expected to be in the first quarter of 2009; therefore, the transaction is being presented in the selected unaudited pro forma condensed combined financial data using the acquisition method of accounting in accordance with Statement of Financial Accounting Standards No. 141R, *Business Combinations*. Please see Note 2 to the unaudited pro forma condensed combined financial statements.

For purposes of the unaudited pro forma condensed combined financial statements, presented elsewhere herein, Nuvelo and ARCA have made allocations of the estimated acquisition consideration to the assets to be acquired and liabilities to be assumed based on preliminary estimates of their fair value. A final determination of these estimated fair values, which cannot be made prior to the completion of the merger, will be based on the actual net assets of Nuvelo that exist as of the date of consummation of the merger. The actual amounts recorded

**Table of Contents**

as of the consummation of the merger may differ materially from the information presented in the unaudited pro forma condensed combined financial statements as a result of:

net cash used in the Nuvelo operations between the pro forma balance sheet date of September 30, 2008 and the closing of the merger;

a change in the fair value of Nuvelo's common stock;

the timing of completion of the merger;

a change in the methodology used to account for the consideration transferred; and

other changes in the Nuvelo net assets that may occur prior to completion of the merger, which could cause material differences in the information presented below.

The estimated acquisition consideration of the Nuvelo acquisition in the unaudited pro forma condensed combined financial statements was based on the market capitalization of Nuvelo as of September 30, 2008, the date on which the proposed merger occurred for purposes of the pro forma financial statements, and the fair values of its vested stock options and warrants outstanding on that date. This was deemed the best estimate of the fair value of Nuvelo as the entity being acquired for accounting purposes on that date and the consideration paid in the transaction. The September 30, 2008 balance sheet of Nuvelo reflected approximately \$59 million of cash, cash equivalents, and marketable securities, and aggregate net assets with a fair value of approximately \$46 million, which significantly exceeded Nuvelo's market capitalization at that date. The application of the rules governing the preparation of the unaudited pro forma condensed combined balance sheet results in significant excess of fair value of acquired net assets over acquisition consideration, on a pro forma basis, which would be recognized as a gain on bargain purchase upon consummation.

The final acquisition consideration allocation will differ significantly from preliminary estimates. The actual acquisition accounting upon consummation of the merger will be based on the fair value of the consideration paid and fair values of Nuvelo's assets and liabilities as determined at the time of consummation. Nuvelo's market capitalization has experienced significant fluctuations during 2008 as a result of market and company-specific factors, and such fluctuations may continue. Further, Nuvelo continues to use its cash and other liquid assets to finance its ongoing operations. As a result, at the date the merger is consummated, Nuvelo's cash, cash equivalents, and marketable securities are expected to be significantly less than at September 30, 2008, and its market capitalization cannot be predicted. ARCA and Nuvelo will re-evaluate the accounting method used to determine the consideration at the time of merger consummation, taking into consideration Nuvelo's market capitalization at the time of consummation, and may consider alternative approaches, such as basing the acquisition consideration on the fair value of Nuvelo's net assets, or based on the fair value of ARCA's common and redeemable convertible preferred stock, rather than Nuvelo's common stock. ARCA and Nuvelo do not anticipate that the final acquisition accounting performed when the merger is consummated will result in a significant gain on bargain purchase amount because the proposed merger is not considered a bargain purchase transaction. Please see Note 2 to the unaudited pro forma condensed combined financial statements for further discussion.

	Nine Months Ended September 30, 2008	Year Ended December 31, 2007
<b>Unaudited Pro Forma Condensed Combined Statement of Operations Data (in thousands, except per share amounts):</b>		
Total revenues(1)	\$ 15,188	\$ 46,861
Research and development expenses	32,999	53,002
Sales, general and administrative expenses	16,887	24,315
Restructuring	2,470	2,336

Edgar Filing: NUVELO INC - Form S-4/A

Facility exit charges	1,472	
Loss from operations	(38,640)	(32,792)
Net loss	(36,314)	(25,742)
Basic and diluted net loss per share	\$ (0.22)	\$ (0.16)



**Table of Contents**

	<b>September 30, 2008</b>
<b><i>Unaudited Pro Forma Condensed Combined Balance Sheet Data (in thousands):</i></b>	
Cash and cash equivalents, marketable securities and restricted cash(2)	\$ 79,339
Working capital(2)	48,009
Total assets(2)	91,164
Accumulated deficit	(20,299)
Total stockholders' equity(2)	48,918

- (1) In the nine months ended September 30, 2008, Nuvelo recorded as revenue \$15.0 million that was received from Bayer HealthCare AG (Bayer) in connection with the termination of its collaboration agreement in June 2007. Following Nuvelo's decision to discontinue further clinical development of alfimeprase, the \$15.0 million, which had been recorded as deferred revenue, was recognized as revenue upon the expiration of the notice period, as defined in the termination agreement with Bayer.

In 2007, Nuvelo recorded as revenue \$45.8 million of the \$50.0 million up-front license fee received from Bayer in January 2006 as a result of the termination of its collaboration agreement in June 2007. The up-front license fee had been recorded as deferred revenue upon receipt and was being recognized on a straight-line basis over the performance period under the agreement, originally estimated to be through September 2020.

- (2) Includes \$8.75 million of notes payable issued by ARCA in October 2008, which convert into common stock upon the closing of the proposed merger.

**Table of Contents****COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA PER SHARE DATA**

*The following information does not give effect to the reverse stock split of Nuvelo common stock described in Nuvelo Proposal No. 2.*

The following information reflects the historical net loss and book value per share of Nuvelo common stock and the historical net loss and book value per share of ARCA common stock in comparison with the unaudited pro forma net loss and book value per share after giving effect to the proposed merger of Nuvelo with ARCA under the acquisition method of accounting. The combined company pro forma per common share data are provided for informational purposes only and are not necessarily indications of the results that would have been achieved had the transaction been completed as of the dates indicated or that may be achieved in the future. We have derived the combined company pro forma per common share data from the unaudited pro forma condensed combined financial statements presented elsewhere in this proxy statement/prospectus/consent solicitation.

You should read the tables below in conjunction with the audited and unaudited financial statements of Nuvelo and the notes related thereto included in this proxy statement/prospectus/consent solicitation and the audited and unaudited financial statements of ARCA and the notes related thereto included in this proxy statement/prospectus/consent solicitation and the unaudited pro forma condensed combined financial information and notes related thereto included elsewhere in this proxy statement/prospectus/consent solicitation.

	<b>Nine Months Ended September 30, 2008</b>	<b>Year Ended December 31, 2007</b>
<b>Nuvelo Historical Per Common Share Data:</b>		
Basic and diluted net loss per share	\$ (0.51)	\$ (0.23)
Book value per share as of the period end	0.83	1.27
<b>ARCA Historical Per Common Share Data:</b>		
Basic and diluted net loss per share	\$ (3.29)	\$ (3.71)
Book value per share as of the period end	(5.92)	(4.45)
<b>Combined Company Pro Forma Per Common Share Data:</b>		
Basic and diluted net loss per share	\$ (0.22)	\$ (0.16)
Book value per share as of the period end	0.30	N/A

---

**Table of Contents**

**RISK FACTORS**

*You should consider the following factors in evaluating whether to approve the proposals described in this proxy statement/prospectus/consent solicitation. These factors should be considered in conjunction with the other information included by Nuvelo and ARCA in this prospectus/proxy statement/consent solicitation.*

**Risks Related to the Proposed Merger and Combined Company**

*Nuvelo and ARCA anticipate that immediately following the merger the business of the combined company will have the same risks associated with ARCA and Nuvelo immediately prior to the merger. As a result, you should give attention to the risk factors set forth below under the headings *Risks Related to ARCA*, *Risks Related to Nuvelo* and the following risks related to the proposed merger and the combined company.*

***If the combined company is not able to successfully develop and commercialize Gencaro, or another product candidate, it may not be able to continue its business operations.***

ARCA and Nuvelo currently have no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly. Following the merger, Gencaro, which is currently the subject of an NDA awaiting FDA approval, will be the combined company's only product candidate at a late stage of clinical development. As a result, the combined company's business is expected to be substantially dependent on its ability to obtain regulatory approval for and successfully commercialize Gencaro in a timely manner.

In addition to Gencaro, the combined company will have two product candidates in clinical trials, NU172 and NU206. These product candidates must be rigorously tested in clinical trials, and be shown to be safe and effective, before the FDA or other regulatory authorities outside the U.S. will consider them for approval. Failure to demonstrate that one or more of the combined company's product candidates is safe and effective, or significant delays in demonstrating such safety and efficacy, could diminish the benefits of the merger. Failure to obtain marketing approval of one or more of the combined company's product candidates from appropriate regulatory authorities, or significant delays in obtaining such approval, could diminish the benefits of the merger. If approved for sale, the combined company's product candidates must be successfully commercialized. Failure to successfully commercialize one or more of the combined company's product candidates could diminish the benefits of the merger, and, in particular, if the NDA for Gencaro is not approved, or is substantially delayed, or if the combined company is unable to successfully commercialize Gencaro, it may not be able to earn sufficient revenues to continue its business.

***If the combined company fails to obtain additional financing, it may be unable to fund its operations and commercialize its product candidates.***

The combined company expects that the cash used in its operations will increase for the next several years, and that it will spend substantial amounts to complete the development, regulatory approval and commercialization of Gencaro and other product candidates and to license or acquire other product candidates. ARCA believes that, if the merger is completed, existing cash and cash equivalents will be sufficient to meet the combined company's projected operating requirements through 2009.

The combined company's future funding requirements will depend on many factors, including:

whether or when Gencaro is approved for sale;

whether or when Gencaro's companion product, the Gencaro companion genetic test, or the Gencaro Test, is approved for sale;

the costs of establishing sales, marketing and distribution capabilities;

---

**Table of Contents**

the terms and timing of any collaborative, licensing and other arrangements that it has or may establish;

cash requirements of any future acquisitions of product candidates;

the scope, results and timing of preclinical studies and clinical trials and other development activities;

the effects of competing clinical, technological and market developments; and

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

Even if the combined company receives FDA approval to commercialize Gencaro, it cannot predict the amount of revenue it will generate from sales of Gencaro. Until the combined company can generate a sufficient amount of product revenue, it expects to finance future cash needs through public or private securities offerings or debt financings. To the extent that additional funds are raised by issuing equity securities, the combined company's stockholders may experience dilution.

If additional debt financing is raised in the future, the combined company may be required to grant any lenders a security interest in all or a portion of its assets and issue warrants to acquire its equity securities, resulting in dilution to its stockholders. In addition, any such debt financing may involve restrictive covenants, including limitations on the combined company's ability to incur additional debt, limitations on its ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact its ability to conduct its business.

The combined company may also be required to:

seek collaborators for its product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and

relinquish, license or otherwise dispose of rights to technologies, product candidates or products that it would otherwise seek to develop or commercialize itself.

Future additional funding may not be available on acceptable terms, or at all. If the combined company is unable to raise additional capital when required or on acceptable terms, then the combined company may have to significantly delay, scale back or discontinue the development or commercialization of one or more of its product candidates.

***The combined company will be relying upon LabCorp to obtain marketing clearance or approval of the companion Gencaro Test. There is no guarantee that the FDA will grant timely clearance or approval of the Gencaro Test, if at all, and failure to obtain such timely clearance or approval would adversely affect the combined company's ability to market Gencaro.***

The drug label being sought for Gencaro would identify the patient receptor genotypes with a likelihood of enhanced efficacy, as well as those with a likelihood of a standard beta-blocker response and the smaller unfavorable subgroup with a low probability of benefit. Accordingly, the combined company believes it will be critical to the successful commercialization of Gencaro to develop a companion genetic test, or the Gencaro Test, that is simple to administer, useful and widely available.

The Gencaro Test is subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome.

Under ARCA's agreement with Laboratory Corporation of America, or LabCorp, LabCorp is responsible for determining the appropriate regulatory pathway for the Gencaro Test and obtaining market clearance or approval from the FDA. Based on FDA guidance, LabCorp plans to submit a PMA regulatory submission in the



---

**Table of Contents**

fourth quarter of 2008. The FDA may decide that the Gencaro Test should be evaluated for clearance under the FDA's 510(k) notification process. LabCorp and ARCA do not believe that any further clinical trials will be required for the Gencaro Test PMA, though there is no guarantee that FDA will not require additional clinical data.

Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if LabCorp is unable to obtain FDA approval of the Gencaro Test at all or in parallel with the approval of Gencaro, or is unable to commercialize the test successfully and in a manner that effectively supports the combined company's commercial efforts, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected. In such cases, the combined company could be forced to identify a new third-party test provider and obtain regulatory approval for that provider's genetic test, which could substantially delay and negatively affect the commercial prospects for Gencaro.

***If Gencaro is approved, the FDA may require that the companion genetic test be administered to all patients before they receive Gencaro, which could limit its potential market.***

Gencaro is a pharmacologically unique beta-blocker and mild vasodilator for heart failure that is more effective in certain patient populations but less effective in other patient populations than other beta-blockers currently being marketed, or potentially not effective at all. Based on certain genetic markers, ARCA believes that it can be determined whether Gencaro will be more effective or less effective for potential patients. ARCA has a contractual relationship with LabCorp to develop, obtain regulatory approval of and commercialize a genetic test to detect these genetic variations in patients.

Because Gencaro may not be effective in some patient populations, and these populations can be identified using the Gencaro Test, the FDA may require that the Gencaro Test be administered to all patients before they receive Gencaro. The FDA could also prohibit prescribing Gencaro to that patient population that is not positively affected by Gencaro. As a result, the market for Gencaro could be restricted, and the combined company's business could be harmed.

***Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the companion genetic test.***

The companion genetic test for Gencaro is an important component of the commercial strategy for Gencaro. ARCA believes that the genetic test helps predict response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The companion genetic test adds an additional step in the prescribing process, an additional cost for the patient, the risk that the test results may not be rapidly available and the possibility that it may not be available at all hospitals and medical centers. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro's ability to compete, and in turn harm the combined company's business.

***If Nuvelo and ARCA are not successful in integrating their organizations, the combined company may not be able to operate efficiently after the merger or to realize any benefits from the merger.***

Achieving the benefits of the merger will depend in part on the successful integration of Nuvelo's and ARCA's technical and business operations and personnel in a timely and efficient manner. The integration process requires coordination of the personnel of both companies, involves the integration of systems, applications, policies, procedures, business processes and operations and is a complex, costly and time-consuming process. The difficulties of combining the operations of the companies include, among others:

consolidating research and development operations;

retaining key employees;

---

**Table of Contents**

consolidating corporate and administrative infrastructures;

preserving the research and development and other important relationships of the companies;

integrating and managing the technology of two companies;

using the combined company's liquid capital and other assets efficiently to develop the business of the combined company;

appropriately managing the liabilities of the combined company;

diverting management's attention from ongoing business concerns; and

coordinating geographically separate organizations.

Neither Nuvelo nor ARCA can assure you that they will receive any benefits of this or any other merger or acquisitions, or that any of the difficulties described above will not adversely affect the combined company. The integration process may be difficult and unpredictable because of possible conflicts and differing opinions on business, scientific and regulatory matters. If Nuvelo and ARCA cannot successfully integrate their technical and business operations and personnel, the combined company may not realize the expected benefits of the merger.

***Nuvelo and ARCA expect to incur significant costs integrating the companies into a single business.***

Nuvelo and ARCA expect to incur significant costs integrating their technical and business operations and personnel, which may include costs for employee redeployment, relocation or severance, conversion of information systems, reorganization of facilities, disposition of excess facilities and relocation or disposition of excess equipment. The benefits of the merger may not be sufficient to justify these integration costs.

***Integrating Nuvelo and ARCA may divert the attention of the combined company's management away from its operations.***

The successful integration of Nuvelo's and ARCA's technical and business operations and personnel may place a significant burden on the combined company's management and internal resources. The diversion of management's attention and any difficulties encountered in the transition and integration process could result in delays in clinical trial and product development programs of the combined company and could otherwise harm the combined company's business, financial condition and operating results.

***Nasdaq considers the anticipated merger a reverse merger and therefore has required that the combined company submit a new listing application, which requires certain actions on the combined company's part which may not be successful and, if unsuccessful, could make it more difficult for holders of shares of the combined company to sell their shares.***

Nasdaq considers the merger proposed in this proxy statement/prospectus/consent solicitation as a reverse merger and has required that the combined company submit a new listing application. Nasdaq may not approve the combined company's new listing application. If this occurs and the merger is still consummated, you may have difficulty converting your investments into cash effectively.

Additionally, as part of the new listing application, the combined company will be required to submit, among other things, a plan for the combined company to conduct a reverse stock split. A reverse stock split would increase the per share trading price by a yet undetermined multiple. The change in share price may affect the volatility and liquidity of the combined company's stock, as well as the marketplace's perception of the stock. As a result, the relative price of the combined company's stock may decline and/or fluctuate more than in the past, and you may have trouble converting your investments in the combined company into cash effectively.

## **Table of Contents**

### ***Failure to complete the merger could adversely affect Nuvelo's stock price and Nuvelo's and ARCA's future business and operations.***

The merger is subject to the satisfaction of closing conditions, including approval by Nuvelo and ARCA stockholders, and neither Nuvelo nor ARCA can assure you that the merger will be approved. In the event that the merger is not consummated, Nuvelo and ARCA may be subject to many significant costs, including legal, accounting and advisory fees related to the merger, which must be paid even if the merger is not completed, and the payment of a termination fee under certain circumstances. If the merger is not consummated, the market price of Nuvelo common stock could decline as a result.

### ***Completion of the merger may result in dilution of future earnings per share to the stockholders of Nuvelo or ARCA.***

The completion of the merger may result in greater net losses or a weaker financial condition compared to that which would have been achieved by either Nuvelo or ARCA on a stand-alone basis. The merger could fail to produce the benefits that the companies anticipate, or could have other adverse effects that the companies currently do not foresee. In addition, some of the desired outcomes of the merger, such as the achievement of operating synergies, may not be realized. In this event, the merger could result in greater losses as compared to the losses that would have been incurred by Nuvelo or ARCA on a stand alone basis if the merger had not occurred.

### ***The costs associated with the merger are difficult to estimate, may be higher than expected and may harm the financial results of the combined company.***

Nuvelo and ARCA estimate that they will incur aggregate direct transaction costs of approximately \$7.7 million associated with the merger, and additional costs associated with the consolidation and integration of operations, which cannot be estimated accurately at this time. If the total costs of the merger exceed Nuvelo's and ARCA's estimates or the benefits of the merger do not exceed the total costs of the merger, the financial results of the combined company could be adversely affected.

### ***Nuvelo and ARCA executive officers and directors may have interests that are different from, or in addition to, those of Nuvelo and ARCA stockholders generally.***

The executive officers and directors of Nuvelo and ARCA may have interests in the merger that are different from, or are in addition to, those of Nuvelo and ARCA stockholders generally. These interests include ownership through affiliated entities of Nuvelo common stock, certain ARCA directors being appointed to and replacing certain Nuvelo directors from the Nuvelo board of directors immediately after the effective time of the merger, certain Nuvelo executive officers receiving change in control payments in connection with the merger and the adoption of new employment agreements for certain ARCA executives in connection with the merger and/or the provision and continuation of indemnification and insurance arrangements for current directors of ARCA following consummation of the merger. See the sections entitled "Interests of Nuvelo's Executive Officers and Directors in the Merger" starting on page 94 and "Interests of ARCA's Executive Officers and Directors in the Merger" starting on page 97.

### ***The combined company will need to significantly increase the size of its organization and may experience difficulties in managing its growth.***

ARCA and Nuvelo are small companies. As of October 31, 2008, ARCA has approximately 49 employees and Nuvelo has approximately 51 employees. The merger will make certain positions redundant; such redundancies will result in terminations. While the merger will create redundancies and result in terminations, the combined company expects that it will need to substantially increase and modify its operations in the future to conduct clinical trials for any future product candidates and commercialize Gencaro and any other future product



---

**Table of Contents**

candidates that the combined company acquires or develops. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. The combined company's future financial performance and its ability to commercialize its product candidates and to compete effectively will depend, in part, on its ability to manage any future growth effectively. To that end, the combined company must be able to:

manage its clinical trials effectively;

integrate current and additional management, administrative, financial and sales and marketing personnel;

hire new personnel necessary to effectively commercialize product candidates it licenses;

develop its administrative, accounting and management information systems and controls; and

hire and train additional qualified personnel.

***The combined company's management will be required to devote substantial time to comply with public company regulations.***

As a public company, the combined company will incur significant legal, accounting and other expenses that ARCA did not incur as a private company. The Sarbanes-Oxley Act of 2002 as well as rules implemented by the SEC and the Nasdaq Global Market, impose various requirements on public companies, including those related to corporate governance practices. The combined company's management and other personnel will need to devote a substantial amount of time to these requirements. ARCA's management, which will substantially continue as the management of the combined company, does not have recent experience in addressing these requirements. Moreover, these rules and regulations will increase the combined company's legal and financial compliance costs relative to those of ARCA and will make some activities more time-consuming and costly.

The Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, the combined company must perform system and process evaluation and testing of its internal controls over financial reporting to allow management and the combined company's independent registered public accounting firm to report on the effectiveness of its internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. The combined company's compliance with Section 404 will require that it incur substantial accounting and related expense and expend significant management efforts. The combined company will need to hire additional accounting and financial staff to satisfy the ongoing requirements of Section 404. Moreover, if the combined company is not able to comply with the requirements of Section 404, or if the combined company or its independent registered public accounting firm identifies deficiencies in its internal controls over financial reporting that are deemed to be material weaknesses, the market price of the combined company's stock could decline and the combined company could be subject to sanctions or investigations by the Nasdaq Global Market, the SEC or other regulatory authorities.

***Material weaknesses may exist when the combined company reports on the effectiveness of its internal control over financial reporting for purposes of its reporting requirements.***

Prior to the filing of the registration statement of which this proxy statement/prospectus/consent solicitation forms a part, ARCA was not subject to the Sarbanes-Oxley Act of 2002. Therefore, ARCA's management and independent registered public accounting firm did not perform an evaluation of ARCA's internal control over financial reporting as of December 31, 2007 in accordance with the provisions of the Sarbanes-Oxley Act. Material weaknesses may exist when the combined company reports on the effectiveness of its internal control over financial reporting for purposes of its reporting requirements under the Exchange Act or Section 404 of the Sarbanes-Oxley Act after the merger. The existence of one or more material weaknesses would preclude a conclusion that the combined company maintains effective internal control over financial reporting. Such a

---

**Table of Contents**

conclusion would be required to be disclosed in the combined company's future Annual Reports on Form 10-K and could impact the accuracy and timing of its financial reporting and the reliability of its internal control over financial reporting, which could harm the combined company's reputation and cause the market price of its common stock to drop.

***Ownership of the combined company's common stock may be highly concentrated, and it may prevent you and other stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause the combined company's stock price to decline.***

ARCA's executive officers, directors and their affiliates beneficially own or control approximately 88.5% of the outstanding common stock of ARCA (see ARCA Security Ownership of Certain Beneficial Owners and Management beginning on page 226 for more information on how ARCA beneficial ownership percentage is calculated and Security Ownership of Certain Beneficial Owners and Management Following the Merger beginning on page 230 for more information on the estimated ownership of the combined company following the merger). Accordingly, these executive officers, directors and their affiliates, acting individually or as a group, will have substantial influence over the outcome of a corporate action of the combined company requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of the combined company's assets or any other significant corporate transaction. These stockholders may also delay or prevent a change in control of the combined company, even if such change in control would benefit the other stockholders of the combined company. The significant concentration of stock ownership may adversely affect the value of the combined company's common stock due to investors' perception that conflicts of interest may exist or arise.

***The combined company's stock price is expected to be volatile, and the market price of its common stock may decline following the merger.***

The market price of the combined company's common stock could be subject to significant fluctuations following the merger. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of the combined company's common stock to fluctuate include:

the regulatory status of Gencaro and the Gencaro Test, and whether and when they are approved for sale, if at all;

the results of the combined company's current and any future clinical trials and NDAs of its current and future product candidates;

the entry into, or termination of, key agreements, including key strategic alliance agreements;

the results and timing of regulatory reviews relating to the approval of the combined company's product candidates;

failure of any of the combined company's product candidates, if approved, to achieve commercial success;

general and industry-specific economic conditions that may affect the combined company's research and development expenditures;

the results of clinical trials conducted by others on drugs that would compete with the combined company's product candidates;

issues in manufacturing the combined company's product candidates or any approved products;

the initiation of material developments in or the conclusion of litigation to enforce or defend any of the combined company's intellectual property rights;

the loss of key employees;

**Table of Contents**

the introduction of technological innovations or new commercial products by competitors of the combined company;

changes in estimates or recommendations by securities analysts, if any, who cover the combined company's common stock;

future sales of the combined company's common stock;

changes in the structure of health care payment systems; and

period-to-period fluctuations in the combined company's financial results.

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company's common stock.

In the past, following periods of volatility in the market price of a company's securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm the combined company's profitability and reputation.

***Nuvelo and ARCA do not expect the combined company to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment in the combined company.***

Nuvelo and ARCA anticipate that the combined company will retain its earnings, if any, for future growth and therefore does not anticipate paying cash dividends in the future. As a result, only appreciation of the price of the combined company's common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in the combined company's common stock.

***Anti-takeover provisions in the combined company's charter and bylaws may prevent or frustrate attempts by stockholders to change the board of directors or current management and could make a third-party acquisition of the combined company difficult.***

The combined company's certificate of incorporation and bylaws, as amended, will contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could limit the price that investors might be willing to pay in the future for shares of the combined company's common stock.

***Nuvelo and ARCA may not be able to complete the merger or may elect to pursue a different strategic transaction, which may not occur on commercially reasonable terms or at all.***

Neither Nuvelo nor ARCA can assure you that they will close the pending merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights, as set forth in more detail in "The Merger Agreement - Conditions to the Completion of the Merger" and "The Merger Agreement - Termination" below. If Nuvelo and ARCA do not close the pending merger, Nuvelo's and ARCA's board of directors may elect to attempt to complete a different strategic transaction. Attempting to complete a different strategic transaction would prove to be costly and time consuming, and neither Nuvelo nor ARCA can make any assurances that a future strategic transaction will occur on commercially reasonable terms or at all.

**Table of Contents****Risks Related to Nuvelo*****Nuvelo may not be able to develop and commercialize any of Nuvelo's product candidates successfully.***

Nuvelo has two product candidates in clinical development, and does not know whether it will be able to develop them successfully. In January 2008, Nuvelo announced its enrollment of the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics of escalating bolus doses of NU172. In April 2008, Nuvelo announced positive results from this Phase 1 trial. In August 2008, Nuvelo completed a Phase 1b proof-of-concept trial, in which NU172 rapidly produced and maintained anticoagulation with a rapid return toward baseline after the infusion ended. Nuvelo anticipates initiating a Phase 2 study evaluating NU172 in coronary artery bypass graft, or CABG, patients in the first half of 2009. Nuvelo cannot predict whether the results of the anticipated Phase 2 study will be consistent with the results of the earlier studies. Nuvelo cannot predict whether it will be able to initiate and complete the Phase 2 study, or whether it will be successful. Nuvelo has only tested NU172 in healthy, normal volunteers, and does not know how active it will be, or how well it will be tolerated, in patients undergoing medical or surgical procedures.

Nuvelo initiated a Phase 1 single ascending dose healthy volunteer trial for NU206 in Australia in July 2008 and expects top-line data from this trial in the fourth quarter of 2008. Nuvelo cannot predict whether Nuvelo will be able to successfully complete the Phase 1 trial for NU206 in healthy volunteers. Currently, Nuvelo does not have approval from the FDA to study NU206 in healthy volunteers. Nuvelo does not know how active NU206 will be in humans, or how well NU206 will be tolerated.

Nuvelo has had material clinical development failures in the past and may again in the future. In 2006, Nuvelo's clinical-stage product candidate, alfimeprase, did not meet its primary endpoint in the first of two planned Phase 3 trials for the treatment of acute peripheral arterial occlusion, or PAO, and in the first of two planned Phase 3 trials for the treatment of catheter occlusion, or CO. All clinical trials for alfimeprase were suspended in December 2006. Nuvelo subsequently reported its decision to close the suspended PAO trial. In the second quarter of 2007, Nuvelo reported its decision to pursue alfimeprase for the treatment of CO in a Phase 2 trial using a single, higher and more concentrated dose of alfimeprase and reported Nuvelo's decision to pursue alfimeprase for the treatment of acute ischemic stroke in a Phase 2 clinical trial. On March 17, 2008, Nuvelo announced that the data from its alfimeprase Phase 2 trial in CO did not show sufficient improvement in catheter opening at the higher dose and concentration evaluated in the study to meet the desired target product profile. As a result, Nuvelo ended further clinical development of alfimeprase, including the programs in CO and acute ischemic stroke.

In August 2007, Nuvelo announced the suspension of its clinical development of Nuvelo's product candidate, rNAPc2, for the treatment of metastatic colorectal cancer and acute coronary syndromes.

Other than Nuvelo's NU172 and NU206 product development programs, all of Nuvelo's potential products and programs, including its research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics, are currently in research or preclinical development, and revenues from the sales of any products may not occur for several years, if at all. If Nuvelo is unable to successfully develop and commercialize its products, Nuvelo's business, results of operations and financial condition will be affected in a materially adverse manner.

***Nuvelo's success is dependent on the proper management of Nuvelo's current and future business operations, and the expenses associated with them.***

Nuvelo's business strategy requires it to manage its operations to provide for the continued research and development of its product candidates. Nuvelo's strategy also calls for it to manage relationships with collaborators and other third parties, while simultaneously managing the expenses generated by these activities. In August 2007, Nuvelo announced a reduction of approximately 30% of its workforce, across its research,

---

**Table of Contents**

clinical development and administrative functions. This reduction in force was a part of Nuvelo's efforts to reduce its operating expenses through prioritization of Nuvelo's development portfolio and streamlining Nuvelo's infrastructure. As a result of the reduction in force, Nuvelo recorded a restructuring charge of approximately \$2.3 million in the third quarter of 2007. On March 17, 2008, Nuvelo announced the decision to discontinue alfimeprase clinical development and restructure to make additional resources available for its other research and development programs. As a result of the reduction in force, Nuvelo recorded a restructuring expense of \$2.5 million in the first quarter of 2008.

Nuvelo continues to believe that strict cost containment in the near term is essential if its current funds are to be sufficient to allow it to continue its currently planned operations. If Nuvelo is unable to effectively manage its current operations, it may not be able to implement its business strategy and its financial condition and results of operations will be adversely affected. If Nuvelo is unable to effectively manage its expenses, Nuvelo may find it necessary to reduce its expenses through another reduction in its workforce, which could adversely affect Nuvelo's operations.

*If Nuvelo encounters difficulties enrolling patients in its clinical trials, its trials could be delayed or otherwise adversely affected.*

Clinical trials for Nuvelo's product candidates require that Nuvelo identify and enroll a large number of patients with the disorder or condition under investigation. Nuvelo may not be able to enroll a sufficient number of patients to complete its clinical trials in a timely manner.

Patient enrollment is affected by factors including:

design of the protocol;

the size of the patient population;

eligibility criteria for the study in question;

perceived risks and benefits of the drug under study;

availability of competing therapies, including the off-label use of therapies approved for related indications;

efforts to facilitate timely enrollment in clinical trials;

the success of Nuvelo's personnel in making the arrangements with potential clinical trial sites necessary for those sites to begin enrolling patients;

patient referral practices of physicians;

availability of clinical trial sites; and

other clinical trials seeking to enroll subjects with similar profiles.

If Nuvelo has difficulty enrolling a sufficient number of patients to conduct its clinical trials as planned, Nuvelo may need to delay or terminate ongoing or planned clinical trials, either of which would have a negative effect on its business. Delays in enrolling patients in Nuvelo's clinical trials would also adversely affect its ability to generate product, milestone and royalty revenues, and could impose significant additional costs on

Nuvelo or on its collaborators.

***Nuvelo's clinical trials for its product candidates may not yield results that will enable Nuvelo to further develop its products and obtain the regulatory approvals necessary to sell them.***

Nuvelo, and its collaborators, will only receive regulatory approval for its product candidates if Nuvelo can demonstrate in carefully designed and conducted clinical trials that the product candidate is safe and effective. Nuvelo does not know whether its current or any future clinical trials will demonstrate sufficient safety and

**Table of Contents**

efficacy to obtain the requisite regulatory approvals or will result in marketable products. Clinical trials are lengthy, complex and expensive processes with uncertain results. Nuvelo has spent, and expects to continue to spend, significant amounts of time and money in the clinical development of its product candidates. It will take Nuvelo several years to complete its testing, and failure can occur at any stage of testing. The results Nuvelo obtains in preclinical testing and early clinical trials may not be predictive of results that are obtained in later studies. Nuvelo may suffer significant setbacks in advanced clinical trials, even after promising results in earlier studies. For example, in December 2006, Nuvelo announced that alfimeprase did not meet its primary endpoint in the first of two planned Phase 3 trials for the treatment of acute PAO and in the first of two planned Phase 3 trials for the treatment of CO. In the second quarter of 2007, Nuvelo reported its decision to close the suspended PAO trial. In March 2008, Nuvelo announced that the data from its alfimeprase Phase 2 program in CO did not show sufficient improvement in catheter opening at the higher dose and concentration evaluated in the study to meet the desired target product profile. As a result, Nuvelo ended further clinical development of alfimeprase, including the programs in CO and acute ischemic stroke. Based on results at any stage of clinical trials, Nuvelo may decide to repeat or redesign a trial or discontinue development of one or more of Nuvelo's product candidates. If Nuvelo fails to adequately demonstrate the safety and efficacy of its products under development, Nuvelo will not be able to obtain the required regulatory approvals to commercialize Nuvelo's product candidates, and its business, results of operations and financial condition would be materially adversely affected.

Clinical trials are subject to continuing oversight by governmental regulatory authorities and institutional review boards, or IRBs, and must meet the requirements of these authorities in the U.S. and in foreign countries, including those for informed consent and good clinical practices. Nuvelo may not be able to comply with these requirements and the FDA, a similar foreign authority, an IRB, or Nuvelo may suspend or terminate clinical trials at any time.

Administering Nuvelo's product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of Nuvelo's product candidates and could result in the FDA or other regulatory authorities denying approval of its product candidates for any or all targeted indications.

If clinical trials for a product candidate are unsuccessful, Nuvelo will be unable to commercialize the product candidate. If one or more of Nuvelo's clinical trials are delayed, it will be unable to meet its anticipated development timelines. Either circumstance could cause the market price of Nuvelo's common stock to decline. For example, in December 2006, after Nuvelo announced that alfimeprase did not meet its primary endpoint in Phase 3 trials for the treatment of PAO and a Phase 3 trial for CO, the closing price of Nuvelo's common stock was \$4.05 on the day of the announcement, as compared with \$19.55 on the trading day prior to the announcement. Similarly, when Nuvelo announced it was terminating all clinical development of alfimeprase in March 2008, the closing price of Nuvelo's common stock was \$0.73 the day after the announcement, as compared with \$1.36 prior to the announcement.

***If Nuvelo fails to maintain existing licenses, or fails to develop new collaborations, its business will be harmed.***

The success of Nuvelo's business is dependent, in significant part, upon its ability to maintain current licensing and collaborative relationships, and to enter into multiple new licenses and collaboration agreements. Nuvelo also must manage effectively the numerous issues that arise from such arrangements and agreements. Management of Nuvelo's relationships with these third parties has required and will require:

a significant amount of Nuvelo's management team's time and effort;

effective allocation of Nuvelo and third-party resources to multiple projects;

agreements with third parties as to ownership of proprietary rights and development plans, including clinical trials or regulatory approval strategy; and

the recruitment and retention of management, scientific and other personnel.



**Table of Contents**

In March 2005, Nuvelo entered into a collaboration agreement with the Kirin Pharma Company, Limited for the development and commercialization of NU206. Nuvelo initiated a Phase 1 single ascending dose healthy volunteer trial for NU206 in Australia in July 2008, and expects top-line data expected from this trial in the fourth quarter of 2008. All operating expenses and any profits related to the development and commercialization of NU206 are being shared 60 percent by Nuvelo and 40 percent by Kirin. If this agreement is terminated, or Nuvelo or Kirin elect under certain circumstances to no longer actively participate in the collaboration, the relationship with respect to NU206 will convert from an expense and profit sharing structure to a royalty-based structure. If the agreement is terminated by Kirin, Nuvelo will be responsible for all costs and expenses associated with Nuvelo's research and development of NU206.

On July 31, 2006, Nuvelo entered into an agreement with Archemix Corporation. Under the agreement, Archemix is responsible for the discovery of short-acting aptamers targeting the coagulation cascade for use in acute cardiovascular procedures, and Nuvelo is responsible for development and worldwide commercialization of these product candidates. Under the agreement, Nuvelo made an upfront license fee payment to Archemix of \$4.0 million. Nuvelo is also funding at least \$5.25 million of Archemix's research in the area of short-acting aptamer discovery over the first six years of the agreement. In addition, Nuvelo may have to make payments to Archemix totaling up to \$35.0 million per development compound on the achievement of specified development and regulatory milestones, along with potential royalty payments based on sales of licensed compounds. In August 2008, Nuvelo completed a Phase 1b proof-of-concept trial, in which NU172 rapidly produced and maintained anticoagulation with a rapid return toward baseline after the infusion ended. Nuvelo anticipates initiating a Phase 2 study evaluating NU172 in CABG patients in the first half of 2009. If and when Nuvelo enrolls the first patient in a Phase 2 study of NU172, a \$3.0 million milestone fee becomes payable to Archemix. At the initiation of the first Phase 3 study for any licensed compound, Archemix has the option to elect to participate in profits from sales of the compound by funding its pro rata share of prior and future product development and commercialization expenses, in lieu of receiving milestone payments and royalties with respect to that compound. Nuvelo also is obligated to purchase Archemix common stock having a value equal to the lesser of \$10.0 million or 15 percent of the total gross proceeds raised by Archemix in a qualified public offering of Archemix stock occurring within five years of the effective date of the collaboration agreement.

Due to the factors discussed above and other possible disagreements with current or potential collaborative partners, Nuvelo may be delayed or prevented from developing or commercializing NU172, NU206 or other preclinical product candidates, or Nuvelo may become involved in litigation or arbitration with its partners, which would be time-consuming or expensive and could have a material adverse effect on Nuvelo's stock price. Nuvelo's relationships with its collaboration partners also may be materially adversely affected by any failure to successfully enroll or complete any of its planned trials of its product candidates. Nuvelo's efforts to manage simultaneously a number of collaboration arrangements may not be successful, and its failure to manage effectively such collaborations would significantly harm its business, financial condition and results of operations.

In addition to Nuvelo's existing collaborations, Nuvelo may enter into new collaborative arrangements whereby Nuvelo would share costs of identifying, developing and marketing product candidates. Nuvelo cannot assure you that it will be able to negotiate new collaboration arrangements of this type on acceptable terms, or at all.

***Nuvelo heavily depends on third parties for manufacturing and a variety of other functions, including clinical trials management. Nuvelo's current and future arrangements with its manufacturers and other third parties may not provide it with the benefits Nuvelo expects.***

Nuvelo does not have the resources, facilities or experience to manufacture its product candidates on its own. Nuvelo relies on third parties, such as contract research and manufacturing organizations, to manufacture its product candidates for clinical trials, and, if Nuvelo's product candidates are approved, in quantities for commercial sales. Nuvelo currently relies on a number of sole-source service providers and suppliers to manufacture bulk drug substance, fill and finish its product candidates and label and package them. Nuvelo does

---

**Table of Contents**

not have long-term supply agreements with these third-party manufacturers. Nuvelo may not be able to finalize contractual arrangements, transfer technology or maintain relationships with such organizations in order to file an investigational new drug application, or IND, with the FDA, and proceed with clinical trials for any of Nuvelo's product candidates.

Since a Phase 2 study of NU172 is to be initiated, and NU206 is in Phase 1 clinical trials, Nuvelo is dependent upon third-party contract manufacturers to develop the necessary production processes and produce the volume of cGMP-grade material needed to complete such trials. Nuvelo has entered into and intends to enter into additional contractual relationships with third parties in order to (i) complete the Good Laboratory Practices, or GLP, toxicology and other studies necessary to file INDs with the FDA, (ii) produce a sufficient volume of cGMP-grade material in order to conduct clinical trials of these other product candidates and (iii) fill and finish and label and package Nuvelo's material. Nuvelo cannot be certain that it will be able to complete these tasks on a timely basis or that it will be able to obtain sufficient quantities of material or other manufacturing services on commercially reasonable terms. In addition, the failure of any of these third parties to perform their obligations may delay Nuvelo's filing for an IND or impede Nuvelo's progress through the clinical trial phase. Any significant delay or interruption would have a material adverse effect on Nuvelo's ability to file an IND with the FDA and/or proceed with the clinical trial phase for any of its product candidates.

Moreover, contract manufacturers that Nuvelo may use must continually adhere to cGMP enforced by the FDA through a facilities inspection program. If one of Nuvelo's contract manufacturers fails to maintain compliance, the production of Nuvelo's product candidate could be interrupted, resulting in delays, additional costs and potentially lost revenues. In addition, if the facilities of such manufacturers do not pass a pre-approval plant inspection, the FDA will not grant pre-market approval of Nuvelo's product candidates.

Nuvelo also currently relies upon third parties to perform administrative functions and functions related to the research, development, preclinical testing and clinical trials of its product candidates. Nuvelo's reliance on third-party contract research organizations and consultants that manage and monitor its clinical trials may result in delays in completing, or in failing to complete, Nuvelo's clinical trials if they fail to perform with the speed and competency Nuvelo expects. Nuvelo's reliance on third-party contract research organizations to conduct research and testing, including GLP, and toxicology studies necessary to gather the data necessary to file INDs with the FDA for any of Nuvelo's product candidates may result in delays in Nuvelo's regulatory filings if the third parties do not conduct their research or testing properly, or if they fail to complete their contract research or testing on the anticipated schedule. In either case, the progress of Nuvelo's clinical programs may be delayed and Nuvelo's research and development costs may increase, which may in turn have a material adverse affect on Nuvelo's business.

Nuvelo's reliance on these manufacturing and other contract services relationships poses a number of risks, including:

inability of third parties to manufacture, including filing and finishing and labeling and packaging, Nuvelo's product candidates in a cost-effective or timely manner or in quantities needed for clinical trials;

changes to current raw material suppliers or product manufacturers (whether the change is attributable to Nuvelo or the supplier or manufacturer), resulting in delayed clinical studies, regulatory submissions and commercialization of Nuvelo's product candidates;

failure to identify acceptable manufacturers or other suppliers or enter into favorable long-term agreements with them;

ineffective clinical trials management or monitoring resulting in delays in or interruptions to Nuvelo's clinical trials;

delays in, or failures to achieve, scale-up to commercial quantities of Nuvelo's product candidates resulting in delayed regulatory submissions and commercialization of Nuvelo's product candidates;

---

**Table of Contents**

Nuvelo's inability to effectively control the resources devoted by Nuvelo's partners to its programs or products;

disagreements with third parties that could disrupt Nuvelo's operation or delay or terminate the research, development or manufacturing of product candidates, or result in litigation or arbitration;

inadequate contractual protection or difficulty in enforcing the contracts if one of Nuvelo's partners fails to perform;

failure of these third parties to comply with regulatory requirements;

conflicts of interest between third parties who work for Nuvelo and their work for another entity or entities, and the resulting loss of their services; and

lack of all necessary intellectual property rights to manufacture and sell Nuvelo's product candidates.

Given these risks, Nuvelo's current and future arrangements with third parties may not be successful. If these efforts fail, Nuvelo would be required to devote additional internal resources to the activities currently performed, or to be performed, by third parties, to seek alternative third-party sources, or to delay Nuvelo's product development or commercialization.

***Nuvelo is dependent on key personnel, and it must attract and retain qualified employees, collaborators and consultants.***

The success of Nuvelo's business is highly dependent on the principal members of Nuvelo's scientific and management staff, including Nuvelo's senior management team. The loss of the services of any such individual might seriously harm Nuvelo's product development efforts. Retaining and training personnel with the requisite skills is challenging and extremely competitive, particularly in Northern California, where Nuvelo is located.

Nuvelo's success will depend on Nuvelo's ability to attract and retain qualified employees to help develop its potential products and execute its research and development strategy. Nuvelo has programs in place to retain personnel, including programs to create a positive work environment and competitive compensation packages. Because competition for employees in Nuvelo's field is intense, however, Nuvelo may be unable to retain its existing personnel or attract qualified individuals to fill open positions. In addition, in August 2007 and again in March 2008 Nuvelo reduced its workforce as part of its efforts to reduce operating expenses through prioritization of its development portfolio and streamlining its infrastructure. These reductions in Nuvelo's workforce, together with its evaluation of strategic alternatives, may impair its ability to recruit and retain qualified employees and to effectively complete administrative and development functions. If Nuvelo needs to rehire terminated individuals or hire individuals with similar skills, it may be unable to do so. Nuvelo's success also depends on the continued availability of outside scientific collaborators, including collaborators at research institutions, to perform research and develop processes to advance and augment Nuvelo's internal research efforts. Competition for collaborators is intense. Nuvelo also relies on services provided by outside consultants. Attracting and retaining qualified outside consultants is competitive, and, generally, outside consultants can terminate their relationship with Nuvelo at will. If Nuvelo does not retain qualified personnel, outside consultants and scientific collaborators, or if it experiences turnover or difficulties recruiting new employees or outside consultants, Nuvelo's research and development programs could be delayed, and it could experience difficulties in generating sufficient revenue to maintain its business.

***Nuvelo may not achieve its projected development goals in the time frames it announces and expects.***

Nuvelo sets goals for, and makes public statements regarding, the timing of certain accomplishments, such as the commencement and completion of clinical trials and the disclosure of trial results, which Nuvelo sometimes refers to as milestones. These milestones may not be achieved, and the actual timing of these events can vary dramatically due to a number of factors such as delays or failures in Nuvelo's clinical trials, disagreements with current or future collaborative partners, the uncertainties inherent in the regulatory approval

---

**Table of Contents**

process and manufacturing scale-up and delays in achieving manufacturing or marketing arrangements sufficient to commercialize Nuvelo's products. There can be no assurance that Nuvelo's clinical trials will be completed, or that it will make regulatory submissions or receive regulatory approvals as planned. If Nuvelo fails to achieve one or more of these milestones as planned, its business will be materially adversely affected, and the price of Nuvelo's shares will decline.

***The success of Nuvelo's potential products in research and preclinical studies does not guarantee that these results will be replicated in humans.***

Several of Nuvelo's drug development programs are currently in the research stage or in preclinical development, including Nuvelo's research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics. Although Nuvelo's clinical development-stage product candidates have shown favorable results in preclinical studies, these results may not be replicated in Nuvelo's clinical trials with humans. Before Nuvelo makes any products available to the public from its research and development programs, Nuvelo or its collaboration partners will need to conduct further research and development and complete laboratory testing and animal studies. These programs may not move beyond their current stages of development. Even if Nuvelo's research does advance, Nuvelo will need to engage in certain additional preclinical development efforts to determine whether a product is sufficiently safe and effective to enter clinical trials. Nuvelo has little experience with these activities with respect to protein candidates and may not be successful in developing these products. Consequently, there is no assurance that the results in Nuvelo's research and preclinical studies are predictive of the results that Nuvelo may see in its clinical trials with humans or that they are predictive of whether any resulting products will be safe and effective in humans.

***FDA and international regulatory approval of Nuvelo's products is uncertain.***

The research, testing, manufacturing and marketing of drug products such as those proposed to be developed by Nuvelo or its collaboration partners are subject to extensive regulation by federal, state and local governmental authorities, including the FDA and comparable agencies in other countries. To obtain regulatory approval of a drug product, Nuvelo or its collaboration partners must demonstrate to the satisfaction of the applicable regulatory agency, among other things, that the product is safe and effective for its intended uses. In addition, Nuvelo must show that the manufacturing facilities used to produce the products are in compliance with current cGMP and that the process for manufacturing the product has been validated in accordance with the requirements of the FDA and comparable agencies in other countries.

The process of obtaining FDA and other required regulatory approvals and clearances typically takes several years and will require Nuvelo to expend substantial capital and resources. Despite the time and expense expended, regulatory approval is never guaranteed. The number of preclinical and clinical tests that will be required for FDA and international regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is in development for, and the regulations applicable to that particular product candidate. The FDA or comparable international regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:

a product candidate may not be safe or effective;

the FDA or comparable international regulatory authorities may interpret data from preclinical and clinical testing in different ways than Nuvelo and Nuvelo's collaboration partners interpret them;

the FDA or comparable international regulatory authorities may not approve Nuvelo's manufacturing processes or facilities or the processes or facilities of Nuvelo's collaboration partners; or

the FDA or comparable international regulatory officials may change their approval policies or adopt new regulations.

**Table of Contents**

In addition, in order to market any products outside of the U.S., Nuvelo and its collaborators must establish and comply with numerous and varying regulatory requirements of other jurisdictions, including the European Medicines Evaluation Agency, or EMEA, regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries differs from that required to obtain FDA approval. The regulatory approval process in other countries can include all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the U.S.

If and when Nuvelo's products obtain such approval or clearances, the manufacturing, marketing and distribution of such products would remain subject to extensive ongoing regulatory requirements. Failure to comply with applicable regulatory requirements could result in:

warning letters;

fines;

civil penalties;

injunctions;

recall or seizure of products;

total or partial suspension of production;

refusal of the government to grant approvals; or

withdrawal of approvals and criminal prosecution.

Any delay or failure by Nuvelo, or its collaboration partners, to obtain regulatory approvals for Nuvelo's product candidates:

would adversely affect Nuvelo's ability to generate product, milestone and royalty revenues;

could impose significant additional costs on Nuvelo or its collaboration partners;

could diminish competitive advantages that Nuvelo may attain;

would adversely affect the marketing of Nuvelo's products; and

## Edgar Filing: NUVELO INC - Form S-4/A

could cause the price of Nuvelo's shares to decline.

Even if Nuvelo receives regulatory approval for its product candidates, the FDA or international regulatory authorities may impose limitations on the indicated uses for which Nuvelo's products may be marketed and subsequently withdraw approval or take other actions against Nuvelo, or its products, that are adverse to Nuvelo's business. The FDA and comparable international regulatory authorities generally approve products for particular indications. An approval for a limited indication reduces the size of the potential market for the product. Product approvals, once granted, may be withdrawn if problems occur after initial marketing.

***Nuvelo has not yet commercialized any of its product candidates; Nuvelo's ability to commercialize products is unproven.***

Nuvelo has not yet commercialized any of its in-licensed therapeutic product candidates. Nuvelo's commercialization of products is subject to several risks, including but not limited to:

the possibility that a product is toxic, ineffective or unreliable;

failure to obtain regulatory approval for the product;

**Table of Contents**

difficulties in manufacturing the product on a large scale;

difficulties in planning, coordinating and executing the commercial launch of the product;

difficulties in marketing, distribution or sale of the product;

the possibility of a failure to comply with laws and regulations related to the marketing sale and reimbursement of the product;

competition from superior products; or

third-party patents that preclude Nuvelo from marketing a product.

Any regulatory approvals that Nuvelo or its collaboration partners receive for Nuvelo's product candidates may be subject to limitations on the intended uses for which the product candidates may be marketed or contain requirements for potentially costly post-marketing follow-up studies. The labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for any approved product will be subject to extensive regulatory requirements. Additionally, Nuvelo, its collaborators and its suppliers may not be able to produce any products in commercial quantities at a reasonable cost or may not be able to successfully market such products. If Nuvelo does not develop a commercially viable product, then Nuvelo will suffer significant harm to its business, financial condition and operating results.

Even if a product candidate is approved for commercial sale, significant strategic planning and resources will be necessary to effectively coordinate the commercial launch of the product in the approved indication or indications, and to effectively market, distribute and sell the product for use in the approved indication or indications. In addition, the marketing, distribution, sale and reimbursement of pharmaceutical products is heavily regulated, and Nuvelo must comply with all such applicable laws and regulations, or incur costs, fees, fines and other liabilities associated with non-compliance. If Nuvelo's or a collaboration partner's commercial launch of a product approved for commercial sale were to be unsuccessful, or if Nuvelo or a collaboration partner were to fail in Nuvelo's or their efforts to properly market, distribute or sell any product approved for sale, Nuvelo's business, financial condition and operating results would suffer significant harm.

*Even if approved, Nuvelo's products may not be accepted in the marketplace, and Nuvelo may not be able to generate significant revenue, if any.*

Even if they are approved for marketing, Nuvelo's products, if any, may never achieve market acceptance among physicians, patients and the medical community. The degree of market acceptance of any products developed by Nuvelo, alone or in conjunction with collaboration partners, will depend on a number of factors, including:

the establishment and demonstration of the clinical efficacy and safety of the products;

convenience and ease of administration;

cost-effectiveness;

Nuvelo's products' potential advantages over alternative treatment methods;

marketing, sales and distribution support of Nuvelo's products; and

reimbursement policies of government and third-party payers.

Physicians, patients or the medical community in general may not accept and utilize any of the products that Nuvelo alone, or in conjunction with Nuvelo's collaboration partners, develops. In practice, competitors may be more effective in marketing their drugs. The lack of such market acceptance would significantly harm Nuvelo's business, financial condition and results of operations. Even if Nuvelo's product candidates are approved for marketing and are accepted by physicians, patients and the medical community, the size of the market for these



---

**Table of Contents**

products may be insufficient to sustain Nuvelo's business, or may not provide an acceptable return on Nuvelo's investment in the development of these products. As a result, the commercialization of any of Nuvelo's product candidates could fail even if Nuvelo receives marketing approval from the FDA or similar foreign authorities, and acceptance by the medical and patient communities.

***Nuvelo faces intense competition.***

The biopharmaceutical industry is intensely competitive, which is accentuated by the rapid pace of technological development. Nuvelo's products, if successfully developed, will compete with a number of traditional drugs and therapies and with new products currently under development. Nuvelo also expects to face increased competition in the future as new companies enter Nuvelo's markets. Research and discoveries by others may result in breakthroughs that render Nuvelo's potential products obsolete even before they begin to generate any revenue. The competitors for Nuvelo's drugs currently in development will vary depending on the particular indication pursued, and may include major pharmaceutical, medical device and biotechnology firms, many of which have substantially greater research and product development capabilities and financial, scientific, marketing and human resources than Nuvelo has. Nuvelo's lead clinical-stage product candidate, NU172, is an anticoagulant that has the potential for predictable anticoagulant effects and rapid self-reversal. If approved, it could face competition from other drugs or devices that are used to anticoagulate a patient in the setting of medical or surgical procedures where human blood is exposed to foreign materials such as coronary artery bypass graft surgery, kidney dialysis and a variety of vascular surgical and coronary interventions. Competition differs depending on the indication and includes, for example, heparin and its antidote, protamine, as well as Angiomax<sup>®</sup> bivalirudin, an approved product of The Medicines Company. Nuvelo's second product candidate, NU206, if approved for the treatment of mucositis, could face competition from drugs such as palifermin, an approved Amgen product.

Nuvelo's competitors may obtain patents and regulatory approvals for their competing products more rapidly than Nuvelo or its collaboration partners, or develop products that are more effective than those developed by Nuvelo or its collaboration partners. All of Nuvelo's products will face competition from companies developing similar products as well as from companies developing other forms of treatment for the same conditions.

Many of the companies developing competing products have greater expertise than Nuvelo or its collaboration partners have in discovery, research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. Other smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies as well as other organizations compete with Nuvelo in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to Nuvelo's programs. Nuvelo may face competition with respect to:

product efficacy and safety;

the timing and scope of regulatory approvals;

availability of resources;

reimbursement coverage; and

price and patent position, including the potentially dominant patent positions of others.

There can be no assurance that research and development by others will not render the products that Nuvelo may develop obsolete or uneconomical, or result in treatments or cures superior to any therapy developed by Nuvelo or that any therapy Nuvelo develops will be preferred to any existing or newly-developed alternative products.

---

## **Table of Contents**

### ***Nuvelo is subject to the risk of natural disasters.***

Nuvelo's facilities are located in Northern California. If a fire, earthquake, flood or other natural disaster disrupts Nuvelo's research or development efforts, Nuvelo's business, financial condition and operating results could be materially adversely affected. Although Nuvelo maintains personal property and general business interruption coverage, it does not maintain earthquake or flood insurance coverage for personal property or resulting business interruption.

### **Risks Related to Nuvelo's Capital Structure and Financial Results and Stock Price Volatility**

#### ***Nuvelo will need to raise additional capital, and such capital may be unavailable to Nuvelo when it needs it or not available on acceptable terms.***

Nuvelo will need to raise significant additional capital to finance the research and clinical development of Nuvelo's product candidates. If future securities offerings are successful, they could dilute Nuvelo's current stockholders' equity interests and reduce the market price of Nuvelo's common stock. Financing may be unavailable when Nuvelo needs it or may not be available on acceptable terms. The unavailability of financing may require Nuvelo to delay, scale back or eliminate expenditures for the research and development of Nuvelo's potential biopharmaceutical products. Nuvelo may also be required to raise capital by granting rights to third parties to develop and market product candidates that Nuvelo would prefer to develop and market on its own, potentially reducing the ultimate value that Nuvelo could realize from these product candidates.

If Nuvelo is unable to obtain additional financing when it needs it, the capital markets may perceive that Nuvelo is not able to raise the amount of financing it desires, or on the terms that it desires. This perception, if it occurs, may negatively affect the market price of Nuvelo's common stock. If sufficient capital is not available, Nuvelo may be forced to delay, reduce the scope of, eliminate or divest one or more of Nuvelo's research or development programs. As an example, in August 2007, Nuvelo announced that it suspended the clinical development of rNAPc2. Any such action could significantly harm Nuvelo's business, financial condition and results of operations.

Nuvelo's future capital requirements and the adequacy of Nuvelo's currently available funds will depend on many factors, including, among others, the following:

any business transactions or arrangements through which the Company acquires or purchases new products, product candidates or other companies;

Nuvelo's ability to maintain, and the financial commitments involved in, Nuvelo's existing collaborative and licensing arrangements, including Nuvelo's ability to continue to receive cost-sharing reimbursements from Kirin;

progress in current and anticipated clinical studies of Nuvelo's products, including NU172 and NU206;

Nuvelo's need to develop, acquire or license new technologies or products;

future funding commitments to new and existing collaborators, such as Archemix, from which Nuvelo is obligated to purchase Archemix common stock having a value equal to the lesser of \$10.0 million or 15% of the total gross proceeds raised by Archemix in a qualified public offering;

the cost of manufacturing Nuvelo's material for preclinical and clinical purposes;

Nuvelo's ability to establish new collaborative relationships with other companies to share costs and expertise of identifying, developing and commercializing product candidates;

the magnitude and scope of Nuvelo's research and development programs, including development of product candidates;

continued scientific progress in Nuvelo's research and development programs, including progress in Nuvelo's research and preclinical studies;

---

**Table of Contents**

the cost involved in maintaining facilities to support research and development of Nuvelo's product candidates;

the cost of prosecuting and enforcing Nuvelo's intellectual property rights;

the time and cost involved in obtaining regulatory approvals;

competing technological and market developments;

current conditions and the uncertainty of future conditions in the financial markets and in the biotech sector; and

other factors not within Nuvelo's control.

***As of September 30, 2008, Nuvelo's stock price does not meet the minimum bid price for continued listing on the Nasdaq Global Market. Nuvelo's ability to publicly or privately sell equity securities and the liquidity of Nuvelo's common stock could be adversely affected if Nuvelo is delisted from the Nasdaq Global Market or if Nuvelo is unable to transfer its listing to another stock market.***

Nasdaq Global Market listing standards require that for continued listing, the bid price of Nuvelo's common stock must be a minimum of \$1.00 per share. Since Nuvelo announced on March 17, 2008 that it was terminating the development of alfimeprase, the bid price of Nuvelo's common stock has been less than \$1.00 each trading day since March 18, 2008. On May 1, 2008, Nuvelo received notice from Nasdaq indicating that, for 30 consecutive business days, the bid price for Nuvelo's common stock had closed below the minimum \$1.00 per share requirement for continued inclusion on the Nasdaq Global Market. Nuvelo was given 180 calendar days, or until October 28, 2008, to regain compliance with this listing requirement, which would be accomplished if the bid price of Nuvelo's common stock closed at \$1.00 per share or more for a minimum of 10 consecutive business days. As of September 30, 2008, the bid price of Nuvelo's common stock closed at \$0.44 per share. The notice from Nasdaq also indicated that, if Nuvelo does not regain compliance by October 28, 2008, Nasdaq would provide a staff determination letter notifying Nuvelo that its common stock will be delisted, after which Nuvelo may appeal the staff determination to the Nasdaq Listing Qualifications Panel. On October 16, 2008, Nasdaq advised Nuvelo that it had suspended until January 19, 2009 the enforcement of the rules requiring a minimum \$1.00 closing bid price for all Nasdaq listed companies.

Following the end of this suspension period and the 12 days balance of Nuvelo's initial 180 days compliance period, Nuvelo expects to receive a staff determination letter if it has not regained compliance by that time. Upon receipt of the determination letter, Nuvelo intends to submit a request to appeal the determination and present a plan for compliance at an oral hearing with Nasdaq in Washington, D.C. The request for appeal will automatically stay the determination until the appeal is heard and a Nasdaq panel rules on whether to grant conditional listing for up to 180 days following the staff determination in order for Nuvelo to complete its plan of compliance. There can be no assurance that the appeal will be successful or on the timeline presented above or that the plan of compliance and the combined company will be able to satisfy the requirements for maintaining a Nasdaq Global Market listing.

As part of this prospectus/proxy statement/consent solicitation, Nuvelo is seeking stockholder approval for a reverse split of its common stock in order to regain compliance with Nasdaq's minimum bid price requirement. See the section of this prospectus/proxy statement/consent solicitation titled "Nuvelo Proposal No. 2 Amendment to Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of Nuvelo's Common Stock." There can be no assurance that the reverse split will be approved or will have its desired effect.

If Nuvelo does not regain compliance with this listing requirement by the new deadline imposed by Nasdaq, but meets the initial inclusion criteria for the Nasdaq Capital Market (except for the bid price requirement), Nuvelo may apply to transfer the listing of Nuvelo's common stock to this market. If accepted by the Nasdaq Capital Market, Nuvelo will be provided with an additional 180-day period to demonstrate compliance. If Nuvelo

---

**Table of Contents**

is not eligible for an additional compliance period at that time, Nasdaq will provide written notification that Nuvelo's securities will be delisted. Upon such notice, Nuvelo may appeal the determination to the Nasdaq Listing Qualifications Panel. There can be no assurance that Nuvelo's common stock would be eligible for transfer to the Nasdaq Capital Market, or, if Nuvelo appeals Nasdaq staff's determination, that such appeal would be successful.

If Nuvelo's common stock is delisted by Nasdaq, its common stock may be eligible for quotation on the OTC Bulletin Board maintained by Nasdaq, another over-the-counter quotation system, or on the pink sheets. Upon any such delisting, Nuvelo's common stock would become subject to the regulations of the Securities and Exchange Commission relating to the market for penny stocks. A penny stock is any equity security not traded on a national securities exchange that has a market price of less than \$5.00 per share. The regulations applicable to penny stocks may severely affect the market liquidity for Nuvelo's common stock and could limit your ability to sell your securities in the secondary market. In such a case, an investor may find it more difficult to dispose of or obtain accurate quotations as to the market value of Nuvelo's common stock, although there can be no assurance that Nuvelo's common stock will be eligible for trading or quotation on any alternative exchanges or markets.

Delisting from Nasdaq could adversely affect Nuvelo's ability to raise additional financing through the public or private sale of equity securities, would significantly affect the ability of investors to trade Nuvelo's securities and would negatively affect the value and liquidity of Nuvelo's common stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities.

***Nuvelo's stock price has historically been and is likely to remain highly volatile, and an investment in Nuvelo's stock could suffer a decline in value.***

Stock prices and trading volumes for many biopharmaceutical companies fluctuate widely for a number of reasons, including factors which may be unrelated to their businesses or results of operations, such as media coverage, legislative and regulatory measures and the activities of various interest groups or organizations. This market volatility, as well as general domestic or international economic, market and political conditions, could materially and adversely affect the market price of Nuvelo's common stock and the return on any investment in Nuvelo's common stock.

Historically, Nuvelo's stock price has been extremely volatile. Between January 1, 2007 and December 31, 2007, the price ranged between a high of \$6.63 per share and a low of \$1.26 per share. Between January 1, 2008 and October 31, 2008, the price ranged between a high of \$1.88 per share and a low of \$0.21 per share. In March 2008, Nuvelo announced that the data from Nuvelo's Phase 2 program in catheter occlusion did not show sufficient improvement in catheter opening at the higher dose and concentration evaluated in the study to meet the desired target product profile and that Nuvelo ended further clinical development of alfimeprase. The closing price of Nuvelo's common stock was \$0.73 the day after this announcement, as compared with \$1.36 prior to this announcement. Significant market price fluctuations of Nuvelo's common stock can be due to a variety of factors, including:

the depth of demand for Nuvelo's common stock;

any announcements of or speculation about strategic transactions involving Nuvelo, such as its merging with, being acquired by, or acquiring another entity;

the experimental nature of, and public concern or expectations with respect to, Nuvelo's product candidates;

actual or anticipated fluctuations in Nuvelo's operating results;

sales of Nuvelo's common stock by existing holders, or sales of shares issuable upon exercise of outstanding options and warrants;

**Table of Contents**

market conditions relating to the biopharmaceutical and pharmaceutical industries;

any announcements of technological innovations, new commercial products or collaborations, or clinical progress or lack thereof by Nuvelo, its collaborative partners or its competitors;

announcements concerning regulatory developments or developments with respect to proprietary rights;

changes in Nuvelo's collaborative arrangements;

changes in or Nuvelo's failure to meet market or, to the extent securities analysts follow Nuvelo's common stock, securities analysts expectations;

loss of key personnel;

changes in accounting principles; and

general market conditions.

In addition, the stock market in general, and the market for biotechnology and other life science stocks in particular, has recently and historically been subject to extreme price and volume fluctuations. This volatility has had a significant effect on the market prices of securities issued by many companies for reasons unrelated to the operating performance of these companies.

***Nuvelo has a significant accumulated deficit and anticipates continuing losses.***

Nuvelo has incurred significant net losses, including \$130.6 million in 2006, \$12.3 million in 2007 and \$27.2 million in the nine months ended September 30, 2008. As of September 30, 2008, Nuvelo had an accumulated deficit of \$497.7 million and Nuvelo anticipate continuing losses for the foreseeable future.

All of Nuvelo's product candidates are in various stages of product development, and some are still in research or in early development. None of them are approved for sale. The process of developing Nuvelo's drug products will require significant additional research and development, preclinical testing, clinical trials and regulatory approvals.

These activities, together with drug manufacturing, general administrative and other expenses, are expected to result in operating losses for the foreseeable future. To date, Nuvelo has not generated any revenues from product sales. Nuvelo does not expect to achieve significant product sales or royalty revenue from product sales for several years, and it may never do so. Nuvelo expects to incur additional operating losses in the future, and these losses may increase significantly as Nuvelo continues preclinical research and clinical trials, applies for regulatory approvals and develops its product candidates. These losses, among other things, have caused and may cause Nuvelo's stockholders' equity and working capital to decrease. Nuvelo may not be successful in developing its product candidates and obtaining regulatory approvals. Nuvelo may never generate profits and, as a result, the market price of Nuvelo's common stock could decline.

Moreover, utilization of Nuvelo's net operating loss and research and development credit carryforwards are subject to an annual limitation under the change in ownership provisions of the Internal Revenue Code of 1986 and similar state law provisions, as a result of certain transactions that Nuvelo has entered into prior to 2006. If the proposed merger with ARCA is consummated, a change in ownership of Nuvelo will occur and Nuvelo's ability to utilize these carryforwards will be substantially reduced.

**Table of Contents**

*Nuvelo may face fluctuations in operating results.*

Nuvelo's operating results may rise or fall significantly from period to period as a result of many factors, including:

any business transactions or arrangements through which Nuvelo acquires or purchases new products or product candidates;

the amount of research and development Nuvelo engages in;

if Nuvelo is obligated to purchase Archemix common stock having a value equal to the lesser of \$10.0 million or 15 percent of the total gross proceeds, in accordance with the collaboration agreement with Archemix;

the number of product candidates Nuvelo has, their progress in research, preclinical and clinical studies and the costs involved in manufacturing them;

Nuvelo's ability to maintain existing and enter into new strategic relationships;

the scope, duration and effectiveness of Nuvelo's licensing and collaborative arrangements;

Nuvelo's ability to maintain its facilities to support its operations;

the costs involved in prosecuting, maintaining and enforcing patent claims;

the possibility that others may have or obtain patent rights that are superior to Nuvelo's;

changes in government regulation;

changes in the price of Nuvelo's common stock or other variables used as a basis for valuing stock-based awards;

changes in accounting policies or principles; and

release of successful products into the market by Nuvelo's competitors.

In addition, as a result of Nuvelo's adoption of SFAS 123(R), Nuvelo must measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee's requisite service period. As the variables that Nuvelo uses as a basis for valuing future awards change over time, the magnitude of the expense that Nuvelo must recognize may vary significantly. Any such variance from one period to the next could cause a significant fluctuation in Nuvelo's operating results.

## Edgar Filing: NUVELO INC - Form S-4/A

All of Nuvelo's potential products are currently in research, preclinical or clinical development, and revenues from the sales of any products resulting from this research and development may not occur for several years, if at all. Nuvelo has a significant amount of fixed costs such as lease obligations, and certain charges to Nuvelo's statement of operations are dependent on movements in the price of Nuvelo's common stock, which historically has been and is likely to remain highly volatile. As a result, Nuvelo may experience fluctuations in its operating results from quarter to quarter and continue to generate losses. Quarterly comparisons of Nuvelo's financial results may not necessarily be meaningful, and investors should not rely upon such results as an indication of Nuvelo's future performance. In addition, investors may react adversely if Nuvelo's reported operating results are less favorable than in a prior period or are less favorable than those anticipated by investors or the financial community, which may result in a drop in the market price of Nuvelo's common stock.

***Future sales or the possibility of future sales of Nuvelo's common stock may depress the market price of Nuvelo's common stock.***

Sales in the public market of substantial amounts of Nuvelo's common stock could depress prevailing market prices of its common stock. As of October 31, 2008, Nuvelo had 53,663,805 shares of common stock



---

**Table of Contents**

outstanding. All of these shares are freely transferable without restriction or further registration under the Securities Act, except for shares held by Nuvelo's directors, officers and other affiliates and unregistered shares held by non-affiliates. As of October 31, 2008, Nuvelo's directors, officers and greater than five percent stockholders held approximately 13 percent of the shares of Nuvelo's outstanding common stock. Although Nuvelo does not believe that Nuvelo's directors, officers and greater than five percent stockholders have any present intentions to dispose of large amounts of any shares of common stock owned by them, there can be no assurance that such intentions will not change in the future. The sale of these additional shares could depress the market price of Nuvelo's common stock.

As of October 31, 2008, Nuvelo had approximately 12,427,026 shares of Nuvelo's common stock which may be issued under Nuvelo's 2004 Equity Incentive Plan, 2002 Equity Incentive Plan, 1995 Stock Option Plan, Non-Employee Director Stock Option Plan, stock option agreements entered into outside of any of Nuvelo's stock option plans, and Nuvelo's Employee Stock Purchase Plan. Included in these 12,427,026 shares are (i) 5,140,278 shares of Nuvelo's common stock issuable under outstanding options to purchase Nuvelo's common stock under the specified plans, (ii) 439,386 shares of Nuvelo's common stock issuable under stock option agreements entered into outside of any of Nuvelo's stock option plans, (iii) 27,332 shares of Nuvelo's common stock issuable under restricted stock units, (iv) 6,537,957 shares of Nuvelo's common stock reserved for future grants under Nuvelo's 2004 Equity Incentive Plan, and (v) 282,073 shares of Nuvelo's common stock reserved for future issuance under Nuvelo's Employee Stock Purchase Plan. As of October 31, 2008, outstanding options to purchase 4,139,459 shares of common stock were exercisable, and no restricted stock units have been vested. If and when these options are exercised, such shares are available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options and share reserves may negatively affect Nuvelo's ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of Nuvelo's common stock received, may also result in downward pressure on the price of Nuvelo's common stock.

As of October 31, 2008, 850,224 shares of Nuvelo's common stock were issuable upon the exercise of outstanding warrants, which were all exercisable as of this date. Once a warrant is exercised, the holder can arrange for the resale of shares either by invoking any applicable registration rights, causing the shares to be registered under the Securities Act and thus freely transferable, or by relying on an exemption to the Securities Act. If these registration rights, or similar registration rights that may apply to securities Nuvelo may issue in the future, are exercised, it could result in additional sales of Nuvelo's common stock in the market, which may have an adverse effect on Nuvelo's stock price.

Nuvelo will need to raise significant additional capital to finance the research, development and commercialization of Nuvelo's drug products. If future securities offerings are successful, they could dilute Nuvelo's current stockholders' equity interests and reduce the market price of its common stock.

***Nuvelo's investments in marketable debt securities are subject to credit risk that may adversely affect their fair value.***

Nuvelo maintains a significant portfolio of investments in marketable debt securities, which are recorded at fair value. To minimize Nuvelo's exposure to credit risk, Nuvelo invests in securities with strong credit ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. Nuvelo does not invest in derivative financial instruments, mortgage-backed securities or auction rate securities, and Nuvelo has not recorded any losses on Nuvelo's securities due to credit or liquidity issues. In 2007 and 2008, rising delinquency and default rates on subprime mortgages and declining home prices had caused a significant decline in the value of residential mortgage-backed securities, which had negatively impacted the entire credit market in the U.S. In recent months, certain other financial instruments had also sustained downgrade in credit ratings and decline in value. Further deterioration in the credit market may have an adverse effect on the fair value of Nuvelo's investment portfolio.

## **Table of Contents**

*Nuvelo does not intend to pay cash dividends on its common stock in the foreseeable future.*

Nuvelo does not anticipate paying cash dividends on its common stock in the foreseeable future. Any payment of cash dividends will depend upon Nuvelo's financial condition, results of operations, capital requirements and other factors and will be at the discretion of Nuvelo's board of directors. Furthermore, Nuvelo may incur additional indebtedness that may severely restrict or prohibit the payment of dividends.

*Nuvelo has implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to Nuvelo's stockholders.*

Provisions of Nuvelo's certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire Nuvelo, even if doing so would benefit Nuvelo's stockholders. These provisions:

establish a classified board of directors so that not all members of Nuvelo's board may be elected at one time;

authorize the issuance of up to 5,000,000 shares of preferred stock that could be issued by Nuvelo's board of directors to increase the number of outstanding shares and hinder a takeover attempt;

limit who may call a special meeting of stockholders;

prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of Nuvelo's stockholders; and

establish advance notice requirements for nominations for election to Nuvelo's board of directors or for proposing matters that can be acted upon at a stockholder meeting.

Specifically, Nuvelo's certificate of incorporation provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The bylaws provide, however, that Nuvelo's stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50 percent of Nuvelo's common stock. These provisions of Nuvelo's certificate of incorporation and bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. Nuvelo designed these provisions to reduce Nuvelo's vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for Nuvelo's shares. As a consequence, they also may inhibit fluctuations in the market price of Nuvelo's shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in Nuvelo's management.

Nuvelo is permitted to issue shares of Nuvelo's preferred stock without stockholder approval upon such terms as Nuvelo's board of directors determines. Therefore, the rights of the holders of Nuvelo's common stock are subject to, and may be adversely affected by, the rights of the holders of Nuvelo's preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of Nuvelo's current stockholders.

Nuvelo is subject to the Delaware anti-takeover laws regulating corporate takeovers. These anti-takeover laws prevent a Delaware corporation from engaging in a merger or sale of more than ten percent of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15 percent or more of the corporation's outstanding voting stock, for six years following the date that the stockholder acquired 15 percent or more of the corporation's stock unless:

the board of directors approved the transaction where the stockholder acquired 15 percent or more of the corporation's stock;

Edgar Filing: NUVELO INC - Form S-4/A

after the transaction in which the stockholder acquired 15 percent or more of the corporation's stock, the stockholder owned at least 85 percent of the corporation's outstanding voting stock, excluding

---

## **Table of Contents**

shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or

on or after this date, the merger or sale is approved by the board of directors and the holders of at least two-thirds of the outstanding voting stock that is not owned by the stockholder.

The provisions of Nuvelo's governing documents, stockholder rights plan and current Delaware law may, collectively:

lengthen the time required for a person or entity to acquire control of Nuvelo through a proxy contest for the election of a majority of Nuvelo's board of directors;

discourage bids for Nuvelo's common stock at a premium over market price; and

generally deter efforts to obtain control of Nuvelo.

***Nuvelo has adopted Change in Control and Severance Benefit Plans that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to Nuvelo's stockholders.***

In December 2004, Nuvelo's board of directors approved an Executive Change in Control and Severance Benefit Plan for Nuvelo's executive officers and other eligible employees, which was amended and restated in August 2007. The purpose of the plan is to provide for the payment of severance benefits and/or change in control benefits to certain of Nuvelo's eligible employees, and the plan supersedes and replaces any change in control and/or severance plans adopted by Nuvelo previously. All of Nuvelo's executive employees at the level of vice president or above have been designated as participants in the plan and Nuvelo's board of directors may designate other eligible individuals as participants. The plan provides that, upon a change in control of the company as defined under the plan, all Nuvelo stock options and stock awards held by a plan participant will become fully vested. Such shares held by a plan participant will also become fully vested if the participant is terminated without cause, or constructively terminated, within one month preceding Nuvelo's change in control. If a participant is terminated without cause or constructively terminated one month before or one year after Nuvelo's change in control, he or she will also be entitled to certain cash severance and continued medical benefits. In June 2008, the compensation committee of Nuvelo's board of directors approved a Change in Control Severance Benefit Plan for Nuvelo's employees who are not eligible for benefits under the Executive Change in Control and Severance Benefit Plan, entitling these employees to certain cash severance and continued medical benefits if terminated without cause within one year after Nuvelo's change of control.

The change in control and severance benefits for certain of Nuvelo's employees provided for under these plans are expected to be triggered by the merger with ARCA. If the merger with ARCA is not consummated, these provisions could make it more difficult and expensive, or less desirable, for a third party to acquire Nuvelo, even if doing so would benefit Nuvelo's stockholders.

### **Risks Related to Nuvelo Intellectual Property and Other Legal Matters**

***Nuvelo is party to securities litigation, and defending these lawsuits could hurt Nuvelo's business. The volatility of the market price of Nuvelo's securities could engender additional class action securities litigation.***

Following periods of volatility in the market price of a company's securities, class action securities litigation has often been instituted against such a company. This risk is especially acute for Nuvelo, because biotechnology companies have experienced greater than average stock price volatility in recent years and, as a result, have been subject to, on average, a greater number of securities class action claims than companies in other industries. Any such litigation instigated against Nuvelo could result in substantial costs and a diversion of management's attention and resources, which could significantly harm Nuvelo's business, financial condition and operating results. For example, in December 2006, after Nuvelo announced that alfimeprase did not meet its primary

**Table of Contents**

endpoint in the first of two planned Phase 3 trials for the treatment of acute peripheral arterial occlusion and in the first of two planned Phase 3 trials for the treatment of catheter occlusion, the closing price of one share of Nuvelo's common stock was \$4.05 on the day of the announcement, as compared with a closing price of \$19.55 on the trading day prior to the announcement. On February 9, 2007, Nuvelo, Inc. and certain of Nuvelo's former and current officers and directors were named as defendants in a purported securities class action lawsuit filed in the U.S. District Court for the Southern District of New York. The suit alleges violations of the Securities Exchange Act of 1934 related to the clinical trial results of alfimeprase, which Nuvelo announced on December 11, 2006, and seeks damages on behalf of purchasers of Nuvelo's common stock during the period between January 5, 2006 and December 8, 2006. Specifically, the suit alleges that Nuvelo misled investors regarding the efficacy of alfimeprase and the drug's likelihood of success. The plaintiff seeks unspecified damages and injunctive relief. Three additional lawsuits were filed in the Southern District of New York on February 16, 2007, March 1, 2007 and March 6, 2007, respectively. On April 10, 2007, three separate motions to consolidate the cases, appoint lead plaintiff, and appoint lead plaintiff's counsel were filed. On April 18, 2007, Nuvelo filed a motion to transfer the four cases to the Northern District of California. The Court granted Nuvelo's motion to transfer the cases to the Northern District of California in July 2007. Plaintiffs have filed motions for consolidation, lead plaintiff and lead plaintiff's counsel in the Northern District of California. Plaintiffs filed their consolidated complaint in the Northern District of California on November 9, 2007. Nuvelo filed a motion to dismiss plaintiffs consolidated complaint on December 21, 2007. Plaintiffs filed an opposition to Nuvelo's motion to dismiss on February 4, 2008. On June 12, 2008, the Court held a hearing on the motion to dismiss. The motion to dismiss the consolidated complaint is still pending. Nuvelo currently cannot determine the impact that this litigation will have on Nuvelo's business, results of operations or financial condition.

In addition, Variagenics, with which Nuvelo merged in 2003, has been named as a defendant in a securities class action lawsuit alleging the failure to disclose additional and excessive commissions purportedly solicited by and paid to underwriters who are also named defendants in the lawsuit. Plaintiffs in the suit allege that underwriters took these commissions and in exchange allocated shares of Variagenics' stock to their preferred customers through alleged agreements with these preferred customers that tied the allocation of initial public offering shares to agreements by the customers to make additional aftermarket purchases at pre-determined prices. As a result of Nuvelo's merger with Variagenics, Nuvelo is obligated to continue to defend against this litigation. Nuvelo believes that any attorneys' fees, loss or settlement payment with respect to this suit will not be material to Nuvelo's financial position or results of operations, and that any loss, settlement payment or attorneys' fees accrued with respect to the suit will be paid by Nuvelo's insurance provider. Because of a recent court ruling, the settlement class, as defined in the settlement papers, is no longer feasible. While a new complaint has not been filed against Nuvelo, there are several "focus" cases against other issuers in which new complaints have been filed. Defendant issuers in the "focus" cases filed motions to dismiss the new complaints. On March 26, 2008, the District Court issued an order granting in part and denying in part the "focus" issuers motions to dismiss. The "focus" issuers had been advised that plaintiffs intended to file new complaints against Nuvelo, but none have been filed yet. Nuvelo could be forced to incur material expenses in the litigation if the parties cannot achieve a settlement, and in the event there is an adverse outcome, Nuvelo's business could be harmed.

***The commercial success of Nuvelo's products will depend upon Nuvelo's ability to protect the intellectual property rights associated with Nuvelo's products and product candidates.***

Nuvelo's competitive success will depend, in part, on Nuvelo's ability to obtain and maintain patent protection for its inventions, technologies and discoveries, including intellectual property that Nuvelo licenses. The patent positions of biotechnology companies involve complex legal and factual questions, and Nuvelo cannot assure you that Nuvelo's patents and licenses will successfully preclude others from using Nuvelo's technology. Nuvelo could incur substantial costs in seeking enforcement of its proprietary rights against infringement.

Nuvelo currently has, or has in-licensed, issued patents and pending patent applications that include claims to Nuvelo's in-licensed clinical products. Nuvelo also currently has patents that cover some of Nuvelo's

## **Table of Contents**

technological discoveries and patent applications that Nuvelo expects to protect some of its gene, protein and technological discoveries. Nuvelo will continue to apply for patents for its discoveries. Nuvelo cannot assure you that any of its applications, or its licensors' applications, will issue as patents, or that any patent issued or licensed to Nuvelo will not be challenged, invalidated, circumvented or held unenforceable by way of an interference proceeding or litigation.

The timing of the grant of a patent cannot be predicted. Patent applications describing and seeking patent protection of methods, compositions, or processes relating to proprietary inventions involving human therapeutics could require Nuvelo to generate data, which may involve substantial costs. Nuvelo's pending patent applications may lack priority over others' applications or may not result in the issuance of patents. Even if issued, Nuvelo's patents may not be sufficiently broad to provide protection against competitors with similar technologies and may be challenged, invalidated or circumvented.

In addition to patents, Nuvelo relies on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop Nuvelo's competitive position with respect to intellectual property. Nevertheless, these measures may not be adequate to safeguard the technology underlying Nuvelo's products. For example, employees, consultants and others who participate in the development of Nuvelo's products may breach their agreements with Nuvelo regarding its intellectual property, and Nuvelo may not have adequate remedies for the breach. Nuvelo's trade secrets could become known through other unforeseen means. Nuvelo depends on its collaborators and other third parties that license intellectual property to Nuvelo to protect its licensed intellectual property. These collaborators and other third parties could fail to take a necessary step to protect Nuvelo's licensed intellectual property, which could seriously harm Nuvelo's intellectual property position.

Nuvelo also may not be able to effectively protect its intellectual property rights in some foreign countries, as many countries do not offer the same level of legal protection for intellectual property as the U.S. Furthermore, certain of the patent applications describing Nuvelo's proprietary methods are filed only in the U.S. Even where Nuvelo has filed its patent applications internationally, for some cases and in certain countries, Nuvelo has chosen not to maintain foreign patent protection by opting not to enter national phase or opting not to pay maintenance annuities.

Notwithstanding Nuvelo's efforts to protect its intellectual property, Nuvelo's competitors may independently develop similar or alternative technologies or products that are equal or superior to Nuvelo's technology. Nuvelo's competitors may also develop similar products without infringing on any of Nuvelo's intellectual property rights or design around Nuvelo's proprietary technologies.

***If the manufacture, use or sale of Nuvelo's products infringe on the intellectual property rights of others, Nuvelo could face costly litigation, which could cause Nuvelo to pay substantial damages or licensing fees and limit its ability to sell some or all of its products.***

Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know-how and determine the enforceability, scope and validity of certain proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S. Patent and Trademark Office interference proceedings, and related legal and administrative proceedings in the U.S. and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time-consuming to pursue, and their outcome is uncertain.

Regardless of merit or outcome, Nuvelo's involvement in any litigation, interference or other administrative proceedings could cause Nuvelo to incur substantial expense and could significantly divert the efforts of Nuvelo's technical and management personnel. An adverse determination may subject Nuvelo to the loss of its proprietary position or to significant liabilities, or require Nuvelo to seek licenses that may include substantial

**Table of Contents**

cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent Nuvelo from manufacturing and selling its products, if any. These outcomes could materially harm Nuvelo's business, financial condition and results of operations.

Nuvelo's market success depends in part on Nuvelo neither infringing valid, enforceable patents or proprietary rights of third parties, nor breaching any licenses that may relate to Nuvelo's technologies and products. Nuvelo is aware of third-party patents and proprietary rights that may relate to Nuvelo's technology. Nuvelo may be required to obtain licenses to patents or other proprietary rights of others for itself, its collaboration partners and its service providers in order to conduct research, development or commercialization of some or all of Nuvelo's programs. Nuvelo plans to seek licenses, as it deems appropriate, but it is possible that Nuvelo may infringe upon these patents or proprietary rights of third parties. If Nuvelo does not obtain these licenses, it may encounter delays in product market introductions, incur substantial costs while Nuvelo attempts to design around existing patents or not be able to develop, manufacture or sell products. In response, third parties may assert infringement or other intellectual property claims against Nuvelo, its collaboration partners or its service providers. Nuvelo may consequently be subjected to substantial damages for past infringement or be required to modify its products if it is ultimately determined that Nuvelo's products infringe a third party's proprietary rights. Further, Nuvelo may be prohibited from selling its products before it obtains a license, which, if available at all, may require Nuvelo to pay substantial royalties, which could adversely impact Nuvelo's product costs and have a negative impact on its business. Further, if Nuvelo does obtain these licenses, the agreed terms may necessitate reevaluation of the potential commercialization of any one of Nuvelo's programs. Failing to obtain a license could result in litigation. Even if these claims are without merit, defending a lawsuit takes significant time, may be expensive and may divert management attention from other business concerns. Any public announcements related to litigation or interference proceedings initiated or threatened against Nuvelo could cause Nuvelo's stock price to decline.

***Nuvelo faces product liability exposure and potential unavailability of insurance.***

Nuvelo risks financial exposure to product liability claims in the event that the use of products developed by Nuvelo, or its collaboration partners, if any, result in personal injury. Nuvelo may experience losses due to product liability claims in the future. Nuvelo has obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to Nuvelo in sufficient amounts or at an acceptable cost, or at all. Nuvelo may not be able to obtain commercially reasonable product liability insurance for any product approved for marketing. A product liability claim or other claim, product recalls, as well as any claims for uninsured liabilities or in excess of insured liabilities, may significantly harm Nuvelo's business, financial condition and results of operations.

***Nuvelo faces heavy government regulation, and any disputes relating to business practices or improper handling, storage or disposal of hazardous materials, chemicals and patient samples could be time consuming and costly.***

Nuvelo's research and development and production activities involve the controlled use of hazardous or radioactive materials, chemicals, including oxidizing and reducing reagents, infectious disease agents, patient tissue and blood samples. Nuvelo, its collaborators, and service providers are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and certain waste products. Nuvelo could be liable for accidental contamination or discharge or any resultant injury from hazardous materials, and conveyance, processing, and storage of and data on patient samples. If Nuvelo, its collaborators, or service providers fail to comply with applicable laws or regulations, Nuvelo could be required to pay penalties or be held liable for any damages that result, and this liability could exceed Nuvelo's financial resources. Further, future changes to environmental health and safety laws could cause Nuvelo to incur additional expense or restrict its operations. In addition, Nuvelo's collaborators and service providers may be working with hazardous materials, including viruses and hazardous chemicals, in connection with Nuvelo's collaborations. In the event of

**Table of Contents**

a lawsuit or investigation, Nuvelo could be held responsible for any injury caused to persons or property by exposure to, or release of, patient samples that may contain viruses and hazardous materials. The cost of this liability could exceed Nuvelo's resources.

Nuvelo also is subject to numerous federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, general business practices, the experimental use of animals, and the environment. In addition, Nuvelo cannot predict the extent of government regulations or the impact of new governmental regulations that might significantly harm the discovery, development, production and marketing of Nuvelo's products. Nuvelo may be required to incur significant costs to comply with current or future laws or regulations, and Nuvelo may be adversely affected by the cost of such compliance.

**Risks Related to ARCA's Business**

*If ARCA is not able to successfully develop and commercialize Gencaro, ARCA may not generate sufficient revenues to continue its business operations.*

ARCA currently has no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly. Gencaro is ARCA's only product candidate at a late stage of clinical development and is currently awaiting approval of its NDA. ARCA has no other product candidates. As a result, ARCA's business is currently substantially dependent on its ability to obtain regulatory approval for and successfully commercialize Gencaro in a timely manner. If the NDA is not approved, or is substantially delayed, or if ARCA is unable to successfully commercialize Gencaro, it may not be able to earn sufficient revenues to continue its business.

*Unless ARCA is able to generate sufficient product revenue, ARCA will continue to incur losses from operations and may not achieve or maintain profitability.*

ARCA is a development stage biopharmaceutical company with a limited operating history. To date, it has not generated any product revenue and has historically funded its operations through investment capital. ARCA has incurred losses in each year since its inception. For its fiscal years ended December 31, 2007, 2006 and 2005, ARCA's net losses were \$14.0 million, \$5.2 million and \$1.5 million, respectively. For its nine months ended September 30, 2008, ARCA's net losses were \$14.3 million. As of September 30, 2008, ARCA had incurred \$35.6 million in net losses since its inception. These losses, among other things, have had and will continue to have an adverse effect on ARCA's stockholders' equity and working capital. Even if ARCA receives regulatory approval for any product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. ARCA's ability to generate revenue depends on a number of factors, including its ability to:

develop and obtain regulatory approval for Gencaro<sup>TM</sup> or other product candidates;

obtain commercial quantities of Gencaro or other product candidates at acceptable cost levels;

successfully market and sell Gencaro or other product candidates;

successfully partner a companion genetic test with the commercial launch of Gencaro; and

successfully conduct and complete clinical trials for Gencaro and other product candidates.

ARCA expects to incur increased general and administrative expenses due to higher sales and marketing expenses. As a result, it expects to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, ARCA may experience larger than expected future losses and may never reach profitability.



---

**Table of Contents**

***ARCA's product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase ARCA's future development costs or impair ARCA's future revenue.***

The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, advertising, promotion, sale, and marketing, and distribution of ARCA's product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and elsewhere. These regulations also vary in important, meaningful ways from country to country. ARCA is not permitted to market a potential drug in the United States until ARCA receives approval of a New Drug Application, or NDA, from the FDA. ARCA has not received an NDA approval from the FDA. There can be no guarantees with respect to ARCA's product candidates that clinical studies will support an ARCA NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful.

To receive regulatory approval for the commercial sale of any product candidates, ARCA must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well-controlled clinical trials of the product candidates. This process is expensive and can take many years, and failure can occur at any stage of the testing. ARCA's failure to adequately demonstrate the safety and efficacy of its product candidates will prevent regulatory approval and commercialization of such products. With respect to Gencaro, the FDA could determine that the preclinical studies and clinical trials conducted by or on Gencaro's behalf were inadequate, and such a determination would prevent regulatory approval and commercialization of Gencaro. For instance, ARCA filed an NDA for Gencaro in July 2008, based primarily on a single Phase 3 trial. The FDA guidelines generally suggest that sponsors conduct two adequate and well-controlled studies to demonstrate the safety and efficacy of a product candidate such as Gencaro in support of FDA approval. FDA interpretation of the statutory requirements also states that a single study may be sufficient to support approval if the FDA determines that, based on relevant science and other confirmatory evidence, there is strong evidence to establish the safety and efficacy of the drug candidate using a single adequate and well-controlled study. If the FDA determines that the clinical data for Gencaro is not sufficiently strong to demonstrate Gencaro's safety and efficacy for chronic heart failure, then Gencaro may not be approved by the FDA for ARCA's proposed indications, may be approved for a more limited indication, or the FDA may require ARCA to conduct additional studies before approving Gencaro for chronic heart failure. Even if ARCA conducted additional studies and submitted the attendant data, FDA may ultimately decide that the NDA does not satisfy the criteria for approval.

In the event that ARCA or its contractors conduct preclinical studies that did not comply with GLP or incorrectly design or carry out human clinical trials or those clinical trials fail to demonstrate clinical significance, ARCA will not likely be able to obtain FDA approval for product development candidates. ARCA's inability to successfully and effectively complete clinical trials for any product candidates on schedule or at all will severely harm ARCA's business. Significant delays in clinical development could materially increase product development costs or allow ARCA's competitors to bring products to market before it does, impairing ARCA's ability to effectively commercialize any future product candidates. ARCA does not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:

delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to ARCA's product candidates or similar product candidates of ARCA's competitors or failure to follow regulatory guidelines;

delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidate for use in trials;

delays or failures in reaching agreement on acceptable terms with prospective study sites;

delays or failures in obtaining approval of ARCA's clinical trial protocol from an institutional review board, or IRB, to conduct a clinical trial at a prospective study site;

---

**Table of Contents**

delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies, availability of clinical trial sites;

other clinical trials seeking to enroll subjects with similar profile;

failure of ARCA's clinical trials and clinical investigators to be in compliance with the FDA's Good Clinical Practices, or GCP;

unforeseen safety issues, including negative results from ongoing preclinical studies;

inability to monitor patients adequately during or after treatment;

difficulty monitoring multiple study sites; and

failure of ARCA's third-party contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines.

In addition, any approvals ARCA may obtain may not cover all of the clinical indications for which it seeks approval. In addition, if ARCA chooses to make claims of superiority over currently marketed competitive products, ARCA must substantiate those claims with scientific evidence from prospectively designed head-to-head clinical trials. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, ARCA may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug's distribution, or a Medication Guide to provide better information to consumers about the drug's risks and benefits. Finally, an approval could be conditioned on ARCA's commitment to conduct further clinical trials, which ARCA may not have the resources to conduct or which may negatively impact ARCA's financial situation.

In September 2008, the FDA formally accepted for filing ARCA's NDA, for Gencaro, with the goal of reviewing the NDA by May 31, 2009. Filing of the NDA indicates that the application is sufficiently complete to allow for FDA to review ARCA's data supporting the safety profile and effectiveness of Gencaro, but does not guarantee approval. All of ARCA's product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to:

side effects;

safety and efficacy;

defects in the design of clinical trials;

the fact that the FDA or other regulatory officials may not approve ARCA's or ARCA's third party manufacturer's processes or facilities; or

---

**Table of Contents**

the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate.

In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product's risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA by May 31, 2009. Indeed, in early 2008, the FDA announced that due to a lack of resources, NDAs may not be reviewed within the performance goals under the Prescription Drug User Fee Act, and from time to time, the FDA has extended the review period for NDAs.

In addition, the manufacture and tableting of Gencaro is done by third party suppliers, who must pass a pre-approval inspection of their facilities before ARCA can obtain marketing approval. The FDA could also request additional information or data, including data from an additional Phase 3 study, which may extend the review period.

In its NDA, ARCA has requested that the FDA approve Gencaro as a therapy that can be prescribed by physicians for patients with heart failure, and specifically for its effect on certain clinical outcomes for these heart failure patients. ARCA has also requested that certain information be included in the prescribing information distributed with Gencaro that shows the effect of genetic differences in patients on the clinical results for Gencaro. The FDA could approve Gencaro, but without including some or all of the prescribing information that ARCA has requested. For instance, FDA could approve Gencaro without some or all of the pharmacogenetic information in the labeling. This, in turn, could substantially and detrimentally impact ARCA's ability to successfully commercialize Gencaro.

***ARCA has no manufacturing capacity which puts it at risk of lengthy and costly delays of bringing its products to market.***

ARCA does not currently operate manufacturing facilities for clinical or commercial production of its product candidates, including their active pharmaceutical ingredients, or API. ARCA has no experience in drug formulation or manufacturing, and it lacks the resources and the capabilities to manufacture any of its product candidates on a clinical or commercial scale. ARCA does not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future.

ARCA has contracted with Groupe Novasep to manufacture commercial quantities of the API for Gencaro. For drug production, ARCA has contracted with Patheon, Inc. to manufacture the Gencaro tablets. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute ARCA's products. In the event of a natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock-outs or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, ARCA may be unable to replace a third-party manufacturer in a timely manner and the production of its product candidates would be interrupted, resulting in delays and additional costs.

---

**Table of Contents**

ARCA or its contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, cost overruns or other problems that could seriously hurt its business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, its contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S. Drug Enforcement Agency and corresponding state agencies and they may fail to meet these agencies' acceptable standards of compliance. If ARCA's contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, ARCA may not be able to continue production of the API or finished product. If the safety of any API or product supplied is compromised due to failure to adhere to applicable law or for other reasons, this may jeopardize ARCA's regulatory approval for Gencaro and other product candidates, and may be held liable for any injuries sustained as a result.

Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including:

the number of potential manufacturers is limited and ARCA may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms;

long lead times are often needed to manufacture drugs;

the manufacturing process is complex and may require a significant learning curve; and

the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections.

***If ARCA's product candidates receive regulatory approval, ARCA would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit its ability to commercialize its potential products.***

If a product candidate of ARCA is approved by the FDA or by another regulatory authority, ARCA would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for postmarketing studies, and could include withdrawal of the products from the market.

Furthermore, ARCA's third-party manufacturers and the manufacturing facilities that they use to make ARCA's product candidates are regulated by the FDA. Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by ARCA or its collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. ARCA and its third-party manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post-market information.

---

## **Table of Contents**

The marketing and advertising of ARCA's drug products by its collaborators or ARCA will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of ARCA's products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize ARCA's ability to market the product.

In addition to the FDA, state or foreign regulations, the marketing of ARCA's drug products by ARCA or its collaborators will be regulated by federal, state or foreign laws pertaining to health care fraud and abuse, such as the federal anti-kickback law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far-reaching nature of these laws, ARCA may be required to discontinue one or more of its practices to be in compliance with these laws. Health care fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against ARCA for violations of these laws, even if ARCA successfully defends against it, could have a material adverse effect on ARCA's business, financial condition and results of operations.

ARCA could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. ARCA may become subject to such litigation and, if ARCA is not successful in defending against such actions, those actions may have a material adverse effect on its business, financial condition and results of operations.

Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be enacted that could prevent or delay regulatory approval of ARCA's product candidate. ARCA cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or elsewhere.

If ARCA, its collaborators or its third-party manufacturers fail to comply with applicable continuing regulatory requirements, ARCA's business could be seriously harmed because a regulatory agency may:

issue warning letters;

suspend or withdraw ARCA's regulatory approval for approved products;

seize or detain products or recommend a product recall;

refuse to approve pending applications or supplements to approved applications filed by ARCA;

suspend any of ARCA's ongoing clinical trials;

impose restrictions on ARCA's operations, including costly new manufacturing requirements;



---

**Table of Contents**

seek an injunction;

close the facilities of ARCA's contract manufacturers; or

impose civil or criminal penalties.

***If LabCorp or certain of its third-party suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the Gencaro Test, these products could be subject to restrictions or withdrawal from the market.***

Any medical device for which LabCorp obtains clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the Gencaro Test, to the extent applicable, LabCorp and certain of its suppliers will be required to comply with the FDA's Quality System Regulation, or QSR, and International Standards Organization, or ISO, requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by LabCorp, or certain of its third-party manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm ARCA's reputation and cause product sales and profitability of Gencaro to suffer and may prevent ARCA from generating revenue.

Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce ARCA's potential to successfully commercialize the product and generate revenue from the product.

***Medical devices related to Gencaro, such as the Gencaro Test, may in the future be subject to product recalls that could harm the combined company's reputation, business and financial results.***

The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a mandatory recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious adverse health consequences or death. In addition, foreign governmental bodies have the authority to require the recall of ARCA's products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, initiate a field correction or removal, known as a recall, for a product if any material deficiency in a device is found. A government-mandated or voluntary recall by ARCA's third-party suppliers, including LabCorp, could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Any such recalls would divert managerial and financial resources and may have an adverse effect on the combined company's and ARCA's financial condition and results of operations.

***If medical devices related to Gencaro, such as the Gencaro Test, cause or contribute to a death or a serious injury, or malfunction in certain ways, ARCA's third-party suppliers will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.***

Under the FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device or one of ARCA's similar devices were to recur. If ARCA's third-party suppliers, including LabCorp, fail to report these events to the FDA within the required timeframes, or at all, the FDA could take enforcement



---

**Table of Contents**

action against ARCA's third-party suppliers, including LabCorp. Any such adverse event involving the Gencaro Test also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, taken by ARCA's third-party suppliers, including LabCorp, may significantly affect the combined company's ability to market Gencaro. In such cases, ARCA or the combined company could be forced to identify a new third-party test provider for the Gencaro Test.

***LabCorp may need to conduct clinical trials to support current or future versions of the Gencaro Test. Delays or failures in any such clinical trials may prevent LabCorp from commercializing any modified or new versions of the Gencaro Test and will adversely affect the combined company's business, operating results and prospects.***

Based on discussions with the FDA, ARCA and LabCorp do not believe that additional clinical data are needed for the Gencaro Test submission. However, the FDA may require clinical data for the Gencaro Test submission and/or future products. Initiating and completing clinical trials necessary to support 510(k)s or PMAs, if required, for current or future products will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product ARCA or its third party suppliers, including LabCorp, advance into clinical trials may not have favorable results in later clinical trials.

Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including: the size of the patient population; the number of patients to be enrolled; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites; and the patients' ability to meet the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of ARCA's products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. In addition, patients participating in clinical trials may die before completion of the trial or suffer adverse medical events unrelated to investigational products.

Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required, and LabCorp, the combined company or ARCA may not adequately develop such protocols to support clearance and approval. Significant risk trials will require the submission and approval of an IDE from the FDA. There is no guarantee that the FDA will approve LabCorp's or ARCA's future IDE submissions. Further, the FDA may require LabCorp or ARCA to submit data on a greater number of patients than originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to ARCA's clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of future products or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in such clinical trials, the FDA may not consider the data to be adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect ARCA's third party suppliers, the combined company's or ARCA's business, operating results and prospects.

***Federal regulatory reforms may adversely affect ARCA's or its suppliers' ability to sell products profitably.***

From time to time, legislation is drafted and introduced in the U.S. Congress that could significantly change the statutory provisions governing the clearance or approval, manufacture and marketing of a medical device. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect the way that medical devices are marketed and promoted. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.

---

**Table of Contents**

Without limiting the generality of the foregoing, last year, the Food and Drug Administration Amendments Act of 2007, or the Amendments, were enacted. The Amendments require, among other things, that the FDA propose, and ultimately implement, regulations that will require manufacturers to label medical devices with unique identifiers unless a waiver is received from the FDA. Once implemented, compliance with those regulations may require manufacturers to take additional steps in the manufacture and labeling of medical devices. These steps may require additional resources and could be costly. In addition, the Amendments require medical device manufacturers to, among other things, comply with clinical trial registration requirements once clinical trials are initiated.

***The loss of any rights to market key products would significantly impair ARCA's operating results.***

ARCA has licensed from Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC, who has licensed rights in Gencaro from Bristol Myers Squibb, or BMS, the exclusive rights to Gencaro for all therapeutic and diagnostic uses in any country until the later of (i) 10 years from the first commercial sale of Gencaro in such country, or (ii) the termination of ARCA's commercial exclusivity in such country. ARCA is obligated to use commercially reasonable efforts to develop and commercialize Gencaro, including obtaining regulatory approvals. ARCA's ability to develop and commercialize Gencaro is dependent on numerous factors, including some factors that are outside of its control. CPEC has the right to terminate ARCA's license if ARCA materially breaches its obligations under the license agreement and fails to cure any such breach within the terms of the license.

If ARCA's license agreement with CPEC is terminated for reasons related to non-payment of fees, or for any other breach, then ARCA would have no further rights to develop and commercialize Gencaro for any indication. The termination of this license, or of any other agreement which enables ARCA to market a key product or product candidate, could significantly and adversely affect ARCA's business.

***If ARCA is unable to establish a direct sales force in the U.S., its business may be harmed.***

ARCA is currently building its sales organization. Assuming Gencaro is approved by the FDA for commercial sale, ARCA intends to market Gencaro in the U.S. to physicians, hospitals and other health care providers using its own sales force. While certain ARCA employees have experience in establishing and managing a sales force, these employees have no such experience since being with ARCA. ARCA will need to incur significant additional expenses and commit significant additional management resources to establish a sufficient sales force for Gencaro.

ARCA may not be able to successfully establish these capabilities despite these additional expenditures. If ARCA elects to rely on third parties to sell Gencaro and any other products, then it may receive less revenue than if it sold such products directly. In addition, ARCA may have little or no control over the sales efforts of those third parties. In the event ARCA is unable to sell Gencaro and other selected product candidates, either directly or through third parties, the commercialization of Gencaro may be delayed indefinitely and ARCA's business may be harmed.

***ARCA's failure to establish and manage a distribution network for its products could delay or compromise the commercialization of Gencaro and other future products.***

ARCA has not yet established systems and processes necessary for distributing products to customers. ARCA plans to contract with one or more wholesale distributors to warehouse its products and distribute them to retail, hospital and other pharmacy suppliers that would then distribute its products directly to patients. This distribution network will require significant coordination with its sales and marketing and finance organizations. Failure to secure contracts with distribution services could negatively impact the distribution of ARCA's products, if any, and failure to coordinate financial systems could negatively impact its ability to accurately report product revenue, if any. If ARCA is unable to effectively establish and manage the distribution process, then the commercialization of Gencaro and other product candidates may be delayed or severely compromised and ARCA's results of operations may be harmed.

---

**Table of Contents**

***If approved by the FDA, Gencaro will be entering into a competitive marketplace and may not succeed.***

Gencaro is a new type of beta-blocker and vasodilator being developed for heart failure and other indications. While ARCA anticipates that this drug will be the first genetically-targeted cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta-blocker class currently on the market. Currently, there are three branded beta-blockers indicated for chronic heart failure in NYHA class II-IV patients: TOPROL-XL (once-a-day formulation), Coreg and Coreg CR (once-a-day). TOPROL-XL and Coreg have generic equivalents commercially available in the U.S. (Metoprolol Succinate and Carvedilol respectively). The price of the generic forms of these drugs will be less than the anticipated price of Gencaro, if approved. As a result, Gencaro may not be successful in competing against these existing drugs.

Additionally, Forest Laboratories may apply for approval to use Bystolic, a drug currently used to treat high blood pressure, for treatment of heart failure. If approved for treatment of heart failure, Gencaro may not be successful in competing against Bystolic, an already well-known name brand. Accordingly, ARCA may not achieve its revenue goals, and its business may be harmed.

ARCA's commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of ARCA's common stock.

***Future sales of ARCA's products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community.***

Gencaro or ARCA's other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro or ARCA's other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. Also, prevalence and severity of side-effects could negatively affect market acceptance of Gencaro. Side-effects observed during clinical trials included fatigue, dizziness and slowed heart beat. Failure to achieve market acceptance of Gencaro would significantly harm ARCA's business.

***If ARCA is unable to obtain acceptable prices or adequate reimbursement from third-party payors for Gencaro, or any other product candidates that ARCA may seek to commercialize, then its revenues and prospects for profitability will suffer.***

ARCA's ability to commercialize Gencaro, or any other product candidates that it may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from:

governmental payors, such as Medicare and Medicaid;

private health insurers, including managed-care organizations; and

other third-party payors.

Many patients will not be capable of paying for ARCA's potential products themselves and will rely on third-party payors to pay for their medical needs. A primary current trend in the U.S. health care industry is toward cost containment. Large private payors, managed-care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly approved health care products. In particular, third-party payors may limit the reimbursed indications.

---

## **Table of Contents**

Cost-control initiatives could decrease the price ARCA might establish for products, which could result in product revenues lower than anticipated. If the prices for ARCA's product candidates decrease or if governmental and other third-party payors do not provide adequate coverage and reimbursement levels, then ARCA's revenue and prospects for profitability will suffer.

***ARCA's competitors may be better positioned in the marketplace and thereby may be more successful than ARCA at developing, manufacturing and marketing approved products.***

Many of ARCA's competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than ARCA. Other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with ARCA in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to ARCA's programs or advantageous to its business. ARCA expects that its ability to compete effectively will depend upon its ability to:

successfully and rapidly complete clinical trials for any future product candidates and obtain all requisite regulatory approvals in a cost-effective manner;

build an adequate sales and marketing infrastructure;

develop competitive formulations of its product candidates;

attract and retain key personnel; and

identify and obtain other product candidates on commercially reasonable terms.

***If ARCA fails to identify and license or acquire other products or product candidates, then it may be unable to expand its business, and the acquisition or licensing of other products or product candidates may put a strain on ARCA's operations and will likely require ARCA to seek additional financing.***

One of ARCA's key strategies is to license or acquire clinical-stage products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of ARCA's competitors may have greater resources than ARCA. Other than this transaction with Nuvelo, ARCA has no definitive agreement regarding any material acquisitions. If ARCA undertakes any additional acquisitions, whether product candidates or other biopharmaceutical companies, the process of integrating an acquired product, candidate or complementary company into ARCA's business may put a strain on its operations, divert personnel, financial resources and management's attention. If ARCA is not successful in identifying and licensing or acquiring other products or product candidates or completing future acquisitions, then it may be unable to expand its pipeline of product candidates beyond Gencaro. In addition, any future acquisition would give rise to additional operating costs and will likely require ARCA to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect ARCA's operating results.

***Any future product revenues could be reduced by imports from countries where ARCA's product candidates are available at lower prices.***

Even if ARCA obtains FDA approval to market Gencaro or other products in the U.S., ARCA's sales in the U.S. may be reduced if ARCA's products are imported into the U.S. from lower priced markets, whether legally or illegally. In the U.S., prices for pharmaceuticals are generally higher than in the bordering nations of Canada and Mexico. There have been proposals to legalize the import of pharmaceuticals from outside the U.S. If such legislation were enacted, then ARCA's future revenues could be reduced.



---

**Table of Contents**

*If product liability lawsuits are successfully brought against ARCA, then ARCA will incur substantial liabilities and may be required to limit commercialization of Gencaro or other product candidates.*

ARCA faces product liability exposure related to the testing of its product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once it begins marketing and distributing its products commercially. If ARCA cannot successfully defend itself against product liability claims, then it will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for its products and product candidates;

injury to its reputation;

withdrawal of clinical trial participants;

costs of related litigation;

substantial monetary awards to patients and others;

loss of revenues; and

the inability to commercialize its products and product candidates.

ARCA does not maintain product liability insurance to cover clinical trials. While ARCA intends to expand its insurance coverage to include the sale of commercial products if marketing approval is obtained for Gencaro or any other product candidate, it does not currently maintain such insurance. Insurance coverage is increasingly expensive; ARCA may not be able to secure insurance coverage at a reasonable cost, and it may not be able to obtain insurance coverage that will be adequate to satisfy any liability that may arise.

*Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive.*

ARCA's research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. ARCA cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. ARCA may be sued or be required to pay fines for any injury or contamination that results from its use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair its research, development and production efforts.

*Third parties may own or control patents or patent applications that ARCA may be required to license to commercialize its product candidates or that could result in litigation that would be costly and time consuming.*

ARCA's ability to commercialize Gencaro and other product candidates depends upon its ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to ARCA. ARCA may choose to seek, or be required to seek, licenses under third party patents, which would likely require the payment of license fees or royalties or both. ARCA may also be unaware of existing patents that may be infringed by Gencaro, the genetic testing ARCA intends to use in connection with Gencaro or its other product candidates. Because patent applications can take many years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro or ARCA's other product candidates. Moreover, a

license may not be available to ARCA on commercially reasonable terms, or at all.

There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that ARCA is infringing on

---

**Table of Contents**

its technology, then ARCA's business and results of operations could be harmed by a number of factors, including:

infringement and other intellectual property claims, even if without merit, are expensive and time-consuming to litigate and can divert management's attention from ARCA's core business;

monetary damage awards for past infringement can be substantial;

a court may prohibit ARCA from selling or licensing product candidates unless the patent holder chooses to license the patent to ARCA; and

if a license is available from a patent holder, ARCA may have to pay substantial royalties.

ARCA may also be forced to bring an infringement action if it believes that a competitor is infringing its protected intellectual property. Any such litigation will be costly, time-consuming and divert management's attention, and the outcome of any such litigation may not be favorable to ARCA.

***ARCA's intellectual property rights may not preclude competitors from developing competing products and ARCA's business may suffer.***

ARCA's competitive success will depend, in part, on ARCA's ability to obtain and maintain patent protection for its inventions, technologies and discoveries, including intellectual property that ARCA licenses. The patent positions of biotechnology companies involve complex legal and factual questions, and ARCA cannot be certain that ARCA's patents and licenses will successfully preclude others from using ARCA's technology. ARCA could incur substantial costs in seeking to enforce its proprietary rights against infringement.

ARCA may not be able to effectively protect its intellectual property rights in some foreign countries, as many countries do not offer the same level of legal protection for intellectual property as the U.S. Furthermore, the patent applications describing ARCA's proprietary methods are filed only in the U.S.

Although Gencaro has an established patent strategy, the timing of the grant of a patent cannot be predicted. Patent applications describing and seeking patent protection of methods, compositions or processes relating to proprietary inventions involving human therapeutics could require ARCA to generate data, which may involve substantial costs. ARCA's pending patent applications may lack priority over others' applications or may not result in the issuance of patents. Even if issued, ARCA's patents may not be sufficiently broad to provide protection against competitors with similar technologies and may be challenged, invalidated or circumvented.

While the composition of matter patents on the compound have expired, ARCA holds the intellectual property arising from the discovery of the interaction of Gencaro with the polymorphisms of the  $\beta_1$  and  $\alpha_2c$  receptors. ARCA has filed patent applications that claim the use of Gencaro with the diagnosis of a patient's receptor genotype. ARCA's NDA requested a label that will include a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. Under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label could be considered as inducing infringement, carrying the same liability as direct infringement.

Nevertheless, these measures may not be adequate to safeguard the technology underlying ARCA's product candidate. For example, employees, consultants and others who participate in the development of ARCA's products may breach their agreements with ARCA regarding its intellectual property, and ARCA may not have adequate remedies for the breach. Third parties could fail to take a necessary step to protect ARCA's licensed intellectual property, which could seriously harm ARCA's intellectual property position. Even if the patents are granted, the approved label may not contain language covered by the patents, or ARCA may be unsuccessful in enforcing them.



## **Table of Contents**

If ARCA is not able to protect its proprietary technology, trade secrets and know-how, then its competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with ARCA; for instance, if the FDA does not require that Gencaro and any equivalent be labeled consistently with any patent protection. Further, ARCA has trade secrets relating to Gencaro, and such trade secrets may become known or independently discovered. ARCA's issued patents and those that may issue in the future, or those licensed to ARCA, may be challenged, opposed, invalidated or circumvented, which could limit ARCA's ability to stop competitors from marketing related products or the term of patent protection that ARCA may have for its product candidates. All of these factors may affect ARCA's competitive position.

***If the manufacture, use or sale of ARCA's products infringe on the intellectual property rights of others, ARCA could face costly litigation, which could cause ARCA to pay substantial damages or licensing fees and limit its ability to sell some or all of its products.***

Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know-how and determine the enforceability, scope and validity of certain proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S. Patent and Trademark Office interference proceedings, and related legal and administrative proceedings in the U.S. and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time-consuming to pursue, and their outcome is uncertain.

Regardless of merit or outcome, ARCA's involvement in any litigation, interference or other administrative proceedings could cause ARCA to incur substantial expense and could significantly divert the efforts of ARCA's technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against Nuvelo could cause Nuvelo's stock price to decline. An adverse determination may subject ARCA to the loss of its proprietary position or to significant liabilities, or require ARCA to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent ARCA from manufacturing and selling its products, if any. These outcomes could materially harm ARCA's business, financial condition and results of operations.

***If ARCA fails to attract and keep senior management and key scientific personnel, it may be unable to successfully develop and commercialize its product candidates.***

ARCA's success depends on its continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel and on its ability to develop and maintain important relationships with leading academic institutions, clinicians and scientists. The loss of services of one or more of ARCA's members of senior management could delay or prevent the successful completion of the commercialization of Gencaro or in other ways harm ARCA's business. In particular, the loss of the service of Richard Brewer, ARCA's president and chief executive officer, or Dr. Michael Bristow, ARCA's founder and chief science and medical officer, could substantially impair ARCA's future prospects. To mitigate a portion of this risk, ARCA currently carries key person insurance on the life of Dr. Bristow in the amount of \$1 million.

There is significant competition from other companies and research and academic institutions for qualified personnel in the areas of ARCA's activities. Competition for personnel with biopharmaceutical skills is intense. If ARCA fails to identify, attract, retain and motivate these highly skilled personnel, then it may be unable to continue its development and commercialization activities.

**Table of Contents**

**FORWARD-LOOKING INFORMATION**

This registration statement includes forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as anticipate, believes, budget, continue, could, estimate, expect, forecast, i plan, potential, predicts, project, should, will and similar expressions are intended to identify such forward-looking statements. Forward-l statements in this prospectus/proxy statement/consent solicitation include, without limitation, statements regarding benefits and timing of the closing of the proposed merger and future expectations concerning available cash and cash equivalents, the expected timing of the conclusion of clinical trials, the timing of regulatory filings and approvals or clearances, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed in or implied by this prospectus/proxy statement/consent solicitation. Such risk factors include, among others: the ability to consummate the proposed merger; the ability of the combined company to develop and commercialize product candidates; the ability to obtain the substantial additional funding required to conduct development and commercialization activities; the ability to obtain regulatory approvals; the ability to comply with Nasdaq listing standards; the ability to conduct clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to products under development and whether such results will be indicative of results obtained in later clinical trials; and the ability to obtain, maintain and enforce patent and other intellectual property protection for product candidates. These and other risks are described in greater detail in the section entitled Risk Factors beginning on page 28 of this prospectus/proxy statement/consent solicitation.

Actual results may differ materially from those contained in the forward-looking statements in this prospectus/proxy statement/consent solicitation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus/proxy statement/consent solicitation. All forward-looking statements are qualified in their entirety by this cautionary statement.

---

**Table of Contents**

**THE SPECIAL MEETING OF NUVELO STOCKHOLDERS**

**Date, Time and Place**

The special meeting of Nuvelo stockholders will be held on January 7, 2009, at Nuvelo, Inc., 201 Industrial Road, Suite 310, San Carlos, California commencing at 9:00 a.m. local time. Nuvelo is sending this proxy statement/prospectus/consent solicitation to you in connection with the solicitation of proxies by the Nuvelo board of directors for use at the Nuvelo special meeting and any adjournments or postponements of the special meeting. This proxy statement/prospectus/consent solicitation is first being furnished to Nuvelo's stockholders on or about November 25, 2008.

**Purposes of the Nuvelo Special Meeting**

The purposes of the Nuvelo special meeting are:

1. To consider and vote upon a proposal to approve the issuance of Nuvelo common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated September 24, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., as amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., and as described in the attached proxy statement/prospectus/consent solicitation. A copy of the merger agreement is attached as *Annex A* to this proxy statement/prospectus/consent solicitation and a copy of the amendment to the merger agreement is attached as *Annex B* to this proxy statement/prospectus/consent solicitation.
2. To consider and vote upon a proposal to approve an amendment to Nuvelo's amended and restated certificate of incorporation in order to effect a reverse stock split of the issued and outstanding shares of Nuvelo's common stock as described in this prospectus/proxy statement/consent solicitation. A copy of this proposed amendment to the Nuvelo amended and restated certificate of incorporation is attached as *Annex F* to this prospectus/proxy statement/consent solicitation.
3. To consider and vote upon a proposal to approve an amendment to Nuvelo's amended and restated certificate of incorporation in order to increase the number of authorized shares of Nuvelo common stock to 250 million as described in this prospectus/proxy statement/consent solicitation. A copy of the proposed amendment to the Nuvelo amended and restated certificate of incorporation is attached as *Annex G* to this prospectus/proxy statement/consent solicitation.
4. To consider and vote upon an adjournment of the special meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposals No. 1 and No. 2.
5. To transact such other business as may properly come before the special meeting or any adjournment or postponement thereof.

**Recommendation of the Nuvelo Board of Directors**

**THE NUVELO BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT THE ISSUANCE OF SHARES OF NUVELO COMMON STOCK IN THE MERGER IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH ISSUANCE. THE NUVELO BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL NO. 1 TO APPROVE THE ISSUANCE OF SHARES OF NUVELO COMMON STOCK IN THE MERGER.**

**THE NUVELO BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT THE APPROVAL OF THE AMENDMENT TO NUVELO'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE ISSUED AND**

---

**Table of Contents**

**OUTSTANDING SHARES OF NUVELO S COMMON STOCK IS ADVISABLE AND IN THE BEST INTERESTS OF, NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH AMENDMENT. THE NUVELO BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL NO. 2 TO APPROVE THE AMENDMENT TO NUVELO S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE ISSUED AND OUTSTANDING SHARES OF NUVELO S COMMON STOCK.**

**THE NUVELO BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT THE APPROVAL OF THE AMENDMENT TO NUVELO S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF NUVELO COMMON STOCK TO 250 MILLION IS ADVISABLE AND IN THE BEST INTERESTS OF, NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH AMENDMENT. THE NUVELO BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL NO. 3 TO APPROVE THE AMENDMENT TO NUVELO S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF NUVELO COMMON STOCK TO 250 MILLION.**

**THE NUVELO BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT ADJOURNING THE SPECIAL MEETING, IF NECESSARY, IF A QUORUM IS PRESENT, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSALS NO. 1 AND NO. 2 IS ADVISABLE AND IN THE BEST INTERESTS OF NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH ADJOURNMENT, IF NECESSARY. NUVELO S BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL NO. 4 TO ADJOURN THE SPECIAL MEETING, IF NECESSARY, IF A QUORUM IS PRESENT, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSALS NO. 1 AND NO. 2.**

**Record Date and Voting Power**

Only holders of record of Nuvelo common stock at the close of business on the record date, November 11, 2008 are entitled to notice of, and to vote at, the Nuvelo special meeting. There were approximately 189 holders of record of Nuvelo common stock at the close of business on the record date. Because many of such shares are held by brokers and other institutions on behalf of stockholders, Nuvelo is unable to estimate the total number of stockholders represented by these record holders. At the close of business on the record date, 53,663,805 shares of Nuvelo common stock were issued and outstanding. Each share of Nuvelo common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval. See Nuvelo Security Ownership by Certain Beneficial Owners and Management for information regarding ownership by management and persons known by management of Nuvelo to be the beneficial owners of more than 5% of the outstanding shares of Nuvelo common stock.

**Voting and Revocation of Proxies**

The proxy accompanying this proxy statement/prospectus/consent solicitation is solicited on behalf of Nuvelo s board of directors for use at the special meeting.

If you are a stockholder of record of Nuvelo as of the record date referred to above, you may vote in person at the special meeting or vote by proxy over the Internet, by telephone or using the enclosed proxy card. Whether or not you plan to attend the special meeting, Nuvelo urges you to vote by proxy to ensure your vote is counted. You may still attend the special meeting and vote in person if you have already voted by proxy.

## Table of Contents

If your shares are registered directly in your name, you may vote:

**Over the Internet.** Go to the web site of Nuvelo's tabulator, Georgeson, Inc., at <http://proxy.georgeson.com> and follow the instructions you will find there. You must specify how you want your shares voted or your Internet vote cannot be completed and you will receive an error message. Your shares will be voted according to your instructions.

**By Telephone.** Call toll-free 1-877-816-0836 from the United States or Canada and follow the instructions. You must specify how you want your shares voted and confirm your vote at the end of the call or your telephone vote cannot be completed. Your shares will be voted according to your instructions.

**By Mail.** Complete, date and sign the enclosed proxy card and mail it in the enclosed postage-paid envelope to Georgeson, Inc., Wall Street Station, P.O. Box 1101, New York, NY 10269-0666. Your proxy will be voted according to your instructions. If you do not specify how you want your shares voted, they will be voted as recommended by Nuvelo's board of directors.

**In Person at the Meeting.** If you attend the meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting.

If your shares are held in street name for your account by a bank broker or other nominee, you may vote:

**Over the Internet or By Telephone.** You will receive instructions from your broker or other nominee if you are permitted to vote over the Internet or by telephone.

**By Mail.** You will receive instructions from your broker or other nominee explaining how to vote your shares.

**In Person at the Meeting.** Contact the bank, broker or other nominee that holds your shares to obtain a broker's proxy card and bring it with you to the meeting. **A broker's proxy is not the form of proxy enclosed with this proxy statement. You will not be able to vote shares you hold in street name at the meeting unless you have a proxy from your broker issued in your name giving you the right to vote the shares.**

All properly executed proxies that are not revoked will be voted at the special meeting and at any adjournments or postponements of the special meeting in accordance with the instructions contained in the proxy. If a holder of Nuvelo's common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted FOR Proposal No. 1 to approve the issuance of shares of Nuvelo's common stock in the merger; FOR Proposal No. 2 to approve an amendment to Nuvelo's certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo's common stock; FOR Proposal No. 3 to approve an amendment to Nuvelo's certificate of incorporation to increase the number of authorized shares of Nuvelo common stock to 250 million; and FOR Proposal No. 4 to adjourn the special meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposals No. 1 and No. 2 in accordance with the recommendation of Nuvelo's board of directors.

Each Nuvelo stockholder of record voting by proxy, other than those stockholders who have executed a voting agreement and irrevocable proxy, has the right to revoke the proxy at any time before the polls close at the special meeting by sending a written notice stating that it would like to revoke its proxy to the Secretary of Nuvelo, by voting again over the Internet or by telephone, by providing a duly executed proxy card bearing a later date than the proxy being revoked or by attending the special meeting and voting in person. Attendance alone at the special meeting will not revoke a proxy. A beneficial owner of Nuvelo's common stock that holds shares in street name must follow directions received from the bank, broker or other nominee that holds the shares to change its voting instructions.



---

## **Table of Contents**

### **Quorum and Required Vote**

The presence, in person or by proxy, at the special meeting of the holders of a majority of the shares of Nuvelo common stock outstanding and entitled to vote at the special meeting is necessary to constitute a quorum at the meeting. If Nuvelo stockholders do not vote by proxy or in person at the special meeting, the shares of common stock of such stockholders will not be counted as present for the purpose of determining a quorum. Abstentions and broker non-votes will be counted towards a quorum.

The affirmative vote of the holders of a majority of the shares of Nuvelo's common stock present in person or represented by proxy and voting on such matter at the special meeting is required for approval of Proposals No. 1 and No. 4. The affirmative vote of holders of a majority of the issued and outstanding shares of Nuvelo's common stock as of the record date for the special meeting is required for approval of Proposals No. 2 and No. 3.

For Proposals No. 1 and No. 4, which require the approval of a majority of the shares of Nuvelo's common stock present in person or represented by proxy and voting on such matter at the special meeting, a failure to submit a proxy card or vote at the special meeting, or an abstention, vote withheld or broker non-votes will have no effect on the outcome of such proposals. For Proposals No. 2 and No. 3, which require the approval of holders of a majority of the outstanding shares of Nuvelo's common stock, a failure to vote by proxy or in person at the special meeting, or an abstention, vote withheld or broker non-vote for such proposal, will have the same effect as a vote against the approval Proposals No. 2 and No. 3.

At the record date for the special meeting, the directors and executive officers of Nuvelo owned approximately 0.29% of the outstanding shares of Nuvelo common stock entitled to vote at the meeting. Stockholders owning approximately 157,081 shares of Nuvelo common stock, representing approximately 0.29% of the outstanding shares of Nuvelo common stock as of the record date, are subject to voting agreements and irrevocable proxies. Each such stockholder has agreed in the voting agreements to vote all shares of Nuvelo common stock owned by him, her or it as of the record date in favor of the issuance of shares of Nuvelo common stock in the merger and the to Nuvelo's amended and restated certificate of incorporation in order to effect a reverse stock split of the issued and outstanding shares of Nuvelo's common stock.

### **Solicitation of Proxies**

In addition to solicitation by mail, the directors, officers, employees and agents of Nuvelo may solicit proxies from Nuvelo's stockholders by telephone, other electronic means or in person. Directors, officers, employees and agents of Nuvelo will not receive any additional compensation for their services, but Nuvelo will reimburse them for their out-of-pocket expenses. Nuvelo also will make arrangements with banks, brokers, nominees, custodians and fiduciaries who are record holders of Nuvelo's common stock for the forwarding of solicitation materials to the beneficial owners of Nuvelo's common stock. Nuvelo will reimburse these banks, brokers, nominees, custodians and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials and in obtaining voting instructions from these owners.

Nuvelo has retained Georgeson, Inc., a proxy solicitation firm, to assist in the solicitation of proxies by mail, telephone or other electronic means or in person for a fee of approximately \$25,000, plus disbursements and a fee for each completed call.

### **Other Matters**

As of the date of this proxy statement/prospectus/consent solicitation, the Nuvelo board of directors does not know of any business to be presented at the Nuvelo special meeting other than as set forth in the notice accompanying this proxy statement/prospectus/consent solicitation. If any other matters should come before the special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.

---

**Table of Contents**

**NUVELO PROPOSAL NO. 1**

**APPROVAL OF ISSUANCE OF SHARES OF NUVELO**

**COMMON STOCK IN THE MERGER**

**THE MERGER**

*This section and the section entitled **The Merger Agreement** in this proxy statement/prospectus/consent solicitation describe the material aspects of the merger, including the merger agreement. While Nuvelo and ARCA believe that this description covers the material terms of the merger and the merger agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus/consent solicitation for a more complete understanding of the merger and the merger agreement, including the merger agreement attached as Annex A, the amendment to the merger agreement attached as Annex B, the opinion of Jefferies and Company, Inc. attached as Annex E, and the other documents to which you are referred herein. See the section entitled **Where You Can Find More Information** in this proxy statement/prospectus/consent solicitation.*

**General Description of the Merger**

Nuvelo, ARCA, and Dawn Acquisition Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Nuvelo, entered into an Agreement and Plan of Merger dated as of September 24, 2008, which the parties amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, by and among Nuvelo, Inc., ARCA and Dawn Acquisition Sub, Inc., and which, unless otherwise indicated, is referred to in this proxy statement/prospectus/consent solicitation as the merger agreement. The merger agreement contains the terms and conditions of the proposed business combination of Nuvelo and ARCA. Pursuant to the merger agreement, on the terms and conditions set forth therein, Dawn Acquisition Sub, Inc., will be merged with and into ARCA, with ARCA surviving the merger as a wholly-owned subsidiary of Nuvelo. Upon the terms and subject to the conditions set forth in the merger agreement, Nuvelo has agreed to issue, and holders of ARCA capital stock will receive, shares of Nuvelo common stock such that following the consummation of the transactions contemplated by the merger agreement, current stockholders of Nuvelo shall own approximately 33% of the common stock of the combined company, and current ARCA stockholders shall own or have the right to acquire approximately 67% of the common stock of the combined company after giving effect to the exercise of all outstanding options and warrants to purchase ARCA capital stock, primarily on a treasury method basis, and without giving effect to the exercise of any options or warrants to purchase Nuvelo common stock. The actual number of shares of Nuvelo common stock to be issued in respect of each share of common stock of ARCA will be determined by dividing an aggregate of 109,009,278 shares of Nuvelo common stock by the number of shares of ARCA common stock outstanding and deemed outstanding pursuant to the formula set forth in the merger agreement and described below under the heading **The Merger Agreement**. In addition, Nuvelo will assume options and warrants to purchase shares of ARCA capital stock.

**Background of the Merger**

***Historical Background for Nuvelo***

Nuvelo has reviewed, from time to time, various business opportunities to further develop and commercialize its compounds as well as opportunities for growth and expansion, including potential business collaboration and acquisition opportunities.

At a meeting of Nuvelo's board of directors on March 14, 2008 at which certain members of management were also present, management recommended, and the Nuvelo board of directors approved discontinuing the clinical development of alfineprase as a result of disappointing clinical trial results and approved a plan to restructure the company. These decisions were described in Nuvelo's Report on Form 8-K and press release of March 17, 2008.



## **Table of Contents**

At a meeting of Nuvelo's board of directors on April 8, 2008, at which certain members of management and a representative of Cooley Godward Kronish LLP, or Cooley, Nuvelo's legal counsel, were also present, the board discussed a variety of business opportunities, including potential corporate partnering, licensing and acquisition opportunities and directed management to pursue various strategic alternatives and identify potential counterparties for a strategic transaction. Thereafter, Nuvelo engaged Jefferies & Company, Inc., or Jefferies, to assist it in evaluating its alternatives and render a fairness opinion should Nuvelo decide to proceed with a transaction.

In early April 2008, Jefferies and Nuvelo management developed a list of 33 potential parties to be contacted regarding a possible business combination with Nuvelo, including four companies that had previously approached Nuvelo regarding such a transaction. In mid-April 2008, Jefferies began contacting these parties to explore their interest in engaging in such discussions.

Beginning in May 2008, public information packages were sent to potential counterparties that had expressed an interest in engaging in business combination discussions. In mid-May 2008, at the direction of the Nuvelo board of directors, Jefferies began obtaining confidentiality agreements from potential counterparties that were interested in receiving non-public information regarding Nuvelo in order to evaluate a potential transaction. Between May 14, 2008 and August 28, 2008, eight potential counterparties executed such a confidentiality agreement.

At a Nuvelo board meeting on June 4, 2008, at which members of management and representatives of Cooley and Jefferies were also present, the board considered the status of discussions with potential counterparties. The Nuvelo board of directors instructed management, working with Jefferies, to distribute a process letter to interested parties describing the next steps to be taken by those interested in continuing discussions with Nuvelo. A process letter describing these steps was sent to the then-interested parties on June 9, 2008. As described below, the process letter was sent to ARCA on June 10, 2008.

Beginning on June 9, 2008, Nuvelo, Jefferies and representatives of potential counterparties engaged in a due diligence review in connection with a possible transaction, with the various potential counterparties and their representatives engaging in diligence calls on a variety of matters relating to the parties. Beginning June 18, 2008, access to an electronic data room containing information relating to Nuvelo was granted to potential counterparties, including ARCA.

Beginning on July 2, 2008, Nuvelo began receiving initial indication of interest letters. By July 16, 2008, Nuvelo had received four initial indication of interest letters, including one from ARCA, as further discussed below.

### ***Historical Background for ARCA***

Since its inception, ARCA's management team has, on an ongoing basis, evaluated various strategic options to maximize value for its stockholders, including potential merger transactions with other companies. During this process, which continued into mid-2008, ARCA held numerous discussions with various parties that included both domestic and foreign public pharmaceutical and biotechnology companies. ARCA held discussions with several parties under confidentiality agreements.

In March 2008, ARCA management initiated discussions with J.P. Morgan to assist the company in raising a new round of private equity financing from outside venture capital firms and other sources, as well as help ARCA explore other strategic alternatives including the potential sale or merger of the company. Over the next several weeks, ARCA and J.P. Morgan prepared marketing materials to be used in discussions with potential investors, potential acquirors and merger partners, including domestic and foreign public pharmaceutical and biotechnology companies.

---

**Table of Contents**

On May 2, 2008, at a meeting of the board of directors of ARCA, the board authorized the engagement of J.P. Morgan as its financial advisor with respect to a possible sale or merger and as placement agent with respect to a possible private placement of securities.

During June, July and August 2008, ARCA and J.P. Morgan held numerous discussions with various parties that included potential investors, as well as both domestic and foreign public pharmaceutical and biotechnology companies.

During the same period, ARCA management and its board of directors came to the determination that, due to a number of factors, a reverse merger with Nuvelo was an attractive strategic alternative for ARCA, including the fact that it would provide the cash resources that could be used to finance the development and commercialization of ARCA's product candidate, enhance ARCA's product development pipeline, and add significant experience to the ARCA management team.

***Background of Development of Transaction Between Nuvelo and ARCA***

In January 2007, Ted W. Love, M.D., Nuvelo's chairman and chief executive officer, met on a nonconfidential basis with Richard B. Brewer, ARCA's president and chief executive officer, and several other executives from each company, to introduce Nuvelo and to learn more about ARCA's business. Mr. Brewer and Dr. Love had known each other professionally for a number of years, having previously worked together at Genentech. This initial discussion led to further discussions over the next several months under a confidentiality agreement, during which the parties performed due diligence and discussed a potential merger transaction. These discussions were terminated in June 2007 while they were still informal and nonbinding, in light of the companies' respective product development goals as well as differing views as to valuation.

On May 2, 2008, at the direction of the Nuvelo board of directors, Jefferies contacted Mr. Brewer regarding the possibility of a transaction involving ARCA and Nuvelo.

On June 10, 2008 Mr. Brewer contacted Dr. Love expressing interest in discussing a possible business combination of ARCA and Nuvelo. The following day, Jefferies sent ARCA the process letter which had been sent to other interested parties.

On June 24, 2008, Nuvelo management met with ARCA management by teleconference to provide an overview on each company's respective business.

On July 2, 2008, members of the ARCA board of directors and ARCA management met by teleconference with representatives of J.P. Morgan to discuss the terms of a proposed preliminary indication of interest regarding a merger transaction to be submitted to Nuvelo. On July 3, 2008, Mr. Brewer submitted ARCA's non-binding indication of interest to Dr. Love.

At a Nuvelo board meeting on July 16, 2008, at which members of management and representatives of Cooley and Jefferies were also present, Jefferies discussed with the board of directors the four indications of interest that had been submitted to date. At one point during the meeting, representatives of ARCA joined the call to discuss ARCA, its business and its products. At another point during the meeting, another party that had submitted an indication of interest joined the meeting to discuss its business and products. The board of directors instructed management and Jefferies to send the four interested parties a second round process letter and draft acquisition agreement on which interested parties should comment in connection with submitting second round proposals.

On August 1, 2008, the second round process letter and draft acquisition agreement were sent to four potential counterparties.

## **Table of Contents**

On August 18, 2008, members of the ARCA board of directors and ARCA management met by teleconference with representatives of J.P. Morgan to discuss the terms of a proposed firm indication of interest regarding a merger transaction to be submitted to Nuvelo. On the evening of August 18, 2008, on behalf of Mr. Brewer, representatives of J.P. Morgan submitted ARCA's firm indication of interest to Dr. Love and to representatives from Jefferies, which included ARCA's proposed revisions to a draft merger agreement.

By August 22, 2008, two second round indications of interest had been received, including the one from ARCA. Only ARCA submitted comments on the proposed acquisition agreement. The other two potential counterparties that had received the second bid process letter indicated that they would not be submitting second round proposals. At a Nuvelo board meeting on August 22, 2008, at which members of management and representatives of Cooley and Jefferies were also present, representatives of Cooley made a presentation regarding the fiduciary duties of the Nuvelo board of directors in the context of the proposed transaction and the terms of the proposed acquisition agreement from ARCA. Representatives of Jefferies also discussed the terms proposed by the two potential counterparties. Following discussion, the Nuvelo board of directors was of the view that the ARCA proposal was substantially superior to the other proposal and instructed management, with the assistance of Jefferies and Cooley, to negotiate the terms of a possible transaction with ARCA.

From August 27, 2008 to September 24, 2008, Nuvelo and ARCA, together with their respective outside legal counsel and financial advisors, continued their mutual due diligence and engaged in negotiations regarding the provisions of the merger agreement and related agreements, including, among other things, the potential adjustments to the number of shares of Nuvelo common stock to be issued in the merger and the net cash requirements of Nuvelo and ARCA. The parties reached final agreement on these and other issues over the course of numerous discussions involving members of Nuvelo and ARCA management and legal counsel.

On August 18, 2008, financial advisors to a potential counterparty that had not previously submitted an indication of interest contacted Jefferies to discuss the possibility of a potential transaction with Nuvelo and the advisors to this counterparty and representatives of Jefferies had a related discussion on August 27, 2008. The potential counterparty submitted a preliminary indication of interest on September 3, 2008. Representatives of Jefferies and the management of Nuvelo discussed the contents of this indication of interest and in light of the absence of compelling terms and the advanced discussions with ARCA, determined not to proceed with discussions relating to a potential transaction with the potential counterparty.

On September 5, September 14 and September 18, 2008, ARCA's board of directors met to review the status of the negotiations regarding the proposed transaction with Nuvelo.

At a Nuvelo board meeting on September 15, 2008, at which members of management and representatives of Cooley and Jefferies were also present, representatives of Cooley made a presentation regarding the current status of the terms of the proposed merger agreement with ARCA. Representatives of Jefferies also discussed the financial terms of the proposed transaction.

On September 24, 2008, the board of directors of ARCA held a meeting by teleconference to discuss and approve the proposed merger with Nuvelo. Prior to the meeting, the board of directors of ARCA received copies of the transaction documents and other related documents. ARCA management, together with representatives from Hogan & Hartson LLP, ARCA's legal advisor, summarized the terms of the merger agreement for the board of directors and answered questions posed by members of the board. Following the discussion, ARCA's board of directors approved the proposed merger with Nuvelo and the merger agreement and all other agreements related to the merger in substantially the form presented to the ARCA board, with such changes as ARCA management deemed necessary or advisable.

On September 24, 2008, the board of directors of Nuvelo held a meeting, at which certain members of management and representatives of Cooley and Jefferies were also present, during which the Nuvelo board of directors received an update from Cooley and Jefferies on the status of the proposed transaction. During the meeting, a representative of Cooley presented a summary of the terms of the draft merger agreement and related

---

**Table of Contents**

agreements and the resolution of the issues in the agreements that were open as of the last board of directors meeting. Representatives of Jefferies made a presentation regarding the financial terms of the proposed transaction. Jefferies then provided the board of directors with its oral opinion, subsequently confirmed in writing on such date, to the effect that, as of that date and based upon and subject to the various assumptions made, procedures followed, matters considered and limitations described in its opinion, the Exchange Ratio, representing the amount of shares of Nuvelo common stock to be exchanged for ARCA capital stock in the merger pursuant to the terms of the merger agreement, was fair, from a financial point of view, to Nuvelo. The Nuvelo board of directors, having deliberated regarding the terms of the proposed transaction, unanimously determined that the issuance of Nuvelo common stock in the merger and the proposed amendment to Nuvelo's amended and restated certificate of incorporation are advisable and fair to, and in the best interests of, Nuvelo and its stockholders, unanimously authorized and approved the execution, delivery and performance of the merger agreement by Nuvelo and unanimously approved the merger and the proposed amendment to Nuvelo's amended and restated certificate of incorporation and unanimously recommended the approval of the issuance of Nuvelo common stock in the merger and the proposed amendment to Nuvelo's amended and restated certificate of incorporation by the Nuvelo stockholders.

The merger agreement and related documents were executed later in the day on September 24, 2008. Before the opening of the market on September 25, 2008, the parties announced the execution of the merger agreement.

On October 28, 2008, following discussions over the preceding days, and the approval of the Nuvelo and ARCA boards of directors by written consent, the parties entered into the first amendment to the merger agreement. The amendment modified the amendment to Nuvelo's amended and restated certificate of incorporation required to be filed as a condition to the closing of the merger to eliminate the increase in the authorized shares of Nuvelo's common stock, and instead required that Nuvelo would use commercially reasonable efforts to solicit the consent of its stockholders to approve a separate amendment to its amended and restated certificate of incorporation to increase the number of authorized shares of Nuvelo's common stock to 250 million. In addition, the parties agreed that following the merger, the certificate of incorporation of ARCA, the surviving corporation in the merger, would be the current amended and restated certificate of incorporation of ARCA, as amended. The parties also agreed that prior to the merger, the authorized size of the Nuvelo board would be expanded to 10 members and agreed upon certain individuals to serve as directors and executive officers of Nuvelo beginning immediately after the effective time of the merger. Finally, the parties agreed to increase the maximum time period permitted between the declaration of effectiveness of Nuvelo's registration statement on Form S-4 and the date of the Nuvelo stockholders' meeting to vote on the merger and related actions.

**Reasons for the Merger**

***Mutual Reasons for the Merger***

Nuvelo and ARCA believe that the combined company resulting from the merger will have the following potential advantages:

the combined company will be a larger cardiovascular focused biotechnology company with a near term commercial opportunity represented by ARCA's product candidate, Gencaro, and longer term product development opportunities represented by Nuvelo's product candidate, NU172;

the combined company will be more securely capitalized to commercialize its late stage product candidate and develop its pipeline of longer term product candidates; and

there are significant potential synergies and cost savings that Nuvelo and ARCA believe can be achieved by consolidating the infrastructures of the two companies and allowing management to fully leverage the combined research, development and administrative capabilities across multiple potential product candidates.

## **Table of Contents**

### ***Nuvelo's Reasons for the Merger***

In evaluating the merger, Nuvelo's board of directors consulted with senior management and Nuvelo's legal and financial advisors, and, in the course of reaching its determination to approve the merger, the merger agreement and the other transactions contemplated by the merger agreement, Nuvelo's board of directors considered a number of factors, including the following:

historical and current information concerning Nuvelo's business, including the termination of its former lead product candidate, alfimeprase, and negative trends in its financial condition, operations and competitive position;

current financial market conditions, and historical market prices, volatility and trading information with respect to Nuvelo's common stock;

Nuvelo's limited prospects if it were to remain an independent, standalone company as a result of factors such as the absence of a late-stage product candidate, its declining cash balance, the expenses and fixed costs associated with its operations and its prospects for development and commercialization of Nuvelo's early stage product candidates, particularly given its limited resources;

the belief that the combination with ARCA would result in a combined company with the potential for enhanced future growth and value as compared to Nuvelo as an independent, standalone company;

the opportunity for Nuvelo's stockholders to participate in the potential future value of the combined company;

Nuvelo's board of directors' view as to the potential for other third parties to enter into strategic relationships with or acquire Nuvelo on favorable terms, if at all, based on the interest expressed by other third parties during the strategic alternatives review process undertaken by Nuvelo;

historical and current information concerning ARCA's business, financial performance, financial condition, operations and management, including the results of a due diligence investigation of ARCA conducted by Nuvelo's management and advisors;

management's belief that the merger was more favorable to Nuvelo's stockholders than any other alternative reasonably available to Nuvelo and its stockholders, including the alternative of remaining an independent, standalone company;

the opinion of Jefferies to the Nuvelo board of directors that, as of September 24, 2008 and subject to the various assumptions made, procedures followed, matters considered and limitations described in the opinion, the Exchange Ratio, representing the amount of shares of Nuvelo common stock to be exchanged for ARCA capital stock in the merger pursuant to the terms of the merger agreement, was fair, from a financial point of view, to Nuvelo, as more fully described below under the caption "Opinion of Nuvelo's Financial Advisor;" and

the terms and conditions of the merger agreement, including:

the determination that the relative percentage ownership of the combined company by Nuvelo's stockholders and ARCA's stockholders is consistent with Nuvelo's perceived valuations of each company at the time Nuvelo's board of directors

approved the merger agreement;

the non-solicitation provisions limiting ARCA's ability to engage in discussions or negotiations regarding, or furnish to any person any information with respect to, assist or participate in any effort or attempt by any person with respect to, or otherwise cooperate in any way with, an alternative acquisition proposal;

Nuvelo's rights under the merger agreement to pursue alternative acquisition proposals received independently under specified circumstances;

the absence of any terms providing for an adjustment to the exchange ratio based on the amount of cash or working capital at closing for Nuvelo provided that Nuvelo complies in all material respects with certain covenants with respect to expenditures and minimum cash balances;

**Table of Contents**

the requirement that holders of the requisite amount of ARCA's capital stock necessary to approve the merger agreement enter into voting agreements providing that such stockholders vote in favor of adoption of the merger agreement and against any proposal made in opposition to, or in competition with, the merger;

Nuvelo's board of directors' belief that the \$947,112 termination fee and obligation to reimburse expenses up to \$500,000 payable to ARCA in the circumstances set forth in the merger agreement was reasonable in the context of termination fees that were payable in other comparable transactions and would not be likely to preclude another party from making a superior acquisition proposal; and

the qualification of the merger as a reorganization for U.S. federal income tax purposes, with the result that in the merger neither Nuvelo's nor ARCA's stockholders will recognize gain or loss for U.S. federal income tax purposes.

In the course of its deliberations, Nuvelo's board of directors also considered a variety of risks and other countervailing factors related to entering into the merger agreement, including the following:

the risk that the merger might not be completed in a timely manner or at all due to failure to satisfy the closing conditions, some of which are outside of Nuvelo's control;

if the merger is not completed, the potential adverse effect of the public announcement of the merger on Nuvelo's business, including its ability to attract and retain key personnel and its overall competitive position;

the immediate and substantial dilution of the equity interests and voting power of Nuvelo's stockholders upon completion of the merger;

the ability of Nuvelo's current stockholders to significantly influence the combined company's business after the completion of the merger;

the risk that the combined company may be unable to raise needed additional capital in and that such additional capital, even if available, will be further dilutive to Nuvelo's stockholders and may be at a lower valuation than reflected in the merger;

the restrictions that the merger agreement imposes on soliciting competing acquisition proposals;

the fact that Nuvelo would be obligated to pay a \$947,112 termination fee to ARCA and reimburse ARCA's expenses of up to \$500,000 if the merger agreement is terminated under certain circumstances;

the restrictions on the conduct of Nuvelo's business prior to the completion of the merger, which require Nuvelo to carry on its business in the usual, regular and ordinary course in substantially the same manner as previously conducted, subject to specific additional restrictions, including restrictions relating to expenditures outside an agreed upon budget or which would result in lower than anticipated cash balances at the end of each completed fiscal quarter and interim stub period prior to the effective time of the merger, which restrictions may delay or prevent Nuvelo from pursuing business opportunities that would otherwise be in its best interests as a standalone company;

## Edgar Filing: NUVELO INC - Form S-4/A

the condition that Nuvelo receive approval from Nasdaq for the re-listing of Nuvelo's common stock in connection with the merger based on the initial listing requirements of any of the Nasdaq Global Select Market, Nasdaq Global Market or Nasdaq Capital Market;

the challenges and costs of combining administrative operations and the substantial expenses to be incurred in connection with the merger, including the risks that delays or difficulties in completing the administrative integration and such other expenses, as well as the additional public company expenses and obligations that ARCA will be subject to in connection with the merger that it has not previously been subject to, could adversely affect the combined company's operating results and preclude the achievement of some benefits anticipated from the merger;



**Table of Contents**

the possible volatility, at least in the short term, of the trading price of Nuvelo's common stock resulting from the announcement and pendency of the merger;

the possible earlier than anticipated loss of key management or other personnel of Nuvelo;

the risk of diverting management's attention from day-to-day operations to implement the merger;

the interests of Nuvelo's executive officers and directors in the transactions contemplated by the merger agreement, as described in the section of this proxy statement/prospectus/consent solicitation entitled "Interests of Nuvelo's Directors and Executive Officers in the Merger"; and

various other applicable risks associated with the business of Nuvelo and the combined company and the merger, including those described in the section of this proxy statement/prospectus/consent solicitation entitled "Risk Factors."

The foregoing discussion of the factors considered by Nuvelo's board of directors is not intended to be exhaustive, but does set forth the principal factors considered by Nuvelo's board of directors. Nuvelo's board of directors collectively reached the unanimous conclusion to approve the merger agreement in light of the various factors described above and other factors that each member of Nuvelo's board of directors deemed relevant. In view of the wide variety of factors considered by the members of Nuvelo's board of directors in connection with their evaluation of the merger agreement and the complexity of these matters, Nuvelo's board of directors did not consider it practical, and did not attempt, to quantify, rank or otherwise assign relative weights to the specific factors it considered in reaching its decision. Nuvelo's board of directors made its decision based on the totality of information presented to and considered by it. In considering the factors discussed above, individual directors may have given different weights to different factors.

Nuvelo's board of directors unanimously determined that the merger agreement and the merger are advisable, fair to and in the best interests of Nuvelo's stockholders and unanimously approved the merger agreement and the issuance of the Nuvelo common stock pursuant to the merger agreement.

The foregoing discussion of Nuvelo's board of directors' considerations concerning the merger is forward looking in nature. This information should be read in light of the discussions under the heading "Forward-Looking Information."

***ARCA's Reasons for the Merger***

In the course of deliberations, ARCA's board reviewed ARCA's historical, present and projected financials under various scenarios, and its historical and short and long-term strategic objectives, the opportunities in the marketplace that ARCA is pursuing and the risks associated therewith.

In evaluating the merger, ARCA's board of directors consulted with senior management and ARCA's legal and financial advisors, and in the course of reaching its determination to approve the merger, the merger agreement and the other transactions contemplated by the merger agreement, ARCA's board of directors considered a number of factors, including, but not limited to:

ARCA's additional capital requirements, which ARCA anticipates can be met with Nuvelo's available cash, together with ARCA's other cash resources, to fund ARCA's projected operating requirements through the end of 2009, beyond the expected date of FDA approval of Gencaro; and, given market conditions, the benefits of this option over others considered by ARCA to finance its operations, such as an equity offering;

Nuvelo's longer term product development opportunities represented by its product candidate, NU172, would be complimentary to Gencaro;

## Edgar Filing: NUVELO INC - Form S-4/A

ARCA's ability to leverage Nuvelo's other non-cardiovascular candidates and research platforms and its experienced clinical, regulatory and administrative employees as a compliment to ARCA's own employees;

**Table of Contents**

the merger with Nuvelo is expected to enhance the combined company's access to capital, providing ARCA with a greater range of options than if it continued as a privately-held company;

the terms and conditions of the merger agreement, including without limitation the following:

the determination that the expected relative ownership interests of ARCA stockholders and Nuvelo stockholders in the combined company is reasonable, based on the board of directors' judgment of the relative valuations of the two companies;

that the terms of the merger agreement are reasonable, including the parties' representations, warranties and covenants and the conditions to the parties' respective obligations, such as the condition that Nuvelo conduct its operations pre-closing in accordance with a budget agreed-to by the parties;

the qualification of the merger as a reorganization for U.S. federal income tax purposes, with the result that in the merger neither Nuvelo's nor ARCA's stockholders will recognize gain or loss for U.S. federal income tax purposes;

that appraisal rights would be available to non-consenting ARCA stockholders under the DGCL; and

the fact that Nuvelo would be obligated to pay a \$947,112 termination fee to ARCA and reimburse ARCA's expenses up to \$500,000 if the merger agreement is terminated under certain circumstances.

In the course of its deliberations, ARCA's board of directors also considered a variety of risks and other countervailing factors related to entering into the merger agreement, including the following:

the risk that the merger might not be completed in a timely manner, or at all, due to failure to satisfy the closing conditions, some of which are outside of ARCA's control, and if the merger is not completed, the potential adverse effect of the public announcement of the merger on ARCA's business, including its ability to attract new sources of capital, retain key personnel and its maintaining its overall competitive position;

the restrictions on ARCA's conduct of business prior to the completion of the merger, which subject to certain limitations, may delay or prevent ARCA from pursuing business opportunities that would otherwise be in its best interests as a standalone company;

the substantial expenses to be incurred in connection with the merger and the fact that ARCA would be obligated to pay a \$1,922,924 termination fee to Nuvelo and reimburse Nuvelo's expenses up to \$500,000 if the merger agreement is terminated under certain circumstances;

expenses and obligations that the combined company would be subject to as a result of being a public company could adversely affect the combined company's operating results and preclude the achievement of some benefits anticipated from the merger;

the possible loss of key management, scientific or other personnel of either of the combining companies as a result of management changes and other changes associated with integrating the businesses;

## Edgar Filing: NUVELO INC - Form S-4/A

the risk that integrating the combined companies will divert management's attention from other strategic priorities;

the interests of ARCA's executive officers and directors in the transactions contemplated by the merger agreement, as described in the section of this proxy statement/prospectus/consent solicitation entitled "Interests of ARCA's Directors and Executive Officers in the Merger"; and

various other applicable risks associated with the business of ARCA, Nuvelo and the combined company and the merger, including those described in the section of this proxy statement/prospectus/consent solicitation entitled "Risk Factors."

---

## **Table of Contents**

The foregoing discussion of the factors considered by ARCA's board of directors is not intended to be exhaustive, but sets forth the principal factors considered by ARCA's board of directors. ARCA's board of directors collectively reached the unanimous conclusion to approve the merger agreement in light of the various factors described above and other factors that each member of ARCA's board of directors deemed relevant. In view of the wide variety of factors considered by the members of ARCA's board of directors in connection with their evaluation of the merger agreement and the complexity of these matters, ARCA's board of directors did not consider it practical, and did not attempt, to quantify, rank or otherwise assign relative weights to the specific factors it considered in reaching its decision. ARCA's board of directors made its decision based on the totality of information presented to and considered by it. In considering the factors discussed above, individual directors may have given different weights to different factors.

ARCA's board of directors unanimously determined that the merger agreement and the merger are advisable, fair to and in the best interests of ARCA's stockholders and unanimously approved the merger agreement and the amendment of ARCA's Restated Charter in accordance with the terms of the merger agreement.

The foregoing discussion of ARCA's board of directors' considerations concerning the merger is forward looking in nature. This information should be read in light of the discussions under the heading "Forward-Looking Information."

### **Opinion of Nuvelo's Financial Advisor**

Jefferies served as Nuvelo's financial advisor in connection with the proposed transaction. On September 24, 2008, Jefferies delivered to the board of Nuvelo its oral opinion, subsequently confirmed in writing on such date, to the effect that, as of that date and based upon and subject to the various assumptions made, procedures followed, matters considered and limitations described in its opinion, the Exchange Ratio, representing the amount of shares of Nuvelo common stock to be exchanged for ARCA capital stock in the merger pursuant to the terms of the merger agreement, was fair, from a financial point of view, to Nuvelo.

**The full text of Jefferies' written opinion, dated September 24, 2008, is attached as *Annex E* to this proxy statement/prospectus/consent solicitation and is incorporated into this proxy statement/prospectus/consent solicitation by reference. You are encouraged to read carefully Jefferies' entire opinion. It describes the assumptions made, procedures followed, factors considered and limitations on the review undertaken by Jefferies in rendering its opinion. The following is a summary of the material aspects of Jefferies' opinion and the methodology that Jefferies used to render its opinion. This summary is qualified in its entirety by reference to the full text of the opinion.**

Jefferies' opinion was provided for the use and benefit of the board of directors of Nuvelo in its consideration of the merger. Jefferies' opinion does not address the relative merits of the transactions contemplated by the merger agreement as compared to any alternative transaction or opportunity that might be available to Nuvelo, nor does it address the underlying business decision by Nuvelo to engage in the merger or the terms of the merger agreement or the documents referred to therein. Furthermore, Jefferies' opinion does not constitute a recommendation as to how any holder of Nuvelo common stock should vote on the merger or any matter related thereto. In addition, Jefferies' opinion does not address, the fairness to, or any other consideration of, the holders of any class of securities or the creditors or other constituencies of Nuvelo or ARCA. The opinion also does not address the fairness of the amount or nature of, or any other aspects relating to, any compensation to be received by any officers, directors or employees of any parties to the merger or any class of such persons, relative to the Exchange Ratio (representing the shares of Nuvelo common stock to be exchanged for ARCA capital stock in the merger pursuant to the terms of the merger agreement) or otherwise.

Jefferies assumed, with the Nuvelo board's consent, for purposes of its opinion that (i) the capitalization of ARCA immediately prior to the effective time of the merger shall be as set forth in Section 2.3 of the merger agreement, but after giving effect to receipt by ARCA of \$8,750,000 in total consideration for the issuance of 6% convertible promissory notes of ARCA and related warrants to purchase ARCA common stock providing for

---

**Table of Contents**

20% warrant coverage issued in connection with the Note and Warrant Purchase Agreement, and (ii) the exchange ratio in the merger (regardless of the value of Nuvelo's common stock at the effective time of the merger) will always result in the conversion of all outstanding shares of ARCA capital stock (including the shares of ARCA common stock issuable upon exercise of the note warrants) and all outstanding ARCA securities that are convertible or exchangeable into ARCA capital stock (other than out-of-the-money ARCA options and warrants) into not more than, in the aggregate, 67% of the outstanding Nuvelo common stock, on a fully diluted basis using the treasury stock method, at the effective time of the merger. For purposes of its opinion, Jefferies ignored, with the Nuvelo board's consent, the value of ARCA options and warrants that will be out-of-the-money when converted into Nuvelo securities at the effective time of the merger. Based on a price per share of Nuvelo's common stock of \$0.39 (representing the five day average closing price of Nuvelo's common stock as of September 19, 2008), 6,471,077 shares of Nuvelo's common stock underlying out-of-the-money options and warrants of existing Nuvelo holders and 849,882 shares of Nuvelo's common stock underlying out-of-the-money options and warrants of Nuvelo would be exchanged for ARCA options and warrants in the merger.

In connection with its opinion, Jefferies, among other things:

reviewed a draft of the merger agreement, dated September 24, 2008, and the exhibits thereto;

reviewed certain publicly available financial and other information about Nuvelo and ARCA;

reviewed certain information furnished to Jefferies by Nuvelo and ARCA, respectively, including financial forecasts and analyses, relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Nuvelo and ARCA, respectively;

held discussions with members of senior management of Nuvelo and ARCA concerning the matters described in the second and third bullet points above;

reviewed certain publicly available information, including share trading price history and valuation multiples, of Nuvelo and certain publicly traded companies that Jefferies deemed comparable to Nuvelo;

performed a liquidation analysis for Nuvelo based on information furnished to Jefferies by Nuvelo's management;

compared the proposed financial terms of the proposed transaction with the financial terms of certain other transactions that Jefferies deemed relevant;

performed a discounted cash flow analysis for Nuvelo and ARCA, utilizing pro forma financial information prepared by, and furnished to Jefferies by, the management of Nuvelo and ARCA, respectively;

considered the pro forma impact of the proposed transaction, taking into account, among other things, product pipeline and ability to raise capital; and

conducted such other financial studies, analyses and investigations as Jefferies deemed appropriate including Jefferies' assessment of general economic, market and monetary conditions.

In Jefferies' review and analysis and in rendering its opinion, Jefferies assumed and relied upon, but did not make, and has not assumed any responsibility for, any independent investigation or verification of, the accuracy and completeness of the financial and other information that was supplied or otherwise made available by Nuvelo or ARCA or that was publicly available to Jefferies (including without limitation, the

## Edgar Filing: NUVELO INC - Form S-4/A

information described above), or that was otherwise reviewed by Jefferies. In its review, Jefferies did not make any independent evaluation or appraisal of any of the assets or liabilities of, nor did Jefferies conduct a physical inspection of any of the properties or facilities of, Nuvelo or ARCA. In addition, Jefferies was not furnished with, nor does Jefferies assume any responsibility to obtain, any such evaluations or appraisals. Jefferies did not evaluate the solvency or fair value of Nuvelo or ARCA under any state or federal laws relating to bankruptcy, insolvency or similar matters. Jefferies also has undertaken no independent analysis of any pending or threatened litigation,

---

**Table of Contents**

regulatory action, possible unasserted claims or other contingent liabilities, to which Nuvelo, ARCA or any of their affiliates is a party, or may be subject, and with the Nuvelo Board's consent, Jefferies' opinion made no assumption concerning, and therefore did not consider, the possible assertion of claims, outcomes or damages arising out of such matters.

With respect to the financial forecasts provided to and examined by it (including forecasts of Nuvelo and ARCA and pro forma forecasts of Nuvelo and ARCA as a combined company), Jefferies noted that projecting future results of any company is inherently subject to uncertainty. Nuvelo and ARCA have informed Jefferies, however, and Jefferies has assumed, that such financial forecasts were reasonably prepared on bases reflecting the best currently available estimates and good faith judgments of the management of Nuvelo as to the future financial performance of Nuvelo, and ARCA as to the future financial performance of ARCA. Jefferies assumed, with the Nuvelo board's consent, that the financial results (including the anticipated pro forma financial effects) reflected in such forecasts will be realized at the times and in the amounts projected by Nuvelo and ARCA. In addition, Jefferies has assumed, with the Nuvelo board's consent, that the information provided to it by Nuvelo in connection with its liquidation analysis for Nuvelo was accurate and complete and based on reasonable assumptions reflecting the good faith judgment of management. Jefferies expressed no opinion as to such financial forecasts, the information provided to Jefferies in connection with its liquidation analysis or the assumptions on which the foregoing are made. Jefferies also expressed no opinion as to the viability of the combined company following the merger, including the potential for or timing of commercialization of any product or service, the nature and extent of the combined company's financing needs or the ability of the combined company to satisfy any such financing needs.

Jefferies' opinion is based on economic, monetary, regulatory, market and other conditions existing and which could be evaluated as of the date of its opinion. Jefferies assumed, with the Nuvelo's board consent, for purposes of computing the exchange ratio that the Parent Trading Price (as defined in the merger agreement) was \$0.39, the five day average closing share price of Nuvelo as of September 19, 2008. Jefferies expressed no opinion as to the price at which the shares of Nuvelo common stock will trade at any future time. Jefferies assumed no responsibility to update or revise its opinion based on circumstances or events occurring after the date of its opinion and disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting its opinion of which Jefferies becomes aware after the date of its opinion. All references to the merger agreement, the Note and Warrant Purchase Agreement and other agreements in any discussion of Jefferies' fairness opinion in this proxy statement/prospectus/consent solicitation refer to such agreements as in effect on the date of Jefferies' fairness opinion.

Jefferies has made no independent investigation of any legal or accounting matters affecting Nuvelo or ARCA, and assumed the correctness in all respects material to its analysis of all legal and accounting advice given to Nuvelo and its board of directors, including, without limitation, advice as to the legal, accounting and tax consequences of the terms of, and transactions contemplated by, the merger agreement to Nuvelo and its stockholders. In addition, in preparing its opinion, Jefferies did not take into account any tax consequences of the transaction to Nuvelo or ARCA. Jefferies assumed that the final form of the merger agreement would be substantially similar to, and would not differ in any material respect from, the last draft reviewed by it. In addition, Jefferies assumed that the merger will be consummated in accordance with the terms of the merger agreement, without waiver, modification or amendment of any material term, condition or agreement and that, in the course of obtaining the necessary regulatory or third party approvals, consents, and releases (contractual or otherwise) for the merger, no delay, limitations, restrictions or conditions, including any divestiture requirements or amendments or modifications, will be imposed that would have an adverse effect on Nuvelo, ARCA or the contemplated benefits of the merger. Jefferies further assumed, with the Nuvelo board's consent, for purposes of its opinion that ARCA shall have received prior to the merger aggregate proceeds of at least \$8,750,000 from the sale and issuance of the ARCA convertible notes and ARCA warrants pursuant to the Note and Warrant Purchase Agreement. Jefferies also assumed that the shares of Nuvelo common stock to be issued in the merger to the stockholders of ARCA will be listed on the Nasdaq Global Market.



---

## **Table of Contents**

The following is a summary of the material financial analyses performed by Jefferies in connection with its opinion. The financial analyses summarized below include information presented in tabular format. To fully understand Jefferies' analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses.

This summary is not intended to be an exhaustive description of the analyses performed by Jefferies. Jefferies did not attribute any particular weight to any analysis, methodology or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor; accordingly, the analyses performed by Jefferies must be considered as a whole. Considering any portion of such analyses and of the factors considered, without considering all analyses and factors, could create a misleading or incomplete view of the process underlying the conclusions expressed in Jefferies' opinion.

### ***Transaction Overview***

Jefferies observed that pursuant to the merger agreement approximately 23.275 million shares of ARCA capital stock (including the shares of ARCA common stock issuable upon exercise of the note warrants) and ARCA securities that are convertible or exchangeable into approximately 4.103 million shares of ARCA capital stock (other than out-of-the-money ARCA options and warrants) would convert into not more than, in the aggregate, 109,009,278 shares of Nuvelo common stock at the effective time of the merger, representing approximately 67% of the outstanding Nuvelo common stock, on a fully diluted basis using the treasury stock method.

### ***Nuvelo Stand-Alone Valuation***

As an initial step, Jefferies analyzed the value of Nuvelo as a stand-alone company, which valuations were then compared to a pro forma valuation of Nuvelo and ARCA as a combined company and the corresponding relative interests of ARCA and Nuvelo stockholders, after giving effect to the merger. To perform the stand-alone valuation, Jefferies reviewed the share trading price history of Nuvelo and performed (i) a comparable company analysis, (ii) a liquidation analysis of Nuvelo and a (iii) discounted cash flow analysis, in each case, as more fully described below. Jefferies' analyses below assume 53,691,137 shares of Nuvelo common stock outstanding on a fully diluted basis as of August 31, 2008. As illustrated below, the range of implied values per share of Nuvelo common stock on a stand-alone basis under the valuation methodologies described below was \$0.42 to \$0.86 per share, the former of which was the low end of the range of share prices of Nuvelo common stock for the 90-day period ending September 19, 2008 and the latter of which was the high end of the range of per share values derived from Jefferies' discounted cash flow analysis.

*Current Market Valuation.* Jefferies noted that the 90-day average closing share price of Nuvelo common stock for the period ending September 19, 2008 and the current share price for Nuvelo common stock as of September 19, 2008 were \$0.57 and \$0.42 per share, respectively.

*Comparable Companies Analysis.* Jefferies reviewed and compared certain trading, financial and operating data of Nuvelo to similar publicly available trading, financial and operating data for the following companies that, like Nuvelo, have encountered clinical delays, negative clinical results or similar major program setbacks or delays:

Inhibitex Inc.

Memory Pharmaceuticals Corp.

Panacos Pharmaceuticals Inc.

Replidyne, Inc.

Telik Inc.

Vanda Pharmaceuticals, Inc.

**Table of Contents**

The financial data analyzed as part of this analysis included the following:

		(\$ Millions)	
	Mean	Median	Nuvelo
Market Capitalization	\$ 25.2	\$ 23.6	\$ 22.5
Debt	\$ 5.8	\$ 0.6	
Cash	\$ 16.8	\$ 53.3	\$ 70.0
Total Enterprise Value*	\$ (19.3)	\$ (26.5)	\$ (47.5)
Cash / Market Cap	195.6%	197.6%	310.7%

\* Total Enterprise Value is defined as market capitalization plus debt less cash and cash equivalents.

Jefferies noted that the foregoing analysis produced an absolute value of mean and median of public comparable companies' market valuation between \$23.6 million and \$25.2 million, representing an implied price per share of Nuvelo common stock in the range of \$0.44 to \$0.47.

*Liquidation Value Analysis.* Jefferies reviewed certain trading, financial and operating data of Nuvelo to determine Nuvelo's liquidation value based on Nuvelo's estimated closing cash balance as of December 31, 2008, net of relevant severance, lease and other liabilities based on estimates and information provided by management of Nuvelo.

Estimated Cash Balance at Closing*	\$56.5 million
Total Estimated Liabilities**	(\$28.0) (\$31.0) million
Liquidation Value	\$25.5 \$28.5 million
Liquidation Value (per share)	\$0.48 \$0.53

\* Represents cash estimates as of December 31, 2008 (including restricted cash) prepared by Nuvelo's management, which estimates were not independently verified by Jefferies.

\*\* Based on an estimate provided by Nuvelo's management, consisting of severance payments (estimated as average salary for three months for employees and one year for three members of the management team), Nuvelo's San Carlos facility lease obligation and Nuvelo's Sunnyvale facility lease obligation, each as of December 31, 2008, and estimated liabilities for trailing cost of clinical trials, other trailing expenses and legal expenses.

The liquidation value is intended to represent the value per share of Nuvelo common stock available to stockholders were Nuvelo to be liquidated and its assets used to satisfy its liabilities to its creditors. Jefferies noted that the liquidation analysis produced an implied price per share of Nuvelo common stock in the range of \$0.48 to \$0.53.

*Discounted Cash Flow Analysis.* Jefferies performed a discounted cash flow analysis of Nuvelo based on forecasts by Nuvelo's management to calculate the estimated present value of stand-alone, unlevered after-tax free cash flow that Nuvelo could generate during the calendar years 2008-2018 and the value of Nuvelo at the end of that period. Jefferies applied a range of revenue exit multiples from 2.00x to 3.00x to Nuvelo's 2018 estimated revenue to derive an assumed value of the cash flows for all periods after the projected period, which is referred to as a terminal value. The present value of the cash flow and terminal value were calculated using discount rates ranging from 37.0% to 43.0%. Assuming an exit multiple of 2.5x with a terminal value based on 2018 projected revenue and the foregoing discount rate range, Jefferies noted that the discounted cash flow analysis produced an implied price per share of Nuvelo common stock in the range of \$0.44 to \$0.86, after adjustment for \$56.5 million in estimated cash at closing of the merger.

**Table of Contents****ARCA Stand-Alone Valuation**

Jefferies also analyzed the value of ARCA as a stand-alone company by performing (i) a comparable companies analysis, (ii) a comparable initial public offering, or IPO, analysis and (iii) a discounted cash flow analysis. As illustrated below, these analyses produced an enterprise value range for ARCA on a stand-alone basis of \$130 million to \$640 million, the former of which was the low end of the range of enterprise values derived from Jefferies comparable companies analysis and the latter of which was the high end of the range of per share values derived from Jefferies discounted cash flow analysis.

*Comparable Companies Analysis.* Jefferies reviewed and compared certain trading, financial and operating data of ARCA to publicly available information for the following public biopharmaceutical companies which, like ARCA, either have a cardiovascular focus or have recently filed a new drug application with the FDA:

AMAG Pharmaceuticals, Inc.

ARYx Therapeutics, Inc.

Cypress Bioscience, Inc.

Cytokinetics Inc.

Momenta Pharmaceuticals Inc.

Nile Therapeutics, Inc.

The financial data analyzed as part of this analysis included the following:

	(\$ Millions)	
	Mean	Median
Market Cap	\$ 340.4	\$ 234.8
Debt	\$ 5.1	\$ 3.3
Cash	\$ 115.1	\$ 107.5
Total Enterprise Value*	\$ 230.4	\$ 132.8
Total Enterprise Value / Revenue** (latest twelve months ending June 30, 2008)	11.4x	13.3x
Total Enterprise Value / Revenue** (2008E)	12.0x	7.8x
Total Enterprise Value / Revenue** (2009E)	8.2x	4.3x

\* Total Enterprise Value is defined as market capitalization plus debt less cash and cash equivalents.

\*\* Projections from Bloomberg estimates.

Jefferies noted that the foregoing analysis produced an absolute value of mean and median of public comparable companies total enterprise value between \$132.8 million and \$230.4 million.



**Table of Contents**

*Comparable IPO Analysis.* Jefferies reviewed and compared certain trading, financial and operating data of ARCA to publicly available financial data for the following companies that completed an initial public offering of their common stock during the period from January 1, 2004 to October 9, 2007. Jefferies selected companies which, like ARCA, were seeking to market a lead product that was approved or close to approval by the FDA at the time of their initial public offering:

Company	Date	(\$ Millions)	
		Gross Proceeds	Pre-Money Valuation
Targanta Therapeutics	10/9/2007	\$ 57.5	\$ 152.2
Jazz Pharmaceuticals	5/31/2007	\$ 108.0	\$ 333.9
Neurogesx	5/1/2007	\$ 44.0	\$ 93.4
Emergent BioSolutions	11/14/2006	\$ 62.5	\$ 280.3
Osiris	8/3/2006	\$ 38.5	\$ 260.0
Replidyne	6/27/2006	\$ 45.0	\$ 219.3
Aspreva Pharmaceuticals	3/3/2005	\$ 79.2	\$ 283.2
Momenta Pharmaceuticals	6/21/2004	\$ 34.8	\$ 124.9
Santarus	3/31/2004	\$ 54.0	\$ 200.9
	Mean	\$ 58.2	\$ 216.4
	Median	\$ 54.0	\$ 219.3

Jefferies noted that the foregoing analysis produced an absolute value of mean and median of initial public offering companies' pre-money valuation between \$216.4 million and \$219.3 million.

*Discounted Cash Flow Analysis.* Jefferies performed a discounted cash flow analysis of ARCA based on ARCA forecasts provided by ARCA's management to calculate the estimated present value of stand-alone, unlevered after-tax free cash flow that ARCA could generate during the calendar years 2008-2013 and the value of ARCA at the end of that period. Jefferies applied a range of revenue exit multiples from 2.00x to 3.00x to ARCA's 2013 estimated revenue to derive a terminal value. The present value of the cash flow and terminal value was calculated using discount rates ranging from 27.0% to 33.0%. Assuming an exit multiple of 2.5x with a terminal value based on 2013 projected revenue and the foregoing discount rate range, Jefferies noted that the discounted cash flow analysis produced an implied ARCA enterprise value of approximately \$577.0 million.

**Relative Contribution Analysis**

Based on information provided by management of each of Nuvelo and ARCA, Jefferies compared the contribution of each of Nuvelo and ARCA to the combined company expected to result from the completion of the merger. The implied contribution was based on estimated cash at closing, projected revenue and projected operating income. Estimates of operating income, however, were determined to not be a meaningful metric given that the forecasts provided by Nuvelo's management projected no operating income for Nuvelo until 2014.

Using the foregoing metrics, Jefferies computed the implied contribution of Nuvelo and ARCA to the combined entity as follows:

Financial Metric	Relative Contribution	Implied % of Combined
	(Nuvelo / ARCA)	Equity (Nuvelo / ARCA)
Cash	89.1% / 10.9%	89.1% / 10.9%
Estimated 2009 Revenue	100.0% / 0.0%	89.2% / 10.8%*
Estimated 2010 Revenue	0.3% / 99.7%	22.2% / 78.2%*
Estimated 2011 Revenue	0.1% / 99.9%	7.4% / 92.6%*
Estimated 2012 Revenue	0.1% / 99.9%	4.6% / 95.4%*
Estimated 2013 Revenue	9.9% / 90.1%	13.1% / 86.9%*

\* Calculated by applying a 2.5x revenue multiple (derived from comparable large-cap public biopharma companies) to each company's revenue. Implied equity value was calculated by adjusting for net debt.



**Table of Contents**

By examining these metrics, Jefferies derived the implied value of the contributions by Nuvelo to the combined company on a percentage basis, which it then compared to the implied ownership percentage of the Nuvelo stockholders in the combined company. In all instances reflected in the comparisons above (other than relative contributions of cash at the effective time of the merger and estimated 2009 revenue), Jefferies noted that Nuvelo's share of the value of the combined company (based on a 33%/67% split as provided by the terms of the merger agreement) exceeded its implied percentage of the combined company.

**Relative Valuation Comparison**

Using (i) the stand-alone equity valuations of Nuvelo and ARCA derived from the comparable public companies analysis and (ii) the stand-alone equity valuations of Nuvelo and ARCA calculated by adding each company's estimated cash at closing to the derived enterprise value from the discounted cash flow analysis, Jefferies also derived a total equity valuation of the combined company. Using this total equity valuation, Jefferies then derived the implied equity value of Nuvelo (based on anticipated pro forma ownership of 33% for Nuvelo) in the aggregate and on a per share basis (based on 53,619,137 shares of Nuvelo outstanding as of August 31, 2008). Jefferies also used the total equity valuation to derive the implied enterprise value of Nuvelo (adjusted for \$56.5 million in estimated cash at closing).

Metric	Nuvelo	ARCA	Total Equity Valuation (Nuvelo + ARCA)	Implied Nuvelo Equity Value	Implied Nuvelo Enterprise Value	Implied Nuvelo Equity Value per Share
<b>Equity Valuation Derived from Comparable Public Companies Analysis</b>						
			(In Millions)			
Low*	\$ 23.6	\$ 234.8	\$ 258.4	\$ 85.3	\$ 28.8	\$ 1.59
High*	\$ 25.2	\$ 340.4	\$ 365.6	\$ 120.7	\$ 64.1	\$ 2.25
<b>Equity Valuation Derived from Discounted Cash Flow Analysis **</b>						
			(In Millions)			
Low	\$ 23.7	\$ 526.9	\$ 550.6	\$ 181.7	\$ 125.2	\$ 3.38
High	\$ 46.1	\$ 646.9	\$ 693.0	\$ 228.7	\$ 172.2	\$ 4.26

\* High and low values were based on mean and median values from Nuvelo and ARCA's public company comparables.

\*\* Equity value was calculated by adding each company's estimated cash at closing to the derived enterprise value from the discounted cash flow analysis.

Jefferies noted that the relative valuation comparison produced an implied value per share of Nuvelo common stock in the range of \$1.59 to \$4.26 as compared to the range of implied values per share of Nuvelo common stock on a stand-alone basis of \$0.42 to \$0.86 per share.

**Pro Forma Combined Company Discounted Cash Flow Analysis**

Jefferies analyzed the pro forma valuation of Nuvelo and ARCA as a combined company after giving effect to the merger. Jefferies prepared a pro forma income statement and calculated free cash flow to be generated by the combined company based on assumptions provided by Nuvelo and ARCA which Jefferies assumed reflected the good faith judgment of such companies' management. Jefferies then compared Nuvelo's stand-alone valuations to Nuvelo's share of the value of the combined company (based on a 33%/67% split as provided by the terms of the merger agreement) based on a pro forma combined company discounted cash flow analysis.

Jefferies performed a discounted cash flow analysis of the combined company based on the Nuvelo and ARCA forecasts to calculate the estimated present value of unlevered after-tax free cash flow that the combined company could generate during the calendar years 2008-2013. Jefferies applied a range of revenue exit multiples from 2.00x to 3.00x to the combined company's 2013 estimated revenue to derive a terminal value. The present value of the



**Table of Contents**

cash flow and terminal value was calculated using discount rates ranging from 30.0% to 40.0%. Using an exit multiple of 2.5x and a discount rate of 35% (representing the middle of the range of revenue exit multiples and discount rates), the discounted cash flow analysis based on the Nuvelo and ARCA forecasts produced an implied enterprise value of \$442.2 million. Jefferies then adjusted the total enterprise value for \$63.4 million of combined estimated cash at closing to determine the total equity valuation of the combined company. Jefferies determined the implied Nuvelo equity value based on anticipated pro forma ownership of 33% of the combined company by the Nuvelo stockholders. Jefferies then compared the implied Nuvelo equity value to the stand-alone equity value methodologies for Nuvelo to determine the implied Nuvelo enterprise value.

<b>Pro Forma DCF Valuation</b>	<b>Total Enterprise Valuation (Nuvelo + ARCA)</b>	<b>Total Equity Valuation (Nuvelo + ARCA)</b>	<b>Implied Nuvelo Equity Value (In Millions)</b>	<b>Relative to Standalone DCF Equity Value</b>	<b>Implied Nuvelo Enterprise Value*</b>
Low	\$ 373.8	\$ 437.2	\$ 144.3	\$ 23.7	\$ 87.8
Midpoint	\$ 442.2	\$ 505.6	\$ 166.9	\$ 33.4	\$ 110.4
High	\$ 525.8	\$ 589.2	\$ 194.4	\$ 46.1	\$ 137.9

\* Adjusted for \$56.5 million of estimated cash of Nuvelo at closing of the merger.

Jefferies noted that the pro forma combined company discounted cash flow analysis produced an implied value per share of Nuvelo common stock in the range of \$2.69 to \$3.63 as compared to the range of implied values per share of Nuvelo common stock on a stand-alone basis of \$0.42 to \$0.86 per share.

**Miscellaneous**

No company or transaction used in the analyses described above is identical to Nuvelo, ARCA, or the proposed transaction. In selecting and evaluating the comparable companies and transactions, Jefferies made certain judgments and assumptions regarding industry performance, general business, economic, market and financial conditions and other matters, many of which are beyond Nuvelo's control and the control of Jefferies, such as (i) the impact of competition on Nuvelo or ARCA or the industry generally, (ii) industry growth, (iii) acceptance of products and success of products in the market and (iv) the absence of any material adverse change in the financial condition and prospects of Nuvelo or ARCA, the industry or in the financial markets in general. Mathematical analysis, such as determining the average or median, is not in itself a meaningful method of using comparable companies or comparable transactions data.

Jefferies is an internationally recognized investment banking and advisory firm. Jefferies, as part of its investment banking business, is regularly engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings, competitive biddings, secondary distributions of listed and unlisted securities, private placements, financial restructurings and other financial services. Nuvelo selected Jefferies to act as its financial advisor because of Jefferies' qualifications, reputation and experience. Pursuant to an engagement letter between Nuvelo and Jefferies dated May 12, 2008, Jefferies was paid a \$50,000 fee upon its engagement by Nuvelo and a \$500,000 fee upon delivery of its opinion. Jefferies also will receive a minimum \$950,000 transaction fee contingent upon consummation of the merger, which amount may increase in the event that the transaction value (computed based on the aggregate amount of cash held by Nuvelo at closing and the fair market value of any securities issued by Nuvelo to ARCA stockholders in the merger) exceeds \$100.0 million (which increase shall equal 1.5% of any such excess). Nuvelo has agreed to indemnify Jefferies against liabilities arising out of or in connection with the services rendered and to be rendered by it in connection with the engagement and to reimburse Jefferies for out-of-pocket expenses incurred by Jefferies in connection with its engagement. In the ordinary course of its business, Jefferies and its affiliates may trade or hold securities of Nuvelo and/or its affiliates for their own account and for the accounts of their customers and, accordingly, may at any time hold long or short positions in those securities. During the two years preceding the date of its opinion, Jefferies provided financial advisory services to Nuvelo in connection with an unrelated matter and received a customary

**Table of Contents**

retainer fee and reimbursement for its out-of-pocket expenses in connection therewith. In addition, Jefferies may seek to, in the future, provide financial advisory and financial services to Nuvelo, ARCA, and/or their respective affiliates, for which Jefferies would expect to receive compensation.

The computation of the applicable exchange ratio relating to the number of shares of Nuvelo common stock to be exchanged for ARCA common stock and other securities in the merger was determined by arms-length negotiations between Nuvelo and ARCA, in consultation with their respective financial advisors and other representatives, and was not established by such financial advisors.

**Officers and Directors of the Combined Company Following the Merger**

Richard B. Brewer is president and chief executive officer of ARCA, and upon closing of the merger, Mr. Brewer will be chief executive officer and chairman of the board of directors of the combined company. Following the merger, in addition to Mr. Brewer, Michael R. Bristow, M.D., Ph.D., currently chairman, and chief science and medical officer of ARCA, will be chief science and medical officer and a director of the combined company, Christopher D. Ozeroff, currently executive vice president and general counsel of ARCA, will be executive vice president and general counsel of the combined company, Joseph Turner, who ARCA expects to hire as its chief financial officer prior to the closing of the proposed merger, will be chief financial officer of the combined company. Randall St. Laurent, currently executive vice president of commercial operations of ARCA, will be the combined company's executive vice president of commercial operations. Lee Bendekgey, currently senior vice president, chief financial officer and general counsel of Nuvelo, will be principal accounting officer of the combined company on a transitional basis, but will not be an executive officer of the combined company.

The combined company will initially have a ten member board of directors, comprised of three individuals who are currently members of the Nuvelo board of directors, Ted W. Love, M.D., Mary K. Pendergast and Burton E. Sobel, M.D., and seven individuals who are currently members of the ARCA board of directors, Mr. Brewer, Dr. Bristow, Jean-François Formela, M.D., J. William Freytag, Ph.D., David G. Lowe, Ph.D., Linda Graiss, M.D. and John L. Zabriskie, Ph.D. Each of these members of the board of directors will serve in one of three classes to be agreed upon by Nuvelo and ARCA prior to the closing of the merger.

**Interests of Nuvelo's Executive Officers and Directors in the Merger**

In considering the recommendation of the Nuvelo board of directors with respect to issuing shares of Nuvelo common stock as contemplated by the merger agreement, Nuvelo stockholders should be aware that certain members of the board of directors and executive officers of Nuvelo have interests in the merger that are different from, or in addition to, their interests as Nuvelo stockholders. These interests present a conflict of interest. The Nuvelo board of directors was aware of these conflicts of interest during its deliberations on the merits of the merger and in making its decision in approving the merger, the merger agreement and the related transactions.

**Ownership Interest**

Assuming that the merger had been consummated on October 31, 2008, the beneficial ownership and other equity interests in the combined company immediately following the merger of Dr. Love, Ms. Pendergast, and Dr. Sobel, each of whom is expected to serve as a director of the combined company, would have been as set forth below:

Name	Total Options Held	Options Exercisable Within 60 Days	Total Shares Beneficially Owned	Beneficial Ownership Percentage
Ted W. Love	2,466,664	2,466,664	2,538,439	1.66%
Mary K. Pendergast	99,166	99,166	99,832	*
Burton E. Sobel	57,500	57,500	57,500	*

\* Represents beneficial ownership of less than 1% of the combined company's common stock.

---

**Table of Contents**

Assuming that the merger had been consummated on October 31, 2008, all directors and executive officers of Nuvelo, together with their affiliates, would have beneficially owned approximately 2.28% of the shares of Nuvelo's common stock after taking into effect of the acceleration of vesting of all unvested stock options granted to the executive officers pursuant to the Nuvelo executive change of control and severance benefit plan.

***Dr. Love's Employment Agreement***

Nuvelo entered into an employment agreement and related addendum, or the Love Employment Agreement, with Dr. Love, its chairman and chief executive officer, in January 2001, and has subsequently amended and restated the addendum to his employment agreement in April 2007 and January 2008. Dr. Love participated in the negotiation and approval of the terms of the merger on behalf of Nuvelo. Upon the closing of the merger, it is anticipated that Dr. Love will continue to serve as a director of Nuvelo but that his employment by Nuvelo will be terminated and that he will be entitled to the severance and other benefits set forth in the Love Employment Agreement and described below.

Pursuant to the terms of the Love Employment Agreement, as amended, in the event of a change of control of Nuvelo, all Nuvelo stock options and stock awards held by Dr. Love will become fully vested.

In addition, if Dr. Love's employment is terminated without cause, or for good reason, both as defined in the Love Employment Agreement or upon the death of Dr. Love while an employee with Nuvelo then:

the vesting of any options granted to Dr. Love within the first four years of his employment with Nuvelo, on his initial options will be fully accelerated;

the time period during which Dr. Love or his heirs will be able to exercise these initial options will be extended by up to an additional 18 months;

the vesting of any equity awards made to Dr. Love after April 30, 2007 will be accelerated by an additional 24 months, such that any awards that would have vested in the 24 months following Dr. Love's termination will be deemed immediately vested;

Dr. Love or his heirs will be paid 24 months of his then current base salary, in one lump sum; and

Nuvelo will pay premiums necessary to continue health insurance benefits for Dr. Love and his family for 18 months at the same level of benefits and the same cost to Dr. Love or his heirs as immediately prior to his termination. Nuvelo will also pay, in one lump sum, the cost of such coverage for an additional six months, provided that Dr. Love has elected continuation of coverage under federal COBRA and analogous state law such that continuation of coverage shall be considered to have been provided pursuant to such laws.

If Dr. Love's employment is terminated without cause or for good reason within 12 months of a change in control of Nuvelo, then, in addition to the benefits described above, Dr. Love will be entitled to a lump sum payment equal to two times his target bonus for the year in which his termination occurred.

As a condition to receipt of any of the termination benefits described above, Dr. Love will be required to provide a general release in favor of Nuvelo. Nuvelo and Dr. Love have agreed in certain circumstances to reduce the amount of his benefits under the Love Employment Agreement to achieve the best after-tax result for Dr. Love. Nuvelo and Dr. Love also agreed that the payment of benefits under the Love Employment Agreement may be adjusted in certain circumstances so that such benefits are not subject to Section 409A(a)(1) of the Internal Revenue Code.

***Executive Change of Control and Severance Benefit Plan***

The Nuvelo board of directors approved an executive change in control and severance benefit plan, or the severance plan, in December 2004. The severance plan provides for the payment of severance benefits and/or change in control benefits to Nuvelo's eligible employees. All of

Nuvelo's employees at the level of vice

## Table of Contents

president or above have been designated by the Nuvelo board as participants in the severance plan. Nuvelo's board may also designate additional individuals as participants. To the extent a participant is entitled to greater benefits under his or her employment agreement with Nuvelo, such additional benefits supersede the benefits payable pursuant to the severance plan. Currently, the only executive officers of Nuvelo who are eligible participants under the severance plan are Dr. Love, Mr. Bendekgey and Mr. Kersten. Mr. Bendekgey participated in the negotiation and approval of the terms of the merger on behalf of Nuvelo. Although it is contemplated that Mr. Bendekgey will continue to serve as principal accounting officer of the combined company for a transition period following the merger, it is currently contemplated that Mr. Bendekgey's employment will be terminated following this transition period and that he will be entitled to the severance and benefits set forth in the severance plan.

The severance plan describes a change in control in Nuvelo as any one of the following events:

a sale or other disposition of all or substantially all of the assets of Nuvelo;

a merger, consolidation, or similar transaction involving Nuvelo where, immediately after the transaction, the stockholders of Nuvelo immediately prior to the transaction do not directly or indirectly own, voting securities representing at least 50% of the combined outstanding voting power of the surviving entity;

any person, entity, or group becomes the beneficial owner of securities of Nuvelo representing at least 50% of the combined voting power of Nuvelo's then-outstanding securities, other than by virtue of a merger, consolidation, or similar transaction; or

the individuals who, at the beginning of any period of two years or less, constituted Nuvelo's board of directors cease, for any reason, to constitute at least a majority of the board of directors, unless the election or nomination for election of each new director was approved by the vote of at least a majority of the directors then still in office who were directors at the beginning of the two year period.

Pursuant to the severance plan, if a change in control occurs, all Nuvelo stock options and stock awards held by a severance plan participant will become fully vested. The Nuvelo stock options and stock awards held by a severance plan participant will also become fully vested if the participant is terminated without cause or constructively terminated within one month preceding a change in control.

In addition, if a participant is terminated without cause or constructively terminated one month before or one year after a change in control, he or she will also be entitled to cash severance and benefits as follows:

payment equivalent to 12 months salary, paid over a 12-month period;

payment equal to the highest cash bonus received by the individual in any consecutive 11-month period within the preceding 36 months; and

reimbursement of premiums paid for continued medical coverage pursuant to COBRA for up to 12 months.

In addition, if a participant is terminated without cause or constructively terminated outside the context of a change in control, he or she will be entitled to 12 months of vesting of all stock options and stock awards held by him or her, and cash severance and benefits as follows:

payment equivalent to 12 months salary, paid over a 12-month period; and

## Edgar Filing: NUVELO INC - Form S-4/A

reimbursement of premiums paid for continued medical coverage pursuant to COBRA for up to 12 months.

For the purposes of the severance plan, constructive termination includes a material diminution in authority, position, or responsibilities, a reduction in base salary, a change in the business location of more than 35 miles, a material breach by Nuvelo of any provisions of the severance plan, or any enforceable written

**Table of Contents**

agreement between Nuvelo and the participant, or any failure by Nuvelo to obtain assumption of the severance plan by a successor. Cause includes a refusal or failure to follow the directions of the Nuvelo board of directors or individual to whom the participant reports, failure to perform duties in a satisfactory manner, or crimes involving moral turpitude, fraud, or dishonesty.

**Summary of Potential Payments in Connection with the Merger**

Promptly following the effective time of the merger, the executive management team of the combined company is expected to be composed primarily of current ARCA executives. Accordingly, it is contemplated that Nuvelo's executive officers will be entitled to severance and other benefits in connection with the termination of their employment within the context of a change of control as provided under the Love Employment Agreement and the severance plan, as applicable.

The following table sets forth information regarding payments and benefits that each executive officer of Nuvelo would receive in connection with the consummation of the merger pursuant to the terms of the Love Employment Agreement or the severance plan described above, as applicable, assuming that the merger had been consummated on October 31, 2008 and, as applicable, such executive's employment was terminated on such date.

Name	Cash Payments(1)	Value of Benefits	Value of Options with Accelerated Vesting(2)	Value of Restricted Stock Units with Accelerated Vesting
Ted W. Love	\$ 1,834,000	\$ 44,788	\$ 3,595,304	\$
Lee Bendekgey	501,449	22,394	705,478	
Brian Kersten	330,382	22,394	121,662	4,133

(1) Amounts represent severance and bonuses payable to the executives.

(2) Amounts represent the fair value of unvested stock options that would be accelerated assuming that the merger was consummated on October 31, 2008. The fair value was determined on the grant date of the respective options in accordance with Statement of Financial Accounting Standards No. 123(R) (revised 2004), *Share Based Payment*, and, therefore, is not indicative of the value that would be ultimately realized by the executives upon exercise of their options. As of October 31, 2008, the closing price of the Nuvelo's common stock was \$0.31, and the exercise prices of all stock options held by the executives as of that date were above \$0.31. Accordingly, the executives would not receive any benefits from the acceleration of stock option vesting as provided in the severance plan if the merger was consummated on October 31, 2008.

**Voting Agreements**

In connection with the execution of the merger agreement, Dr. Love, Mr. Bendekgey, and Mark Perry, a director of Nuvelo, entered into agreements with ARCA that provide, among other things, that they will vote in favor of the issuance of Nuvelo common stock pursuant to the merger agreement and the amendment of Nuvelo's amended and restated certificate of incorporation to give effect to the reverse stock split and grant to ARCA an irrevocable proxy to vote all of their shares of Nuvelo common stock in favor of such proposals and against any proposal made in opposition to, or in competition with, such proposals. See Other Agreements Relating to the Merger Voting Agreements.

**Interests of ARCA's Executive Officers and Directors in the Merger**

In considering the recommendation of the ARCA board of directors with respect to adopting the merger agreement, ARCA stockholders should be aware that certain members of the board of directors and executive officers of ARCA have interests in the merger that may be different from, or in addition to, interests they may

**Table of Contents**

have as ARCA stockholders or the interests of other ARCA stockholders. As discussed below, certain of ARCA's directors and executive officers hold options to purchase ARCA common stock that will be assumed in the merger and, with their affiliates, own a controlling interest in the voting securities of ARCA. Certain of ARCA's directors, including Dr. Formela, Dr. Lowe, Dr. Grais and Mr. Lefkoff, are affiliates of ARCA investors that hold convertible promissory notes and warrants, and shares of ARCA's convertible preferred stock, whose interest may be different from the interests of the ARCA common stockholders. Each of the Nuvelo and ARCA boards of directors were aware of these potential conflicts of interest and considered them, among other matters, in reaching their respective decisions to approve the merger agreement and the merger, and to recommend that their respective stockholders approve the Nuvelo and ARCA proposals, as applicable.

**Stock Options**

Under the terms of the merger agreement, at the effective time of the merger, each outstanding and unexercised option to purchase shares of ARCA common stock that were granted under ARCA's 2004 Stock Incentive Plan, or the ARCA Option Plan, whether vested or unvested, will be assumed by Nuvelo and will become an option to acquire, on the same terms and conditions as were applicable under the stock option agreement by which such option is evidenced and the stock option plan under which such option was issued, shares of Nuvelo common stock. See [The Merger Stock Options](#) and [The Merger Warrants](#) below.

The table below sets forth, as of October 31, 2008, information with respect to options held by each of ARCA's current executive officers and directors.

Name	Total Options Held	Vested	Unvested	Weighted Average Exercise Price Per Share
<b>Executive Officers:</b>				
Richard B. Brewer(1)	992,000	992,000(4)	0	\$ 0.15
Michael R. Bristow, M.D., Ph.D.(1)	44,286	0	44,286	\$ 0.01
Christopher D. Ozeroff	24,562	0	24,562	\$ 0.01
Randall St. Laurent	180,000	0	180,000	\$ 0.31
Patrick Wheeler(2)	185,000	28,125	176,875	\$ 0.284
<b>Directors:</b>				
Francis J. Bullock(3)	107,383	50,140	57,243	\$ 0.21
John L. Zabriskie, Ph.D.	107,383	51,595	55,788	\$ 0.21
J. William Freytag, Ph.D.	107,000	37,000	70,000	\$ 0.29

(1) These executive officers are also directors of ARCA.

(2) This executive officer will not serve as an executive officer of the combined company following the merger.

(3) This director will not serve on the board of directors of the combined company following the merger.

(4) These options are subject to certain repurchase rights held by ARCA pursuant to the stock option agreement between Mr. Brewer and ARCA, as described under [Executive Compensation and Other Information](#) Richard B. Brewer Employment and Retention Agreement; Stock Option Agreements; Restricted Stock Agreement.

**Ownership Interests**

As of October 31, 2008, all directors and executive officers of ARCA, together with their affiliates, beneficially owned approximately 88.49% of the shares of ARCA capital stock. See [ARCA Security Ownership of Certain Beneficial Owners and Management](#) below. ARCA cannot complete the merger unless the merger agreement is adopted by the affirmative vote of (a) the holders of a majority of the shares of ARCA common stock and ARCA preferred stock outstanding on the record date and entitled to consent as a single class and on an





**Table of Contents**

as-converted basis, and (b) a majority of the Principal Series Preferred Stockholders, which include Atlas Venture, Skyline Ventures, InterWest Ventures and Boulder Ventures. Each of the Principal Series Preferred Stockholders had the right to nominate one director for election to ARCA's board of directors and nominated Dr. Formela, Dr. Lowe, Dr. Grais and Mr. Lefkoff, respectively, as their representatives on ARCA's current board of directors. Certain ARCA officers and directors, and their affiliates, have also entered into voting agreements in connection with the merger, including Richard B. Brewer, Patrick M. Wheeler, Michael R. Bristow, M.D., Ph.D., Christopher D. Ozeroff, Francis J. Bullock, Lansing Brown Investments, LLC, Skyline Venture Partners Qualified Purchaser Fund IV, L.P., InterWest Partners IX, LP, Atlas Venture Fund VII, L.P., Boulder Ventures IV (Annex), L.P., and Boulder Ventures IV, L.P. For a more detailed discussion of the voting agreements see "Other Agreements Related to the Merger - Voting Agreements" on page 123 of this proxy statement and consent solicitation/prospectus.

Assuming that the merger had been consummated on November 19, 2008 at an exchange ratio of 3.3395, and based on their beneficial ownership and equity interests in ARCA as of October 31, 2008, the beneficial ownership and other equity interests in the combined company immediately following the merger of Mr. Brewer, Dr. Bristow, Mr. Ozeroff, Mr. St. Laurent, Dr. Formela, Dr. Freytag, Dr. Grais, Dr. Zabriskie and Dr. Lowe, each of whom is expected to serve as an executive officer or a director of the combined company, would have been as set forth below:

Name	Total	Total	Options		Beneficial Ownership Percentage
	Shares		Exercisable	Warrants	
	Beneficially Owned	Options Held	Within 60 Days		
Richard B. Brewer	1,669,750	3,312,784	3,312,784	0	3.23%
Michel R. Bristow, M.D., Ph.D.	5,453,417	147,893	147,893	0	3.71
Christopher D. Ozeroff	1,587,725	82,025	82,025	0	1.11
Randall St. Laurent	0	601,110	0	0	0.00
Jean-Francois Formela	27,938,190	0	0	1,508,948	19.34
J. William Freytag, Ph.D.	0	357,327	161,548	0	0.11
Linda Grais, M.D.	14,012,076	0	0	600,299	9.65
John L. Zabriskie, Ph.D.	583,602	358,606	210,367	0	0.53
David G. Lowe, Ph.D.	17,499,339	0	0	749,698	12.04

See "Security Ownership of Certain Beneficial Owners and Management Following the Merger" below.

**Summary of Potential Payments in Connection with the Merger**

ARCA has entered into employment and retention agreements, stock option agreements and/or restricted stock agreements with each of its executive officers. See "Executive Compensation and Other Information - Employment Agreements and Potential Payment Upon Termination or Change of Control." With the exception of the restricted stock agreement between ARCA and Mr. Brewer, the consummation of the merger will not result in the payment of any severance or the acceleration of any benefits of any of the executive officers. ARCA has also entered into stock option agreements with certain of its directors described in the table above under "Stock Options." The consummation of the merger will not result in the acceleration of any vesting of the stock subject to these options. Mr. Brewer's restricted stock agreement, as amended in October 2008, provides that all 500,000 shares subject to the agreement will vest in full upon the closing of the merger. See "Executive Compensation and Other Information - ARCA's Compensation Discussion and Analysis."

**Limitations of Liability and Indemnification**

In addition to the indemnification required in ARCA's amended and restated bylaws, ARCA entered into indemnification agreements with each of its directors. These agreements provide for the indemnification of the directors of ARCA for all reasonable expenses and liabilities incurred in connection with any action or

## **Table of Contents**

proceeding brought against them by reason of the fact that they are or were agents of ARCA. ARCA believes that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors.

### **Stock Options**

ARCA has granted options to purchase shares of its common stock under the ARCA Option Plan. Each outstanding option to purchase shares of ARCA common stock that is not exercised prior to the effective time of the merger will be assumed by Nuvelo at the effective time of the merger in accordance with the terms of the ARCA Option Plan under which the option was issued and the terms of the stock option agreement by which the option is evidenced, including the vesting terms. Each assumed option will become an option to purchase shares of Nuvelo common stock. The number of shares of Nuvelo common stock subject to each assumed option will be determined by multiplying the number of shares of ARCA common stock underlying the option prior to the effective time of the merger by an exchange ratio determined pursuant to the merger agreement. Any resulting fractional shares will be rounded down to the nearest whole number of shares of Nuvelo common stock. The per share exercise price for the assumed options will be determined by dividing the per share exercise price of the option as in effect immediately prior to the effective time of the merger by the exchange ratio and rounding that result up to the nearest whole cent.

### **Warrants**

ARCA has issued warrants to purchase shares of its Series B-1 preferred stock and Series B-2 preferred stock to Silicon Valley Bank and warrants to purchase shares of its common stock to certain other stockholders of ARCA who participated in a convertible note bridge financing that closed on October 10, 2008. Each outstanding warrant to purchase shares of ARCA Series B-1 preferred stock, Series B-2 preferred stock and common stock will be assumed by Nuvelo at the effective time of the merger in accordance with its terms and will become a warrant to purchase shares of Nuvelo common stock. The number of shares of Nuvelo common stock subject to each assumed warrant will be determined by multiplying the number of shares of ARCA capital stock that was subject to each warrant prior to the effective time of the merger by an exchange ratio determined pursuant to the merger agreement. Any resulting fractional shares will be rounded down to the nearest whole number of shares of Nuvelo common stock. The per share exercise price for the assumed warrants will be determined by dividing the per share exercise price of the warrant as in effect immediately prior to the effective time of the merger by the exchange ratio and rounding that result up to the nearest whole share. For further discussion regarding the terms of the warrants, see Other Agreements Related to the Merger Note and Warrant Purchase Agreement.

### **ARCA Preferred Stock**

In accordance with the Series A Preferred Stock Purchase Agreement dated February 22, 2006, the Series B Preferred Stock Purchase Agreement dated May 31, 2007 and the Supplemental Agreement to Series B Preferred Stock Purchase Agreement dated December 28, 2007, ARCA issued shares of its preferred stock to certain investors named in the purchase agreements. Each share of Series A preferred stock will convert immediately prior to the merger into one share of ARCA common stock. Each share of Series B-1 and Series B-2 preferred stock will convert immediately prior to the merger into a number of shares of ARCA common stock equal to the original issue price for such share divided by the then effective conversion price for the Series B-1 or Series B-2 share, as applicable. The issuance of the notes and warrants under the Note and Warrant Purchase Agreement will result in adjustments to the conversion prices for the Series B-1 and Series B-2 preferred stock in accordance with the anti-dilution provisions in ARCA's Restated Charter. The amount of the adjustments depends on the actual conversion price for the notes, which will not be determined until the closing of the merger. See Other Agreements Related to the Merger Note and Warrant Purchase Agreement. However, in no event will the conversion price for the notes be less than \$1.6265 and in no event will the adjusted conversion prices for the Series B-1 and Series B-2 preferred stock be less than \$2.00, as set forth in ARCA's Restated Certificate.

---

## **Table of Contents**

Assuming that the note conversion price will be \$1.6265 and the conversion prices for the Series B-1 and Series B-2 preferred stock will be \$2.00, then (i) the Series B-1 preferred stock's conversion price will be \$1.219875 per share, and (ii) the Series B-2 preferred stock's conversion price will be \$1.6265 per share.

### **Convertible Promissory Notes and Warrants**

ARCA issued convertible promissory notes and warrants to certain stockholders as is more fully described in Other Agreements Related to the Merger Note and Warrant Purchase Agreement.

### **Regulatory Approvals**

As of the date of this proxy statement/prospectus/consent solicitation, neither Nuvelo nor ARCA is required to obtain approvals or clearances from any antitrust regulatory authorities in the United States or other countries to consummate the merger. In the United States, Nuvelo must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq, in connection with the issuance of shares of Nuvelo common stock in the merger and the filing of a registration statement, of which this proxy statement/prospectus/consent solicitation is a part, with the SEC. As of the date hereof, the registration statement has not become effective. Nuvelo has filed an initial listing application with the Nasdaq Global Market pursuant to Nasdaq's reverse merger rules to effect the initial listing of Nuvelo's common stock issuable in connection with the merger.

### **Appraisal Rights**

If the merger is completed, ARCA stockholders who do not consent to approve the merger are entitled to appraisal rights under Section 262 of the DGCL, or Section 262, provided that they comply with the conditions established by Section 262.

The discussion below is not a complete summary regarding an ARCA's stockholder's appraisal rights under the DGCL and is qualified in its entirety by reference to the text of the relevant provisions of the DGCL, which are attached to this proxy statement/prospectus/consent solicitation as *Annex H*. Stockholders intending to exercise appraisal rights should carefully review *Annex H*. Failure to follow precisely any of the statutory procedures set forth in *Annex H* may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that ARCA stockholders exercise their appraisal rights under the DGCL.

Under Section 262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders under Section 228 of the DGCL, either one of the constituent corporations before the effective date of the merger or the surviving corporation, within 10 days after the effective date of the merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of the merger and that appraisal rights are available. Following receipt of written consents signed by the requisite stockholders to approve the proposals, ARCA will notify those of ARCA's stockholders who did not execute a written consent that the proposals have been adopted and of the availability of appraisal rights in connection with the merger in compliance with the requirements of Section 262. If you, as an ARCA stockholder, wish to consider exercising your appraisal rights, you should carefully review the text of Section 262 contained in *Annex H* attached hereto because failure to timely and properly comply with the requirements of Section 262 will result in the loss of your appraisal rights under the DGCL.

Holders of shares of ARCA capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to ARCA within 20 days after the mailing of the notice by ARCA of the approval of the merger by written consent. Stockholders who would like to exercise appraisal rights must not have previously delivered a written consent approving the merger. A demand for appraisal must reasonably inform ARCA of the identity of the stockholder and that such stockholder intends to demand appraisal of the shares of ARCA capital stock held by the stockholder. Failure to deliver a written consent to the merger will not in and of itself constitute a written demand for appraisal rights satisfying the requirements of Section 262.

## **Table of Contents**

If you execute and deliver a written consent or if you fail to deliver a written demand for appraisal within the time period specified above and the merger is completed, you will be entitled to receive the merger consideration for your shares of ARCA capital stock as provided for in the merger agreement, but you will have no appraisal rights with respect to your shares of ARCA capital stock.

To be effective, a demand for appraisal by a holder of shares of ARCA capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder's name appears on the stockholder's stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to ARCA. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other nominee, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner's right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time of the merger.

If you hold your shares of ARCA capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.

At any time within 60 days after the effective time of the merger, any stockholder who has demanded an appraisal has the right to withdraw the demand and accept the terms of the merger by delivering a written withdrawal of the stockholder's demands for appraisal. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section 262, you will have the right to receive the merger consideration for your shares of ARCA capital stock.

Within 120 days after the effective date of the merger, any stockholder who has delivered a demand for appraisal in accordance with Section 262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the merger agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10 days after the stockholder's written request is received by the surviving corporation or within 10 days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120 days after the effective date of the merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section 262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by such stockholder. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and ARCA, which will be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder's previously written demand for appraisal.

If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20 days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names

---

**Table of Contents**

and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section 262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.

After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the fair value of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the merger, but will include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares.

In determining fair value, and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In *Weinberger v. UOP, Inc.*, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court should be considered, and that fair price obviously requires consideration of all relevant factors involving the value of a company.

Section 262 provides that fair value is to be exclusive of any element of value arising from the accomplishment or expectation of the merger. In *Cede & Co. v. Technicolor, Inc.*, the Delaware Supreme Court stated that this exclusion is a narrow exclusion [that] does not encompass known elements of value, but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In *Weinberger*, the Delaware Supreme Court construed Section 262 to mean that elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.

You should be aware that the fair value of your shares as determined under Section 262 could be more than, the same as or less than the value that you are entitled to receive under the terms of the merger agreement.

Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys' fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the effective time of the merger, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120 days after the effective time of the merger, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the merger within 60 days after the effective time of the merger, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her ARCA capital stock pursuant to the merger agreement. Any withdrawal of a demand for appraisal made more than 60 days after the effective time of the merger may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.

## **Table of Contents**

Failure to follow the steps required by Section 262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section 262, stockholders who may wish to dissent from the merger and pursue appraisal rights should consult their legal advisors.

### **Material U.S. Federal Income Tax Consequences of the Merger**

The following discussion summarizes the material U.S. federal income tax consequences of the merger that are expected to apply generally to ARCA stockholders upon an exchange of their ARCA capital stock for Nuvelo common stock and cash in lieu of fractional shares of Nuvelo common stock. This summary is based upon current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing Treasury Regulations, and current administrative rulings and court decisions, all of which are subject to change and to differing interpretations, possibly with retroactive effect. Any change could alter the tax consequences to Nuvelo, ARCA, or the stockholders of ARCA, as described in this summary. This summary is not binding on the Internal Revenue Service, or the IRS, and there can be no assurance that the IRS (or a court, in the event of an IRS challenge) will agree with the conclusions stated herein. No ruling has been or will be requested from the IRS in connection with the merger. The discussion below does not address the following: the tax consequences of the mergers under U.S. federal non-income tax laws or under state, local, or foreign tax laws; the tax consequences of transactions effectuated before, after, or at the same time as the mergers, whether or not they are in connection with the merger, including, without limitation, transactions in which ARCA shares are acquired or Nuvelo shares are disposed of; the tax consequences to holders of options issued by ARCA that are assumed, replaced, exercised, or converted, as the case may be, in connection with the merger; or the tax consequences of the receipt of Nuvelo shares other than in exchange for ARCA shares.

No attempt has been made to comment on all U.S. federal income tax consequences of the merger that may be relevant to particular holders of ARCA capital stock that are subject to special treatment under U.S. federal income tax laws, including, without limitation:

dealers, brokers and traders in securities;

foreign persons or entities;

tax-exempt entities;

financial institutions, regulated investment companies, real estate investment trusts or insurance companies;

partnerships or limited liability companies that are not treated as corporations for U.S. federal income tax purposes, subchapter S corporations and other pass-through entities and investors in such entities;

holders who are subject to the alternative minimum tax provisions of the Code;

holders who acquired their shares in connection with stock option or stock purchase plans or in other compensatory transactions;

holders who hold shares that constitute small business stock within the meaning of Section 1202 of the Code;

holders with a functional currency other than the U.S. dollar;

## Edgar Filing: NUVELO INC - Form S-4/A

holders who hold their shares as part of an integrated investment such as a hedge or as part of a hedging, straddle or other risk reduction strategy; or

holders who do not hold their shares as capital assets within the meaning of Section 1221 of the Code (generally, property held for investment will be a capital asset).

**Accordingly, holders of ARCA capital stock are advised and expected to consult their own tax advisors regarding the U.S. federal income tax consequences of the merger in light of their personal circumstances and the consequences of the merger under U.S. federal non-income tax laws and state, local, and foreign tax laws.**



---

**Table of Contents**

It is a condition to the consummation of the transaction that each of Hogan & Hartson L.L.P., outside counsel to ARCA, and Cooley Godward Kronish LLP, outside counsel to Nuvelo, render a tax opinion to their respective clients to the effect that the merger will qualify as a reorganization pursuant to Section 368(a) of the Code. The tax opinion of Hogan & Hartson L.L.P., and the tax opinion of Cooley Godward Kronish LLP, discussed in this section are each conditioned upon certain assumptions stated in their respective tax opinions and certain customary representations being delivered by ARCA, Dawn Acquisition Sub, Inc., and Nuvelo.

In addition, stockholders of ARCA should be aware that as the tax opinions discussed in this section are not binding on the IRS, the IRS could adopt a contrary position and a contrary position could be sustained by a court. In addition, if any of the representations or assumptions upon which the closing tax opinions of Hogan & Hartson L.L.P., and Cooley Godward Kronish LLP are based are inconsistent with the actual facts, the tax consequences of the merger could be adversely affected. Assuming that the merger will be treated for U.S. federal income tax purposes as a reorganization within the meaning of Section 368 of the Code, the following material U.S. federal income tax consequences will result:

Nuvelo, Dawn Acquisition Sub, Inc., ARCA and the Nuvelo stockholders will not recognize any gain or loss solely as a result of the merger;

ARCA stockholders will not recognize any gain or loss upon receipt of solely Nuvelo common stock in exchange for their ARCA capital stock, other than with respect to cash received in lieu of fractional shares of Nuvelo common stock;

the aggregate tax basis of the shares of Nuvelo common stock received by a ARCA stockholder in the merger (including any fractional share deemed received, as described below) will be equal to the aggregate tax basis of the shares of ARCA capital stock surrendered in exchange therefor;

the holding period of the shares of Nuvelo common stock received by a ARCA stockholder in the merger will include the holding period of the shares of ARCA capital stock surrendered in exchange therefor; and

generally, cash payments received by ARCA stockholders in lieu of fractional shares of Nuvelo common stock will be treated as if such fractional shares were issued in the merger and then redeemed by Nuvelo for cash resulting in a recognition of gain or loss equal to the difference, if any, between the stockholder's basis in the fractional share and the amount of cash received. The gain or loss recognized by stockholders will be a capital gain and will be long term capital gain if the stockholder's holding period for his, her, or its ARCA capital stock is more than one year.

ARCA stockholders that owned at least one percent (by vote or value) of the total outstanding stock of ARCA are required to attach a statement to their tax returns for the year in which the merger is completed that contains the information listed in Treasury Regulations Section 1.368-3(b). Such statement must include the stockholder's tax basis in the stockholder's ARCA common and preferred stock and the fair market value of such stock.

For purposes of the above discussion of the bases and holding periods for shares of ARCA capital stock and Nuvelo common stock, stockholders who acquired different blocks of ARCA capital stock at different times for different prices must calculate their basis, gains and losses, and holding periods separately for each identifiable block of such stock exchanged, converted, canceled or received in the merger.

The above discussion does not apply to ARCA stockholders who properly perfect appraisal rights. Generally, an ARCA stockholder who perfects appraisal rights with respect to such stockholder's shares of ARCA common or preferred stock will recognize capital gain or loss equal to the difference between such stockholder's tax basis in those shares and the amount of cash received in exchange for those shares.

Certain noncorporate ARCA stockholders may be subject to backup withholding, at a rate of 28%, on cash received pursuant to the merger. Backup withholding will not apply, however, to an ARCA stockholder who

---

**Table of Contents**

(1) furnishes a correct taxpayer identification number and certifies that the ARCA stockholder is not subject to backup withholding on IRS Form W-9 or a substantially similar form, (2) provides a certification of foreign status on an appropriate Form W-8 or successor form, or (3) is otherwise exempt from backup withholding. If an ARCA stockholder does not provide a correct taxpayer identification number on IRS Form W-9 or a substantially similar form, the ARCA stockholder may be subject to penalties imposed by the IRS. Amounts withheld, if any, are generally not an additional tax and may be refunded or credited against the ARCA stockholder's U.S. federal income tax liability, provided that the ARCA stockholder timely furnishes the required information to the IRS.

**Anticipated Accounting Treatment**

The merger will be treated by Nuvelo as a reverse merger and will be accounted for as a business combination using the acquisition method of accounting in accordance with GAAP. For accounting purposes, ARCA is considered to be acquiring Nuvelo in this transaction. Therefore, the aggregate acquisition consideration paid in connection with the merger will be allocated to Nuvelo's tangible and intangible assets and liabilities based on their fair market values. The unaudited pro forma condensed combined financial statements included in this proxy statement/prospectus/consent solicitation have been prepared in accordance with Article 11 of Regulation S-X, as the merger is expected to close after December 31, 2008, and is recorded as a business acquisition pursuant to SFAS 141R. Please see Note 2 to the unaudited pro forma condensed combined financial statements appearing elsewhere in this proxy statement/prospectus/consent solicitation.

**Vote Required; Recommendation of Board of Directors**

The affirmative vote of the holders of a majority of the Nuvelo common stock having voting power present in person or represented by proxy at the special meeting is required to approve the issuance of Nuvelo common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated September 24, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., as amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., as described in the attached proxy statement/prospectus/consent solicitation.

A failure to submit a proxy card or vote at the special meeting, or an abstention, vote withheld or broker non-vote will have no effect on the outcome of Proposal No. 1.

**NUVELO'S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL NO. 1 TO APPROVE THE ISSUANCE OF NUVELO COMMON STOCK PURSUANT TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, DATED SEPTEMBER 24, 2008, BY AND AMONG NUVELO, INC., DAWN ACQUISITION SUB, INC., AND ARCA BIOPHARMA, INC. AS AMENDED BY THAT AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, DATED OCTOBER 28, 2008, BY AND AMONG NUVELO, INC., DAWN ACQUISITION SUB, INC., AND ARCA BIOPHARMA, INC.**

---

**Table of Contents**

**THE MERGER AGREEMENT**

*The following description describes the material terms of the merger agreement. This description of the merger agreement is qualified in its entirety by reference to the full text of the merger agreement which is attached as Annex A to this proxy statement/prospectus/consent solicitation and the full text of the amendment to the merger agreement which is attached as Annex B to this proxy statement/prospectus/consent solicitation, both of which are incorporated herein by reference. The merger agreement and amendment have been included to provide you with information regarding their terms. We encourage you to read the entire merger agreement and amendment. The merger agreement and amendment are not intended to provide any other factual information about Nuvelo or ARCA. Such information can be found elsewhere in this proxy statement/prospectus/consent solicitation and in the case of Nuvelo, in the other public filings of Nuvelo made with the SEC, which are available without charge at [www.sec.gov](http://www.sec.gov).*

*The merger agreement contains representations and warranties that Nuvelo and merger sub, on the one hand, and ARCA, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the merger agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the merger agreement. While Nuvelo and ARCA do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached merger agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Nuvelo or ARCA, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Nuvelo and merger sub and ARCA and are modified by the disclosure schedules.*

**General**

Nuvelo, ARCA, and Dawn Acquisition Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Nuvelo, entered into an Agreement and Plan of Merger dated as of September 24, 2008, as amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, which, as amended, unless otherwise indicated, is referred to in this proxy statement/prospectus/consent solicitation as the merger agreement. The merger agreement contains the terms and conditions of the proposed business combination of Nuvelo and ARCA. Pursuant to the merger agreement, on the terms and conditions set forth therein, Dawn Acquisition Sub, Inc., will be merged with and into ARCA, with ARCA surviving the merger as a wholly-owned subsidiary of Nuvelo. After completion of the merger, current stockholders of Nuvelo will own approximately 33% of the common stock of the combined company, and current ARCA stockholders will own 67% of the common stock of the combined company, after giving effect to shares issuable pursuant to ARCA's outstanding options and warrants, primarily on a treasury stock basis, and without giving effect to shares issuable pursuant to Nuvelo's outstanding options and warrants.

**Closing of the Merger**

The closing of the transactions contemplated by the merger agreement will occur no later than the fifth business day after the last of the conditions to the transaction have been satisfied or waived. Concurrently with, or as soon as practicable after the closing, ARCA will file a certificate of merger with the Secretary of State of the State of Delaware. The transaction will become effective upon the filing of this certificate or at another time as may be designated by Nuvelo and specified in the certificate of merger.

**Merger Consideration**

At the effective time of the merger, each share of ARCA capital stock not held by Nuvelo, any subsidiary of Nuvelo or any subsidiary of ARCA, shall be converted into a right to receive a number of shares of Nuvelo

---

**Table of Contents**

common stock equal to the Exchange Ratio. The Exchange Ratio shall equal: (i) 109,009,278 *divided by* (ii) the sum of (A) the number of shares of ARCA common stock issued and outstanding immediately prior to the effective time of the merger, (B) the number of shares of ARCA common stock issuable upon the conversion of each share of ARCA preferred stock issued and outstanding immediately prior to the effective time of the merger (as calculated in accordance with ARCA's certificate of incorporation in effect immediately prior to the effective time of the merger), (C) the number of Treasury Method Shares of ARCA Common Stock Outstanding, and (D) the number of shares of ARCA common stock issuable pursuant to or upon conversion of any convertible notes or other rights outstanding as of immediately prior to the effective time (whether or not currently exercisable) to acquire shares of ARCA capital stock, *including* the notes issued pursuant to the convertible note purchase agreement by and between ARCA and certain of its stockholders dated September 24, 2008, or the Note and Warrant Purchase Agreement, and the warrants to purchase ARCA capital stock issued pursuant to the Note and Warrant Purchase Agreement but *excluding* other options and warrants to purchase ARCA capital stock, or issuable upon conversion of any ARCA preferred stock issuable pursuant to or upon conversion of any convertible notes or other rights outstanding as of immediately prior to effective time of the merger.

For purposes of determining the Exchange Ratio, the Treasury Method Shares of ARCA Common Stock Outstanding shall be equal to (i) the product of the number of shares of ARCA common stock underlying each option and warrant to purchase ARCA capital stock (other than warrants issued in connection with the Note and Warrant Purchase Agreement) that is outstanding and unexercised as of immediately prior to the effective time of the merger multiplied by the difference between (A) the ARCA Share Value and (B) the per share exercise price for each such ARCA option or warrant that is outstanding and unexercised as of immediately prior to the effective time of the merger; divided by (ii) the ARCA Share Value (ignoring any ARCA option or warrant that has a per share exercise price that is greater than or equal to the ARCA Share Value as of the effective time of the merger). The ARCA Share Value shall be equal to the product of (i) the average closing price of Nuvelo's common stock on Nasdaq for the five consecutive trading days immediately preceding the date upon which the merger is consummated, or Nuvelo Closing Price, and (ii) the Exchange Ratio.

Pursuant to the terms of the merger agreement, ARCA and Nuvelo have agreed upon a methodology to determine the Exchange Ratio as defined above. For illustration purposes, assuming the merger closed on November 19, 2008, and assuming the respective capitalizations of Nuvelo and ARCA as of November 19, 2008, the Exchange Ratio would have been 3.3395 shares of Nuvelo common stock per share of ARCA capital stock. The Exchange Ratio shall be determined as of immediately prior to the effective time of the merger and is subject to change based upon the number of shares of ARCA capital stock outstanding and issuable upon exercise of outstanding options and warrants, the Nuvelo Closing Price and certain other transactions affecting the value of Nuvelo's common stock.

Immediately after the merger, based on the Exchange Ratio, existing ARCA stockholders will own approximately 67% of the common stock of the combined company and Nuvelo stockholders will own approximately 33% of the common stock of the combined company, after giving effect to the issuance of shares of ARCA capital stock issuable upon exercise of options and warrants to purchase ARCA capital stock outstanding immediately prior to the effective time, primarily on a treasury stock basis, and without giving effect to options and warrants to purchase Nuvelo common stock outstanding immediately prior to the effective time. As described above, the number of shares of ARCA capital stock issuable pursuant to outstanding options and warrants to purchase capital stock immediately prior to the effective time (other than warrants issued in connection with the Note and Warrant Purchase Agreement) will be determined by calculating the Treasury Method Shares of ARCA Common Stock Outstanding.

The merger agreement does not include a price-based termination right, and while changes in the Nuvelo Closing Price will affect the number of Treasury Shares Method of ARCA Common Stock Outstanding and the number of shares of ARCA capital stock issuable in connection with the Note and Warrant Purchase Agreement, no changes in the Nuvelo Closing Price are expected to have a material effect on the relative ownership of the current ARCA stockholders and current Nuvelo stockholders as described above. Accordingly, the market value

## **Table of Contents**

of the shares of Nuvelo common stock issued pursuant to the merger will depend on the market value of the shares of Nuvelo common stock at the time the merger closes, and could vary significantly from the market value on the date of this proxy statement/prospectus/consent solicitation.

The Exchange Ratio is subject to adjustment to account for the effect of the reverse stock split of Nuvelo's common stock.

### **Assumption of ARCA Stock Options and Warrants**

Each option and warrant to purchase ARCA capital stock outstanding at the effective time of the merger shall be assumed by Nuvelo. Each such option or warrant shall be converted into a option or warrant, as applicable, to acquire that number of shares of Nuvelo common stock equal to the product obtained by multiplying (i) the number of shares of ARCA capital stock subject to such option or warrant by (y) the Exchange Ratio, rounded down to the nearest whole share of Nuvelo common stock. Each such option or warrant shall have a purchase price per share of Nuvelo common stock equal to the quotient obtained by dividing (i) the per share purchase price of ARCA capital stock subject to such option or warrant by (ii) the Exchange Ratio rounded up to the nearest whole cent. Each such option or warrant shall otherwise be subject to the same terms and conditions (including as to vesting and exercisability) as were applicable under the respective option warrant to purchase ARCA capital stock immediately prior to the effective time of the merger.

### **Fractional Shares**

No fractional shares of Nuvelo common stock will be issuable pursuant to the merger to ARCA stockholders. Instead, each ARCA stockholder who would otherwise be entitled to receive a fraction of a share of Nuvelo common stock, after aggregating all fractional shares of Nuvelo common stock issuable to such stockholder, will be entitled to receive in cash the dollar amount, rounded to the nearest whole cent, without interest, determined by multiplying such fraction by the closing price of a share of Nuvelo common stock as quoted on the Nasdaq Global Market, on the date the merger becomes effective.

### **Exchange of ARCA Stock Certificates**

The merger agreement provides that, at the effective time of the merger, Nuvelo will deposit with an exchange agent reasonably acceptable to ARCA stock certificates representing the shares of Nuvelo common stock issuable to the ARCA stockholders and a sufficient amount of cash to make payments in lieu of fractional shares.

Promptly after the effective time of the merger, the exchange agent will mail to each record holder of ARCA capital stock immediately prior to the effective time of the merger a letter of transmittal and instructions for surrendering and exchanging the record holder's ARCA stock certificates for shares of Nuvelo common stock. Upon surrender of a ARCA stock certificate for exchange to the exchange agent, together with a duly signed letter of transmittal and such other documents as the exchange agent or Nuvelo may reasonably require, the ARCA stock certificate surrendered will be cancelled and the holder of the ARCA stock certificate will be entitled to receive the following:

a certificate representing the number of whole shares of Nuvelo common stock that such holder has the right to receive pursuant to the provisions of the merger agreement; and

cash in lieu of any fractional share of Nuvelo common stock.

If any ARCA stock certificate has been lost, stolen or destroyed, Nuvelo may, in its discretion, and as a condition to the delivery of any shares of Nuvelo common stock, require the owner of such lost, stolen or destroyed certificate to deliver an affidavit claiming such certificate has been lost, stolen or destroyed and post a bond indemnifying Nuvelo against any claim that may be made against Nuvelo, the exchange agent or ARCA with respect to such certificate.

---

## **Table of Contents**

From and after the effective time of the merger, until it is surrendered, each ARCA stock certificate will be deemed to represent only the right to receive shares of Nuvelo common stock, and cash in lieu of any fractional share of Nuvelo common stock. No dividends or other distributions with respect to Nuvelo common stock with a record date after the effective time of the merger shall be paid or otherwise delivered to the holder of any unsurrendered ARCA stock certificate with respect to the shares of Nuvelo common stock that such holder has a right to receive in the merger until such holder surrenders such ARCA stock certificate.

### **Amended and Restated Certificate of Incorporation of Nuvelo**

The merger agreement provides that Nuvelo's stockholders must approve, as a condition to closing the merger, an amendment to Nuvelo's amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo's common stock, which requires the affirmative vote of holders of a majority of Nuvelo's issued and outstanding common stock as of the record date for the special meeting. Upon the effectiveness of the amendment to Nuvelo's certificate of incorporation, the outstanding shares of Nuvelo's common stock will be reclassified and combined into a lesser number of shares such that one share of Nuvelo's common stock will be issued for a specified number of shares, which shall be greater than one and equal to or less than 50, of outstanding Nuvelo common stock, with the exact number within the range to be determined by Nuvelo's board of directors prior to the effective time of such amendment and publicly announced by Nuvelo. As applicable Nasdaq Global Market initial listing standards require Nuvelo to have, among other things, a \$5.00 per share minimum bid price, the reverse stock split is necessary in order to satisfy a condition precedent to the merger, and unless such condition is waived, to consummate the merger. The merger agreement further provides, as a condition to closing the merger, that the amendment to Nuvelo's amended and restated certificate of incorporation to effect the reverse stock split of the issued and outstanding shares of Nuvelo's common stock shall have been accepted for filing by the Secretary of State of the State of Delaware.

### **Conditions to the Completion of the Merger**

In addition to the approval and filing of the amendment of Nuvelo's amended and restated certificate of incorporation, each party's obligation to complete the merger is subject to the satisfaction or waiver by each of the parties, at or prior to the merger, of various conditions, which include the following:

all representations and warranties of the other party in the merger agreement must be true and correct on the date of the merger agreement and as of the closing date of the merger as if made on the closing date, or as of a particular date if such representations and warranties address matters as of that particular date, disregarding materiality qualifications limiting the scope of representations and warranties; except that such inaccuracies will be disregarded if they collectively would not reasonably be expected to have a material adverse effect (as discussed in the section of this proxy statement/prospectus/consent solicitation entitled "The Merger Agreement Material Adverse Effect") on the party making the representations and warranties;

all of the covenants and obligations contained in the merger agreement that Nuvelo, Dawn Acquisition Sub, Inc., and ARCA are required to comply with or to perform at or prior to the closing shall have been complied with and performed in all material respects;

the registration statement on Form S-4, of which this proxy statement/prospectus/consent solicitation is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any SEC stop order or proceeding or threatened proceeding seeking a stop order;

the initial listing application on the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market shall have been conditionally approved, and the shares of Nuvelo common stock to be issued in the merger shall be conditionally approved for listing on the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market, both subject only to the completion of the merger and completion by Nuvelo of any reverse stock split required by Nasdaq;

**Table of Contents**

since the signing of the merger agreement, there shall not have occurred and be continuing and material adverse effect with respect to the other party, and no event shall have occurred or circumstance shall exist that, in combination with any other events or circumstances, would reasonably be expected to have or result in a material adverse effect with respect to the other party;

the requisite stockholders of Nuvelo must have approved the issuance of the Nuvelo common stock pursuant to the merger agreement and the requisite stockholders of ARCA must have approved the merger and adopted the merger agreement;

the other party to the merger agreement party must have received all required third-party and governmental consents, and such consents must be in full force and effect at the closing of the merger;

the other party must have delivered certain certificates and other documents required under the merger agreement for the closing of the merger;

no temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the merger shall have been issued by any court of competent jurisdiction or other governmental body and remain in effect, and there shall not be any legal requirement enacted or deemed applicable to the merger that makes consummation of the merger illegal;

there shall be no pending or threatened any legal proceeding in which a governmental body is or is threatened to become a party:

challenging or seeking to restrain, prohibit, rescind or unwind the consummation of the merger or any of the transactions contemplated by the merger agreement;

relating to the merger or any of the transactions contemplated by the merger agreement and seeking to obtain from Nuvelo or ARCA any damages or other relief that would reasonably be expected to be material to Nuvelo or ARCA;

seeking to prohibit or limit in any material respect Nuvelo's ability to vote, transfer, receive dividends with respect to or otherwise exercise ownership rights with respect to the stock of the surviving corporation;

that could materially and adversely affect the right or ability of Nuvelo or ARCA to own any of the material assets or operate the business of ARCA;

seeking to compel any of ARCA or Nuvelo to dispose of or hold separate any material assets or business as a result of the Merger or any of the transactions contemplated by the merger agreement;

seeking to impose (or that could result in the imposition of) any criminal sanctions or liability on Nuvelo or ARCA.

In addition, the obligation of Nuvelo and the merger sub to complete the merger is further subject to ARCA obtaining the necessary written consent of its stockholders to, effective upon the closing date, terminate the following agreements of ARCA: Amended and Restated Stockholders Agreement, dated as of May 31, 2007; Amended and Restated Investor Rights Agreement, dated as of May 31, 2007; Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of May 31, 2007; and the Amended and Restated Voting Agreement, dated as of May 31, 2007 which are referred to collectively as the ARCA Stockholder Agreements.

**Conduct of Business Prior to the Merger**

## Edgar Filing: NUVELO INC - Form S-4/A

Except as expressly contemplated or permitted by the merger agreement, as set forth in the disclosure schedules to the merger agreement, as required by law, or as approved in advance by the other party in writing, Nuvelo and ARCA have agreed that each will:

conduct their businesses in the ordinary course, in accordance with past practices and in compliance with all applicable laws, rules and regulations;



**Table of Contents**

pay its debts and taxes when due;

pay or perform all material obligations when due; and

use reasonable best efforts, consistent with past practices and policies, to:

preserve intact its present business organization;

keep available the services of its present officers and employees; and

preserve its relationships with customers, suppliers, distributors, licensors, licensees and others with which it has significant business dealings.

Except as expressly contemplated or permitted by the merger agreement, as set forth in the disclosure schedules to the merger agreement, in certain circumstances as contemplated in each company's operating budget, or without the prior written consent of the other, which consent shall not be unreasonably withheld, both Nuvelo and ARCA have also agreed that they will refrain from doing any of the following prior to the effectiveness of the merger:

propose to adopt any amendments to or amend its certificate of incorporation or bylaws or comparable organizational documents;

authorize for issuance, issue, sell, deliver or agree or commit to issue, sell or deliver (whether through the issuance or granting of options, warrants, other equity-based (whether payable in cash, securities or other property or any combination of the foregoing) commitments, subscriptions, rights to purchase or otherwise) any of its securities or any securities of any of its subsidiaries, except for (i) the issuance and sale of shares of common stock pursuant to stock options or restricted stock units outstanding prior to the date hereof, and (ii) grants of purchase rights under Nuvelo's employee stock purchase plan for the three month offering periods commencing September 1, 2008 and December 1, 2008 pursuant to terms substantially similar with respect to the determination of offering price and participation limits as in effect for the offering period commenced September 1, 2008;

amend any of its securities (including options, warrants and similar rights) or any securities of any of its subsidiaries; provided, however, that Nuvelo or ARCA may dissolve and/or merge into any of their subsidiaries certain other subsidiaries that are not material to it and its subsidiaries, taken as a whole;

incur any indebtedness or guarantee any indebtedness for borrowed money or issue or sell any debt securities or guarantee any debt securities or other obligations of others or create an encumbrance over any of its assets;

declare, set aside or pay any dividend or other distribution of property in respect of any shares of capital stock, make any other actual, constructive or deemed distribution of property in respect of the shares of capital stock or effect or commit to any stock repurchase or redemption of its capital stock;

propose or adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of it or any of its Subsidiaries (other than the transactions contemplated hereby); provided, however, that Nuvelo or ARCA may dissolve and/or merge into any of their subsidiaries certain other subsidiaries that are not material to it and its

subsidiaries, taken as a whole;

forgive any loans of any party, including its employees, officers or directors or any employees, officers or directors of any of its subsidiaries, or any of its affiliates;

increase the compensation payable or to become payable to its officers, employees or consultants, or grant any severance or termination pay to, or enter into any severance agreement with any director, officer, consultant or other employee, or establish, adopt, enter into or amend any collective bargaining, bonus, profit sharing, thrift, compensation, stock option, restricted stock, pension, retirement, deferred compensation, employment, termination, severance or other plan, agreement, trust,

**Table of Contents**

fund, policy or arrangement for the benefit of any such director, officer, consultant or employee, except the parties may make any amendments to existing employee benefit plans to the extent necessary to maintain their compliance with applicable legal requirements (including any amendments necessary or desirable to comply with Section 409A of the Code so as to avoid the imposition of additional tax with respect thereto) and the parties may make grants of equity awards as provided in the merger agreement;

acquire, sell, lease, license or dispose of any material property or assets in any single transaction or series of related transactions, except for (i) transactions pursuant to existing contracts, or (ii) transactions in the ordinary course of business consistent with past practice;

except as may be required by applicable legal requirements or GAAP, make any change in any of the accounting principles or practices used by it;

make or change any material tax election, adopt or change any tax accounting method, settle or compromise any material tax liability, or consent to the extension or waiver of the limitations period applicable to a material tax claim or assessment;

enter into any material contract;

amend in any material respect (other than an amendment where the only material amendment is to the amount to be paid or received by Nuvelo or ARCA, as applicable, and does not increase the amount to be so paid, or decrease the amount to be so received, by more than \$100,000) any material contract, or grant any release or relinquishment of any material rights under any material contract;

sell, assign, transfer, license or sublicense, pledge or otherwise encumber any intellectual property owned by Nuvelo or ARCA, as applicable (other than non-exclusive licenses in the ordinary course of business consistent with past practice);

acquire (by merger, consolidation or acquisition of stock or assets) any other Person or any equity interest therein;

mortgage, pledge or subject to encumbrance, any of its assets or properties;

authorize, incur or commit to incur any new capital expenditure(s) which in the aggregate exceed \$100,000; *provided, however*, that the foregoing shall not limit any maintenance capital expenditures or capital expenditures required pursuant to existing contracts;

settle or compromise any pending or threatened legal proceeding or pay, discharge or satisfy or agree to pay, discharge or satisfy any liability;

initiate any material legal proceeding;

except as required by applicable legal requirements or GAAP, revalue in any material respect any of its properties or assets, including writing-off notes or accounts receivable other than in the ordinary course of business consistent with past practice;

## Edgar Filing: NUVELO INC - Form S-4/A

authorize, incur or commit to any clinical trial or other action that would trigger obligations to make milestone or other payments or commitments which in the aggregate exceed \$100,000; or

enter into a contract to do any of the foregoing or knowingly take any action which is reasonably expected to result in any of the conditions to the consummation of the transactions contemplated hereby not being satisfied, or knowingly take any action which would make any of its representations or warranties set forth in the merger agreement untrue or incorrect in any material respect, or that would materially impair its ability to consummate the transactions contemplated by the merger agreement in accordance with the terms therein.

In addition, during the time period from the signing of the merger agreement until the effective time of the merger, both Nuvelo and ARCA will use reasonable best efforts to control their revenues and expenditures within an operating budget as described in the merger agreement, and each shall provide the other with unaudited

---

**Table of Contents**

consolidated balance sheets, consolidated statements of operations, and a consolidated statement of cash flows, including a comparison of the month's results with the operating budget as described in the merger agreement, within 10 business days of the end of each month. Without the prior written consent of the other party:

Nuvelo's net cash must not be less than 95 percent of the net cash amount forecast in its operating budget for (i) each fiscal quarter prior to the closing of the merger and (ii) if the closing occurs more than 45 days after the end of a fiscal quarter, the interim period from the start of the then current fiscal quarter to last day of the calendar month ending no less than 10 business days prior to the closing; and

ARCA's net cash must not be less than the net cash amount forecast in its operating budget, minus \$500,000, for (i) each fiscal quarter prior to the closing of the merger and (ii) if the closing occurs more than 45 days after the end of a fiscal quarter, the interim period from the start of the then current fiscal quarter to last day of the calendar month ending no less than 10 business days prior to the closing.

**Limitation on Soliciting, Discussing or Negotiating Other Acquisition Proposals**

Pursuant to the merger agreement, each of Nuvelo and ARCA agreed that, except as described below, they will not, during the pre-closing period, directly or indirectly:

solicit, initiate, knowingly encourage, induce or facilitate the making, submission or announcement of any acquisition proposal or acquisition inquiry or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry;

furnish any nonpublic information regarding ARCA or Nuvelo, as the case may be, or any of its subsidiaries, to any person in connection with or in response to an acquisition proposal or acquisition inquiry;

engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry;

approve, endorse or recommend any acquisition proposal or acquisition inquiry; or

enter into any letter of intent or similar document or any contract contemplating or otherwise relating to any acquisition transaction. An acquisition inquiry means any inquiry, indication of interest or request for nonpublic information (other than an inquiry, indication of interest or request for nonpublic information made or submitted by Nuvelo or ARCA, as the case may be) that would reasonably be expected to lead to an acquisition proposal (as defined below).

An acquisition proposal means any offer or proposal (other than an offer or proposal made or submitted by Nuvelo or ARCA, as the case may be) contemplating or otherwise relating to any acquisition transaction (as defined below).

An acquisition transaction means any transaction or series of transactions involving:

any merger, exchange, consolidation, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, takeover offer, tender offer, exchange offer or other similar transaction: (i) in which ARCA or Nuvelo, as the case may be or any material subsidiary of ARCA or Nuvelo, as the case may be is a constituent corporation or is otherwise involved; (ii) in which a Person or group (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding voting securities of

Edgar Filing: NUVELO INC - Form S-4/A

ARCA or Nuvelo, as the case may be or any material subsidiary of ARCA or Nuvelo, as the case may be; or (iii) in which ARCA or Nuvelo, as the case may be, or any of its material subsidiaries issues securities representing more than 20% of the outstanding voting securities of ARCA or such material subsidiary of ARCA;

---

## **Table of Contents**

any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated net revenues, consolidated net income or consolidated assets of ARCA and its subsidiaries or Nuvelo and its subsidiaries, as the case may be; or

any liquidation or dissolution of ARCA or any of its material subsidiaries or Nuvelo or any of its material subsidiaries, as the case may be.

Notwithstanding the foregoing, prior to obtaining the consent of their stockholders, either party may furnish information regarding such party to, and may enter into discussions or negotiations with, any third party in response to an unsolicited bona fide written acquisition proposal made or received after the date of the merger agreement, which such party's board of directors determines in good faith, after consultation with a nationally recognized independent financial advisor, constitutes or is reasonably likely to result in a superior offer, (as defined in the merger agreement and explained in this proxy statement/prospectus/consent solicitation), if:

neither such party nor any representative of such party has breached the no solicitation provisions of the merger agreement described above;

such party gives the other party at least two business days' prior notice of the identity of the third party and of their intention to furnish information to, or enter into discussions or negotiations with, such third party before furnishing any information or entering into discussions or negotiations with such person, and such party receives from the third party an executed confidentiality agreement; and

at least two business days' prior to the furnishing of any information to a third party, the other party furnishes the same information to the other party to the extent not previously furnished.

A superior offer means an unsolicited bona fide written offer by an unaffiliated third party to acquire pursuant to a tender offer, exchange offer, merger, consolidation or other business combination: (i) all or substantially all of the assets of a party; or (ii) more than 50% of the outstanding voting securities of a party and as a result of which the stockholders of that party immediately preceding such transaction would cease to hold at least 50% of the equity interests in the surviving or resulting entity of such transaction or any direct or indirect payment thereof, in exchange for consideration that is determined by the board of directors of that party, in its good faith judgment, after obtaining and taking into account the advice of an independent financial advisor of nationally recognized reputation, and after taking into account the likelihood and anticipated timing of consummation, to be more favorable from a financial point of view to a party's stockholders than the merger.

### **Change in Recommendation**

The merger agreement provides that neither Nuvelo nor ARCA shall withdraw or modify, or adopt any resolution of the board of directors or any committee to withdraw or modify, in a manner adverse to the other party its recommendation to (i) issue shares of common stock in connection with the merger, (ii) approve the amendment to the Nuvelo amended and restated certificate of incorporation to effect the reverse stock split, or (iii) approve the merger agreement, as the case may be. Notwithstanding the foregoing, Nuvelo or ARCA may withdraw or modify their recommendation in a manner adverse to the other party prior to the Nuvelo stockholder meeting or approval of the merger agreement by the ARCA stockholders, as the case may be, if:

the party seeking to withdraw or modify its recommendation, or the Modifying Party, has provided to other party, at least five business days prior to each meeting of Modifying Party's board of directors at which such board of directors considers the possibility of withdrawing its recommendation or modifying its recommendation in a manner adverse to the other party, written notice of such meeting together with reasonably detailed information regarding the circumstances giving rise to the consideration of such possibility; and

the Modifying Party's board of directors determines in good faith, after taking into account the advice of its outside legal counsel, that the withdrawal or modification of its recommendation is required in order for the Modifying Party's board of directors to comply with

its fiduciary obligations to its stockholders under applicable law.



## **Table of Contents**

### **Meeting of Stockholders; Stockholder Consent**

Nuvelo is obligated under the merger agreement to call, give notice of and hold a special meeting of its stockholders for the purposes of considering the issuance of shares of Nuvelo common stock and amendment to the Nuvelo's amended and restated certificate of incorporation. The meeting shall be held not later than 25 days after the registration statement of which this proxy statement/prospectus/consent solicitation is a part is declared effective. Subject to certain termination provisions, upon request of ARCA, Nuvelo shall proceed with holding the stockholder meeting despite Nuvelo's withdrawal or modification of its recommendation.

Within 72 hours after Nuvelo has provided ARCA with notice of the effectiveness of the registration statement of which this proxy statement is a part, ARCA shall solicit and obtain irrevocable written consents of its stockholders (i) approving the merger and related transactions, (ii) acknowledging that such approval is irrevocable and such stockholder is aware of its appraisal rights, and (iii) acknowledging that by its approval of the merger such stockholder waives its appraisal rights. Subject to certain termination provisions, upon request of Nuvelo, ARCA shall proceed with soliciting the stockholder consent despite ARCA's withdrawal or modification of its recommendation.

### **Other Agreements**

Each of Nuvelo and ARCA has agreed to use its commercially reasonable efforts to:

take, or cause to be taken, all actions necessary to complete the merger and other transactions contemplated by the merger agreement;

file, as soon as practicable after the date of the merger agreement, all notices, reports and other documents required to be filed by such party with any governmental body with respect to the merger and the other transactions contemplated by the merger agreement and provide the other party any information that is required to effectuate such filings;

obtain each consent (if any) required to be obtained (pursuant to any applicable legal requirement or contract, or otherwise) by such party in connection with the merger;

lift any restraint, injunction or other legal bar to the merger;

cause their respective legal advisors to deliver an opinion as to whether the merger qualifies as a reorganization within the meaning of Section 368 of the Code; and

consult each other about any public statement or press release either will make concerning the merger.

Nuvelo and ARCA also have agreed:

that Nuvelo will, in consultation with ARCA, file an application for initial inclusion on The Nasdaq Global Market or Nasdaq Capital Market in connection with the listing of Nuvelo's common stock pursuant to Nasdaq's reverse merger rules and use its reasonable best efforts to cause the shares issued in the merger to be approved for listing;

that Nuvelo and ARCA shall jointly determine: (i) a course of action to approach Nasdaq with the objective of obtaining an extension of time for Nuvelo to regain compliance with Nasdaq Marketplace Rule 4450(a)(5) and (ii) the magnitude of the reverse stock split to be given effect by the amendment to Nuvelo's amended and restated certificate of incorporation;

that prior to the Nuvelo stockholder meeting, Nuvelo shall have taken or caused to be taken all necessary corporate action such that immediately after the effective time of the merger, the board of directors of Nuvelo shall be composed of the persons agreed upon by Nuvelo and ARCA pursuant to the merger agreement;

that ARCA shall use commercially reasonable efforts to cause to be delivered to Nuvelo a letter of KPMG LLP, dated no more than two business days before the date on which the registration statement

**Table of Contents**

of which this proxy statement/prospectus/consent solicitation is a part becomes effective (and reasonably satisfactory in form and substance to Nuvelo), that is customary in scope and substance for letters delivered by independent public accountants in connection with such registration statements;

that ARCA will obtain the necessary written consent of its stockholders to, effective upon the closing of the merger, terminate the ARCA Stockholder Agreements;

that Nuvelo shall use commercially reasonable efforts to solicit the consent of its stockholders to approve an amendment to Nuvelo's amended and restated certificate of incorporation to increase the number of authorized shares of Nuvelo common stock to 250 million;

that immediately prior to the effective time of the merger, Nuvelo shall file the amendments to its amended and restated certificate of incorporation approved by the Nuvelo stockholders with the Secretary of State of the State of Delaware to become effective immediately prior to the effective time of the merger; and

that, pursuant to Rule 16b-3(d) of the Exchange Act, the board of directors of Nuvelo will adopt a resolution approving the issuance pursuant to the merger of Nuvelo common stock to parties that are or will become officers and directors of Nuvelo and their affiliates so that such issuances are exempt from application of Section 16b of the Exchange Act.

**Representations and Warranties**

The merger agreement contains customary representations and warranties of Nuvelo and ARCA relating to, among other things:

subsidiaries, corporate organization, authority and qualifications;

capital structure;

financial statements and available cash, and with respect to Nuvelo, documents filed with the SEC and the accuracy of information contained in those documents;

absence of material changes or events;

title to assets;

receivables and customers;

equipment and leaseholds;

intellectual property rights and agreements;

material agreements, contracts and commitments;

absence of undisclosed liabilities;

permits and compliance with applicable laws;

tax matters;

employee and labor matters and employee benefit plans;

environmental matters;

insurance;

related party transactions;

legal proceedings and orders;

authorization to enter into the merger agreement and consummate the associated transactions;

**Table of Contents**

inapplicability of anti-takeover statutes;

stockholder votes required for approval of the merger agreement and associated transactions;

non-contravention of merger agreement with existing corporate documents or contracts;

the receipt of fairness opinions from financial advisors;

brokers and finders fees;

with respect to Nuvelo, valid issuance of the shares to be issued in the merger; and

the accuracy of information supplied in connection with this proxy statement/prospectus/consent solicitation and the registration statement of which it is a part.

**Material Adverse Effect**

Several of the representations, warranties, covenants and closing conditions of Nuvelo and ARCA in the merger agreement are qualified by reference to whether the item in question has had or could reasonably be expected to have a material adverse effect on the applicable company.

The merger agreement provides that material adverse effect means, when used in connection with Nuvelo: any effect that, considered together with all other effects, has a material adverse effect on the business, financial condition, operations or results of operations of Nuvelo and its subsidiaries taken as a whole or the ability of Nuvelo to consummate the merger or to perform any of its covenants or obligations under the merger agreement. None of the following shall constitute or be taken into account in determining whether there has been or will be, a material adverse effect with respect to Nuvelo:

effects resulting from conditions generally affecting the industries in which Nuvelo participates or the U.S. or global economy or capital markets as a whole, to the extent that such conditions do not have a disproportionate impact on Nuvelo and its subsidiaries taken as a whole;

changes in the trading price or trading volume of Nuvelo common stock (it being understood, however, that any effect causing or contributing to such changes in the trading price or trading volume of Nuvelo common stock may constitute a Nuvelo material adverse effect and may be taken into account in determining whether a Nuvelo material adverse effect has occurred);

any failure by Nuvelo or any of its subsidiaries to meet internal projections or forecasts or third party revenue or earnings predictions for any period ending (or for which revenues or earnings are released) on or after the date of the merger agreement (it being understood, however, that any effect causing or contributing to such failures to meet projections or predictions may constitute a Nuvelo material adverse effect and may be taken into account in determining whether a Nuvelo material adverse effect has occurred);

the execution, delivery, announcement or performance of the obligations under the merger agreement or the announcement, pendency or anticipated consummation of the merger;

## Edgar Filing: NUVELO INC - Form S-4/A

any natural disaster or any acts of terrorism, sabotage, military action or war or any escalation or worsening thereof;

any changes (after the execution of the merger agreement) in GAAP or applicable legal requirements;

the taking of any action required by the merger agreement; and

any matter or event arising from certain investigations, ongoing litigation and settlement agreements previously disclosed to ARCA. The merger agreement provides that material adverse effect means, when used in connection with ARCA: any effect that, considered together with all other effects, has a material adverse effect on: (i) the business,

## **Table of Contents**

financial condition, operations or results of operations of ARCA and its subsidiaries taken as a whole; (ii) the ability of ARCA to consummate the merger or to perform any of its covenants or obligations under the merger agreement; or (iii) Nuvelo's ability to vote, transfer, receive dividends with respect to or otherwise exercise ownership rights with respect to the stock of the surviving corporation. None of the following shall constitute or be taken into account in determining whether there has been or will be, a material adverse effect with respect to ARCA:

effects resulting from conditions generally affecting the industries in which ARCA participates or the U.S. or global economy or capital markets as a whole, to the extent that such conditions do not have a disproportionate impact on ARCA and its subsidiaries taken as a whole;

any failure by ARCA or any of its subsidiaries to meet internal projections or forecasts or third party revenue or earnings predictions for any period ending (or for which revenues or earnings are released) on or after the date of the merger agreement (it being understood, however, that any effect causing or contributing to such failures to meet projections or predictions may constitute a ARCA material adverse effect and may be taken into account in determining whether a ARCA material adverse effect has occurred);

the execution, delivery, announcement or performance of the obligations under the merger agreement or the announcement, pendency or anticipated consummation of the merger;

any natural disaster or any acts of terrorism, sabotage, military action or war or any escalation or worsening thereof; any changes (after the execution of the merger agreement) in GAAP or applicable Legal Requirements;

the taking of any action required by the merger agreement;

the FDA's failure to file ARCA's NDA for Gencaro (provided that the NDA is promptly re-submitted and accepted for filing by the FDA within 30 days); and

the FDA's failure to determine the approvability of ARCA's NDA by the closing date of the merger.

### **Termination of the Merger Agreement**

The merger agreement may be terminated prior to the effective time of the merger (whether before or after adoption of the merger agreement by ARCA's stockholders and whether before or after approval of the issuance of Nuvelo common stock in the merger by Nuvelo's stockholders):

by mutual written consent of Nuvelo and ARCA, duly authorized by their respective boards of directors;

by either Nuvelo or ARCA if the merger shall not have been consummated by the February 28, 2009; provided, however, that a party shall not be permitted to terminate the merger agreement on this basis if the failure to consummate the merger by such date is attributable to a failure on the part of such party to perform any covenant or obligation in the merger agreement required to be performed by such party at or prior to the effective time of the merger;

by either Nuvelo or ARCA if a court of competent jurisdiction or other governmental body shall have issued a final and nonappealable order, or shall have taken any other final and nonappealable action, having the effect of permanently restraining, enjoining or otherwise prohibiting the consummation of the merger;

by either Nuvelo or ARCA if: (i) the Nuvelo stockholders meeting (including any adjournments and postponements thereof) shall have been held and Nuvelo's stockholders shall have taken a final vote on the issuance of shares of Nuvelo common stock in the merger; and (ii) the issuance of Nuvelo common stock in the merger shall not have been approved at the Nuvelo stockholders meeting (and shall not have been approved at any adjournment or postponement thereof);



---

**Table of Contents**

by Nuvelo if: (i) any of the representations and warranties of ARCA contained in the merger agreement shall have been inaccurate as of the date of the merger agreement or shall have become inaccurate as of a date subsequent to the date of the merger agreement (if made as of such subsequent date), provided, however, that any inaccuracies to such representations and warranties will be disregarded if such inaccuracies do not collectively constitute, and would not reasonably be expected to have or result in, a material adverse effect, or (ii) any of ARCA's covenants or obligations contained in the merger agreement shall have been breached such that the requirement that ARCA comply with or perform all of its covenants and obligations pursuant to the merger agreement in all material respects prior to the closing of the merger would not be satisfied; *provided, however*, that if an inaccuracy in any of ARCA's representations and warranties as of a date subsequent to the date of the merger agreement or breach of a covenant or obligation by ARCA is curable by ARCA, and ARCA is continuing to exercise commercially reasonable efforts to cure such inaccuracy or breach, then Nuvelo may not terminate the merger agreement on this basis on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of 30 days commencing on the date that Nuvelo gives ARCA notice of such inaccuracy or breach;

by ARCA if: (i) any of the representations and warranties of Nuvelo or the merger sub contained in the merger agreement shall have been inaccurate as of the date of the merger agreement or shall have become inaccurate as of a date subsequent to the date of the merger agreement (if made as of such subsequent date) provided, however, that any inaccuracies to such representations and warranties will be disregarded if such inaccuracies do not collectively constitute, and would not reasonably be expected to have or result in, a material adverse effect, or (ii) any of Nuvelo's covenants or obligations contained in the merger agreement shall have been breached such that the requirement that Nuvelo comply with or perform all of its covenants and obligations pursuant to the merger agreement in all material respects prior to the closing of the merger would not be satisfied; *provided, however*, that if an inaccuracy in any of Nuvelo's or the merger sub's representations and warranties as of a date subsequent to the date of the merger agreement or breach of a covenant or obligation by Nuvelo is curable by Nuvelo or the merger sub, and Nuvelo is continuing to exercise commercially reasonable efforts to cure such inaccuracy or breach, then ARCA may not terminate the merger agreement on this basis on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of 30 days commencing on the date that ARCA gives Nuvelo notice of such inaccuracy or breach;

by Nuvelo immediately prior to entering into a definitive agreement with respect to a superior offer, provided that (i) the Nuvelo board of directors has withdrawn or modified recommendation in accordance with the terms and conditions of the merger agreement and authorized Nuvelo to enter into a definitive agreement for a transaction that constitutes a superior offer, (ii) immediately prior to the termination of the merger agreement, Nuvelo pays to ARCA the termination fee described below, and (iii) immediately following such termination Nuvelo enters into a definitive agreement to effect such superior offer; or

by ARCA immediately prior to entering into a definitive agreement with respect to a superior offer, provided that (i) the ARCA board of directors of has withdrawn or modified its recommendation in accordance with the terms and conditions of the merger agreement and authorized ARCA to enter into a definitive agreement for a transaction that constitutes a superior offer, (ii) immediately prior to the termination of the merger agreement, ARCA pays to Nuvelo the termination fee described below, and (iii) immediately following such termination of ARCA enters into a definitive agreement to effect such superior offer.

---

## **Table of Contents**

### **Termination Fees**

#### ***Fees Payable by Nuvelo***

Nuvelo must pay ARCA a nonrefundable fee of \$947,112 and reimburse ARCA for up to \$500,000 in actual out of pocket legal, accounting and investment advisory fees paid or payable in connection with the transactions contemplated by the merger agreement if:

the merger agreement is terminated by Nuvelo immediately prior to Nuvelo entering into definitive agreement for a transaction that constitutes a superior offer; or

the merger agreement is terminated by Nuvelo or ARCA if the stockholders of Nuvelo do not approve the issuance of Nuvelo common stock and the resulting change in control of Nuvelo at the Nuvelo special meeting of stockholders, and all of the following conditions are met:

prior to the Nuvelo special meeting of stockholders, an acquisition proposal with respect to Nuvelo has been publicly made and not withdrawn;

within nine months of the termination of the merger agreement, Nuvelo enters into a definitive agreement to consummate an acquisition transaction with a party other than ARCA; and

such acquisition transaction is consummated pursuant to a definitive agreement.

#### ***Fees Payable by ARCA***

ARCA must pay Nuvelo a nonrefundable fee of \$1,922,924 and reimburse Nuvelo for up to \$500,000 in actual out of pocket legal, accounting and investment advisory fees paid or payable in connection with the transactions contemplated by the merger agreement if the merger agreement is terminated by ARCA immediately prior to ARCA entering into a definitive agreement for a transaction that is a superior offer.

### **Amendment and Waiver of the Merger Agreement**

#### ***Amendment***

The merger agreement may be amended with the approval of the respective boards of directors of ARCA and Nuvelo at any time (whether before or after the adoption of the merger agreement by ARCA's stockholders and whether before or after approval of the issuance of Nuvelo common stock in the merger by Nuvelo's stockholders); provided, however, that: (i) after any such adoption of the merger agreement by ARCA's stockholders, no amendment shall be made which by law requires further approval of ARCA's stockholders without the further approval of ARCA's stockholders; and (ii) after any such approval of the issuance of Nuvelo common stock in the merger by Nuvelo's stockholders, no amendment shall be made which by law or any rule or regulation of Nasdaq requires further approval of Nuvelo's stockholders without the further approval of Nuvelo's stockholders. The merger agreement may not be amended except by an instrument in writing signed on behalf of each of the parties to the merger agreement.

#### ***Waiver***

At any time prior to the effective time of the merger, Nuvelo or ARCA may: (i) extend the time for the performance of any of the obligations or other acts of the other parties to the merger agreement; (ii) waive any inaccuracy in or breach of any representation, warranty, covenant or obligation of the other party in the merger agreement or in any document delivered pursuant to the merger agreement; and (iii) waive compliance with any covenant, obligation or condition for the benefit of such party contained in the merger agreement; with the following exceptions:

Edgar Filing: NUVELO INC - Form S-4/A

no failure on the part of Nuvelo or ARCA to exercise any power, right, privilege or remedy under the merger agreement, and no delay on the part of Nuvelo or ARCA in exercising any power, right,

**Table of Contents**

privilege or remedy under the merger agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy; and

neither Nuvelo nor ARCA shall be deemed to have waived any claim arising out of the merger agreement, or any power, right, privilege or remedy under the merger agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of Nuvelo or ARCA; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

**Table of Contents**

**OTHER AGREEMENTS RELATED TO THE MERGER**

**Voting Agreements**

*The following description of the voting agreements describes the material terms of the voting agreements. This description of the voting agreements is qualified in its entirety by reference to the form of Nuvelo voting agreement which is attached as Annex C and by reference to the form of ARCA voting agreement which is attached as Annex D to this proxy statement/prospectus/consent solicitation and is incorporated herein by reference. We encourage you to read the entire form of voting agreements.*

In order to induce Nuvelo to enter into the merger agreement, several ARCA stockholders entered into voting agreements and irrevocable proxies with Nuvelo pursuant to which, among other things, each of these stockholders agreed, solely in his capacity as a stockholder, to vote all of his shares of ARCA capital stock and other ARCA securities:

in favor of the merger, the execution and delivery by ARCA of the merger agreement and the adoption and approval of the merger agreement and the terms thereof, in favor of each of the other actions contemplated by the merger agreement and in favor of any action in furtherance of any of the foregoing;

against any action or agreement that would result in a breach of any representation, warranty, covenant or obligation of ARCA in the merger agreement;

against the following actions:

any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving ARCA or any subsidiary of ARCA;

any sale, lease or transfer of a material amount of assets of ARCA or any subsidiary of ARCA;

any reorganization, recapitalization, dissolution or liquidation of ARCA or any subsidiary of ARCA;

any change in a majority of the board of directors of ARCA;

any amendment to ARCA's certificate of incorporation or bylaws which would in any manner frustrate, prevent, or nullify the merger, the merger agreement or any transactions contemplated by the merger agreement or change in any manner the voting rights of any class of ARCA's capital stock;

any material change in the capitalization of ARCA or the ARCA's corporate structure; and

any other action which is intended, or could reasonably be expected, to impede, interfere with, delay, postpone, discourage or adversely affect the merger or any of the other transactions contemplated by the merger agreement or the voting agreement.

These ARCA stockholders also granted Nuvelo an irrevocable proxy to their respective shares in accordance with the voting agreement. These ARCA stockholders may vote their shares of ARCA capital stock on all other matters not referred to in such proxy.

## Edgar Filing: NUVELO INC - Form S-4/A

Under these voting agreements executed by ARCA stockholders, subject to certain exceptions, such stockholders also have agreed not to sell or transfer ARCA capital stock and securities held by them, or any voting rights with respect thereto, until the earlier of the termination of the merger agreement or the completion of the merger. To the extent that any such sale or transfer is permitted pursuant to the exceptions included in the voting agreement, each person to which any shares of ARCA capital stock or securities are so sold or transferred must agree in writing to be bound by the terms and provisions of the voting agreement.

---

**Table of Contents**

Also under these voting agreements, if ARCA shall solicit action by written consent of its stockholders to approve matters covered by the voting agreement, such stockholders have agreed to take all actions required by the voting agreement as soon as reasonably practicable following receipt of any such written consent solicitation, which in no event shall be later than the later of (i) 72 hours after the registration statement which includes this proxy statement/prospectus/consent solicitation is declared effective or (ii) 24 hours after receipt of such written consent solicitation. ARCA stockholders that executed these voting agreements also waived their ability to exercise any appraisal or similar rights in connection with the merger or any related transaction. Additionally, such ARCA stockholders have agreed not to engage in certain actions that would solicit, encourage or support acquisition transactions other than the merger.

As of September 24, 2008, the stockholders of ARCA that entered into voting agreements owned in the aggregate 3,553,635 shares of ARCA common stock and 16,785,136 shares of ARCA preferred stock, representing approximately 84.97% of the outstanding capital stock of ARCA, including approximately 92.11% of ARCA's outstanding preferred stock, on an as converted basis, of ARCA. All of these stockholders are executive officers, directors, or entities affiliated with such persons, or 5% stockholders, of ARCA, and include the Principal Series Preferred Stockholders.

In addition, in order to induce ARCA to enter into the merger agreement, several Nuvelo stockholders entered into voting agreements and irrevocable proxies with ARCA pursuant to which, among other things, each of these stockholders agreed, solely in his capacity as a stockholder, to vote all of his shares of Nuvelo common stock:

in favor of issuance of the shares of Nuvelo common stock in the merger;

in favor of the amendment to Nuvelo's amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo common stock;

against any action or agreement that would result in a breach of any representation, warranty, covenant or obligation of Nuvelo in the merger agreement; and

against the following actions:

any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving Nuvelo or any subsidiary of Nuvelo;

any sale, lease or transfer of a material amount of assets of Nuvelo or any subsidiary of Nuvelo;

any reorganization, recapitalization, dissolution or liquidation of Nuvelo or any subsidiary of Nuvelo;

any change in a majority of the board of directors of Nuvelo;

any amendment to Nuvelo's certificate of incorporation or bylaws other than the amendment to Nuvelo's amended and restated certificate of incorporation;

any material change in the capitalization of Nuvelo or the Nuvelo's corporate structure; and

## Edgar Filing: NUVELO INC - Form S-4/A

any other action which is intended, or could reasonably be expected, to impede, interfere with, delay, postpone, discourage or adversely affect the merger or any of the other transactions contemplated by the merger agreement or the voting agreement. These Nuvelo stockholders also granted ARCA an irrevocable proxy to their respective shares in accordance with the voting agreement. These Nuvelo stockholders may vote their shares of Nuvelo common stock on all other matters not referred to in such proxy.

Nuvelo stockholders that executed these voting agreements have agreed not to engage in certain actions that would solicit, encourage or support acquisition transactions other than the merger.



## **Table of Contents**

As of September 24, 2008, the stockholders of Nuvelo that entered into voting agreements owned in the aggregate number of shares of Nuvelo common stock representing approximately 4.3% of the outstanding Nuvelo common stock.

### **Note and Warrant Purchase Agreement**

As agreed to in the merger agreement, ARCA entered into a Note and Warrant Purchase Agreement dated September 24, 2008, as amended October 10, 2008, with certain holders of ARCA preferred stock pursuant to which ARCA sold, for an aggregate consideration of \$8.75 million, its 6% Convertible Promissory Notes due March 31, 2009, or the Notes, and warrants, or the Warrants, to purchase a number of shares of ARCA's common stock as determined pursuant to the Warrants. The outstanding principal and accrued interest on the Notes will convert into that number of shares of ARCA common stock immediately prior to the closing of the merger equal to the amount of unpaid principal and interest due as of the date of conversion divided by the conversion price. The conversion price is equal to the lesser of: (i) \$3.253 or (ii) the product of (a) the average closing price of Nuvelo common stock on the Nasdaq Global Market for the five consecutive trading days immediately preceding (but not including) the date the merger is consummated and (b) the Exchange Ratio; provided, however that in no event will the conversion price be less than \$1.6265. The number of shares of ARCA common stock subject to the Warrants issued in the convertible bridge note financing is calculated by dividing (i) 20% of the sum of the principal amount of each Note plus the consideration paid for the associated Warrants by (ii) the conversion price for the Notes. The Warrants have an exercise price equal to the conversion price and have a five-year exercise period. Assuming the lowest conversion price possible under the Notes, the Warrants will be exercisable for an aggregate of 1,075,933 shares of ARCA common stock.

In connection with the closing of the Note and Warrant Purchase Agreement, ARCA amended its Restated Certificate to (i) increase the authorized number of shares of ARCA common stock to 40,000,000 shares, and (ii) make certain technical changes with respect to the merger, including alterations to the anti-dilution provisions of certain preferred stockholders of ARCA, as set forth in the Certificate of Amendment to the Restated Certificate.

**Table of Contents**

**NUVELO PROPOSAL NO. 2**

**AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION**

**TO EFFECT A REVERSE STOCK SPLIT OF NUVELO S COMMON STOCK**

**Overview**

The Nuvelo board of directors has unanimously approved a proposal to amend its amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of its common stock. The board has recommended that this proposal be presented to its stockholders for approval. The text of the form of proposed amendment to Nuvelo s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo s common stock is attached to this proxy statement/prospectus/consent solicitation as *Annex F*.

The proposed amendment to Nuvelo s amended and restated certificate of incorporation would effect a reverse stock split whereby a number of outstanding shares of Nuvelo s common stock between and including 1 and 50, such number consisting only of whole shares, will be combined into one share of Nuvelo s common stock, with this exact number within the range to be determined by the Nuvelo board of directors, subject to its obligation under the merger agreement to agree with ARCA on such determination. The Nuvelo board of directors believes that stockholder approval of an amendment granting the board this discretion, rather than approval of a specified ratio, provides the Nuvelo board of directors with appropriate flexibility to react to then-current market conditions and, therefore, is in the best interests of Nuvelo and its stockholders.

By approving this amendment, stockholders will approve a series of amendments to Nuvelo s amended and restated certificate of incorporation pursuant to which any whole number of outstanding shares of Nuvelo s common stock between and including 1 and 50 would be combined into one share of Nuvelo s common stock, and authorize the Nuvelo board of directors to file only one such amendment, as determined by the Nuvelo board of directors in the manner described herein, and to abandon each amendment not selected by the Nuvelo board of directors. The Nuvelo board of directors may also elect not to undertake any reverse stock split.

If approved by the stockholders, and following such approval, the Nuvelo board of directors determines that effecting a reverse stock split is in the best interests of Nuvelo and its stockholders, the reverse stock split will become effective upon filing one such amendment with the Secretary of State of the State of Delaware. The amendment filed thereby will contain the number of shares selected by the Nuvelo board of directors within the limits set forth in this proposal to be combined into one share of Nuvelo s common stock.

If the board elects to effect a reverse stock split following stockholder approval, the number of issued and outstanding shares of common stock would be reduced in accordance with an exchange ratio determined by the Nuvelo board of directors within the limits set forth in this proposal. Except for adjustments that may result from the treatment of fractional shares as described below, each stockholder will hold the same percentage of Nuvelo s outstanding common stock immediately following the reverse stock split as such stockholder held immediately prior to the reverse stock split. The par value of Nuvelo s common stock would remain unchanged at \$0.001 per share.

**Reasons for the Reverse Stock Split**

The Nuvelo board of directors believes that a reverse stock split may be desirable for a number of reasons. First, the Nuvelo board of directors believes that a reverse stock split may allow Nuvelo to remain listed on the Nasdaq Global Market. Second, the Nuvelo board of directors believes that a reverse stock split could improve the marketability and liquidity of Nuvelo s common stock.

Nuvelo s common stock is currently quoted on the Nasdaq Global Market. According to applicable Nasdaq rules, in a transaction constituting a reverse merger in which an issuer combines with a non-Nasdaq entity, resulting in a change of control of the issuer and potentially allowing the non-Nasdaq entity to obtain a Nasdaq listing, the issuer must apply for initial inclusion on the applicable Nasdaq market. The merger agreement

---

**Table of Contents**

requires, as a condition to closing of the merger, that Nuvelo have received conditional approval to list the shares issuable in connection with the merger on the Nasdaq Global Market, Nasdaq Global Select Market or Nasdaq Capital Market. The listing standards of the Nasdaq Global Market require, among other things, a \$5.00 per share minimum bid upon the effective time of the merger and the listing standards of the Nasdaq Capital Market require, among other things, a \$4.00 per share minimum bid upon the effective time of the merger. Nuvelo has filed an initial listing application for the Nasdaq Global Market in connection with the merger. On November 21, 2008 Nuvelo's common stock closed at \$0.27 per share. Therefore, the reverse stock split is necessary in order to consummate the merger unless this condition is waived.

In addition to the initial listing requirement for the Nasdaq Global Market that Nuvelo must satisfy in connection with the merger, in order for Nuvelo common stock to continue to be quoted on the Nasdaq Global Market after the completion of the merger, Nuvelo must satisfy certain listing maintenance standards established by the Nasdaq Global Market. Among other things, if the closing bid price of Nuvelo's common stock is under \$1.00 per share for 30 consecutive trading days and does not thereafter reach \$1.00 per share or higher for a minimum of ten consecutive trading days during the 180 calendar days following notification by Nasdaq, Nasdaq may delist Nuvelo's common stock from trading on the Nasdaq Global Market. On May 1, 2008, Nuvelo received a letter from Nasdaq advising it that Nuvelo's common stock had not met the Nasdaq Global Market's minimum bid price requirement for 30 consecutive trading days and that, if Nuvelo was unable to demonstrate compliance with this requirement during the 180 calendar days ending October 28, 2008, its common stock would be delisted at that time, however, such delisting would be stayed pending any appeal Nuvelo makes to Nasdaq. On October 16, 2008, Nasdaq announced that it had suspended the enforcement of its rules requiring a minimum bid price of \$1.00 per share through January 16, 2009. As a result of this suspension, Nuvelo does not expect to receive a staff determination letter with respect to the delisting of Nuvelo common stock unless it has failed to demonstrate compliance with the minimum bid requirement on or before January 30, 2009. In the event that Nuvelo receives a determination letter from the staff at Nasdaq with respect to its non-compliance with the minimum bid requirement, Nuvelo expects to appeal such determination and present a plan for compliance to Nasdaq that includes the consummation of the merger and the implementation of the reverse stock split. The Nuvelo board of directors expects that a reverse stock split of its common stock will increase the market price of its common stock so that Nuvelo is able to achieve the initial listing requirements for the Nasdaq Global Market upon completion of the merger and thereafter maintain compliance with the Nasdaq minimum bid price listing standard for the foreseeable future. Even if the merger is not consummated, Nuvelo believes the reverse stock split is necessary to maintain compliance with this minimum bid requirement. Notwithstanding the foregoing, there can be no assurance that the market price per share following the merger and the reverse stock split will remain in excess of the minimum bid price for a sustained period of time. In addition, there can be no assurance that the Nuvelo common stock will not be delisted due to a failure to meet other continued listing requirements even if the market price per post-reverse split share of Nuvelo's common stock remains in excess of the minimum bid requirement.

The Nuvelo board of directors also believes that the increased market price of Nuvelo common stock expected as a result of implementing a reverse stock split will improve the marketability and liquidity of Nuvelo common stock and will encourage interest and trading in Nuvelo common stock. Because of the trading volatility often associated with low-priced stocks, many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. Some of those policies and practices may function to make the processing of trades in low-priced stocks economically unattractive to brokers. Additionally, because brokers' commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stocks, the current average price per share of Nuvelo common stock can result in individual stockholders paying transaction costs representing a higher percentage of their total share value than would be the case if the share price were substantially higher. It should be noted that the liquidity of Nuvelo common stock may be harmed by the proposed reverse stock split given the reduced number of shares that would be outstanding after the reverse stock split. The Nuvelo board of directors is hopeful,

---

**Table of Contents**

however, that the anticipated higher market price will reduce, to some extent, the negative effects of the policies and practices of institutional investors and brokerage houses described above on the liquidity and marketability of the common stock.

**Effects of the Reverse Stock Split**

After the effective date of the proposed reverse stock split, each stockholder will own a reduced number of shares of Nuvelo common stock. However, the proposed reverse stock split will affect all of Nuvelo's stockholders uniformly and will not affect any stockholder's percentage ownership interests in Nuvelo, except to the extent that the reverse stock split results in any of Nuvelo's stockholders owning a fractional share as described below. Proportionate voting rights and other rights and preferences of the holders of Nuvelo common stock will not be affected by the proposed reverse stock split (other than as a result of the payment of cash in lieu of fractional shares). For example, a holder of 2% of the voting power of the outstanding shares of Nuvelo common stock immediately prior to reverse stock split would continue to hold 2% of the voting power of the outstanding shares of Nuvelo common stock immediately after the reverse stock split. The number of stockholders of record will not be affected by the proposed reverse stock split (except to the extent that any stockholder holds only a fractional share interest and receives cash for such interest after the proposed reverse stock split).

The amendment to Nuvelo's amended and restated certificate of incorporation to effect the reverse stock split will not change the number of authorized shares of Nuvelo common stock. As a result, one of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This effective increase will occur even if the proposal to amend Nuvelo's amended and restated certificate to increase the authorized shares of common stock to 250 million is not approved. This could result in Nuvelo or the combined company being able to issue more shares without further stockholder approval.

The proposed reverse stock split will reduce the number of shares of common stock available for issuance under Nuvelo's equity incentive plans in proportion to the exchange ratio selected by the Nuvelo board of directors within the limits set forth in this proposal. Nuvelo also has certain outstanding stock options and warrants to purchase shares of Nuvelo common stock. Under the terms of the outstanding stock options and warrants, the proposed reverse stock split will effect a reduction in the number of shares of common stock issuable upon exercise of such stock options and warrants in proportion to the exchange ratio of the reverse stock split and will effect a proportionate increase in the exercise price of such outstanding stock options and warrants. In connection with the proposed reverse stock split, the number of shares of common stock issuable upon exercise or conversion of outstanding stock options will be rounded to the nearest whole share and no cash payment will be made in respect of such rounding.

If a proposed reverse stock split is implemented, it will increase the number of stockholders of Nuvelo who own odd lots of less than 100 shares of Nuvelo common stock. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares of common stock. Accordingly, a reverse stock split may not achieve the desired results of increasing marketability and liquidity of Nuvelo common stock that have been outlined above.

Nuvelo common stock is currently registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, and Nuvelo is subject to the periodic reporting and other requirements of the Securities Exchange Act. The proposed reverse stock split will not affect the registration of the common stock under the Securities Exchange Act. If the proposed reverse stock split is implemented, and Nuvelo's initial listing application with the Nasdaq Global Market is approved, Nuvelo common stock will continue to be reported on the Nasdaq Global Market under the symbol NUVO (although Nasdaq would likely add the letter D to the end of the trading symbol for a period of 20 trading days to indicate that the reverse stock split has occurred). It is expected that following the merger, the combined company will change its name to ARCA biopharma, Inc. and that its trading symbol will be changed. ARCA has reserved the ticker symbol ABIO for this purpose.

## **Table of Contents**

### **Effective Date**

The proposed reverse stock split would become effective on the date of filing of the certificate of amendment to Nuvelo's amended and restated certificate of incorporation with the office of the Secretary of State of the State of Delaware. Except as explained below with respect to fractional shares, on the effective date, shares of Nuvelo common stock issued and outstanding immediately prior to the effective date will be combined and converted, automatically and without any action on the part of the stockholders, into new shares of common stock in accordance with the reverse stock split ratio determined by the Nuvelo board of directors within the limits set forth in this proposal.

### **Payment for Fractional Shares**

No fractional shares of common stock will be issued as a result of the proposed reverse stock split. Instead, Nuvelo stockholders who otherwise would be entitled to receive fractional shares, upon surrender to the exchange agent (as defined below) of such certificates representing such fractional shares, will be entitled to receive cash in an amount equal to the product obtained by multiplying (i) the closing sales price of Nuvelo common stock on the effective date of the reverse stock split as reported on the Nasdaq Global Market by (ii) the number of shares of Nuvelo common stock held by such Nuvelo stockholder that would otherwise have been exchanged for such fractional share interest.

### **Exchange of Stock Certificates**

As soon as practicable after the effective date of the reverse stock split, stockholders will be notified that the reverse stock split has been effected. Nuvelo's transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre-reverse stock split shares will be asked to surrender to the exchange agent certificates representing pre-reverse stock split shares in exchange for certificates representing post-reverse stock split shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by Nuvelo. No new certificates will be issued to a Nuvelo stockholder until such Nuvelo stockholder has surrendered such stockholder's outstanding certificate(s) together with the properly completed and executed letter of transmittal to the exchange agent. **Nuvelo Stockholders should not destroy any stock certificate and should not submit any certificates until requested to do so.**

### **Accounting Consequences**

The par value per share of Nuvelo common stock would remain unchanged at \$0.001 per share after the reverse stock split. As a result, on the effective date of the reverse stock split, the stated capital on Nuvelo balance sheet attributable to the Nuvelo common stock will be reduced proportionally, based on the exchange ratio of the reverse stock split, from its present amount, and the additional paid-in capital account shall be credited with the amount by which the stated capital is reduced. The per share common stock net income or loss and net book value will be increased because there will be fewer shares of Nuvelo common stock outstanding. Nuvelo does not anticipate that any other accounting consequences would arise as a result of the reverse stock split.

### **Material U.S. Federal Income Tax Consequences of the Reverse Stock Split**

The following is a summary of important tax considerations of the proposed reverse stock split. This summary is based upon current provisions of the Code, existing Treasury Regulations, and current administrative rulings and court decisions, all of which are subject to change and to differing interpretations, possibly with retroactive effect. Any change could alter the tax consequences to Nuvelo or Nuvelo stockholders, as described in this summary. This summary is not binding on the IRS, and there can be no assurance that the IRS (or a court, in the event of an IRS challenge) will agree with the conclusions stated herein. No ruling has been or will be requested from the IRS in connection with the reverse stock split. The discussion below does not address the

**Table of Contents**

following: the tax consequences of the reverse stock split under U.S. federal non-income tax laws or under state, local, or foreign tax laws; the tax consequences of transactions effectuated before, after, or at the same time as the reverse stock split, whether or not they are in connection with the reverse stock split, including, without limitation, transactions in which Nuvelo shares are acquired or disposed of and in particular the acquisition of common stock of Nuvelo in exchange for Capital Stock of ARCA in the reverse stock split; the tax consequences to holders of options issued by Nuvelo that are exercised, adjusted or converted, as the case may be, in connection with the reverse stock split; or the tax consequences of the receipt of Nuvelo shares other than in exchange for Nuvelo shares in the reverse stock split.

No attempt has been made to comment on all U.S. federal income tax consequences of the reverse stock split that may be relevant to particular holders of Nuvelo stock that are subject to special treatment under U.S. federal income tax laws, including, without limitation:

dealers, brokers and traders in securities;

foreign persons or entities;

tax-exempt entities;

financial institutions, regulated investment companies, real estate investment trusts or insurance companies;

partnerships or limited liability companies that are not treated as corporations for U.S. federal income tax purposes, subchapter S corporations and other pass-through entities and investors in such entities;

holders who are subject to the alternative minimum tax provisions of the Code;

holders who acquired their shares in connection with stock option or stock purchase plans or in other compensatory transactions;

holders who hold shares that constitute small business stock within the meaning of Section 1202 of the Code;

holders with a functional currency other than the U.S. dollar;

holders who hold their shares as part of an integrated investment such as a hedge or as part of a hedging, straddle or other risk reduction strategy;

holders who do not hold their shares as capital assets within the meaning of Section 1221 of the Code (generally, property held for investment will be a capital asset);

holders who will receive shares of Nuvelo common stock in exchange for ARCA capital stock in the merger.

**Accordingly, holders of Nuvelo stock are advised and expected to consult their own tax advisors regarding the U.S. federal income tax consequences of the reverse stock split in light of their personal circumstances and the consequences of the reverse stock split under U.S. federal non-income tax laws and state, local, and foreign tax laws.**

## Edgar Filing: NUVELO INC - Form S-4/A

The reverse stock split is expected to qualify for one or more non-recognition provisions of the Code. Assuming the reverse stock split so qualifies, the following consequences will result:

No gain or loss will be recognized by Nuvelo as a result of the reverse stock split,

a Nuvelo stockholder who receives only Nuvelo stock in the reverse stock split generally will not recognize any gain or loss on the reverse stock split, and the aggregate tax basis of the post-reverse split shares received will be equal to the aggregate tax basis of the pre-reverse split shares exchanged therefor,

## **Table of Contents**

a Nuvelo stockholder who receives both Nuvelo stock and cash in lieu of fractional in lieu of fractional shares of Nuvelo stock in the reverse stock split generally will recognize any gain inherent in the Nuvelo stock surrendered up to the amount of cash received, but will not recognize any loss. The aggregate tax basis of the post-reverse split shares received will be equal to the aggregate tax basis of the pre-reverse split shares exchanged therefor, increased by the amount of any gain recognized as a result of the reverse stock split,

the holding period of Nuvelo stock received in the reverse split shares received will include the holding period of the pre-reverse split shares exchanged,

a Nuvelo stockholder who receives only cash in exchange for Nuvelo stock in the reverse stock split generally will recognize gain or loss equal to the difference between such stockholder's tax basis in the shares of Nuvelo stock exchanged and the amount of cash received in exchange for those shares, and

any gain or loss recognized by a Nuvelo stockholder as a result of the reverse stock split will be a capital gain or loss and will be long term capital gain or loss if the stockholder's holding period for the shares of Nuvelo stock exchanged is more than one year. Nuvelo stockholders that own at least one percent (by vote or value) of the total outstanding stock of Nuvelo prior to the reverse stock split or Nuvelo stock with a tax basis of \$1 million or more may be required to attach a statement to their tax returns for the year in which the reverse stock split is completed that contains the information listed in Treasury Regulations Section 1.368-3(b). Such statement must include the stockholder's tax basis in the stockholder's Nuvelo stock and the fair market value of such stock.

For purposes of the above discussion of the bases and holding periods for shares of Nuvelo stock, and except as provide therein, stockholders who acquired different blocks of Nuvelo stock at different times for different prices must calculate their basis, gains and losses, and holding periods separately for each identifiable block of such stock exchanged, converted, canceled or received in the reverse stock split.

Certain noncorporate Nuvelo stockholders may be subject to backup withholding, at a rate of 28%, on cash received pursuant to the reverse stock split. Backup withholding will not apply, however, to a Nuvelo stockholder who (1) furnishes a correct taxpayer identification number and certifies that the Nuvelo stockholder is not subject to backup withholding on IRS Form W-9 or a substantially similar form, (2) provides a certification of foreign status on an appropriate Form W-8 or successor form, or (3) is otherwise exempt from backup withholding. If a Nuvelo stockholder does not provide a correct taxpayer identification number on IRS Form W-9 or a substantially similar form, the Nuvelo stockholder may be subject to penalties imposed by the IRS. Amounts withheld, if any, are generally not an additional tax and may be refunded or credited against the Nuvelo stockholder's U.S. federal income tax liability, provided that the Nuvelo stockholder timely furnishes the required information to the IRS.

### **No Appraisal Rights**

Under the DCGL, Nuvelo stockholders are not entitled to dissenter's appraisal rights with respect to the proposed amendment to the Nuvelo amended and restated certificate of incorporation to effect the reverse stock split and Nuvelo will not independently provide Nuvelo stockholders with any such right.



**Table of Contents**

**Vote Required; Recommendation of Board of Directors**

The affirmative vote of the holders of a majority of the Nuvelo common stock issued and outstanding is required to approve the proposal to amend its amended and restated certificate of incorporation to effect the reverse stock split.

A failure to submit a proxy card or vote at the special meeting, or an abstention, vote withheld or broker non-vote will have the same effect as a vote against Proposal No. 2.

**NUVELO S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL NO. 2 TO APPROVE THE PROPOSAL TO AMEND ITS AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE ISSUED AND OUTSTANDING SHARES OF ITS COMMON STOCK.**

---

**Table of Contents**

**NUVELO PROPOSAL NO. 3**

**AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION**

**TO INCREASE THE AUTHORIZED SHARES OF NUVELO COMMON STOCK**

**Overview**

The Nuvelo board of directors has unanimously approved a proposal to amend its amended and restated certificate of incorporation to increase the authorized shares of common stock of Nuvelo to 250 million shares. The board has recommended that this proposal be presented to its stockholders for approval. The text of the form of proposed amendment to Nuvelo's amended and restated certificate of incorporation to increase the authorized shares of common stock of Nuvelo to 250 million shares is attached to this proxy statement/prospectus/consent solicitation as *Annex G*.

Upon filing the certificate of amendment to Nuvelo's amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 100 million to 250 million, the fourth paragraph of Article IV of Nuvelo's amended and restated certificate of incorporation will be as follows:

The total number of shares of all classes of stock this Corporation shall have authority to issue following the Effective Time is 255,000,000 consisting of 250,000,000 shares of Common Stock, par value \$0.001 per share, and 5,000,000 shares of Preferred Stock, par value \$0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.

**Reasons for the Increase in Authorized Shares**

Although at present, apart from the shares to be issued pursuant to the merger, Nuvelo's board of directors has no other plans to issue the additional shares of common stock, it desires to have the shares available to provide additional flexibility to use its capital stock for business and financial purposes in the future. The additional shares may be used for various purposes without further stockholder approval. These purposes may include, among others:

raising capital;

providing equity incentives to employees, officers or directors;

establishing strategic relationships with other companies; and

expanding Nuvelo's business or product lines through the acquisition of other businesses or products.

The terms of additional shares of common stock will be identical to those of the currently outstanding shares of Nuvelo common stock. However, because holders of Nuvelo common stock have no preemptive rights to purchase or subscribe for any unissued stock of Nuvelo, the issuance of any additional shares of common stock authorized as a result of the increase in the number of authorized shares of common stock will reduce the current stockholders' percentage of ownership interest in the total outstanding shares of common stock.

**Effects of the Increase in Authorized Shares**

The proposed increase in the authorized number of shares of common stock could have a number of effects on the stockholders of Nuvelo depending upon the exact nature and circumstances of any actual issuances of authorized but unissued shares. The increase could have an anti-takeover effect, in that additional shares could be issued (within the limits imposed by applicable law) in one or more transactions that could make a change in control or takeover of Nuvelo difficult. For example, additional shares could be issued by Nuvelo so as to dilute the stock ownership or voting rights of person seeking to obtain control of Nuvelo. Similarly, the issuance of additional shares to certain persons allied

## Edgar Filing: NUVELO INC - Form S-4/A

with Nuvelo's management could have the effect of making it more difficult to remove Nuvelo's management by diluting the stock ownership or voting rights of persons seeking to cause such removal.

**Table of Contents**

At any time prior to the effectiveness of the filing of this proposed amendment to Nuvelo's restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000, notwithstanding stockholder approval of this proposed amendment, Nuvelo's board of directors may abandon this proposed amendment without any further action by Nuvelo's stockholders.

**Vote Required; Recommendation of Board of Directors**

The affirmative vote of the holders of a majority of the Nuvelo common stock issued and outstanding is required to approve the proposal to amend its amended and restated certificate of incorporation increase the authorized shares of common stock of Nuvelo to 250 million shares.

A failure to submit a proxy card or vote at the special meeting, or an abstention, vote withheld or broker non-vote will have the same effect as a vote against Proposal No. 3.

**NUVELO'S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL NO. 3 TO APPROVE THE PROPOSAL TO AMEND ITS AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED SHARES OF NUVELO COMMON STOCK TO 250 MILLION.**

**Table of Contents**

**NUVELO PROPOSAL NO. 4**  
**APPROVAL OF POSSIBLE ADJOURNMENT**  
**OF THE SPECIAL MEETING**

**Overview**

If Nuvelo fails to receive a sufficient number of votes to approve Proposals 1 or 2, Nuvelo may propose to adjourn the special meeting, if a quorum is present, for a period of not more than 30 days for the purpose of soliciting additional proxies to approve Proposals 1 or 2. Nuvelo currently does not intend to propose adjournment at the special meeting if there are sufficient votes to approve Proposals 1 and 2.

**Vote Required; Recommendation of Board of Directors**

The affirmative vote of the holders of a majority of the Nuvelo common stock having voting power present in person or represented by proxy at the special meeting is required to approve the adjournment of the special meeting for the purpose of soliciting additional proxies to approve Proposals 1 or 2.

A failure to submit a proxy card or vote at the special meeting, or an abstention, vote withheld or broker non-vote will have no effect on the outcome of Proposal 4.

**NUVELO S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE FOR PROPOSAL 4 TO ADJOURN THE SPECIAL MEETING, IF NECESSARY, IF A QUORUM IS PRESENT, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSALS 1 OR 2.**

---

**Table of Contents**

**WRITTEN CONSENT OF ARCA STOCKHOLDERS**

ARCA is sending this proxy statement/prospectus/consent solicitation to you in connection with the solicitation of written consents in lieu of a meeting of ARCA stockholder by the ARCA board of directors. This proxy statement/prospectus/consent solicitation is first being furnished to ARCA's stockholders on or about November 25, 2008.

**ARCA PROPOSAL APPROVAL OF THE MERGER, MERGER AGREEMENT AND THE TRANSACTIONS CONTEMPLATED THEREBY**

The purposes of this solicitation of written consent in lieu of a meeting of ARCA stockholders is to adopt the Agreement and Plan of Merger and Reorganization, dated September 24, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., as amended by that Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., and to approve the merger and the transactions contemplated thereby. A copy of the Agreement and Plan of Merger and Reorganization is attached as *Annex A* to the accompanying proxy statement/prospectus/consent solicitation and a copy of Amendment No.1 to Agreement and Plan of Merger and Reorganization is attached as *Annex B* to the accompanying proxy statement/prospectus/consent solicitation. In addition, by consenting to the adoption of the merger agreement, and approving the merger and transactions contemplated thereby, each ARCA stockholder acknowledges that:

- (i) such stockholder's consent to the adoption of the merger agreement and approval of the merger is irrevocable;
- (ii) such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section 262 of the DGCL, and that such stockholder has received and read a copy of Section 262 of the DGCL; and
- (iii) such stockholder is not entitled to appraisal rights with respect to its shares in connection with the merger and that the stockholder hereby waives any rights to receive payment of the fair value of ARCA capital stock under the DGCL.

**Recommendation of ARCA's Board of Directors**

**ARCA'S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT ARCA STOCKHOLDERS VOTE TO ADOPT THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, DATED SEPTEMBER 24, 2008, BY AND AMONG NUVELO, INC., DAWN ACQUISITION SUB, INC., AND ARCA BIOPHARMA, INC. AS AMENDED BY THAT AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, DATED OCTOBER 28, 2008, BY AND AMONG NUVELO, INC., DAWN ACQUISITION SUB, INC., AND ARCA BIOPHARMA, INC., AND APPROVE THE MERGER AND THE TRANSACTIONS CONTEMPLATED THEREBY.**

**Record Date and Voting Power**

Only holders of record of ARCA's common stock and preferred stock as of the close of business on the record date are entitled to vote by written consent. In accordance with the DGCL, the record date shall be the first date on which a signed written consent is delivered to ARCA. At the close of business on November 20, 2008, there were 5,713,818 shares of ARCA common stock and 15,677,836 shares of ARCA preferred stock issued and outstanding, consisting of 9,222,257 shares of Series A preferred stock, 3,688,902 shares of Series B-1 preferred stock and 2,766,677 shares of Series B-2 preferred stock, outstanding and entitled to vote via written consent. Each share of ARCA common stock entitles its holder to one vote by written consent on ARCA's proposals. Each share of ARCA preferred stock entitles its holder to one vote for each share of common stock into which such share converts, which, assuming the lowest conversion rate under the outstanding convertible promissory notes, is on a one-for-one basis for Series A preferred stock, 1.219875 to 1 basis for Series B preferred stock and

## **Table of Contents**

1.6265 to 1 basis for Series B-2 preferred stock. See ARCA Security Ownership by Certain Beneficial Owners and Management for information regarding ownership by ARCA management persons and other persons known to the management of ARCA to be the beneficial owners of more than 5% of the outstanding shares of ARCA's capital stock.

### **Irrevocability of Written Consents**

The written consents that are being solicited by this prospectus/proxy statement/consent solicitation are irrevocable.

### **Execution and Delivery of Written Consents**

Complete, date and sign the enclosed written consent and mail it in the enclosed postage-paid envelope to ARCA biopharma, Inc., Attn: General Counsel, Executive Vice President of Business Development, 8001 Arista Place, Suite 200, Broomfield, CO 80021 no later than November 28, 2008. All properly executed written consents will be treated as votes to approve the merger, the merger agreement and the transactions contemplated by the merger agreement. Any holders of ARCA common stock and ARCA preferred stock who do not execute and return written consents as instructed will be deemed to have voted their shares against these proposals.

### **Required Consent**

This proposal requires the affirmative vote of holders of (a) a majority of the shares of ARCA common stock and ARCA preferred stock, voting together as a single class, with holders of ARCA preferred stock voting on an as-converted basis and (b) a majority of the following ARCA stockholders, who we refer to as the Principal Series Preferred Stockholders : Atlas Venture Fund VII, L.P. and its affiliates, Boulder Ventures IV, L.P. and Boulder Ventures IV (Annex), L.P. and their respective affiliates, Skyline Venture Partners Qualified Purchaser Fund IV, L.P. and its affiliates, and InterWest Partners IX, L.P. and its affiliates.

Pursuant to certain voting agreements with ARCA, the holders of approximately 84.97% of ARCA's outstanding capital stock, including approximately 92.11% of ARCA's outstanding preferred stock, on an as converted basis, and all of the Principal Series Preferred Stockholders, have agreed to consent to the proposal.

### **Appraisal Rights**

Under the DGCL, holders of ARCA's capital stock who do not execute a written consent to the adoption and approval of the merger, the merger agreement and the transactions contemplated by the merger agreement will have the right to seek appraisal of the fair value of their shares as determined by the Delaware Court of Chancery if the merger is completed, but only if they submit a written demand for an appraisal within 20 days after the mailing of notice by ARCA that the merger was approved by written consent of the ARCA stockholders and they comply with the other procedures under the DGCL explained in the accompanying proxy statement/prospectus/consent solicitation. See The Merger Appraisal Rights.

**Table of Contents****INFORMATION ABOUT NUVELO'S BUSINESS****Overview**

Nuvelo, Inc. is a biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor that has completed Phase 1 development for use as a short-acting anticoagulant during medical or surgical procedures, and Phase 1 clinical candidate NU206, a recombinant, secreted protein for the potential treatment of gastrointestinal, or GI, diseases, including cancer therapy induced mucositis and inflammatory bowel disease, in addition to bone disease and wound healing. In addition, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics.

***NU172***

NU172 is a short-acting aptamer, a single-stranded nucleic acid that forms a well-defined three-dimensional shape conceptually similar to an antibody. NU172 was designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical or surgical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied as a potential short-acting anticoagulant for use during procedures such as coronary artery bypass graft, or CABG, surgery, kidney dialysis and a variety of vascular surgical and coronary interventions. Approximately 450,000 CABG procedures and 50 million dialysis procedures are performed annually in the U.S. In these procedures, heparin is often paired with its antidote protamine as the anticoagulation effect of heparin needs to be reversed once the procedure has been completed. Data from the Phase 1 trial and preclinical studies suggest that NU172 has the potential to produce rapid and predictable onset and offset of anticoagulation, work in stagnant blood, avoid thrombocytopenia, and has the potential for non-renal clearance. These studies also suggest that NU172 may have a short half-life in patients, giving it the potential to be rapidly reversed without the need for an antidote.

In August 2008, Nuvelo completed the Phase 1b proof-of-concept trial, demonstrating that NU172 rapidly produced and maintained anticoagulation with a rapid return toward baseline after the infusion ended. The single-center, Phase 1b trial examined the safety, tolerability and pharmacokinetics of intravenous bolus plus infusion dosing of NU172 in 24 healthy male volunteers. Volunteers were given a 2 mg/kg bolus dose followed by escalating infusion doses of NU172 for four hours. In all four cohorts, NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time, or ACT, prothrombin time, or PT, and activated partial thromboplastin time, or aPTT. The highest infusion dose rate tested, 6.0 mg/kg/hr, resulted in an average ACT per subject ranging from 373 to 414 seconds and an increase of approximately three times baseline. Average PT values per subject ranged from 56 to 92 seconds and had an increase of approximately five times baseline. Average aPTT values per subject ranged from 130 to 178 seconds and had an increase of approximately five times baseline. All measurements were maintained stably throughout the four-hour infusion. Once the infusion ended, the ACT and other coagulation parameters showed a rapid return toward baseline, consistent with the short plasma half-life of NU172 observed in the Phase 1a trial. In addition, NU172 was well-tolerated with no serious adverse events.

Nuvelo anticipates initiating a Phase 2 study evaluating NU172 in CABG patients in the first half of 2009.

Nuvelo is developing NU172 through a collaboration with Archemix Corporation, under which Nuvelo is responsible for development and worldwide commercialization of NU172 and other potential product candidates that may be developed under this collaboration. In February 2008, Nuvelo paid Archemix a \$1.0 million milestone fee in connection with the dosing of the first patient in the Phase 1 trial for NU172. If Nuvelo enrolls the first patient in a Phase 2 trial of NU172, which Nuvelo expects may occur in the first half of 2009, Nuvelo will be obligated to pay Archemix a \$3.0 million milestone fee.



## **Table of Contents**

### ***NU206***

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, a critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues including the GI epithelium and bone. NU206 works by antagonizing an inhibitor of the Wnt pathway, DKK1, thereby turning on the pathway. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced GI injury, inflammatory bowel disease, bone disease and wound healing. In animal models of GI disease, the effect of NU206 was transient and reversible in normal tissue. Once administration of NU206 is stopped, the epithelium of the intestine reverts to its normal state and does not continue to proliferate.

Nuvelo initiated a Phase 1 single ascending dose trial in healthy volunteers in July 2008 and expect data from the trial in the fourth quarter of 2008. Nuvelo also plans to initiate a Phase 1b multiple ascending dose trial in healthy volunteers in the fourth quarter of 2008 or first quarter of 2009. Nuvelo is currently evaluating partnership and out-licensing opportunities for NU206.

In March 2005, Nuvelo entered into a collaboration agreement with the Kirin Pharma Company, Limited for the development and commercialization of NU206. Under this agreement, all operating expenses and any profits related to the development and commercialization of NU206 are being shared 60 percent by Nuvelo and 40 percent by Kirin.

### ***Research Programs***

In addition to Nuvelo's clinical and development-stage drug candidates, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics. Nuvelo is currently evaluating partnership and out-licensing opportunities for its research programs.

#### ***Leukemia Therapeutic Antibody Program***

Nuvelo is developing monoclonal antibody, or mAbs, candidates discovered by Nuvelo's leukemia therapeutic antibody program. Nuvelo is completing preclinical studies with a series of chimeric mAbs to select drug candidates for the potential treatment of chronic lymphocytic leukemia, or CLL, and acute myelogenous leukemia, or AML.

Through its genomic discovery effort, Nuvelo had identified three new mAb targets for leukemia. Nuvelo has generated a series of high affinity and selective mAbs against cell surface receptors restricted to lymphoid and myeloid cells. These mAbs are potent in cytotoxic assays and murine (mouse) cancer models. Nuvelo's lead mAb was developed against the extra cellular domain of the CD2-related cell surface receptor, NTB-A. NTB-A is a novel cell surface receptor that is primarily expressed on lymphoid cells, including B lymphocytes from CLL and lymphoma patients. Nuvelo has generated a NTB-A mouse-human chimeric antibody, or IgG1, and conducted extensive ex vivo and preclinical studies. NTB-A mAb is a potent cytotoxic agent against B lymphocytes from CLL patients. NTB-A mAb also acts as a potent anti-cancer agent in mouse xenograft models. In addition to NTB-A mAb, Nuvelo identified two mAb targets that Nuvelo is currently studying for the treatment of AML. Nuvelo has developed mAbs (NU2444 and NU10458) against both targets, conducted ex vivo cytotoxic assays on blast cells from AML patients and generated a chimeric mAb, which are currently being assessed in murine tumor models.

#### ***Wnt Therapeutics Program***

Nuvelo has identified several drug candidates as part of Nuvelo's Wnt therapeutic program. Nuvelo's lead candidate in this program is NU206, a Wnt regulator also known as R-Spondin1, or RSp1. NU206 is the focus of Nuvelo's collaboration with Kirin. Nuvelo's Wnt therapeutics program targets a broad range of indications

## **Table of Contents**

where cell regeneration and differentiation are important to disease processes, such as gastrointestinal disease, bone disorders, wound healing and cancer.

The Wnt signaling pathway is critical for regulating cell growth and differentiation during homeostasis and pathogenesis. Nuvelo has developed a comprehensive approach to target key receptors and secreted proteins that modulate the Wnt pathway. In addition, Nuvelo has produced mAbs and secreted recombinant proteins with biological activity in cellular assays and animal disease models. Potential indications include: Inflammatory Bowel Disease, or IBD, peptic ulcers, mucositis, wound healing, and cancer, as well as bone disorders and osteolytic lesions caused by osteoarthritis and multiple myeloma.

The R-Spondin, or RSpO, family of secreted proteins can be used to enhance endogenous Wnt signaling in vivo and, therefore, can provide therapeutic potential in diseases that are dependent on the Wnt pathway for restoration of homeostasis or tissue repair. RSpO proteins are highly potent therapeutic agents in murine colitis and mucositis models and are currently being assessed in additional indications including wound healing, osteolytic lesions and cancer.

RSpO proteins are novel regulators of the Wnt pathway and were first identified by Nuvelo as potent gastrointestinal mitogens in transgenic mice. Nuvelo has recently demonstrated that RSpO proteins regulate the Wnt pathway by antagonizing the Wnt inhibitor DKK1 and subsequently control the cell surface levels of LRP5/6. Numerous studies have implicated DKK1 as a key negative regulator in bone remodeling in diseases such as osteoarthritis and multiple myeloma. Therefore, RSpO proteins have the potential to be exciting therapeutic options to improve bone restoration.

In addition to RSpO proteins, Nuvelo is currently developing mAbs against DKK1 and key receptors in Wnt signaling including LRP6, LRP5 and Frizzled receptors. Nuvelo has identified a series of mAbs against LRP6 that block DKK1 inhibition in cellular assays.

## **Nuvelo's Strategy**

Nuvelo is focused on building a sustainable, fully-integrated business based on the discovery, development and commercialization of therapies that can be sold by a specialty sales force.

### ***Leverage Nuvelo's expertise in cardiovascular disease and other debilitating medical conditions to advance Nuvelo's clinical development programs***

Nuvelo is primarily focused on the development of acute, hospital-based, cardiovascular drug candidates. Nuvelo believes this portfolio leverages Nuvelo's expertise in cardiovascular drug development, enabling it to pursue a more rapid path toward drug commercialization.

### ***Build a diversified pipeline of product candidates***

Nuvelo is pursuing several drug development candidates in various stages of clinical and preclinical development. In addition, Nuvelo seeks to identify drug development candidates that have the potential to receive regulatory approval to treat a number of different indications, thereby further diversifying Nuvelo's risk by providing each drug candidate with a number of potential commercialization paths. Nuvelo believes this strategy reduces its exposure to the impact of any single product failure, maximizes its potential returns from successful compounds, and increases its flexibility to eliminate programs Nuvelo deems less promising. By broadening its portfolio across indications and products, Nuvelo intends to increase the probability of clinical and commercial success. In addition, Nuvelo focuses on molecules that it believes have a greater chance of success due to the predictability of preclinical models used in their development.

---

## **Table of Contents**

### ***Opportunistically seek to license or acquire complementary products***

Nuvelo intends to supplement its internal drug discovery efforts through the acquisition of products that complement its development strategy. Nuvelo continues to identify, evaluate and pursue the acquisition or licensing of strategically valuable product opportunities.

### ***Commercialize Nuvelo's products in the United States***

Rather than license other companies to commercialize its products in the United States, Nuvelo intends to sell them itself through its own specialty sales force. Nuvelo believes that the resources required to develop a sales and marketing organization to sell products to hospitals or targeted physician groups is manageable for a company of Nuvelo's size and will allow it to capture more value from its clinical development successes.

### **Corporate Information**

Nuvelo was incorporated as Hyseq, Inc. in Illinois in 1992 and reincorporated in Nevada in 1993. On January 31, 2003, Nuvelo merged with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts, and, in connection with the merger, changed its name to Nuvelo, Inc. On March 25, 2004, Nuvelo reincorporated from Nevada to Delaware. Nuvelo's principal executive offices are located at 201 Industrial Road, Suite 310, San Carlos, California 94070.

Nuvelo files its annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 electronically with the Securities and Exchange Commission. The public may read or copy any materials Nuvelo files with the SEC at the SEC's Public Reference Rooms at 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is <http://www.sec.gov>.

You may obtain a free copy of Nuvelo's annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports on the day of filing with the SEC on Nuvelo's website, on the Internet at <http://www.nuvelo.com> or by contacting the Investor Relations Department at Nuvelo's corporate office by calling (650) 517-8000 or sending an e-mail message to [ir@nuvelo.com](mailto:ir@nuvelo.com). Information found on Nuvelo's website is not incorporated by reference into this report.

### **Research and Development Collaborations**

Expenditures for research and development were \$42.7 million, \$89.4 million and \$57.8 million in 2007, 2006 and 2005, respectively. Nuvelo's significant research and development collaborations are as follows:

#### ***Archemix***

In July 2006, Nuvelo expanded its collaboration with Archemix Corporation, a privately held biotechnology company located in Cambridge, Massachusetts, by entering into a new agreement with them, which replaces the former 50/50 collaboration signed in January 2004. Under the new agreement, Archemix is responsible for the discovery of short-acting aptamers targeting the coagulation cascade for use in acute cardiovascular procedures, and Nuvelo is responsible for development and worldwide commercialization of these product candidates. In August 2006, Nuvelo made an upfront license fee payment to Archemix of \$4.0 million. Nuvelo is also funding at least \$5.25 million of Archemix's research in the area of short-acting aptamer discovery over the first three years of the agreement. Archemix may receive payments totaling up to \$35.0 million per development compound on the achievement of specified development and regulatory milestones, along with potential royalty payments based on sales of licensed compounds. In February 2008, Nuvelo paid Archemix a \$1.0 million milestone fee that

---

**Table of Contents**

was accrued upon dosing of the first patient in the Phase 1 trial for NU172. If Nuvelo enrolls the first patient in a Phase 2 trial of NU172, which Nuvelo anticipates may occur in the first half of 2009, Nuvelo is obligated to pay Archemix a \$3.0 million milestone fee. In addition, Nuvelo is obligated to purchase Archemix common stock having a value equal to the lesser of \$10.0 million or 15 percent of the shares issued by Archemix in a qualified public offering of Archemix stock occurring within five years of the effective date of the 2006 collaboration agreement. At the initiation of the first Phase 3 study for any licensed compound, Archemix has the option to elect to participate in profits from sales of the compound by funding its pro rata share of prior and future product development and commercialization expenses, in lieu of receiving milestone payments and royalties with respect to that compound.

***Kirin Pharma Company, Limited***

In March 2005, Nuvelo entered into a collaboration agreement with Kirin for the development and commercialization of NU206. In accordance with the terms of this agreement, Nuvelo received a \$2.0 million upfront cash payment from Kirin in April 2005, and Nuvelo agreed to lead worldwide development, manufacturing and commercialization of the compound. All operating expenses and any profits related to the development and commercialization of NU206 are being shared 60 percent by Nuvelo and 40 percent by Kirin. If this agreement is terminated, or Kirin or Nuvelo elect under certain circumstances to no longer actively participate in the collaboration, the relationship with respect to NU206 will convert from an expense and profit-sharing structure to a royalty-based structure.

***Dendreon***

Nuvelo obtained exclusive worldwide rights to all indications of rNAPc2 and all other rNAPc molecules owned by Dendreon Corporation as a result of a licensing agreement entered into with them in February 2004. Under the terms of the agreement, Nuvelo paid Dendreon an upfront fee of \$4.0 million (\$0.5 million in cash and \$3.5 million in Nuvelo common stock), in 2004. Future milestone payments to Dendreon could reach as much as \$23.5 million if all development and commercialization milestones are achieved, although Nuvelo currently cannot predict if or when any of these milestones will be achieved. If rNAPc2 is commercialized, Nuvelo will also be responsible for paying royalties to Dendreon depending on sales of rNAPc2.

In 2007, Nuvelo suspended Nuvelo's clinical development of rNAPc2, which could impact Nuvelo's current relationship and license with Dendreon.

***Amgen***

In October 2004, Nuvelo obtained worldwide rights to develop and commercialize alfimeprase from Amgen Inc., in exchange for the future payment to Amgen of future development milestones and royalties. Future milestone payments under the license agreement could total as much as \$35.0 million. Nuvelo has discontinued development of alfimeprase and cannot predict if or when any of these additional milestones will be achieved.

***Bayer***

In June 2007, Nuvelo agreed to terminate its January 2006 collaboration with Bayer Healthcare AG (Bayer) for the development and commercialization of alfimeprase. As part of the termination agreement with Bayer, Nuvelo agreed to waive Bayer's obligation to provide Nuvelo 12 months' notice of termination in consideration of Bayer's agreement to pay Nuvelo a lump sum of \$15.0 million. Nuvelo also granted Bayer the option to reacquire rights to alfimeprase upon the initiation of a pivotal stroke trial or upon Nuvelo's public announcement that Nuvelo is discontinuing further development of alfimeprase in the stroke indications. The notice period during which Bayer could exercise the option would begin upon Nuvelo making certain information available to Bayer and last for 30 days after delivery of the information.

## **Table of Contents**

As a result of the termination of the collaboration agreement with Bayer, Nuvelo recognized in June 2007 the remaining unamortized balance of the \$50.0 million up-front license fee received from Bayer in January 2006, which totaled approximately \$44.9 million. The up-front license fee had been recorded as deferred revenue upon receipt and was being recognized on a straight-line basis over the performance period under the agreement, originally estimated to be through September 2020.

On March 17, 2008, Nuvelo announced its decision to discontinue further clinical development of alfineprase, including the programs in catheter occlusion and acute ischemic stroke. In April 2008, Nuvelo provided the information to Bayer as required by the termination agreement. The \$15.0 million termination payment, which had been recorded as deferred revenue, was recognized as revenue in May 2008 upon the expiration of the notice period.

### **Manufacturing**

Nuvelo does not currently have any long-term supply agreements in place for the manufacture of NU172 or NU206.

### **Patents and Trade Secrets**

Nuvelo owns or has rights in a number of patents and patent applications relating to each of Nuvelo's clinical candidate molecules, and Nuvelo also owns or has acquired rights in many of its preclinical molecules and technologies. The table below shows the estimated year that the primary patent for each of Nuvelo's clinical candidate molecules expires:

<b>Clinical Molecule</b>	<b>Territory</b>	<b>Anticipated Expiration</b>
NU172	U.S.	2026
NU172	Europe	2026
NU206 (Composition of Matter)	U.S.	2022
NU206 (Composition of Matter)	Europe	2022
NU206 (Method of Use)	U.S.	2025
NU206 (Method of Use)	Europe	2025

In some cases, certain of the U.S. patents may be entitled to an extension of their term and certain European patents may be entitled to supplemental protection in one or more countries in Europe. The length of any such extension, if an extension is granted, will vary by country. Nuvelo cannot predict whether any such extensions will be granted.

Nuvelo cannot ensure that any of the patents that Nuvelo owns or has rights in will provide sufficient legal protection for the molecules or processes that such patents cover, or will provide any competitive advantage. Any of Nuvelo's granted patents could be challenged, held unenforceable or invalid in legal proceedings, or could be infringed or circumvented by others. Further, it is possible that others could obtain patent protection for molecules, processes and the like that are competitive with Nuvelo's potential products. In addition, other patent holders could assert their patents against Nuvelo, claiming that such patents prevent Nuvelo from marketing Nuvelo's products. Upon expiration of each of the relevant patents, other entities could enter the market with competitive products and/or processes in each country where a patent has expired.

Nuvelo places a high value on its trade secrets. To protect these trade secrets, Nuvelo typically requires employees to enter into a confidentiality agreement upon commencing employment. In addition, Nuvelo generally requires its consultants, licensing and collaboration partners, and scientific advisors to enter into confidentiality agreements. There can be no assurance, however, that these confidentiality agreements will be honored or that Nuvelo can effectively protect its rights to such unpatented trade secrets. Moreover, there can be

---

## **Table of Contents**

no assurance that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to Nuvelo's trade secrets.

### **Competition**

The biopharmaceutical industry is intensely competitive, which is accentuated by the rapid pace of technological development. Nuvelo's products, if successfully developed, will compete with a number of traditional drugs and therapies and with new products currently under development. Nuvelo also expects to face increased competition in the future as new companies enter Nuvelo's markets. Research and discoveries by others may result in breakthroughs that render Nuvelo's potential products obsolete even before they begin to generate any revenue. The competitors for Nuvelo's drugs currently in development will vary depending on the particular indication pursued, and may include major pharmaceutical, medical device and biotechnology firms, many of which have substantially greater research and product development capabilities and financial, scientific, marketing and human resources than Nuvelo. Nuvelo's product candidate, NU172, if approved, could face competition from the paired dosing of heparin and its antidote, protamine, as well as Angiomax<sup>®</sup> bivalirudin, from The Medicines Company. Nuvelo's second product candidate, NU206, if approved for the treatment of mucositis, could face competition from drugs such as palifermin, an approved Amgen product.

Nuvelo's competitors may obtain patents and regulatory approvals for their competing products more rapidly than Nuvelo, or Nuvelo's collaboration partners, or develop products that are more effective than those developed by Nuvelo, or Nuvelo's collaboration partners. All of Nuvelo's products will face competition from companies developing similar products as well as from companies developing other forms of treatment for the same conditions.

Many of the companies developing competing products have greater expertise than Nuvelo or Nuvelo's collaboration partners have, in discovery, research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. Other smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies as well as other organizations compete with Nuvelo in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to Nuvelo's programs.

Nuvelo may face competition with respect to product efficacy and safety, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, and price and patent position, including the potentially dominant patent positions of others. There can be no assurance that research and development by others will not render the products that Nuvelo may develop obsolete or uneconomical, or result in treatments or cures superior to any therapy developed by Nuvelo, or that any therapy Nuvelo develops will be preferred to any existing or newly-developed alternative products.

### **Government Regulation**

Regulation by governmental authorities in the United States and most foreign countries will be a significant factor in manufacturing and marketing Nuvelo's potential products and in Nuvelo's ongoing research and product development activities. Virtually all of Nuvelo's products and those of Nuvelo's partners will require regulatory approval by governmental agencies prior to commercialization. In particular, human therapeutic products are subject to rigorous preclinical and clinical testing and other approval requirements by regulatory agencies, such as the U.S. Food and Drug Administration, or FDA, and comparable agencies in foreign countries.

Preclinical studies are generally conducted in the laboratory to evaluate the potential efficacy and safety of a therapeutic product. In the United States, the results of these studies are submitted to the FDA as part of an Investigational New Drug application, or IND, which must be reviewed by FDA personnel before clinical testing can begin. A similar process occurs in foreign countries. Typically, clinical evaluation involves three sequential phases, which may overlap. During Phase 1, clinical trials are conducted with a relatively small number of subjects or patients to determine the early safety profile of a drug, as well as the pattern of drug distribution and

---

## **Table of Contents**

drug metabolism. In Phase 2, trials are conducted with groups of patients afflicted by a specific target disease to determine preliminary efficacy, optimal dosages, and dosage tolerance and to gather additional safety data. In Phase 3, larger-scale, multi-center trials are conducted with patients afflicted with a specific target disease to provide data for the statistical proof of efficacy and safety as required by regulatory agencies. Regulatory agencies, the clinical trial sponsor or the investigator may suspend clinical trials at any time if they believe that clinical subjects are being exposed to an unacceptable health risk.

In the United States, the results of preclinical and clinical testing are submitted to the FDA in the form of a Biologic License Application (BLA) or a New Drug Application (NDA). In responding to a BLA or NDA, the FDA may grant marketing approval, request additional information, or deny the application if the FDA determines that the application does not satisfy its regulatory approval criteria. Product approvals may subsequently be withdrawn if compliance with regulatory standards is not maintained or if problems are identified after the product reaches the market. The FDA may require testing and surveillance programs to monitor the effect of a new product and may prevent or limit future marketing of the product based on the results of these post-marketing programs.

Whether or not FDA approval has been obtained, approval of a product by comparable foreign regulatory authorities is necessary prior to the commencement of marketing of a product in those countries. The approval procedures vary among countries and can involve additional testing. The time required to obtain approval may differ from that required for FDA approval. Although there are some centralized procedures for filings in the European Union countries, in general each country has its own procedures and requirements.

Even if regulatory approval for a product is obtained, the product and the facilities manufacturing the product are subject to continued review and periodic inspection. Each drug-manufacturing establishment in the United States must be registered with the FDA. Domestic and foreign manufacturing establishments are subject to inspections by the FDA and must comply with the FDA's current Good Manufacturing Practices, or cGMP, regulations, as well as regulatory agencies in other countries if products are sold outside the United States. The FDA stringently applies regulatory standards for manufacturing drugs, biologics, and medical devices. The FDA's cGMP regulations require that drugs and medical devices be manufactured and records be maintained in a prescribed manner with respect to manufacturing, testing and control activities.

Nuvelo's policy is to conduct research activities in compliance with the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules. Nuvelo also is subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with Nuvelo's work. The extent and character of governmental regulation that might result from future legislation or administrative action cannot be accurately predicted.

### **Human Resources**

As of October 31, 2008, Nuvelo had 51 full-time equivalent employees, 18 of whom hold Ph.D., M.D., J.D., or other advanced degrees. Approximately 31 of these employees are engaged in research and development activities, and approximately 20 are engaged in finance, legal, human resources and administration. None of Nuvelo's employees are represented by a collective bargaining agreement, nor has Nuvelo experienced work stoppages. Nuvelo believes that relations with its employees are good.

### **Properties**

In January 2005, Nuvelo entered into a seven-year facility lease agreement for 61,826 square feet of industrial space at 201 Industrial Road in San Carlos, California, which became Nuvelo's primary headquarters in September 2005. The lease commenced on September 1, 2005 and contains an option to cancel the lease after five years upon payment of certain amounts specified in the lease, two options to extend the lease for five

---

## **Table of Contents**

additional years, each at 95% of the then-current fair market rental rate (but not less than the existing rental rate), rights of first refusal over all vacant space in the building during the first two years of the lease, and an expansion option for a specified amount of space. In March 2006, the lease was amended to provide for the exercise of Nuvelo's expansion option over 7,624 square feet of rentable space, for which the related lease rental payments commenced in August 2006. In January 2008, Nuvelo entered into a sublease agreement, pursuant to which a subtenant leases from Nuvelo approximately 6,754 square feet of space available in the San Carlos facility from February 2008 to January 2011. The term of the sublease can be extended by the subtenant for three additional periods of one year each, subject to certain conditions contained in the sublease agreement. Nuvelo believes that its current facilities are adequate for its needs for the foreseeable future.

Nuvelo also leases approximately 139,000 square foot of space at 985 Almanor Avenue in Sunnyvale, California, which expires in May 2011. In December 2006, Nuvelo exited this facility and has no intention of reoccupying it.

## **Legal Proceedings**

On February 9, 2007, Nuvelo, Inc. and certain of Nuvelo's former and current officers and directors were named as defendants in a purported securities class action lawsuit filed in the United States District Court for the Southern District of New York. The suit alleges violations of the Securities Exchange Act of 1934 related to the clinical trial results of alfimeprase, which Nuvelo announced on December 11, 2006, and seeks damages on behalf of purchasers of Nuvelo's common stock during the period between January 5, 2006 and December 8, 2006. Specifically, the suit alleges that Nuvelo misled investors regarding the efficacy of alfimeprase and the drug's likelihood of success. The plaintiff seeks unspecified damages and injunctive relief. Three additional lawsuits were filed in the Southern District of New York on February 16, 2007, March 1, 2007 and March 6, 2007, respectively. On April 10, 2007, three separate motions to consolidate the cases, appoint lead plaintiff, and appoint lead plaintiff's counsel were filed. On April 18, 2007, Nuvelo filed a motion to transfer the four cases to the Northern District of California. The Court granted Nuvelo's motion to transfer the cases to the Northern District of California in July 2007. Plaintiffs have filed motions for consolidation, lead plaintiff and lead plaintiff's counsel in the Northern District of California. Plaintiffs filed their consolidated complaint in the Northern District of California on November 9, 2007. Nuvelo filed a motion to dismiss plaintiffs consolidated complaint on December 21, 2007. Plaintiffs filed an opposition to Nuvelo's motion to dismiss on February 4, 2008. On June 12, 2008, the Court held a hearing on the motion to dismiss. The motion to dismiss the consolidated complaint is still pending. Nuvelo currently cannot determine the impact that this litigation will have on Nuvelo's business, results of operations or financial condition.

On March 19, 2007, Nuvelo received a summons related to a derivative suit that had been filed in the Superior Court for California, San Mateo County, by an alleged individual stockholder of Nuvelo, purportedly on behalf of Nuvelo against certain of Nuvelo's current and former officers and directors. The complaint alleges among other claims, that the defendants breached their fiduciary duties to Nuvelo by issuing or failing to prevent the issuance of purportedly false and misleading statements between January 5, 2006 and December 11, 2006 relating to the clinical trial results of alfimeprase, which Nuvelo announced on December 11, 2006, and that certain defendants benefited from these actions. On April 18, 2007, Nuvelo filed a demurrer to the complaint on the ground that plaintiff was not excused from issuing a demand to the board prior to filing the lawsuit. Plaintiffs filed oppositions to Nuvelo's demurrer, and Nuvelo has subsequently filed replies to Plaintiffs' oppositions. The Court heard this motion on July 30, 2007, and granted Nuvelo's demurrer, but also granted plaintiffs the opportunity to file an amended complaint. Plaintiffs filed an amended complaint on October 15, 2007. Nuvelo filed its reply to their amended complaint on December 6, 2007. The Court heard the motion on December 17, 2007. On January 2, 2008, the Superior Court for California, San Mateo County, entered final judgment dismissing in its entirety, with prejudice, the second amended consolidated derivative complaint.

On or about December 6, 2001, Variagenics, Inc. was sued in a complaint filed in the United States District Court for the Southern District of New York naming it and certain of its officers and underwriters as defendants.



**Table of Contents**

The complaint purportedly is filed on behalf of persons purchasing Variagenics stock between July 21, 2000 and December 6, 2000, and alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended and Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The complaint alleges that, in connection with Variagenics July 21, 2000 initial public offering, or IPO, the defendants failed to disclose additional and excessive commissions purportedly solicited by and paid to the underwriter defendants in exchange for allocating shares of Variagenics stock to preferred customers and alleged agreements among the underwriter defendants and preferred customers tying the allocation of IPO shares to agreements to make additional aftermarket purchases at predetermined prices. Plaintiffs claim that the failure to disclose these alleged arrangements made Variagenics registration statement on Form S-1 filed with the SEC in July 2000 and the prospectus, a part of the registration statement, materially false and misleading. Plaintiffs seek unspecified damages. On or about April 19, 2002, an amended complaint was filed which makes essentially the same allegations. On or about July 15, 2002, Variagenics and the individuals filed a motion to dismiss. Nuvelo is involved in this litigation as a result of Nuvelo's merger with Variagenics in January 2003. On July 16, 2003, Nuvelo's board of directors approved a settlement proposal initiated by the plaintiffs. However, because of a recent court ruling, the settlement class, as defined in the settlement papers, is no longer feasible. While a new complaint has not been filed against Nuvelo, there are several focus cases against other issuers in which new complaints have been filed. Defendant issuers in the focus cases filed motions to dismiss the new complaints. On March 26, 2008, the District Court issued an order granting in part and denying in part the focus issuers motions to dismiss. The focus issuers had been advised that plaintiffs intended to file new complaints against Nuvelo, but none have been filed yet. Nuvelo believes that any attorneys' fees, loss or settlement payment with respect to this suit will be paid by Nuvelo's insurance provider. However, it is possible that Nuvelo could be forced to incur material expenses in the litigation if the parties cannot achieve a settlement, and, in the event of an adverse outcome, Nuvelo's business could be harmed.

---

**Table of Contents**

**INFORMATION ABOUT ARCA'S BUSINESS**

**Overview**

ARCA is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's first product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, being developed for chronic heart failure, or CHF, and other indications. Gencaro is an oral tablet formulation, dosed twice daily. ARCA has identified common genetic variations that predict patient response to Gencaro. Subject to FDA approval, ARCA, through its partnership with Laboratory Corporation of America, or LabCorp, anticipates introducing a test for these genetic markers concurrent with the market launch of Gencaro, potentially making Gencaro the first genetically-personalized cardiovascular drug. When prescribed using these markers, ARCA believes that Gencaro can become an important new therapy for many chronic heart failure patients, with the potential for good clinical outcomes and good tolerability in those patients with a favorable genetic profile. In September 2008, the FDA formally accepted for filing ARCA's New Drug Application, or NDA, for Gencaro as a potential treatment for CHF. In accordance with the Prescription Drug User Free Act, or PDUFA, the FDA's goal is to complete and review all materials regarding Gencaro by May 31, 2009.

Chronic heart failure is one of the largest health care problems in the United States and the rest of the world. It is estimated that there are currently about 6 million people in the United States with CHF, and about 550,000 new cases are diagnosed annually. Beta-blockers are part of the current standard of care for CHF, and are considered to be among the most effective drug classes for the disease. However, a significant percentage of eligible patients in the United States is not being treated, or does not tolerate or respond well to those beta-blockers currently approved for the treatment of CHF. Under current treatment practice, determining whether a patient is responding well or tolerating beta-blockade can be a lengthy process, and an adverse clinical event is often the first significant evidence that the therapy is not working. ARCA believes there is an opportunity for new heart failure therapies with improved efficacy, response rates and tolerability, and for which individual patient response can be better predicted prior to therapy.

Gencaro was the subject of a major, U.S. based heart failure Phase 3 trial, which will provide the primary basis for approval of Gencaro in the U.S. ARCA anticipates that the FDA will reach a decision on the approvability of Gencaro in the second or third quarter of 2009. Subject to FDA approval on this schedule, ARCA plans to commence commercial sales of Gencaro in the fourth quarter of 2009, or the first quarter of 2010.

ARCA has collaborated with Laboratory Corporation of America, or LabCorp, to develop the Gencaro Test, a companion test for the genetic markers that predict clinical response to Gencaro. The proposed use of the Gencaro Test, if cleared and approved by the FDA, will be to enable a physician to determine, prior to therapy, whether a patient is likely to have a good response to Gencaro. LabCorp has developed the Gencaro Test to be administered using a blood test or a cheek swab, and to provide prompt results to the treating physician. The Gencaro Test is expected to be submitted through the Premarket Approval, or PMA, process in the fourth quarter of 2008, and an FDA decision on approval, based on FDA guidance, is expected in the second or third quarter of 2009. ARCA and LabCorp intend to closely coordinate the commercial launch of Gencaro and the Gencaro Test.

ARCA holds worldwide rights to Gencaro and plans to commercialize the drug in the U.S. through its own specialized sales force. ARCA's commercial effort in the United States will focus on cardiologists specializing in heart failure, and selected other physicians. ARCA may seek partners to assist it in commercializing Gencaro in international markets. ARCA believes that Gencaro will be covered by statutory exclusivity following commercial launch, and will also potentially have protection under patent applications, which ARCA believes will extend market exclusivity substantially. ARCA also plans to pursue several significant follow-on indications for Gencaro, including various forms of cardiac arrhythmias.

## **Table of Contents**

ARCA believes that its expertise in cardiovascular pathophysiology and genetics, and its clinical and commercial experience, will enable it to identify and develop other genetically-personalized cardiovascular therapies. ARCA is currently exploring several such opportunities.

ARCA was incorporated in Delaware in 2004 and commenced operations in 2005. Its principal executive offices are located in Broomfield, Colorado.

## **Market Opportunity**

CHF is one of the world's most significant health care challenges. Industry sources estimate that about 6 million Americans are living with CHF and nearly 550,000 new patients are diagnosed annually. In addition, CHF is the underlying reason for approximately 12 to 15 million annual visits to physicians, 6.5 million annual hospital days and over \$34 billion in direct and indirect healthcare costs. Some sources estimate that the number of chronic heart failure patients in countries within the European Union is significantly higher than in the U.S.

Medical therapy has made progress in treating CHF, but morbidity and mortality remain high. The current standard of care for CHF involves the use of various therapies that operate to inhibit the activity of the renin-angiotensin-aldosterone system, which include angiotensin converting enzyme, or ACE, inhibitors, , angiotensin II receptor blockers, or ARBs, and aldosterone receptor antagonists and diuretics, as well as drugs in the class known as beta-blockers.

Beta-blockers are named for their characteristic mechanism of binding to certain receptors in the nervous system of the heart, and in doing so blocking those receptors from being activated by another molecule. This drug class is part of the current standard of care in patients with CHF and left ventricular dysfunction. The American Heart Association and the American College of Cardiology physician guidelines for the treatment of CHF state the following:

Beta-blockers should be prescribed to all patients with stable heart failure due to reduced left ventricular ejection fraction, unless they have a contraindication to their use or have been shown to be unable to tolerate treatment with the drugs. Because of favorable effects of beta-blockers on survival and disease progression, treatment with a beta-blocker should be initiated as soon as left ventricular dysfunction is diagnosed.

The benefits of beta-blockade are well established and applicable to the majority of the CHF population. Beta-blockers are effective in mortality reduction and are considered to be the most effective drugs for CHF. However, approximately 40% of eligible CHF patients are not being treated with beta-blockers in the U.S. ARCA estimates that in the European Union 50% of eligible chronic heart failure patients are not being treated with beta-blockers. ARCA believes this lack of adoption may be due in part to the fact or perception that a significant percentage of chronic heart failure patients do not tolerate the beta-blockers currently approved for CHF, or do not respond well to them.

Moreover, it is difficult to predict how an individual patient will respond to a beta-blocker, and this creates particular issues in the treatment of CHF. The current standard of practice in prescribing a beta-blocker to a CHF patient involves a multi-week or multi-month-long process in which the dosage is gradually increased to allow the patient to adjust to the therapy, and to determine if the patient is responding positively. This is necessary because the therapeutic mechanism of this drug class involves the inhibition of mechanisms in the failing heart that initially help the heart to compensate for diminished cardiac function, and because it can take a substantial period of time for the therapy to show benefit. The dosage is generally increased gradually over time to avoid withdrawing these compensatory mechanisms too abruptly. As a result, patients newly introduced to beta-blocker therapy often do not feel better, or even feel worse, and it can be weeks or months before there is objective evidence of therapeutic benefit. Because of these factors, it can be difficult for the physician to determine whether a patient is tolerating or responding positively to the therapy, and a serious adverse event, such as a

## **Table of Contents**

hospitalization for an acute episode, or death, may be the first significant indication that the patient is not responding well. Accordingly, ARCA believes there is a substantial need for new heart failure therapies that have improved efficacy, response rates and better tolerability, and for which response and tolerability can be better predicted prior to the onset of therapy. ARCA believes Gencaro can help to address these unmet needs.

### **ARCA Strategy**

ARCA's mission is to become a leading biopharmaceutical company developing and commercializing cardiovascular therapies, with an emphasis on genetically-targeted therapies. To achieve this goal, ARCA is pursuing the following strategies:

*Obtain FDA approval for Gencaro for the treatment of chronic heart failure and maximize its potential.* ARCA believes that Gencaro has a clinical record that supports its approvability. Gencaro's New Drug Application, or NDA, was accepted for filing by the FDA in September 2008. ARCA expects a decision by the FDA on the approvability of Gencaro in the second or third quarter of 2009. If Gencaro is approved, ARCA intends to market it as the first pharmacogenetic cardiovascular therapy through its own sales force. ARCA plans to differentiate Gencaro based on its pharmacogenetic profile, unique mode of action, the Gencaro Test's expected ability to predict response, favorable tolerability and improved clinical endpoints. ARCA plans to support its commercialization effort with a publication strategy, appropriate contacts with key opinion leaders, a hospital-based heart failure patient registry and a focused reimbursement strategy, in compliance with applicable federal requirements.

*Build a specialty sales and marketing capability.* In anticipation of the potential commercial launch of Gencaro in the U.S., ARCA is building specialty sales and marketing organization, focusing on cardiologists that specialize in heart failure, and other physicians that treat heart failure or are influential. ARCA's management and employees, including its chief executive officer and its executive in charge of commercialization, have extensive experience in the commercialization of cardiovascular therapies, including specialty sales and marketing organizations. ARCA also intends to use this sales and marketing organization to commercialize future product candidates in the U.S.

*Expand Gencaro indications.* ARCA plans to pursue clinical development of several potential additional indications for Gencaro, including the prevention of several forms of arrhythmia. ARCA believes these indications have pharmacogenetic potential, reasonable clinical development paths, will help differentiate Gencaro, and could potentially be successfully marketed by ARCA's specialty sales and marketing organization.

*Build a cardiovascular pipeline.* ARCA's management and employees, including its chief executive officer and its founder and chief science and medical officer, have extensive experience in cardiovascular research, molecular genetics, cardiovascular clinical development, and the commercialization of cardiovascular therapies. ARCA will leverage this expertise to seek to identify, acquire, develop and commercialize other cardiovascular products or candidates, with an emphasis on pharmacogenetic applications.

### **Gencaro**

Gencaro is a pharmacologically unique beta-blocker and mild vasodilator being developed by ARCA for the treatment of chronic heart failure and other potential cardiovascular indications. Gencaro is considered part of the beta-blocker class because of its property of blocking both beta-1, or  $\beta_1$  and beta-2, or  $\beta_2$  receptors in the cardiac nervous system from binding with other molecules that activate these receptors. Because of its mild vasodilator effects, Gencaro is well-tolerated in patients with advanced CHF. Originally developed by Bristol-Myers Squibb, the active pharmaceutical ingredient, or API, in Gencaro, bucindolol has been tested clinically in approximately 4,500 patients. Gencaro was the subject of a Phase 3 heart failure mortality trial of over 2,700, mostly U.S. patients, known as the BEST trial. The BEST trial included a DNA bank of over 1,000 patients, which was used to conduct studies of the effect of genetic variation on bucindolol response.

---

**Table of Contents**

At the time of the BEST trial, ARCA's founding scientists, Dr. Michael Bristow and Dr. Stephen Liggett, hypothesized that the unique pharmacologic properties of Gencaro would interact with common genetic variations or polymorphisms of the  $\beta_1$ , and  $\alpha_{2C}$ , or  $\alpha_{2C}$ , receptors, which are important receptors that regulate cardiac function. They tested this hypothesis prospectively in a sub-study conducted using data from the BEST DNA bank. On the basis of this study, Drs. Bristow and Liggett determined that patients with certain variations, or polymorphisms, in these receptors had substantially improved outcomes on primary and certain secondary clinical endpoints in the trial, such as mortality, heart failure progression and hospitalization, relative to the general patient population of the BEST trial. ARCA believes that these polymorphisms, which are detectable using standard genetic testing technology, can serve as diagnostic markers for predicting enhanced therapeutic response to Gencaro, and avoiding adverse events, in individual patients.

***Pharmacology and Pharmacogenetics***

Gencaro's pharmacology appears to be different from other compounds in the beta-blocker class in two fundamental respects. First, studies conducted by ARCA researchers indicate that in human myocardial preparations, in addition to inhibiting the binding activity of the  $\beta_1$  receptor like a typical beta-blocker, Gencaro also significantly inactivates high functioning  $\beta_1$  receptors through a separate mechanism. Second, these same ARCA studies indicate that Gencaro lowers the systemic levels of the neurotransmitter norepinephrine, or NE, which is released by cardiac and other sympathetic nerves. These two properties interact with common genetic variations in two cardiac receptors, the  $\beta_1$  or  $\alpha_{2C}$  receptors, to produce the unique pharmacogenetic profile of Gencaro. ARCA believes that these two properties, and their pharmacogenetic implications, are unique to Gencaro. These receptors, their genetic variants, and the biological system in which they function, are illustrated below:

Gencaro has an important interaction with the  $\beta_1$  receptor found on muscle cell, or cardiac myocyte, of the heart. The general role of the  $\beta_1$  receptor and its downstream signaling cascades is to regulate the strength and rate of the heart's contractions. NE serves as an activator of the  $\beta_1$  receptor, causing the receptor to initiate signaling to the cardiac myocyte. Although this signaling may be beneficial to the failing heart in the short term, in chronic heart failure patients the  $\beta_1$  receptor also initiates harmful, or cardiomyopathic signaling. Eventually this process exacerbates the heart's functional and structural decline. Beta-blockers counteract this destructive process by reducing  $\beta$ receptor signaling. They do this by binding to the receptor and blocking NE molecules from binding and activating the signaling activity, and in Gencaro's case by also inactivating the constitutively active (active in the absence of NE stimulation) state of certain  $\beta_1$  receptors.

There are two common genetic variations of the  $\beta_1$  receptor, each of which ARCA estimates is present in approximately 50% of the U.S. population. One of these variations is known as the  $\beta$ Arg/Arg variant.

## Table of Contents

Laboratory studies indicate that this variation results in a higher functioning  $\beta_1$  receptor, one which has greater ability to mediate the stimulatory effects of NE and is also more likely to be constitutively active and signal the cardiac myocyte to contract in the absence of NE. Heart failure patients with this genotype may have the potential for greater cardiomyopathic  $\beta_1$  signaling. The other variation, the  $\beta$ -Gly carrier, also present in about 50% of the U.S. population, results in a  $\beta_1$  receptor that is much lower functioning and, according to laboratory studies, has less probability of being in an active state compared to the  $\beta_1$ -Arg/Arg receptor.

Gencaro has a powerful interaction with the higher-functioning  $\beta_1$ -Arg/Arg variation of the  $\beta_1$  receptor. Laboratory studies show that constitutively active receptors will continue to signal in the presence of standard beta-blockade. Laboratory studies in isolated human heart preparations also show that Gencaro has the unusual ability of being able to stop the signaling of constitutively active receptors. ARCA believes that individuals with the  $\beta_1$ -Arg/Arg genotype potentially will recognize an enhanced therapeutic response to Gencaro because of the greater potential for active state, cardiomyopathic signaling among individuals with this genotype, and the larger reduction in signaling that these individuals experience when taking Gencaro, relative to individuals with the  $\beta_1$ -Gly carrier genotype.

The other receptor that appears to give Gencaro its pharmacogenetic properties is the  $\alpha_{2c}$  receptor. This receptor is located on the terminus of the sympathetic cardiac nerve, at its junction with the cardiac myocyte. The role of this receptor is to modulate the amount of NE that is present at this junction, which in turn affects the activation of  $\beta_1$  receptors and the heart's activity. There are two important genetic variations of this receptor that appear to affect the performance of Gencaro. Approximately 13-15% of the general population in the U.S. has a modified  $\alpha_{2c}$  receptor resulting from at least one modified gene that functions poorly. Patients with this variant, also known as the deletion variant,  $\alpha_{2c}$  322-325 DEL, are believed to have a diminished ability to regulate the amount of NE released by the cardiac nerve. The remaining 85% of the population has a normal functioning version of this receptor, referred to as the  $\alpha_{2c}$ -wild type.

Individuals with the deletion variant of the  $\alpha_{2c}$  receptor tend to have abnormally high levels of NE in their cardiac nervous system. Gencaro, unlike other  $\beta$ -blocking agents, exhibits the pharmacologic property of sympatholysis, or the ability to lower systemic NE levels, through effects that are mediated at least in part by blockade of  $\beta_2$ -receptors residing on sympathetic nerve terminals. When chronic heart failure patients are treated with Gencaro, some of them may be more likely to experience an adverse clinical effect leading to loss of efficacy related to an exaggerated lowering of NE resulting from Gencaro interacting with  $\alpha_{2c}$  322-325 DEL receptors. This risk may be more pronounced with late stage chronic heart failure patients, who are more dependent on sympathetic (NE) support of cardiac function. In contrast to those with the  $\alpha_{2c}$  deletion variant, the majority of patients with the  $\alpha_{2c}$ -wild type variant appear to experience only a mild reduction in NE levels from Gencaro. In these patients, mild NE lowering by Gencaro appears to have a favorable therapeutic effect.

The DNA substudy of patients from the BEST trial conducted by Drs. Bristow and Liggett indicated that the combinations of these polymorphisms in individual patients appear to influence the response to Gencaro with respect to significant clinical endpoints. As a result, ARCA anticipates three broad treatment groups for Gencaro:

The very favorable group, constituting an estimated 47-50% of the U.S. population and comprised of patients with the Arg/Arg genotype. ARCA believes these individuals may have an enhanced therapeutic response to Gencaro because of its powerful effect on this higher-functioning/constitutively active  $\beta_1$  receptor variant, regardless of their  $\alpha_{2c}$  receptor genotype.

A second favorable group, comprising an estimated 40% of the U.S. population, and comprised of individuals with the Gly carrier  $\beta_1$  receptor and wild-type  $\alpha_{2c}$  receptor. ARCA believes these individuals will benefit therapeutically from Gencaro (although not as much as the very favorable group), because of Gencaro's enhanced efficacy in the wild-type  $\alpha_{2c}$  receptor population combined with some (although reduced) efficacy in  $\beta_1$ -Gly carriers.

A third and much smaller, unfavorable group, constituting about 10-13% of the U.S. population, comprised of individuals with both  $\beta_1$ -Gly carrier  $\beta_1$  receptors and the deletion variant  $\alpha_{2c}$  receptors. In

---

**Table of Contents**

these patients, compensatory support to the failing heart may be compromised when Gencaro is administered, likely due to the inability of the lower functioning  $\beta_1$ -Gly carrier  $\beta_1$  receptor to compensate for the increased NE reduction from the deletion variant  $\alpha_{2C}$  receptor. Clinical data suggest Gencaro should not be administered to these patients.

***The BEST Trial***

Bucindolol was originally developed by Bristol-Myers Squibb for hypertension, and was licensed in the early 1990s to Intercardia, a biopharmaceutical company. Around the time of completion of the Phase 2 clinical trials with bucindolol, a group of leading heart failure researchers proposed to The U.S. Department of Veteran Affairs Cooperative Clinical Studies Program a large mortality study of beta-blockers in chronic heart failure. This grant application was approved, and shortly thereafter the U.S. National Heart, Lung and Blood Institute (NHLBI) agreed to join in the sponsorship of the trial, known as the Beta-Blocker Evaluation of Survival Trial, or BEST. The Steering Committee of the BEST trial selected bucindolol as the agent to be tested against placebo, and Intercardia joined the trial as a sponsor.

The BEST trial was a double-blind, placebo-controlled, multi-center study of bucindolol on mortality and morbidity in an advanced chronic heart failure population. Most of the patients were from the United States. The basis for the selection of bucindolol as the tested  $\beta$ -blocker included its Phase 2 clinical results and its high tolerability in more advanced CHF patients. The trial was planned to run four and one-half years, and enroll 2,800 patients. Under the umbrella of the BEST trial substudies program, a DNA bank and substudy was created, and 1,040 of the BEST patients participated by providing blood for DNA analysis. The DNA bank provided data for the DNA substudy of BEST patients conducted by Drs. Bristow and Liggett.

The BEST trial began in 1995 and enrolled a total of 2,708 chronic heart failure patients. The patients were the most advanced ever studied in a large mortality heart failure trial based on baseline systolic blood pressure and other criteria, and disease clinical stability was not an entry criterion for the trial. The primary endpoint of the BEST trial was total mortality and the prespecified main secondary endpoint was progression of heart failure, defined as heart failure death, cardiac transplant, heart failure hospitalization, or emergency room visit for the treatment of worsening heart failure not requiring hospitalization. Other prespecified secondary endpoints included death from cardiovascular causes, a composite of death or heart transplantation, heart failure hospitalization, improvement in left ventricular ejection fraction, incidence of myocardial infarction, quality of life, and any change in the need for concomitant heart failure therapy, including administration of intravenous inotropic agents, intravenous diuretics, or increase in doses of orally-administered diuretics.

In 1999, the BEST trial was terminated prior to the completion of follow-up, in response to a recommendation of the BEST trial Data and Safety Monitoring Board that the trial be discontinued. The primary reason for termination was loss of investigator equipoise. In other words, the fact that the BEST investigators were no longer uncertain regarding the comparative therapeutic merits of giving a placebo versus giving a beta-blocker to a CHF patient. Positive mortality results from two other heart failure trials involving other beta-blockers had been reported, and a substantial number of BEST trial investigators concluded that it was unethical to continue to give placebo to BEST trial participants. As a result, some investigators began to prescribe these other beta-blockers to patients in the trial, which threatened to destroy the trial's integrity. At the time the BEST study was terminated, approximately 70% of the trial information was available, with 2,708 of a projected 2,800 patients enrolled and 797 out of 916 deaths reported. A companion trial to the BEST trial, known as the BEAT trial, studying European patients with left ventricular dysfunction and a history of heart attack, was terminated when BEST was terminated, with approximately 10% of trial information available (including 343 of 2,000 patients enrolled and 53 out of 630 deaths reported).

Following termination, the preliminary results of both studies were analyzed and published. The preliminary determination, and general perception were that the BEST trial had failed, on the basis of not meeting its primary endpoint of total mortality. The published values were a 10% risk reduction in mortality with a p-value of 0.10.

**Table of Contents****Clinical Results and the DNA Substudy**

In 2003 and 2004, the results of the DNA substudy conducted by Drs. Bristow and Liggett began to be released and analyzed. The DNA substudy results indicated a significant enhancement of response on the major clinical endpoints from the BEST trial in patients with the very favorable genotype. The risk reduction on clinical efficacy endpoints such as mortality and hospitalization ranged from approximately 35% to approximately 48% in this genotype. In addition, in arrhythmia endpoints of atrial fibrillation or ventricular fibrillation tracked by safety analyses, the risk reduction by bucindolol in the very favorable genotype appeared to be even greater, by 62-70%. Also, beginning in 2005, ARCA began to more fully analyze the overall BEST results in accordance with FDA-approved, prespecified statistical plans, which had not been done by the sponsors when the BEST trial was terminated. For example, as re-analyzed by ARCA in accordance with the statistical plan, there appeared to be a 13% risk reduction on the primary endpoint in the BEST trial of mortality for the entire patient population taking bucindolol, with a p-value of 0.053. In addition, the prespecified main secondary endpoint, reduction in the progression of heart failure, had not been analyzed when the BEST trial ended. As analyzed by ARCA, the results of the BEST trial indicated a 20% risk reduction on this secondary endpoint for the entire patient population taking bucindolol, that was highly statistically significant ( $p = 0.00003$ ). The endpoint of heart failure progression, in similar forms, was the original basis of approval for the two beta-blockers currently approved in the U.S. for CHF.

Shown below are certain of the primary and secondary endpoint data from the BEST DNA substudy results, by genotype:

**BEST Clinical Responses<sup>1</sup> by Genotype Groups**

Endpoint (% of study population)	Very Favorable patients (47%)	Favorable patients (40%)	Unfavorable patients (13%)
All Cause Mortality (ACM), TTE	↓38%*	↓25%	h4%
Cardiovascular Mortality (CVM), TTE	↓48%*	↓40%*	h11%
ACM + transplantation	↓43%*	↓24%	h4%
Heart failure (HF) Morbidity & Mortality, CRF, TTE	↓34%**	↓20%	↓1%
HF M&M, TTE (Adj.)	↓42%**	↓27%	↓16%
HF Hosp days/patient	↓48%**	↓17%	h19%
AF prevention (from AE db)	↓62%*	↓11%	↓4%



VT/VF prevention (from AE db)

↓70%\*\*

↓44%

↓9%

<sup>1</sup> Covariate adjusted, transplant censored analysis

\* p<0.05; \*\*p≤0.007; TTE: Time To Event; CRF: Case Report Form; Adj.: Adjudicated

While the results of the DNA substudy of the BEST trial indicate that Gencaro's efficacy varies by genotype with the most robust clinical effects found in patients with the very favorable genotype, they also indicate that patients with the favorable genotype may also benefit from the drug. The results of the DNA substudy indicate that patients in the unfavorable genotype group are not recommended for Gencaro. ARCA estimates that approximately 10-13% of the U.S. CHF patient population falls into the unfavorable genotype group. In addition

---

**Table of Contents**

to these results, there was a 45-47% reduction in myocardial infarction in all patients in the BEST trial taking bucindolol. This result, which is unique to Gencaro, was supported by the limited results of the companion BEAT trial in Europe, in which Gencaro, with only approximately 10% of the trial information available, demonstrated a statistically significant improvement in combined myocardial infarction endpoints versus placebo, in patients with left ventricular dysfunction and a history of myocardial infarction.

***Regulatory Strategy***

In 2005, ARCA approached the FDA to discuss the results of the DNA substudy and ARCA's revised analysis of data from the BEST trial, as well as the prospect of an NDA for Gencaro for the treatment of CHF. Through a number of meetings over the next several years, ARCA received guidance from the FDA on the potential NDA and the coordination of the NDA with a potential application for approval of the Gencaro Test.

The regulatory strategy for Gencaro and the Gencaro Test has been guided by this interaction with the FDA. In the NDA submitted for Gencaro, ARCA argues that Gencaro is approvable based on the full clinical program associated with its development, including data from the total patient cohort population in the BEST trial. The Gencaro clinical development program encompassed numerous clinical studies, including four randomized and placebo controlled studies in patients with CHF or myocardial infarction, of which two, the BEST and BEAT trials, evaluated rigorous clinical endpoints, including mortality, hospitalization and myocardial infarction. The remaining clinical studies include the Phase 2 study conducted by Bristol-Myers Squibb for the treatment of hypertension, several safety studies in other patient populations and a Phase 1 program in healthy subjects. The NDA presents the pharmacogenetic data from the DNA substudy conducted by Drs. Bristow and Liggett as important to the prescribing information in the proposed label for Gencaro, but not as the basis for its approval.

ARCA believes that the clinical trial results for Gencaro, including the results of the BEST trial and DNA substudy, demonstrate the efficacy and safety of Gencaro for treatment of patients with CHF, both for decreasing the risk of mortality and cardiovascular or heart failure hospitalization, and also for reducing the risk of ischemic events and myocardial infarction. The primary endpoint of mortality (when analyzed in accordance with the prespecified plan) was reduced in all BEST trial patients on bucindolol by 13%, with a p-value of 0.053, while the FDA typically views significance as a p-value of less than 0.05, this is within the range found sufficient for approval based on same FDA precedent. This primary endpoint result is enhanced by the response of the BEST trial patient population with respect to eight secondary endpoints, all of which were positive and statistically significant. As prespecified with FDA, heart failure progression was the most important secondary endpoint, and was positive and statistically significant; a heart failure progression endpoint was FDA's basis of approval for the two beta-blockers approved for CHF. ARCA also believes that other statistical analyses and the attributes of the BEST trial itself add to its credibility.

ARCA believes Gencaro's status as a beta-blocker adds further support to its clinical record, as this class has a well-established record of safety and efficacy. The results of the BEST trial are supported by qualitatively consistent results from almost every trial in the beta-blocker class for the treatment of CHF. ARCA believes the use of class effects to support marketing approval of Gencaro by the FDA is consistent with prior precedent, especially within the precedent of approvals in cardiovascular and heart-specific therapies.

ARCA believes that the pharmacogenetic data generated from the DNA substudy conducted by Drs. Bristow and Liggett create a separate public health rationale for approval of Gencaro. These DNA substudy results are not the primary basis for approval as set forth in the Gencaro NDA, but ARCA believes they will represent an important part of the prescribing information in the label being sought for Gencaro. ARCA believes the genetic results will provide physicians with a tool to help predict individual patient response prior to therapy. This unique attribute of Gencaro represents a new approach in treating CHF; one that ARCA believes has the potential to improve the standard of care.

---

**Table of Contents*****Licensing and Partnership Obligations***

ARCA has licensed worldwide rights to Gencaro, including all preclinical and clinical data, from CPEC, a licensing entity which hold the rights of the biotechnology companies that are the successors to InterCardia. Under this license agreement, ARCA has the obligation to make milestone payments of up to \$13.0 million in the aggregate upon regulatory approval in the U.S., Europe and Japan, and to pay royalties based on a percentage of annual sales of Gencaro in any jurisdiction worldwide.

ARCA has also licensed worldwide rights to intellectual property covering the pharmacogenetic response of bucindolol hydrochloride based on the cardiac receptor polymorphisms, which is owned by the University of Colorado. ARCA has no material future financial obligations under this license. ARCA has also licensed the nonexclusive rights to develop and commercialize diagnostics for these receptor polymorphisms, for the purpose of prescribing Gencaro, from the licensee of these rights, CardioDx, Inc. ARCA has certain milestone and royalty obligations under this license agreement, which have been assumed by LabCorp under the parties' collaboration agreement.

**The Gencaro Test**

If cleared or approved, ARCA believes that the Gencaro will be the first cardiovascular drug to be integrated with a companion diagnostic to predict enhanced efficacy. The drug label being sought for Gencaro would identify the patient receptor genotypes that can expect enhanced efficacy, as well as those with a likelihood of a standard beta-blocker response and the small unfavorable subgroup with a low probability of benefit. The label being sought would recommend receptor genotype testing prior to initiation of therapy. Accordingly, ARCA believes it is critical to the successful commercialization of Gencaro to develop a companion genetic test that is simple to administer, useful and widely available.

ARCA has partnered with LabCorp to develop and commercialize the Gencaro Test. Under the terms of the collaboration, which has a 10 year term, ARCA has licensed to LabCorp the rights to commercialize a receptor genotype diagnostic for the  $\beta 1$  and  $\alpha_2c$  polymorphisms. In return, LabCorp has agreed to develop the Gencaro Test, obtain FDA clearance or approval of the Gencaro Test in parallel with the Gencaro NDA and commercially launch the Gencaro Test in parallel with the commercial launch of Gencaro and in coordination with ARCA's commercial plan for Gencaro. LabCorp assumed all financial obligations of ARCA's license for the diagnostic technology, and retains all the economic benefits.

LabCorp has developed the commercial method for the Gencaro Test, which will use either a blood draw or a cheek swab to obtain a sample, and is preparing to file a regulatory submission to FDA. ARCA believes that the Gencaro Test involves a fairly simple genetic test that uses technology that has already been well-validated. Based on FDA guidance, LabCorp plans to submit a PMA regulatory submission in the fourth quarter of 2008, with the expectation of a decision on approval in the second or third quarter of 2009. LabCorp and ARCA believe that no further clinical trials will be required for the Gencaro Test submission, though there is no guarantee that FDA will not require additional clinical data. The clinical basis for the Gencaro Test will be the clinical studies discussed in ARCA's NDA for Gencaro, which the LabCorp submission will cross-reference.

ARCA and LabCorp are developing a joint commercialization and marketing plan, which addresses commercial performance metrics such as turnaround time and distribution, the coordination of the drug and diagnostic sales and marketing programs, and strategies for third-party reimbursement.

**Marketing and Sales**

ARCA's strategy is to market Gencaro as the first pharmacogenetically targeted cardiovascular therapy for CHF patients. For the U.S. market, ARCA plans to build its own specialized sales force, which it expects to be experienced in heart failure and cardiovascular drug sales. Cardiologists specializing in heart failure and selected other physicians will be the focus of ARCA's specialty sales force. ARCA believes a relatively small number of

## **Table of Contents**

cardiologists and other heart failure specialists treat a significant percentage of CHF patients, and, ARCA believes, also have a disproportionate influence on the prescribing practices of other health care providers that treat CHF. Accordingly, ARCA believes that the CHF market may be successfully targeted by a specialized sales strategy.

Key elements of ARCA's U.S. marketing and sales strategy include:

*Publication plan.* ARCA has developed a plan that it believes is consistent with applicable federal laws and regulations and which includes the publication of the revisited analysis of the Gencaro clinical results.

*National and regional key opinion leader development.* ARCA plans to develop appropriate contacts with key decision makers in the heart failure market.

*Registry.* ARCA intends to develop an observational database integrating genetic and CHF data.

*Reimbursement.* ARCA plans to implement a comprehensive reimbursement plan for Gencaro and the Gencaro Test in connection with the commercial launch of both products and in compliance with applicable federal requirements.

ARCA holds world-wide rights to Gencaro and has filed its patent applications covering Gencaro in the major international pharmaceutical markets. ARCA plans to accelerate its international commercialization strategy for Gencaro in 2009, by obtaining guidance from foreign regulatory agencies and engaging in discussions with potential international partners.

## **Competition**

Currently, there are two beta-blockers (three branded formulations) approved for the treatment of CHF in the U.S.:

TOPROL-XL®;

Coreg® and Coreg CR® (a sustained release formulation)

TOPROL-XL and immediate release Coreg have generic equivalents commercially available in the U.S. (Metoprolol Succinate and Carvedilol respectively). It is anticipated that both of these generic equivalents will be priced at less than the price of Gencaro. Total sales of beta-blockers were nearly \$4 billion in the U.S. in 2007, with generic formulation accounting for 30% of the market. While reports vary on the heart failure indication's contribution of the beta-blocker market, ARCA believes CHF contributes to a significant portion of the U.S. market.

Gencaro may not be successful in competing against the existing beta-blockers approved for CHF or their generic equivalents. The companies that sell the existing therapies are much larger than ARCA and have much greater resources. In addition, ARCA's proposed prescribing information for Gencaro includes a recommendation for genetic testing, which will add additional cost and procedures to the process of prescribing Gencaro, and may make it more difficult for ARCA to compete against existing therapies.

## **Other Potential Indications for Gencaro**

ARCA is exploring the potential of Gencaro for the prevention of atrial fibrillation, and/or ventricular tachycardia/ventricular fibrillation. ARCA believes these would be follow-on indications to CHF, and would require one or more additional clinical trials. ARCA believes that data from the BEST trial suggests that Gencaro has potential for these indications, and that the clinical response is also pharmacogenetic, based on the same genetic markers that stratify response on CHF endpoints.



---

## **Table of Contents**

### **Manufacturing and Product Supply**

Gencaro is a small molecule drug with an established manufacturing history. Multiple manufacturers of both the API and drug product have successfully produced Gencaro for use in clinical trials over the course of its clinical development. ARCA outsources all manufacturing and analytical testing of the API of Gencaro and the drug product. Third party contract manufacturing organizations have been selected by ARCA on the basis of their technical and regulatory expertise. ARCA's approach with its contract manufacturing partners has been to replicate the manufacturing processes that were used to support the pivotal clinical trials with Gencaro, and to minimize any changes from these baseline processes, thereby reducing technical and regulatory risk.

ARCA has contracted with Groupe Novasep to manufacture commercial quantities of the API for Gencaro. Registration batches have been completed to support the NDA submission for Gencaro, with all batches meeting specifications.

For drug product production, ARCA has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. Six separate dosage strengths are manufactured, with the maximum recommended dose of 50mg twice daily for patient weighing 75kg or less and 100mg twice daily for patients weighing more than 75kg. This is consistent with dosages studied in pivotal clinical trials of Gencaro, and ARCA believes they support the appropriate titration and chronic dosages required for CHF patients. Registration batches have been completed to support the NDA submission for Gencaro with all batches meeting specifications.

ARCA's focus for the remainder of 2008 and 2009 will be to complete the process validation programs and to build product inventory in anticipation of potential commercial launch. ARCA believes both facilities have adequate production capacity to support the projected market demand for Gencaro. ARCA's current and future arrangements with third party manufacturers may not be successful. If these efforts fail, ARCA would be required to devote additional internal resources to the activities currently performed, or to be performed, by third parties, to seek alternative third-party arrangements, or to delay ARCA's commercialization of Gencaro.

### **Government Regulation**

Governmental authorities in the U.S. at the federal, state, and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products.

#### ***Premarket Approval of Drugs***

FDA approval is required before any new drug, dosage form, indication, or strength can be marketed in the U.S. ARCA anticipates that virtually all of its products will require regulatory approval by governmental agencies prior to commercialization. The process of obtaining approval and the subsequent process of maintaining substantial compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. In addition, these statutes, rules, regulations and policies may change and ARCA's products may be subject to new legislation or regulations. There are numerous FDA sanctions for non-compliance.

The steps required before new human therapeutic products are marketed in the U.S. include rigorous preclinical and clinical testing and other approval requirements by regulatory agencies, such as the FDA and comparable agencies in foreign countries.

*Preclinical Phase.* Preclinical studies are generally conducted in the laboratory to evaluate the potential efficacy and safety of a product candidate. These studies include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals. Preclinical studies are governed by numerous regulations.

---

**Table of Contents**

*Clinical Phase.* Before human clinical trials can commence, an Investigational New Drug, or IND, application, submitted to FDA must become effective. The clinical phase of development involves the performance of human studies, including adequate and well-controlled human clinical trials to establish the safety and effectiveness of the product for each proposed indication. Typically, clinical evaluation involves three sequential phases, which may overlap. During Phase 1, clinical trials are conducted with a relatively small number of subjects or patients to determine the early safety profile of a product candidate, as well as dose tolerance, absorption, and the pattern of drug distribution and drug metabolism. In Phase 2, trials are conducted with groups of patients afflicted by a specific target disease to determine preliminary efficacy, optimal dosages and dosage tolerance and to identify possible adverse effects and safety risks. In Phase 3, larger-scale, multi-center trials are conducted with patients afflicted with a specific target disease to provide data for the statistical proof of efficacy and safety as required by regulatory agencies. The conduct of the clinical trials is subject to extensive regulation.

*NDA Submission.* In the U.S., the results of preclinical and clinical testing along with chemistry, manufacturing and controls information, are submitted to the FDA in the form of an NDA. In September 2008, the FDA formally accepted for filing ARCA's NDA, for Gencaro as a potential treatment for chronic heart failure.

Under PDUFA, after submission of an NDA and payment, or waiver, of the required fee, the FDA assigns a goal to review most standard NDAs within 10 months from acceptance of the application to the time the FDA decides to issue a complete response, or approve the NDA. The PDUFA date for Gencaro is May 31, 2009. The review process is often significantly extended by FDA requests for additional information or clarification. In addition, the FDA has recently begun to miss PDUFA dates for various products. The FDA may ultimately decide that the NDA does not satisfy the criteria for approval.

In responding to an NDA, the FDA may grant marketing approval or deny the application if the FDA determines that the application does not satisfy its regulatory approval criteria. A denial may include a request for additional information, including additional clinical data and/or an additional Phase 3 clinical trial. Data from clinical trials are not always conclusive and FDA may interpret data differently than ARCA interprets data. For instance, ARCA believes that results from a single Phase 3 study, the BEST study, are sufficient to support approval of Gencaro's NDA. Under the Food and Drug Modernization Act of 1997, the FDA is authorized to approve a drug based on a single adequate and well-controlled study if such study and other confirmatory data are sufficient to establish the drug's effectiveness. However, it has long been the FDA's general position that the standard of proof of a drug's effectiveness generally requires at least two well-controlled and adequate Phase 3 clinical studies with p-values of less than 0.05 on the primary endpoint.

In addition, in accordance with current FDA law and regulations, if the FDA determines that no active ingredient of a drug has been approved in any other application, the FDA must refer that drug to an advisory committee for review prior to approval or provide reasons in its action letter as to why it did not refer it to an advisory committee. In some cases, FDA may require completion, within a specified time period, of additional clinical studies after approval, referred to as Phase IV clinical studies, to monitor the effect of a new product and may prevent or limit future marketing of the product based on the results of these post-marketing programs. Furthermore, prior to granting approval, the FDA generally conducts an inspection of the facilities, including outsourced facilities that will be involved in the manufacture, production, packaging, testing and control of the drug substance and finished drug product for compliance with current Good Manufacturing Practice, or cGMP, requirements.

If the FDA approves the NDA, the product becomes available for physicians to prescribe. Even if the FDA approves the NDA, the agency may decide later to withdraw product approval if compliance with regulatory standards is not maintained or if safety problems are recognized after the product reaches the market. In addition, the FDA requires surveillance programs to monitor approved products that have been commercialized, and the agency has the power to require changes in labeling or to prevent further marketing of a product based on the results of these post-marketing programs.

---

**Table of Contents**

Whether or not FDA approval has been obtained, approval of a product candidate by comparable foreign regulatory authorities is necessary prior to the commencement of marketing of a product candidate in those countries. The approval procedures vary among countries and can involve additional testing. The time required to obtain approval may differ from that required for FDA approval. Although there are some centralized procedures for filings in the European Union countries, in general each country has its own procedures and requirements.

*Postapproval Compliance.* If regulatory approval for a drug or medical device is obtained, the product and the facilities manufacturing the product are subject to periodic inspection and continued regulation by regulatory authorities, including labeling, advertising, promotion, recordkeeping, and reporting requirements, including the reporting of adverse experiences. In addition, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved label. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.

*Drug Price Competition and Patent Term Restoration Act of 1984.* Under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, Congress created an abbreviated FDA review process for generic versions of pioneer (brand name) drug products. The Hatch-Waxman Act also provides for patent term restoration and the award, in certain circumstances, of non-patent marketing exclusivities.

*Generic Drug Approval.* The Hatch-Waxman Act established an abbreviated FDA review process for drugs that are shown to be equivalent to approved pioneer drugs. Approval for a generic drug is obtained by filing an abbreviated NDA, or ANDA. Generic drug applications are abbreviated because they generally do not include clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must establish that its product is bioequivalent to an approved drug and that it is the same as the approved drug with respect to active ingredient(s), route of administration, dosage form, strength and recommended conditions of use (labeling). The FDA will approve the generic as suitable for an ANDA if it finds that the generic does not raise questions of safety and effectiveness as compared to the pioneer drug. A drug is not eligible for ANDA approval if the FDA determines that it is not equivalent to the pioneer drug or if it is intended for a different use. Any applicant who files an ANDA seeking approval of a generic version of an approved drug listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book, before expiration of the patent(s) listed in the Orange Book for that approved drug, must certify to the FDA for each patent that (i) no patent information on the drug has been submitted to the FDA; (ii) that such patent has expired; (iii) the date on which such patent expires; or (iv) that such patent is invalid, unenforceable or will not be infringed by the manufacture, use or sale of the generic drug. If the ANDA applicant makes a Paragraph IV certification, the NDA owner is entitled to an automatic 30-month stay of FDA's ability to approve the ANDA. This 30-month stay will end early upon any decision by a court that the patent is invalid, unenforceable or not infringed by the generic drug.

*Patent Term Restoration.* The Hatch-Waxman Act provides for the restoration of a portion of the patent term lost during product development and FDA review of an application. However, the maximum period of restoration cannot exceed five years, or restore the total remaining term of the patent to greater than 14 years from the date of FDA approval of the product. In the future, ARCA may consider applying for patent term restoration for some of its currently owned or licensed patents, depending on the expected length of clinical trials and other factors.

*Non-Patent Marketing Exclusivities.* Separate and apart from patent protection, the Hatch-Waxman Act entitles approved drugs to various periods of non-patent statutory protection, known as marketing exclusivity. The Hatch-Waxman Act provides five years of new chemical entity marketing exclusivity to the first applicant to gain approval of an NDA for a product that contains an active moiety not found in any other approved product. This exclusivity means that another manufacturer cannot submit an ANDA or 505(b)(2)



---

**Table of Contents**

NDA until the marketing exclusivity period ends. This exclusivity protects the entire new chemical entity franchise, including all products containing the active ingredient for any use and in any strength or dosage form, but will not prevent the submission or approval of stand-alone NDAs where the applicants have conducted their own clinical studies to demonstrate safety and effectiveness. There is an exception, however, for a competitor that seeks to challenge a patent with a Paragraph IV certification. Four years into the five-year exclusivity period, a manufacturer who alleges that one or more of the patents listed with the NDA is invalid, unenforceable or not infringed may submit an ANDA or 505(b)(2) NDA for a generic or modified version of the product.

The Hatch-Waxman Act also provides three years of new use marketing exclusivity for the approval of NDAs, and supplements, where those applications contain the results of new clinical investigations (other than bioavailability studies) essential to the FDA's approval of the applications. Such applications may be submitted for new indications, dosage forms, strengths, or new conditions of use of approved products. So long as the studies are essential to the FDA's approval or were conducted by or for the applicant, this three-year exclusivity prohibits the final approval of ANDAs or 505(b)(2) NDAs for products with the specific changes associated with those studies. It does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for other products containing the same active ingredient, without those changes.

***FDA Approval of Medical Devices***

Unless an exemption applies, each medical device that a company wishes to market in the U.S. will require either 510(k) clearance or approval of a PMA from the FDA. The FDA classifies medical devices into one of three classes:

Class I devices, which are subject to only general controls (e.g., labeling, medical devices reporting, and prohibitions against adulteration and misbranding) and, in some cases, to the 510(k) premarket clearance requirements;

Class II devices, generally requiring 510(k) premarket clearance before they may be commercially marketed in the United States; and

Class III devices, consisting of devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device, generally requiring submission of a PMA supported by clinical trial data.

Devices deemed to pose lower risks are placed in either class I or II, which may require the manufacturer to submit to the FDA a 510(k) requesting permission to commercially distribute the device. This process is generally known as 510(k) clearance. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, or for which there is no predicate, are placed in class III, requiring approval of a PMA.

Based on FDA guidance, it is anticipated that LabCorp will submit a PMA regulatory submission in the fourth quarter of 2008, with the expectation of a decision on approval in the second or third quarter of 2009, although the FDA may later decide that the Gencaro Test should be evaluated for clearance under the FDA's 510(k) notification process.

*510(k) Clearance Pathway.* When a 510(k) clearance is required, a company must submit a premarket notification demonstrating that its proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of PMAs. By regulation, the FDA is required to clear or deny a 510(k) premarket notification within 90 days of submission of the application. As a practical matter, clearance may take longer. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence.

---

**Table of Contents**

If the FDA issues an order declaring the device to be Not Substantially Equivalent, or NSE, and places it into a class III or PMA category, a company can then request a de novo classification of the product. De novo is generally requested where there is no predicate device and the company believes the device is sufficiently safe so that no PMA should be required. If the FDA classifies the device into class II, company will then receive an approval order to market the device. This device type can then be used as a predicate device for future 510(k) submissions. However, if the FDA subsequently determines that the device will remain in the class III category, the device cannot be marketed until the company has obtained an approved PMA. If ARCA is required to follow a de novo process and is successful in having the Gencaro Test classified as Class II, an additional 60 to 90 days or more will be added on to the original 90 days required for the initial 510(k) review.

*Premarket Approval (PMA) Pathway.* A PMA must be submitted if the device cannot be cleared through the 510(k) process. The premarket approval application process is generally more costly and time consuming than the 510(k) process. Generally, a PMA must be supported by extensive data including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA's satisfaction the safety and effectiveness of the device for its intended use. After a PMA is sufficiently complete, the FDA will accept the application and begin an in-depth review of the submitted information and will generally conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance. By statute, the FDA has 180 days to review the accepted application, although, generally, review of the application can take between one and three years, but it may take significantly longer.

*Clinical Trials.* Clinical trials are generally required to support a PMA application and are sometimes required for 510(k) clearance. Based on discussions with FDA, ARCA believes that the clinical trials in the Gencaro NDA are sufficient to support the NDA, and ARCA and LabCorp believe that no further clinical trials will be required for the Gencaro Test submission. Following the FDA's guidance from these discussions, the Gencaro Test regulatory filing will cross-reference the Gencaro NDA. However, there is no guarantee that FDA will not require additional clinical data to support the Gencaro Test submission.

*Continuing Regulation.* After a device is placed on the market, numerous regulatory requirements apply to the manufacturer, or holder of a 510(k) clearance or PMA approval. With respect to the Gencaro Test, LabCorp will be responsible for compliance with such requirements. The FDA has broad post-market and regulatory enforcement powers. Accordingly, LabCorp's facilities and the manufacturing facilities of certain of its suppliers will be subject to inspections by the FDA to determine those facilities' level of compliance with various regulations. Failure by these entities to comply with applicable regulatory requirements can result in enforcement action by the FDA or other regulatory authorities, which may result in a wide variety of sanctions. The occurrence of enforcement actions against LabCorp and/or the Gencaro Test could impact ARCA's ability to market the Gencaro drug product.

*International Marketing Approvals.* International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country and are subject to change. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ.

*Other Regulatory Requirements.* ARCA is also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with ARCA's work. The extent and character of governmental regulation that might result from future legislation or administrative action cannot be accurately predicted.

---

**Table of Contents****Intellectual Property**

The future success of ARCA's business will partly depend on its ability to maintain market exclusivity in the United States and important international markets for Gencaro, and for other products or product candidates that it may acquire or develop. ARCA will rely on statutory protection, patent protection, trade secrets, know-how, and in-licensing of technology rights to maintain protection for its products.

Gencaro has an intellectual property portfolio that ARCA believes forms the basis for potential U.S. and international market exclusivity. The composition of matter patents that originally covered bucindolol have expired, as a result of bucindolol's long development history. However, bucindolol has never received regulatory approval in any jurisdiction, and therefore ARCA believes it will qualify as a New Chemical Entity, or NCE, in all markets. As an NCE, bucindolol will, upon approval, enjoy statutory protection in the United States and most international markets under data exclusivity statutes. These statutes provide for an exclusivity period beginning from regulatory approval during which any generic competitor is barred from submitting an application that relies on the data of the NCE. In the U.S., the Hatch-Waxman Act provides for an initial period of four or five years from approval of the NCE, during which a generic application attempting to rely on the data of the NCE cannot be filed with FDA. This period can be extended under certain circumstances, and ARCA believes it has the potential to extend this period to seven and one-half years from FDA approval, as discussed below.

Many international markets have data exclusivity statutes that are analogous to Hatch-Waxman and often more protective. The analogous statute in the EMEA will, in general, provide Gencaro with a minimum of eight years of protection before a generic application may be filed, and ten years of protection before such an application may be approved. Protection under Hatch-Waxman and other data exclusivity statutes is sometimes considered superior to patent protection, as the generic application cannot be filed, thus eliminating the need to initiate patent infringement litigation with its accompanying risks and costs.

In addition to protection under data exclusivity statutes, Gencaro will potentially benefit from ARCA's ongoing patent strategy. ARCA has worldwide rights to the intellectual property arising from the discovery of the interaction of Gencaro with the polymorphisms of the  $\beta_1$  and  $\alpha_{2c}$  receptors. ARCA has filed patent applications that claim the use of Gencaro with these genetic markers, in the United States and in other jurisdictions ARCA believes that this patent strategy may help to exclude generic competition, because the labeling of the drug is expected to include a recommendation to genotype patients, a use covered by the patent applications. Consequently, if the patents are granted and ARCA's patent strategy is successful, ARCA believes that the possibility of generic competition to Gencaro could be significantly reduced until the expiration of these patents, which would be in 2025. ARCA also believes that if these patents are granted, ARCA may be able to extend its initial period of exclusivity under Hatch-Waxman to seven and one-half years from approval, by filing a litigation stay against a company attempting to enter the market with a generic.

The patent positions of biopharmaceutical companies such as ARCA are uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued. Consequently, ARCA cannot be certain that any of its patent applications will result in the issuance of patents or, if any patents are issued, that they will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the U.S. and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, ARCA cannot be certain of the priority of inventions covered by pending patent applications. Moreover, ARCA may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office to determine priority of invention or in opposition proceedings in a foreign patent office, any of which could result in substantial cost to ARCA, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any patents issued valid. An adverse outcome could subject ARCA to significant liabilities to third parties, require disputed rights to be licensed from third parties or require ARCA to cease using such technology.

## **Table of Contents**

ARCA also relies on trade secret protection for its confidential and proprietary information. ARCA cannot be sure that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to ARCA trade secrets or disclose such technology or that ARCA can meaningfully protect its trade secrets.

ARCA requires its employees, consultants, business partners and members of its scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with ARCA. These agreements provide that all confidential information developed or made known during the course of the relationship with ARCA be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for ARCA, utilizing the property or relating to the business of ARCA and conceived or completed by the individual during employment shall be the exclusive property of ARCA to the extent permitted by applicable law. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for ARCA trade secrets in the event of unauthorized use or disclosure of such information.

### **Employees**

As of September 30, 2008, ARCA had 44 full-time employees. Most of these employees operate out of ARCA's Broomfield, Colorado location while others operate from home-based offices in other states. None of its employees are represented by any collective bargaining unit. ARCA believes that it maintains good relations with its employees.

### **Facilities**

ARCA's facilities currently consist of approximately 15,000 square feet of newly constructed office space serving as ARCA's headquarters in Broomfield, Colorado, which is leased until June 2013. ARCA also leases approximately 1,500 square feet of laboratory facilities located in Aurora, Colorado. ARCA believes that these facilities are adequate to meet its current needs.

### **Legal Proceedings**

ARCA is not currently subject to any material legal proceedings.

**Table of Contents****MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR NUVELO**

*This Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as anticipate, believes, budget, continue, could, estimate, expect, forecast, intend, may, plan, potential, predicts, project, should, will and similar expressions are intended to identify such forward-looking statements. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors discussed herein and elsewhere including, in particular, those factors described under the Risk Factors set forth above, and in Nuvelo's other periodic reports filed from time to time with the SEC. Actual results and performance could also differ materially from time to time from those projected in Nuvelo's filings with the SEC.*

**Overview**

Nuvelo, Inc. is a biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor that has completed Phase 1 development for use as a short-acting anticoagulant during medical or surgical procedures, and Phase 1 clinical candidate NU206, a recombinant, secreted protein for the potential treatment of gastrointestinal, or GI, diseases, including cancer therapy induced mucositis and inflammatory bowel disease, in addition to bone disease and wound healing. In addition, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics.

**NU172**

NU172 is a short-acting aptamer, a single-stranded nucleic acid that forms a well-defined three-dimensional shape conceptually similar to an antibody. NU172 was designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical or surgical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied as a potential short-acting anticoagulant for use during procedures such as coronary artery bypass graft, or CABG, surgery, kidney dialysis and a variety of vascular surgical and coronary interventions. Approximately 450,000 CABG procedures and 50 million dialysis procedures are performed annually in the U.S. In these procedures, heparin is often paired with its antidote protamine as the anticoagulation effect of heparin needs to be reversed once the procedure has been completed. Data from the Phase 1 trial and preclinical studies suggest that NU172 has the potential to produce rapid and predictable onset and offset of anticoagulation, work in stagnant blood, avoid thrombocytopenia, and has the potential for non-renal clearance. These studies also suggest that NU172 may have a short half-life in patients, giving it the potential to be rapidly reversed without the need for an antidote.

In August 2008, Nuvelo completed the Phase 1b proof-of-concept trial, demonstrating that NU172 rapidly produced and maintained anticoagulation with a rapid return toward baseline after the infusion ended. The single-center, Phase 1b trial examined the safety, tolerability and pharmacokinetics of intravenous bolus plus infusion dosing of NU172 in 24 healthy male volunteers. Volunteers were given a 2 mg/kg bolus dose followed by escalating infusion doses of NU172 for four hours. In all four cohorts, NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time, or ACT, prothrombin time, or PT, and activated partial thromboplastin time, or aPTT. The highest infusion dose rate tested, 6.0 mg/kg/hr, resulted in an average ACT per subject ranging from 373 to 414 seconds and an increase of approximately three times baseline. Average PT values per subject ranged from 56 to 92 seconds and had an increase of approximately five times baseline. Average aPTT values per subject ranged from 130 to 178 seconds and had an increase of approximately five times baseline. All measurements were maintained stably throughout the four-hour infusion. Once the infusion ended, the ACT and other coagulation parameters showed a rapid return toward baseline, consistent with the short plasma half-life of NU172 observed in the Phase 1a trial. In addition, NU172 was well-tolerated with no serious adverse events.

## **Table of Contents**

Nuvelo anticipates initiating a Phase 2 study evaluating NU172 in CABG patients in the first half of 2009.

Nuvelo is developing NU172 through a collaboration with Archemix Corporation, under which Nuvelo is responsible for development and worldwide commercialization of NU172 and other potential product candidates that may be developed under this collaboration. In February 2008, Nuvelo paid Archemix a \$1.0 million milestone fee in connection with the dosing of the first patient in the Phase 1 trial for NU172. If Nuvelo enrolls the first patient in a Phase 2 trial of NU172, which Nuvelo expects may occur in the first half of 2009, Nuvelo will be obligated to pay Archemix a \$3.0 million milestone fee.

### ***NU206***

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, a critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues including the GI epithelium and bone. NU206's function is to antagonize an inhibitor of the Wnt pathway, DKK1, thereby turning on the pathway. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced GI injury, inflammatory bowel disease, bone disease and wound healing. In animal models of GI disease, the effect of NU206 was transient and reversible in normal tissue. Once administration of NU206 is stopped, the epithelium of the intestine reverts to its normal state and does not continue to proliferate.

Nuvelo initiated a Phase 1 single ascending dose trial in healthy volunteers in July 2008 and expect data from the trial in the fourth quarter of 2008. Nuvelo also plans to initiate a Phase 1b multiple ascending dose trial in healthy volunteers in the fourth quarter of 2008 or first quarter of 2009. Nuvelo is currently evaluating partnership and out-licensing opportunities for NU206.

In March 2005, Nuvelo entered into a collaboration agreement with the Kirin Pharma Company, Limited for the development and commercialization of NU206. Under this agreement, all operating expenses and any profits related to the development and commercialization of NU206 are being shared 60 percent by Nuvelo and 40 percent by Kirin.

### ***Research Programs***

In addition to Nuvelo's clinical and development-stage drug candidates, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics. Nuvelo is currently evaluating partnership and out-licensing opportunities for both of its research programs.

#### ***Leukemia Therapeutic Antibody Program***

Nuvelo is developing monoclonal antibody, or mAbs, candidates discovered by its leukemia therapeutic antibody program. Nuvelo is completing preclinical studies with a series of chimeric mAbs to select drug candidates for the potential treatment of chronic lymphocytic leukemia and acute myelogenous leukemia.

#### ***Wnt Therapeutics Program***

The Wnt signaling pathway is critical for regulating cell growth and differentiation during homeostasis and pathogenesis. Nuvelo has developed a comprehensive approach to target key receptors and secreted proteins that modulate the Wnt pathway. In addition, Nuvelo has produced mAbs and secreted recombinant proteins with biological activity in cellular assays and animal disease models. Potential indications include: inflammatory bowel disease, peptic ulcers, mucositis, wound healing, and cancer, as well as bone disorders and osteolytic lesions caused by osteoarthritis and multiple myeloma. Nuvelo's lead candidate in this program is NU206, a Wnt regulator also known as R-Spondin1, which Nuvelo is developing in collaboration with Kirin.

## Table of Contents

### Results of Operations

#### *Nine-Month Period Ended September 30, 2008 Compared to Nine-Month Period Ended September 30, 2007*

##### *Contract Revenues*

Contract revenues were \$15.2 million for nine months ended September 30, 2008, compared with \$46.8 million in the corresponding period of 2007.

In the nine months ended September 30, 2008, Nuvelo recorded as revenue \$15.0 million that was received from Bayer HealthCare AG, or Bayer, in connection with the termination of its collaboration agreement in June 2007. Following Nuvelo's decision to discontinue further clinical development of alfimeprase, the \$15.0 million, which had been recorded as deferred revenue, was recognized as revenue in May 2008 upon the expiration of the notice period, as defined in the termination agreement with Bayer.

In the nine months ended September 30, 2007, Nuvelo recorded as revenue \$45.8 million of the \$50.0 million up-front license fee received from Bayer in January 2006 as a result of the termination of its collaboration agreement in June 2007. The up-front license fee had been recorded as deferred revenue upon receipt and was being recognized on a straight-line basis over the performance period under the agreement, originally estimated to be through September 2020.

Nuvelo expects the quarterly amortization of existing deferred revenue for the remainder of 2008 to be \$63,000 due to the ongoing revenue recognition from an up-front license fee received from Kirin under Nuvelo's NU206 collaboration agreement. Nuvelo currently does not have any other sources of revenue. In the future, Nuvelo may not be able to obtain additional collaboration partners or obtain revenue from other sources, which could have a material adverse effect on its revenues, operating results and cash flows.

##### *Research and Development Expenses*

Research and development, or R&D, expenses primarily consist of clinical trial and drug manufacturing costs, personnel costs, including related stock-based compensation expense, license, collaboration and royalty fees and allocated facilities expenses.

R&D expenses for Nuvelo's significant programs were as follows for the periods indicated (including up-front fees and collaboration cost-sharing credits, and excluding occupancy costs and stock-based compensation expense):

Program	Since Inception	Nine Months Ended September 30,	
		2008	2007
		(In millions)	
Alfimeprase	\$ 124.2	\$ 4.8	\$ 5.4
NU172	17.6	4.5	7.1
NU206	13.7	4.1	2.9

R&D expenses were \$24.6 million for the nine months ended September 30, 2008, compared with \$33.5 million for the corresponding period in 2007, net of cost sharing credits billable to collaboration partners of \$2.8 million and \$4.9 million, respectively. The decrease of \$8.9 million in the nine months ended September 30, 2008 was primarily attributable to the following: a \$3.7 million decrease in expenses related to rNAPc2 due to the suspension of development in 2007, a \$2.6 million decrease in NU172-related expenses, a \$0.6 million decrease in alfimeprase-related expenses, and a \$2.4 million decrease in employees' stock-based compensation expense, partially offset by a \$1.2 million increase in NU206-related expenses.

The decrease in NU172-related expenses in the nine months ended September 30, 2008 was primarily attributable to decreased expenditures in manufacturing and toxicology studies, partially offset by increases in clinical trial and

## **Table of Contents**

collaboration expenses as a result of the initiation of the Phase 1a and Phase 1b trials. The increase in NU206-related expenses in the nine months ended September 30, 2008 was primarily attributable to increased expenditures in manufacturing, process development, toxicology studies and clinical trials.

In addition to the development programs discussed above, Nuvelo has research programs, including leukemia therapeutic antibodies and Wnt therapeutics. For the nine months ended September 30, 2008, research expenses totaled \$5.0 million, compared with \$4.6 million for the corresponding period in 2007.

Nuvelo expects that total R&D expenses in the fourth quarter of 2008 would be comparable with those in the third quarter of 2008.

The timing, cost of completing the clinical development of any product candidate, and any potential future product revenues will depend on a number of factors, including the maintenance of existing collaboration agreements with cost-sharing arrangements, disease or medical condition to be treated, clinical trial design and endpoints, availability of patients to participate in trials and the relative efficacy of the product versus treatments already approved.

### *General and Administrative Expenses*

General and administrative, or G&A, expenses primarily consist of personnel costs, including related stock-based compensation expense, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs.

G&A expenses were \$11.4 million for the nine months ended September 30, 2008, compared with \$16.8 million in the corresponding period of 2007. The decrease of \$5.4 million in the nine months ended September 30, 2008 was primarily attributable to a \$3.9 million decrease in personnel-related expenses as a result of a reduction in headcount and a \$1.1 million charge related to the impairment of software implementation costs recorded in the nine months ended September 30, 2007.

Nuvelo expects G&A expenses in the fourth quarter of 2008 to be consistent with or higher than that in the third quarter of 2008 primarily due to merger related expenses.

### *Restructuring*

On March 17, 2008, Nuvelo announced that data from its alfimeprase Phase 2 program in catheter occlusion or CO, known as SONOMA-3, did not show sufficient improvement in catheter opening at the higher dose and concentration evaluated in the study to meet the desired target product profile. As a result, Nuvelo ended further clinical development of alfimeprase, including the programs in CO and acute ischemic stroke, and restructured the company to make additional resources available for Nuvelo's other research and development programs. In connection with the restructuring, Nuvelo reduced its workforce by approximately 19 percent and recorded a restructuring expense of \$2.5 million, including \$1.3 million of termination benefits and \$1.2 million of non-cash stock-based compensation expense for the nine months ended September 30, 2008.

On August 1, 2007, Nuvelo announced a reduction in its workforce by approximately 30 percent to realign its organization to focus on core development programs that Nuvelo believes would produce nearest-term proof-of-concept data. In addition, Nuvelo announced the decision to suspend development of rNAPc2 in all indications including cancer and acute coronary syndromes. As a result, Nuvelo recorded a restructuring expense of \$2.3 million for the nine months ended September 30, 2007, including \$1.4 million of termination benefits and \$0.9 million of non-cash stock-based compensation expense.

### *Facility Exit Charge*

In December 2006, Nuvelo exited the facility located in Sunnyvale, California, and recorded a liability for the remaining lease obligations, less estimated sublease income, for the remainder of the lease term. For the nine



**Table of Contents**

months ended September 30, 2008, Nuvelo recorded a \$1.5 million charge reflecting the change in its sublease assumption, as Nuvelo determined that the likelihood of subleasing the Sunnyvale facility has become remote. Nuvelo will continue to pursue sublease opportunities and make necessary adjustments to the liability if and when Nuvelo enters into a sublease agreement in the future.

*Impairment of Goodwill*

In the first quarter of 2008, Nuvelo performed a goodwill impairment test due to the significant decline of its stock price subsequent to the March 17, 2008 alimeprase announcement discussed above. As a result of the impairment test, Nuvelo determined that goodwill was not impaired as management concluded that the market capitalization following the initial market reaction to the announcement did not provide a good indication of Nuvelo's fair value based on the upward trend in the price of the Nuvelo's common stock following the initial decrease after the announcement and through the filing of the Form 10-Q for the first quarter of 2008.

In the second quarter of 2008, Nuvelo performed an additional goodwill impairment test as the upward trend in the market price of Nuvelo's common stock did not continue and Nuvelo's market capitalization remained lower than its carrying value. As a result of this impairment test, Nuvelo determined that goodwill was impaired as of June 30, 2008. Accordingly, Nuvelo recorded an impairment charge of the full balance of goodwill totaling \$4.7 million in the second quarter of 2008 (also see Note 8 to Nuvelo's Condensed Consolidated Financial Statements for the nine months ended September 30, 2008).

*Interest Income, Net*

Interest income, net, was \$2.2 million for the nine months ended September 30, 2008, compared with \$5.2 million in the corresponding period of 2007. The decrease was primarily due to declining balances in cash, cash equivalents and marketable securities and a substantial reduction in the yield on cash equivalents and marketable securities.

***Year Ended December 31, 2007 Compared to Year Ended December 31, 2006, and Year Ended December 31, 2006 Compared to Year Ended December 31, 2005****Contract Revenues*

Contract revenues were \$46.9 million in 2007, compared to \$3.9 million in 2006 and \$0.5 million in 2005. The \$43.0 million increase in 2007 from 2006 was primarily due to the recognition of the remaining unamortized balance of the \$50.0 million up-front license fee received from Bayer in January 2006, as a result of the termination of the collaboration agreement in June 2007, which totaled \$44.9 million. The up-front license fee had been recorded as deferred revenue upon receipt and was being recognized on a straight-line basis over the performance period under the agreement, originally estimated to be through September 2020. The \$3.4 million increase in 2006 from 2005 was primarily due to the recognition of revenue from the \$50.0 million up-front license fee received from Bayer in January 2006.

*Research and Development Expenses*

	Years Ended December 31,			% Change	% Change
	2007	2006	2005	in 2007	in 2006
	(In thousands)				
Research and development	\$ 42,654	\$ 89,370	\$ 57,778	(52)%	55%

R&D expenses primarily consist of clinical trial and drug manufacturing costs, R&D personnel costs, including related stock-based compensation expense, license, collaboration and royalty fees and allocated facilities expenses.

**Table of Contents**

R&D expenses for Nuvelo's significant programs were as follows for the periods indicated (including up-front fees and collaboration cost-sharing credits, and excluding occupancy costs and stock-based compensation expense):

Program	Since Inception through December 31, 2007	Years Ended December 31,		
		2007	2006	2005
Alfimeprase	\$ 119.4	\$ 8.3	\$ 49.5	\$ 34.8
NU172	13.1	8.0	5.1	
NU206	9.6	3.6	3.3	2.7

The \$46.7 million decrease in R&D expense in 2007 as compared to 2006 was primarily due to a significant decrease in alfimeprase development expenses of \$41.2 million and reductions of \$3.5 million in facilities expenses as a result of the exit charges accrued in December 2006 for the facility in Sunnyvale, California, and \$0.9 million in employees' stock-based compensation expense, partially offset by an increase in NU172 development expenses of \$2.9 million.

The decrease in alfimeprase-related expenses in 2007 was largely due to a \$19.0 million charge in 2006 to expense previously capitalized clinical trial supplies related to alfimeprase. The charge was based on a change in estimate related to alternative future uses triggered by the failure of the first trial in each of the two Phase 3 programs for alfimeprase to meet their primary endpoints in 2006. The decrease in 2007 was also due to a significant reduction in clinical trial related expenditures in 2007 as Nuvelo's two alfimeprase Phase 3 trials were suspended during the first half of 2007. Additionally, Nuvelo entered into a Settlement Agreement with its contract manufacturer of alfimeprase in June 2007, pursuant to which certain obligations to this contract manufacturer Nuvelo had previously accrued in 2006 were reversed. Accordingly, Nuvelo recorded a credit to R&D expenses of approximately \$2.9 million, net of cost sharing with Nuvelo's collaboration partner.

The \$31.6 million increase in R&D expense in 2006 as compared to 2005 was primarily due to increases in expenses related to alfimeprase, NU172 and NU206 totaling \$20.4 million, an increase of \$6.5 million in expenses related to rNAPc2, of which the development was suspended in 2007, and an increase in employee stock-based compensation expense of \$4.6 million as a result of the implementation of Statement of Financial Accounting Standards No. 123 (revised 2004), *Share-Based Payment* (SFAS 123(R)). The increase in alfimeprase-related expenses in 2006 was primarily due to the \$19.0 charge in December 2006 as discussed above.

The timing, cost of completing the clinical development of any product candidate, and any potential future product revenues will depend on a number of factors, including the disease or medical condition to be treated, clinical trial design and endpoints, availability of patients to participate in trials and the relative efficacy of the product versus treatments already approved. Due to these uncertainties, Nuvelo is unable to estimate the length of time or the costs that will be required to complete the development of these product candidates.

*General and Administrative Expenses*

	Years Ended December 31,			% Change in 2007	% Change in 2006
	2007	2006	2005		
General and administrative	\$ 20,762	\$ 30,632	\$ 15,805	(32)%	94%

G&A expenses primarily consist of G&A personnel, including related stock-based compensation expense, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs.

---

## **Table of Contents**

The \$9.9 million decrease in G&A expense in 2007 as compared to 2006 was primarily due to a decrease in personnel costs of \$3.7 million, of which \$1.5 million was related to employee stock-based compensation expense, as well as reductions of \$2.5 million in commercialization-related expenses for alfimeprase and \$2.4 million in facilities expenses as a result of the exit charges in 2006 for the facility in Sunnyvale, California.

The \$14.8 million increase in G&A expense in 2006 as compared to 2005 was primarily due to a \$8.4 million increase in G&A personnel costs, including a \$6.6 million increase in employee stock-based compensation expense as a result of the implementation of SFAS 123(R), a \$1.9 million increase in outside service and consulting expenses, primarily related to pre-commercialization activities for alfimeprase, and a \$1.7 million increase in facilities expenses allocated to G&A.

### *Facility Exit Charges*

In December 2006, Nuvelo ceased use of its facility at 985 Almanor Avenue in Sunnyvale, California, as it was no longer required for its business. In accordance with Statement of Financial Accounting Standards No. 146, *Accounting for Costs Associated with Exit or Disposal Activities* (SFAS 146), on December 31, 2006 Nuvelo recorded a liability of \$26.6 million, representing the estimated present value of future lease-related payments through May 30, 2011, less estimated sublease income. A charge of \$21.1 million was recorded concurrently to the statement of operations, after deducting the remaining deferred rent of \$5.5 million as of December 31, 2006. Additionally, on December 31, 2006, Nuvelo recorded an impairment charge under Statement of Financial Accounting Standards No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets* (SFAS 144), of \$3.4 million, being the carrying value of leasehold improvements previously made to this facility plus capitalized restoration costs.

### *Restructuring Expense*

In August 2007, Nuvelo announced a reduction of approximately 30% of its workforce, across its research, clinical development and administrative functions, to realign Nuvelo's organization to focus on core development programs. As a result, Nuvelo recorded a restructuring expense of \$2.3 million in 2007, including \$1.4 million of termination benefits and \$0.9 million of non-cash stock-based compensation expense.

### *Interest Income, Net*

Net interest income was \$6.6 million in 2007, as compared to \$7.8 million in 2006 and \$1.4 million in 2005. The decrease in net interest income in 2007 was primarily due to declining cash and investment balances and lower interest rates. The increase in net interest income in 2006 was primarily due to higher cash and investment balances and higher interest rates.

### *Cumulative Effect of Change in Accounting Principle*

On October 1, 2006, Nuvelo adopted the provisions of FASB Staff Position No. EITF 00-19-2, *Accounting for Registration Payment Arrangements* (EITF 00-19-2), which requires that contingent obligations to make future payments under a registration payment arrangement be recognized and measured separately in accordance with SFAS No. 5, *Accounting for Contingencies*. Under previous guidance, the fair value of the warrant issued to Kingsbridge in August 2005 under Nuvelo's Committed Equity Financing Facility, or CEFF, was recorded as a current liability in Nuvelo's balance sheet, due to a potential cash payment feature in the warrant. The current liability was marked-to-market at each quarter end, using the Black-Scholes option-pricing model, with the change being recorded to general and administrative expenses. Under the new guidance in EITF 00-19-2, as Nuvelo believed the likelihood of such a cash payment to be not probable, Nuvelo did not need to recognize a liability for such obligations. Accordingly, a cumulative-effect adjustment of \$2.2 million was made as of October 1, 2006, representing the difference between the initial fair value of this warrant and its fair value as of this date.

**Table of Contents***Net Loss*

Since Nuvelo's inception, Nuvelo has incurred significant net losses, and as of December 31, 2007, Nuvelo's accumulated deficit was \$470.5 million. Nuvelo incurred a net loss of \$12.3 million in 2007, as compared to a net loss of \$130.6 million in 2006. The decrease in net loss was primarily due to the recognition of the remaining unamortized balance of the Bayer up-front license payment in the second quarter of 2007 and a reduction in R&D and G&A expenses noted above. Nuvelo incurred a net loss \$130.6 million in 2006, as compared to \$71.6 million in 2005. The increase in net loss resulted primarily from the increases in expenses noted above, including an \$11.2 million increase in total employee stock-based compensation expense in 2006 as a result of the implementation of SFAS 123(R), partially offset by higher revenues and interest income.

**Liquidity and Capital Resources**

	September 30, 2008	December 31, 2007 (In thousands)	December 31, 2006
Cash and cash equivalents	\$ 35,168	\$ 32,061	\$ 60,335
Marketable securities	23,964	65,506	92,791
Restricted cash	6,000	6,000	
	\$ 65,132	\$ 103,567	\$ 153,126

As of September 30, 2008, Nuvelo had total cash and cash equivalents, marketable securities and restricted cash of \$65.1 million, as compared with \$103.6 million as of December 31, 2007. The decrease of \$38.5 million resulted primarily from operating expenditures during the period. As of December 31, 2007, Nuvelo had total cash and cash equivalents, marketable securities and restricted cash of \$103.6 million, as compared to \$153.1 million as of December 31, 2006. The decrease of \$49.5 million resulted primarily from operating expenditures during the period.

As of September 30, 2008, all of Nuvelo's investments in marketable securities have been classified as available-for-sale securities, as defined by Statement of Financial Accounting Standards No. 115, *Accounting for Certain Investments in Debt and Equity Securities*. These securities are recorded at their fair value and primarily consist of corporate debt securities. Nuvelo makes its investments in accordance with its investment policy. The primary objectives of Nuvelo's investment policy are liquidity and safety of principal.

**Cash Flows from Operating, Investing and Financing Activities**

	Nine Months Ended September 30, 2008		Years Ended December 31, 2007		
	2008	2007	2007	2006	2005
	(In thousands)				
<b>Net cash provided by (used in):</b>					
Operating activities	\$ (38,227)	\$ (32,310)	\$ (45,958)	\$ (37,060)	\$ (59,035)
Investing activities	41,187	20,313	21,085	(62,064)	(1,175)
Financing activities	147	(3,210)	(3,401)	121,695	81,163
Net increase (decrease) in cash and cash equivalents	\$ 3,107	\$ (15,207)	\$ (28,274)	\$ 22,571	\$ 20,953

Net cash used in operating activities was \$38.2 million in the nine months ended September 30, 2008, compared with \$32.3 million in the corresponding period of 2007. The increase of \$5.9 million in net cash used in operating activities in the nine months ended September 30, 2008 was primarily attributable to the receipt of \$15.0 million from Bayer in the 2007 period in connection with the termination of the collaboration agreement, partially offset by an overall reduction in R&D and G&A expenses in the 2008 period.

**Table of Contents**

Net cash used in operating activities was \$46.0 million in 2007, as compared to \$37.1 million in 2006 and \$59.0 million in 2005. The increase of \$8.9 million in 2007 was primarily attributable to the \$50.0 million up-front license fee received from Bayer in 2006, partially offset by the \$15.0 million received from Bayer related to the termination of the collaboration agreement and an overall reduction in operating expenses in 2007. The decrease of \$22.0 million in 2006 was primarily attributable to the \$50.0 million up-front license fee received from Bayer in 2006, partially offset by an increase in spending primarily related to clinical trials and drug manufacturing for alfineprase.

Net cash provided by investing activities was \$41.2 million in the nine months ended September 30, 2008, compared with \$20.3 million in the corresponding period of 2007. The increase of \$20.9 million was primarily attributable to an increase in maturities, net of purchases, of marketable securities.

Net cash provided by investing activities was \$21.1 million in 2007, as compared to net cash used in investing activities of \$62.1 million and \$1.2 million in 2006 and 2005, respectively. The change of \$83.2 million in 2007 was primarily attributable to an increase in maturities, net of purchases, of marketable securities, partially offset by a transfer of \$6.0 million to a certificate of deposit to collateralize a letter of credit for the unoccupied facility at 985 Almanor Avenue in Sunnyvale, California. The change of \$60.9 million in 2006 was primarily attributable to an increase in purchases, net of maturities, of marketable securities.

Net cash provided by financing activities was \$0.1 million in the nine months ended September 30, 2008, compared with net cash used in financing activities of \$3.2 million in the corresponding period of 2007. The change was primarily attributable to the payment in full of bank loans and related party line of credit in 2007.

Net cash used in financing activities was \$3.4 million in 2007, as compared to net cash provided by financing activities of \$121.7 million and \$81.2 million in 2006 and 2005, respectively. In 2007, Nuvelo paid in full the remaining principal balances related to the related party line of credit and the loans from Silicon Valley Bank totaling \$3.8 million. In 2006 and 2005, net cash provided by financing activities primarily consisted of net proceeds from public offerings of \$112.0 million and \$68.4 million, respectively, plus additional net cash proceeds of \$10.0 million from a draw-down under the Kingsbridge CEFF in 2006 and \$14.2 million from two draw-downs under this facility in 2005.

***Sources and Uses of Capital***

Nuvelo's primary sources of liquidity to date have been financing activities and collaboration receipts. In order to complete development of Nuvelo's current product pipeline, Nuvelo will need to raise funds through additional public and/or private offerings and collaboration activities in the future. Nuvelo's primary uses of capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items.

In August 2005, Nuvelo entered into a Committed Equity Financing Facility with Kingsbridge Capital Ltd. under which Kingsbridge committed to purchase up to a total of \$75.0 million of Nuvelo's common stock, not to exceed 8,075,000 shares, within a three-year period, subject to certain conditions and limitations. Under the CEFF, Nuvelo sold 1,839,400 shares for gross proceeds of \$14.4 million in the fourth quarter of 2005, and a further 568,247 shares for gross proceeds of \$10.0 million in October 2006. There has been no further sale of shares to Kingsbridge since October 2006. The CEFF expired on October 13, 2008.

In July 2006, Nuvelo entered into a collaboration agreement with Archemix. Under the agreement, Archemix is responsible for the discovery of short-acting aptamers targeting the coagulation cascade for use in acute cardiovascular procedures, and Nuvelo is responsible for development and worldwide commercialization of these product candidates. If Nuvelo enrolls the first patient in a Phase 2 trial of NU172, which Nuvelo anticipates may occur in the first half of 2009, a \$3.0 million milestone fee is payable to Archemix. In addition, Nuvelo is

**Table of Contents**

obligated to purchase Archemix common stock having a value equal to the lesser of \$10.0 million or 15 percent of the total gross proceeds raised by Archemix in a qualified public offering of Archemix stock occurring within five years of the effective date of the collaboration agreement.

Nuvelo has a \$6.0 million letter of credit issued to the landlord of Nuvelo's Sunnyvale facility as required by the lease agreement of this facility, and the letter of credit is being collateralized by a certificate of deposit of the same amount, which is recorded as restricted cash.

Nuvelo's future capital requirements and the adequacy of available funds will depend on many factors, including those set forth under the Nuvelo Risk Factors section of this proxy/prospectus/consent solicitation. Nuvelo may not be able to secure additional financing to meet its funding requirements on acceptable terms, if at all. If Nuvelo raises additional funds by issuing equity securities, substantial dilution to Nuvelo's existing stockholders may result. If Nuvelo is unable to obtain additional funds, Nuvelo will have to reduce its operating costs and delay its research and development programs. Nuvelo believes that it has adequate balance in cash, cash equivalents and marketable securities to fund its operations for at least the next twelve months.

**Contractual Obligations**

The following table summarizes Nuvelo's significant contractual obligations as of December 31, 2007, and the effect such obligations are expected to have on Nuvelo's liquidity and cash flow in future periods (in thousands):

	2008	2009	2010	2011	2012	Thereafter	Total
Operating lease obligations(a)	\$ 9,741	\$ 8,328	\$ 8,628	\$ 4,979	\$ 1,539	\$	\$ 33,215
Facility restoration obligation	757						757
	\$ 10,498	\$ 8,328	\$ 8,628	\$ 4,979	\$ 1,539	\$	\$ 33,972

- (a) Amounts represent future minimum rental payments under non-cancelable operating leases for Nuvelo's facilities. It includes approximately \$22.9 million in total of future minimum rental payments related to the Sunnyvale facility, of which the fair value of these payments, net of estimated sublease rental income, was classified as *Accrued Facility Exit Costs* in the consolidated balance sheet as of December 31, 2007.

The foregoing table does not include milestone payments potentially payable by Nuvelo under its collaboration agreements and licenses. Such milestone payments are dependent upon the occurrence of specific and contingent events, and not the passage of time. In February 2008, Nuvelo paid Archemix a \$1.0 million milestone fee that was accrued upon dosing of the first patient in the Phase 1 trial for NU172. An additional \$3.0 million milestone is payable to Archemix if Nuvelo enrolls the first patient in a Phase 2 trial of NU172, which may occur in the first half of 2009. In addition, Nuvelo's obligation to purchase Archemix common stock having a value equal to the lesser of \$10.0 million or 15 percent of the total gross proceeds raised by Archemix in the event of a qualified public offering of their stock, subject to conditions detailed in Nuvelo's collaboration agreement, is also excluded, as it is dependent upon the occurrence of a specific and contingent event.

**Table of Contents****Selected Quarterly Financial Data (Unaudited)**

Summarized selected quarterly unaudited financial data is as follows (in thousands, except per share amounts):

	Quarter Ended		
	September 30, 2008	June 30, 2008	March 31, 2008
Contract revenues	\$ 63	\$ 15,062	\$ 63
Restructuring			2,470
Facility exit charge			1,472
Impairment of goodwill		4,671	
Operating loss	(9,042)	(892)	(19,406)
Net loss	(8,518)	(231)	(18,408)
Basic and diluted net loss per share	(0.16)	(0.00)	(0.34)

	Quarter Ended			
	December 31, 2007	September 30, 2007	June 30, 2007	March 31, 2007
Contract revenues	\$ 63	\$ 63	\$ 45,825	\$ 910
Restructuring		2,336		
Operating income (loss)	(13,058)	(15,971)	27,319	(17,181)
Net income (loss)	(11,636)	(14,358)	29,042	(15,349)
Basic and diluted net income (loss) per share*	(0.22)	(0.27)	0.54	(0.29)

	Quarter Ended			
	December 31, 2006	September 30, 2006	June 30, 2006	March 31, 2006
Contract revenues	\$ 910	\$ 908	\$ 1,005	\$ 1,065
Facility exit charges	24,460			
Operating loss	(69,589)	(28,794)	(20,955)	(21,235)
Loss before cumulative effect of change in accounting principle	(67,560)	(26,668)	(18,898)	(19,651)
Cumulative effect of change in accounting principle	2,224			
Net loss	(65,336)	(26,668)	(18,898)	(19,651)
Basic and diluted net loss per share*:				
Loss before cumulative effect of change in accounting principle	(1.27)	(0.51)	(0.36)	(0.40)
Basic and diluted net loss per share	(1.23)	(0.51)	(0.36)	(0.40)

\* The sum of earnings per share for the four quarters may be different from the full year amount as a result of computing the quarterly and full year amounts based on the weighted average number of common shares outstanding in the respective periods.

**Critical Accounting Policies and Estimates**

Nuvelo's discussion and analysis of its operating results and financial condition is based upon Nuvelo's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of the financial statements requires Nuvelo to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent amounts. While Nuvelo believes Nuvelo's estimates, judgments and assumptions are reasonable, the inherent nature of estimates is that actual results will likely differ from the estimates made. Nuvelo's senior management has reviewed these critical accounting policies and related

---

**Table of Contents**

disclosures with Nuvelo's Audit Committee. Nuvelo's significant accounting policies are described in Note 1 to the Consolidated Financial Statements for the year ended December 31, 2007 included elsewhere in this proxy

statement/prospectus/consent solicitation. Nuvelo believes the following critical accounting policies affect Nuvelo's most significant judgments, assumptions, and estimates used in the preparation of Nuvelo's consolidated financial statements and, therefore, are important in understanding Nuvelo's financial condition and results of operations.

***Clinical Trial and Drug Manufacturing Expenses***

Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by the contract research organizations, or CROs, clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and may be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Nuvelo monitors the activity levels through close communication with the CROs and other vendors, including detailed invoice and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Nuvelo may also request certain significant vendors to provide an estimate of costs incurred but not invoiced on a periodic basis. For accrual of expenses related to CROs and clinical study sites, Nuvelo's estimate is based on patient enrollment or progress made against specified milestones or targets in each period. All estimates may differ from the actual amounts subsequently invoiced. No adjustments for material changes in estimates have been recognized in any period presented.

In accordance with Statement of Financial Accounting Standards No. 2, *Accounting for Research and Development Costs* (SFAS 2), Nuvelo capitalizes clinical trial drug manufacturing costs as clinical trial supplies, a current asset on Nuvelo's balance sheet, as long as there are alternative future uses for the related clinical trial drug material in other indications not currently being studied.

In December 2006, as a result of the failure of the first trial in each of two Phase 3 programs for alfimeprase to meet their primary endpoints, Nuvelo suspended enrollment in the second trial in each of these programs. Due to the increased uncertainty over the future of this drug program, Nuvelo's management reassessed the probability of alternative future use of capitalized alfimeprase clinical trial supplies and determined that previously capitalized amounts no longer met the criteria for capitalization under SFAS 2, which represents a change in estimate for accounting purposes. Accordingly, in December 2006, Nuvelo recognized \$21.2 million in expense, including \$19.0 million related to alfimeprase, and \$2.2 million related to other drug programs, as a result of a similar review. During 2007 and the first nine months of 2008, Nuvelo determined that there were no alternative future uses of clinical trial supplies for all current drug programs and that all expenditures related to clinical trial supplies were charged to expense as incurred. In the future, Nuvelo will continue to assess whether alternative future use exists for Nuvelo's drugs under development.

***Revenue Recognition***

Nuvelo recognizes revenue in accordance with Staff Accounting Bulletin No. 104, *Revenue Recognition* (SAB 104), when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed and determinable, and (iv) collectibility is reasonably assured. In situations where Nuvelo has no continuing performance obligations, or Nuvelo's continuing obligations are perfunctory or inconsequential, Nuvelo recognizes up-front non-refundable fees as revenues on the effective date of the related agreement. Up-front non-refundable licensing fees that require continuing involvement in the form of development, manufacturing or other commercialization efforts by Nuvelo are recognized as revenue ratably over the performance period. Judgment is required in determining this performance period, and the effects of any changes to the estimated period are recognized prospectively.

Nuvelo evaluates revenue from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting as defined in EITF Issue No. 00-21,



---

**Table of Contents**

*Revenue Arrangements with Multiple Deliverables* (EITF 00-21). To recognize revenue for a delivered item in a multiple element arrangement, EITF 00-21 requires that the delivered items have value to the customer on a stand-alone basis, there is objective and reliable evidence of fair value of the undelivered items, and delivery of any undelivered items is probable and within Nuvelo's control if delivered items have a general right of return. The determination that multiple elements in an arrangement meet the criteria for separate units of accounting requires Nuvelo to exercise its judgment.

**Stock-based Compensation**

Effective January 1, 2006, Nuvelo adopted the provisions of Statement of Financial Accounting Standards No. 123 (revised 2004), *Share-Based Payment* (SFAS 123(R)). SFAS 123(R) establishes accounting for stock-based awards exchanged for employee and non-employee services. Under SFAS 123(R), employee stock-based compensation cost is generally measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee's requisite service period, net of estimated forfeitures. Nuvelo previously applied Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees* (APB 25), and related Interpretations to account for employee stock-based compensation, and provided the required pro forma disclosures of SFAS No. 123, *Accounting for Stock-Based Compensation* (SFAS 123). Nuvelo adopted the modified prospective application method as provided by SFAS 123(R). Under the modified prospective method, the fair values of new and previously granted but unvested stock options are recognized as compensation expense in the statement of operations over the related vesting periods from the date of adopting SFAS 123(R), and prior period results are not restated.

Nuvelo uses the Black-Scholes option pricing model as management believes that it is the most appropriate fair-value method for Nuvelo's stock-based awards. The Black-Scholes option pricing model requires assumptions to be made for the expected term of the awards, expected volatility of Nuvelo's stock price, risk-free interest rates and expected dividend yields. These assumptions are highly subjective and involve inherent uncertainties and are based on management's best estimates and judgment. If alternative assumptions are used instead of those presented in the notes to the financial statements, stock-based compensation expense could be materially different from amounts recorded in the financial statements under SFAS 123(R) and disclosed on a pro forma basis under SFAS 123. In addition, under SFAS 123(R) Nuvelo is required to estimate the expected forfeiture rate of awards and only recognize expense for those awards expected to vest. If the actual forfeiture rate is materially different from the estimate, the stock-based compensation expense could be materially different from amounts recorded in the financial statements. For options granted prior to January 1, 2006, Nuvelo continues to use the graded-vested (multiple-option) method for expense attribution. Prior to January 1, 2006, option forfeitures were recognized on a pro forma basis as they occurred. For options granted since January 1, 2006, Nuvelo has been using the straight-line (single-option) method for expense attribution, estimates forfeitures based on historical data and only recognizes expense for those shares expected to vest. Adjustments to the forfeiture rate are made if actual forfeitures differ from previous estimates.

To determine the expected term of the options granted, Nuvelo uses historical data, including post-vesting termination behavior and the contractual term to estimate future exercises and cancellations. For options granted prior to January 1, 2006, the expected volatility was based solely on the historical volatility of Nuvelo's common stock. For options granted since January 1, 2006, Nuvelo has been using a combination of historic and implied volatility of Nuvelo's common stock in deriving expected volatility. The risk-free interest rate assumptions are based on the yield of U.S. Treasury instruments with similar durations as the expected term of the related awards. The expected dividend yield assumption is based on Nuvelo's historic and expected dividend payouts.

Nuvelo accounts for stock-based compensation expense for consultants based on the fair values estimated using the Black-Scholes model on the date of grant and re-measured at each reporting date until vested, in compliance with Emerging Issues Task Force No. 96-18, *Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services*. Nuvelo is using the straight-line method in order to expense the value associated with any non-employee awards.

---

**Table of Contents**
***Goodwill and Other Long-Lived Assets Impairment Assessments***

Nuvelo tests goodwill for impairment using a fair value approach at the reporting unit level on an annual basis or when events indicate that the carrying value of the asset may be impaired in accordance with Statement of Financial Accounting Standards No. 142, *Goodwill and other Intangible Assets*, (SFAS 142). Consistent with the determination that Nuvelo has only one reporting segment, it has determined that there is only one reporting unit and, therefore, goodwill is tested at the entity level. Nuvelo has elected October 31<sup>st</sup> as its measurement date. Nuvelo completed its last annual goodwill tests as of October 31, 2007, and no impairments were recognized.

SFAS 142 requires a two-step test for goodwill impairment. In the first step, Nuvelo compares the fair value of Nuvelo to its carrying value. Nuvelo generally bases its fair value on its market capitalization, which is based on quoted market prices of its common stock, taking into account other factors that may affect the fair value of the Nuvelo as a whole. If the fair value of the Nuvelo exceeds the carrying value of its net assets, goodwill is not impaired and Nuvelo is not required to proceed to the second step of the impairment test.

In the first quarter of 2008, Nuvelo performed a goodwill impairment test due to the significant decline of its stock price subsequent to the announcement on March 17, 2008 to discontinue further clinical development of alfineprase. Significant judgment is required to evaluate the fair value of a company, as quoted market prices of a company's common stock and consequently market capitalization may experience significant fluctuations in reaction to disclosures of new information about the company. Based on the upward trend in the price of Nuvelo's common stock following the initial decrease after the announcement and through the filing of the Form 10-Q for the first quarter of 2008, Nuvelo concluded that the market capitalization following the initial market reaction to the announcement did not provide a good indication of Nuvelo's fair value. Accordingly, Nuvelo concluded that the carrying value of its net assets at that time did not exceed its fair value and consequently, goodwill was not impaired at March 31, 2008.

In the second quarter of 2008, Nuvelo performed an additional goodwill impairment test as the upward trend in the market price of Nuvelo's common stock did not continue and Nuvelo's market capitalization remained lower than its carrying value. Since the carrying value exceeded the fair value, at June 30, 2008, Nuvelo performed the second step in order to determine the implied fair value of the goodwill and compare it to the carrying value of goodwill. The activities in the second step included valuing the tangible and intangible assets and liabilities of Nuvelo based on their fair value and determining the implied goodwill based upon the difference between the fair value of the reporting unit and the net fair values of identified tangible and intangible assets and liabilities. Based on the results of the second step of calculating the implied goodwill, Nuvelo recorded an impairment charge of the full balance of goodwill totaling \$4.7 million.

In accordance with Statement of Financial Accounting Standards No. 144, *Accounting for Impairment or Disposal of Long-Lived Assets*, or SFAS 144, Nuvelo evaluates long-lived assets, other than goodwill, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on expected undiscounted cash flows attributable to that asset. The amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.

Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, competition to Nuvelo's products and internal factors such as changes in Nuvelo's business strategy and Nuvelo's internal forecasts. Although Nuvelo believes the assumptions and estimates Nuvelo has made in the past have been reasonable and appropriate, different assumptions and estimates and certain events could materially impact Nuvelo's reported financial results.

***Exit and Disposal Activities***

Nuvelo records costs and liabilities associated with exit and disposal activities, as defined in SFAS 146, at fair value in the period the liability is incurred. SFAS 146 requires that the estimated future cash flows to be used

---

## **Table of Contents**

in the fair value calculation be discounted using a credit-adjusted risk-free interest rate and that such interest rate shall have a maturity date that approximates the expected timing of future cash flows. Future cash flows related to lease obligations shall include the effect of sublease rental income and other lease operating expenses. Nuvelo re-evaluates its sublease assumptions on a quarterly basis considering current market data, including vacancy rates and lease activities for similar facilities within the area. In periods subsequent to initial measurement, changes to a liability resulting from changes in sublease assumptions are measured using the same credit-adjusted risk-free rate that was applied in the initial period. In addition, accretion of the liability due to the passage of time is recorded as an expense. Changes to the sublease assumptions may potentially have a significant effect on Nuvelo's financial condition and results of operations.

In December 2006, Nuvelo exited the facility located in Sunnyvale, California, and recorded a liability of \$26.6 million related to the remaining lease obligations, less estimated sublease income, for the remainder of the lease term. As of March 31, 2008, Nuvelo determined that the likelihood of subleasing this facility during the remainder of the lease term has become remote and, therefore, recorded an additional \$1.5 million charge to reflect such change in the sublease assumption. Nuvelo will continue to pursue sublease opportunities and make necessary adjustments to the liability if and when Nuvelo enters into a sublease agreement in the future.

### ***Income Taxes***

Income taxes are accounted for under the liability method pursuant to Statement of Financial Accounting Standards No. 109, *Accounting for Income Taxes* (SFAS 109). Under SFAS 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Nuvelo records a valuation allowance to reduce deferred tax assets to an amount that is more likely than not to be realized. Assessment of the realization of deferred income tax assets requires that estimates and assumptions be made as to the taxable income of future periods. Nuvelo's deferred tax assets have been reduced to zero, as Nuvelo's management believes that it is more likely than not that the deferred tax assets will not be realized. Projection of future period earnings is inherently difficult as it involves consideration of numerous factors such as Nuvelo's overall strategies and estimates of new product development and acceptance, product lifecycles, selling prices and volumes, responses by competitors, manufacturing costs and assumptions as to operating expenses and other industry specific and macro and micro economic factors. In addition, consideration is also given to ongoing and constantly evolving global tax laws and Nuvelo's own tax minimization strategies.

Utilization of Nuvelo's net operating loss and research and development credit carryforwards are subject to an annual limitation under the change in ownership provisions of the Internal Revenue Code of 1986 and similar state law provisions as a result of certain transactions that Nuvelo entered into prior to 2006. If the proposed merger with ARCA is consummated, a change in ownership of Nuvelo will occur and Nuvelo's ability to utilize these carryforwards will be substantially reduced.

On January 1, 2007, Nuvelo adopted the provisions of FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109* (FIN 48). FIN 48 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not (i.e. a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

---

**Table of Contents****Recent Accounting Pronouncements**

On January 1, 2008, Nuvelo adopted Statement of Financial Accounting Standards (SFAS) No. 157, *Fair Value Measurements* (SFAS 157). SFAS 157 establishes a common definition for fair value to be applied to U.S. GAAP requiring use of fair value, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. In February 2008, Financial Accounting Standards Board (FASB) issued FASB Staff Position No. FAS 157-2, *Effective Date of FASB Statement No. 157* (FSP 157-2), which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except items that are recognized or disclosed at fair value on a recurring basis (at least annually), until fiscal years beginning after November 15, 2008. The implementation of SFAS 157 for financial assets and financial liabilities did not have a material impact on Nuvelo's consolidated financial position and results of operations. Nuvelo is currently assessing the impact of adopting SFAS 157 for nonfinancial assets and nonfinancial liabilities on its financial position and results of operations.

In February 2007, the FASB issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities* (SFAS 159). SFAS 159 allows entities to voluntarily choose, at specified election dates, to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. The effective date for Nuvelo was January 1, 2008. To date, Nuvelo has not elected this fair value option for any assets or liabilities.

In June 2007, the FASB ratified the consensus reached by the Emerging Issues Task Force (EITF) on EITF Issue No. 07-3, *Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities* (EITF 07-3). EITF 07-3 addresses the diversity that exists with respect to the accounting for the non-refundable portion of a payment made by a research and development entity for future research and development activities. Under EITF 07-3, an entity would defer and capitalize non-refundable advance payments made for research and development activities until the related goods are delivered or the related services are performed. The effective date for Nuvelo was January 1, 2008. The adoption of EITF 07-3 did not have a material effect on Nuvelo's consolidated financial statements.

In December 2007, the FASB issued Statement 141R, *Business Combinations* (SFAS 141R). SFAS 141R replaces SFAS 141. SFAS 141R requires the acquirer of a business to recognize and measure the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree at fair value. SFAS 141R also requires transactions costs related to the business combination to be expensed as incurred. SFAS 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The effective date for Nuvelo will be January 1, 2009. Nuvelo has not yet determined the impact of SFAS 141R related to future acquisitions, if any, on Nuvelo's consolidated financial statements.

In December 2007, the FASB ratified the consensus reached by the EITF on EITF Issue 07-1, *Accounting for Collaborative Arrangements* (EITF 07-1). EITF 07-1 requires collaborators to present the results of activities for which they act as the principal on a gross basis and report any payments received from (made to) other collaborators based on other applicable GAAP or, in the absence of other applicable GAAP, based on analogy to authoritative accounting literature or a reasonable, rational, and consistently applied accounting policy election. The effective date Nuvelo will be January 1, 2009. Nuvelo has not yet determined the impact of EITF 07-1 on Nuvelo's consolidated financial statements.

**Off-Balance Sheet Arrangements**

Nuvelo has not participated in any transactions with unconsolidated entities, such as special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

**Table of Contents**

**Indemnifications**

In the ordinary course of business, Nuvelo enters into contractual arrangements under which Nuvelo may agree to indemnify certain parties from any losses incurred relating to the services they perform on Nuvelo's behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. Historically, payments made related to these indemnifications have been insignificant. In addition, Nuvelo has entered into indemnity agreements with each of its directors and officers. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. Nuvelo also maintains an insurance policy for its directors and executive officers insuring against certain liabilities arising in their capacities as such.

**Table of Contents**

**NUVELO QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Nuvelo's investments in marketable debt securities are subject to interest rate and credit risks. To minimize the exposure due to an adverse shift in interest rates, Nuvelo invests primarily in short-term securities and maintain an average maturity of 12 months or less. As of September 30, 2008, a hypothetical change in market interest rates by 100 basis points would result in a change in market value of Nuvelo's investment portfolio by approximately \$0.1 million and annual interest income by approximately \$0.6 million. To minimize its exposure to credit risk, Nuvelo invests in securities with strong credit ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. Nuvelo does not invest in derivative financial instruments, mortgage-backed securities or auction rate securities, and Nuvelo has not recorded any losses on its securities due to credit or liquidity issues. Nuvelo continues to monitor its credit exposure and may modify its investment guidelines as necessitated by changing market conditions.

---

**Table of Contents**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION  
AND RESULTS OF OPERATIONS FOR ARCA**

*This Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as anticipate, believes, budget, continue, could, estimate, expect, forecast, intend, may, plan, potential, predicts, project, should, will and similar expressions are intended to identify such forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors discussed herein and elsewhere including, in particular, those factors described under the Risk Factors. The following discussion and analysis should be read in conjunction with ARCA's financial statements and related notes included elsewhere in this proxy statement/prospectus/consent solicitation.*

**Overview**

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro<sup>TM</sup> (bucindolol hydrochloride), a twice-a-day oral formulation that has been developed for the treatment of chronic heart failure. ARCA believes it has identified common genetic variations that help predict patient response to Gencaro. The FDA accepted ARCA's NDA for Gencaro in September 2008. ARCA believes that Gencaro, if approved, will be the first genetically-targeted cardiovascular drug.

ARCA holds worldwide rights to Gencaro and, if it is approved, plans to commercialize the drug in the U.S., through its own specialized sales force. ARCA may seek commercial partners outside the United States. ARCA has collaborated with Laboratory Corporation of America, or LabCorp, to develop and launch a companion genetic test for Gencaro, in conjunction with any commercialization of Gencaro.

ARCA was incorporated in 2001, reorganized as a Delaware corporation in 2004 and began substantial operations in 2005. ARCA is in the development stage and has incurred net losses since inception. From inception through September 30, 2008, ARCA's activities have been focused primarily on conducting research and development, hiring personnel and raising capital to support these activities. ARCA expects to incur net losses in the future as research and development activities continue and it prepares to commercialize Gencaro.

ARCA's costs associated with Gencaro have represented substantially all of ARCA's research and development expenses to date. For the fiscal years ended December 31, 2007, 2006 and 2005, ARCA's net losses were \$14.0 million, \$5.2 million and \$1.5 million, respectively. For the nine months ended September 30, 2008, ARCA's net losses were \$14.3 million. As of September 30, 2008, ARCA had \$5.5 million in cash and cash equivalents and marketable securities, working capital of \$840,000 and an accumulated deficit since inception of \$35.6 million. ARCA expects significant costs for the foreseeable future while it awaits the FDA's decision on the NDA for Gencaro and builds its sales and marketing organization in anticipation of the potential commercial launch of Gencaro.

ARCA has not generated any revenues from sales of commercial products since inception and does not expect to generate any revenues unless and until the NDA for Gencaro is approved. To date, substantially all of ARCA's operations have been funded through the private placement of equity securities and convertible debt. Since inception, ARCA has raised net cash proceeds of \$33.0 million from the sale of preferred stock. In August 2008, ARCA drew \$4.0 million on its bank line of credit. In October 2008, ARCA sold convertible promissory notes and warrants to purchase common stock for total consideration of \$8.75 million.

---

## **Table of Contents**

### **Critical Accounting Policies and Estimates**

Management's discussion and analysis of ARCA's financial condition and results of operations is based on ARCA's financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires ARCA to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported expenses during the reporting periods. ARCA bases its estimates on various assumptions that are believed to be reasonable under circumstances, and evaluates its estimates and judgments on an ongoing basis. Actual results may differ materially from these estimates.

ARCA believes that the following accounting policies and estimates are most critical to a full understanding and evaluation of ARCA's reported financial results.

#### ***Cash and Cash Equivalents***

ARCA considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. ARCA's cash and cash equivalents are maintained at two financial institutions in the U.S. Deposits held with these financial institutions may, from time to time, exceed the amount of insurance provided on such deposits.

#### ***Long Lived Assets and Impairments***

ARCA reviews long lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Management believes that no impairment of its long lived assets has occurred from ARCA's inception on December 17, 2001 through September 30, 2008. As a development stage company, ARCA has not generated positive cash flows from operations, and such cash flows may not materialize for a significant period in the future, if ever. Additionally, ARCA may make changes to its business plan that would result in changes to expected cash flows from long lived assets. As a result, it is reasonably possible that future evaluations of long lived assets may result in an impairment.

#### ***Accrued Expenses***

As part of the process of preparing its financial statements, ARCA is required to estimate accrued expenses. This process involves identifying services that third parties have performed on ARCA's behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to drug product, and professional service fees, such as attorneys and consultants. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known and accounts for these estimates in accordance with accounting principles involving accrued expenses generally accepted in the U.S.

#### ***Research and Development Costs***

ARCA's research and development expenses consist primarily of salaries and related employee benefits, costs associated with regulatory activities, including the costs of contract research organizations, upfront license fees and milestone payments for acquired product rights that have not been developed into saleable products or approved by regulatory agencies, and which have no future alternative use. Research and development costs are expensed as incurred. ARCA has issued shares of common stock in exchange for certain licenses and sublicenses. Total research and development expense recorded for the fair value of these issuances was approximately \$20,000, \$150,000, \$44,000 and \$214,000 in 2007, 2006, 2005 and the period from inception through December 31, 2007, respectively. No shares were issued for licenses and sublicenses in 2008.



**Table of Contents**

To date, ARCA's major research and development project has been the regulatory filing of the Gencaro NDA with the FDA. On July 31, 2008 ARCA submitted the Gencaro NDA to the FDA and the submission was accepted by the FDA in September 2008. ARCA anticipates a determination with respect to the NDA from the FDA in the second quarter of 2009. ARCA has spent approximately \$23.5 million on research and development from ARCA's inception through September 30, 2008, a substantial majority of which was related to the Gencaro NDA. Included in these total expenditures are licensing costs for the active pharmaceutical ingredient, or API, of Gencaro, bucindolol, of \$1.5 million. This includes a \$500,000 milestone payment based on ARCA's July 31, 2008 submission of its NDA for Gencaro. If ARCA obtains approval from the FDA it will owe an additional milestone royalty of \$8.0 million to this licensor and must make the payment within 180 days after receiving approval.

ARCA could incur additional costs in defense of its NDA. These costs could be significant but are not currently estimable or certain. The FDA could also require ARCA to do additional research and development work, the scope and cost of which are not currently foreseeable or certain. If ARCA is required to perform additional research and development work, the costs and time related to which could be significant, then the commercialization of Gencaro and ARCA's ability to generate revenues will also be delayed.

**Share-Based Compensation**

Prior to January 1, 2006, ARCA accounted for employee stock options using the intrinsic-value method in accordance with Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees*, and related interpretations, or APB No. 25. In accordance with APB No. 25, stock-based compensation was calculated using the intrinsic-value method and represented the difference between the estimated fair value of ARCA common stock and the per share exercise price of the stock option at the grant date. Based on this method, ARCA did not incur any compensation expense under APB No. 25. Effective January 1, 2006, ARCA adopted SFAS 123(R), *Share-Based Payment*, using the prospective transition method, which requires the measurement and recognition of compensation expense for all share-based payment awards granted or modified to employees and directors after January 1, 2006, based on the estimated fair value of the award at the grant date. The fair value of stock options is estimated using the Black-Scholes option pricing model. This model requires the input of subjective assumptions, including expected stock price volatility, expected life and estimated forfeitures of each award. Management believes its assumptions regarding these inputs are reasonable. The estimated grant-date fair value of stock-based awards is amortized over the vesting period of the award, and ARCA has elected to use the straight-line method of amortization. Due to the limited amount of historical data available to ARCA, particularly with respect to stock-price volatility, employee exercise patterns and forfeitures, future estimates of grant-date fair value could utilize different assumptions, and actual forfeiture rates could differ from those estimated through September 30, 2008.

Information regarding ARCA's stock option grants for the years ended December 31, 2006 and 2007, and the nine months ended September 30, 2008 is summarized as follows:

<b>Stock Option Grant Date</b>	<b>Number of Options Granted</b>	<b>Exercise Price</b>
August 3, 2006	302,400	\$ 0.15
November 2, 2006	1,186,199	\$ 0.15
February 2, 2007	285,821	\$ 0.28
May 3, 2007	126,500	\$ 0.30
November 1, 2007	94,000	\$ 0.31
February 12, 2008	803,500	\$ 0.31
May 2, 2008	75,000	\$ 0.31
May 5, 2008	29,800	\$ 0.31
August 20, 2008	793,500	\$ 0.45

**Table of Contents**

In evaluating the fair value of ARCA's common stock, ARCA followed procedures that are consistent with the recommendations of the American Institute of Certified Public Accountants Technical Practice Aid regarding *Valuation of Privately Held Company Equity Securities Issued as Compensation*.

ARCA's board of directors, with the assistance of management, performed contemporaneous fair value analyses of the estimated fair value of ARCA's common stock at or near the time of each stock option grant. Determining the fair value of ARCA common stock required complex and subjective judgments, assumptions and estimates. Given the absence of any trading market for ARCA's common stock, uncertainty of the results of regulatory approval, and other risk and factors affecting ARCA, ARCA's board of directors, with input from management, determined the estimated fair value of its common stock on the date of the grant of stock options based on several factors, including:

ARCA's actual financial condition and results of operations during the relevant period;

ARCA's future financial outlook;

uncertainties involved in gaining regulatory approval to market Gencaro;

the progress of ARCA's business model, including the status of ARCA's efforts to recruit and retain the talent required to support ARCA's business objectives and strategies;

ARCA's capitalization;

the price at which ARCA last issued convertible preferred stock and the rights and preferences associated with those and previously issued preferred stock;

the illiquidity of ARCA's common stock as a private company;

the likelihood of achieving a liquidity event for shares of ARCA's common stock, such as an acquisition of ARCA or becoming a publicly traded company in the imminent future;

ARCA's competitive position in the marketplace;

research concerning the biotechnology industry;

research and comparative analysis of similar public companies; and

general economic conditions and the outlook for the U.S. economy.

*Grants Made on August 3, 2006*

## Edgar Filing: NUVELO INC - Form S-4/A

For the stock-based awards granted in August 2006, ARCA's board of directors, based on relevant factors, concluded that the fair value of ARCA's common stock was \$0.15 per share at the time of grant. The main factors accounting for the increase in value were:

ARCA's progress in constructing a knowledgeable and experienced regulatory management team to assist with the NDA for Gencaro, including the hiring an Executive Vice President of Regulatory Affairs in July 2006; and

an evaluation of the risks related to the filing of ARCA's Gencaro NDA, and the impact that filing delays encountered in the second quarter of 2006 would have on ARCA's business plan and value.

*Grants Made on November 2, 2006*

For the stock-based awards granted in November 2006, ARCA's board of directors, based on relevant factors, concluded that the fair value of ARCA's common stock was \$0.15 per share at the time of grant. The estimated value of common stock was unchanged primarily because of the following factors:

delays in the submission of the Gencaro NDA as a result of new analyses by the ARCA regulatory team;

**Table of Contents**

increases in the cost estimate to complete the Gencaro NDA of \$1.4 million; and

receipt of additional guidance from the FDA regarding ARCA's upcoming submittal of the Gencaro NDA.

*Grants Made on February 2, 2007*

For the stock-based awards granted in February 2007, ARCA's board of directors, based on relevant factors, concluded that the fair value of ARCA's common stock was \$0.28 per share at the time of grant. The main factors for the increase in value were:

the closing of the second tranche of the Series A preferred financing in December 2006, providing \$5 million of capital to fund its programs for the coming year;

the hiring in November 2006 of an experienced, pharmaceutical and biotechnology executive to assume the role of President and Chief Executive Officer;

the hiring in October 2006 of an Executive Vice President of Pharmaceutical Operations to manage the Chemistry, Manufacturing and Controls sections of the NDA and ARCA's manufacturing requirements in preparation for the commercialization of Gencaro;

continued guidance from the FDA regarding its upcoming submittal of the Gencaro NDA; and

the anticipated Gencaro NDA timeline, which was unchanged as ARCA expected feedback from the FDA on the clinical component in the second half of 2007 and a response on the complete NDA filing for Gencaro in the second quarter of 2008.

*Grants Made on May 3, 2007*

For the stock-based awards granted in May 2007, ARCA's board of directors, based on relevant factors, concluded that the fair value of ARCA's common stock was \$0.30 per share at the time of grant. The reasons for the increase in value were:

continued incremental progress on the filing of the Gencaro NDA. ARCA was still on target to submit its NDA filing in June or July of 2007 and expected feedback from the FDA on the clinical component in the second half of 2007 with the results of the full NDA filing expected in the second quarter of 2008;

execution of a contract with LabCorp, one of the largest clinical laboratories in the U.S., to develop, gain regulatory approval of and commercialize the companion genetic test for Gencaro;

a pending additional equity funding of approximately \$15.0 to \$25.0 million in a Series B redeemable convertible preferred stock to continue to support the Gencaro NDA submission and related research and development;

the determination of ARCA's management that ARCA would require a total of approximately \$80.0 million in financing through 2009 (including the projected Series B financing) to meet ARCA's financial obligations; and

## Edgar Filing: NUVELO INC - Form S-4/A

the availability of a pending bank line of credit of approximately \$4.0 to \$5.0 million.

*Grants Made on November 1, 2007*

For the stock-based awards granted in November 2007, ARCA's board of directors, based on relevant factors, concluded that the fair value of ARCA's common stock was \$0.31 per share at the time of grant. The reason for the increase in value, despite a six-month delay in the Gencaro NDA submission until December 2007 and an additional associated costs, was the closing of the Series B preferred stock financing in May 2007, of which \$9.0 million had been funded in May, and the remaining \$9.0 million was contingent upon the satisfactory review and adjudication of certain clinical trial data.

## **Table of Contents**

### *Grants Made on February 12, 2008 and May 5, 2008*

For the stock-based awards granted in February 2008 and May 2008, ARCA's board of directors, based on relevant factors, concluded that the fair value of ARCA's common stock was \$0.31 per share at the time of each grant. The main factors for maintaining the value during this period were:

the closing of the second tranche of the Series B preferred stock financing of \$9.0 million upon satisfactorily meeting investor milestones related to the clinical trial data;

an additional three-month delay in the Gencaro NDA submission with a projected submission date of March 2008; and

revised financial projections for 2008 through 2011, reflecting a one-year shift in the commencement of commercialization and generation of revenue resulting from the delay in filing the Gencaro NDA.

### *Grants Made on August 20, 2008*

For the stock-based awards granted on August 20, 2008, ARCA's board of directors, based on relevant factors, concluded that the fair value of ARCA's common stock was \$0.45 per share at the time of grant. The main factor for increasing the value during this period was the submission of the NDA to the FDA on July 31, 2008.

### *Board Experience*

ARCA's board of directors includes individuals with significant business, finance and/or venture capital experience. During the periods set forth above, ARCA's board of directors was comprised of several individuals with experience in valuing early stage biopharmaceutical companies and pricing stock options. These board members are familiar with the valuations of biopharmaceutical companies entering the public market, as well as with the market for the acquisition of biopharmaceutical companies similar to ARCA's stage of development.

### ***Warrants for Series B-1 Redeemable Preferred Stock and Series B-2 Redeemable Preferred Stock***

On January 1, 2006, ARCA adopted SFAS No. 150, *Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity*, and related FASB Staff Position 150-5, *Issuer's Accounting under FASB Statement No. 150 for Freestanding Warrants and Other Similar Investments on Shares That Are Redeemable*, or FSP 150-5. In July 2007, ARCA issued warrants to purchase 31,790 shares of Series B-1 redeemable preferred stock to a financial institution in connection with a credit facility. The warrants have an exercise price of \$2.43975 per share, a 10 year life and were fully vested and exercisable at the time of grant. ARCA also issued warrants to purchase 24,592 shares of its Series B-2 redeemable preferred stock in August 2008 in connection with the draw down of the full balance of the credit facility. The warrants have an exercise price of \$3.253 per share, a 10 year life and were fully vested and exercisable at the time of grant.

In accordance with FSP 150-5, the warrants are reported as long-term liabilities at their estimated fair value at the time of issuance. At each reporting period, ARCA updates the estimated fair value of the warrants based upon current valuation factors, and the change in the estimated fair value is reported in the statement of operations. Fair value is estimated using assumptions that management believes are reasonable.

Upon the closing of the merger, all warrants to purchase ARCA capital stock will be assumed by Nuvelo and will become warrants to purchase a number of shares of Nuvelo common stock calculated in accordance with the exchange ratio set forth in the merger agreement. At such time, the estimated fair value of such warrants will be re-classified to equity.

---

## **Table of Contents**

### ***Redeemable Convertible Preferred Stock***

ARCA's redeemable convertible preferred stock is classified on its balance sheet between liabilities and stockholders' deficit as the holders of the redeemable convertible preferred stock have the right to request redemption in the future if certain classes of stockholders vote in favor of such redemption. Immediately prior to the closing of the merger, all of ARCA's outstanding shares of preferred stock and convertible promissory notes will convert into shares of common stock and the redemption right and rights in liquidation will terminate.

### ***Income Taxes***

The current provision for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. ARCA has recorded a valuation allowance against all of its net deferred tax assets, as management is unable to conclude that it is more likely than not that the net deferred tax asset will be realized through future taxable income, based primarily on ARCA's history of operating losses.

### **Results of Operations**

#### ***Nine-Month Period Ended September 30, 2008 Compared to Nine-Month Period Ended September 30, 2007***

##### ***Research and Development Expenses***

Research and development expenses were \$8.4 million for the nine months ended September 30, 2008, as compared to \$7.3 million for the corresponding period in 2007. Costs associated with ARCA's regulatory operations decreased by \$1.4 million because the Gencaro NDA was nearing submission. The decrease in regulatory costs was largely offset by cost increases of approximately \$2.5 million during the nine months ended September 30, 2008 as ARCA expanded its quality assurance, clinical operations and medical affairs activities in anticipation of the commercialization of Gencaro. ARCA's NDA for Gencaro was submitted to the FDA in July 2008.

Research and development expenses are expected to increase for the remainder of 2008 as ARCA:

- completes selected Phase I clinical trials for Gencaro;

- initiates additional manufacturing and process controls projects for tableting and packaging Gencaro to support Gencaro's anticipated commercial launch timeline, assuming the Gencaro NDA is approved by the FDA; and

- incurs consulting and advisory services costs in support and defense of ARCA's NDA for Gencaro.

##### ***Selling General and Administrative Expenses***

Selling, general and administrative expenses were \$6.0 million for the nine months ended September 30, 2008, as compared to \$3.3 million for the corresponding period in 2007. The \$2.7 million increase was primarily due to increased personnel costs related to the development of ARCA's commercial organization. ARCA also incurred additional costs for consulting and professional services associated with developing ARCA's commercialization strategy such as market research, branding and continuing medical education programs. ARCA expects its marketing and sales related costs to continue to increase during the remainder of 2008 and in future periods as ARCA expands its sales and marketing organization to support the anticipated potential commercialization of Gencaro. General and administrative costs are expected to increase as a result of increased compensation costs, as well as additional legal, accounting, insurance and other professional services costs relating to the compliance obligations associated with the merger and with operating as a public company.





**Table of Contents***Interest and Other Income*

Interest and other income was \$204,000 for the nine months ended September 30, 2008, as compared to \$358,000 for the corresponding period in 2007. The decrease was primarily due to reduced cash balances throughout the nine month period ended September 30, 2008 as compared to the corresponding period in 2007.

*Interest and Other Expense*

Interest and other expense was \$60,000 for the nine months ended September 30, 2008, as compared to \$3,000 for the corresponding period in 2007. The increase was due to approximately \$36,000 in interest expense on ARCA's credit facility plus the change in estimated fair value of the warrants to purchase shares of Series B preferred stock issued in 2007 and 2008 to ARCA's lender in connection with its credit facility. The remainder of the increase was due to the loss of approximately \$24,000 on assets disposed of as part of the relocation of ARCA's principal corporate office.

***Year Ended December 31, 2007 Compared to Year Ended December 31, 2006****Research and Development Expenses*

Research and development expenses were \$10.2 million for the year ended December 31, 2007 compared to \$4.0 million for the year ended December 31, 2006. Increased personnel and related costs accounted for approximately \$1.7 million of the cost increase. ARCA increased its headcount in the second half of 2006 and in 2007 to expand its regulatory capabilities to prepare the Gencaro NDA for submission. In addition to ARCA's own personnel, ARCA also increased its utilization of outside professional services, such as contract manufacturers, contract research organizations, or CROs, and consultants in connection with the preparation of the Gencaro NDA. These activities accounted for approximately \$5.7 million of increased costs. ARCA's licensing costs decreased approximately \$1.2 million in 2007 because the fees paid in 2006 for ARCA's initial licensing of the API for Gencaro and related technology were non-recurring costs.

*Selling General and Administrative Expenses*

Selling, general and administrative expenses were \$4.2 million for the year ended December 31, 2007, as compared to \$1.5 million for the year ended December 31, 2006. The increase was primarily due to increased personnel costs of approximately \$1.6 million related to staffing to support ARCA's growth, approximately \$1.1 million of costs for market research, business development activities and professional service fees, which were principally legal expenses related to general corporate and licensing activities and patent filings.

*Interest and Other Income*

Interest and other income was \$468,000 for the year ended December 31, 2007, as compared to \$287,000 for the year ended December 31, 2006. The increase was due to higher overall cash balances throughout 2007 as compared to 2006. In May and December 2007, ARCA sold shares of its Series B preferred stock in preferred stock financings yielding aggregate net proceeds of \$17.9 million.

*Interest and Other Expense*

Interest expense was \$8,000 for the year ended December 31, 2007, as compared to \$5,000 for the year ended December 31, 2006. Interest expense in 2007 related to amortization of financing costs for a credit facility obtained in July 2007. Interest expense in 2006 related to interest on convertible notes payable. These notes were fully converted to Series A preferred stock in February 2006.

***Year Ended December 31, 2006 Compared to Year Ended December 31, 2005****Research and Development Expenses*

Research and development expenses were \$4.0 million for the year ended December 31, 2006 compared to \$846,000 for the year ended December 31, 2005. Increased costs for professional services, such as CROs and

---

**Table of Contents**

consultants, accounted for approximately \$1.4 million of additional expenses. Research and development activities in 2006 included the acceleration of ARCA's clinical regulatory efforts for Gencaro, the design of ARCA's manufacturing and process development strategy and the selection of ARCA's manufacturing vendors for Gencaro. Licensing expense increased approximately \$1.2 million as ARCA incurred initial licensing costs for the API for Gencaro and for technology to develop Gencaro. Personnel and related costs comprised approximately \$500,000 of the increase due to the hiring of additional senior management and staff needed to develop Gencaro.

*Selling, General and Administrative Expenses*

Selling, general and administrative expenses were \$1.5 million for the year ended December 31, 2006, as compared to \$569,000 for the year ended December 31, 2005. Approximately \$350,000 of the increase was attributable to increased personnel and related costs for staff necessary to support ARCA's growth, including recruiting and hiring ARCA's current chief executive officer. The remaining cost increase consisted primarily of consulting, legal and other professional service costs for strategic business development and commercialization planning, as well as legal expenses related to general corporate and licensing activities and patent filings.

*Interest and Other Income*

Interest and other income was \$287,000 for the year ended December 31, 2006, as compared to \$0 for the year ended December 31, 2005. The increase was due to higher overall cash balances throughout 2006 as compared to 2005. In February and December 2006, ARCA sold shares of its Series A preferred stock in preferred stock financings for aggregate net proceeds of \$14.2 million.

*Interest and Other Expense*

Interest expense was \$5,000 for the year ended December 31, 2006, as compared to \$44,000 for the year ended December 31, 2005. The decrease was due to interest expense that ceased to incur on convertible notes payable when such notes were converted to Series A preferred stock in 2006.

**Liquidity and Capital Resources***Sources and Uses of Capital*

ARCA has incurred losses since its inception in 2001. As of September 30, 2008, ARCA had an accumulated deficit of \$35.6 million. ARCA has funded its operations to date principally from private placements of equity securities and convertible notes totaling \$33.0 million through December 31, 2007. As of September 30, 2008, ARCA had \$5.5 million in cash and cash equivalents. In addition, ARCA has a \$4.0 million revolving credit facility in place which it drew down in full in August 2008 to fund its operations. Current investors have also provided debt financing totaling \$8.75 million in principal amount of convertible notes and in consideration for related warrants in a bridge loan financing that was completed in October 2008. These convertible notes, plus accrued interest, will convert into ARCA common stock immediately prior the closing of the merger equal to the amount of unpaid principal and interest due as of the date of conversion divided by the conversion price. The conversion price is equal to the lesser of: (i) \$3.253 or (ii) the product of (a) the average closing price of Nuvelo common stock on the Nasdaq Global Market for the five consecutive trading days immediately preceding (but not including) the date the merger is consummated and (b) the Exchange Ratio; provided, however that in no event will the conversion price be less than \$1.6265. In connection with the issuance of these notes, ARCA also issued warrants to purchase shares of common stock. The warrants are exercisable for a number of shares of ARCA's common stock determined by dividing (i) 20% of the sum of the principal amount of each note plus the consideration paid for the warrants divided by (ii) the conversion price of the notes. The warrants have an exercise price equal to the conversion price of the notes and have a five-year exercise period.

---

**Table of Contents**

As of September 30, 2008, ARCA had total cash and cash equivalents of \$5.5 million, as compared with \$15.9 million as of December 31, 2007. The decrease of approximately \$10.4 million resulted primarily from operating expenditures during the period. As of December 31, 2007, ARCA had total cash and cash equivalents of \$15.9 million, as compared to \$9.7 million as of December 31, 2006. The increase of \$6.2 million is the net effect of ARCA's Series B preferred stock financing of \$18.0 million completed during the year offset by operating expenditures during the period.

***Cash Flows from Operating, Investing and Financing Activities***

Net cash used in operating activities was \$13.2 million in the nine months ended September 30, 2008, compared with \$8.8 million in the corresponding period of 2007. The increase of \$4.4 million in net cash used in operating activities was primarily due to an overall increase in the selling general and administrative expenses attributable to commercialization preparations on Gencaro.

Net cash used in operating activities was \$11.6 million in 2007, as compared to \$4.7 million in 2006 and \$1.4 million in 2005. The increase of \$6.9 million in 2007 was primarily due to the growth of the organization and increased work on the Gencaro NDA filing resulting in increases in overall operating expenses. The increase of \$3.3 million in 2006 was also attributable to overall growth of ARCA as it completed its Series A preferred stock financing in 2006 and initiated work on the Genacaro NDA.

Net cash used in investing activities was \$1.2 million in the nine months ended September 30, 2008, compared with \$86,000 in the corresponding period of 2007. The increase of approximately \$1.1 million was primarily due to an increase in capital expenditures associated with ARCA's move of its principal corporate office. Net cash used in investing activities was \$120,000 in 2007, as compared to net cash used in investing activities of \$122,000 and \$24,000 in 2006 and 2005, respectively. The net cash used in investing activities in each of these years was used to purchase property and equipment to support the growth of the organization.

Net cash provided by financing activities was \$4.1 million in the nine months ended September 30, 2008, compared with net cash provided by financing activities of \$8.9 million in the corresponding period of 2007. In May 2007, ARCA completed the sale of \$9 million in shares of its Series B preferred stock. In the nine months ended September 30, 2008, ARCA borrowed the full \$4.0 million available under its credit facility. The remainder of the financing activity was attributable to exercises of stock options held by employees.

Net cash provided by financing activities was \$17.9 million in 2007, as compared to net cash provided by financing activities of \$14.1 million and \$1.6 million in 2006 and 2005, respectively. The 2007 activity reflects ARCA's sale of Series B preferred stock during the year. In 2006, the activity reflects ARCA's sale of Series A preferred stock. The 2005 activity includes the issuance of convertible notes payable that were converted to common stock during the year.

From ARCA's inception through September 30, 2008, ARCA has obtained \$38.2 million through financing activities, and utilized \$31.1 million in funding its operating activities and \$1.6 million in purchasing property and equipment.

ARCA anticipates that it will continue to incur substantial net losses for the next several years as it develops Gencaro, prepares for a potential commercial launch of Gencaro and expands its corporate infrastructure. ARCA does not anticipate generating any revenues until after it receives regulatory approval from the FDA for Gencaro.

ARCA believes that its current cash and cash equivalents and credit facilities will be sufficient to satisfy its anticipated cash needs for working capital and capital expenditures through February 2009, without regard to the merger. ARCA's future capital requirements depend on a number of factors, including, but not limited to, the following:

timing and outcomes of regulatory approvals, in particular the approval of ARCA's NDA for Gencaro by the FDA;

**Table of Contents**

the costs of establishing or contracting for marketing and sales capabilities, including the establishment of ARCA's own sales force;

the extent to which ARCA is able to acquire or in-license new products, technologies or businesses;

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and

the terms and timing of any additional collaborative, strategic partnership or licensing agreements that ARCA may establish.

If ARCA's available cash and cash equivalents and funding received or made available are insufficient to satisfy its liquidity requirements, or if ARCA develops additional products or pursues additional applications for its products or conduct additional clinical trials beyond those currently contemplated, ARCA may seek to sell additional equity or incur additional indebtedness. The sale of additional equity or convertible debt securities may result in additional dilution to ARCA's stockholders. If ARCA raises additional funds through the incurrence of additional indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA capital stock and could contain covenants that would restrict ARCA's operations. ARCA may require additional capital beyond its currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all. If ARCA is unable to obtain additional financing, it may be required to modify or limit its planned research, development and commercialization strategies, which could adversely affect its business.

**Contractual Obligations**

ARCA's future contractual obligations, including financing costs, as of December 31, 2007, included the following:

	Total	Payments Due by Period			More than 5 Years
		Less than 1 Year	1-3 Years	3-5 Years	
Operating lease obligations	\$ 131	\$ 131	\$	\$	\$

The above table reflects only payment obligations that are fixed and determinable. ARCA's commitments for operating leases relate to the lease for its office and laboratory facilities in Colorado.

As of September 30, 2008 ARCA had incurred additional payment obligations which are fixed and determinable. These obligations, as of September 30, 2008, are summarized in the following table:

	Total	Payments Due by Period			More than 5 Years
		Less than 1 Year	1-3 Years	3-5 Years	
Operating lease obligations(1)	\$ 1,146	\$ 228	\$ 477	\$ 441	\$
Note payable(2)	4,000	1,451	2,549		
	\$ 5,146	\$ 1,679	\$ 3,026	\$ 441	\$

- (1) On February 8, 2008, ARCA entered into a lease agreement for approximately 15,000 square feet of newly constructed office space in Broomfield, Colorado.

## Edgar Filing: NUVELO INC - Form S-4/A

(2) On August 19, 2008, ARCA drew the full \$4.0 million balance of its credit facility. Repayment of the loan begins January 1, 2009. In addition to the amounts in the above tables, in August 2008 ARCA paid CPEC \$500,000 in recognition of a milestone royalty due based on the July 31, 2008 submission of the ARCA's NDA with the FDA. If the Gencaro NDA is approved by the FDA, ARCA will be obligated to pay CPEC an additional milestone royalty of \$8 million payable with 180 days of receiving approval from the FDA.

## **Table of Contents**

### **Recent Accounting Pronouncements**

Effective January 1, 2008, ARCA adopted SFAS No. 157, *Fair Value Measurements*. In February 2008, the FASB issued FASB Staff Position No. FASB 157-2, *Effective Date of FASB Statement No. 157*, which provides a one-year deferral of the effective date of SFAS No. 157 for non-financial assets and non-financial liabilities, except those that are recognized or disclosed in the financial statements at fair value at least annually. SFAS No. 157 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The standard describes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that may be used to measure fair value. The adoption of SFAS No. 157 had no impact on ARCA's financial statements.

In December 2007, the FASB issued SFAS No. 141(R), *Business Combinations*, and SFAS No. 160, *Accounting and Reporting of Noncontrolling Interest in Consolidated Financial Statements, an amendment of ARB No. 51*. These new standards will significantly change the financial accounting and reporting of business combination transactions and noncontrolling, or minority, interests in consolidated financial statements. As discussed previously in the Selected Unaudited Pro Forma Condensed Combined Financial Data section, because the merger transaction will be consummated in 2009, SFAS No. 141(R) will apply.

### **Off-Balance Sheet Arrangements**

Since its inception, ARCA has not engaged in material off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

**Table of Contents**

**ARCA QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK**

ARCA's exposure to market risk is confined to its cash and cash equivalents that have original maturities of less than three months. The primary objective of ARCA's investment activities is to preserve its capital for the purpose of funding operations while at the same time maximizing the income it receives from its investments without significantly increasing risk. To achieve these objectives, ARCA's investment policy allows ARCA to maintain a portfolio of cash equivalents and investments in a variety of marketable securities, including U.S. government and mortgage backed securities, money market funds and under certain circumstances, derivative financial instruments. ARCA's cash and cash equivalents as of September 30, 2008 included liquid money market accounts.

**Table of Contents**

**ARCA CONTROLS AND PROCEDURES**

Prior to the filing of the registration statement of which this proxy statement/prospectus/consent solicitation forms a part, ARCA was not subject to the Sarbanes-Oxley Act of 2002. Therefore, ARCA's management and independent registered public accounting firm did not perform an evaluation of ARCA's internal control over financial reporting as of December 31, 2007 in accordance with the provisions of the Sarbanes-Oxley Act.

Material weaknesses may exist when the combined company reports on the effectiveness of its internal control over financial reporting for purposes of its reporting requirements under the Exchange Act or Section 404 of the Sarbanes-Oxley Act after the merger. The existence of one or more material weaknesses would preclude a conclusion that the combined company maintains effective internal control over financial reporting. Such a conclusion would be required to be disclosed in the combined company's future Annual Reports on Form 10-K and could impact the accuracy and timing of its financial reporting and the reliability of its internal control over financial reporting.



**Table of Contents****MANAGEMENT OF THE COMBINED COMPANY AFTER THE MERGER****Executive Officers and Directors*****Resignation of Nuvelo's Current Executive Officers and Directors***

Pursuant to the merger agreement, it is contemplated that all of Nuvelo's current executive officers except Lee Bendekgey and all of Nuvelo's current directors except Dr. Love, Ms. Pendergast and Dr. Sobel, will resign immediately prior to the completion of the merger. Following the merger, Mr. Bendekgey's position will change from Sr. Vice President, Chief Financial Officer and General Counsel, to Principal Accounting Officer, a non-executive position that he will hold on a transitional basis.

***Executives Officers and Directors of Nuvelo Following the Merger***

Nuvelo's board of directors is currently comprised of six directors and is divided into three classes, with each class serving a staggered three-year term. Prior to the effective time of the merger, the board of directors of Nuvelo will increase to ten members and continue to be classified into three classes, with each class serving staggered three-year terms. In connection with this increase, Nuvelo's bylaws will be amended, in accordance with Article VII of the bylaws, to permit up to ten directors.

Pursuant to the merger agreement, prior to closing, Nuvelo will take such actions as are necessary to have seven of the ten directors be individuals that have been designated by ARCA. It is anticipated that the directors following the merger will be appointed to the three classes of directors as follows:

Dr. Love, Dr. Sobel, Dr. Freytag and Dr. Formela would be in the class of directors whose terms expire at the 2009 annual meeting of stockholders.

Dr. Zabriskie, Dr. Lowe and Dr. Grais would be in the class of directors whose terms expire at the 2010 annual meeting of stockholders.

Ms. Pendergast, Dr. Bristow and Mr. Brewer would be in the class of directors whose terms expire at the 2011 annual meeting of stockholders.

The following table lists the names and ages as of October 31, 2008, and positions of the individuals who are expected to serve as directors and executive officers of Nuvelo upon completion of the merger:

<b>Name</b>	<b>Age</b>	<b>Position</b>
Richard B. Brewer	57	Chief Executive Officer and Director
Michael R. Bristow, M.D., Ph.D.	64	Chairman and Chief Science and Medical Officer
Joseph L. Turner	57	Chief Financial Officer
Christopher D. Ozeroff	49	Executive Vice President of Business Development and General Counsel
Randall St. Laurent	47	Executive Vice President of Commercial Operations
John L. Zabriskie, Ph.D.	69	Director
J. William Freytag, Ph.D.	57	Director
Jean-François Formela, M.D.	52	Director
Ted W. Love, M.D.	49	Director
Mary K. Pendergast	58	Director
Burton E. Sobel, M.D.	71	Director
David G. Lowe, Ph.D.	51	Director
Linda Grais, M.D.	52	Director

*Richard B. Brewer.* Mr. Brewer joined ARCA in November 2006. Prior to joining ARCA, from January 2003 Mr. Brewer was managing partner of Crest Asset Management, where he provided guidance to and invested in biotechnology opportunities. Before that, Mr. Brewer was president

and CEO of Scios, Inc. Before Scios, Brewer served as chief operating officer of Heartport, a cardiovascular device company developing minimally

**Table of Contents**

invasive approaches to major heart surgery. Prior to that, he spent over a decade at Genentech in various management positions, including senior vice president of sales and marketing and senior vice president of Genentech Europe and Canada. Mr. Brewer holds a B.S. from Virginia Polytechnic Institute and an M.B.A. from Northwestern University.

*Michael R. Bristow, M.D., Ph.D.* Dr. Bristow joined ARCA as one of ARCA's founders in September 2004, and served as Chairman and Chief Executive Officer of ARCA until he was appointed to his current position of Chief Science and Medical Officer in November 2006. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen's Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006.

*Joseph L. Turner.* It is anticipated that Mr. Turner will become ARCA's Chief Financial Officer effective January 1, 2009, and will be the combined company's Chief Financial Officer following the completion of the merger. Prior to joining ARCA, Mr. Turner served in various capacities at Myogen, Inc., a publicly held biopharmaceutical company, which was acquired by Gilead Sciences, Inc., or Gilead, in November 2006. From November 2006, to January 2007, Mr. Turner served in a transition capacity at Myogen following Myogen's acquisition by Gilead. Prior to Myogen's acquisition by Gilead, from December 1999 to November 2006, Mr. Turner served initially as Myogen's acting Chief Financial Officer in a part-time capacity, and, from September 2000, as the Chief Financial Officer of Myogen. Mr. Turner also served as Senior Vice President of Finance and Administration of Myogen from December 2003 to November 2006, and as Vice President of Finance and Administration from September 2000 to November 2003. From July 1999 to May 2000 and from January 2007 to the present, Mr. Turner was an independent strategic consultant to emerging and private companies. From November 1997 to June 1999, Mr. Turner worked at Centaur Pharmaceuticals, a biopharmaceutical company, where he served in several positions, including Vice President of Finance and Chief Financial Officer. From March 1992 to October 1997, Mr. Turner served as Vice President, Finance and Chief Financial Officer of Cortech, Inc., a biopharmaceutical company. Previously, Mr. Turner spent 12 years with Eli Lilly and Company, where he held a variety of financial management positions both within the United States and abroad. He currently serves on the Board of Directors of Sequel Pharmaceuticals and Kythera Biopharmaceuticals. Mr. Turner holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, an M.B.A. from the University of North Carolina at Chapel Hill and a B.A. in chemistry from Swarthmore College.

*Christopher D. Ozeroff.* Mr. Ozeroff was a co-founder of ARCA in September 2004 and has been its Executive Vice President of Business Development and General Counsel since that date. From August 1999, Mr. Ozeroff was previously a partner with the law firm of Hogan & Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings and licensing. Mr. Ozeroff completed his undergraduate degree at Stanford University, and his law degree at the University of Chicago Law School.

*Randall St. Laurent.* Mr. St. Laurent joined ARCA in January 2008. From March 2001 until he joined ARCA, Mr. St. Laurent was employed by Scios, a Johnson & Johnson company, first as the vice president of sales and marketing and later as the vice president of commercial development. From September 1999 until March 2001, Mr. St. Laurent was an executive sales director at Transkaryotic Therapies in Cambridge, Massachusetts. Mr. St. Laurent received a B.A. with a major in marketing from the Ohio State University.

*John L. Zabriskie, Ph.D.* Dr. Zabriskie has served as a member of ARCA's board of directors since March 2005. Dr. Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief Executive Officer and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products in July 1997, Dr. Zabriskie was President and Chief Executive Officer of Pharmacia and Upjohn Inc. Prior to joining Upjohn in 1994, Dr. Zabriskie was Executive Vice President for Merck & Co., Inc. He currently serves on the board of directors of Array

---

**Table of Contents**

BioPharma Inc., Kellogg Co. and Protein Forest Inc. Dr. Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his Ph.D. in organic chemistry from the University of Rochester.

*J. William Freytag, Ph.D.* Dr. Freytag has served as a member of ARCA's board of directors since March 2007. Dr. Freytag served as President and CEO of Aspreva Pharmaceuticals from July 2007 until January 2008. From July 1998 until November 2006, Dr. Freytag was President, Chief Executive Officer and Chairman of the board of directors of Myogen, Inc. From October 1994 to May 1998, Dr. Freytag was a Senior Vice President at Somatogen, Inc., a biopharmaceutical company, where he was responsible for corporate and commercial development. Prior to Somatogen, he was President of Research and Development at Boehringer Mannheim Corporation, an international healthcare company, from May 1990 to September 1994. Previously, Dr. Freytag spent 10 years with DuPont in various research and business positions in the Medical Products Department. Dr. Freytag is a member of the board of directors of Immunicon Corporation. Dr. Freytag received a B.S. from Purdue University and a Ph.D. in biochemistry from the University of Kansas Medical Center.

*Jean-François Formela.* Dr. Formela has served as a member of ARCA's board of directors since February 2006. Dr. Formela is a Partner and joined Atlas Venture in 1993 to help build the US Life Sciences franchise. Previously, he was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the U.S. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, Dr. Formela directed the US Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University Hospital in Paris. Since joining Atlas Venture, Jean-François has been involved in the formation of companies such as Archemix, ArQule, Aureon Laboratories, Cellzome, deCODE, Exelixis, MorphoSys, NxStage, Resolvix Pharmaceuticals and SGX Pharmaceuticals. He was also an investor in CIPHERGEN Biosystems and Nuvelo. Dr. Formela received his M.D. from Paris University School of Medicine, and his M.B.A. from Columbia University.

*Ted W. Love, M.D.* Dr. Love served as Nuvelo's president since January 2001, as its chief executive officer since March 2001, as a member of its board of directors since February 2001 and as chairman of its board of directors since September 2005. Dr. Love served as Nuvelo's president and chief operating officer from January 2001 until March 2001. Prior to joining Nuvelo, Dr. Love served as senior vice president of development at Theravance Inc. from 1998 to 2001 and as a research physician and vice president of product development at Genentech from 1992 to 1998. Dr. Love also serves as a member of the board of directors of Santarus, Inc., and Affymax, Inc. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

*Mary K. Pendergast.* Ms. Pendergast has served as a member of Nuvelo's board of directors since May 2002. Since September 2003, Ms. Pendergast has been president of Pendergast Consulting. Ms. Pendergast served as executive vice president, government affairs for Elan Corporation from 1998 to December 2003. Ms. Pendergast was deputy commissioner and senior advisor to the Commissioner, Food and Drug Administration, Department of Health and Human Services from 1990 to 1998. Ms. Pendergast received her LL.M. from Yale Law School in 1977, her J.D. from the University of Iowa College of Law in 1976 and her B.A. from Northwestern University in 1972.

---

## **Table of Contents**

*Burton E. Sobel, M.D.* Dr. Sobel has served as a member of Nuvelo's board of directors since September 2004. Since June 2005, Dr. Sobel has served as professor of medicine and biochemistry at the University of Vermont and Fletcher Allen Health Care, where he formerly served as chair of the department of medicine from 1994 to June 2005. Dr. Sobel served as senior counsel to the executive dean of the University of Vermont College of Medicine and to the executive vice president of Fletcher Allen Health Care from 1996 to 1998. From 1994 to 1996, Dr. Sobel served as professor of medicine at Washington University in St. Louis, Missouri. Dr. Sobel serves as a member of the board of directors of Ariad Pharmaceuticals, Inc. and Clinical Data, Inc. Dr. Sobel received his M.D. from the Harvard Medical School, magna cum laude, and his A.B. from Cornell University.

*David G. Lowe, Ph.D.* Dr. Lowe has served as a member of ARCA's board of directors since May 2007. Dr. Lowe is a Managing Director of and joined Skyline Ventures in June 2002. Dr. Lowe is a molecular biologist and was Director of Cardiovascular Research at Genentech, Inc., where he worked for 16 years until November 2001. Dr. Lowe also serves as a director of Applied Genetic Technologies Corp. Dr. Lowe holds a Ph.D. in biochemistry from the University of Toronto, Canada.

*Linda Grais, M.D.* Dr. Grais has served as a member of ARCA's board of directors since May 2007. She is currently a partner at InterWest, where she has been since May 2005. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School.

### ***Director Independence***

Under applicable Nasdaq rules, a director will only qualify as an independent director if, in the determination of Nuvelo's board of directors, that person does not have a relationship which would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Of the six current members of the of Nuvelo board of directors, five have been determined to be independent within the meaning of the applicable Nasdaq rules.

In connection with the consummation of the merger, the incumbent directors of the Nuvelo's board of directors will amend the bylaws of Nuvelo and take necessary action to fix the size of the Nuvelo board at ten directors. James R. Gavin, Mark L. Perry and Kimberly Popovits will tender their resignations effective as of the effective time of the merger and the incumbent board of Nuvelo will appoint Richard B. Brewer, Michael R. Bristow, Jean-François Formela, J. William Freytag, Linda Grais, David G. Lowe and John L. Zabriskie to fill the vacancies created by such resignations and the increase to the size of Nuvelo's board. Prior to appointing these individuals to Nuvelo's board of directors, and before the effectiveness of the resignations of James R. Gavin, Mark L. Perry and Kimberly Popovits, the incumbent directors will determine whether the directors to be appointed to such vacancies are independent as defined under the applicable Nasdaq rules. Additionally, the incumbent directors of Nuvelo will determine whether those individuals meet the additional independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934. Finally, the incumbent directors of Nuvelo will determine whether all of the members of each of the board of directors three standing committees will be independent as defined under the applicable Nasdaq rules.

### **Committees of the Board of Directors**

The board of directors of the combined company will have three standing committees: the compensation committee, the audit committee and the nominating and corporate governance committee.

## **Table of Contents**

### ***Compensation Committee***

The combined company's compensation committee's responsibilities will include: reviewing and approving the company's goals and objectives relevant to the compensation of executive officers and other senior management; setting compensation and bonus levels for the company's executive officers that correspond to the company's goals and objectives; reviewing and making recommendations to its board of directors regarding the company's compensation policies, programs, practices, and procedures designed to contribute to the company's success, in accordance with its charter; evaluating the company's goals and objectives related to the compensation of its chief executive officer and his performance in light of such goals and objectives and setting the chief executive officer's compensation level and bonus based on this evaluation; reviewing with management the compensation discussion and analysis included in the company's proxy statements for its annual meetings of stockholders and considering whether to recommend its inclusion in such proxy statements and other filings; administering the company's stock and equity incentive plans.

Following completion of the merger, Dr. Freytag, as the chairperson, Dr. Formela and Dr. Grais will serve on the compensation committee.

### ***Audit Committee***

The combined company's audit committee's responsibilities will include: selecting, evaluating, and where necessary, replacing the independent registered public accounting firm retained by the company; consulting with the company's independent registered public accounting firm regarding their audit, their opinion, and the company's Forms 10-Q and 10-K; approving the audit and non-audit services of the company's independent registered public accounting firm and the terms of their engagement; meeting with the company's management; reviewing both the independent registered public accounting firm and management reports; recommending changes in financial policies and procedures that may be suggested by the company's independent registered public accounting firm; and preparing the audit committee report included in the company's proxy statements for its annual meetings of stockholders.

Following completion of the merger Dr. Zabriskie, as the chairperson, Dr. Lowe and Dr. Sobel will serve on the audit committee. It is expected that the board of the combined company will determine at least Dr. Zabriskie is an audit committee financial expert as defined in Item 401(h) of Regulation S-K.

### ***Nominating and Corporate Governance Committee***

The responsibilities of the nominating and corporate governance committee of the combined company will include: considering the qualifications of, proposing, and recommending individuals for board membership and senior management positions; making recommendations to the board of directors regarding the company's corporate governance policies, business conduct, and ethics; evaluating the size and composition of the board of directors and its committees; and reviewing the annual performance of the board of directors.

Following completion of the merger, Ms. Pendergast, as the chairperson, Dr. Sobel and Dr. Grais will serve on the nominating and corporate governance committee.

### ***Compensation of Directors***

Nuvelo has not yet determined whether the compensation for the directors of the combined company will remain the same as that for Nuvelo directors currently.

---

**Table of Contents**

**EXECUTIVE COMPENSATION AND OTHER INFORMATION**

The following compensation discussion and analysis sections provide information regarding the compensation, compensation philosophy, and objectives for each of ARCA and Nuvelo as standalone entities in relation to the individuals who served as the principal executive officer, the principal financial officer or one of the three most highly paid executive officers as of December 31, 2007 of Nuvelo or ARCA and who are expected to serve as executive officers following consummation of the merger. These individuals are referred to as the named executive officers in the compensation discussion and analysis sections below and the tables that follow.

Following completion of the merger, it is expected that Richard B. Brewer, Dr. Michael R. Bristow, Joseph L. Turner, Christopher D. Ozeroff and Randall St. Laurent will be the executive officers of the combined company. Each of these executive officers, except Mr. Turner, is currently an executive officer of ARCA. Mr. Turner is expected to become the Chief Financial Officer of ARCA prior to the closing of the proposed merger, but as of the date of this proxy statement/prospectus/consent solicitation, has not commenced employment with ARCA. Additional executive officers of the combined company are expected to be identified and appointed following the merger. The discussion and analysis below titled "ARCA's Compensation Discussion and Analysis" applies to Mr. Brewer, Dr. Bristow and Mr. Ozeroff. Mr. St. Laurent joined ARCA during 2008, so his compensation is not discussed below.

**ARCA's Compensation Discussion and Analysis**

***Overview of Executive Compensation Program***

The compensation committee of the ARCA board of directors has responsibility for establishing, implementing and monitoring ARCA's executive compensation program philosophy and practices. During fiscal year 2007, Dr. Bullock, Dr. Grais and Dr. Formela were the members of ARCA's compensation committee. The compensation committee seeks to ensure that the total compensation paid to ARCA's named executive officers is fair, reasonable and competitive. Generally, the types of compensation and benefits provided to the named executive officers are similar to those provided to ARCA's other officers. The board of directors has also established an award committee comprised of members of the compensation committee and delegated to this committee the authority to approve and authorize grants under ARCA's 2004 Stock Incentive Plan, or the ARCA Plan.

***Compensation Philosophy and Objectives***

The components of ARCA's executive compensation consist of salary, annual performance-based cash bonuses based on the achievement of company goals established by the compensation committee, discretionary cash bonuses awarded from time to time based on the compensation committee's subjective assessment of each individual executive's job performance during the past year, and grants of restricted stock and/or stock options to provide executives with longer-term incentives.

ARCA's compensation committee believes that an effective executive compensation program should provide base annual compensation that is reasonable in relation to the individual executive's job responsibilities and reward the achievement of both annual and long-term strategic goals of ARCA. The compensation committee uses annual cash bonuses to reward an officer's achievement of specific goals and employee stock options as a retention tool and as a means to align the executive's long-term interests with those of ARCA's stockholders, with the ultimate objective of improving stockholder value. ARCA's compensation committee has also used grants of restricted stock as a means to provide incentives to executive officers to achieve longer-term key strategic objectives of the company. ARCA's compensation committee evaluates both performance and compensation to maintain ARCA's ability to attract and retain excellent employees in key positions and to assure that compensation provided to key employees remains competitive relative to the compensation paid to similarly situated executives of comparable companies. To that end, ARCA's compensation committee believes executive

## **Table of Contents**

compensation packages provided by ARCA to the named executive officers should include both cash compensation and equity.

Because of ARCA's size, the small number of executive officers, and ARCA's financial priorities, the compensation committee has decided not to implement or offer any pension benefits, deferred compensation plans, or similar plans for ARCA's named executive officers.

As a biopharmaceutical company engaged in developing potential products that, to date, have not generated any revenues and are not expected to generate significant revenues or profits for several years, the compensation committee also takes ARCA's financial and working capital condition into account in its compensation decisions.

### ***Role of Executive Officers in Compensation Decisions***

ARCA's compensation committee makes all compensation decisions for ARCA's named executive officers and approves recommendations regarding equity awards to all of ARCA's officers. Decisions regarding the non-equity compensation of ARCA's other officers are made by ARCA's president and chief executive officer.

ARCA's compensation committee and the president and chief executive officer annually review the performance of each named executive officer (other than the president and chief executive officer, whose performance is reviewed only by the compensation committee and other non-management directors). The conclusions reached and recommendations based on these reviews, including with respect to salary adjustments and annual award amounts, are presented to the compensation committee. ARCA's compensation committee can exercise its discretion in modifying any recommended adjustments or awards to executives.

### ***Setting Executive Compensation***

Based on the foregoing objectives, the compensation and award committees have structured ARCA's annual cash and incentive-based cash and non-cash executive compensation to seek to motivate the named executive officers to achieve the business goals set by ARCA's management and board of directors, to reward the executives for achieving these goals and to retain and attract top executive talent. For fiscal year 2008, ARCA has retained Radford Consulting and Surveys, a division of Aon Corporation, or Radford, independent compensation consultants, to evaluate and provide recommendations on the compensation for ARCA's executive officers.

### ***2007 Executive Compensation Components***

For 2007, the principal components of compensation for ARCA's named executive officers were base salary, annual performance bonuses and equity incentive compensation.

#### ***Base Salary***

ARCA provides its named executive officers and other employees with base salary to compensate them for services rendered during the year. Base salary ranges for ARCA's named executive officers are determined for each named executive officer based on his position and responsibility. During its review of base salaries for ARCA's executives, ARCA's compensation committee primarily considers:

the negotiated terms of each executive's employment agreement, to the extent that one exists;

internal review of the executive's compensation, both individually and relative to other named executive officers; and

individual performance of the executive.

In February 2008, ARCA's board of directors and compensation committee completed a review of ARCA executive compensation in light of general market conditions in the life science industry. The compensation





---

**Table of Contents**

committee concluded that the competition for executive talent remained strong as a result of the solid economic performance of the industry, the continued high level of investment by venture capital firms in the new and existing life science companies and the specialized skills and experiences required to manage life science companies. The compensation committee's assessment of general market conditions in the life science industry was based on the experience of the committee members who were and are actively involved in venture capital investing, and Radford and other survey data in making its base salary assessments. In light of its considerations, the compensation committee recommended and the board of directors approved increases to base salary of 3.8% for Mr. Brewer to \$311,400, 3.8% for Dr. Bristow to \$259,500, and 3.8% for Mr. Ozeroff to \$228,360. The increased base salaries became effective in March 2008.

*Annual and Special Bonuses*

In February 2007, ARCA's compensation committee and the board of directors established a bonus structure for the entire ARCA executive team, including all of ARCA's named executive officers. The philosophy employed was to create incentives for the executive officers to achieve key corporate goals. The compensation committee set a potential bonus target of 50% of base salary for Mr. Brewer and Dr. Bristow and 30% of base salary for Mr. Ozeroff. The compensation committee retained discretion to change the bonus structure and the bonus payment amounts as it considered appropriate. The compensation committee and board of directors agreed to nine equally weighted goals. The compensation committee believed attaining these goals would take a high level of executive performance, particularly as they related to the submission of the Gencaro NDA. These nine goals included:

execution of an agreement with LabCorp with respect to the development of the Gencaro companion genetic test;

securing manufacturing arrangements for the API for Gencaro and tablet formulation of the drug;

submission of the clinical portion of the NDA for Gencaro;

in-license of a second product candidate;

execution of a partnership for a sustained release development for Gencaro;

cost management initiatives;

organizational development, key hires and growth initiatives;

execution of a commercial partnership for Gencaro; and

submission of the chemistry, manufacturing and controls section of the NDA for Gencaro.

In March 2008, performance bonuses for 2007 were paid. At that time, the compensation committee and board of directors concluded that the 2007 corporate goals described above had been met at the 65% level, and each executive officer therefore received a bonus based on corporate goal achievement equal to his respective bonus percentage level multiplied by his base salary and adjusted pursuant to the compensation committee's discretion to account for its assessment of each named executive officer's individual performance. Cash bonuses paid to ARCA's named executive officers were \$97,500 for Mr. Brewer, \$81,250 for Dr. Bristow, and \$35,750 for Mr. Ozeroff.

For incentive bonuses tied to 2008 performance, the compensation committee and board of directors have approved a similar bonus structure as they approved for 2007. All company executives remain at their respective bonus target levels. For 2008, the board of directors, with the participation of the compensation committee and members of management, formulated 12 equally weighted corporate performance goals that

## Edgar Filing: NUVELO INC - Form S-4/A

were consistent with the maturation of the Gencaro development program, financing activities, and pre-commercialization activities planned by ARCA. These goals were related to the submission and acceptance of the Gencaro NDA with the

**Table of Contents**

FDA, obtaining financing and pre-commercialization activities. The ARCA board of directors believes that these goals are attainable with a very high level of executive performance and that such goals will be challenging to achieve. The 12 goals included:

submission of the NDA for Gencaro s adequate for FDA filing and approval;

submission by LabCorp of a genetic test application associated with the FDA s review of the NDA for Gencaro to the FDA, sufficient for approval;

securing financing sufficient to fund ARCA through Gencaro s anticipated launch in 2009;

development of the Gencaro commercial plan;

securing the manufacturing, tableting and packaging arrangements adequate for the anticipated commercial launch of Gencaro;

key opinion leader identification and recruitment;

investor relations and public relations development and execution;

relocation of ARCA to new Colorado offices;

design and implementation of the bucindolol genetic registry;

implementation of the Gencaro reimbursement plan;

preparation for a possible cardio-renal advisory committee meeting for Gencaro Test; and

sales force and field force hiring and deployment.

*Equity Incentive Compensation*

ARCA s compensation committee considered the equity ownership of the executive officers and, based upon the committee members experience investing in and serving on the boards of similar life sciences companies, and upon the executive officers ownership percentages in ARCA, the compensation committee did not approve any additional grants to ARCA s named executive officers in 2007.

*Retirement Plans, Perquisites and Other Personal Benefits*

ARCA has adopted a tax-qualified employee savings and retirement plan, the 401(k) Plan, for eligible employees, including ARCA s named executive officers. Eligible employees may elect to defer a percentage of their eligible compensation in the 401(k) Plan, subject to the statutorily prescribed annual limit. ARCA has elected to make safe harbor matching contributions on behalf of all participants in the 401(k) Plan in accordance with statutory requirements. Participants are fully vested in all matching contributions. During fiscal 2007, ARCA s matching

## Edgar Filing: NUVELO INC - Form S-4/A

contributions were equal to 100% of each employee's first 3% of pretax deferrals and 50% of each employee's next 2% of pretax deferrals. ARCA intends the 401(k) Plan, and the accompanying trust, to qualify under Sections 401(k) and 501 of the Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that ARCA will be able to deduct its contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, may invest the assets of the 401(k) Plan in any of a number of investment options.

ARCA's executive officers are eligible to participate in all ARCA employee benefit plans, such as medical, dental, vision, group life, disability and accidental death and dismemberment insurance, in each case on the same basis as other employees, subject to applicable law. ARCA also provides vacation and other paid holidays to all employees, including executive officers, which ARCA believes are comparable to those provided at peer companies. ARCA does not provide any of Messrs. Brewer, Bristow and Ozeroff with any other perquisites or personal benefits.

---

## **Table of Contents**

### ***Equity Compensation; Ownership Guidelines***

ARCA's long-term incentive compensation consists solely of periodic grants of stock options to the named executive officers. The stock option program is intended to:

link the creation of stockholder value with executive compensation;

provide increased equity ownership by executives;

function as a retention tool, because participants must remain employed by ARCA as a condition to the vesting of options granted by the compensation and award committees; and

maintain competitive levels of total compensation.

ARCA's compensation and award committees may grant stock options to new executive officers when they join ARCA based on their position with ARCA and their relevant prior experience. Options generally vest over four years. Prior to the exercise of an option, the holder has no rights as a stockholder with respect to the shares subject to such option, including voting rights and the right to receive dividends or dividend equivalents.

In addition to the stock option grant, certain executives have been issued restricted stock upon payment by the executive of a price equal to the fair market value of the stock on the date of issuance. The restricted stock is subject to repurchase by ARCA for any unvested portion. To date, only Mr. Brewer has been granted an award of restricted stock and his grant will vest in full upon the closing of the merger.

On an annual basis, ARCA's compensation committee assesses the appropriate individual and corporate goals for its executive officers and may provide additional option grants based upon the achievement by the executive officers of both individual and corporate goals. The compensation committee expects that it will continue to provide new employees with initial option grants in the future to provide long-term compensation incentives and will continue to rely on performance-based and retention grants to provide additional incentives for current employees. Additionally, in the future, the compensation committee may again consider awarding additional or alternative forms of equity incentives, such as grants of restricted stock, restricted stock units and other performance-based awards. ARCA's compensation committee has no requirement that any of its executive officers maintain a minimum ownership interest in ARCA.

### ***Tax and Accounting Implications***

#### ***Deductibility of Executive Compensation***

As part of its role, ARCA's compensation committee reviews and considers the deductibility of executive compensation under Section 162(m) of the Internal Revenue Code, which provides that corporations may not deduct compensation, excluding certain performance-based compensation, of more than \$1,000,000 that is paid to certain individuals. ARCA's compensation committee believes that compensation paid to ARCA executive officers generally is fully deductible for federal income tax purposes.

#### ***Accounting for Share-Based Compensation***

ARCA accounts for share-based compensation in accordance with the requirements of FASB Statement 123(R), *Share-Based Payment*. See Note 1(n) to ARCA's financial statements included in this proxy statement/prospectus/consent solicitation. Although this accounting treatment is one of the factors ARCA's compensation committee considers in awarding options, it has not had a significant impact on its granting practices, since ARCA's compensation committee believes stock options remain a highly valued component of the overall compensation package for management of a growth company such as ARCA and are the primary means by which executive officers share in the company's growth.



**Table of Contents****Compensation Committee Interlocks and Insider Participation in Compensation Decisions**

The compensation committee of the combined company is expected to consist of Dr. Freytag, as the chairperson, Dr. Formela and Dr. Grais. None of Dr. Freytag, Dr. Formela or Dr. Grais (i) was formerly an officer or employee of either Nuvelo or ARCA, (ii) was formerly an officer of either Nuvelo or ARCA, nor any of Nuvelo or ARCA's subsidiaries, or (iii) engaged in any related transactions as defined in Item 404(a) of Regulation S-K except as otherwise disclosed in this proxy statement/prospectus/consent solicitation in the section entitled "Related Party Transactions Involving Directors and Executive Officers Following The Merger." During the fiscal year ended December 31, 2007, none of the individuals that will serve as an executive officer of the combined company served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on Nuvelo's or ARCA's board of directors or compensation committee.

**Summary Compensation Table**

The following table presents summary information concerning all compensation paid to or earned by Mr. Brewer, Dr. Bristow and Mr. Ozeroff for services rendered to ARCA in all capacities during the fiscal year ended December 31, 2007. These individuals are referred to below collectively as the named executive officers. The named executive officers are the only individuals who served as the principal executive officer, principal financial officer or one of the next three most highly compensated executive officers of ARCA as of December 31, 2007 and who will also continue to serve in similar capacities at Nuvelo following the merger. Mr. Turner is expected to become the Chief Financial Officer of ARCA prior to the closing of the proposed merger, but as of the date of this proxy statement/prospectus/consent solicitation has not commenced employment with ARCA, and is therefore not included among the named executive officers referred to below.

**Summary Compensation Table**

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Option Awards (\$)(1)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
Richard B. Brewer	2007	300,000		22,832	97,500(2)	37,250(3)	457,582
ARCA President and Chief Executive Officer							
Michael R. Bristow, M.D., Ph.D.	2007	250,000	150,000		81,250(2)	9,000(4)	490,250
ARCA Chief Science and Medical Officer							
Christopher D. Ozeroff	2007	220,000			35,750(2)	4,806(4)	260,556
ARCA Executive Vice President of Business Development and General Counsel							

- (1) The amounts set forth in this column represent the share-based compensation expense recognized in fiscal 2007 and 2006 for financial reporting purposes under Statement of Financial Accounting Standards No. 123(R), "Share-Based Payment," excluding any estimate of forfeitures related to service-based vesting conditions. The methodology, including underlying estimates and assumptions used in calculating these values with respect to Mr. Brewer, is set forth in Note 1(n) to ARCA's audited financial statements included elsewhere in this proxy statement/prospectus/consent solicitation.
- (2) These amounts consist of the actual cash bonuses awarded to the named executive officers under the ARCA performance bonus program described above under "ARCA's Compensation Discussion and Analysis." These bonuses were earned in fiscal year 2007 and were paid in March 2008.
- (3) This amount represents the value of 250,000 shares of common stock issued to Mr. Brewer in consideration for prior services pursuant to a Restricted Stock Agreement dated November 2, 2006, as amended.



(4) These amounts consist of matching contributions made by ARCA under ARCA's 401(k) Plan.

**Table of Contents****Grants of Plan-Based Awards**

The following table shows information concerning estimated payouts under non-equity incentive plan awards and the grant of equity awards to the named executive officers in the fiscal year ended December 31, 2007. In 2007, ARCA did not make any grants of stock options or restricted stock to any named executive officers.

Name	Grant Date	Approval Date	Threshold (\$)	Estimated Possible Payouts Under Non-Equity Incentive Plan Awards		All Other Option Awards: Number of Securities Underlying Options (#)	Exercise of Base Price of Option Awards (\$/Sh)	Grant Date Fair Value of Stock and Option Awards (\$)
				Target (\$)	Maximum (\$)			
Richard B. Brewer				150,000(1)				
Michael R. Bristow, M.D., Ph.D.				125,000(1)				
Christopher D. Ozeroff				66,000(1)				

- (1) These amounts reflect the amount of cash bonus payable to the named executive officers under the ARCA performance bonus program described above under ARCA's Compensation Discussion and Analysis if all of the fiscal 2007 corporate and individual goals were met. The Summary Compensation Table above reflects the actual amounts paid to these individuals under the performance bonus program for fiscal 2007.

**Holdings of Previously Awarded Equity**

The following table sets forth outstanding equity awards held by the named executive officers as of December 31, 2007, each of which were awarded under the ARCA Plan.

**2007 Outstanding Equity Awards at Fiscal Year-End**

Name	Option Awards(1)				Stock Awards	
	Number of Securities Underlying Unexercised Options (#)		Option Exercise Price (\$)	Option Expiration Date	Number of Shares of Stock That Have Not Vested (#)	Market Value of Shares of Stock That Have Not Vested (\$)
Exercisable	Unexercisable					
Richard B. Brewer	992,000(2)		0.15	11/02/2016	500,000(5)	155,000(5)
Michael R. Bristow, M.D., Ph.D.	531,435(3)	177,145	0.01	01/03/2015		
Christopher D. Ozeroff	294,750(4)	98,250	0.01	01/03/2015		

- (1) References to options or shares held by all other executive officers in the table refer to options or shares of ARCA.
- (2) These options vested immediately, subject to ARCA's right of repurchase, which lapses at the rate of 6.25% of the shares subject to the option at the end of each three-month period following the first anniversary of the November 2, 2006 grant date. Of these options, as of December 31, 2007, 744,000 were subject to a right of repurchase in favor of ARCA.
- (3) These stock options were granted on January 3, 2005, and vest (i) with respect to 25% of the shares subject to the options, on October 18, 2005, and (ii) with respect to the remaining shares subject to the options, at the rate of 6.25% of such shares at the end of each three-month

period thereafter.

- (4) These stock options were granted on January 3, 2005, and vest (i) with respect to 25% of the shares subject to the options, on October 18, 2005, and (ii) with respect to the remaining shares subject to the options, at the rate of 6.25% of such shares at the end of each three-month period thereafter.
- (5) All shares are scheduled to vest upon the closing of the merger. The market value of the shares is based on the \$0.31 per share fair value of ARCA's common stock as of December 31, 2007 as determined by the ARCA board of directors.

**Table of Contents**

**Option Exercises and Stock Vested**

No stock options were exercised and no shares of restricted stock held by any of the named executive officers vested during fiscal 2007.

**Employment Agreements and Potential Payment Upon Termination or Change of Control**

***Richard B. Brewer Employment and Retention Agreement; Stock Option Agreements; Restricted Stock Agreement***

Mr. Brewer is employed as ARCA's president and chief executive officer under an Employment and Retention Agreement dated November 2, 2006 that was amended and restated as of July 7, 2008. Under his employment agreement, Mr. Brewer is entitled to receive an annual base salary of \$300,000, subject to annual increases if approved by the ARCA board of directors (or ARCA's compensation committee) and is eligible to receive an annual bonus as determined by the board of directors (or ARCA's compensation committee) in its sole discretion. Mr. Brewer is permitted to serve on a maximum of four outside corporate board of directors, so long as it does not interfere with his duties as president and chief executive officer of ARCA.

If ARCA terminates Mr. Brewer's employment without cause, or if Mr. Brewer terminates his employment with good reason (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr. Brewer a severance payment equivalent to (i) 12 months of his base salary and (ii) a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that the incentive bonus would have been paid had the termination not occurred. ARCA may elect to pay Mr. Brewer additional severance equal to up to 12 months of his base salary, which additional payments would extend Mr. Brewer's obligations under his Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. Severance payments may be made by ARCA on a monthly basis or, at ARCA's election, in a lump sum. The severance payment is conditioned on the execution by Mr. Brewer of a legal release in a form acceptable to ARCA. A termination for cause includes willful misconduct, gross negligence, theft, fraud or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure or inability to perform material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other agreement, with ARCA. Good reason includes a decrease in current base salary, with certain exceptions; change in title or reporting relationship; failure of the ARCA stockholders to elect Mr. Brewer to the board of directors; a move of the ARCA headquarters to a location greater than 60 miles from Denver, Colorado; resignation within 90 days of a corporate transaction; or ARCA's unilateral decision to significantly and detrimentally reduce Mr. Brewer's job responsibilities.

In connection with the execution of his employment agreement, in November 2006, Mr. Brewer was granted the option to purchase 992,000 shares of ARCA's common stock pursuant to a Stock Option Agreement between ARCA and Mr. Brewer and the other terms and conditions of the ARCA 2004 Stock Incentive Plan. The options were exercisable immediately, subject to ARCA's right to repurchase any shares that have been exercised at the exercise price upon a voluntarily resignation by Mr. Brewer, his termination for cause or upon his death or disability. ARCA's right of repurchase lapses at the rate of 6.25% at the end of each quarter following the first anniversary of the grant date. In addition, ARCA's right of repurchase lapses in full upon the earlier of a corporate transaction (as defined in his employment agreement) or upon a termination other than for cause or by Mr. Brewer for good reason. The closing of the merger will not result in the acceleration in the rate at which ARCA's right of repurchase lapses with respect to these options.

In addition to the options, Mr. Brewer was issued 500,000 shares of restricted stock pursuant to a Restricted Stock Agreement dated November 2, 2006 that was amended on February 19, 2007. Mr. Brewer paid \$37,750 for 250,000 of the shares and received the remaining shares in consideration for prior services. The amount

---

**Table of Contents**

Mr. Brewer paid for the shares was equal to the fair market value of the stock on the date of issuance. Under his Restricted Stock Agreement, the shares are unvested and subject to ARCA's repurchase right at the purchase price until the earlier to occur of the listing of ARCA's common stock on a national securities exchange or a change in control. In October 2008, Mr. Brewer's Restricted Stock Agreement was amended to provide that the shares of restricted stock will vest in full upon the closing of the merger. As of October 31, 2008, no shares of restricted stock had vested.

***Michael R. Bristow, M.D., Ph.D. Employment and Retention Agreement; Stock Option Agreement***

Michael R. Bristow, M.D., Ph.D. serves as ARCA's chief science and medical officer under an Employment and Retention Agreement that was amended and restated as of June 4, 2008. Dr. Bristow is permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it does not interfere with his duties as chairman and chief science and medical officer.

Under his employment agreement, Dr. Bristow is entitled to receive an annual base salary of \$200,000, subject to annual increases if approved by the ARCA board of directors (or ARCA's compensation committee) and is eligible to receive an annual bonus as determined by the board of directors (or ARCA's compensation committee) in its sole discretion.

If ARCA terminates Dr. Bristow's employment without cause, or if Dr. Bristow terminates his employment with good reason (as these terms are defined in his employment agreement), ARCA has agreed to pay Dr. Bristow a severance payment equivalent to (i) 12 months of his base salary, (ii) a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii) reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 12 months, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition ARCA may elect in its sole discretion, to pay additional severance equal to up to 12 months base salary, which additional payment would extend the covenants and obligations under Dr. Bristow's Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Dr. Bristow of a legal release in a form acceptable to ARCA. A termination for cause includes willful misconduct, gross negligence, theft, fraud or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure or inability to perform material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other agreement, with ARCA. Good reason includes a relocation of normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA's unilateral decision to significantly and detrimentally reduce Dr. Bristow's job responsibilities.

In January 2005 Dr. Bristow was granted an option to purchase 708,850 shares of ARCA's common stock pursuant to a Stock Option Agreement between ARCA and Dr. Bristow and the other terms and conditions of the ARCA 2004 Stock Incentive Plan. Twenty-five percent of the shares issuable upon exercise of the option vested on October 18, 2005 and 6.25% of the shares issuable upon exercise vest at the end of each three-month period thereafter. If a change of control of ARCA occurs prior to expiration of the option and at a time when Dr. Bristow remains in service, 50% of the unvested option shares vest and become immediately exercisable and any remaining options continue to vest in accordance with the vesting schedule set forth above, provided, however, that on the earlier of (i) the one year anniversary of the closing date of any change of control and (ii) the date Dr. Bristow's employment is terminated by ARCA without cause or by Dr. Bristow for good reason within 12 months of a change of control of ARCA, any shares that remain unvested vest and become immediately exercisable. The closing of the merger will not result in the acceleration of any stock options held by Dr. Bristow.

---

**Table of Contents*****Christopher D. Ozeroff Employment and Retention Agreement; Stock Option Agreement***

Christopher D. Ozeroff is employed as the executive vice president of business development and general counsel pursuant to an employment agreement amended and restated as of June 12, 2008. Under his employment agreement, Mr. Ozeroff is entitled to receive an annual base salary of \$200,000, subject to annual increases if approved by the ARCA board of directors (or ARCA's compensation committee) and is eligible to receive an annual bonus as determined by the ARCA board of directors (or ARCA's compensation committee) in its sole discretion.

If ARCA terminates Mr. Ozeroff's employment without cause, or if Mr. Ozeroff terminates his employment with good reason (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr. Ozeroff a severance payment equivalent to (i) 12 months of his base salary, (ii) a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii) reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 12 months, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition ARCA may elect in its sole discretion, to pay additional severance equal to up to 12 months base salary, which additional payment would extend the covenants and obligations under Mr. Ozeroff's Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Mr. Ozeroff of a legal release in a form acceptable to ARCA. A termination for cause includes willful misconduct, gross negligence, theft, fraud or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure or inability to perform material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other agreement, with ARCA. Good reason includes a relocation of normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA's unilateral decision to significantly and detrimentally reduce Mr. Ozeroff's job responsibilities.

In January 2005 Mr. Ozeroff was granted an option to purchase 393,000 shares of ARCA's common stock pursuant to a Stock Option Agreement between ARCA and Mr. Ozeroff and the other terms and conditions of the ARCA 2004 Stock Incentive Plan. Twenty-five percent of the shares issuable upon exercise of the option vested on October 18, 2005 and 6.25% of the shares issuable upon exercise vest at the end of each three-month period thereafter. If a change of control of ARCA occurs prior to expiration of the option and at a time when Mr. Ozeroff remains in service, 50% of the unvested option shares vest and become immediately exercisable and any remaining options shall continue to vest in accordance with the vesting schedule set forth above, provided, however, that on the earlier of (i) the one year anniversary of the closing date of any change of control and (ii) the date Mr. Ozeroff's employment is terminated by ARCA without cause or by Mr. Ozeroff for good reason within 12 months of a change of control of ARCA, any shares that remain unvested vest and become immediately exercisable. The closing of the merger will not result in the acceleration of any stock options held by Mr. Ozeroff.

**Quantification of Termination Payments and Benefits**

ARCA has entered into employment agreements, stock option agreements and/or restricted stock agreements with each of its named executive officers that provide for certain payments and acceleration and continuation of benefits upon specified terminations of employment or upon a change in control of ARCA. The post-termination arrangements under these agreements are described above under Employment Agreements and Potential Payment Upon Termination or Change of Control .

**Table of Contents**

The following table reflects the estimated potential payments upon certain terminations of employment or a change in control that would be payable to each of the named executive officers who were employed on December 31, 2007. For purposes of calculating the potential payments set forth in the tables below, ARCA has assumed that (i) the date of termination or change in control was December 31, 2007 and (ii) the value of each share subject to a stock option or a restricted stock grant that would be accelerated, or for which ARCA's right of repurchase lapses, in the circumstances set forth in the table below equals \$0.31, which represents the fair value of ARCA's common stock as of December 31, 2007 as determined by ARCA's board of directors.

Except as noted in the footnotes following the table, the closing of the merger will not result in the payment or acceleration of any benefits to the named executive officers. The terms "cause", "good reason", "disability" and "corporate transaction" in the table and the footnotes below are as defined in the applicable agreement.

Name	Termination Without Cause	Resignation for Good Reason	Death or Disability	Corporate Transaction	
				Termination Without Cause or Resignation for Good Reason	No Termination
<b>Richard B. Brewer</b>					
Cash severance under Employment and Retention Agreement dated November 2, 2006	\$ 397,500(1)	\$ 397,500(1)		\$ 397,500(1)	
Lapse of ARCA Repurchase Right under Incentive Stock Option Agreement dated November 2, 2006	119,040(2)	119,040(2)		119,040(2)	\$ 119,040(2)
Lapse of ARCA Repurchase Right under Restricted Stock Agreement dated November 2, 2006, as amended				80,000(3)	80,000(3)
<b>Michael R. Bristow, M.D., Ph.D.</b>					
Cash severance under Employment and Retention Agreement dated January 3, 2005	331,250(4)	331,250(4)			
Acceleration of vesting under Incentive Stock Option Agreement dated January 3, 2005				53,146(5)	26,572(5)
<b>Christopher D. Ozeroff</b>					
Cash severance under Employment and Retention Agreement dated January 3, 2005	257,750(4)	257,750(4)			
Acceleration of vesting under Incentive Stock Option Agreement dated January 3, 2005				29,475(5)	14,738(5)

- (1) Represents a severance benefit equal to 12 months of base salary for fiscal 2007 and the amount of the bonus compensation payable to Mr. Brewer under the performance bonus plan approved by ARCA's compensation committee for fiscal 2007. In each event, ARCA may elect, in its sole discretion, to pay Mr. Brewer additional severance equal to up to 12 months salary, which additional payment would extend Mr. Brewer's covenants and obligations under his Employee Intellectual Property, Confidentiality, and Non-Compete Agreement for such additional period.
- (2) In November 2006, Mr. Brewer was granted the option to purchase 992,000 shares of ARCA's common stock. The options vested immediately, subject to ARCA's right of repurchase which lapses in full upon the earlier of a corporate transaction or upon a termination other than a termination for cause or a termination for good reason. The amount reflected in the table above represents the value of the shares with respect to which ARCA's right of repurchase would lapse following the occurrence of the events shown in the table.
- (3) In November 2006, ARCA issued Mr. Brewer 500,000 shares of common stock pursuant to a restricted stock agreement. ARCA has repurchase rights (allowing ARCA to repurchase the shares at the price paid by Mr. Brewer) with respect to these shares, which lapse as to 250,000 of the shares if (a) ARCA's common stock is listed on a national exchange, when the date on which the average market

## Edgar Filing: NUVELO INC - Form S-4/A

capitalization of ARCA, as reported by such exchange over the immediately preceding ten business days, is at least \$250 million, or (b) a corporate transaction results in consideration paid by the acquirer is at least \$250 million. Repurchase rights on the full 500,000 shares would lapse



**Table of Contents**

on the same terms as the first 250,000 if the two conditions above were met with values of at least \$500 million. Amounts reflected in the table above assume ARCA's repurchase rights lapse with respect to all 500,000 of these shares. In October 2008, Mr. Brewer's restricted stock agreement was amended to provide that ARCA's repurchase rights will lapse with respect to all 500,000 shares on the closing of the merger.

- (4) Represents a severance benefit equal to 12 months of base salary for fiscal 2007, the amount of the bonus compensation payable to the officers under the performance bonus plan approved by ARCA's compensation committee for fiscal 2007 and reimbursement of \$1,515 per month for 12 months of group health insurance benefits under COBRA. These amounts are payable over a 12-month period or, at ARCA's discretion, in a lump sum payment. In each event, ARCA may elect, in its sole discretion, to pay the officers additional severance equal to up to 12 months salary, which additional payment would extend the officer's covenants and obligations under his Employee Intellectual Property, Confidentiality, and Non-Compete Agreement for such additional period.
- (5) If a change of control of ARCA occurs prior to expiration of the option and at a time when the officer remains in service, 50% of the unvested option shares will vest and become immediately exercisable and any remaining options will continue to vest in accordance with the normal time-based vesting schedule, provided, however, that on the earlier of (i) the one year anniversary of the closing date of such change of control and (ii) the date the officer's employment is terminated by ARCA without cause or by the officer for good reason, any shares that remain unvested shall vest and become immediately exercisable.

Actual amounts that a named executive officer could receive in the future could differ materially from the amounts reported above as a result of many factors, including changes in ARCA's stock price, changes in base salary, target and actual bonus amounts, and the vesting provisions and grants of additional equity awards.

**ARCA 2004 Stock Incentive Plan**

***General***

ARCA has adopted the ARCA Plan to enhance the ability of ARCA and its affiliates' ability to attract and retain highly qualified officer, directors, key employees and other persons, and to motivate them to serve ARCA and to expend maximum effort to improve the business results and earnings of ARCA, by providing to such officers, directors, key employees and other persons an opportunity to acquire or increase a direct proprietary interest in the operations and future success of ARCA. The ARCA Plan was originally adopted by the ARCA board of directors and stockholders on September 30, 2004, with certain amendments to the ARCA Plan having been subsequently approved by the board of directors and stockholders.

The ARCA Plan authorizes the granting of awards to ARCA's employees, officers, consultants and directors and to employees, officers, consultants and directors of its subsidiaries. The following awards are available under the ARCA Plan:

options to purchase shares of common stock, which may be incentive stock options or non qualified stock options; and

restricted stock.

The aggregate number of shares of ARCA common stock reserved and available for awards under the ARCA Plan is 6,356,550 shares. As of October 31, 2008, there were 5,646,647 shares previously issued or subject to outstanding Plan awards and 709,903 shares were reserved for issuance pursuant to future awards under the ARCA Plan. Prior to the effective time of the merger, ARCA's board of directors intends to amend the ARCA Plan to increase the number of shares of ARCA common stock reserved and available for awards under the ARCA Plan by 2,000,000 shares to 8,356,550 shares, subject to ARCA stockholder approval. ARCA anticipates granting options awards prior to the effective time of the merger. Shares of ARCA common stock reserved for awards but not covered by awards made prior to the effective time of the merger will not be assumed by Nuvelo and after such effective time no further awards can be made under the ARCA Plan.

## **Table of Contents**

### ***Administration***

The ARCA board of directors has delegated to the compensation committee of the board of directors the full and final authority to administer the ARCA Plan, including the authority to:

designate participants;

determine the types of awards to grant to each participant;

determine the number of shares of stock to be subject to a grant;

establish the terms and conditions of each grant (including, but not limited to, the option price of any option, the nature and duration of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer or forfeiture of a grant or the shares of stock subject thereto and any terms or conditions that may be necessary to qualify options as incentive stock options);

prescribe the form of each award agreement evidencing a grant; and

amend, modify or supplement the terms of any outstanding grant.

The ARCA board of directors has also authorized a sub-committee of the compensation committee, or the award committee to approve and authorize stock option grants to employees.

### ***Awards***

The following is a summary of the types of awards that the ARCA compensation and award committees of the ARCA board of directors may grant to participants pursuant to the ARCA Plan.

#### ***Stock Option***

The ARCA compensation committee is authorized to grant both incentive stock options and nonqualified stock options. The exercise price of an incentive stock option may not be less than the fair market value of the underlying stock on the date of grant. If, however, a participant is a ten-percent stockholder, the option price of an incentive stock option granted to the participant may not be less than 110% of the fair market value of a share of ARCA common stock on the grant date. To the extent required by law, the exercise price of a nonqualified stock option may not be less than 85% of the fair market value of the underlying stock on the date of grant. In no case is the option price of any option less than the par value of a share of ARCA common stock. No option may have a term of more than 10 years from the grant date.

#### ***Restricted Stock***

The ARCA compensation committee may make awards of restricted stock, subject to restrictions on transferability and other restrictions as the compensation committee may impose (including limitations on the right to vote restricted stock or the right to receive dividends, if any, on the restricted stock).

#### ***Limitations on Transfer; Beneficiaries***

Shares acquired pursuant to a grant under the ARCA Plan may not be sold, pledged, assigned, gifted, transferred or otherwise disposed of to any person or entity without complying with conditions prescribed by the compensation or award committees, including first offering the shares to ARCA for purchase on the same terms and conditions as those offered the proposed transferee. This right of first refusal restriction does not apply to a transfer of stock that occurs as a result of the death of a participant or of any subsequent transferee (but does apply to the executor, the

## Edgar Filing: NUVELO INC - Form S-4/A

administrator or personal representative, the estate and the legatees, beneficiaries and assigns thereof). Furthermore, stock issued upon exercise of an option or pursuant to the grant of restricted stock may be subject to rights of repurchase or other transfer restrictions as the compensation and award committees

## **Table of Contents**

may determine. Any additional restrictions are set forth in the applicable award agreement. The right of first refusal, repurchase right and other restrictions terminate as of the first date that the ARCA common stock is listed on the Nasdaq Global Market or is publicly traded in an established securities market.

Except for certain authorized transfers to family members: (i) during the lifetime of a participant, only the participant (or, in the event of legal incapacity or incompetency, the participant's guardian or legal representative) may exercise an option and (ii) no option shall be assignable or transferable by the participant to whom it is granted, other than by will or the laws of descent and distribution.

### ***Assumption of Awards Upon Certain Reorganizations***

If ARCA is the surviving entity in any reorganization, merger or consolidation with one or more entities and in which no change of control occurs, any outstanding awards under the ARCA Plan will pertain to and apply solely to the common stock to which the participant would have been entitled immediately following such reorganization, merger or consolidation with a corresponding adjustment in the price of any options.

### ***Acceleration Upon Certain Events***

In the event of a change of control (as defined in the ARCA Plan) of ARCA in which ARCA is not the surviving entity, all outstanding options and restricted stock may be assumed or continued, or substituted for new common stock options and new common stock restricted stock relating to the stock of a successor entity, or its parent or subsidiary, if provision is made in writing in connection with the change of control. In this event, appropriate adjustments as to the number of shares and option prices would be made and outstanding options and restricted stock would continue in the manner and under the terms so provided. If the options and restricted stock awards are not to be assumed, continued or substituted, then (i) all outstanding shares of restricted stock will be deemed to have vested, and with the exception of any rights of first refusal, repurchase rights or other restrictions as formerly discussed, all restrictions and conditions applicable to shares of restricted stock will be deemed to have lapsed immediately prior to such change of control, and (ii) either of the following two actions shall have been taken: (x) 15 days prior to the scheduled consummation of a change of control, all options outstanding shall become immediately exercisable and shall remain exercisable for a period of 15 days or (y) the compensation committee may elect to cancel any outstanding grants and pay or deliver, or cause to be paid or delivered, to each participant an amount in cash or securities having an equivalent value (as determined by the ARCA compensation committee in good faith).

### ***Termination and Amendment***

The ARCA compensation committee may, at any time and from time to time, amend, suspend or terminate the ARCA Plan as to any shares of stock as to which grants have not been made. An amendment to the ARCA Plan is contingent on approval of ARCA's shareholders only to the extent required by applicable law, regulations or rules. No grants can be made after termination of the ARCA Plan. No amendment, suspension or termination of the ARCA Plan will, without the consent of the participant, alter or impair rights or obligations under any grant theretofore awarded under the ARCA Plan.

## **Table of Contents**

### **ARCA 401(k) Plan**

ARCA maintains a 401(k) employee savings and retirement plan that is intended to be a tax qualified defined contribution plan under Section 401(k) of the Internal Revenue Code. In general, substantially all employees of ARCA are eligible to participate in the 401(k) plan on the first day of the month following their date of hire. The ARCA 401(k) plan allows participants to contribute a portion of their current compensation to the plan, subject to statutory limits. The 401(k) plan provides for safe harbor matching contributions by ARCA, and for fiscal 2007 ARCA made matching contributions equal to 100% of the employee's first 3% of pretax deferrals and 50% of the employee's next 2% of pretax deferrals. Participants are fully vested in the matching contributions.

### **Compensation of Directors**

#### ***ARCA Director Compensation***

ARCA compensates its independent, nonemployee directors through grants of stock options to attract and retain qualified candidates to serve on its board of directors. Directors who also are employees of ARCA or affiliated with its venture capital investors receive no compensation for their service as directors or as members of board committees, other than reimbursement of business expenses incurred in connection with serving on the board of directors. In setting director compensation, ARCA considers the significant amount of time that directors dedicate to the fulfillment of their director responsibilities, as well as the competency and skills required of directors.

#### ***Nuvelo Director Compensation***

The nominating and corporate governance committee of the board of directors of Nuvelo, in accordance with its charter, is responsible for periodically making recommendations to the board of directors with respect to the compensation of board members. The Nuvelo nominating and corporate governance committee performed an evaluation of board member compensation in December 2007, and recommended no changes to Nuvelo board member compensation, which recommendation was accepted by the Nuvelo board of directors.

#### ***Annual Cash Retainer Fees***

Each non-employee director is entitled to an annual retainer fee of \$20,000. The audit committee chair is entitled to receive an additional \$20,000 for service as the audit committee chair. If a non-employee director is the chair of any other committee, that director is entitled to receive an additional \$10,000 per chair. Each of the members of the audit committee, other than the chair, is entitled to receive an additional \$10,000 for his or her service on the audit committee. For membership on any other committee, except for the chair of such Committee, a non-employee director is entitled to receive an additional \$5,000. Board members are not entitled to receive any other cash compensation for their board service. If a board member were to resign or assume additional board responsibilities within a year, the Board member's cash compensation would be adjusted the next quarter to reflect the change. Finally, each director has the option to convert the previously mentioned retainer fees into deferred stock units, in accordance with the terms of a deferred stock unit plan pursuant to Nuvelo's 2004 Equity Incentive Plan or 2004 Plan.

#### ***Annual Stock Option Grants***

On the date of the 2008 annual meeting of the stockholders, Ms. Pendergast and Dr. Sobel each received a fully vested option to purchase 15,000 shares of the Nuvelo's common stock under the 2004 Plan. The purchase price for these options was \$0.73, which was equal to the average of the high and the low price for Nuvelo's common stock on the date of Nuvelo's 2008 annual meeting of stockholders.

**Table of Contents***Appointment Grants*

If at any time Nuvelo's board of directors appoints a new, non-employee chairman of the board, the new chairman will be granted an option to purchase 50,000 shares of Nuvelo's common stock at the average of the high and the low price for Nuvelo's common stock on the date of grant. If at any time Nuvelo's board appoints a new, non-employee vice chair of the board, the new vice chair will be granted an option to purchase 35,000 shares of Nuvelo's common stock at the average of the high and the low price for Nuvelo's common stock on the date of grant. If at any time the board appoints a new non-employee director, the new director will be granted an option to purchase 25,000 shares of Nuvelo's common stock at average of the high and the low price for Nuvelo's common stock on the date of grant. These grants of Nuvelo's common stock for appointments will vest 50% on the date of grant and 50% on the first year anniversary of the date of grant.

The annual grants issued to Nuvelo's board in 2007 and 2008 were made pursuant to the forms of Stock Option Agreement and Notice of Grant of Stock Option filed as exhibits to the Form 8-K filed by Nuvelo on September 20, 2004, as amended in March 2005. In March 2005, Nuvelo's compensation committee approved the amendment of the form of Stock Option Agreement for the members of Nuvelo's board to provide that the period of exercisability of the stock option following termination of service as a director will begin to run upon the expiration of any lock-up agreement that the director has entered into to facilitate a transaction, rather than upon termination of board service.

**Non-Employee Director Compensation**

The following table sets forth the fiscal year 2007 compensation paid to or earned by the individuals who are expected to serve as non-employee directors of the combined company upon completion of the merger. All references to options or shares held by Ms. Pendergast or Dr. Sobel refer to options or shares of Nuvelo. References to options or shares held by all other directors in the table refer to options or shares of ARCA.

**Director Compensation Table**

Name(1)	Fees Earned or Paid in		Total (\$)
	Cash (\$)	Option Awards \$(2)	
John L. Zabriskie, Ph.D.(4)		\$ 1,109(3)	\$ 1,109
J. William Freytag, Ph.D.(5)		\$ 3,637(3)	\$ 3,637
Jean-Francois Formela, M.D.			
Linda Grais, M.D.			
Mary K. Pendergast	\$ 30,000	\$ 40,115(6)	\$ 70,115
Burton E. Sobel, M.D.	\$ 35,000	\$ 40,115(6)	\$ 75,115
David G. Lowe			

- (1) Ted W. Love, M.D. is expected to be a director of the combined company, and is currently the chief executive officer of Nuvelo, but is not a named executive officer for purposes of this proxy statement/prospectus/consent solicitation. Dr. Love served as a director of Nuvelo during fiscal year 2007 but received no additional compensation for his services as a director. Pursuant to Instruction 5(a)(ii) to Regulation S-K, he is omitted from this table.
- (2) Amounts reflect stock-based compensation expense recognized for financial statement reporting purposes for the year ended December 31, 2007, in accordance with Statement of Financial Accounting Standards No. 123 (revised 2004), *Share-Based Payment* (SFAS 123R), and include amounts attributable to awards granted in and before 2007. Amounts shown above exclude the impact of estimated forfeitures related to service-based vesting conditions.
- (3) Assumptions used in the determination of the grant date fair value of the stock options held by these directors are disclosed in Note 1(n) to ARCA's audited financial statements included in the elsewhere in this proxy statement/prospectus/consent solicitation. As of December 31, 2007, Dr. Zabriskie and Dr. Freytag

**Table of Contents**

held options to purchase 82,383 and 82,000, respectively, shares of the Company's common stock, respectively.

- (4) As of December 31, 2007, Dr. Zabriskie held options to purchase 82,383 shares, of which 23,283, 34,100 and 25,000 shares vest in accordance with the standard four-year vesting provision commencing on August 3, 2005, August 3, 2006, and February 2, 2007, respectively. The exercise price of these options is equal to the fair market value of the common stock on the date of grant as determined by the board of directors.
- (5) As of December 31, 2007, Dr. Freytag held options to purchase 82,000 shares, all of which vest in accordance with the standard four-year vesting provision commencing on February 2, 2007. The exercise price of these options is equal to the fair market value of the common stock on the date of grant as determined by the board of directors.
- (6) The grant date fair values of options granted to each of the above indicated directors in 2007 were each \$40,115. Grant date fair values were determined in accordance with SFAS 123R. Assumptions used in the valuation of stock options are disclosed in Note 1 to Nuvelo's consolidated financial statements for the year ended December 31, 2007 included elsewhere in this proxy statement/prospectus/consent solicitation. As of December 31, 2007, Ms. Pendergast and Dr. Sobel held options to purchase 84,166 and 42,500 shares of Nuvelo common stock, respectively.

**Table of Contents**

**RELATED PARTY TRANSACTIONS INVOLVING  
DIRECTORS AND EXECUTIVE OFFICERS FOLLOWING THE MERGER**

**Nuvelo Transactions**

Under Nuvelo's policies applicable to transactions involving related persons, transactions involving related persons are assessed by the independent directors on Nuvelo's board of directors. Related persons include Nuvelo directors and executive officers, as well as immediate family members of directors and officers. If the determination is made that a related person has a material interest in any Nuvelo transaction, then Nuvelo's independent directors would review, approve or ratify it, and the transaction would be required to be disclosed in accordance with the applicable law and Nasdaq listing requirements. If the related person at issue is a director of Nuvelo, or a family member of a director, then that director would not participate in those discussions. Other than transactions with respect to compensation otherwise described in this proxy statement/prospectus/consent solicitation, Nuvelo has not engaged in any related party transactions with individuals expected to serve as directors or executive officers of the combined company.

**ARCA Transactions*****Transactions Involving Stock Options with Executive Officers and Directors of ARCA***

The following current executive officers and directors of ARCA, who will each also continue as an executive officer or director of the combined company following the merger, were granted stock options to purchase ARCA common stock as is set forth opposite such executive officer's or director's name in the following table. The options were granted under the ARCA Plan and are subject to the terms and conditions of stock option agreements between ARCA and each director and executive officer.

<b>Name</b>	<b>Grant Date</b>	<b>Option Shares</b>	<b>Exercise Price</b>	<b>Exercise Date</b>	<b>Vesting</b>
Richard B. Brewer	11/2/2006	992,000	\$ 0.15	N/A	Fully exercisable at date of grant, subject to ARCA's right of repurchase(1)
Michael R. Bristow, M.D., Ph.D.	01/03/2005	708,580	\$ 0.01	02/18/08(2) 09/09/08(3)	25% on October 18, 2005; 6.25% at the end of each three month period thereafter
John L. Zabriskie, Ph.D.	08/05/2005	23,283	\$ 0.10	N/A	5,823 shares on May 5, 2006; 1,455 shares at the end of each quarter thereafter
	08/03/2006	34,100	\$ 0.15	N/A	8,528 shares on August 3, 2007; 2,131 shares at the end of each quarter thereafter
	02/02/2007	25,000	\$ 0.28	N/A	6,250 shares on February 2, 2008; 1,563 shares at the end of each quarter thereafter
	05/02/2008	25,000	\$ 0.31	N/A	6,250 shares at the end of each quarter following the Grant Date
J. William Freytag, Ph.D.	2/2/2007	82,000	\$ 0.28	N/A	20,500 shares on February 2, 2008; 5,125 shares at the end of each quarter thereafter.
	5/2/2008	25,000	\$ 0.31	N/A	6,250 shares at the end of each quarter following the Grant Date



**Table of Contents**

Name	Grant Date	Option Shares	Exercise Price	Exercise Date	Vesting
Jean-François Formela, M.D.					
David G. Lowe, Ph.D.					
Christopher D. Ozeroff	01/03/2005	393,000	\$ 0.01	09/23/2008(4)	25% on October 18, 2005; 6.25% at the end of each three month period thereafter
Linda Grais, M.D.					
Randall St. Laurent	02/12/2008	180,000	\$ 0.31		25% on January 2, 2009; 6.25% at the end of each three month period thereafter

(1) The options were exercisable immediately and if exercised are subject to ARCA's right of repurchase, which lapses at the rate of 25% upon grant and 6.25% at the end of each three-month period following the first anniversary of the November 2, 2006 grant date. Of these options, as of December 31, 2007, 744,000 were subject to a right of repurchase in favor of ARCA.

(2) 575,721 shares exercised.

(3) 88,573 shares exercised.

(4) 368,438 shares exercised.

**Transactions Involving Capital Stock with Executive Officers and Directors of ARCA**

The following current executive officers and directors of ARCA, who will each also continue as an executive officer or director of Nuvelo following the merger, purchased ARCA capital stock in such amounts and prices as is set forth opposite such executive officer's or director's name in the following table:

Name	Type of Stock	Number of Shares	Date of Purchase	Purchase Price \$
Richard B. Brewer	Common Stock	500,000	02/19/2007	75,000
Michael R. Bristow, M.D., Ph.D.	Common Stock(8)	776,580	09/30/2004	(8)
	Series A Preferred Stock(1)	192,130	02/22/2006	312,499.45
John L. Zabriskie, Ph.D.(2)	Series A Preferred Stock(1)	155,915	02/22/2006	253,595.75
	Series B-1 Preferred Stock(3)	7,723	05/31/2007	18,842.19
	Series B-2 Preferred Stock(4)	5,792	12/28/2007	18,841.38
J. William Freytag, Ph.D.				
Jean-François Formela, M.D.(5)	Series A Preferred Stock(1)	5,533,354	02/22/2006	9,000,000.28
	Series B-1 Preferred Stock(3)	274,097	05/31/2007	668,728.16
	Series B-2 Preferred Stock(4)	205,572	12/28/2007	668,725.72
David G. Lowe, Ph.D.(6)	Series B-1 Preferred Stock(3)	1,707,142	05/31/2007	4,164,999.70
	Series B-2 Preferred Stock(4)	1,280,357	12/28/2007	4,165,001.33
Christopher D. Ozeroff	Common Stock(9)	107,000	01/03/2005	1,070.00
Randall St. Laurent				

Edgar Filing: NUVELO INC - Form S-4/A

Linda Grais, M.D.(7)	Series B-1 Preferred Stock(3)	1,366,943	05/31/2007	3,334,999.19
	Series B-2 Preferred Stock(4)	1,025,208	12/28/2007	3,335,001.63

---

**Table of Contents**

- (1) These shares were acquired pursuant to a Series A Preferred Stock Purchase Agreement dated February 22, 2006 between ARCA and the purchasers named therein, as amended December 8, 2006.
- (2) These shares were acquired by Lansing Brown Investments, LLC. Dr. Zabriskie is the President of Lansing Brown Investments, LLC.
- (3) These shares were acquired pursuant to a Series B Preferred Stock Purchase Agreement dated May 31, 2007 between ARCA and the purchasers named therein.
- (4) These shares were acquired pursuant to a Supplemental Agreement to Series B Preferred Stock Purchase Agreement dated December 28, 2007 between ARCA and the purchasers named therein.
- (5) These shares were acquired by Atlas Venture Fund VII, L.P. Dr. Jean-François Formela is a director of Atlas Venture Associates VII, Inc., which is the general partner of Atlas Venture Associates VII, L.P., which is the general partner of Atlas Venture Fund VII, L.P.
- (6) These shares were acquired by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. David G. Lowe is a Managing Director of Skyline Ventures.
- (7) These shares were acquired by InterWest Partners IX, LP. Linda Grais is a venture member of InterWest Management Partners IX, LLC, the general partner of InterWest Partners IX, LP.
- (8) Represents shares purchased by Dr. Bristow upon formation of ARCA.
- (9) Represents shares issued to Mr. Ozeroff in consideration for the conversion of the outstanding principal and accrued interest under a promissory note issued by ARCA to Mr. Ozeroff dated July 4, 2004 in the principal amount of \$1,000.00 pursuant to a Subscription Agreement dated January 3, 2005 entered into between ARCA and Mr. Ozeroff.

***Transactions with ARCA's Chief Science and Medical Officer and Chairman***

ARCA entered into an unrestricted research grant with a research laboratory of the University of Colorado led by Dr. Michael R. Bristow, ARCA's chief science and medical officer and chairman of the board of directors, for the advancement of research in chronic heart failure. Under this agreement, ARCA paid the research laboratory \$22,500 per quarter and \$7,500 per month to offset salary expenses at the laboratory. This arrangement was in place through June 2007.

Effective July 1, 2007, ARCA terminated its prior grant funding arrangement and entered into another unrestricted research grant with Dr. Bristow's research laboratory for \$23,917 per month. Total expenses under these arrangements for the nine months ended September 30, 2008 and 2007 were \$226,920, and \$112,834, respectively. Total expenses during fiscal years 2007, 2006 and 2005 were \$222,502, \$154,992 and \$123,311, respectively, and \$742,638 from inception through September 30, 2008.

ARCA also entered into a materials transfer agreement with the University of Colorado, under which ARCA has agreed to pay \$35,000 per year to maintain the Heart Tissue Bank associated with Dr. Bristow's research laboratory at the University of Colorado. Total expenses for the nine months ended September 30, 2008 and 2007 were \$26,250 and \$17,500, respectively. Total expenses during fiscal years 2007, 2006 and 2005 were \$35,000, \$35,000 and \$35,000, respectively, and \$140,000 from inception through September 30, 2008.

***Gilead Sciences, Inc. (formerly Myogen Inc.)***

## Edgar Filing: NUVELO INC - Form S-4/A

On October 7, 2005, ARCA entered into a strategic alliance agreement with Myogen, Inc., now known as Gilead Sciences, Inc., in exchange for certain sublicenses and licenses for technology licensed by Myogen. At that time, Dr. Bristow served as a director of Myogen and as its chief science and medical officer and as ARCA's chief executive officer and chairman of ARCA's board of directors. Dr. Freytag was also president, chief executive officer and chairman of the board of directors of Myogen at that time, and until the acquisition of

**Table of Contents**

Myogen by Gilead Sciences in November 2006, but was not then a director of ARCA. On February 21, 2006, Dr. Bristow resigned as Myogen's chief science and medical officer. In connection with the strategic alliance agreement, ARCA issued 614,834 shares of common stock to Myogen. The estimated fair value of the shares granted was \$0.12 per share. ARCA recorded the estimated fair value of the shares as research and development expense because the rights granted under the agreement have no alternate use other than ARCA's research and development efforts.

***Convertible Promissory Notes and Warrants***

As agreed to in the merger agreement, ARCA entered into a Note and Warrant Purchase Agreement dated September 24, 2008, as amended on October 10, 2008, with certain holders of ARCA preferred stock. See *Agreements Related to the Merger* Note and Warrant Purchase Agreement above. Atlas Venture Fund VII, L.P., of which Dr. Jean-François Formela is a partner in the life sciences group, purchased \$3,674,630 in principal amount of notes and corresponding warrants, Skyline Venture Partners Qualified Purchaser Fund IV, L.P., of which David G. Lowe is a partner, purchased \$1,825,696 in principal amount of notes and corresponding warrants, and InterWest Partners IX, L.P., of which Dr. Linda Grais is a partner, purchased \$1,461,872 in principal amount of notes and corresponding warrants. Each of these investors acquired convertible notes and warrants on the same terms and conditions as the other investors under the Note and Warrant Purchase Agreement.

***University of Colorado's University License Equity Holdings, Inc.***

ARCA entered into an exclusive license agreement with University of Colorado's License Equity Holdings, Inc., or ULEHI, whereby ULEHI licensed to ARCA patent applications covering use of Gencaro therapy and various options to license future inventions and targets, and ARCA agreed to pay a per year minimum royalty beginning in 2006. A portion of the license revenue received by ULEHI is allocated to the research laboratory of Dr. Bristow, ARCA's chief science officer and chairman. ARCA expensed \$18,750 and \$25,000 for the nine months ended September 30, 2008 and 2007, respectively. During 2007, 2006 and 2005, ARCA paid \$25,000, \$25,000 and \$0, respectively and has paid \$68,750 from ARCA's inception through September 30, 2008. In addition, ARCA will owe royalties based upon its commercial sales (other than Gencaro) and other milestones, if any. In August 2007 ARCA executed an amendment to the license agreement to acquire additional patent rights and paid \$15,000 for those rights.

As part of its licensing arrangement, ARCA has issued to ULEHI at total of 302,785 shares of common stock. Pursuant to an anti-dilution provision in the license agreement, ARCA issued 69,882 shares, 142,903 shares, and 0 shares in 2007, 2006, 2005, respectively, and 212,785 shares from inception through December 31, 2007. The estimated fair value of shares granted in 2007 was \$0.29 per share. The anti-dilution provision was fully satisfied in May 2007 with ARCA's Series B preferred stock financing.

***Investor Rights Agreement and Related Financing Documents***

In connection with its preferred stock financings, ARCA entered into an Amended and Restated Investor Rights Agreement dated May 31, 2007 with its investors, including Atlas Venture Fund VII, L.P., and Skyline Venture Partners Qualified Purchaser Fund IV, L.P. and InterWest Partners, IX, L.P., pursuant to which such investors received registration rights with respect to their shares of preferred stock, an Amended and Restated Right of First Refusal and Co-Sale Agreement and Amended and Restated Voting Agreement. As a condition to completion of the merger, each of these agreements and the rights thereunder will be terminated.

***Indemnification of Directors and Officers***

ARCA's amended and restated bylaws provide that ARCA will indemnify each of its directors and officers to the fullest extent permitted by the DGCL. Furthermore, ARCA has entered into indemnification agreements

**Table of Contents**

with each of its directors. These agreements provide for the indemnification of the directors of ARCA for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were agents of ARCA. ARCA believes that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors.

**Procedures for Approval of Related Person Transactions**

As of February 2008, ARCA's audit committee was authorized to review and approve all related party transactions on an ongoing basis in accordance with its charter. Prior to that date, related party transactions were reviewed and approved by the board of directors.

**Table of Contents**

**NUVELO SECURITY OWNERSHIP OF  
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth certain information regarding the beneficial ownership of Nuvelo's common stock as of October 31, 2008, by: (1) each of Nuvelo's directors; (2) each of Nuvelo's named executive officers set forth in the table titled "Summary Compensation Table" in Nuvelo's proxy statement filed with the SEC on April 23, 2008; (3) each person known by Nuvelo to be the beneficial owner of more than 5% of Nuvelo's outstanding common stock; and (4) all of Nuvelo's directors and current executive officers as a group. As of October 31, 2008, Nuvelo had 53,663,805 shares of common stock outstanding.

Name and address of Beneficial Owner(1)	Shares Beneficially Owned(1)	
	Number of Shares	Percentage
RA Capital Management, LLC(2) 111 Huntington Avenue, Suite 610 Boston, MA 02199	3,579,728	6.67%
Sopris Capital Advisors, LLC(3) 314 South Galena Street, Suite 300 Aspen, CO 81611	3,255,550	6.07%
Ted W. Love, M.D.(4)	1,938,019	3.49%
James R. Gavin III, M.D., Ph.D.(5)	55,000	*
Mary K. Pendergast(6)	99,832	*
Mark L. Perry(7)	95,833	*
Kimberly Popovits(5)	75,000	*
Burton E. Sobel, M.D.(5)	57,500	*
Lee Bendekgey(8)	419,751	*
Michael D. Levy, M.D.(9)(11)	544,015	1.00%
H. Ward Wolff(12)	2,872	*
All directors and current executive officers as a group (7 persons)(10)	2,740,935	4.87%

\* Represents beneficial ownership of less than 1% of Nuvelo's common stock.

(1) Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act and generally includes voting or investment power with respect to securities. Shares of common stock subject to options and warrants which are currently exercisable, or will become exercisable within 60 days of October 31, 2008, are deemed outstanding for computing the percentage of the person or entity holding such securities but are not outstanding for computing the percentage of any other person or entity. Except as indicated by footnote, and subject to the community property laws where applicable, to Nuvelo's knowledge the persons named in the table above have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. Unless otherwise indicated, the address for each person is Nuvelo's address at 201 Industrial Road, Suite 310, San Carlos, CA 94070.

(2) Information is based solely on Schedule 13G jointly filed with the SEC on May 16, 2008 by the following persons: Richard H. Aldrich, Peter Kolchinsky, RA Capital Management, LLC, RA Capital Biotech Fund, L.P. and RA Capital Biotech Fund II, L.P. Mr. Aldrich and

## Edgar Filing: NUVELO INC - Form S-4/A

Mr. Kolchinsky are the managers of RA Capital Management, LLC ( Capital ), which is the sole general partner of each of RA Capital Biotech Fund, L.P. ( Fund I ) and RA Capital Biotech Fund II, L.P. ( Fund II ). The beneficial ownership of each reporting person is as follows: (i) Fund I beneficially owns 3,534,787 shares, (ii) Fund II beneficially owns 44,941 shares and (iii) Capital, as the sole general partner of each of Fund I and Fund II, and Mr. Aldrich and Mr. Kolchinsky as the managers of Capital, each beneficially owns 3,579,728 shares.



---

**Table of Contents**

- (3) Information is based solely on Schedule 13G/A jointly filed with the SEC on February 13, 2008 by the following persons: Aspen Advisors LLC ( Aspen Advisors ), Sopris Capital Advisors, LLC ( Sopris Advisors ), Sopris Partners Series A, of Sopris Capital Partners, L.P. ( Sopris Partners ), Sopris Capital, LLC ( Sopris Capital ), and Nikos Hecht. Of the shares reported as beneficially owned in this Schedule 13G/A, 2,110,600 shares are owned directly by Sopris Partners, 596,500 shares are owned by private clients of Aspen Advisors, and 548,450 shares are owned by private clients of Sopris Advisors. Sopris Capital is the general partner of Sopris Partners and, as such, may be deemed to share beneficial ownership of the Common Stock owned directly by Sopris Partners. Mr. Hecht is the managing member of each of Aspen Advisors and Sopris Advisors and the sole member of the managing member of Sopris Capital. As the managing member of Aspen Advisors and Sopris Advisors, the sole member of the managing member of Sopris Capital and the owner of a majority of the membership interests in each of Sopris Capital, Aspen Advisors and of Sopris Advisors, Mr. Hecht may be deemed to be the controlling person of Sopris Capital, Aspen Advisors and of Sopris Advisors, and through Sopris Capital, Sopris Partners. Each of Aspen Advisors and Sopris Advisors, as investment manager for their respective private clients, and with respect to Sopris Advisors, also as investment manager for Sopris Partners, has discretionary investment authority over the Common Stock held by their respective private clients and Sopris Partners, as applicable. Accordingly, Mr. Hecht may be deemed to be the beneficial owner of the Common Stock held by Sopris Partners and the private clients of Aspen Advisors and Sopris Advisors. Each of Sopris Partners and Sopris Capital disclaims any beneficial interest in the Common Stock owned by the accounts managed by Sopris Advisors and Aspen Advisors.
- (4) Includes 1,866,244 shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
- (5) Represents shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
- (6) Includes 99,166 shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
- (7) Includes 30,000 shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
- (8) Includes 400,278 shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
- (9) Includes 523,194 shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
- (10) Includes 2,583,188 shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
- (11) Dr. Levy's employment with Nuvelo was terminated on March 20, 2008.
- (12) Mr. Wolff's employment with Nuvelo was terminated on August 14, 2007.

**Table of Contents**

**ARCA SECURITY OWNERSHIP OF  
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table shows the beneficial ownership, as of October 31, 2008, of the common stock of ARCA held by each director and named executive officer of ARCA, by each stockholder known to ARCA to beneficially own greater than 5% of ARCA's outstanding voting stock and by all of ARCA's current directors and executive officers as a group. The following table assumes conversion of all shares of outstanding preferred stock into common stock at the following assumed rates: each share of Series A Preferred Stock converts into one share of common stock; each share of Series B-1 Preferred Stock converts into 1.219875 shares of common stock; and each share of Series B-2 Preferred Stock converts into 1.6265 shares of common stock.

In addition, the table below reflects shares of common stock issuable upon conversion of the outstanding principal and accrued interest under ARCA's convertible promissory notes dated October 10, 2008, or the Notes, and warrants, or the Warrants, to purchase a number of shares of common stock equal to (a) 20% of the total consideration paid for each Note and Warrant divided by (b) the conversion rate under the Notes. The share information in the table below assumes a conversion rate for the Notes of \$1.6265 and a conversion date on January 9, 2009, the date by which the parties reasonably anticipate that the merger will close and the Notes will automatically convert. It further assumes an exercise price of \$1.6265 under the Warrants resulting in the issuance of Warrants to purchase 1,627 shares of common stock for every \$1,000 in principal amount under the Notes.

The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has the sole or shared voting power or investment power, and includes any shares that the individual has the right to acquire within 60 days of October 31, 2008 through the exercise of any stock option or other right. The percentage of shares beneficially owned is computed on the basis of 23,936,074 shares of ARCA's common stock, on an as converted basis, outstanding as of October 31, 2008.

**Table of Contents**

Shares of ARCA's common stock that a person has the right to acquire within 60 days of October 31, 2008, including shares that may be acquired upon exercise of stock options or warrants or upon conversion of the Notes, are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. To ARCA's knowledge, except as set forth in the footnotes to this table and subject to applicable community property laws, each person or entity named in the table has sole voting and dispositive power with respect to the shares set forth opposite such person's or entity's name. Unless otherwise indicated, the address for each person or stockholder listed below is c/o ARCA biopharma, Inc., 8001 Arista Place, Suite 200, Broomfield, CO 80021.

Name of Beneficial Owner	Number of Shares of Common Stock Beneficially Owned	Percent of Class(1)
<b>Directors and Named Executive Officers</b>		
Richard B. Brewer(2)	1,492,000	5.99%
Patrick M. Wheeler(3)	31,875	*
Michael R. Bristow, M.D., Ph.D.(4)	1,677,290	6.99%
Christopher D. Ozeroff (5)	500,000	2.09%
Francis J. Bullock, Ph.D.(6)	153,762	*
Jean-Francois Formela(7)	8,842,281	33.27%
J. William Freytag, Ph.D.(8)	48,375	*
Linda Graiss, M.D.(9)	4,385,346	17.55%
David G. Lowe, Ph.D.(10)	5,476,753	21.69%
Kyle Lefkoff(11)	4,810,244	19.24%
John L. Zabriskie, Ph.D.(12)	237,750	*
All Directors and Executive Officers as a Group 12 persons	27,655,676	88.49%
<b>5% Stockholders</b>		
Skyline Venture Partners Qualified Purchaser Fund IV, L.P.(13)	5,476,753	21.69%
InterWest Partners IX, L.P.(14)	4,385,346	17.55%
Atlas Venture Fund VII, L.P.(15)	8,842,281	33.27%
Boulder Ventures IV (Annex), L.P.(16)	4,810,244	19.24%

\* Less than 1% ownership of ARCA's common stock.

- (1) Includes 5,713,818 shares of ARCA common stock, 9,222,257 shares of common stock issuable upon conversion of 9,222,257 shares of Series A Preferred Stock, 4,499,999 shares of common stock issuable upon conversion of 3,688,902 shares of Series B-1 Preferred Stock, and 4,500,000 shares of common stock issuable upon conversion of 2,766,677 shares of Series B-2 Preferred Stock, in each case outstanding as of October 31, 2008.
- (2) Includes options to purchase 992,000 shares that are exercisable within 60 days of October 31, 2008.
- (3) Includes options to purchase 11,875 shares that are exercisable within 60 days of October 31, 2008.
- (4) Includes (a) options to purchase 44,286 shares that are exercisable within 60 days of October 31, 2008, and (b) 192,130 shares of Series A Preferred Stock, on an as converted basis.
- (5) Includes options to purchase 24,562 shares that are exercisable within 60 days of October 31, 2008.

## Edgar Filing: NUVELO INC - Form S-4/A

- (6) Includes (a) options to purchase 61,539 shares that are exercisable within 60 days of October 31, 2008, and (b) 92,223 shares of Series A Preferred Stock, on an as converted basis. The address for Dr. Bullock is 48 Bay Lane, Chatham, MA 02633.
  
- (7) Includes the following held by Atlas Venture Fund VII, L.P., or AV VII, (a) 2,188,354 shares issuable upon conversion of a convertible promissory note, (b) 451,846 shares issuable upon exercise of a warrant, (c) 5,533,354 shares of Series A Preferred Stock, on an as converted basis, (d) 334,364 shares of Series B-1 Preferred Stock, on an as converted basis, and (e) 334,363 shares of Series B-2 Preferred Stock, on an as converted basis. As general partner of AV VII, Atlas Venture Associates VII, L.P., or AVA VII LP, may also be deemed to beneficially own these shares. As the general partner of AVA VII LP, Atlas Venture

**Table of Contents**

Associates VII, Inc. or AVA VII Inc. may be deemed to beneficially own these shares. In his capacity as a director of AVA VII Inc., Mr. Formela, one of ARCA's directors, may be deemed to beneficially own these shares. Mr. Formela disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Each of AV VII, AVA VII LP and AVA VII Inc. disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. The address for Mr. Formela is 890 Winter Street, Suite 320, Waltham, MA 02451.

- (8) Includes options to purchase 48,375 shares that are exercisable within 60 days of October 31, 2008. The address for Dr. Freytag is 7169 Waterford Court, Niwot, CO 80503.
- (9) Includes the following shares held by InterWest Partners IX, LP: (a) 870,589 shares issuable upon conversion of a Note, (b) 179,757 shares issuable upon exercise of a Warrant, (c) 1,667,500 shares of Series B-1 Preferred Stock, on an as converted basis, and (d) 1,667,501 shares of Series B-2 Preferred Stock, on an as converted basis. Ms. Grais, one of ARCA's current directors, is a venture member of InterWest Management Partners IX, LLC, the general partner of InterWest Partners IX, LP. Ms. Grais has shared voting and dispositive powers over the shares held by InterWest Partners IX, LP. She disclaims beneficial ownership of these shares, except to the extent of her pro rata partnership interest therein. The address for Ms. Grais is 2710 Sand Hill Road, Second Floor, Menlo Park, CA 94025.
- (10) Includes the following shares held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P.: (a) 1,087,258 shares issuable upon conversion of a Note, (b) 224,494 shares issuable upon exercise of a Warrant, (c) 2,082,500 shares of Series B-1 Preferred Stock, on an as converted basis, and (d) 2,082,501 shares of Series B-2 Preferred Stock, on an as converted basis. John G. Freund and Yasunori Kaneko are the Managing Members of Skyline Venture Management IV, LLC, which is the general partner of Skyline Venture Partners Qualified Purchaser Fund IV, L.P., and as such Drs. Freund and Kaneko may be deemed to share voting and dispositive power with respect to all shares of common stock held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. In addition, Dr. Lowe, one of ARCA's current directors and a director of the combined company, is a Managing Director of Skyline Ventures and as such may be deemed to share voting and dispositive power with respect to all shares of common stock held by Skyline Venture Partners Qualified Purchasers Fund IV, L.P. Each of Drs. Freund, Kaneko and Lowe disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any. The address for Dr. Lowe is Skyline Ventures, 525 University Avenue, Ste 520, Palo Alto, CA 94301.
- (11) Includes the following shares held by (i) Boulder Ventures IV (Annex), L.P.: (a) 831,008 shares issuable upon conversion of a Note, (b) 171,585 shares issuable upon exercise of a Warrant, (c) 1,832,791 shares of Series A Preferred Stock, on an as converted basis, (d) 314,103 shares of Series B-1 Preferred Stock, on an as converted basis, and (e) 314,102 shares of Series B-2 Preferred Stock, on an as converted basis, and (ii) Boulder Ventures IV, L.P.: (a) 55,023 shares issuable upon conversion of a Note, (b) 11,361 shares issuable upon exercise of a Warrant, (c) 121,353 shares of Series A Preferred Stock, on an as converted basis, (d) 20,798 shares of Series B-1 Preferred Stock, on an as converted basis, and (e) 20,798 shares of Series B-2 Preferred Stock, on an as converted basis. Mr. Lefkoff, one of ARCA's current directors, is a managing member of BV Partners IV, L.L.C., the general partner of each of Boulder Ventures IV (Annex), L.P. and Boulder Ventures IV, L.P. Mr. Lefkoff has shared voting and dispositive powers over the shares held by Boulder Ventures IV (Annex), L.P. and Boulder Ventures IV, L.P. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them. The address for Mr. Lefkoff is 1900 Ninth Street, Suite 200, Boulder, CO 80302.
- (12) Includes (a) options to purchase 62,994 shares that are exercisable within 60 days of October 31, 2008, and (b) the following shares held by Lansing Brown Investments, LLC: (i) 155,915 shares of Series A Preferred Stock, on an as converted basis, (ii) 9,421 shares of Series B-1 Preferred Stock, on an as converted basis, and (iii) 9,421 shares of Series B-2 Preferred Stock, on an as converted basis. Dr. Zabriskie, one of ARCA's current directors and a director of the combined company, is the President of Lansing Brown Investments, LLC. Dr. Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them. The address for Dr. Zabriskie is 207 Juniper Court, Basalt, CO 81621.
- (13) Includes the following shares held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P.: (a) 1,087,258 shares issuable upon conversion of a Note, (b) 224,494 shares issuable upon exercise of a



---

**Table of Contents**

Warrant, (c) 2,082,500 shares of Series B-1 Preferred Stock, on an as converted basis, and (d) 2,082,501 shares of Series B-2 Preferred Stock, on an as converted basis. The address for Skyline Venture Partners Qualified Purchaser Fund IV, L.P. is 525 University Avenue, Ste 520, Palo Alto, CA 94301.

- (14) Includes the following shares held by InterWest Partners IX, LP: (a) 870,589 shares issuable upon conversion of a Note, (b) 179,757 shares issuable upon exercise of a Warrant, (c) 1,667,500 shares of Series B-1 Preferred Stock, on an as converted basis, and (d) 1,667,501 shares of Series B-2 Preferred Stock, on an as converted basis. The address for InterWest Partners IX, LP is 2710 Sand Hill Road, Second Floor, Menlo Park, CA 94025.
- (15) Includes the following shares held by Atlas Venture Fund VII, L.P.: (a) 2,188,354 shares issuable upon conversion of a Note, (b) 451,846 shares issuable upon exercise of a Warrant, (c) 5,533,354 shares of Series A Preferred Stock, on an as converted basis, (d) 334,364 shares of Series B-1 Preferred Stock, on an as converted basis, and (e) 334,363 shares of Series B-2 Preferred Stock, on an as converted basis. The address for Atlas Venture Fund VII, L.P. is 890 Winter Street, Suite 320, Waltham, MA 02451. As general partner of AV II, Atlas Venture Associates VII, L.P., or AVA VII LP, may also be deemed to beneficially own these shares. As the general partner of AVA VII L.P., Atlas Venture Associates VII, Inc., or AVA VII Inc., may be deemed to beneficially own these shares. In his capacity as a director of AVA VII Inc., Mr. Formela, one of ARCA's directors, may be deemed to beneficially own these shares. Mr. Formela disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Each of AV VII, AVA VII L.P. and AVA VII Inc. disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.
- (16) Includes the following shares held by (i) Boulder Ventures IV (Annex), L.P.: (a) 831,008 shares issuable upon conversion of a Note, (b) 171,585 shares issuable upon exercise of a Warrant, (c) 1,832,791 shares of Series A Preferred Stock, on an as converted basis, (d) 314,103 shares of Series B-1 Preferred Stock, on an as converted basis, and (e) 314,102 shares of Series B-2 Preferred Stock, on an as converted basis, and (ii) Boulder Ventures IV, L.P.: (a) 55,023 shares issuable upon conversion of a Note, (b) 11,361 shares issuable upon exercise of a Warrant, (c) 121,353 shares of Series A Preferred Stock, on an as converted basis, (d) 20,798 shares of Series B-1 Preferred Stock, on an as converted basis, and (e) 20,798 shares of Series B-2 Preferred Stock, on an as converted basis. The address for each of Boulder Ventures IV (Annex), L.P. and Boulder Ventures IV, L.P. is 1900 Ninth Street, Suite 200, Boulder, CO 80302.

**Table of Contents****SECURITY OWNERSHIP OF CERTAIN****BENEFICIAL OWNERS AND MANAGEMENT FOLLOWING THE MERGER**

The following table shows certain information regarding the beneficial ownership of Nuvelo common stock immediately following consummation of the merger held by:

each person or group who is known to ARCA and Nuvelo to become the beneficial owner of more than 5% of Nuvelo's common stock upon consummation of the merger;

each director of Nuvelo upon consummation of the merger; and

all directors and executive officers as a group of Nuvelo upon consummation of the merger.

The percentage of shares beneficially owned is computed on the basis of 150,757,714 shares of Nuvelo's common stock outstanding upon consummation of the merger and assumes that the exchange ratio to be used in the merger is 3.3395 shares of common stock for each share ARCA common stock. The shares held by existing ARCA stockholders assumes conversion of all outstanding shares of preferred stock at the conversion rates, and the conversion of ARCA's outstanding convertible notes and the number of shares of ARCA common stock subject to the warrants based on the conversion price, in each case, as set forth in ARCA Security Ownership of Certain Beneficial Owners and Management Following the Merger above.

The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has the sole or shared voting power or investment power, and includes any shares that the individual has the right to acquire within 60 days of October 31, 2008 through the exercise of any stock option or other right.

Shares of common stock that a person has the right to acquire within 60 days of October 31, 2008, including shares that may be acquired upon exercise of stock options or warrants or upon conversion of the Notes, are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. To ARCA's and Nuvelo's knowledge, except as set forth in the footnotes to this table, the Voting Agreements and subject to applicable community property laws, each person or entity named in the table has sole voting and dispositive power with respect to the shares set forth opposite such person's or entity's name.

Name of Beneficial Owner	Number of Shares of Common Stock Beneficially Owned	Percent of Class(1)
<b>Directors and Executive Officers</b>		
Richard B. Brewer(2)	4,982,534	3.23%
Michael R. Bristow, M.D., Ph.D.(3)	5,601,310	3.71
Christopher D. Ozeroff(4)	1,669,750	1.11
Jean-Francois Formela(5)	29,447,130	19.34
J. William Freytag, Ph.D.(6)	161,548	*
Linda Graiss, M.D.(7)	14,612,374	9.65
David G. Lowe, Ph.D.(8)	18,249,037	12.04
Ted W. Love, M.D.(9)	2,538,439	1.66
Mary K. Pendergast(10)	99,832	*
Burton E. Sobel, M.D.(11)	57,500	*
John L. Zabriskie, Ph.D.(12)	793,968	*
All Directors and Executive Officers as a Group (12 persons)	78,213,422	48.84





**Table of Contents**

Name of Beneficial Owner	Number of Shares of Common Stock Beneficially Owned	Percent of Class(1)
<b>5% Stockholders</b>		
Boulder Ventures IV (Annex), L.P.(14)	16,030,747	10.59
Skyline Venture Partners Qualified Purchaser Fund IV, L.P.(15)	18,249,037	12.04
InterWest Partners IX, L.P.(16)	14,612,374	9.65
Atlas Venture Fund VII, L.P.(17)	29,447,130	19.34

\* Less than 1% ownership of Nuvelo's common stock following consummation of the merger.

- (1) Assumes that 97,093,909 shares of Nuvelo common stock are issued to holders of ARCA capital stock in connection with the merger and 53,663,805 shares of Nuvelo common stock are held by holders of Nuvelo common stock prior to the merger.
- (2) Includes options to purchase 3,312,784 shares that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio.
- (3) Includes options to purchase 147,893 shares that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio.
- (4) Includes options to purchase 82,025 shares that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio.
- (5) Includes warrants to purchase 1,508,940 shares held by Atlas Venture Fund VII, L.P., or AV VII, that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio. As general partner of AV II, Atlas Venture Associates VII, L.P., or AVA VII LP, may also be deemed to beneficially own these shares. As the general partner of AVA VII L.P., Atlas Venture Associates VII, Inc., or AVA VII Inc., may be deemed to beneficially own these shares. In his capacity as a director of AVA VII Inc., Mr. Formela, one of the combined company's directors following the merger, may be deemed to beneficially own these shares. Mr. Formela disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Each of AV VII, AVA VII L.P. and AVA VII Inc. disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.
- (6) Includes options to purchase 161,548 shares that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio.
- (7) Includes warrants to purchase 600,299 shares held by InterWest Partners IX, LP that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio. Ms. Grais, one of the combined company's directors following the merger, is a venture member of InterWest Management Partners IX, LLC, the general partner of InterWest Partners IX, LP. Ms Grais has shared voting and dispositive powers over the shares held by InterWest Partners IX, LP. She disclaims beneficial ownership of these shares, except to the extent of her pro rata partnership interest therein.
- (8) Includes warrants to purchase 749,698 shares held by Skyline Venture Partners Qualified Purchasers Fund IV, L.P that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio. John G. Freund and Yasunori Kaneko are the Managing Members of Skyline Venture Management IV, LLC, which is the general partner of Skyline Venture Partners Qualified Purchaser Fund IV, L.P., and as such Drs. Freund and Kaneko may be deemed to share voting and dispositive power with respect to all shares of common stock held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. In addition, Dr. Lowe, one of the combined

## Edgar Filing: NUVELO INC - Form S-4/A

company's directors following the merger, is a Managing Director of Skyline Ventures and as such may be deemed to share voting and dispositive power with respect to all shares of common stock held by Skyline Venture Partners Qualified Purchasers Fund IV, L.P. Each of Drs. Freund, Kaneko and Lowe disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any.

- (9) Includes options to purchase 2,466,664 shares that are exercisable within 60 days of October 31, 2008.

---

**Table of Contents**

- (10) Includes options to purchase 99,166 shares that are exercisable within 60 days of October 31, 2008.
  
- (11) Represents shares issuable upon exercise of options currently exercisable or exercisable within 60 days of October 31, 2008.
  
- (12) Includes (a) options to purchase 210,367 shares that are exercisable within 60 days of October 31, 2008 and (b) 583,602 shares held by Lansing Brown Investments, as converted according to the assumed Exchange Ratio. Dr. Zabriskie, one of the combined company's directors following the merger, is the President of Lansing Brown Investments, LLC. Dr. Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them.
  
- (13) Includes warrants to purchase (a) 573,008 shares held by Boulder Ventures IV (Annex), L.P. and (b) 37,940 by shares held by Boulder Ventures IV, L.P., that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio. Kyle Lefkoff, one of ARCA's current directors, is a managing member of BV Partners IV, L.L.C., the general partner of each of Boulder Ventures IV (Annex), L.P. and Boulder Ventures IV, L.P. Mr. Lefkoff has shared voting and dispositive powers over the shares held by Boulder Ventures IV (Annex), L.P. and Boulder Ventures IV, L.P. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them.
  
- (14) Includes warrants to purchase 749,698 shares held by Skyline Venture Partners Qualified Purchasers Fund IV, L.P. that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio. The address for Skyline Venture Partners Qualified Purchaser Fund IV, L.P. is 525 University Avenue, Ste 520, Palo Alto, CA 94301.
  
- (15) Includes warrants to purchase 600,299 shares held by InterWest Partners IX, LP that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio.
  
- (16) Includes warrants to purchase 1,508,940 shares held by Atlas Venture Fund VII, L.P. that are exercisable within 60 days of October 31, 2008, as converted according to the assumed Exchange Ratio. As general partner of AV II, Atlas Venture Associates VII, L.P., or AVA VII LP, may also be deemed to beneficially own these shares. As the general partner of AVA VII L.P., Atlas Venture Associates VII, Inc., or AVA VII Inc., may be deemed to beneficially own these shares. In his capacity as a director of AVA VII Inc., Mr. Formela, one of the combined company's directors following the merger, may be deemed to beneficially own these shares. Mr. Formela disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Each of AV VII, AVA VII L.P. and AVA VII Inc. disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.

---

**Table of Contents**

**DESCRIPTION OF NUVELO S CAPITAL STOCK**

The following is only a summary of the material terms of Nuvelo s capital stock. Because it is only a summary, it does not contain all the information that may be important to you. Accordingly, you should read carefully the more detailed provisions of Nuvelo s amended and restated certificate of incorporation and bylaws , each of which has been filed with the SEC, as well as applicable Delaware law.

Nuvelo currently has authorized 100,000,000 shares of common stock, par value \$0.001, and, 5,000,000 shares of preferred stock, par value \$0.001. As of October 31, 2008, Nuvelo had 53,663,805 shares of common stock outstanding, and no shares of preferred stock outstanding. As of October 31, 2008, Nuvelo had an aggregate of 5,167,610 shares of common stock reserved for issuance upon exercise of outstanding stock options and restricted stock units granted under Nuvelo s 2004 Equity Incentive Plan, 2002 Equity Incentive Plan, 1995 Stock Option Plan, and Non-Employee Director Stock Option Plan, and an aggregate of 6,537,957 shares of common stock reserved for issuance pursuant to future grants under the 2004 Equity Incentive Plan. As of October 31, 2008, Nuvelo also had 282,073 shares of common stock reserved for issuance under Nuvelo s Employee Stock Purchase Plan. As of October 31, 2008, Nuvelo had an aggregate of 439,386 shares of common stock reserved for issuance upon the exercise of stock options granted outside of any of Nuvelo s stock option plans. As of October 31, 2008, Nuvelo had warrants to purchase an aggregate of 850,224 shares of Nuvelo s common stock outstanding, with exercise prices ranging from \$12.07 to \$24.87 per share, and a weighted average exercise price of \$19.57 per share.

**Preferred Stock**

Nuvelo s board of directors is authorized, subject to any limitations under its certificate of incorporation or prescribed by law, without further stockholder approval, to issue up to an aggregate of 5,000,000 shares of preferred stock, of which 100,000 shares have been designated Series A Junior Participating Preferred Stock. Nuvelo s board of directors may establish the applicable and relative designations, number of authorized shares, dividend rates and terms, redemption or sinking fund provisions, conversion or exchange rates, anti-dilution provisions, voting rights, liquidation preferences and other terms, preferences and limitations of any series of preferred stock it determines to issue.

**Common Stock**

Holders of Nuvelo s common stock are entitled to one vote per share for the election of directors and all other matters submitted for stockholder vote, except matters submitted to the vote of another class or series of shares. Holders of common stock are not entitled to cumulative voting rights. The approval of 66 <sup>2</sup>/<sub>3</sub>% of the voting rights of the common stock is required to make certain amendments to Nuvelo s certificate of incorporation, amend Nuvelo s bylaws, and to remove a director from Nuvelo s board of directors.

The holders of common stock are entitled to dividends in such amounts and at such times, if any, as may be declared by Nuvelo s board of directors out of legally available funds. Nuvelo has not paid any dividends on Nuvelo s common stock and does not anticipate paying any cash dividends on its common stock in the foreseeable future. Upon liquidation, dissolution or winding up of Nuvelo, the holders of its common stock are entitled to share ratably in all net assets available for distribution to stockholders after payments to creditors and holders of senior securities. The common stock is not redeemable and has no preemptive, conversion or sinking fund rights. The rights of the holders of Nuvelo s common stock are subject to the rights of the holders of any preferred stock which may, in the future, be issued. All outstanding shares of Nuvelo s common stock are duly authorized, validly issued, fully paid and non-assessable.

**Limitation of Liability and Indemnification**

To the fullest extent permitted by the Delaware law, Nuvelo s certificate of incorporation provides that directors shall not be personally liable to Nuvelo or any of Nuvelo s stockholders for monetary damages for

---

## **Table of Contents**

breach of fiduciary duty as a director. However, this provision does not eliminate the duty of care, and in appropriate circumstances, equitable remedies such as injunctive or other forms of nonmonetary relief that will remain available under Delaware law. In addition, each director will continue to be subject to liability for (i) breach of the directors duty of loyalty to us or Nuvelo's stockholders, (ii) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) violating Section 174 of the DGCL, or (iv) any transaction from which the director derived an improper personal benefit. The provision also does not affect a director's responsibilities under any other law, such as the federal securities laws or state or federal environmental laws.

In accordance with Delaware law, Nuvelo's bylaws provide that Nuvelo shall indemnify any person who was or is a party or is threatened to be made a party to, or otherwise becomes involved in, any proceeding (other than an action by or in the right of Nuvelo) by reason of the fact that he is an officer, director or agent of Nuvelo against losses actually and reasonably incurred by that person if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to Nuvelo's best interests. Losses are the total amount that the officer, director or agent becomes legally obligated to pay, including judgments, fines, amounts paid in settlement, attorneys' fees, expenses of establishing a right to indemnification and other expenses. If the proceeding is a criminal proceeding, the person to be indemnified must have had no reasonable cause to believe his or her conduct was unlawful.

Nuvelo's bylaws provide for similar indemnification for expenses resulting from an action by or in the right of Nuvelo, except that no indemnification will be made if the person is adjudged by a court of competent jurisdiction after exhaustion of all appeals to be liable to us or for amounts paid in settlement to us unless the court determines that the person is fairly and reasonably entitled to indemnity for expenses. Expenses of officers, directors and agents include attorneys' fees, any expenses of establishing a right to indemnification and amounts paid in settlement. Nuvelo's bylaws also provide for advancement of expenses.

Nuvelo also maintains liability insurance for its officers and directors and has entered into indemnification agreements with them.

### **Additional Information Concerning Nuvelo's Capital Stock**

#### ***Anti-takeover effects of Nuvelo's certificate of incorporation and bylaws***

Nuvelo's certificate of incorporation and bylaws include a number of provisions that may have the effect of encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with Nuvelo's board of directors rather than pursue non-negotiated takeover attempts. These provisions:

establish a classified board of directors so that not all members of Nuvelo's board may be elected at one time;

establish that the holders of 66<sup>2</sup>/3% of the voting rights of all classes of stock entitled to vote are required to remove Nuvelo's directors or to amend the bylaws and certain provisions of Nuvelo's certificate of incorporation;

authorize the issuance of up to 5,000,000 shares of preferred stock that could be issued by Nuvelo's board of directors to increase the number of outstanding shares and hinder a takeover attempt;

limit who may call a special meeting of stockholders;

prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of Nuvelo's stockholders; and

establish advance notice requirements for nominations for election to Nuvelo's board of directors or for proposing matters that can be acted upon at a stockholder meeting.

## Edgar Filing: NUVELO INC - Form S-4/A

These provisions could discourage, delay or prevent certain types of transactions involving an actual or potential change in control of us, including transactions in which stockholders might otherwise receive a premium for their shares over current market prices.

**Table of Contents**

***Business combination statute under Delaware law***

Nuvelo is also subject to provisions of Delaware law that could discourage, delay or prevent an actual or potential change in control of Nuvelo. These anti-takeover laws prevent a Delaware corporation from engaging in a merger or sale of more than 10 percent of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15 percent or more of the corporation's outstanding voting stock, for three years following the date that the stockholder acquired 15 percent or more of the corporation's stock unless:

the board of directors approved the transaction where the stockholder acquired 15 percent or more of the corporation's stock;

after the transaction in which the stockholder acquired 15 percent or more of the corporation's stock, the stockholder owned at least 85 percent of the corporation's outstanding voting stock, excluding shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or

on or after the date the stockholder acquired 15 percent or more of the corporation's stock, the merger or sale is approved by the board of directors and the holders of at least two-thirds of the outstanding voting stock that is not owned by the stockholder.

***Transfer Agent***

The transfer agent and registrar for Nuvelo's common stock is Computershare Trust Company N.A. Its offices are located at 1745 Gardena Ave., Glendale, California 91204, and its telephone number is (818) 502-1404.



**Table of Contents****COMPARATIVE RIGHTS OF NUVELO STOCKHOLDERS AND ARCA STOCKHOLDERS**

Nuvelo is incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of Nuvelo are currently, and will continue to be, governed by the Delaware General Corporation Law, or the DGCL. ARCA is incorporated under the laws of the State of Delaware, and prior to the consummation of the merger, the rights of ARCA stockholders are governed by the DGCL. Before the consummation of the merger, the rights of the holders of Nuvelo's common stock are also governed by the amended and restated certificate of incorporation of Nuvelo and the bylaws of Nuvelo. After the consummation of the merger, the rights of Nuvelo and ARCA stockholders will continue to be governed by the DGCL, the amended and restated certificate of incorporation of Nuvelo and the bylaws of Nuvelo. Due to differences between the governing documents of Nuvelo and ARCA, the merger will result in ARCA stockholders having different rights once they become Nuvelo stockholders.

The following is a summary of the material differences between the rights of Nuvelo stockholders and the rights of ARCA stockholders under each company's respective certificate of incorporation. While we believe that this summary covers the material differences between the two, this summary may not contain all of the information that is important to you. This summary is not intended to be a complete discussion of the respective rights of Nuvelo and ARCA stockholders and is qualified in its entirety by reference to the DGCL and the various documents of Nuvelo and ARCA that we refer to in this summary. You should carefully read this entire proxy statement/prospectus/consent solicitation and the other documents we refer to in this proxy statement/prospectus/consent solicitation for a more complete understanding of the differences between being a stockholder of Nuvelo and being a stockholder of ARCA. Nuvelo has filed its documents referred to herein with the SEC and will send copies of these documents to you upon your request.

	<b>ARCA</b>	<b>Nuvelo</b>
Authorized Capital Stock	ARCA's certificate of incorporation currently authorizes the issuance of 55,734,218 shares, consisting of two classes, common stock and preferred stock. 40,000,000 shares of common stock, par value \$0.001, and 15,734,218 shares of preferred stock, par value \$0.001, are authorized. Of the preferred stock, 9,222,257 shares are designated as Series A Preferred Stock, 3,720,692 shares are designated as Series B-1 Preferred Stock, and 2,791,269 shares are designated as Series B-2 Preferred Stock. The Series A Preferred, the Series B-1 Preferred and the Series B-2 Preferred are collectively referred to as the Series Preferred.	Nuvelo's certificate of incorporation currently authorizes the issuance of 105,000,000 shares, consisting of two classes, common stock and preferred stock. 100,000,000 shares of common stock, par value \$0.001, and 5,000,000 shares of preferred stock, par value \$0.001, are authorized. The preferred stock may be issued from time to time in one or more series.
Redemption	ARCA's certificate of incorporation provides that ARCA must redeem the Series Preferred as follows:  (i) A majority of the Principal Series Preferred Stockholders may	Nuvelo's certificate of incorporation provides that the board of directors is authorized to fix or alter the rights and terms of redemption (including sinking fund provisions, if any), and the redemption price or prices of

**Table of Contents**

<b>ARCA</b>	<b>Nuvelo</b>
require ARCA, to the extent it lawfully may do so, to redeem the then outstanding Series Preferred in three annual installments beginning with the fourth anniversary of the original issue date of the Series B-1 Preferred Stock and ending with the date two years from such date (each a Redemption Date ), provided that ARCA receives written notice of such election at least 60 days prior to the first Redemption Date. For purposes of ARCA s certificate of incorporation, Principal Series Preferred Stockholders means the following four entities or groups of entities, so long as such entity or group of entities owns at least 20% of the originally issued Series Preferred purchased by such entity or group of entities:	any wholly unissued series of preferred stock.
(A) Atlas Venture Fund VII, L.P. and its affiliates;	
(B) Boulder Ventures IV, L.P. and Boulder Ventures IV (Annex), L.P. and their respective affiliates;	
(C) Skyline Venture Partners Qualified Purchaser Fund IV, L.P. and its affiliates; and	
(D) InterWest Partners IX, LP and its affiliates.	
(ii) The number of shares that ARCA shall be required to redeem is equal to the quotient determined by dividing (A) the aggregate number of shares of Series Preferred outstanding immediately prior to the Redemption Date by (B) the number of remaining Redemption Dates (including the redemption date to which such calculation applies).	

Edgar Filing: NUVELO INC - Form S-4/A

(iii) If ARCA does not have sufficient funds legally available to redeem all the shares to be redeemed on a Redemption Date, it shall redeem such shares on a pro

**Table of Contents**

**ARCA**

**Nuvelo**

rata basis, and shall redeem the remaining shares as soon as sufficient funds are legally available.

(iv) If all of the shares to be redeemed are not redeemed by ARCA due to an insufficient legally available funds or an event of Default, the shares shall remain outstanding and shall be entitled to all the rights and preferences provided in the certificate of incorporation. If the shares are redeemed, all rights of the holder of such shares as a holder of Series Preferred shall cease and terminate with respect to those shares. A Default occurs when ARCA fails to redeem all of the required Series Preferred on any Redemption Date, unless such failure to redeem is approved by a majority of the members of ARCA's board of directors, acting in accordance with applicable law. Upon Default, the unpaid balance shall accrue interest at a rate of ten percent per annum, payable quarterly in arrears. If a Default continues for more than 90 days after the Redemption Date, the holders of the Series Preferred shall be entitled to elect a majority of the member of the board of directors for such period of time until the Default is cured and ARCA pays the holders of the Series Preferred any unpaid redemption price and any accrued interest.

(v) In the event of a call for redemption for any shares of Series Preferred, the Conversion Rights for such Series Preferred shall terminate as to the shares designated for redemption on the last business day preceding the applicable Redemption Date, unless Default is made in payment of the redemption price.

**Table of Contents**

	<b>ARCA</b>	<b>Nuvelo</b>
Dividends	<p>ARCA's certificate of incorporation provides for the payment of non-cumulative cash dividends to the holders of Series Preferred, in preference to the holders of common stock, if and when declared by the board of directors, at the greater of (i) a rate of 8% of the Original Issue Price per annum, and (ii) in the event that dividends are paid on any share of common stock, the per share amount equal (computed on an as-if-converted to common stock basis) to the amount paid or set aside for each share of common stock.</p>	<p>Nuvelo's certificate of incorporation provides that the board of directors is authorized to fix or alter the dividend rights and dividend rates of any wholly unissued series of preferred stock. Nuvelo's certificate of incorporation is silent as to dividends with respect to common stock. The board of directors may therefore declare and pay dividends upon shares of common stock in the manner and upon the terms and conditions provided in the DGCL.</p>
Rights on Liquidation	<p>ARCA's certificate of incorporation provides that upon a liquidation, dissolution or winding up of the Company, whether voluntary or involuntary (a "Liquidation Event"), before any distribution or payment shall be made to the holder of common stock, the holders of Series Preferred shall be entitled to be paid out of the assets of ARCA legally available for distribution an amount equal to the Original Issue Price (as defined in the certificate of incorporation) of the applicable series of Series Preferred (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like), plus all declared and unpaid dividends (the "Series Preferred Liquidation Amount"). If ARCA's assets are insufficient to make payment in full to all Series Preferred holders, then such assets shall be distributed among the Series Preferred holders ratably in proportion to the full amounts to which they would otherwise be respectively entitled.</p> <p>After payment of the full liquidation preference set forth above, ARCA's assets legally</p>	<p>Nuvelo's certificate of incorporation provides that the board of directors is authorized to fix or alter the liquidation preferences of any wholly unissued series of preferred stock.</p>

**Table of Contents**

	<b>ARCA</b>	<b>Nuvelo</b>
	<p>available for distribution, if any, shall be distributed ratably to the holders of common stock and Series Preferred on an as-if-converted to common stock basis, until such holders of Series Preferred have received an aggregate amount per share of Series Preferred equal to three times the applicable Original Issue Price (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like); thereafter, the remaining assets legally available for distribution, if any, shall be distributed ratably to the holders of common stock.</p>	
Asset Transfer or Acquisition Rights	<p>ARCA's certificate of incorporation provides that, in the event that ARCA is a party to an Acquisition or Asset Transfer, as defined in the certificate of incorporation, then (i) each holder of Series Preferred shall be entitled to receive, for each share of Series Preferred then held, out of the proceeds of such Acquisition or Asset Transfer, an amount of cash, securities or other property that such holder would be entitled to receive pursuant to the liquidation preferences set forth above, and (ii) subject to the preceding clause, each holder of common stock shall be entitled to receive, for each share of common stock then held, out of the proceeds of such Acquisition or Asset Transfer, the amount of cash, securities or other property to which such holder would be entitled to receive pursuant to the liquidation preference set forth above.</p>	<p>Nuvelo's certificate of incorporation is silent as to asset transfer or acquisition rights, but generally authorizes the board of directors to fix or alter any designations, preferences and relative, participating, optional or other special rights, and any qualifications, limitations or restrictions thereof, of any wholly unissued series of preferred stock.</p>

**Table of Contents**

	<b>ARCA</b>	<b>Nuvelo</b>
Conversion Rights	<p>ARCA's certificate of incorporation provides that any shares of Series Preferred may, at the option of the holder, be converted at any time into a number of shares of common stock equal to the product obtained by multiplying the applicable Series Preferred Conversion Rate then in effect by the number of shares of Series Preferred being converted. The Conversion Rate is equal to the quotient obtained by dividing the Original Issue Price by the Series Preferred Conversion Price (as defined in the certificate of incorporation and subject to adjustment as described below).</p>	<p>Nuvelo's certificate of incorporation authorizes the board of directors to fix or alter any conversion rights of any wholly unissued series of preferred stock.</p>

In addition, ARCA's certificate of incorporation provides for the automatic conversion of each share of Series Preferred into shares of common stock, based on the then-effective Series Preferred Conversion Price (A) at any time upon the affirmative election of the Principal Series Preferred Stockholders, (B) immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of common stock for the account of the company in which (i) the per share price is at least two times the then-effective Series Preferred Conversion Price for the Series B-1 Preferred or the Series B-2 Preferred, whichever is higher, and (ii) the net cash proceeds to the company (after underwriting discounts, commissions and fees) are at least \$30,000,000, or (B) if the effective time of the merger with Nuvelo occurs prior to 11:59 p.m. Eastern Time on March 31, 2009, then immediately prior to the effective time of the merger.

**Table of Contents**

	<b>ARCA</b>	<b>Nuvelo</b>
	Finally, the certificate of incorporation provides for adjustments to the Conversion Price for stock splits, combinations, certain common stock dividends and distributions, reclassifications, exchanges, substitutions, reorganizations, mergers, consolidations and certain sales of shares below the Conversion Price.	
Number of Directors and Election	<p>ARCA's certificate of incorporation provides that the number of directors is to be set by the board of directors as provided in the bylaws, subject to the approval rights of the stockholders described under "Stockholder Approval Rights" below. Directors are to be elected as follows:</p> <p>(i) For so long as at least 20% of the originally issued shares of Series A Preferred remain outstanding, the holders of Series A Preferred, voting as a separate class, shall be entitled to elect two members of the Board, and to remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors.</p> <p>(ii) For so long as at least 20% of the originally issued shares of Series B Preferred remain outstanding, and unless and until a Pro Rata Event (as defined in that certain Voting Agreement by and among ARCA and certain holders of common stock and the holders of Series Preferred dated May 31, 2007) occurs, the holders of Series B Preferred, voting as a separate class, shall be entitled to elect two members of the board, and to remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors. In the event of a Pro Rata Event and for so long as at least 20% of the originally issued shares of Series B Preferred</p>	<p>Nuvelo's certificate of incorporation provides that the board shall have that number of directors as set forth in the bylaws of the company. The board is divided into three classes, as nearly equal in number as possible. At each annual meeting of stockholders or special meeting in lieu thereof, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders or special meeting in lieu thereof after their election and until their successors are duly elected and qualified.</p> <p>Newly created directorships resulting from an increase in the authorized number of directors or any vacancies resulting from death, resignation, retirement, disqualification, removal from office or other cause may be filled only by a majority vote of the directors then in office even though less than a quorum, or the sole remaining director, and not by the stockholders.</p>



**Table of Contents**

	<b>ARCA</b>	<b>Nuvelo</b>
	<p>remain outstanding, the holders of Series B Preferred, voting as a separate class, will only be entitled to elect one member of the board, and to remove from office such director and to fill any vacancy caused by the resignation, death or removal of such director.</p>	
	<p>(iii) The holders of common stock, voting as a separate class, shall be entitled to elect one member of the board, and to remove from office such director and to fill any vacancy caused by the resignation, death or removal of such director.</p>	
	<p>(iv) The holders of common stock and Series Preferred, voting together as a single class on an as-if-converted basis, shall be entitled to elect all remaining members of the board, and to remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors.</p>	
Stockholder Action by Written Consent	<p>ARCA's certificate of incorporation does not contain a provision disallowing stockholder action by written consent.</p>	<p>Nuvelo's certificate of incorporation provides that no action shall be taken by the stockholders except at a duly called annual or special meeting of stockholders, and that the stockholders may not take action by written consent.</p>
Amendment of Charter	<p>ARCA's certificate of incorporation provides that it may be amended as described in Stockholder Approval Rights below.</p>	<p>Nuvelo's certificate of incorporation provides that it may be amended by an affirmative vote of the holders of a majority of the voting rights of all classes of stock entitled to vote, provided, however, that no amendment, alteration, change or repeal of any provision requiring the affirmative vote of the holders of more than a majority of the voting rights may be made unless approved by the affirmative vote of such greater number of holders. The affirmative vote of the holders of 66 2/3% of the voting rights is required to amend, repeal or adopt any provision inconsistent with the provisions of the certificate of</p>

**Table of Contents**

	<b>ARCA</b>	<b>Nuvelo</b>
		incorporation relating to: (i) the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii) the authority and power of the board of directors and the procedure required to amend the corporation's bylaws; (iii) the percentage of the shares necessary to amend the certificate of incorporation; (iv) the elimination of directors' personal liability for monetary damages arising from their negligence and gross negligence; and (v) indemnification of directors, officers and other persons.
Amendment of Bylaws	ARCA's certificate of incorporation expressly empowers the board of directors to adopt, amend or repeal the bylaws of the company; provided, however, that, in addition to any vote of the holders of any class or series of stock of as required by law or by the certificate of incorporation (as described under "Stockholder Approval Rights" below), the affirmative holders of at least a majority of voting power of all of the then-outstanding ARCA capital stock of ARCA entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, adopt or repeal any provision of ARCA's bylaws.	Nuvelo's certificate of incorporation expressly empowers the board of directors to make, alter or repeal the bylaws of the company. Notwithstanding the foregoing, the bylaws may be rescinded, altered, amended or repealed in any respect by the affirmative vote of the holders of at least 66 2/3% of the outstanding voting stock of the company, voting together as a single class.
Stockholder Approval Rights	ARCA's certificate of incorporation provides that, in addition to any other vote or consent required by the charter or by law, at least a majority of the Principal Series Preferred Stockholders shall be necessary for effecting or validating the following actions:  (i) Any amendment, alteration, or repeal of any provision of ARCA's certificate of incorporation or bylaws;	Nuvelo's certificate of incorporation provides that the affirmative vote of the holders of shares representing a majority of the outstanding common stock shall be required to approve (a) the sale of U.S. Patent 5,202,231, or (b) exclusive license or assignment to a single person or entity, other than a wholly-owned subsidiary, which license or assignment has the same effect as a sale of all rights, title and interest in U.S. Patent 5,202,231.

**Table of Contents**

<b>ARCA</b>	<b>Nuvelo</b>
(ii) Any authorization or any designation, whether by reclassification or otherwise, of any new class or series of stock or any other securities convertible into equity securities of ARCA ranking on parity with or senior to the Series Preferred in right of redemption, liquidation preference, voting or dividend rights;	
(iii) With certain exceptions, any redemption, repurchase, payment or declaration of dividends or other distributions with respect to common stock or preferred stock;	
(iv) Any agreement by ARCA or its stockholders regarding an Asset Transfer or Acquisition;	
(v) Any Liquidation Event (as defined in the certificate of incorporation);	
(vi) Any acquisition by ARCA of another entity or person;	
(vii) Any increase or decrease in the authorized number of members of ARCA's board of directors;	
(viii) Any exclusive license entered into by ARCA not in the ordinary course of business, any license granted by ARCA of Bucindolol, or any license granted by ARCA with respect to any intellectual property owned or controlled by ARCA relating to Bucindolol;	
(ix) Any guarantee or endorsement given by ARCA, or otherwise if the company becomes directly or contingently liable on any indebtedness of any other person, firm or	

other entity;

(x) With certain exceptions, any grant by ARCA of a security interest in the assets of ARCA;

(xi) The creation of any subsidiary;

**Table of Contents**

**ARCA**

**Nuvelo**

(xii) Any loan or advance to any officer, director, employee, consultant or any other person, or any subsidiary or other corporation, partnership, person, individual or other entity;

(xiii) Any transaction with any director, officer or employee of the company or any associate (as such term is defined in Rule 12b-2 of the Securities Exchange Act of 1934) of any such person except transactions made in the ordinary course of business, pursuant to reasonable requirements of the Company's business and upon either (A) fair and reasonable terms or (B) terms that are otherwise approved by a majority of the members of the board;

(xiv) Any material change to the principal business of the company, entry into a new principal line of business, or exit from the current principal line of business;

(xv) The hiring, firing or change to the compensation of the company's Chief Executive Officer; or

(xvi) Any new borrowings by the company in excess of \$250,000.

Voting Rights

ARCA's certificate of incorporation provides that each holder of shares of Series Preferred shall be entitled to the number of votes equal to the number of shares of common stock into which such shares of Series Preferred could be converted and shall have voting rights and powers equal to the voting rights and powers of the common stock. Except as otherwise provided in the certificate of incorporation, the Series Preferred shall vote with the common stock and not as a separate class.

Nuvelo's certificate of incorporation is silent on the voting rights of stockholders; therefore, Nuvelo stockholders have the voting rights accorded to them by the DGCL.

**Table of Contents**

	<b>ARCA</b>	<b>Nuvelo</b>
Limitation of Personal Liability of Directors	ARCA's certificate of incorporation provides that, to the fullest extent permitted by law, a director of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as a director. Further, the certificate of incorporation provides that if any law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the company shall be eliminated or limited to the fullest extent permitted by Delaware law.	Nuvelo's certificate of incorporation provides that, to the fullest extent permitted by law, as the same exists or as may hereafter be amended, a director of the company shall not be personally liable to the company or its stockholders for monetary damages for breach of fiduciary duty as a director.
Indemnification of Officers and Directors	ARCA's certificate of incorporation does not provide for indemnification of officers and directors.	Nuvelo's certificate of incorporation provides that, to the fullest extent permitted by law, Nuvelo may indemnify and advance indemnification expenses to any person made or threatened to be made a party to any action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she or his or her testator or intestate is or was a director, officer or employee of the company or any predecessor of the company, or serves or served at any time as a director, officer or employee at the request of the company or any predecessor to the company. The company may, to the fullest extent permitted by law, purchase and maintain insurance on behalf of any such director or officer against any liability which may be asserted against him or her and may enter into contract providing for the indemnification of any such person to the fullest extent permitted by law.

---

**Table of Contents**

**UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS**

*Except where specifically noted, the following information and all other information contained in this proxy statement prospectus/consent solicitation does not give effect to the proposed reverse stock split described in Nuvelo Proposal No. 2.*

The following unaudited pro forma condensed combined financial statements give effect to the proposed business combination of Nuvelo and ARCA. For accounting purposes, ARCA is considered to be acquiring Nuvelo in the merger inasmuch as the existing stockholders of ARCA will have a controlling interest in the combined company and the management of ARCA will be the management of the combined company. Accordingly, the acquisition consideration is allocated among the fair values of the assets and liabilities of Nuvelo, while the historical results of ARCA are reflected in the results of the combined company.

In the unaudited pro forma condensed combined financial statements included in the proxy statement/prospectus/consent solicitation filed on October 30, 2008, the proposed merger transaction was presented as a business combination using the purchase method of accounting in accordance with Statement of Financial Accounting Standard No. 141, *Business Combinations*, or SFAS 141, as the consummation of the transaction was assumed to be on or before December 31, 2008. The stockholders' meeting and consummation of the transaction is now expected to be in the first quarter of 2009; therefore, the transaction is presented in these unaudited pro forma condensed combined financial statements using the acquisition method of accounting in accordance with Statement of Financial Accounting Standards No. 141R, *Business Combinations*, or SFAS 141R.

For purposes of these unaudited pro forma condensed combined financial statements, Nuvelo and ARCA have made allocations of the estimated acquisition consideration to the assets to be acquired and liabilities to be assumed based on preliminary estimates of their fair value, as described in Note 2 to these unaudited pro forma condensed combined financial statements. A final determination of these estimated fair values, which cannot be made prior to the completion of the merger, will be based on the actual net assets of Nuvelo that exist as of the date of completion of the merger. The actual amounts recorded as of the completion of the merger may differ materially from the information presented in these unaudited pro forma condensed combined financial statements as a result of:

net cash used in the Nuvelo operations between the pro forma balance sheet date of September 30, 2008 and the closing of the merger;

a change in the fair value of Nuvelo's common stock;

the timing of completion of the merger;

a change in the methodology used to determine the consideration transferred; and

other changes in the Nuvelo net assets that may occur prior to completion of the merger, which could cause material differences in the information presented below.

The unaudited pro forma condensed combined balance sheet as of September 30, 2008 gives effect to the proposed merger as if it occurred on September 30, 2008 and combines the historical balance sheets of Nuvelo and ARCA as of September 30, 2008 and \$8.75 million of notes payable issued by ARCA in October 2008, which convert into common stock upon the closing of the proposed merger. The ARCA balance sheet information was derived from its unaudited balance sheet as of September 30, 2008 included herein. The Nuvelo balance sheet information was derived from its unaudited condensed consolidated balance sheet included in its Form 10-Q for the quarterly period ended September 30, 2008 and also included herein. The estimated acquisition consideration of the Nuvelo acquisition in these unaudited pro forma condensed combined financial statements was based on the market capitalization of Nuvelo as of September 30, 2008, the date on which the proposed merger occurred for purposes of these pro forma financial statements, and the fair values of its vested stock options and warrants outstanding on that date. This was deemed the best estimate of the fair value of Nuvelo as the entity being acquired for accounting purposes on that date and the consideration paid in the





---

**Table of Contents**

transaction. The September 30, 2008 balance sheet of Nuvelo reflected approximately \$59 million of cash, cash equivalents, and marketable securities, and aggregate net assets with a fair value of approximately \$46 million, which significantly exceeded Nuvelo's market capitalization at that date. The application of the rules governing the preparation of this unaudited pro forma condensed combined balance sheet results in significant excess of fair value of acquired net assets over acquisition consideration, on a pro forma basis, which would be recognized as a gain on bargain purchase upon consummation.

The final acquisition consideration allocation will differ significantly from preliminary estimates. The actual acquisition accounting upon consummation of the merger will be based on the fair value of the consideration paid and fair values of Nuvelo's assets and liabilities as determined at the time of consummation. Nuvelo's market capitalization has experienced significant fluctuations during 2008 as a result of both market and company-specific factors, and such fluctuations may continue. Further, Nuvelo continues to use its cash and other liquid assets to finance its ongoing operations. As a result, at the date the merger is consummated, Nuvelo's cash, cash equivalents, and marketable securities are expected to be significantly less than at September 30, 2008, and its market capitalization cannot be predicted. ARCA and Nuvelo will re-evaluate the accounting method used to determine the consideration at the time of merger consummation, taking into consideration Nuvelo's market capitalization at the time of consummation, and may consider alternative approaches, such as basing the acquisition consideration on the fair value of Nuvelo's net assets, or based on the fair value of ARCA's common and redeemable convertible preferred stock, rather than Nuvelo's common stock. ARCA and Nuvelo do not anticipate that the final acquisition accounting performed when the merger is consummated will result in a significant gain on bargain purchase amount because the proposed merger is not considered a bargain purchase transaction. Please see the notes to these unaudited pro forma condensed combined financial statements for further discussion.

The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2008 and the year ended December 31, 2007 are presented as if the merger was consummated on January 1, 2007, and combine the historical results of Nuvelo and ARCA for the nine months ended September 30, 2008 and the year ended December 31, 2007, respectively. The historical results of ARCA were derived from its unaudited statement of operations for the nine months ended September 30, 2008 and its audited statement of operations for the year ended December 31, 2007, included herein. The historical results of Nuvelo were derived from its unaudited condensed consolidated statement of operations for the nine months ended September 30, 2008 included in its Form 10-Q for the quarterly period ended September 30, 2008, and its audited consolidated statement of operations included in its Annual Report on Form 10-K for the year ended December 31, 2007, which are also included herein. The unaudited pro forma condensed combined financial statements do not account for the effect of a reverse stock split of Nuvelo common stock to be implemented prior to the consummation of the merger.

The unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized had Nuvelo and ARCA been a combined company during the specified periods. The pro forma adjustments are based on the preliminary information available at the time of the preparation of this proxy statement/prospectus/consent solicitation. The unaudited pro forma condensed combined financial statements, including the notes thereto, are qualified in their entirety by reference to, and should be read in conjunction with, the historical financial statements of ARCA for the nine months ended September 30, 2008 and for the year ended December 31, 2007 included herein, and the historical condensed consolidated financial statements of Nuvelo included in its Form 10-Q for the quarterly period ended September 30, 2008, and the historical consolidated financial statements of Nuvelo included in its Annual Report on Form 10-K for the year ended December 31, 2007, also included herein.

**Table of Contents****Unaudited Pro Forma Condensed Combined Balance Sheet**

As of September 30, 2008

(in thousands)

	Historical Nuvelo	ARCA	Pro Forma Adjustments		Pro Forma Combined
<b>ASSETS</b>					
Current assets:					
Cash and cash equivalents	\$ 35,168	\$ 5,457	\$ 8,750	M	\$ 49,375
Marketable securities	23,964				23,964
Collaboration receivables	835				835
Other current assets	950	740	(564)	B	1,126
<b>Total current assets</b>	<b>60,917</b>	<b>6,197</b>	<b>8,186</b>		<b>75,300</b>
Restricted cash	6,000				6,000
Property and equipment, net	7,383	1,289	(5,949)	D	2,723
In-process research and development			6,000	D	6,000
Other assets	1,099	42			1,141
<b>Total assets</b>	<b>\$ 75,399</b>	<b>\$ 7,528</b>	<b>\$ 8,237</b>		<b>\$ 91,164</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)</b>					
Current liabilities:					
Accounts payable	\$ 2,642	\$ 1,653	\$		\$ 4,295
Accrued compensation and employee benefits	1,191	859			2,050
Current portion of notes payable		1,451			1,451
Current portion of deferred revenue	250		(250)	D	
Current portion of deferred rent	1,444		(1,444)	D	314
			314	D	
Current portion of accrued facility exit costs	6,816		37	D	6,853
Accrued expenses and other current liabilities	2,002	1,394	6,200	B	12,328
			2,732	E	
<b>Total current liabilities</b>	<b>14,345</b>	<b>5,357</b>	<b>7,589</b>		<b>27,291</b>
Non-current portion of notes payable, net of discount		2,490			2,490
Non-current portion of deferred revenue	875		(875)	D	
Non-current portion of deferred rent	4,514	457	(4,514)	D	1,355
			898	D	
Non-current portion of facility exit costs	10,105		229	D	10,334
Other liabilities	845		(69)	D	776
Restricted stock subject to repurchase		75	(75)	A	
Warrants for preferred stock		113	(113)	A	
<b>Total liabilities</b>	<b>30,684</b>	<b>8,492</b>	<b>3,070</b>		<b>42,246</b>
Redeemable convertible preferred stock		32,851	(32,851)	A	
Stockholders' equity deficit:					
Common stock and additional paid-in-capital	542,475	1,762	32,964	A	69,217
			(542,422)	C	
			24,149	C	

Edgar Filing: NUVELO INC - Form S-4/A

			8,750	M	
			814	M	
			725	A	
Accumulated other comprehensive loss	(90)		90	C	
Accumulated deficit	(497,670)	(35,577)	502,112	C	(20,299)
			(6,764)	B	
			(2,732)	E	
			21,796	F	
			(814)	M	
			(650)	A	
<b>Total stockholders equity (deficit)</b>	44,715	(33,815)	38,018		48,918
<b>Total liabilities and stockholders equity (deficit)</b>	\$ 75,399	\$ 7,528	\$ 8,237		\$ 91,164

See accompanying notes to the unaudited pro forma condensed combined financial statements

**Table of Contents****Unaudited Pro Forma Condensed Combined Statement of Operations**

(in thousands, except per share data)

	For the Nine Months Ended September 30, 2008				Combined
	Nuvelo	ARCA	Adjustments	Pro Forma	
Contract revenues	\$ 15,188	\$	\$		\$ 15,188
Operating expenses:					
Research and development	24,555	8,363	(568)	G	32,999
			649	H	
Sales, general and administrative	11,359	6,037	(572)	G	16,887
			194	H	
			(131)	I	
Restructuring	2,470				2,470
Facility exit charges	1,472				1,472
Impairment of goodwill	4,671		(4,671)	J	
Total operating expenses	44,527	14,400	(5,099)		53,828
Operating loss	(29,339)	(14,400)	5,099		(38,640)
Interest income, net	2,182	144			2,326
Net loss	(27,157)	(14,256)	5,099		(36,314)
Less: Accretion of redeemable convertible preferred stock		(42)	42	K	
Net loss attributable to common stockholders	\$ (27,157)	\$ (14,298)	\$ 5,141		\$ (36,314)
Basic and diluted net loss per share attributable to common stockholders	\$ (0.51)	\$ (3.29)			\$ (0.22)
Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders	53,536	4,343	103,571	L	161,450

See accompanying notes to the unaudited pro forma condensed combined financial statements

**Table of Contents****Unaudited Pro Forma Condensed Combined Statement of Operations**

(in thousands, except per share data)

	For the Year Ended December 31, 2007				Combined
	Historical Nuvelo	ARCA	Adjustments	Pro Forma	
Contract revenues	\$ 46,861	\$	\$		\$ 46,861
Operating expenses:					
Research and development	42,654	10,244	(758)	<b>G</b>	53,002
			862	<b>H</b>	
Sales, general and administrative	20,762	4,210	(760)	<b>G</b>	24,315
			258	<b>H</b>	
			(155)	<b>I</b>	
Restructuring	2,336				2,336
Total operating expenses	65,752	14,454	(553)		79,653
Operating loss	(18,891)	(14,454)	553		(32,792)
Interest income, net	6,590	460			7,050
Net loss	(12,301)	(13,994)	553		(25,742)
Less: Accretion of redeemable convertible preferred stock		(38)	38	<b>K</b>	
Net loss attributable to common stockholders	\$ (12,301)	\$ (14,032)	\$ 591		\$ (25,742)
Basic and diluted net loss per share attributable to common stockholders	\$ (0.23)	\$ (3.71)			\$ (0.16)
Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders	53,333	3,781	104,133	<b>L</b>	161,247

See accompanying notes to the unaudited pro forma condensed combined financial statements

**Table of Contents****NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS****1. Basis of Presentation**

On September 24, 2008, Nuvelo and ARCA entered into an Agreement and Plan of Merger and Reorganization, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated October 28, 2008, under which Dawn Acquisition, Inc., a wholly-owned subsidiary of Nuvelo formed by Nuvelo in connection with the merger, will merge with and into ARCA. ARCA will become a wholly-owned subsidiary of Nuvelo and the surviving corporation of the merger. Upon completion of the merger, Nuvelo will change its name to ARCA biopharma, Inc. Pursuant to the terms of the merger agreement, Nuvelo will issue to the stockholders of ARCA shares of Nuvelo common stock and will assume all of the stock options and stock warrants of ARCA outstanding as of the merger closing date, such that ARCA stockholders, including holders of common stock and redeemable convertible preferred stock, convertible note holders, option holders and warrant holders will own approximately 67% of the combined company on a pro forma fully diluted basis and Nuvelo stockholders and option holders will own approximately 33% of the combined company on a pro forma fully diluted basis. The merger is intended to qualify as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code. The merger is subject to customary closing conditions, including approval by Nuvelo and ARCA stockholders.

Because ARCA security holders will own approximately 67% of the voting stock of the combined company after the transaction and the management of ARCA will be the management of the combined company, ARCA is deemed to be the acquiring company for accounting purposes and the transaction will be accounted for as a reverse acquisition under the acquisition method of accounting for business combinations in accordance with accounting principles generally accepted in the United States. Accordingly, the assets and liabilities of Nuvelo will be recorded as of the merger closing date at their estimated fair values.

**2. Acquisition Accounting In Accordance with SFAS 141R**

In December 2007, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 141R, *Business Combinations*, or SFAS 141R, which replaces Statement of Financial Accounting Standards No. 141, *Business Combinations*, or SFAS 141. SFAS 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The effective date of SFAS 141R for ARCA will be January 1, 2009.

In the unaudited pro forma condensed combined financial statements included in the proxy statement/prospectus/consent solicitation filed on October 30, 2008, the proposed merger transaction was presented as a business combination using the purchase method of accounting in accordance with SFAS 141, as the consummation of the transaction was assumed to be on or before December 31, 2008. The stockholders meeting and consummation of the transaction is now expected to be in the first quarter of 2009; therefore, the transaction is being presented in these unaudited pro forma condensed combined financial statements in accordance with SFAS 141R.

The following items have been presented in accordance with SFAS 141R differ from how they would have been accounted for under SFAS 141:

The transaction costs incurred in connection with the transaction by ARCA totaling \$5.1 million are recorded as an expense in the period incurred rather than as part of the acquisition consideration.

Negative goodwill (if any) is not allocated to reduce the carrying values of various assets, but instead will be recorded as an ordinary gain resulting from a bargain purchase in the statement of operations in the period of consummation, as opposed to an extraordinary gain.

The restructuring expenses estimated at \$2.0 million owed to Nuvelo employees as a result of severance agreement payments that will become due as a result of the merger and additional costs

**Table of Contents**

related to the planned exit of the Nuvelo facility or costs to terminate other duplicative activities will be recorded as expense in the period costs are incurred rather than part of the acquisition accounting. However, contractual compensation liabilities as a result of change of control provision per certain executive employment agreements totaling \$2.7 million remain as part of the acquisition accounting.

The acquired in-process research and development, with a fair value estimated at \$6.0 million at September 30, 2008, will be measured at fair value as of the date of the transaction and recorded as an indefinite-lived asset on the balance sheet and reviewed for impairment rather than charged to expense as of the acquisition date. If the related development is completed, the acquired intangible asset is considered a finite-lived asset and amortized to the statement of operations. If the related development is abandoned or the asset is otherwise impaired, the asset is written off.

The estimated total acquisition consideration of Nuvelo was based on the market capitalization of Nuvelo as of September 30, 2008, the date on which the proposed merger is deemed to have occurred for purposes of the unaudited pro forma condensed combined balance sheet, and the fair values of its vested stock options and warrants outstanding on that date, as this was deemed the best estimate of the fair value of Nuvelo as the entity being acquired for accounting purposes on that date, and is as follows (in thousands):

Market capitalization of Nuvelo common stock	\$ 23,612
Estimated fair value of options and warrants assumed	590
<b>Total estimated acquisition consideration</b>	<b>\$ 24,202</b>

Under the acquisition method of accounting, in accordance with SFAS 141R, the total estimated acquisition consideration as shown in the table above is allocated to the Nuvelo tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the date of the consummation of the transaction.

The estimated acquisition consideration and the preliminary allocation of the estimated acquisition consideration are in part based upon a preliminary management valuation, as described below, and ARCA's and Nuvelo's estimates and assumptions are subject to change until the consummation of the merger.

*Cash and cash equivalents, marketable securities and other tangible assets and liabilities:* The tangible assets and liabilities were valued at their respective carrying amounts, except for adjustments to certain property and equipment, deferred revenue, deferred rent, facility exit charges and other liabilities, as ARCA and Nuvelo believe that these amounts approximate their current fair values.

*In-process research and development:* In-process research and development represents incomplete Nuvelo research and development projects. ARCA and Nuvelo estimate that approximately \$6.0 million of the acquisition consideration represents purchased in-process research and development primarily related to projects associated with the Nuvelo NU206, NU172 and cancer antibody programs. The fair value of in-process research and development was determined using an income approach, as well as discussions with Nuvelo management and a review of certain program-related documents and forecasts prepared by Nuvelo management. The income approach, a valuation method that establishes the business value based on a stream of future economic benefits, such as net cash flows, discounted to their present value, included probability adjustments to project expenses and revenue in order to reflect the expected probabilities of incurring development cost prior to commercialization and the probability of achieving commercial revenue due to drug discovery and regulatory risks. The rates utilized to discount probability adjusted net cash flows to their present values range from 16% to 18%, and reflect the time value of money and risks of commercialization, sales, and competition, which are risk elements explicitly not addressed in the probability adjustments.

**Table of Contents**

*Pre-acquisition contingencies:* ARCA and Nuvelo have not currently identified any pre-acquisition contingencies where a liability is probable and the amount of the liability can be reasonably estimated. If information becomes available to ARCA and Nuvelo prior to the end of the measurement period, which would indicate that a liability is probable and the amount can be reasonably estimated, such items will be included in the acquisition consideration allocation.

The final determination of the acquisition consideration allocation will be based on the fair values of the assets acquired and liabilities assumed as of the date the proposed merger is consummated. The preliminary allocation of the estimated acquisition consideration assuming the merger had closed on September 30, 2008 is as follows (in thousands):

	<b>Amount</b>
Preliminary pro forma acquisition consideration allocation:	
Cash and cash equivalents	\$ 35,168
Marketable securities	23,964
Collaboration receivable	835
Other current assets	950
Restricted cash	6,000
Property and equipment	1,434
In-process research and development	6,000
Other long-term assets	1,099
Accounts payable	(2,642)
Accrued employee liabilities	(1,191)
Other current liabilities	(6,444)
Accrued facility exit costs	(17,187)
Other liabilities	(776)
Unfavorable lease obligation	(1,212)
Gain on bargain purchase	(21,796)
<b>Total pro forma acquisition consideration</b>	<b>\$ 24,202</b>

In accordance with SFAS 141R, any excess of fair value of acquired net assets over the acquisition consideration results in a gain on bargain purchase. Prior to recording a gain, the acquiring entity shall reassess whether all acquired assets and assumed liabilities have been identified and recognized and perform re-measurements to verify that the consideration paid, assets acquired, and liabilities assumed have been properly valued.

The final acquisition consideration allocation may change significantly from preliminary estimates. The actual acquisition accounting upon consummation of the merger will be based on the fair value of the consideration paid and fair values of Nuvelo's assets and liabilities as determined at the time of consummation. Nuvelo's market capitalization has experienced significant fluctuations during 2008 as a result of both market and company-specific factors, and such fluctuations may continue. Further, Nuvelo continues to use its cash and other liquid assets to finance its ongoing operations. As a result, at the date the merger is consummated, Nuvelo's cash, cash equivalents, and marketable securities are expected to be significantly less than at September 30, 2008, and its market capitalization cannot be predicted. ARCA will re-evaluate the determination of the acquisition consideration at the time of merger consummation, taking into consideration both Nuvelo's market capitalization at the time of consummation, and may consider alternative approaches, such as basing the acquisition consideration on the fair value of Nuvelo's net assets, or based on the fair value of ARCA's common and redeemable convertible preferred stock rather than Nuvelo's common stock. ARCA and Nuvelo do not anticipate that the final acquisition accounting performed when the merger is consummated will result in a significant gain on bargain purchase amount because the proposed merger is not considered a bargain purchase transaction.



---

**Table of Contents**

**3. Pro Forma Adjustments**

Pro forma adjustments are necessary to reflect the estimated acquisition consideration and to adjust amounts related to Nuvelo's tangible and identifiable intangible assets and liabilities to a preliminary estimate of their fair values.

The pro forma adjustments included in the unaudited pro forma condensed combined financial statements are as follows (dollar amounts in thousands):

- (A) To reflect the conversion of all shares of ARCA preferred stock and restricted stock to Nuvelo common stock. The adjustment includes an adjustment of \$650 for an October 2008 modification of an ARCA executive's restricted stock agreement such that the restricted stock will vest upon the closing of the proposed merger.
- (B) To reflect the ARCA and Nuvelo estimated transaction costs payable in cash that have not been incurred as of September 30, 2008, plus \$564 of transaction costs incurred by ARCA through September 30, 2008.
- (C) To reflect the elimination of Nuvelo's additional paid-in capital, accumulated deficit and accumulated other comprehensive loss.
- (D) To adjust Nuvelo's historical assets and liabilities to their estimated fair values, including an estimated \$6,000 in in-process research and development related to projects associated with the Nuvelo NU206, NU172 and cancer antibody programs. Please see Note 2 to these unaudited pro forma condensed combined financial statements for further discussion.
- (E) To reflect contractual compensation liabilities as a result of a change in control provision per certain executive employment agreements.
- (F) To record gain on bargain purchase. Gain on bargain purchase is calculated as the excess of the fair value of Nuvelo's assets acquired and liabilities assumed over the acquisition consideration. The \$21,796 of gain on bargain purchase is reflected on the pro forma condensed combined balance sheet as of September 30, 2008 as a decrease of accumulated deficit. Such amount would be recorded as a gain in the period that the transaction is consummated. Because this gain is directly attributable to the transaction and will not have a continuing impact, this gain is not reflected in the pro forma condensed combined statements of operations. The final acquisition consideration allocation may change significantly from preliminary estimates. ARCA and Nuvelo do not anticipate that the final acquisition accounting performed when the merger is consummated will result in a significant gain on bargain purchase amount because the proposed merger is not considered a bargain purchase transaction (see Note 2 to these unaudited pro forma combined condensed financial statements for further discussion).
- (G) To reflect a reduction of Nuvelo's historical depreciation and amortization expense associated with the reduction in the carrying value of property and equipment to fair value.
- (H) Adjustment to rent expense based on the fair value of the estimated unfavorable lease obligation.
- (I) Adjustment to accretion expense related to the facility exit charge to reflect a changed fair value.
- (J) Adjustment to reverse the impairment of goodwill. Nuvelo recorded goodwill impairment in the period ended June 30, 2008 in accordance with the two-step process per SFAS No. 142, *Goodwill and other Intangible Assets*. Had this proposed merger been consummated on

## Edgar Filing: NUVELO INC - Form S-4/A

January 1, 2007, the goodwill would have been eliminated in acquisition accounting.

- (K) Adjustment to reverse the accretion of ARCA preferred stock that will be converted to common stock as part of the merger.
- (L) Represents pro forma Nuvelo common shares, net of ARCA weighted common shares outstanding, issued at January 1, 2007, to ARCA stockholders upon the closing of the merger.

**Table of Contents**

- (M) Reflects the issuance by ARCA of \$8,750 of notes payable, which convert into common stock upon the closing of the proposed merger. As part of the arrangement, note holders also received warrants to purchase ARCA common stock. For the purposes of the accompanying unaudited pro forma condensed combined financial statements, the fair value of the warrants was estimated based on the closing price of Nuvelo's common stock on September 30, 2008, which resulted in an estimated fair value of approximately \$814. This estimated fair value results in a discount to the carrying value of the notes and a charge to accumulated deficit through interest expense. The financing may also result in recognition of a beneficial conversion feature, which is dependent on the exchange ratio of ARCA and Nuvelo shares on the closing date and cannot be estimated until the closing of the proposed merger.

**4. Non-recurring Transaction Fees**

ARCA and Nuvelo have incurred and will continue to incur certain non-recurring expenses in connection with the transaction. These expenses are currently estimated as follows (in thousands):

Financial advisors' fee	\$ 5,100
Accounting and legal fees	2,150
Printing fees and other miscellaneous expenses	400
 Total fees	 \$ 7,650

The estimated expenses totaling \$6.2 million that have not been incurred as of September 30, 2008 are reflected in the pro forma condensed combined balance sheet as of September 30, 2008 as an adjustment to accrued expenses (see Note 3, Pro Forma Adjustments above), but are not reflected in the pro forma condensed combined statements of operations for the nine months ended September 30, 2008 as they are not expected to have a continuing impact on operations. Nuvelo's non-recurring expenses in connection with this transaction incurred as of September 30, 2008 totaling approximately \$900,000 are included in sales, general and administrative expenses in its statement of operations for the nine months ended September 30, 2008 and as a reduction to net assets in its balance sheets at September 30, 2008. ARCA's non-recurring transaction fees of approximately \$564,000 are included in its September 30, 2008 balance sheet as deferred transaction costs and as a reduction in net assets through a pro forma adjustment in the pro forma balance sheets.

**Table of Contents**

**LEGAL MATTERS**

Cooley Godward Kronish LLP will pass upon the validity of the Nuvelo common stock to be issued in the merger and certain federal income tax consequences of the merger for Nuvelo and Hogan & Hartson LLP will pass upon certain federal income tax consequences of the merger for ARCA.

**EXPERTS**

The consolidated financial statements of Nuvelo, Inc. at December 31, 2007 and 2006 and for the years then ended, appearing in this proxy statement/prospectus/consent solicitation and registration statement have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

The consolidated statements of operations, stockholders' equity, and cash flows of Nuvelo, Inc. and subsidiary for the year ended December 31, 2005, have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.

The financial statements of ARCA biopharma, Inc. as of December 31, 2007 and 2006, and for each of the years in the three-year period ended December 31, 2007, have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. This report refers to ARCA biopharma, Inc.'s adoption of Statement of Financial Accounting Standards No. 123(R), *Share-Based Payment*, in 2006.

**Table of Contents**

**WHERE YOU CAN FIND MORE INFORMATION**

Nuvelo has filed annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information that Nuvelo files at the SEC's public reference room in Washington, D.C. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Nuvelo's public filings are also available to the public from commercial document retrieval services and at the Internet web site maintained by the SEC at <http://www.sec.gov>. Reports, proxy statements and other information concerning Nuvelo also may be inspected at the offices of the National Association of Securities Dealers, Inc., Listing Section, 1735 K Street, Washington, D.C. 20006.

Nuvelo has filed a Form S-4 registration statement to register with the SEC the offer and sale of the shares of Nuvelo common stock to be issued in connection with the merger with ARCA. This proxy statement/prospectus/consent solicitation is a part of that registration statement and constitutes a prospectus and proxy statement of Nuvelo.

Nuvelo has supplied all information contained in this proxy statement/prospectus/consent solicitation relating to Nuvelo and Merger Sub, and ARCA has supplied all information relating to ARCA.

You should rely only on the information contained in this proxy statement/prospectus/consent solicitation to vote your shares at the special meeting. We have not authorized anyone to provide you with information that differs from that contained in this proxy statement/prospectus/consent solicitation. This proxy statement/prospectus/consent solicitation is dated \_\_\_\_\_, 2008. You should not assume that the information contained in this proxy statement/prospectus/consent solicitation is accurate as of any date other than that date, and neither the mailing of this proxy statement/prospectus/consent solicitation to stockholders nor the issuance of shares of Nuvelo common stock in the merger shall create any implication to the contrary.

Nuvelo, the Nuvelo logos and all other Nuvelo product and service names are registered trademarks or trademarks of Nuvelo, Inc. in the United States and in other select countries. ARCA, the ARCA logos and all other ARCA product and service names are registered trademarks or trademarks of ARCA in the United States and in other select countries. ® and ™ indicate U.S. registration and U.S. trademark, respectively. Other third-party logos and product/trade names are registered trademarks or trade names of their respective companies.

**Table of Contents**

**INDEX TO FINANCIAL STATEMENTS**

**NUVELO, INC.**

	<b>PAGE</b>
Unaudited Condensed Consolidated Financial Statements for the Nine Months Ended September 30, 2008:	
<u>Condensed Consolidated Balance Sheets as of September 30, 2008 and December 31, 2007</u>	F-2
<u>Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2008 and 2007</u>	F-3
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2008 and 2007</u>	F-4
<u>Notes to Condensed Consolidated Financial Statements</u>	F-5
Consolidated Financial Statements for the Year Ended December 31, 2007:	
<u>Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</u>	F-13
<u>Report of KPMG LLP, Independent Registered Public Accounting Firm</u>	F-14
<u>Consolidated Balance Sheets as of December 31, 2007 and 2006</u>	F-15
<u>Consolidated Statements of Operations for the Years ended December 31, 2007, 2006 and 2005</u>	F-16
<u>Consolidated Statements of Stockholders' Equity for the Years ended December 31, 2007, 2006 and 2005</u>	F-17
<u>Consolidated Statements of Cash Flows for the Years ended December 31, 2007, 2006 and 2005</u>	F-18
<u>Notes to Consolidated Financial Statements</u>	F-19

**ARCA biopharma, Inc.**

**(a developmental stage enterprise)**

	<b>PAGE</b>
Financial Statements for the Years Ended December 31, 2007, 2006 and 2005 and the Nine Months Ended September 30, 2008 and 2007:	
<u>Report of KPMG LLP, Independent Registered Public Accounting Firm</u>	F-44
<u>Balance Sheets as of September 30, 2008 (unaudited), and as of December 31, 2007 and 2006 (Including Pro Forma Stockholders' Equity as of September 30, 2008)</u>	F-45
<u>Statements of Operations for the Years ended December 31, 2007, 2006 and 2005, for the Nine Months Ended September 30, 2008 and 2007 (unaudited), and from December 17, 2001 to September 30, 2008 (unaudited)</u>	F-46
<u>Statements of Preferred Stock and Stockholders' Deficit</u>	F-47
<u>Statements of Cash Flows for the Years ended December 31, 2007, 2006 and 2005, for the Nine Months Ended September 30, 2008 and 2007 (unaudited), and from December 17, 2001 to September 30, 2008 (unaudited)</u>	F-49
<u>Notes to Financial Statements</u>	F-50

F-1

**Table of Contents**

## NUVELO, INC.

## CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

	September 30, 2008	December 31, 2007
	(In thousands)	
<b>ASSETS</b>		
Cash and cash equivalents	\$ 35,168	\$ 32,061
Marketable securities	23,964	65,506
Collaboration receivables	835	588
Other current assets	950	1,831
<b>Total current assets</b>	<b>60,917</b>	<b>99,986</b>
Restricted cash	6,000	6,000
Property and equipment, net	7,383	8,906
Goodwill		4,671
Other assets	1,099	1,120
<b>Total assets</b>	<b>\$ 75,399</b>	<b>\$ 120,683</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Accounts payable	\$ 2,642	\$ 2,307
Accrued compensation and employee benefits	1,191	2,350
Accrued clinical trial and drug manufacturing costs	1,463	3,232
Current portion of deferred revenue	250	250
Current portion of deferred rent	1,444	1,400
Current portion of accrued facility exit costs	6,816	7,389
Other current liabilities	539	1,259
<b>Total current liabilities</b>	<b>14,345</b>	<b>18,187</b>
Non-current portion of deferred revenue	875	16,063
Non-current portion of deferred rent	4,514	5,597
Non-current portion of accrued facility exit costs	10,105	13,098
Other liabilities	845	79
<b>Total liabilities</b>	<b>30,684</b>	<b>53,024</b>
Stockholders' equity:		
Preferred stock		
Common stock	53	53
Additional paid-in capital	542,422	538,070
Accumulated other comprehensive income (loss)	(90)	49
Accumulated deficit	(497,670)	(470,513)
<b>Total stockholders' equity</b>	<b>44,715</b>	<b>67,659</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 75,399</b>	<b>\$ 120,683</b>

See accompanying notes to condensed consolidated financial statements.





**Table of Contents**

## NUVELO, INC.

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
	(In thousands, except per share data)			
Contract revenues	\$ 63	\$ 63	\$ 15,188	\$ 46,798
Operating expenses:				
Research and development	5,407	9,494	24,555	33,452
General and administrative	3,698	4,204	11,359	16,843
Restructuring		2,336	2,470	2,336
Facility exit charge			1,472	
Impairment of goodwill			4,671	
Total operating expenses	9,105	16,034	44,527	52,631
Operating loss	(9,042)	(15,971)	(29,339)	(5,833)
Interest income, net	524	1,613	2,182	5,168
Net loss	\$ (8,518)	\$ (14,358)	\$ (27,157)	\$ (665)
Basic and diluted net loss per share	\$ (0.16)	\$ (0.27)	\$ (0.51)	\$ (0.01)
Weighted average shares used in computing basic and diluted net loss per share	53,616	53,361	53,536	53,310

See accompanying notes to condensed consolidated financial statements.

**Table of Contents****NUVELO, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(unaudited)**

	<b>Nine Months Ended September 30,</b>	
	<b>2008</b>	<b>2007</b>
	<b>(In thousands)</b>	
<b>Cash flows from operating activities:</b>		
Net loss	\$ (27,157)	\$ (665)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Depreciation and amortization	1,739	1,766
Stock-based compensation expense	4,171	7,876
Non-cash facility exit charge and accretion expense	2,622	1,485
Impairment of assets	4,671	1,117
<b>Changes in operating assets and liabilities:</b>		
Collaboration receivables	(247)	8,129
Other current assets	881	2,175
Other assets	21	290
Accounts payable	335	(4,545)
Accrued compensation and employee benefits	(1,159)	(523)
Accrued clinical trial and drug manufacturing costs	(1,769)	(10,423)
Other current liabilities	35	(269)
Deferred revenue	(15,188)	(31,798)
Deferred rent	(1,039)	(996)
Accrued facility exit costs	(6,188)	(6,011)
Accrued interest		82
Other non-current liabilities	45	
<b>Net cash used in operating activities</b>	<b>(38,227)</b>	<b>(32,310)</b>
<b>Cash flows from investing activities:</b>		
Maturities of marketable securities	86,013	119,578
Purchases of marketable securities	(44,610)	(92,912)
Purchases of property and equipment	(216)	(353)
Increase in restricted cash		(6,000)
<b>Net cash provided by investing activities</b>	<b>41,187</b>	<b>20,313</b>
<b>Cash flows from financing activities:</b>		
Proceeds from issuance of common stock under employee stock purchase plan	181	377
Payments on bank loans and capital lease obligations	(34)	(1,524)
Payments on related party line of credit		(2,063)
<b>Net cash provided by (used in) financing activities</b>	<b>147</b>	<b>(3,210)</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>3,107</b>	<b>(15,207)</b>
Cash and cash equivalents at beginning of period	32,061	60,335
<b>Cash and cash equivalents at end of period</b>	<b>\$ 35,168</b>	<b>\$ 45,128</b>

See accompanying notes to condensed consolidated financial statements.



---

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**September 30, 2008**

**(Unaudited)**

**1. Basis of Presentation and Significant Accounting Policies**

***Basis of Presentation***

The accompanying unaudited condensed consolidated financial statements have been prepared by Nuvelo, Inc. ( Nuvelo, or the Company ) in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying financial information is unaudited but includes all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet as of December 31, 2007 is derived from the Company's audited financial statements. Certain prior period amounts have been reclassified to conform to the current period's presentation, including other current liabilities in the condensed consolidated balance sheets and statements of cash flows. The results of operations for the interim period shown herein are not necessarily indicative of operating results expected for the entire year. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2007.

The unaudited condensed consolidated financial statements include the accounts of Nuvelo, Inc. and its subsidiaries. All inter-company transactions and accounts have been eliminated on consolidation.

Nuvelo is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions.

***Use of Estimates***

Conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent amounts. The Company bases its estimates on historical experience and on assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for the judgments made about the carrying values of assets and liabilities that are not readily apparent from other sources. Future results may differ from these estimates. The Company believes significant judgment is involved in evaluating whether alternative future use exists for materials and equipment acquired for use in research and development, in estimating goodwill and long-lived asset impairment, facility exit costs, clinical trial accruals, stock-based compensation, income taxes and in determining revenue recognition.

***Fair Value Disclosures***

On January 1, 2008, the Company adopted FASB Statement of Financial Accounting Standards No. 157, *Fair Value Measurements* (SFAS 157). SFAS 157 establishes a common definition for fair value to be applied to U.S. GAAP requiring use of fair value, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. In February 2008, the FASB issued FASB Staff Position No. FAS 157-2, *Effective Date of FASB Statement No. 157* (FSP 157-2), which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except items that are recognized or disclosed at fair value on a recurring basis (at least annually), until fiscal years beginning after November 15, 2008. The implementation of SFAS 157 for financial assets and financial liabilities did not have a material impact on Nuvelo's consolidated financial position and results of operations. The Company is currently assessing the impact of adopting SFAS 157 for nonfinancial assets and nonfinancial liabilities on its financial position and results of operations.

**Table of Contents****NUVELO, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****September 30, 2008****(Unaudited)**

SFAS 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). SFAS 157 classifies the inputs used to measure fair value into the following hierarchy:

Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities

Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quotes prices that are observable for the asset or liability

Level 3 Unobservable inputs for the asset or liability

The following table represents the Company's fair value hierarchy for its financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis as of September 30, 2008 (in thousands):

	Level 1	Level 2	Level 3	Total
Money market funds	\$ 30,286	\$	\$	\$ 30,286
Corporate debt securities		27,953		27,953
<b>Total</b>	<b>\$ 30,286</b>	<b>\$ 27,953</b>	<b>\$</b>	<b>\$ 58,239</b>

Money market funds, which are expected to maintain a net asset value of \$1 per share, are categorized in Level 1 of the fair value hierarchy. Corporate debt securities are categorized in Level 2 of the fair value hierarchy. The fair value of these securities is generally based on pricing models which take into consideration market prices of identical or similar securities from multiple sources and the securities' accreted balance on the reporting day.

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities* (SFAS 159). SFAS 159 allows entities to voluntarily choose, at specified election dates, to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. The effective date for the Company is January 1, 2008. To date, the Company has not elected this fair value option for any assets or liabilities.

**2. Proposed Merger with ARCA biopharma, Inc.**

On September 24, 2008, Nuvelo entered into an Agreement and Plan of Merger and Reorganization (the *Merger Agreement*) with ARCA biopharma, Inc., a private Delaware corporation (ARCA), and Dawn Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Nuvelo (Merger Sub), amended October 28, 2008, pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will be merged with and into ARCA, with ARCA surviving the merger (the *Merger*) as a wholly-owned subsidiary of Nuvelo. Upon the terms and subject to the conditions set forth in the Merger Agreement, Nuvelo will issue, and holders of ARCA capital stock will receive, shares of common stock of Nuvelo, such that following the consummation of the transactions contemplated by the Merger Agreement, current stockholders of Nuvelo are expected to own approximately 33% of the common stock of the combined company and current ARCA stockholders, together with holders of ARCA options and warrants assumed by Nuvelo, are expected to own or have the right to

## Edgar Filing: NUVELO INC - Form S-4/A

acquire approximately 67% of the common stock of the combined company, after giving effect to the issuance of shares pursuant to ARCA's outstanding options and warrants primarily on a treasury-method basis, and without giving effect to any shares issuable pursuant to Nuvelo's outstanding options and warrants. The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the U.S. Internal Revenue Code of 1986, as amended.

F-6

**Table of Contents****NUVELO, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****September 30, 2008****(Unaudited)**

Consummation of the Merger is subject to closing conditions, including among other things, (i) declaration of effectiveness by the Securities and Exchange Commission of the registration statement on Form S-4 with respect to the registration of the shares of Nuvelo common stock to be issued in the Merger, filed on October 30, 2008; (ii) approval and adoption of the Merger Agreement and Merger by the requisite vote of the stockholders of ARCA; (iii) approval of the issuance of shares of Nuvelo common stock in connection with the Merger by the requisite vote of Nuvelo stockholders; and (iv) conditional approval for the listing of Nuvelo common stock to be issued in the Merger on any of the Nasdaq Global Select Market, Nasdaq Global Market or Nasdaq Capital Market. In order to comply with Nasdaq listing requirements, Nuvelo intends to seek stockholder approval to effect a reverse stock split of its common stock in conjunction with the closing of this transaction.

The Merger will be treated by Nuvelo as a reverse merger and will be accounted for as a business combination using the acquisition method of accounting in accordance with GAAP. For accounting purposes, ARCA is considered to be acquiring Nuvelo in the Merger, as the existing stockholders of ARCA will have a controlling interest in the combined company and ARCA's management will be the management of the combined company. The transaction will be accounted for under the acquisition method of accounting in accordance with Statement of Financial Accounting Standards No. 141R, *Business Combinations*, as the Merger is expected to close after December 31, 2008.

The Merger Agreement contains certain termination rights for both Nuvelo and ARCA, and further provides that, upon termination of the Merger Agreement under specified circumstances, ARCA may be required to pay Nuvelo a termination fee of approximately \$1.9 million and Nuvelo may be required to pay ARCA a termination fee of approximately \$0.9 million.

**3. Net Loss Per Share**

The Company has computed net loss per common share according to Statement of Financial Accounting Standards No. 128, *Earnings Per Share*, which requires disclosure of basic and diluted earnings per share. Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share reflects the potential dilution of securities by adding other potential common shares to the weighted-average number of common shares outstanding during the period, if dilutive.

In calculating diluted net loss per share, the Company excluded the following outstanding shares of common stock equivalents, as the effect would be anti-dilutive (in thousands):

	<b>September 30,</b>	
	<b>2008</b>	<b>2007</b>
Stock options and restricted stock units	5,608	7,572
Warrants	850	850
<b>Total</b>	<b>6,458</b>	<b>8,422</b>

Table of Contents

## NUVELO, INC.

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

**4. Comprehensive Loss**

The components of comprehensive loss for each period presented, net of any related tax effects, are as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Net loss, as reported	\$ (8,518)	\$ (14,358)	\$ (27,157)	\$ (665)
Change in unrealized gain (loss) on available-for-sale securities	(102)	16	(139)	1
Change in unrealized gain (loss) on hedging instruments				(6)
Comprehensive loss	\$ (8,620)	\$ (14,342)	\$ (27,296)	\$ (670)

**5. Stock-based Compensation**

Stock-based compensation expense related to employee stock options, restricted stock units and employee stock purchase plan purchase rights was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Research and development	\$ 153	\$ 783	\$ 512	\$ 2,924
General and administrative	805	1,170	2,422	4,023
Restructuring		926	1,237	926
Total	\$ 958	\$ 2,879	\$ 4,171	\$ 7,873

Stock-based compensation expense related to non-employees was negligible in these periods.

The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense and, as a result, a full valuation allowance is applied to this deferred tax asset.

The fair values of employee stock options granted under the Company's stock option plans during the periods presented were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted-average grant date fair values per share:

Three Months Ended  
September 30,

Nine Months Ended  
September 30,



Edgar Filing: NUVELO INC - Form S-4/A

	2008	2007	2008	2007
Expected term		4.80 years	4.63 years	4.94 years
Expected volatility		0.92	0.95	0.88
Risk-free interest rate		4.50%	2.78%	4.66%
Expected dividend yield				
Weighted-average grant date fair value per share		\$ 1.64	\$ 1.08	\$ 2.48

F-8

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2008**

**(Unaudited)**

No options were granted to employees in the three months ended September 30, 2008. In the nine months ended September 30, 2008, the Company granted employees options to purchase 1,285,800 shares of its common stock. In the three and nine months ended September 30, 2007, the Company granted employees options to purchase 51,200 and 1,567,750 shares of common stock, respectively.

The Company terminated two executives in connection with its reduction in force announced in March 2008 (see Note 6, Restructuring). The two former executives were entitled to a 12-month acceleration in vesting of their options at the time of their termination. For the nine months ended September 30, 2008, the Company recorded \$1.2 million of stock-based compensation expense as a result of this acceleration in vesting of these options and classified this expense as part of restructuring expense.

**6. Restructuring**

On March 17, 2008, the Company announced its decision to discontinue alfimeprase clinical development and restructure to make additional resources available for its other research and development programs. In connection with the restructuring, the Company reduced its workforce by approximately 19 percent and recorded a restructuring expense of \$2.5 million, including \$1.3 million of termination benefits and \$1.2 million of non-cash stock-based compensation expense, for the nine months ended September 30, 2008. As of September 30, 2008, \$0.4 million of termination benefits remained unpaid and were classified under accrued compensation and employee benefits in the condensed consolidated balance sheet.

In connection with the restructuring announced in August 2007, the Company recorded a restructuring expense of \$2.3 million, including \$1.4 million of termination benefits and \$0.9 million of non-cash stock-based compensation expense, for the nine months ended September 30, 2007. Of the \$1.4 million termination benefits, \$1.0 million was paid in 2007 and the balance was paid in the nine months ended September 30, 2008.

**7. Facility Exit Costs**

The Company has a lease commitment for a 139,000-square-foot facility at 985 Almanor Avenue, Sunnyvale, California, which expires on May 30, 2011. In September 2005, Nuvelo relocated the Company's headquarters to a facility located at 201 Industrial Road, San Carlos, California. Through December 2006, the Company retained the Sunnyvale facility as a storage location. In December 2006, the Company approved a plan to exit the Sunnyvale facility and restore the building for potential sublease. On December 31, 2006, the Company exited the Sunnyvale facility and accrued \$26.6 million to reflect the estimated present value of future lease-related payments less estimated net income from sublease rental. The future lease-related payments are scheduled to be made periodically until the lease expires.

The balance of accrued facility exit costs represents the fair value of the lease liability based on assumptions regarding the vacancy period, sublease terms, and the probability of subleasing this space. The estimates and assumptions are re-evaluated each quarter and are based upon current market data, including vacancy rates and lease activities for similar facilities within the area. As of March 31, 2008, the Company determined that the likelihood of subleasing the Sunnyvale facility during the remainder of the lease term has become remote and, therefore, recorded a \$1.5 million charge to reflect such change in the sublease assumption. The charge increased the net loss per share by \$0.03 for the nine months ended September 30, 2008.

**Table of Contents****NUVELO, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****September 30, 2008****(Unaudited)**

The following table summarizes the activity related to facility exit costs liabilities for the nine months ended September 30, 2008 (in thousands):

Balance as of December 31, 2007	\$ 20,487
Amounts paid during the period	(6,188)
Non-cash accretion	1,150
Change in fair value due to change in sublease assumption	1,472
<b>Balance as of September 30, 2008</b>	<b>\$ 16,921</b>

The non-cash accretion, which was included in general and administrative expenses, was \$0.4 million and \$1.2 million for the three and nine months ended September 30, 2008, and \$0.5 million and \$1.5 million for the three and nine months ended September 30, 2007, respectively.

The Company has also recorded a \$0.8 million facility restoration obligation related to the Sunnyvale facility. The Company currently expects to complete the facility restoration in 2011. Accordingly, this obligation was classified as other long-term liabilities as of September 30, 2008.

**8. Goodwill**

The Company tests goodwill for impairment using a fair value approach at the reporting unit level on an annual basis or when events indicate that the carrying value of the asset may be impaired in accordance with Statement of Financial Accounting Standards No. 142, *Goodwill and other Intangible Assets*, (SFAS 142). Consistent with the determination that the Company has only one reporting segment, it has determined that there is only one reporting unit and, therefore, goodwill is tested at the entity level. The Company has elected October 31<sup>st</sup> as its measurement date. The Company completed its last annual goodwill tests as of October 31, 2007, and no impairments were recognized.

SFAS 142 requires a two-step test for goodwill impairment. In the first step, the Company compares the fair value of the Company to its carrying value. The Company generally bases its fair value on its market capitalization, which is based on quoted market prices of its common stock, taking into account other factors that may affect the fair value of the Company as a whole. If the fair value of the Company exceeds the carrying value of its net assets, goodwill is not impaired and the Company is not required to proceed to the second step of the impairment test.

In the first quarter of 2008, the Company performed a goodwill impairment test due to the significant decline of its stock price subsequent to the alfimeprase announcement on March 17, 2008 (see Note 6, Restructuring). Significant judgment is required to evaluate the fair value of a company, as quoted market prices of a company's common stock and consequently market capitalization may experience significant fluctuations in reaction to disclosures of new information about the company. Based on the upward trend in the price of the Company's common stock following the initial decrease after the announcement and through the filing of the Form 10-Q for the first quarter of 2008, management concluded that the market capitalization following the initial market reaction to the announcement did not provide a good indication of the Company's fair value. Accordingly, management concluded that the carrying value of the net assets at that time did not exceed the Company's fair value and consequently, goodwill was not impaired at March 31, 2008.

---

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2008**

**(Unaudited)**

In the second quarter of 2008, the Company performed an additional goodwill impairment test as the upward trend in the market price of the Company's common stock did not continue and the Company's market capitalization remained lower than its carrying value. Since the carrying value exceeded the fair value, at June 30, 2008, the Company performed the second step in order to determine the implied fair value of the Company's goodwill and compare it to the carrying value of goodwill. The activities in the second step included valuing the tangible and intangible assets and liabilities of the Company based on their fair value and determining the implied goodwill based upon the difference between the fair value of the reporting unit and the net fair values of identified tangible and intangible assets and liabilities. Based on the results of the second step of calculating the implied goodwill, the Company recorded an impairment charge of the full balance of goodwill totaling \$4.7 million.

**9. Agreements with Bayer**

In June 2007, the Company and Bayer Healthcare AG (Bayer) terminated their January 2006 license and collaboration agreement for the development and commercialization of alfimeprase. As part of the termination agreement with Bayer, the Company agreed to waive Bayer's obligation to provide Nuvelo 12 months' notice of termination in consideration of Bayer's agreement to pay Nuvelo a lump sum of \$15.0 million. Nuvelo also granted Bayer the option to reacquire rights to alfimeprase upon the initiation of a pivotal stroke trial or upon Nuvelo's public announcement that it is discontinuing further development of alfimeprase in the stroke indication. The notice period during which Bayer could exercise the option would begin upon the Company making certain information available to Bayer and last for 30 days after delivery of the information.

The Company announced its decision to discontinue alfimeprase clinical development on March 17, 2008 and provided the information to Bayer as required by the termination agreement in April 2008. The \$15.0 million termination payment, which had been recorded as deferred revenue, was recognized as revenue in May 2008 upon the expiration of the notice period.

**10. Segment Information**

The Company is engaged in the discovery, development and commercialization of novel acute cardiovascular and cancer therapies. The Company has only one reportable segment and, therefore, all segment-related financial information required by Statement of Financial Accounting Standards No. 131, *Disclosures About Segments of an Enterprise and Related Information*, is included in the condensed consolidated financial statements. The reportable segment reflects the Company's structure, reporting responsibilities to the chief executive officer and the nature of the products under development.

**11. Nasdaq Listing Requirement**

On May 1, 2008, the Company received a notice from The Nasdaq Stock Market indicating that, for 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum \$1.00 per share requirement for continued inclusion on the Nasdaq Global Market. The Company was given 180 calendar days, or until October 28, 2008, to regain compliance with this listing requirement, which would be accomplished if the bid price of the Company's common stock closed at \$1.00 per share or more for a minimum of 10 consecutive business days. The notice from Nasdaq also indicated that, if the Company does not regain compliance by October 28, 2008, Nasdaq would provide a staff determination letter notifying the Company that its common stock will be delisted, after which Nuvelo may appeal the staff determination to the Nasdaq Listing Qualifications Panel. On October 16, 2008, Nasdaq advised the Company that it had suspended until January 19, 2009 the enforcement of the rules requiring a minimum \$1.00 closing bid price for all Nasdaq listed companies.

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2008**

**(Unaudited)**

Following the end of this suspension period and the 12 days balance of the Company's initial 180 days compliance period, the Company expects to receive a staff determination letter if it has not regained compliance by that time. Upon receipt of the determination letter, the Company intends to submit a request to appeal the determination and present a plan for compliance at an oral hearing with Nasdaq in Washington, D.C. The request for appeal will automatically stay the determination until the appeal is heard and a Nasdaq panel rules on whether to grant conditional listing for up to 180 days following the staff determination in order for the Company to complete its plan of compliance. There can be no assurance that the appeal will be successful or on the timeline presented above or that the plan of compliance and the Company will be able to satisfy the requirements for maintaining a Nasdaq Global Market listing.

If the Company does not regain compliance with this listing requirement by the new deadline imposed by Nasdaq, but meets the initial inclusion criteria for the Nasdaq Capital Market (except for the bid price requirement), the Company may apply to transfer the listing of its common stock to this market. If accepted by the Nasdaq Capital Market, the Company will be provided with an additional 180-day period to demonstrate compliance. If the Company is not eligible for an additional compliance period at that time, Nasdaq will provide written notification that the Company's securities will be delisted. Upon such notice, the Company may appeal the determination to the Nasdaq Listing Qualifications Panel. There can be no assurance that the Company's common stock would be eligible for transfer to the Nasdaq Capital Market, or, if the Company appeals Nasdaq staff's determination, that such appeal would be successful.

**Table of Contents**

**REPORT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The Board of Directors and Stockholders of Nuvelo, Inc.:

We have audited the accompanying consolidated balance sheets of Nuvelo, Inc. as of December 31, 2007 and 2006, and the related consolidated statements of operations, stockholders' equity, and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Nuvelo, Inc. at December 31, 2007 and 2006, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

As discussed in Note 1 to the consolidated financial statements, Nuvelo, Inc. changed its method of accounting for stock-based compensation as of January 1, 2006. As discussed in Note 9 to the consolidated financial statements, Nuvelo, Inc. changed its method of accounting for registration payment arrangements as of October 1, 2006.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Nuvelo, Inc.'s internal control over financial reporting as of December 31, 2007, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 11, 2008 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Palo Alto, California

March 11, 2008

**Table of Contents**

**REPORT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The Board of Directors and Stockholders of Nuvelo, Inc.:

We have audited the accompanying consolidated statements of operations, stockholders' equity, and cash flows of Nuvelo, Inc. and subsidiary for the year ended December 31, 2005. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the results of operations and cash flows of Nuvelo, Inc. and subsidiary for the year ended December 31, 2005, in conformity with U.S. generally accepted accounting principles.

/s/ KPMG LLP

San Francisco, California

March 15, 2006

**Table of Contents****NUVELO, INC.****CONSOLIDATED BALANCE SHEETS**

	As of December 31, 2007                      2006 (In thousands, except share and per share information)	
<b>ASSETS</b>		
Cash and cash equivalents	\$ 32,061	\$ 60,335
Marketable securities	65,506	92,791
Collaboration receivables	588	8,559
Other current assets	1,831	4,650
<b>Total current assets</b>	<b>99,986</b>	<b>166,335</b>
Restricted cash	6,000	
Property and equipment, net	8,906	11,978
Goodwill	4,671	4,671
Other assets	1,120	1,421
<b>Total assets</b>	<b>\$ 120,683</b>	<b>\$ 184,405</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Accounts payable	\$ 2,760	\$ 7,026
Accrued compensation and employee benefits	2,350	3,098
Accrued clinical trial and drug manufacturing costs	3,232	14,415
Current portion of deferred revenue	250	3,640
Current portion of deferred rent	1,400	1,342
Current portion of accrued facility exit costs	7,389	7,674
Accrued interest		2,172
Current portion of bank loans		1,367
Related party line of credit		2,292
Other current liabilities	806	813
<b>Total current liabilities</b>	<b>18,187</b>	<b>43,839</b>
Non-current portion of deferred revenue	16,063	44,533
Non-current portion of deferred rent	5,597	6,998
Non-current portion of accrued facility exit costs	13,098	18,942
Non-current portion of bank loans		125
Other liabilities	79	125
<b>Total liabilities</b>	<b>53,024</b>	<b>114,562</b>
Commitments and contingencies (Notes 8 and 17)		
Stockholders' equity:		
Preferred stock, par value \$0.001; 5,000,000 shares authorized; none issued and outstanding as of December 31, 2007 and 2006		
Common stock, par value \$0.001; 100,000,000 shares authorized; 53,421,516 and 53,151,781 issued and outstanding as of December 31, 2007 and 2006, respectively		
	53	53
Additional paid-in capital	538,070	527,992
Accumulated other comprehensive income	49	10
Accumulated deficit	(470,513)	(458,212)
<b>Total stockholders' equity</b>	<b>67,659</b>	<b>69,843</b>



Edgar Filing: NUVELO INC - Form S-4/A

Total liabilities and stockholders' equity	\$ 120,683	\$ 184,405
--	------------	------------

See accompanying Notes to Consolidated Financial Statements.

F-15

**Table of Contents****NUVELO, INC.****CONSOLIDATED STATEMENTS OF OPERATIONS**

	Year Ended December 31,		
	2007	2006	2005
	(In thousands, except per share data)		
Contract revenues	\$ 46,861	\$ 3,888	\$ 545
Operating expenses:			
Research and development	42,654	89,370	57,778
General and administrative	20,762	30,632	15,805
Restructuring	2,336		
Facility exit charges		24,460	
Total operating expenses	65,752	144,462	73,583
Operating loss	(18,891)	(140,574)	(73,038)
Interest income	6,693	8,385	2,431
Interest expense	(103)	(588)	(1,004)
Loss before cumulative effect of change in accounting principle	(12,301)	(132,777)	(71,611)
Cumulative effect of change in accounting principle		2,224	
Net loss	\$ (12,301)	\$ (130,553)	\$ (71,611)
Basic and diluted net loss per share:			
Loss before cumulative effect of change in accounting principle	\$ (0.23)	\$ (2.58)	\$ (1.73)
Cumulative effect of change in accounting principle		0.04	
Basic and diluted net loss per share	\$ (0.23)	\$ (2.54)	\$ (1.73)
Weighted average shares used in computing basic and diluted net loss per share	53,333	51,451	41,279

See accompanying Notes to Consolidated Financial Statements

Table of Contents

## NUVELO, INC.

## CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

For the Years Ended December 31, 2007, 2006 and 2005

	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss) (In thousands)	Accumulated Deficit	Total Stockholders Equity
	Shares	Amount				
<b>Balance at December 31, 2004</b>	32,229	\$ 32	\$ 301,811	\$ (206)	\$ (256,048)	\$ 45,589
Components of comprehensive loss:						
Net loss					(71,611)	(71,611)
Change in unrealized gains or losses on hedging instruments				(197)		(197)
Change in unrealized gains or losses on available-for-sale securities				153		153
Comprehensive loss						(71,655)
Issuance of common stock upon exercise of stock options and under employee stock purchase plan	307		1,717			1,717
Issuance of common stock through a public offering in February 2005, net of issuance cost of \$4,865	9,775	10	68,438			68,448
Issuance of common stock under Kingsbridge CEFF, net of issuance cost of \$220	1,839	2	14,180			14,182
Fair value of warrant granted in connection with Kingsbridge CEFF			(2,078)			(2,078)
Stock-based compensation expense			561			561
<b>Balance at December 31, 2005</b>	44,150	44	384,629	(250)	(327,659)	56,764
Components of comprehensive loss:						
Net loss					(130,553)	(130,553)
Change in unrealized gains or losses on hedging instruments				203		203
Change in unrealized gains or losses on available-for-sale securities				57		57
Comprehensive loss						(130,293)
Issuance of common stock upon exercise of stock options and under employee stock purchase plan	943	1	8,010			8,011
Issuance of common stock upon cashless exercise of warrants	16					
Issuance of common stock through a public offering in February 2006, net of issuance cost of \$7,581	7,475	7	112,019			112,026
Issuance of common stock under Kingsbridge CEFF	568	1	9,999			10,000
Reclassification of warrant fair value upon adoption of a new accounting principle			2,078			2,078
Stock-based compensation expense			11,257			11,257
<b>Balance at December 31, 2006</b>	53,152	53	527,992	10	(458,212)	69,843
Components of comprehensive loss:						
Net loss					(12,301)	(12,301)
Change in unrealized gains or losses on available-for-sale securities				45		45
Change in unrealized gains or losses on hedging instruments				(6)		(6)
Comprehensive loss						(12,262)
Issuance of common stock upon exercise of stock options and under employee stock purchase plan	179		426			426
Issuance of common stock upon cashless exercise of warrants	91					

Edgar Filing: NUVELO INC - Form S-4/A

Stock-based compensation expense					9,652				9,652		
<b>Balance at December 31, 2007</b>	53,422	\$	53	\$	538,070	\$	49	\$	(470,513)	\$	67,659

See accompanying Notes to Consolidated Financial Statements.

F-17

**Table of Contents****NUVELO, INC.****CONSOLIDATED STATEMENTS OF CASH FLOWS**

	<b>Year Ended December 31,</b>		
	<b>2007</b>	<b>2006</b>	<b>2005</b>
	<b>(In thousands)</b>		
<b>Cash flows from operating activities:</b>			
Net loss	\$ (12,301)	\$ (130,553)	\$ (71,611)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>			
Depreciation and amortization	2,343	3,182	2,668
Stock-based compensation expense	9,652	11,257	561
Non-cash accretion expense and facility exit charges	1,915	24,460	
Impairment of assets	1,117		
Loss (gain) on sale, disposal or write-off of assets	(130)	366	4
Change in fair value of warrant liability		567	(567)
Other non-cash items		(113)	(31)
<b>Changes in operating assets and liabilities:</b>			
Collaboration receivables	7,971	(7,352)	(1,070)
Clinical trial supplies		12,448	360
Other current assets	2,800	(2,683)	635
Other assets	301	782	(103)
Accounts payable	(4,266)	2,107	1,812
Accrued employee liabilities	(748)	826	935
Accrued clinical trial and drug manufacturing costs	(11,183)	9,933	3,551
Deferred revenue	(31,860)	46,360	1,813
Deferred rent	(1,343)	(6,469)	335
Accrued facility exit costs	(8,044)		
Accrued interest	(2,172)	(920)	751
Other current liabilities	(10)	(1,258)	922
<b>Net cash used in operating activities</b>	<b>(45,958)</b>	<b>(37,060)</b>	<b>(59,035)</b>
<b>Cash flows from investing activities:</b>			
Maturities of marketable securities	143,936	54,424	64,161
Purchases of marketable securities	(116,606)	(114,586)	(62,766)
Increase in restricted cash	(6,000)		
Purchases of property and equipment	(381)	(2,442)	(2,570)
Proceeds from sale of assets	136	540	
<b>Net cash provided by (used in) investing activities</b>	<b>21,085</b>	<b>(62,064)</b>	<b>(1,175)</b>
<b>Cash flows from financing activities:</b>			
Proceeds from issuance of common stock upon exercise of options, warrants and under employee stock purchase plan	426	8,011	1,717
Proceeds from issuance of common stock from public offerings and under Kingsbridge CEFF, net		122,026	82,630
Payments on related party line of credit	(2,292)	(2,750)	(2,750)
Payments on bank loans	(1,492)	(1,540)	(1,068)
Payments on capital lease obligations	(43)	(52)	(1,057)
Payment of promissory notes		(4,000)	
Proceeds from release of restricted cash			191
Proceeds from bank loans			1,500
<b>Net cash provided by (used in) financing activities</b>	<b>(3,401)</b>	<b>121,695</b>	<b>81,163</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(28,274)</b>	<b>22,571</b>	<b>20,953</b>
Cash and cash equivalents at beginning of year	60,335	37,764	16,811
<b>Cash and cash equivalents at end of year</b>	<b>\$ 32,061</b>	<b>\$ 60,335</b>	<b>\$ 37,764</b>

## Edgar Filing: NUVELO INC - Form S-4/A

Supplemental disclosures of cash flow information:			
Interest paid	\$	2,312	\$ 250
<b>Non-cash investing and financing activities:</b>			
Acquisition of leasehold improvements under tenant improvement allowances	\$	\$ 1,006	\$ 8,856
Acquisition of equipment under capital leases	\$	\$ 198	\$
Capitalized building restoration costs	\$	\$ 383	\$ 346
Reclassification of warrant fair value	\$	\$ (2,078)	\$ 2,078

See accompanying Notes to Consolidated Financial Statements.

F-18

---

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**1. Organization and Summary of Significant Accounting Policies**

***Organization***

Nuvelo, Inc. ( Nuvelo, or the Company ) was incorporated as Hyseq, Inc. in Illinois in 1992 and reincorporated in Nevada in 1993. On January 31, 2003, the Company merged with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts, and, in connection with the merger, changed its name to Nuvelo, Inc. On March 25, 2004, the Company was reincorporated from Nevada to Delaware. The Company's wholly-owned subsidiary, Hyseq Diagnostics, Inc., is inactive.

Nuvelo is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions.

***Basis of Presentation and Principles of Consolidation***

The consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (GAAP). The consolidated financial statements include the accounts of Nuvelo, Inc. and Hyseq Diagnostics, Inc. All significant inter-company transactions and accounts have been eliminated on consolidation.

***Use of Estimates***

Conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent amounts. The Company bases its estimates on historical experience and on assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for the judgments made about the carrying values of assets and liabilities that are not readily apparent from other sources. Future results may differ from these estimates. The Company believes significant judgment is involved in evaluating whether alternative future use exists for materials and equipment acquired for use in research and development, in estimating goodwill and long-lived asset impairment, facility exit costs, clinical trial accruals, stock-based compensation, income taxes and in determining revenue recognition.

***Liquidity and Concentration Risk***

The Company's primary sources of liquidity are from financing activities and collaboration receipts. The Company plans to continue to raise funds through additional public and/or private offerings and collaboration activities in the future. The primary use of capital has been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments and spending on capital items.

The Company currently relies on a number of sole-source service providers and suppliers to manufacture bulk drug substance, fill and finish its drug product candidates, and label and package them, and the Company does not have long-term supply agreements with these third-party manufacturers. If these service providers and suppliers are unable to produce the Company's drug product candidates in the quantities and with the quality required, if and when they are needed, the Company could incur significant additional expenses and efforts to complete its ongoing and anticipated clinical trials.

***Cash Equivalents and Marketable Securities***

Cash equivalents consist of money market funds and debt securities with maturities of 90 days or less at the time of purchase. The Company considers its investments in marketable debt securities, which may consist of

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

U.S. government agency, corporate debt and asset-backed securities, as available for use in current operations. Accordingly, the Company has classified these investments as short-term, even though the stated maturity date may be more than one year from the current balance sheet date. The Company invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.

The Company classifies all cash equivalents and marketable securities as available-for-sale securities, as defined by Statement of Financial Accounting Standards No. 115, *Accounting for Certain Investments in Debt and Equity Securities*, and records investments at fair value, based on quoted market prices. Unrealized holding gains and losses on available-for-sale securities, net of any tax effect, are excluded from earnings and are reported in accumulated other comprehensive income (loss), a separate component of stockholders' equity, until realized. The specific identification method is utilized to calculate the cost to determine realized gains and losses from the sale of available-for-sale securities. Realized gains and losses and declines in value judged to be other than temporary are included in interest income in the statements of operations.

***Restricted Cash***

Restricted cash represents a certificate of deposit used to collateralize a letter of credit as required by the lease agreement for the unoccupied facility at 985 Almanor Avenue in Sunnyvale, California. See Note 5, Facility Exit Costs, for discussion of the related lease commitment, and Note 7, Borrowing Arrangements, for discussion of the letter of credit arrangement.

***Property and Equipment***

Property and equipment are recorded at cost less accumulated depreciation. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets. The Company has leasehold improvements related to its corporate facilities office in San Carlos, California. The lease term on this office space is seven years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term. Maintenance and repairs are charged to expenses as incurred. Estimated useful lives are as follows:

<b>Category</b>	<b>Estimated Useful Lives</b>
Leasehold improvements	Shorter of lease term or economic life
Furniture and equipment	5 years
Computer software and equipment	2 to 3 years

***Exit and Disposal Activities***

The Company records costs and liabilities associated with exit and disposal activities, as defined in Statement of Financial Accounting Standards No. 146, *Accounting for Costs Associated with Exit or Disposal Activities* (SFAS 146), at fair value in the period the liability is incurred. SFAS 146 requires that the estimated future cash flows to be used in the fair value calculation be discounted using a credit-adjusted risk-free interest rate and that such interest rate shall have a maturity date that approximates the expected timing of future cash flows. Future cash flows related to lease obligations shall include the effect of sublease rental income and other lease operating expenses. The Company re-evaluates its sublease assumptions on a quarterly basis considering current market data, including vacancy rates and lease activities for similar facilities within the area. In periods subsequent to initial measurement, changes to a liability resulting from changes to the sublease assumptions are



---

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

measured using the same credit-adjusted risk-free rate that was applied in the initial period. Changes to the sublease assumptions may potentially have a significant effect on the Company's financial condition and results of operations. In addition, accretion of the liability due to the passage of time is recorded as a general and administrative expense.

***Goodwill and Other Long-Lived Assets Impairment Assessments***

The Company has made acquisitions of businesses that include goodwill. The Company assesses goodwill for impairment in accordance with Statement of Financial Accounting Standards No. 142, *Goodwill and other Intangible Assets* (SFAS 142), which requires that goodwill be tested for impairment at the reporting unit level (reporting unit) at least annually and more frequently upon the occurrence of certain events, as defined by SFAS 142. Consistent with the Company's determination that it has only one reporting segment, it has determined that there is only one reporting unit. The Company tests goodwill for impairment in the annual impairment test on October 31 using the two-step process required by SFAS 142. First, the Company reviews the carrying amount of the reporting unit compared to the fair value of the reporting unit based on quoted market prices of Nuvelo's common stock and on discounted cash flows based on analyses prepared by management. An excess carrying value compared to fair value would indicate that goodwill may be impaired. Second, if the Company determines that goodwill may be impaired, then the Company compares the implied fair value of the goodwill, as defined by SFAS 142, to its carrying amount to determine the impairment loss, if any. Based on these estimates, the Company determined that as of October 31, 2007 there was no impairment of goodwill. Since October 31, 2007, there have been no indications of impairment. The next annual impairment test will occur as of October 31, 2008; however, the Company will continue to review for signs of impairment on a quarterly basis.

In accordance with Statement of Financial Accounting Standards No. 144, *Accounting for Impairment or Disposal of Long-Lived Assets* (SFAS 144), the Company evaluates long-lived assets, other than goodwill, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on expected undiscounted cash flows attributable to that asset. The amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. In June 2007, the Company recorded a \$1.1 million charge related to an impairment of software implementation costs that were previously capitalized and deemed not recoverable, as the Company determined that the likelihood of completing the software implementation is remote. The \$1.1 million charge was included in general and administrative expenses for the year ended December 31, 2007.

***Revenue Recognition***

The Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, *Revenue Recognition* (SAB 104), when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed and determinable, and (iv) collectibility is reasonably assured. In situations where the Company has no continuing performance obligations, or the continuing obligations are perfunctory or inconsequential, up-front non-refundable fees are recognized as revenues on the effective date of the related agreement. Up-front non-refundable licensing fees that require continuing involvement in the form of development, manufacturing or other commercialization efforts by the Company are recognized as revenue ratably over the performance period.

The Company evaluates revenue from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting as defined in EITF Issue No. 00-21, *Revenue Arrangements with Multiple Deliverables* (EITF 00-21). To recognize revenue for a delivered item in

---

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

a multiple element arrangement, EITF 00-21 requires that the delivered items have value to the customer on a stand-alone basis, there is objective and reliable evidence of fair value of the undelivered items, and delivery of any undelivered items is probable and within the Company's control if delivered items have a general right of return.

***Clinical Trial and Drug Manufacturing Expenses***

Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (CROs), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and may be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the CROs and other vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Certain significant vendors may also provide an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical study sites are primarily based on patient enrollment or progress made against specified milestones or targets in each period.

In accordance with Statement of Financial Accounting Standards No. 2, *Accounting for Research and Development Costs* (SFAS 2), the Company capitalizes clinical trial drug manufacturing costs as clinical trial supplies, a current asset on the balance sheet, as long as there are alternative future uses for the related clinical trial drug material in other indications not currently being studied.

In December 2006, as a result of the failure of the first trial in each of two Phase 3 programs for alfimeprase to meet their primary endpoints, the Company suspended enrollment in the second trial in each of these programs. Due to the increased uncertainty over the future of this drug program, management reassessed the probability of alternative future use of previously capitalized alfimeprase clinical trial supplies and determined that they no longer met the criteria for capitalization under SFAS 2, which represents a change in accounting estimate. Accordingly, in December 2006, a \$19.0 million charge was recorded related to alfimeprase clinical trial supplies, and an additional \$2.2 million was charged in relation to other drug programs as a result of a similar review. The total charge of \$21.2 million, or \$0.41 per share, was included in research and development expenses in the 2006 statement of operations. During 2007, the Company determined that there were no alternative future uses for all current drug supplies and that all expenditures related to clinical trial supplies were charged to expense as incurred in 2007.

***Stock-based Compensation***

Effective January 1, 2006, the Company adopted the provisions of Statement of Financial Accounting Standards No. 123 (revised 2004), *Share-Based Payment* (SFAS 123(R)). SFAS 123(R) establishes accounting for stock-based awards exchanged for employee and non-employee services. Under SFAS 123(R), employee stock-based compensation cost is generally measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee's requisite service period, net of estimated forfeitures. The Company previously applied Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees* (APB 25), and related Interpretations to account for employee stock-based compensation, and provided the required pro forma disclosures of SFAS No. 123, *Accounting for Stock-Based Compensation* (SFAS 123). The Company has adopted the modified prospective application method as provided by SFAS 123(R). Under the modified prospective method, the fair values of new and previously granted but unvested stock options are recognized as compensation expense in the statement of operations over the related vesting periods from the date of adopting SFAS 123(R), and prior period results are not restated.

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The Company uses the Black-Scholes option pricing model as the Company believes it is the most appropriate fair-value method for its stock-based awards. The Black-Scholes option-pricing model requires assumptions to be made for the expected term of the awards, expected volatility of the Company's stock price, risk-free interest rates and expected dividend yields. The Company then amortizes compensation cost for awards expected to vest over the related vesting periods, generally four years for employee stock options. For options granted prior to January 1, 2006, the Company continues to use the graded-vested (multiple-option) method for expense attribution. Prior to January 1, 2006, option forfeitures were recognized on a pro forma basis as they occurred. For options granted after January 1, 2006, the Company is using the straight-line (single-option) method for expense attribution, estimates forfeitures based on historical data and only recognizes expense for those shares expected to vest. Adjustments to the forfeiture rate are made if actual forfeitures differ from previous estimates.

For all option grants, the Company considers historical data, including post-vesting termination behavior, and the contractual term to estimate future exercises and cancellations, and therefore the expected term of each option. For options granted prior to January 1, 2006, the expected volatility was based solely on the historical volatility of the Company's common stock. For options granted after January 1, 2006, the Company is using a combination of historic and implied volatility of the Company's common stock to derive expected volatility. The risk-free interest rate assumptions are based on the yield of U.S. Treasury instruments with similar durations as the expected term of the related awards. The expected dividend yield assumption is based on the Company's historic and expected dividend payouts.

The Company accounts for stock-based compensation expense for non-employees based on the fair values estimated using the Black-Scholes model on the date of grant and re-measured at each reporting date until vested, in compliance with Emerging Issues Task Force Issue No. 96-18, *Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services*. The Company is using the straight-line method in order to expense the value associated with any non-employee awards.

The fair values of employee stock options granted under the Company's stock option plans during the periods presented were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted-average grant date fair values per share:

	<b>Year Ended December 31,</b>		
	<b>2007</b>	<b>2006</b>	<b>2005</b>
<b>Assumptions:</b>			
Expected term	4.94 years	5.3 years	5.6 years
Expected volatility	0.88	0.61	0.71
Risk-free interest rate	4.65%	4.87%	4.11%
Expected dividend yield			
Weighted-average grant date fair value per share	\$ 2.47	\$ 9.51	\$ 5.58

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The fair values of purchase rights granted under the Company's employee stock purchase plan during the periods presented were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted-average grant date fair values per share:

	Year Ended December 31,		
	2007	2006	2005
Assumptions:			
Expected term	0.25 years	0.25 years	0.25 years
Expected volatility	0.84	0.45	0.34
Risk-free interest rate	4.51%	4.86%	3.95%
Expected dividend yield			
Weighted-average grant date fair value per share	\$ 0.94	\$ 4.47	\$ 7.81

**Income Taxes**

Income taxes are accounted for under the liability method pursuant to Statement of Financial Accounting Standards No. 109, *Accounting for Income Taxes* (SFAS 109). Under SFAS 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce deferred income tax assets to an amount that is more likely than not to be realized.

On January 1, 2007, the Company adopted the provisions of FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes - An Interpretation of FASB Statement No. 109* (FIN 48). FIN 48 provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements in accordance with SFAS 109. Tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of FIN 48 and in subsequent periods. The adoption of FIN 48 did not have a material impact on the Company's results of operations or financial position.

**Net Loss Per Share**

Basic and diluted net loss per share are presented in conformity with Statement of Financial Accounting Standards No. 128, *Earnings Per Share* (SFAS 128), for all periods presented. In accordance with SFAS 128, basic and diluted net loss per share has been computed using the weighted average number of shares of common stock outstanding during the period. In 2007, 2006 and 2005, the Company excluded the following outstanding shares of common stock equivalents, as they were anti-dilutive (in thousands):

	December 31,		
	2007	2006	2005
Stock options and restricted stock units	6,748	7,962	7,013
Warrants	850	1,227	1,787
	7,598	9,189	8,800

---

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Recent Accounting Pronouncements***

In September 2006, the FASB issued Statement 157, *Fair Value Measurements* (SFAS 157). SFAS 157 establishes a framework for measuring fair value by providing a standard definition of fair value as it applies to assets and liabilities. SFAS 157, which does not require any new fair value measurements, clarifies the application of other accounting pronouncements that require or permit fair value measurements. The effective date for the Company is January 1, 2008. However, in February 2008, the FASB issued FASB Staff Position No. FAS 157-2, *Effective Date of FASB Statement No. 157* (FSP 157-2), which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except items that are recognized or disclosed at fair value on a recurring basis (at least annually), until fiscal years beginning after November 15, 2008. The Company is evaluating the impact of adopting SFAS 157 and FSP 157-2 on its consolidated financial statements.

In February 2007, the FASB issued Statement 159, *The Fair Value Option for Financial Assets and Financial Liabilities* (SFAS 159). SFAS 159 allows entities to voluntarily choose, at specified election dates, to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. The effective date for the Company is January 1, 2008. The Company is evaluating the impact of the provisions of SFAS 159 on its consolidated financial statements and has not yet elected this fair value option for any assets or liabilities.

In June 2007, the FASB ratified the consensus reached by the Emerging Issues Task Force ( EITF ) on EITF Issue No. 07-3, *Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities* (EITF 07-3). EITF 07-3 addresses the diversity that exists with respect to the accounting for the non-refundable portion of a payment made by a research and development entity for future research and development activities. Under EITF 07-3, an entity would defer and capitalize non-refundable advance payments made for research and development activities until the related goods are delivered or the related services are performed. The effective date for the Company is January 1, 2008. The Company is currently evaluating the effect of EITF 07-3 on its consolidated financial statements.

In December 2007, the FASB issued Statement 141R, *Business Combinations* (SFAS 141R). SFAS 141R replaces SFAS 141. SFAS 141R requires the acquirer of a business to recognize and measure the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree at fair value. SFAS 141R also requires transactions costs related to the business combination to be expensed as incurred. SFAS 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The effective date for the Company will be January 1, 2009. The Company has not yet determined the impact of SFAS 141R related to future acquisitions, if any, on its consolidated financial statements.

In December 2007, the FASB ratified the consensus reached by the EITF on EITF Issue 07-1, *Accounting for Collaborative Arrangements* (EITF 07-1). EITF 07-1 requires collaborators to present the results of activities for which they act as the principal on a gross basis and report any payments received from (made to) other collaborators based on other applicable GAAP or, in the absence of other applicable GAAP, based on analogy to authoritative accounting literature or a reasonable, rational, and consistently applied accounting policy election. The effective date for the Company will be January 1, 2009. The Company has not yet determined the impact of EITF 07-1 on its consolidated financial statements.

---

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2. Stock-based Compensation**

*Stock Plans*

On March 14, 2007, the 2004 Equity Incentive Plan and the Employee Stock Purchase Plan were amended by the Company's Board of Directors to increase the number of shares available for issuance under the plans by 2,000,000 and 500,000 shares, respectively. On May 31, 2007, the increases for the plans were approved by the Company's stockholders.

The Company has five stock plans pursuant to which it has outstanding grants of stock awards to employees, directors or consultants. In general, the plans authorize the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options under the employee stock plans become exercisable at a rate of 25% per year for a period of four years from date of grant and have a maximum term of ten years. The exercise prices of stock options under employee stock plans generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.

In May 2004, the Company adopted the 2004 Equity Incentive Plan (2004 Plan) to authorize the grant of stock options (including indexed options), stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and deferred stock units. Under the 2004 Plan, awards may be granted to employees, directors and consultants of the Company, except for incentive stock options, which may be granted only to employees. The 2004 Plan supersedes all prior option plans (detailed below), and no new awards will be granted under these prior plans. As a result of the adoption of the 2004 Plan, all shares previously reserved for issuance under the prior plans and remaining for grant are now reserved for issuance under the 2004 Plan. Additionally, shares outstanding under the prior plans that are subject to options that expire or otherwise are forfeited become reserved for issuance under the 2004 Plan. As of December 31, 2007, options to purchase 5,394,114 shares and 86,000 restricted stock units were outstanding under the 2004 Plan, and 5,759,732 shares were reserved for future awards.

The Company's other stock plans under which options remain outstanding are the 1995 Employee Stock Option Plan, the Non-Employee Director Stock Option Plan, the Scientific Advisory Board/Consultants Stock Option Plan and the 2002 Equity Incentive Plan. As of December 31, 2007, options to purchase 494,390 shares were outstanding under these stock plans. Additionally, as of December 31, 2007, options to purchase 773,539 shares granted outside of any of the Company's stock option plans were outstanding.

In December 2004, the Company's Board of Directors approved an Executive Change in Control and Severance Benefit Plan for executive officers and other eligible employees, which was amended and restated in May 2005 and again in August 2007. The purpose of the plan is to provide for the payment of severance benefits and/or change in control benefits to certain eligible employees, and the plan supersedes and replaces any change in control and/or severance plans adopted previously. The plan provides that, upon a change in control of the Company as defined under the plan, all Nuvelo stock options and stock awards held by a plan participant will become fully vested. Such shares held by a plan participant will also become fully vested if the participant is terminated without cause or constructively terminated within one month preceding a change in control. In addition, if a participant is terminated without cause or constructively terminated outside the context of change in control, he or she shall be immediately credited with an additional year of vesting with respect to Nuvelo stock options and stock awards held. If a change in control occurs in the future, it is possible that material additional stock-based compensation expense could be incurred.

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Under the Company's employee stock purchase plan (ESPP), eligible employees may elect to purchase shares of the Company's stock through payroll deductions at a price equal to the lower of 85% of the fair market value of the stock as of the first or last business day of each three-month period. As of December 31, 2007, there were 507,268 shares available for issuance under the ESPP. During 2007, 2006 and 2005, the Company issued 177,513 shares, 58,623 shares and 63,332 shares of its common stock under the ESPP at a weighted average price per share of \$2.37, \$12.37 and \$6.64, respectively.

**Stock-based Compensation Stock Options, Restricted Stock Units and ESPP**

Stock-based compensation expense related to employee stock options, restricted stock units and ESPP purchase rights was as follows (in thousands):

	<b>Year Ended December 31,</b>	
	<b>2007</b>	<b>2006</b>
Research and development	\$ 3,712	\$ 4,622
General and administrative	5,008	6,529
Restructuring	926	
<b>Total</b>	<b>\$ 9,646</b>	<b>\$ 11,151</b>

Stock-based compensation expense related to non-employees was negligible in 2007, 2006 and 2005.

The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation cost, as a result of the full valuation allowance on its net deferred tax assets.

A summary of the Company's stock option activity for the years ended December 31, 2007, 2006 and 2005, and related information as of December 31, 2007, is as follows:

	<b>Number of Shares</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Remaining Contractual Term (In years)</b>	<b>Aggregate Intrinsic Value (In thousands)</b>
<b>Options outstanding at December 31, 2004</b>	4,766,669	\$ 18.77		
Granted	3,232,000	8.69		
Exercised	(243,065)	5.34		
Forfeited or expired	(742,081)	13.76		
<b>Options outstanding at December 31, 2005</b>	7,013,523	15.11		
Granted	2,227,200	16.49		
Exercised	(884,671)	8.24		
Forfeited or expired	(394,407)	13.33		
<b>Options outstanding at December 31, 2006</b>	7,961,645	16.35		

Edgar Filing: NUVELO INC - Form S-4/A

Granted	1,597,750	3.48		
Exercised	(1,208)	4.10		
Forfeited or expired	(2,896,144)	10.76		
<b>Balances at December 31, 2007:</b>				
Options outstanding	6,662,043	\$ 15.70	6.82	\$ 3
Options vested and expected to vest	5,962,406	\$ 16.33	6.66	\$ 2
Options exercisable	4,512,084	\$ 18.52	6.19	\$

F-27



**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Of the total 1,597,750 options granted in 2007, 95,000 vested immediately and 1,307,750 vest ratably over a three-year period.

For the years ended December 31, 2007, 2006 and 2005, the weighed average grant date fair value of options granted was \$2.47, \$9.51 and \$5.58 per share, respectively. For the years ended December 31, 2006 and 2005, the total intrinsic value of options exercised was \$8.8 million and \$0.8 million respectively. The total intrinsic value of options exercised in 2007 was negligible. For the years ended December 31, 2007, 2006 and 2005, the fair value of options vested was \$8.7 million, \$11.5 million and \$9.1 million, respectively. The unamortized compensation expense related to unvested options as of December 31, 2007, excluding estimated forfeitures, was \$15.0 million. The weighted-average period over which compensation expense related to these options is expected to be recognized is 1.74 years.

The following table summarizes information about stock options outstanding and exercisable as of December 31, 2007:

Range of Exercise Prices	Number of Shares	Options Outstanding		Options Exercisable	
		Weighted Average Remaining Contractual Term (In years)	Weighted Average Exercise Price	Number of Shares	Weighted Average Exercise Price
\$ 1.44 \$ 3.54	891,635	8.79	\$ 3.40	260,921	\$ 3.50
3.67 8.62	892,952	6.64	6.43	816,025	6.37
8.73 9.17	1,069,915	7.48	9.15	629,853	9.14
9.21 9.82	905,320	6.73	9.67	733,868	9.65
9.83 10.18	832,438	6.56	10.07	640,327	10.07
10.19 16.73	871,565	8.30	16.12	398,517	15.54
16.74 37.69	835,009	4.93	24.70	669,364	26.56
39.00 285.56	363,209	2.12	94.21	363,209	94.21
	6,662,043	6.82	15.70	4,512,084	18.52

As of December 31, 2006 and 2005, 3,629,540 and 2,854,933 options were exercisable at a weighted average exercise price of \$20.87 and \$24.05, respectively.

A summary of the Company's restricted stock unit activity for the year ended December 31, 2007, is as follows:

	Number of Units	Aggregate Intrinsic Value (In thousands)
Units unvested at December 31, 2006		
Granted	183,000	
Vested		
Forfeited	(97,000)	
Units unvested at December 31, 2007	86,000	\$ 157

Edgar Filing: NUVELO INC - Form S-4/A

Units vested and expected to vest	60,628	\$	111
Units exercisable		\$	

F-28

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

All restricted stock units granted in 2007 have a grant date fair value of \$3.54 per unit and a three-year vesting period during which one-third of the units vest at the anniversary date of the grant. No restricted stock units were granted prior to 2007. Restricted stock units granted under the 2004 Plan have no exercise price and have a fair value equal to the average of the high and low prices of the Company's common stock on the date of grant, in accordance with the Company's stock award pricing practice. The unamortized compensation expense related to unvested restricted stock units as of December 31, 2007, excluding estimated forfeitures, was \$0.5 million. The weighted average period over which compensation expense related to these restricted stock units is expected to be recognized is 2.09 years.

The Company terminated two executives in connection with its reduction in force announced in August 2007 (see Note 6, Restructuring). The two former executives were entitled to a 12-month acceleration in vesting of their options in accordance with the Company's Executive Change in Control and Severance Benefit Plan. The Company recorded \$0.9 million of stock-based compensation expense as a result of this acceleration in vesting of options and classified this expense as part of restructuring costs.

The following table illustrates the pro forma effect under SFAS 123, of options and ESPP purchase rights granted, on the Company's net loss and net loss per share, net of related tax effects for the year ended December 31, 2005 (in thousands, except for per share data):

Net loss, as reported	\$ (71,611)
Add: Stock-based employee compensation expense included in reported net loss	394
Deduct: Total stock-based employee compensation expense determined under fair value-based method for all awards	(10,899)
Pro forma net loss	\$ (82,116)
Basic and diluted loss per share:	
Basic and diluted net loss per share, as reported	\$ (1.73)
Pro forma basic and diluted net loss per share	\$ (1.99)

**Table of Contents**

## NUVELO, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

**3. Financial Instruments***Available-for-sale Investments*

The cost and fair value of the Company's available-for-sale investments as of December 31, 2007 and 2006 are as follows (in thousands):

	December 31, 2007			Estimated
	Amortized	Gross	Gross	Fair
	Cost	Unrealized	Unrealized	Value
		Gains	Losses	
Corporate debt securities	\$ 78,521	\$ 47	\$ (16)	\$ 78,552
Asset-backed securities	9,936	18		9,954
Money market funds	8,243			8,243
	\$ 96,700	\$ 65	\$ (16)	\$ 96,749

## Reported as:

Cash equivalents				\$ 31,243
Marketable securities				65,506
				\$ 96,749

	December 31, 2006			Estimated
	Amortized	Gross	Gross	Fair
	Cost	Unrealized	Unrealized	Value
		Gains	Losses	
Corporate debt securities	\$ 100,874	\$ 9	\$ (12)	\$ 100,871
U.S. government agencies	26,228	9		26,237
Asset-backed securities	4,678		(2)	4,676
Money market funds	14,229			14,229
	\$ 146,009	\$ 18	\$ (14)	\$ 146,013

## Reported as:

Cash equivalents				\$ 53,222
Marketable securities				92,791
				\$ 146,013

The following is a summary of amortized cost and estimated fair value of available-for-sale investments by contract maturity (in thousands):

December 31, 2007		December 31, 2006	
Amortized	Estimated	Amortized	Estimated
Cost	Fair Value	Cost	Fair Value

Edgar Filing: NUVELO INC - Form S-4/A

Due in less than one year	\$ 94,724	\$ 94,754	\$ 146,009	\$ 146,013
Due in more than one year	1,976	1,995		
<b>Total</b>	<b>\$ 96,700</b>	<b>\$ 96,749</b>	<b>\$ 146,009</b>	<b>\$ 146,013</b>

F-30

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following is a summary of available-for-sale investments with unrealized losses and their related fair value by the period of time each investment has been in an unrealized loss position (in thousands):

	December 31, 2007		December 31, 2006	
	Unrealized Losses	Estimated Fair Value	Unrealized Losses	Estimated Fair Value
Unrealized loss position for less than one year	\$ (16)	\$ 35,236	\$ (14)	\$ 33,005

Due to the short maturities of investments, the type and quality of security held, the relatively small size of unrealized losses compared to fair value, the short duration of such unrealized losses, and the Company's intent and ability to hold these investments for a period of time sufficient to allow for any anticipated recovery in market value, the Company believes these unrealized losses to be temporary in nature.

***Fair Value of Other Financial Instruments***

The carrying amount of other financial instruments, including cash and accrued liabilities, approximate fair value due to the short maturities of these instruments. The carrying amount of the Company's debt instruments approximate fair value as their fixed interest rates approximate current market lending rates offered for similar debt instruments by the Company's current banking institution. As of December 31, 2007, the Company did not have any debt or foreign exchange forward contracts outstanding.

**4. Property and Equipment, Net**

Property and equipment, net, consist of the following (in thousands):

	December 31,	
	2007	2006
Leasehold improvements	\$ 10,458	\$ 10,458
Machinery, equipment and furniture	6,132	6,345
Computers and software	2,264	4,397
	18,854	21,200
Accumulated depreciation and amortization	(9,948)	(9,222)
	\$ 8,906	\$ 11,978

**5. Facility Exit Costs**

The Company currently has a lease commitment for a 139,000-square-foot facility at 985 Almanor Avenue, Sunnyvale, California (Sunnyvale facility), which expires on May 30, 2011. In September 2005, Nuvelo relocated the Company's headquarters to a facility located at 201 Industrial Road, San Carlos, California. Through December 2006, the Company retained the Sunnyvale facility as a storage location. In December 2006, the Company approved a plan to exit the Sunnyvale facility and restore it for potential sublease. On December 31, 2006, the Company exited the Sunnyvale facility and recorded a \$21.1 million charge under SFAS 146 to reflect the \$26.6 million estimated present value of future lease-related payments less estimated net income from sublease rental, offset by the \$5.5 million reduction in the balance of deferred rent related to the facility as of this date. Future lease-related payments are scheduled to be made periodically until the lease expires. In addition to the \$21.1 million charge, the Company recorded an impairment charge of \$3.4 million on December 31, 2006 to reflect the excess of the carrying value of leasehold improvements for the Sunnyvale



**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

facility over their estimated fair value, which was assessed to be zero, as they are not expected to provide any future economic benefit to the Company. Both charges are included in the statement of operations under the caption Facility exit charges.

The following table summarizes the activity related to accrued facility exit costs for the year ended December 31, 2007 (in thousands):

Balance as of December 31, 2006	\$ 26,616
Amounts paid during the period	(8,044)
Non-cash accretion	1,915
Balance as of December 31, 2007	\$ 20,487

The non-cash accretion expense of \$1.9 million was included in general and administrative expenses for the year ended December 31, 2007.

The Company has also recorded an accrual for \$0.8 million of facility restoration obligation related to the Sunnyvale facility. As of December 31, 2007, this accrual was included in other current liabilities in the consolidated balance sheet.

**6. Restructuring**

On August 1, 2007, the Company announced a reduction in its workforce by approximately 30 percent to realign its organization to focus on core development programs that it believes will produce nearest-term proof-of-concept data. In addition, the Company suspended development of rNAPc2 in all indications including cancer and acute coronary syndromes. The Company had completed the restructuring plan and recorded a restructuring expense of \$2.3 million, including \$1.4 million of termination benefits and \$0.9 million of non-cash stock-based compensation expense, for the year ended December 31, 2007. As of December 31, 2007, \$0.4 million of termination benefits remained unpaid, which were classified under accrued employee liabilities in the consolidated balance sheet.

**7. Borrowing Arrangements**

The Company had a Loan and Security Agreement with Silicon Valley Bank (SVB) under which it had a fully-utilized term loan facility of \$4.1 million and an \$8.0 million revolving credit line facility which expired on August 28, 2007. The Company had not drawn down any of the funds available under the \$8.0 million revolving credit line, although \$6.0 million of this amount was reserved to collateralize a letter of credit issued to The Irvine Company, the landlord of the Sunnyvale facility, and of the remaining \$2.0 million, a portion was reserved as collateral for foreign exchange hedging contracts with SVB and a portion was available for working capital and other general business needs. Any borrowings under this line bore interest at SVB's prime rate and would cause replacement collateral to be required for the items above. In September 2007, the Company repaid in full the remaining principal balance under the SVB term loan facility and did not renew the Loan and Security Agreement after its expiration. The \$6.0 million letter of credit is now being collateralized by a certificate of deposit of the same amount, which is recorded as restricted cash, and the Company has no outstanding foreign currency hedging contracts.



**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****8. Commitments**

In January 2005, the Company entered into a seven-year facility lease agreement for 61,826 square feet of space at 201 Industrial Road in San Carlos, California, at \$2.35 per square foot per month, subject to annual increases of \$0.07 per square foot per month. The Company uses this facility for its headquarters. The lease term commenced on September 1, 2005, and the lease contains an option to cancel after five years upon payment of certain amounts specified in the lease, two options to extend the lease for five additional years, each at 95% of the then-current fair market rental rate (but not less than the existing rental rate), rights of first refusal over all vacant space in the building during the first two years of the lease, and an expansion option for a specified amount of space. The lease contains a tenant improvement allowance of \$8.9 million, which was fully utilized in 2005, and has been recorded to leasehold improvements and deferred rent, with the respective balances being charged to depreciation and credited to rent expense over the lease term. The rent expense for the lease on the San Carlos facility is being recognized as expense on a straight-line basis. In March 2006, the lease on this property was amended to provide for the exercise of the Company's expansion option over 7,624 square feet of rentable space. The amendment allows for a tenant improvement allowance of \$1.0 million, which was fully utilized in 2006, and the related lease rental payments commenced in August 2006.

The Company also has a lease commitment for the Sunnyvale facility, which expires on May 30, 2011. Under the terms of this lease, as amended, if the Company raises \$75.0 million or more in cash as a result of a single public or private equity offering, a portion of the remaining lease payments equal to the lesser of (i) 10% of any amount raised in excess of \$75.0 million, or (ii) the remaining outstanding rent deferrals as specified in the lease, or amendments thereto, becomes payable upon closing of the equity offering. In February 2006, as a result of a public offering (see Note 9), the Company paid the landlord \$3.7 million of the outstanding rent deferrals under this provision of the lease. As of December 31, 2007, the remaining outstanding rent deferrals totaled \$1.7 million. The Company also has a letter of credit related to this lease in the amount of \$6.0 million (see Note 7). As of December 31, 2006, the Company ceased use of the Sunnyvale facility, as it was no longer required for the Company's business (see Note 5).

As of December 31, 2007, future minimum rental payments under non-cancelable operating leases for both of these facilities are as follows (in thousands):

<b>Years Ending December 31,</b>	
2008	\$ 9,741
2009	8,328
2010	8,628
2011	4,979
2012	1,539
<b>Total</b>	<b>\$ 33,215</b>

In January 2008, the Company entered into a sublease agreement, pursuant to which a subtenant leases from the Company approximately 6,754 square feet of space available in the San Carlos facility from February 2008 to January 2011. The term of the sublease can be extended by the subtenant for three additional periods of one year each, subject to certain conditions contained in the sublease agreement. The total future minimum rent to be received from the sublease is \$0.8 million.

Rent expense was \$0.7 million, \$6.3 million and \$6.9 million for the years ended December 31, 2007, 2006 and 2005, respectively. Rent expense in 2007 did not include any amount related to the Sunnyvale facility, as the Company had recorded a charge in December 2006 to expense the estimated fair value of all future lease related payments for the Sunnyvale facility (see Note 5).

---

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****9. Stockholders' Equity*****Preferred Stock***

The Company is authorized to issue 5,000,000 shares of preferred stock. The Company's Board of Directors may set the rights and privileges of any preferred stock issued. As of December 31, 2007 and 2006, there were no issued and outstanding shares of preferred stock.

On June 5, 1998, the Company's Board of Directors adopted a rights plan and declared a dividend with respect to each share of common stock then outstanding. This dividend took the form of a right that entitles the holders to purchase one one-thousandth of a share of the Company's Series A junior participating preferred stock at a purchase price that is subject to adjustment from time to time. These rights have also been issued in connection with each share of common stock issued after June 5, 1998. The rights are exercisable only if a person or entity or affiliated group of persons or entities acquires, or has announced its intention to acquire, 15% (27.5% in the case of certain approved stockholders) or more of the Company's outstanding common stock. The adoption of the rights plan makes it more difficult for a third party to acquire control of the Company without the approval of the Board of Directors. This rights agreement was amended in March 2004 to reflect the Company's reincorporation under Delaware law.

***Common Stock***

In February 2006, the Company raised \$112.0 million in a public offering, after deducting underwriters' fees and stock issuance costs of \$7.6 million, from the sale of 7,475,000 shares of common stock at a public offering price of \$16.00 per share. The Company intends to use the net proceeds from this offering for general corporate purposes, including the advancement of drug candidates in clinical trials, capital spending and working capital.

In August 2005, the Company entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Ltd. (Kingsbridge), under which Kingsbridge has committed to purchase up to \$75.0 million of the Company's common stock within a three-year period, subject to certain conditions and limitations. As part of the arrangement, the Company issued a warrant to Kingsbridge to purchase 350,000 shares of the Company's common stock at a price of approximately \$12.07 per share, which is exercisable beginning six months after the date of grant and for a period of five years thereafter. Under the CEFF, the Company may require Kingsbridge to purchase newly-issued shares of common stock at prices between 90% and 94% of the volume weighted average price (VWAP) on each trading day during an eight-day pricing period. The value of the maximum number of shares the Company may issue in any pricing period is the lesser of 2.5% of the Company's market capitalization immediately prior to the commencement of the pricing period, or \$10.0 million. The minimum VWAP for determining the purchase price at which the Company's stock may be sold in any pricing period is the greater of \$2.50 or 85% of the closing price of the Company's common stock on the day prior to the commencement of the pricing period. The CEFF also required the Company to file a resale registration statement with respect to the resale of shares issued pursuant to the CEFF and underlying the warrant, to use commercially reasonable efforts to have the registration statement declared effective by the SEC, which occurred in October 2005, and to maintain its effectiveness. The Company may sell a maximum of 8,075,000 shares under the CEFF (exclusive of the shares underlying the warrant), which may further limit the potential proceeds from the CEFF. The Company is not obligated to sell any of the \$75.0 million of common stock available under the CEFF, and there are no minimum commitments or minimum use penalties. Under the CEFF, the Company sold 1,839,400 shares for gross proceeds of \$14.4 million in the fourth quarter of 2005, and a further 568,247 shares for gross proceeds of \$10.0 million in October 2006, and may sell the balance of 5,667,353 shares to Kingsbridge through the expiration of the CEFF in October 2008, limited to the remaining \$50.6 million available under the facility, subject to the limitations noted above.

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Warrants**

As of December 31, 2007, warrants to purchase 850,224 shares of common stock were outstanding and exercisable at exercise prices ranging from \$12.07 to \$24.87, with a weighted average exercise price per share of \$19.57. These warrants, which were granted as part of various financing and business agreements, expire at various times between January 2009 and February 2011. Warrants are recorded at their estimated fair market value at the date of grant using the Black-Scholes option-pricing model.

The fair value of the warrant issued to Kingsbridge, which was \$2.1 million, or \$5.94 per share, on the date of grant, was initially recorded as a deferred financing cost to additional paid-in capital, with the opposing entry being to other current liabilities in the balance sheet due to the existence of a cash payment feature in the agreement that compensates Kingsbridge based on any reduction in the fair value of shares held by Kingsbridge as a result of this agreement during a period in which Nuvelo fails to maintain the effectiveness of the abovementioned registration statement, or electively imposes a trading blackout (i.e. a registration payment arrangement). The amount of compensation is payable in cash in both circumstances, or, at the sole discretion of Nuvelo, in shares of the Company's common stock in the event of a trading blackout. Through September 30, 2006, the current liability was marked-to-market at each quarter end, using the Black-Scholes option-pricing model, with the change being recorded to general and administrative expenses. As of December 31, 2005 and September 30, 2006, the fair value of the warrant recorded in the Company's balance sheet was \$1.5 million and \$4.3 million, with \$0.6 million and \$2.8 million having been credited and charged to expense in 2005 and 2006, respectively. On October 1, 2006, the Company early adopted the provisions of FASB Staff Position No. EITF 00-19-2, *Accounting for Registration Payment Arrangements*, which requires that contingent obligations to make future payments under a registration payment arrangement be recognized and measured separately in accordance with SFAS No. 5, *Accounting for Contingencies*. The Company believes the likelihood of such a cash payment to be not probable, and therefore does not need to recognize a liability for such obligations. Accordingly, on October 1, 2006, a cumulative-effect adjustment of \$2.2 million was recorded in the statement of operations to reflect the difference between the initial fair value of this warrant and its fair value as of this date, and the initial fair value of the warrant of \$2.1 million was reclassified from other current liabilities to additional paid-in capital in the consolidated balance sheet.

**10. Accumulated Other Comprehensive Income**

The components of accumulated other comprehensive income for each period presented, net of any related tax effects, are as follows (in thousands):

	<b>December 31,</b>	
	<b>2007</b>	<b>2006</b>
Unrealized gain on available-for-sale securities	\$ 49	\$ 4
Unrealized gain on hedging instruments		6
	\$ 49	\$ 10

**11. Collaborative Agreements****Amgen**

In October 2004, Nuvelo obtained worldwide rights to develop and commercialize alfimeprase from Amgen, in exchange for payments to Amgen of milestones and royalties. As a result of dosing the first patient in the first Phase 3 clinical trial for alfimeprase in April 2005, Nuvelo paid a \$5.0 million milestone fee to Amgen in May 2005, which was charged to research and development expense. Future milestone payments under the license agreement could total as much as \$35.0 million.



---

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Archemix***

In July 2006, Nuvelo entered into a collaboration agreement with Archemix Corporation. Under the agreement, Archemix is responsible for the discovery of short-acting aptamers targeting the coagulation cascade for use in acute cardiovascular procedures, and Nuvelo is responsible for development and worldwide commercialization of these product candidates. Nuvelo made an up-front license fee payment to Archemix of \$4.0 million in August 2006, which was recorded as a research and development expense, and is also funding at least \$5.25 million of Archemix's research over the first three years of the agreement. Archemix may receive payments totaling up to \$35.0 million per development compound on the achievement of specified development and regulatory milestones, along with potential royalty payments based on sales of licensed compounds. In February 2008, Nuvelo paid Archemix a \$1.0 million milestone fee that was accrued upon dosing of the first patient in the Phase 1 trial for NU172. If Nuvelo enrolls the first patient in a Phase 2 trial of NU172, which may occur within the next 12 months, a \$3 million milestone fee is payable to Archemix. At the initiation of the first Phase 3 study for any licensed compound, Archemix has the option to elect to participate in profits from sales of the compound by funding its pro rata share of prior and future product development and commercialization expenses, in lieu of receiving milestone payments and royalties with respect to that compound.

Nuvelo is obligated to purchase Archemix common stock having a value equal to the lesser of \$10.0 million or 15 percent of the total gross proceeds raised by Archemix in a qualified public offering of Archemix stock occurring within five years of the effective date of the collaboration agreement. On July 25, 2007, Archemix filed a registration statement for an initial public offering of its common stock with the Securities and Exchange Commission. However, on February 6, 2008, Archemix filed with the SEC to request for a withdrawal of this registration statement because of unfavorable market conditions.

***Kirin Pharma Company, Limited***

In March 2005, Nuvelo entered into a collaboration agreement with Kirin Pharma Company, Limited (Kirin) for the development and commercialization of NU206. In accordance with the terms of this agreement, the Company received a \$2.0 million up-front cash payment from Kirin in April 2005, which was deferred and is being recognized on a straight-line basis over the related performance period through 2013. Nuvelo leads worldwide development, manufacturing and commercialization of the compound. All operating expenses and any profits related to the development and commercialization of NU206 are being shared 60 percent by Nuvelo and 40 percent by Kirin. If this agreement is terminated, or Kirin or Nuvelo elects under certain circumstances to no longer actively participate in the collaboration, the relationship with respect to NU206 will convert from an expense and profit-sharing structure to a royalty-based structure.

***Dendreon***

Nuvelo obtained exclusive worldwide rights to all indications of rNAPc2 and all other rNAPc molecules owned by Dendreon Corporation, as a result of a licensing agreement entered into in February 2004. Under the terms of the agreement, the Company paid Dendreon an up-front fee of \$4.0 million (\$0.5 million in cash and \$3.5 million in Nuvelo common stock) in 2004, which was recorded as a research and development expense. Future milestone payments to Dendreon could reach as much as \$23.5 million if all development and commercialization milestones are achieved. If rNAPc2 is commercialized, Nuvelo will also be responsible for paying royalties to Dendreon depending on sales of rNAPc2. The Company has suspended its clinical development of rNAPc2, which could impact its current relationship and license with Dendreon.

---

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Bayer***

The Company and Bayer agreed to terminate their January 2006 license and collaboration agreement for the development and commercialization of alfimeprase effective June 30, 2007. The Company agreed to waive Bayer's obligation to provide Nuvelo 12 months' notice of termination in consideration of Bayer's agreement to pay Nuvelo a lump sum of \$15.0 million. Nuvelo also granted Bayer the option to reacquire rights to alfimeprase upon the initiation of a pivotal stroke trial or upon Nuvelo's public announcement that it is discontinuing further development of alfimeprase in the stroke indication. The notice period during which Bayer may exercise the option begins upon the Company making certain information available to Bayer and lasts for 30 days after delivery of the information. If Bayer exercises the option, Bayer is required to make a \$15.0 million non-refundable payment to Nuvelo and the parties are required to enter into a new license and collaboration agreement on substantially the same terms as the original agreement, with the exception of the \$50.0 million up-front payment and the milestone payment related to a Phase 2 trial in a stroke indication that were part of the terms of the original agreement.

Under the original terminated agreement, Bayer had the right to commercialize alfimeprase in all territories outside the United States and, if commercialized, would pay tiered royalties on net sales of alfimeprase, if any. Nuvelo retained all commercialization rights and profits from any alfimeprase sales in the United States. The Company received a non-refundable, up-front cash payment from Bayer of \$50.0 million upon entry into the agreement. The \$50.0 million up-front cash payment was deferred upon receipt and was being recognized as revenue on a straight-line basis over the performance period under the agreement, originally estimated to be through September 2020. Nuvelo was responsible for 60 percent of any costs for alfimeprase global development programs, and Bayer was responsible for the remaining 40 percent, where global development programs refers to clinical trials conducted to support regulatory approval in major countries around the world.

As a result of the termination of the license and collaboration agreement in June 2007, the Company recognized in revenues the remaining unamortized balance of the cash up-front payment, which totaled \$44.9 million, as the Company had no additional obligations or deliverables under the agreement. The \$15.0 million payment related to the termination was recorded as deferred revenue and will remain as such until the Bayer option is exercised or expires at the conclusion of the notice period.

Under the cost-sharing arrangement, a total of \$3.0 million and \$28.9 million was billed to Bayer for Nuvelo's alfimeprase-related global development spending for the years ended December 31, 2007 and 2006, respectively, and was recorded as an offset to research and development expense in the statements of operations.

**12. Foreign Currency Derivatives**

In June 2005, the Company entered into a development and validation agreement with Avecia under which Nuvelo's payments to Avecia are denominated in British pounds. In order to reduce exposure to fluctuations in the British pound prior to any payment made under this contract, the Company had entered into a number of foreign currency forward hedging contracts, all maturing or having matured within one year, and all being designated as cash flow hedges under SFAS 133. In accordance with SFAS 133, all derivatives, such as foreign currency forward contracts, are recognized as either assets or liabilities in the balance sheet and measured at fair value. At hedge inception, critical terms in the derivative contract that may not precisely match the contract over its life are evaluated for effectiveness using regression analysis. Ongoing effectiveness had been calculated by affirming the probability of the transaction and comparing, on a spot-to-spot basis, the change in fair value of the hedge contract to the change in fair value of the forecasted transaction (the underlying hedged item). The effective component of hedge gains and losses was recorded in other comprehensive income (loss) within stockholders' equity in the balance sheet and reclassified to research and development expenses in the statement

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

of operations when the forecasted transaction itself was recorded to the statement of operations. Any residual change in the fair value of the hedge contracts, such as ineffectiveness or time value excluded from effectiveness testing, was recognized immediately as a general and administrative expense. All hedging contracts that were outstanding as of December 31, 2006 expired in 2007. The Company does not expect to enter into any new hedging contracts.

The following table summarizes the activities in accumulated other comprehensive income (loss) related to derivatives classified as cash flow hedges held by the Company during the periods presented (in thousands):

	Year Ended December 31,		
	2007	2006	2005
Balance at beginning of year	\$ 6	\$ (197)	\$
Increase (decrease) in fair value of derivatives, net		971	(191)
Reclassifications to expense from accumulated other comprehensive income (loss)	(6)	(768)	(6)
Balance at end of year	\$	\$ 6	\$ (197)

**13. Income Taxes**

The reconciliations between the amounts computed by applying the U.S. federal statutory tax rate of 34% to loss from continuing operations and the actual provision for income taxes are as follows (in thousands):

	Year Ended December 31,		
	2007	2006	2005
Loss from continuing operations	\$ (12,301)	\$ (132,777)	\$ (71,611)
Federal tax benefit at statutory rate	\$ (4,182)	\$ (45,144)	\$ (24,348)
Current year net operating losses and temporary differences, for which a full valuation allowance is recorded	2,225	45,229	24,556
State taxes, net of federal benefit	1	1	3
Stock-based compensation	1,956	(86)	(211)
Provision for income taxes	\$	\$	\$

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets for financial reporting and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets for federal and state income taxes are as follows (in thousands):

	December 31,	
	2007	2006
Deferred tax assets:		
Property and equipment	\$ 3,598	\$ 4,707
Accruals and reserves	15,154	10,772
Net operating loss carryforwards	126,503	125,292

Edgar Filing: NUVELO INC - Form S-4/A

Research and other tax credit carryforwards	6,893	12,882
Capital loss carryforward discontinued operations	3,152	3,152
Capitalized research and development costs	10,846	12,313
Stock-based compensation	1,784	232
Other	7,200	9,538
Total deferred tax assets	175,130	178,888
Valuation allowance	(175,130)	(178,888)
Deferred tax assets, net of valuation allowance	\$	\$

F-38



**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Deferred tax assets are reduced by a valuation allowance, as management believes that it is more likely than not that the deferred tax assets will not be realized. The valuation allowance decreased by \$3.8 million for the year ended December 31, 2007, increased by \$52.6 million for the year ended December 31, 2006 and decreased by \$20.0 million for the year ended December 31, 2005. The deferred tax assets and related valuation allowance as of December 31, 2006 and 2005 have been adjusted to reflect the annual limitation as a result of ownership changes discussed below. In addition, the Company performed a reconciliation of other deferred tax assets and made certain adjustments reflected in the deferred tax asset and valuation allowance balances for the years ended December 31, 2006, 2005 and 2004. None of these adjustments had any impact on the Company's statement of operations or financial position.

The utilization of the Company's net operating loss carryforwards and tax credit carryforwards are subject to annual limitation due to the ownership changes per the Internal Revenue Code and similar state provisions. Such an annual limitation may result in the expiration of the net operating loss before utilization. In 2007 the Company completed a review of its ownership changes and concluded certain common stock offerings prior to 2006 resulted in ownership changes that triggered a net operating loss carryforward annual limitation. This annual limitation per Section 382 of the Internal Revenue Code results in approximately \$119.0 million in net operating loss carryforwards for years up to and including 2005 expiring not utilized. Similarly, approximately \$12.0 million of research tax credits will expire unused. Adjusting for the annual limitation, at December 31, 2007, the Company had net operating loss carryforwards for federal income tax purposes of approximately \$351.3 million which begin to expire in year 2009, and federal tax credits of approximately \$2.5 million which begin to expire in 2026. At December 31, 2007, the Company also had state net operating loss carryforwards of approximately \$142.7 million which begin to expire in 2012 and state tax credits of approximately \$6.6 million which have no expiration date.

Approximately \$13.3 million of the federal net operating losses and \$7.2 million of the state net operating losses relate to deductions from stock-based compensation. The benefit from the realization of these losses will be an adjustment to Additional Paid-in Capital.

On December 3, 2004, the Company sold its subsidiaries, Callida Genomics and N-Mer. The related capital loss carryforward is \$7.9 million. The federal and California capital loss carryforwards will expire in 2009.

The Company adopted FIN 48 which requires that the Company recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. No adjustment to the Company's accumulated deficit was required upon its adoption of FIN 48 on January 1, 2007.

The Company had cumulative unrecognized tax benefit of approximately \$6.2 million as of January 1, 2007. The following table summarizes the activity related to the unrecognized tax benefit for the year ended December 31, 2007 (in thousands):

Balance at January 1, 2007	\$ 6,159
Increase related to current year tax position	1,075
Balance at December 31, 2007	\$ 7,234

As of December 31, 2007 and 2006, the cumulative unrecognized tax benefit was netted against deferred tax assets with a full valuation allowance or other fully reserved amounts, and if recognized there would be no effect on the Company's effective tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefit will significantly increase or decrease within the next 12 months.

---

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The Company recognizes interest accrued and penalties related to unrecognized tax benefits in general and administrative expense. During the years ended December 31, 2007, 2006 and 2005, the Company recognized no interest and penalties.

The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and the appropriate state income taxing authorities for all years due to the net loss carryovers from those years.

**14. Transactions with Related Parties**

Dr. Rathmann, a former member of the Company's Board of Directors and current chairman emeritus, provided a \$20.0 million line of credit to the Company in August 2001, of which \$11.0 million was drawn down, with the remaining \$9.0 million having expired unused. The related promissory note bore interest at the prime rate plus 1%. In November 2003, the Company began repaying the outstanding balance over 48 months with equal monthly principal payments of \$0.2 million. The Company paid in full the accrued interest balance of \$2.3 million and made the final principal payment in October 2007. Interest expense related to this line of credit was \$0.1 million, \$0.3 million and \$0.5 million for the years ended December 31, 2007, 2006 and 2005, respectively.

**15. Note Receivable**

In connection with the sale of its subsidiary to SBH Genomics, Inc. (SBH) on December 3, 2004, the Company received a convertible promissory note from SBH with a principal amount of \$0.9 million. The promissory note is convertible into SBH's preferred shares if SBH raises at least \$2.0 million in venture capital financing within four years after the date of the sale. This preferred stock will be converted at the same price per share at which it is sold to the venture capital investors and will be granted the same rights and preferences as those provided to the venture capital investors. If SBH fails to raise at least \$2.0 million in venture capital financing within this period, the promissory note will become due and payable. No interest or principal was payable on the promissory note for the two years through December 3, 2006. Simple interest of prime rate plus 1% per annum is payable in the third and fourth years on a quarterly basis. Prime rate was set as of the second anniversary of the sale and adjusted on the third anniversary. The Company has assessed the value of the promissory note to be zero due to the improbability of any collection. Interest income is credited to income in the period received.

**16. Segment and Revenue Concentration Data**

***Segment data***

The Company is engaged in the discovery, development and commercialization of novel acute cardiovascular and cancer therapies. The Company has only one reportable segment and, therefore, all segment-related financial information required by Statement of Financial Accounting Standards No. 131, *Disclosures About Segments of an Enterprise and Related Information*, is included in the consolidated financial statements. The reportable segment reflects the Company's structure, reporting responsibilities to the chief executive officer and the nature of the products under development.

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Revenue Concentration Data**

Revenues from collaborative agreements or other sources representing 10% or more of total revenues in each period were as follows:

Source:	Year Ended December 31,		
	2007	2006	2005
Bayer	99%	87%	*
MTHFR technology sublicensing	*	*	66%
Kirin	*	*	34%

\* less than 10%

**17. Legal Matters**

On February 9, 2007, Nuvelo, Inc. and certain of its former and current officers and directors were named as defendants in a purported securities class action lawsuit filed in the United States District Court for the Southern District of New York. The suit alleges violations of the Securities Exchange Act of 1934 related to the clinical trial results of alfimeprase, which the Company announced on December 11, 2006, and seeks damages on behalf of purchasers of the Company's common stock during the period between January 5, 2006 and December 8, 2006. Specifically, the suit alleges that the Company misled investors regarding the efficacy of alfimeprase and the drug's likelihood of success. The plaintiff seeks unspecified damages and injunctive relief. Six additional lawsuits were filed in the Southern District of New York on February 16, 2007, March 1, 2007 and March 6, 2007, respectively. On April 10, 2007, six separate motions to consolidate the cases, appoint lead plaintiff, and appoint lead plaintiff's counsel were filed. On April 18, 2007, the Company filed a motion to transfer the four cases to the Northern District of California. The Court granted the Company's motion to transfer the cases to the Northern District of California in July 2007. Plaintiffs have filed motions for consolidation, lead plaintiff and lead plaintiff's counsel in the Northern District of California. Plaintiffs filed their consolidated complaint in the Northern District of California on November 9, 2007. The Company filed a motion to dismiss plaintiffs consolidated complaint on December 21, 2007. Plaintiffs filed an opposition to the Company's motion to dismiss on February 4, 2008. The motion to dismiss the consolidated complaint is still pending. The Company currently cannot determine the impact that this litigation will have on its business, results of operations or financial condition.

On March 19, 2007, the Company received a summons related to a derivative suit that had been filed in the Superior Court for California, San Mateo County, by an alleged individual stockholder of Nuvelo, purportedly on behalf of Nuvelo against certain of Nuvelo's current and former officers and directors. The complaint alleges among other claims, that the defendants breached their fiduciary duties to Nuvelo by issuing or failing to prevent the issuance of purportedly false and misleading statements between January 5, 2006 and December 11, 2006 relating to the clinical trial results of alfimeprase, which the Company announced on December 11, 2006, and that certain defendants benefited from these actions. On April 18, 2007, the Company filed a demurrer to the complaint on the ground that plaintiff was not excused from issuing a demand to the board prior to filing the lawsuit. Plaintiffs filed oppositions to the Company's demurrer, and the Company has subsequently filed replies to Plaintiffs' oppositions. The Court heard this motion on July 30, 2007, and granted the Company's demurrer, but also granted plaintiffs the opportunity to file an amended complaint. Plaintiffs filed an amended complaint on October 15, 2007. The Company filed its reply to their amended complaint on December 6, 2007. The Court heard the motion on December 17, 2007. On January 2, 2008, the Superior Court for California, San Mateo County, entered final judgment dismissing in its entirety, with prejudice, the second amended consolidated derivative complaint.

**Table of Contents**

**NUVELO, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

On or about December 6, 2001, Variagenics, Inc. was sued in a complaint filed in the United States District Court for the Southern District of New York naming it and certain of its officers and underwriters as defendants. The complaint purportedly is filed on behalf of persons purchasing Variagenics stock between July 21, 2000 and December 6, 2000, and alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended and Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The complaint alleges that, in connection with Variagenics July 21, 2000 initial public offering, or IPO, the defendants failed to disclose additional and excessive commissions purportedly solicited by and paid to the underwriter defendants in exchange for allocating shares of Variagenics stock to preferred customers and alleged agreements among the underwriter defendants and preferred customers tying the allocation of IPO shares to agreements to make additional aftermarket purchases at predetermined prices. Plaintiffs claim that the failure to disclose these alleged arrangements made Variagenics registration statement on Form S-1 filed with the SEC in July 2000 and the prospectus, a part of the registration statement, materially false and misleading. Plaintiffs seek unspecified damages. On or about April 19, 2002, an amended complaint was filed which makes essentially the same allegations. On or about July 15, 2002, Variagenics and the individuals filed a motion to dismiss. The Company is involved in this litigation as a result of the merger with Variagenics in January 2003. On July 16, 2003, Nuvelo's Board of Directors approved a settlement proposal initiated by the plaintiffs. However, because of a recent court ruling, the settlement class, as defined in the settlement papers, is no longer feasible. While a new complaint has not been filed against the Company, there are several focus cases against other Issuers in which new complaints have been filed. In these cases the defendant Issuers have moved to dismiss the complaints and have also opposed plaintiffs revised motions for class certification. The Company and other defendant issuers have been advised that the plaintiffs intend to file second, amended, consolidated complaints against the Company and the other defendant issuers at some point. If such a complaint is filed, the Company intends to file another motion to dismiss. The Company believes that any attorneys fees, loss or settlement payment with respect to this suit will be paid by the Company's insurance provider. However, it is possible that the Company could be forced to incur material expenses in the litigation if the parties cannot achieve a settlement, and, in the event of an adverse outcome, the Company's business could be harmed.

**Table of Contents****NUVELO, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****18. Selected Quarterly Financial Data (Unaudited)**

Summarized selected quarterly financial data is as follows (in thousands, except per share amounts):

	Quarter Ended			
	December 31, 2007	September 30, 2007	June 30, 2007	March 31, 2007
Contract revenues	\$ 63	\$ 63	\$ 45,825	\$ 910
Restructuring		2,336		
Operating income (loss)	(13,058)	(15,971)	27,319	(17,181)
Net income (loss)	(11,636)	(14,358)	29,042	(15,349)
Basic and diluted net income (loss) per share*	(0.22)	(0.27)	0.54	(0.29)

	Quarter Ended			
	December 31, 2006	September 30, 2006	June 30, 2006	March 31, 2006
Contract revenues	\$ 910	\$ 908	\$ 1,005	\$ 1,065
Facility exit charges	24,460			
Operating loss	(69,589)	(28,794)	(20,955)	(21,235)
Loss before cumulative effect of change in accounting principle	(67,560)	(26,668)	(18,898)	(19,651)
Cumulative effect of change in accounting principle	2,224			
Net loss	(65,336)	(26,668)	(18,898)	(19,651)
Basic and diluted net loss per share*:				
Loss before cumulative effect of change in accounting principle	(1.27)	(0.51)	(0.36)	(0.40)
Basic and diluted net loss per share	(1.23)	(0.51)	(0.36)	(0.40)

\* The sum of earnings per share for the four quarters may be different from the full year amount as a result of computing the quarterly and full year amounts based on the weighted average number of common shares outstanding in the respective periods.

**Table of Contents**

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The Board of Directors and Stockholders of

ARCA biopharma, Inc.:

We have audited the accompanying balance sheets of ARCA biopharma, Inc. (a development stage enterprise) (the Company) as of December 31, 2007 and 2006, and the related statements of operations; preferred stock and stockholders' deficit; and cash flows for each of the years in the three-year period ended December 31, 2007. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ARCA biopharma, Inc. (a development stage enterprise) as of December 31, 2007 and 2006, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2007, in conformity with U.S. generally accepted accounting principles.

As discussed in note 1 to the financial statements, in 2006, the Company adopted Statement of Financial Accounting Standards No. 123(R), *Share-Based Payment*.

/s/ KPMG LLP

Boulder, Colorado

October 28, 2008

F-44

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****BALANCE SHEETS****(in thousands, except share and per share amounts)**

	September 30, 2008 (unaudited)	December 31, 2007	2006	Pro forma Stockholders Deficit September 30, 2008 (unaudited)
<b>ASSETS</b>				
Current assets:				
Cash and cash equivalents	\$ 5,457	\$ 15,862	\$ 9,712	
Receivables from employees and directors			35	
Deferred transaction costs	564			
Deposits and other current assets	176	78	29	
<b>Total current assets</b>	<b>6,197</b>	<b>15,940</b>	<b>9,776</b>	
Property and equipment, net	1,289	208	165	
Other assets	42	56		
<b>Total assets</b>	<b>\$ 7,528</b>	<b>\$ 16,204</b>	<b>\$ 9,941</b>	
<b>LIABILITIES AND STOCKHOLDERS DEFICIT</b>				
Current liabilities:				
Accounts payable	\$ 1,653	\$ 1,669	\$ 570	
Accrued compensation	859	610	35	
Accrued expenses and other liabilities	1,289	675	161	
Note payable, current portion	1,451			
Deferred rent, current portion	105			
<b>Current and total liabilities</b>	<b>5,357</b>	<b>2,954</b>	<b>766</b>	
Notes payable, net of discount and current portion	2,490			
Stock subject to repurchase	75	75		
Warrants for preferred stock	113	55		
Debt discount	(59)			
Deferred rent, net of current portion	457			
<b>Total liabilities</b>	<b>8,492</b>	<b>3,084</b>	<b>766</b>	
Commitments and contingencies				
<b>Preferred Stock:</b>				
Redeemable, convertible preferred stock, \$0.001 par value.				
Series A, authorized 9,222,257 shares; issued and outstanding 9,222,257 shares at September 30, 2008 (unaudited) and December 31, 2007 and 2006; no shares issued and outstanding, pro forma (unaudited); liquidation preference of \$15,000,000 at September 30, 2008 (unaudited) and December 31, 2007 and 2006				
	14,953	14,938	14,919	\$
Series B, authorized 6,511,961 shares at September 30, 2008; 6,455,579 issued and outstanding at September 30, 2008 (unaudited); 6,455,579 shares authorized at December 31, 2007; issued and outstanding 6,455,579 shares at December 31, 2007; no shares issued and outstanding, pro forma (unaudited); liquidation preference of				
	17,898	17,871		

## Edgar Filing: NUVELO INC - Form S-4/A

\$18,000,000 at September 30, 2008 (unaudited) and December 31, 2007

**Stockholders deficit:**

Common stock, \$0.001 par value; authorized 40,000,000 shares; issued and outstanding 5,713,818 shares at September 30, 2008 (unaudited); issued and outstanding 4,416,648 and 3,666,765 shares at December 31, 2007 and 2006, respectively; 21,391,654 shares issued and outstanding at September 30, 2008, pro forma (unaudited)

	5	4	4	21
Additional paid-in capital	1,757	1,628	1,579	34,592
Deficit accumulated during the development stage	(35,577)	(21,321)	(7,327)	(35,577)
<b>Total stockholders deficit</b>	<b>(33,815)</b>	<b>(19,689)</b>	<b>(5,744)</b>	<b>\$ (964)</b>
<b>Total liabilities and stockholders deficit</b>	<b>\$ 7,528</b>	<b>\$ 16,204</b>	<b>\$ 9,941</b>	

See accompanying notes to financial statements.

F-45



**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****STATEMENTS OF OPERATIONS****(in thousands, except share and per share amounts)**

	Nine Months Ended September 30,		Year Ended December 31,			Period from December 17, 2001 (date of inception) to September 30, 2008 (unaudited)
	2008 (unaudited)	2007 (unaudited)	2007	2006	2005	
Costs and expenses:						
Research and development	\$ 8,363	\$ 7,270	\$ 10,244	\$ 3,978	\$ 846	\$ 23,491
Sales, general and administrative	6,037	3,332	4,210	1,545	569	12,971
Total costs and expenses	(14,400)	(10,602)	(14,454)	(5,523)	(1,415)	(36,462)
Loss from operations	(14,400)	(10,602)	(14,454)	(5,523)	(1,415)	(36,462)
Interest and other income	204	358	468	287		985
Interest and other expense	(60)	(3)	(8)	(5)	(44)	(100)
Net loss	\$ (14,256)	\$ (10,247)	\$ (13,994)	\$ (5,241)	\$ (1,459)	\$ (35,577)
Less: Accretion of redeemable convertible preferred stock	(42)	(25)	(37)	(17)		(97)
Net loss attributable to common stockholders	\$ (14,298)	\$ (10,272)	\$ (14,031)	\$ (5,258)	\$ (1,459)	\$ (35,674)
Net loss attributable to common stockholders per share basic and diluted	\$ (3.29)	\$ (2.73)	\$ (3.71)	\$ (1.62)	\$ (1.16)	
Weighted average shares outstanding basic and diluted	4,342,539	3,768,883	3,780,922	3,247,281	1,257,542	
Pro forma net loss attributable to common stockholders per share basic and diluted (unaudited)	\$ (0.71)		\$ (0.92)			
Pro forma weighted average shares outstanding basic and diluted (unaudited)	20,020,375		15,188,728			

See accompanying notes to financial statements.



**Table of Contents****ARCA BIOPHARMA, INC.**

(a development stage enterprise)

**STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS DEFICIT**

(in thousands, except share and per share amounts)

	Preferred Stock				Stockholders Equity (Deficit)			Total
	Series A		Series B		Common stock	Additional Paid In Capital	Deficit Accumulated During the Development Stage	
	Shares	Amount	Shares	Amount				Shares
<b>Balance, December 17, 2001 (date of inception)</b>		\$		\$				
Issuance of common stock to founders on December 31, 2002, for cash, at \$0.01 per share					93,000		1	1
Net loss							(116)	(116)
<b>Balance, December 31, 2003</b>					93,000		1	(116)
Issuance of common stock on September 30, 2004, for cash, at \$0.01 per share					708,580	1	6	7
Net loss							(511)	(511)
<b>Balance, December 31, 2004</b>					801,580	1	7	(627)
Issuance of common stock on January 3, 2005, for cash, at \$0.01 per share					105,000		1	1
Issuance of common stock on January 3, 2005, upon conversion of notes payable and related accrued interest at \$0.01 per share					107,000		1	1
Issuance of common stock on October 14, 2005, for intellectual property license rights, at \$1.36 per share					32,450		44	44
Issuance of common stock on October 14, 2005, upon conversion of notes payable and related accrued interest					1,117,323	1	1,353	1,354
Net loss							(1,459)	(1,459)
<b>Balance, December 31, 2005</b>					2,163,353	2	1,406	(2,086)
Issuance of common stock on February 21, 2006, for intellectual property license rights, at \$0.12 per share					624,197	1	74	75
Issuance of Series A on February 22, 2006, for cash, at \$1.6265 per share	5,727,354	9,316						
Issuance of Series A on February 22, 2006, upon conversion of notes payable and related accrued interest, at \$1.6265 per share	420,817	684						
Issuance of common stock upon exercise of stock options for cash					288,125		3	3
Issuance of common stock on February 22, 2006, for intellectual property and product license rights, at \$0.12 per share					499,719	1	59	60
Issuance of common stock on June 23, 2006, for intellectual property license rights, at \$0.15 per share					90,000		15	15
Issuance of common stock on November 7, 2006, for intellectual property license rights, at \$0.15 per share					1,371			
Issuance of Series A on December 8, 2006, for cash, at \$1.6265 per share	3,074,086	5,000						
Series A offering costs		(98)						
Share-based compensation							39	39

Edgar Filing: NUVELO INC - Form S-4/A

Accretion of offering costs of redeemable convertible preferred stock		17				(17)	(17)
Net loss						(5,241)	(5,241)
<b>Balance, December 31, 2006</b>	9,222,257	14,919	3,666,765	4	1,579	(7,327)	(5,744)

F-47

**Table of Contents****ARCA BIOPHARMA, INC.**

(a development stage enterprise)

**STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS DEFICIT (Continued)**

(in thousands, except share and per share amounts)

	Preferred Stock				Stockholders			Equity (Deficit)	
	Series A		Series B		Common stock		Additional	Accumulated	Total
	Redeemable	Convertible	Redeemable	Convertible	Shares	Amount	Paid In	During the	
	Preferred Stock	Preferred Stock	Preferred Stock	Preferred Stock	Shares	Amount	Capital	Development	
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Stage	
Issuance of Series B convertible redeemable preferred stock, on May 31, 2007 for \$2.439 per share.			3,688,902	9,000					
Issuance of Series B convertible redeemable preferred stock, on December 28, 2007 for \$3.253 per share.			2,766,677	9,000					
Series B offering costs				(147)					
Accretion of Series A offering Costs		19						(19)	(19)
Accretion of Series B offering costs				18				(18)	(18)
Issuance of common stock for intellectual property license rights on January 18, 2007 at \$0.28 per share					46,814		13		13
Issuance of common stock for intellectual property license rights, on June 30, 2007 at \$0.30 per share					23,068		7		7
Issuance of common stock for commercial license rights on July 19, 2007					100,000				
Share-based compensation							50		50
Issuance of shares to executive on February 19, 2007, vesting upon achievement of specified criteria, subject to repurchase					500,000				
Issuance of common stock upon exercise of stock options for cash					80,001		16		16
Net loss								(13,994)	(13,994)
<b>Balance, December 31, 2007</b>	9,222,257	14,938	6,455,579	17,871	4,416,648	4	1,628	(21,321)	(19,689)
Accretion of Series A offering costs (unaudited)		15						(15)	(15)
Accretion of Series B offering costs (unaudited)				27				(27)	(27)
Share-based compensation (unaudited)							121		121
Issuance of common stock upon exercise of stock options for cash (unaudited)					1,297,170	1	50		51
Net loss (unaudited)								(14,256)	(14,256)
<b>Balance, September 30, 2008 (unaudited)</b>	9,222,257	\$ 14,953	6,455,579	\$ 17,898	5,713,818	\$ 5	\$ 1,757	\$ (35,577)	\$ (33,815)

See accompanying notes to financial statements.

**Table of Contents****ARCA BIOPHARMA, INC.**

(a development stage enterprise)

**STATEMENTS OF CASH FLOWS**

(in thousands, except share and per share amounts)

	Nine Months Ended September 30,		Year Ended December 31,			Period from December 17, 2001 (date of inception) to September 30, 2008
	2008 (unaudited)	2007 (unaudited)	2007	2006	2005	(unaudited)
<b>Cash flows provided by operating activities:</b>						
Net loss	\$ (14,256)	\$ (10,247)	\$ (13,994)	\$ (5,241)	\$ (1,459)	\$ (35,577)
Adjustments to reconcile net loss to net cash used in operating activities:						
Depreciation and amortization	132	56	78	24	17	252
Non-cash interest expense	(2)		8			6
Amortization of deferred financing costs	14	3				14
Share-based compensation	121	75	87	39		247
Issuance of common stock for license rights		20	20	150	44	214
Interest on notes converted to Series A Preferred Stock				5		5
Interest on notes converted to common stock					36	48
Loss from disposal of property and equipment	24					24
Change in operating assets and liabilities:						
Receivables from employees and directors		35	35	(35)		
Other current assets	(96)	(60)	(48)	(17)	(1)	(168)
Deposits and other assets		(8)	(8)			(14)
Accounts payable	(16)	154	1,098	266	(100)	1,653
Accrued expenses and other liabilities	863	1,187	1,088	131	55	2,147
Deferred rent	562					562
<b>Net cash used in operating activities</b>	<b>(12,654)</b>	<b>(8,785)</b>	<b>(11,636)</b>	<b>(4,678)</b>	<b>(1,408)</b>	<b>(30,587)</b>
<b>Cash flows used in investing activities:</b>						
Payment of deferred transaction costs	(564)					(564)
Purchase of property and equipment	(1,243)	(86)	(120)	(122)	(24)	(1,570)
Proceeds from sale of property and equipment	5					5
<b>Net cash used in investing activities</b>	<b>(1,802)</b>	<b>(86)</b>	<b>(120)</b>	<b>(122)</b>	<b>(24)</b>	<b>(2,129)</b>
<b>Cash flows provided by financing activities:</b>						
Proceeds from issuance of convertible notes payable					1,562	2,091
Proceeds from issuance of notes payable	4,000					4,000
Proceeds from stock subject to repurchase		38	38			38
Proceeds from the issuance of preferred stock		9,000	18,000	14,316		32,316
Preferred stock offering costs		(124)	(148)	(98)		(246)
Proceeds from the issuance of common stock	51	16	16	3	1	79
Repayment of principal on convertible notes payables				(82)	(9)	(105)
<b>Net cash provided by financing activities</b>	<b>4,051</b>	<b>8,930</b>	<b>17,906</b>	<b>14,139</b>	<b>1,554</b>	<b>38,173</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(10,405)</b>	<b>59</b>	<b>6,150</b>	<b>9,339</b>	<b>122</b>	<b>5,457</b>
Cash and cash equivalents, beginning of period	15,862	9,712	9,712	373	251	
<b>Cash and cash equivalents, end of period</b>	<b>\$ 5,457</b>	<b>\$ 9,771</b>	<b>\$ 15,862</b>	<b>\$ 9,712</b>	<b>\$ 373</b>	<b>\$ 5,457</b>

Edgar Filing: NUVELO INC - Form S-4/A

Supplemental cash flow information:										
Interest paid	\$	7	\$	\$	\$	1	\$	2	\$	10
Supplemental disclosure of noncash investing and financing transactions:										
Accrued interest converted to equity on notes payable	\$		\$	\$	\$	7	\$	5	\$	12
Warrant issued in connection with credit facility, classified as a long-term liability	\$	62	\$	56	\$	49	\$		\$	111
Compensation recorded on issuance of restricted stock	\$		\$	37	\$	37	\$		\$	37

See accompanying notes to financial statements.

F-49

---

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA'S FINANCIAL STATEMENTS**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and  
for the period from Inception to September 30, 2008 is unaudited)**

**(1) The Company and Summary of Significant Accounting Policies**

***(a) Description of Business***

ARCA biopharma, Inc., or the Company, a Delaware corporation, is located in Broomfield, Colorado and was formed to develop and commercialize genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's first target drug candidate is Gencaro, a next generation beta-blocker and vasodilator for advanced heart failure and other indications, which management believes has the potential to be the first genetically targeted cardiovascular drug. Gencaro was the subject of a Phase III heart failure mortality trial involving more than 2,700 patients and was unique in gathering DNA data on over 1,000 of its participants. The Company has licensed exclusive, worldwide rights to Gencaro™. On July 31, 2008, the Company filed its New Drug Application for Gencaro with the Food and Drug Administration (FDA). The Company was founded December 17, 2001, or Inception.

***(b) Development Stage Risks***

The Company is in the development stage and devotes substantially all of its efforts towards regulatory approval, product commercialization, and raising capital. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and approval of commercially viable products, the need to obtain adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of convertible notes payable, and common and preferred stock.

Since Inception, the Company has incurred substantial losses and negative cash flows from operations. For the year ended December 31, 2007, the Company incurred a net loss of \$14.0 million and had negative cash flows from operations of \$11.6 million. During 2007, the Company received approximately \$18 million from the sale of shares of Series B Preferred Stock. For the nine months ended September 30, 2008, the Company incurred a net loss of \$14.3 million and had an accumulated deficit of \$35.6 million at September 30, 2008.

The Company is dependent upon raising additional capital through sales of equity securities, issuances of debt or other financing vehicles. The Company's ability to secure such capital is highly dependent on its success in developing and commercializing its technology including receiving approval of its New Drug Application from the FDA. Management expects operating losses and negative cash flows to continue over the short term, but anticipates that cash on hand at September 30, 2008 and funds raised through the issuance of convertible notes in October 2008 will be sufficient to continue operations at least through February 2009. Depending on the Company's cash requirements, additional equity or debt financing or the implementation of cost reductions may be required in order to meet future working capital needs and achieve intended business objectives. There can be no assurance that such additional financing will be available or, if available, that such financing can be obtained on terms satisfactory to the Company.

***(c) Basis of Presentation***

The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, commercialization, and raising capital. Accordingly, the Company is considered to be in the development stage at December 31, 2007 and September 30, 2008, as defined in Statement of Financial Accounting Standards, or SFAS, No. 7, *Accounting and Reporting by Development Stage Enterprises*.





---

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

***(d) Unaudited Interim Financial Statements***

The financial statements as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 have been prepared by the Company without an audit in accordance with generally accepted accounting principles for interim information. Accordingly, they do not contain all of the information and footnotes required by generally accepted accounting principles for complete financial statements. All disclosures as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception through September 30, 2008, presented in the notes to the financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) considered necessary to present fairly the financial condition as of September 30, 2008 and results of operations and cash flows for the nine months ended September 30, 2008 and 2007, and for the period from Inception through September 30, 2008, have been made. The results of operations for the nine months ended September 30, 2008 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2008.

***(e) Pro Forma Stockholders Deficit (Unaudited)***

The unaudited pro forma stockholders deficit as of September 30, 2008 gives effect to the automatic conversion of all redeemable convertible preferred stock into an aggregate of 15,677,836 shares of common stock, upon completion of the Company s proposed merger with Nuvelo, Inc. as further discussed in Note 12.

***(f) Cash and Cash Equivalents***

The Company considers cash and highly liquid investments, which are readily convertible into cash and have maturities when purchased of three months or less, to be cash and cash equivalents. Cash equivalents consist primarily of money market investments.

***(g) Accounting Estimates in the Preparation of Financial Statements***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates on various assumptions that are believed to be reasonable under the circumstances. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future.

***(h) Receivables from Employees and Directors***

The Company has, from time to time, receivables due from its employees and directors related to the reimbursement of expenses. These receivables do not bear interest and are deemed to be realizable.

***(i) Property and Equipment***

## Edgar Filing: NUVELO INC - Form S-4/A

Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for major improvements, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. Replacements and renewals are capitalized. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations.

F-51

---

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and  
for the period from Inception to September 30, 2008 is unaudited)**

The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.

***(j) Concentrations of Credit Risk***

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, and other receivables. The Company has no accounts receivable and has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.

***(k) Accrued Expenses***

As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company's behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the drug product, and professional service fees, such as attorneys and consultants. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.

***(l) Long-Lived Assets and Impairments***

The Company reviews long-lived assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Management believes that there is no indication that an impairment of its long-lived assets has occurred from Inception through December 31, 2007, and through September 30, 2008. As a development stage company, the Company has not generated positive cash flows from operations, and such cash flows may not materialize for a significant period in the future, if ever. Additionally, the Company may make changes to its business plan that would result in changes to expected cash flows from long-lived assets. As a result, it is reasonably possible that future evaluations of long-lived assets may result in impairment.

***(m) Segments***

The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.

***(n) Stock-Based Compensation***

Effective January 1, 2006, the Company adopted SFAS No. 123(R) using the prospective method of transition. Under that transition method, compensation cost recognized in each subsequent period includes: (a) compensation costs for current period vesting of all share-based payments

## Edgar Filing: NUVELO INC - Form S-4/A

granted prior to January 1, 2006, based on the intrinsic value method prescribed by APB Opinion No. 25, and (b) compensation cost for current period vesting of all share-based payments granted or modified subsequent to January 1, 2006, based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123(R).

F-52

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

From Inception through December 31, 2005, the Company accounted for issuances of stock-based compensation under the intrinsic-value-based method of accounting prescribed by Accounting Principles Board, or APB, Opinion No. 25, *Accounting for Stock Issued to Employees*, and related interpretations, including FASB Interpretation No. 44, *Accounting for Certain Transactions Involving Stock Compensation an Interpretation of APB Opinion No. 25*, to account for its employee stock options. Under this method, compensation expense is generally recorded on the date of grant only if the estimated fair value of the underlying stock exceeds the exercise price.

**(o) Net Loss Per Share**

The Company calculates net loss per share in accordance with SFAS No. 128, *Earnings Per Share*. Basic net loss per share was determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company's potentially dilutive shares, which include redeemable convertible preferred stock, options and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

A reconciliation of numerator and denominator used in the calculation of basic and diluted net loss per share follows:

	Nine Months Ended September 30,		Year Ended December 31		
	2008 (unaudited)	2007 (unaudited)	2007	2006	2005
	(in thousands, except shares and per share data)				
<b>Numerator</b>					
Net loss	\$ (14,256)	\$ (10,247)	\$ (13,994)	\$ (5,241)	\$ (1,459)
Less: Accretion of redeemable convertible preferred stock	(42)	(25)	(37)	(17)	
Net loss attributable to common stockholders	\$ (14,298)	\$ (10,272)	\$ (14,031)	\$ (5,258)	\$ (1,459)
<b>Denominator</b>					
Weighted-average shares of common stock outstanding	4,942,539	4,204,048	4,257,634	3,247,281	1,257,542
Less: Weighted-average shares of unvested common stock	(600,000)	(435,165)	(476,712)		
Total weighted-average number of shares used in computing net loss per share attributable to common stockholders basic and diluted	4,342,539	3,768,883	3,780,922	3,247,281	1,257,542

Edgar Filing: NUVELO INC - Form S-4/A

Basic and diluted (loss) per share	\$	(3.29)	\$	(2.73)	\$	(3.71)	\$	(1.62)	\$	(1.16)
------------------------------------	----	--------	----	--------	----	--------	----	--------	----	--------

F-53

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

Potentially dilutive securities representing 18.9 million and 13.0 million weighted average shares of common stock were excluded from the nine month periods ended September 30, 2008 and 2007, respectively. Potentially dilutive securities representing 18.2 million, 11.3 million, 700,000 weighted average shares of common stock were excluded for the years ended December 31, 2007, 2006, and 2005, respectively. The dilutive securities have been excluded from the calculation of diluted net loss per common share for the periods presented because including them would have an anti dilutive effect on net loss attributable to common stockholders per share.

Unaudited pro forma net loss per share assuming the conversion of all redeemable convertible preferred stock, which converts automatically upon completion of the proposed merger, at the beginning of the period or the date of issuance if later, is as follows:

	<b>Nine Months Ended September 30, 2008 (unaudited) (in thousands, except shares and per share data)</b>	<b>Year Ended December 31, 2007</b>
<b>Numerator</b>		
Net loss	\$ (14,256)	\$ (13,994)
<b>Denominator</b>		
<b>Weighted-average shares</b>		
Common stock outstanding	4,342,539	3,780,922
Plus: Assumed conversion of redeemable preferred stock outstanding	15,677,836	11,407,806
Pro forma total weighted-average number of shares used in computing net loss per share attributable to common stockholders basic and diluted (unaudited)	20,020,375	15,188,728
Pro forma net loss attributable to common stockholders per share basic and diluted (unaudited)	\$ (0.71)	\$ (0.92)

**(p) Fair Value of Financial Instruments**

The carrying amounts of financial instruments, including cash and cash equivalents and accounts payable, approximate their fair value due to their short term maturities.

On January 1, 2006, the Company adopted SFAS No. 150, *Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity*, and related FASB Staff Position 150-5, *Issuer s Accounting under FASB Statement No. 150 for Freestanding Warrants and Other Similar Investments on Shares That Are Redeemable*, or FSP 150-5. The Company granted warrants for redeemable preferred stock in 2007. The warrants are reported as long-term liabilities at their estimated fair value at December 31, 2007 and 2006 and September 30, 2008. Changes in fair value during 2007 and 2006 and for the nine months ended September 30, 2008 are reflected in the statements of operations as interest expense.



## Edgar Filing: NUVELO INC - Form S-4/A

On January 1, 2008, the Company adopted FASB Statement of Financial Accounting Standards No. 157, *Fair Value Measurements*, or SFAS No. 157. SFAS No. 157 establishes a common definition for fair value to be applied to U.S. GAAP requiring use of fair value, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. In February 2008, the FASB issued FASB Staff Position No. FAS 157-2,

F-54

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

*Effective Date of FASB Statement No. 157*, or FSP 157-2, which delays the effective date for SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except items that are recognized or disclosed at fair value on a recurring basis (at least annually), until fiscal years beginning after November 15, 2008. The implementation of SFAS No. 157 for financial assets and financial liabilities did not have a material impact on the Company's financial position and results of operations. The Company is currently assessing the impact of adopting SFAS No. 157 for nonfinancial assets and nonfinancial liabilities on its financial position and results of operations.

SFAS 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). SFAS 157 classifies the inputs used to measure fair value into the following hierarchy:

Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities

Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quotes prices that are observable for the asset or liability

Level 3 Unobservable inputs for the asset or liability

The Company's fair value hierarchy for its financial assets measured at fair value on a recurring basis as of September 30, 2008 include only Level 1 financial assets. Level 1 financial assets as of September 30, 2008 comprise money market funds totaling approximately \$5.2 million.

***(q) Research and Development***

Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.

The Company issued shares of common stock in exchange for certain licenses and sublicenses. Total research and development expense recorded for the estimated fair value of these issuances was \$20,028, \$149,841, \$44,132, and \$214,001 in 2007, 2006, 2005, and the period from Inception through December 31, 2007, respectively, and \$20,028 for the nine-month period ended September 30, 2007. No shares were issued in 2008.

The Company has concluded that these licenses have no alternate use other than in the Company's research and development efforts.

***(r) Income Taxes***

The current provision for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of

## Edgar Filing: NUVELO INC - Form S-4/A

deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against its deferred tax assets, as

F-55

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

management is unable to conclude that it is more likely than not that the net deferred tax asset will be realized through future taxable income, based primarily on the Company's history of operating losses.

**(s) Recent Accounting Pronouncements**

Effective January 1, 2008, the Company adopted SFAS No. 157. In February 2008, the FASB issued FASB Staff Position No. FAS 157-2, which provides a one year deferral of the effective date of SFAS 157 for non-financial assets and non-financial liabilities, except those that are recognized or disclosed in the financial statements at fair value at least annually. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The standard describes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that may be used to measure fair value. The adoption of SFAS No. 157 had no impact on the Company's financial statements. The Company is currently evaluating the impact of adopting the provisions of SFAS No. 157 for non-financial assets and liabilities. Costs associated with the merger are being recorded as deferred transaction costs. On January 1, 2009, as part of the Company's adoption of SFAS No. 141(R), the balance of deferred transaction costs will be expensed.

In December 2007, the FASB issued SFAS No. 141(R), *Business Combinations*, and SFAS No. 160, *Accounting and Reporting of Noncontrolling interest in Consolidated Financial Statements, an amendment of ARB No. 51*. These new standards will significantly change the financial accounting and reporting of business combination transactions and noncontrolling (or minority) interests in consolidated financial statements. The Company will be required to adopt SFAS No. 141(R) and SFAS No. 160 on January 1, 2009.

As discussed in Note 10, effective, January 1, 2007, the Company adopted FASB Interpretation No. 48 *Accounting of Uncertainty in Tax Positions - an Interpretation of FASB Statement No. 109*.

**(2) Property and Equipment**

Property and equipment consist of the following:

	Estimated Life	September 30, 2008	December 31, 2007	2006
(in thousands)				
Computer equipment	3 years	\$ 184	\$ 101	\$ 42
Lab equipment	5 years	81	82	82
Furniture and fixtures	5 years	388	51	21
Computer software	3 years	116	72	41
Leasehold improvements	Lesser of useful life			
	or life of the lease	739	21	21

Edgar Filing: NUVELO INC - Form S-4/A

	1,508	327	207
Less accumulated depreciation and amortization	(219)	(119)	(42)
	\$ 1,289	\$ 208	\$ 165

Depreciation and amortization expense for the nine months ended September 30, 2008 and 2007 was \$132,130 and \$56,062, respectively. For the years ended December 31, 2007, 2006, and 2005, and for the period

F-56

---

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA'S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

from Inception through September 30, 2008, depreciation and amortization expense was \$77,711, \$23,896, \$16,715, and \$251,764 respectively.

**(3) Employee Benefit Plans**

The Company has a 401(k) plan and makes a matching contribution equal to 100% of the employee's first 3% of the employee's contributions and 50% of the employee's next 2% of contributions. The Company adopted the plan in 2006 and contributed \$92,000 and \$56,000 for the nine months ended September 30, 2008 and 2007, respectively. For the years ended December 31, 2007 and 2006, the Company contributed \$76,000 and \$25,000, respectively, and has contributed \$193,000 from Inception through September 30, 2008.

**(4) Convertible Promissory Notes**

In 2002 and 2004, the Company entered into promissory notes with its Chief Science and Medical Officer, or CSMO, and Chairman of the Board at varying interest rates and maturities. Total proceeds from these notes were \$1,370 and \$13,500 in 2002 and 2004, respectively. The principal and accrued interest on the notes issued in 2004 was subsequently paid in 2004. The principal and accrued interest on the note issued in 2002 was subsequently paid in 2005.

In May 2004, the Company entered into a convertible promissory note with principal of \$7,500 and interest at 7% whereby payment of the outstanding principal and interest could be called at any time after June 1, 2004. The note was convertible upon the issuance by the Company of Preferred Stock with aggregate proceeds of greater than \$2.0 million. The note was to be converted at the same price per share as the Preferred Stock issued. The Company paid all outstanding principal and interest in December 2005.

In July 2004, the Company entered into a convertible promissory note with principal of \$1,000 and interest at 7% whereby payment of the outstanding principal and interest could be called at any time. The note was convertible upon the issuance by the Company of Preferred Stock with aggregate proceeds of greater than \$2.0 million. The note was to be converted at the same price per share as the Preferred Stock issued. In January 2005, upon agreement by both parties, the principal and the accrued interest of \$70 was converted into 107,000 shares of common stock.

In September 2004, the Company entered into a convertible promissory note with principal of \$5,000 and interest at 7% per annum. The entire principal and accrued interest was due on March 30, 2006. The note was convertible upon the issuance by the Company of Preferred Stock with aggregate proceeds of greater than \$2.0 million. The note was to be converted at the same price per share as the Preferred Stock issued. In February 2006, upon the issuance of Series A Preferred Stock, the principal and the accrued interest of \$498, less \$7 paid in cash, was converted into 3,376 shares of Series A Preferred Stock. As of December 31, 2007 and 2006, there was no outstanding principal and interest on the note.

In October 2004, the Company entered into two convertible promissory notes with a venture capital firm with principal of \$468,950, and \$31,050, for total proceeds of \$500,000. In March 2005, these notes were amended to provide for additional principal of \$468,950 and \$31,050, for total proceeds under the notes of \$1.0 million. The notes bore interest at 5% per annum. The entire principal and accrued interest was due on March 31, 2006. The notes were convertible, upon issuance by the Company of shares of common stock or

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and  
for the period from Inception to September 30, 2008 is unaudited)**

preferred stock with proceeds greater than \$5.0 million, into a number of shares of common stock equal to 20% of the total outstanding equity securities of the Company prior to such transaction. They were also convertible at the option of the lender upon written notice. Upon such notice, in October 2005, the principal of \$1.0 million and the accrued interest of \$38,218 was converted into 830,831 and 55,011 shares, respectively, of common stock.

In July 2005, the Company entered into two convertible promissory notes with a venture capital firm with principal of \$58,618 and \$3,881, for total proceeds of \$62,500. The notes bore interest at 5% per annum. The entire principal and accrued interest was due on July 1, 2006. The notes were convertible into 43,421 and 2,875 shares of common stock. The notes were convertible upon issuance by the Company of shares of common stock or preferred stock with proceeds greater than \$5 million or at the option of the lender upon written notice. Upon such notice, in October 2005, the principal of \$62,500 and the accrued interest of \$693 was converted into 43,421 and 2,875 shares, respectively, of common stock.

In August 2005, the Company entered into two convertible promissory notes with a venture capital firm with principal of \$234,475 and \$15,525, for total proceeds of \$250,000. The notes bore interest at 5% per annum. The entire principal and accrued interest was due on August 8, 2006. The notes were convertible into 173,685 and 11,500 shares of common stock. The notes were convertible upon issuance by the Company of shares of common stock or preferred stock with proceeds greater than \$5.0 million or at the option of the lender upon written notice. Upon such notice, in October 2005, the principal of \$250,000 and the accrued interest of \$2,260 converted into 173,685 and 11,500 shares, respectively, of common stock.

In October 2005, the Company entered into two convertible promissory notes with a venture capital firm with principal of approximately \$468,950 and \$31,050, for total proceeds of \$500,000. The notes bore interest at 5% per annum. The entire principal and accrued interest was due in October 2006. The note was convertible into Preferred Stock upon the issuance by the Company of Preferred Stock with aggregate proceeds of greater than \$5.0 million. The note was to be converted at the same price per share as the Preferred Stock issued. In February 2006, upon the issuance of Series A Preferred Stock, the principal of \$500,000 and the accrued interest of \$8,706 was converted into 293,339 and 19,422 shares, respectively, of Series A Preferred Stock.

In November 2005, the Company entered into a convertible promissory note with principal of \$250,000 and interest at 5% per annum. The entire principal and accrued interest was due on November 6, 2006. The note was convertible into Preferred Stock upon the issuance by the Company of Preferred Stock with aggregate proceeds of greater than \$5 million. The note was to be converted at the same price per share as the Preferred Stock issued. In February 2006, upon the issuance of Series A Preferred Stock, the principal of \$250,000 and the accrued interest of \$3,804, less \$83,542 paid in cash, was converted into 104,680 shares of Series A Preferred Stock.

**(5) Commitments and Contingencies**

**(a) Employment Agreements**

The Company maintains employment agreements with several key executive employees. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of the Company.





**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

**(b) Operating Leases**

The Company occupied certain facilities under operating leases, which ended in 2008. Rent expense under these leases was \$206,089 and \$135,785 for the nine months ended September 30, 2008 and 2007, respectively. Rent expense was \$210,503, \$83,200, \$55,984 the years ended December 31, 2007, 2006, 2005, respectively, and \$576,111 for the period from Inception through September 30, 2008. Below is a summary of the future minimum lease payments committed under these leases as of December 31, 2007:

**Year ended December 31:**

2008	\$ 131,000
------	------------

See also Note 12 to ARCA s Financial Statements regarding the Company s new facilities lease.

**(c) CardioDx, Inc.**

The Company entered into a license agreement with CardioDx, Inc. The license gives the Company a nonexclusive, royalty bearing license for diagnostic rights to key genetic markers that are relevant for prescribing Gencaro. The term of the agreement extends to the latest expiring patent underlying the diagnostic rights. The license permits the Company to sublicense its rights under certain conditions, and in February 2007, the Company sublicensed its rights and transferred its royalty and other fee obligations to a third-party provider.

**(d) Commercialization and Licensing Agreement**

The Company entered into a commercialization and licensing agreement with a third-party provider to develop, make, market and sell diagnostic tests in connection with the medical prescription of the Company s lead compound, Gencaro.

**(e) Laboratory Corporation of America**

The Company entered into a commercialization and licensing agreement with Laboratory Corporation of America, or LabCorp, to develop, make, market and sell diagnostic tests in connection with the medical prescription of the Company s lead compound, Gencaro. Under the agreement the Company granted to LabCorp an exclusive license to its diagnostic rights under the CardioDx agreement and the Company s diagnostic rights associated with Gencaro. The license agreement has a term of 10 years. The sublicense transferred the royalty and all other fee obligations of the Company arising out of the sale of diagnostic tests by LabCorp. Royalty payments will be made directly to CardioDx by LabCorp. If LabCorp does not fulfill its royalty payment and other fee obligations, the Company is responsible for the payments. In addition, the Company granted to LabCorp 100,000 shares of common stock. The shares are subject to a restricted stock agreement in which shares vest upon the attainment of certain regulatory approval and drug product sales milestones.

**(f) Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC**

## Edgar Filing: NUVELO INC - Form S-4/A

Under the terms of its strategic license agreement with CPEC, a licensing subsidiary of Indevus Pharmaceuticals Inc., holding ownership rights to certain clinical trial data of Gencaro, the Company will incur milestone and royalty obligations upon the occurrence of certain events. The Company will owe CPEC LLC a milestone payment of \$500,000 upon the submission of its New Drug Application, or NDA, with the United

F-59

---

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and  
for the period from Inception to September 30, 2008 is unaudited)**

States Food and Drug Administration, and upon receiving marketing approval for the drug will owe CPEC another milestone payment of \$8 million. The Company's royalty obligation ranges from 7.5% to 20% based on achievement of specified product sales levels.

See also Note 12 to ARCA's Financial Statements regarding the payment of the CPEC milestone obligation.

**(g) Legal Matters**

The Company may encounter asserted or unasserted claims during the normal course of business. No such claims had been asserted to date, nor is the Company aware of any unasserted claims.

**(h) Silicon Valley Bank**

In July 2007 the Company obtained a credit facility from Silicon Valley Bank, or the Credit Facility. The total amount available under the Credit Facility is \$4.0 million, secured by all tangible and intangible assets of the Company except those specified, including patents, in the loan documents. The facility bears interest at the Bank's Prime Rate, and is subject to customary non-financial related covenants. The loan agreement restricts the Company's ability to do several things such as dispose of part of its business or property, engage in any other business activities, liquidate or dissolve, change executive management, mergers, acquisitions, pay dividends, and incur debt without the bank's prior approval.

At December 31, 2007, \$2.0 million of the credit facility was available to the Company. The remaining \$2,000,000 became available upon the Company's submission of a major portion of its New Drug Application to the Federal Drug Administration, which occurred in July 2008. Advances from the credit facility require interest only payments for the lesser of six months or until January 2009. In January 2009, repayment of the outstanding balance on the Credit Facility begins and requires monthly principal and interest payments over the next 24 months. The Credit Facility matures in December 2010. In connection with obtaining the Credit Facility, the Company issued warrants for its Series B Redeemable Preferred Stock (see Note 7 to ARCA's Financial Statements). Furthermore, if the Company draws upon the credit facility, the Company is required to issue additional warrants for Series B Redeemable Preferred Stock in amounts that are dependent upon the amount drawn.

In August 2008 the Company borrowed the full \$4.0 million available under its Credit Facility, the details of which are more fully described in Note 12 to ARCA's Financial Statements regarding Credit Facility activity and issued additional warrants for its Series B Redeemable Preferred Stock.

**(6) Related Parties**

**(a) Transactions with the Company's Chief Science and Medical Officer and Chairman**

The Company has entered into certain transactions with its CSMO and Chairman of the board of directors for the advancement of research in chronic heart failure. The Company entered into an unrestricted research grant with its CSMO and Director's research laboratory for \$22,500 per quarter. In addition, the Company agreed to pay \$7,500 per month to offset salary expenses at the lab. This arrangement was in place through

Edgar Filing: NUVELO INC - Form S-4/A

June 2007.

Effective July 1, 2007, the Company terminated its prior grant funding arrangement and entered into an unrestricted research grant with its CSMO and Director s research laboratory for \$23,917 per month. Total

F-60

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

expense under these arrangements for the nine months ending September 30, 2008 and 2007 was \$226,920, and \$112,834, respectively. Total expense during 2007, 2006 and 2005 was \$222,502, \$154,992 and \$123,311, respectively, and \$742,638 from Inception through September 30, 2008.

The Company is a party to a materials transfer agreement with the University of Colorado, under which the Company has agreed to pay \$35,000 per year to maintain the Heart Tissue Bank associated with the CSMO and Director's research lab at the University of Colorado. Total expense for the nine months ending September 30, 2008 and 2007 was \$26,250 and \$17,500, respectively. Total expense during 2007, 2006 and 2005 were \$35,000, \$35,000 and \$35,000, respectively, and \$140,000 from Inception through September 30, 2008.

**(b) Cardiovascular Pharmacology and Engineering Consultants, LLC (CPEC)**

The Company has entered into a strategic license agreement with CPEC, a licensing subsidiary of Indevus Pharmaceuticals Inc., which holds ownership rights to certain clinical trial data of Gencaro, for exclusive license rights to use this data and an exclusive sublicense to develop, make, have made, use, import, offer for sale, market, commercialize, distribute, and sell and otherwise dispose of the product Gencaro. In connection with this agreement, the Company issued 400,000 shares of common stock. The estimated fair value of shares granted was \$0.12 per share. The Company recorded the estimated fair value of the shares as research and development expense because the rights granted under the agreement have no alternate use other than the Company's research and development efforts. In addition, the Company owes royalties based upon its commercial sales and other milestones, including the closing of the Series B financing and certain regulatory approvals. Total expense and payments for the nine months ended September 30, 2008 and 2007 were each \$0. Total expense during 2007, 2006 and 2005 were \$0, \$1 million and \$0, respectively, and \$1.5 million from Inception through September 30, 2008.

See also Note 12 to ARCA's Financial Statements regarding recent milestone payments to CPEC.

**(c) Gilead Colorado, Inc. (formerly Myogen Inc.)**

The Company has entered into a strategic alliance agreement with Myogen in exchange for certain sublicenses and licenses for technology licensed by Myogen. In connection with this agreement, the Company issued 614,834 shares of common stock, based upon the amount equivalent to 10% of total shares outstanding prior to commencement of the Series B Preferred Stock Offering. The estimated fair value of shares granted was \$0.12 per share. The Company recorded the estimated fair value of the shares as research and development expense because the rights granted under the agreement have no alternate use other than the Company's research and development efforts.

**(d) University of Colorado's University License Equity Holdings, Inc., or ULEHI**

In October 2005, the Company entered into an exclusive license agreement to patent applications covering use of Gencaro therapy and various options to license future inventions and targets. The Company has agreed to pay a per year minimum royalty beginning in 2006. The Company expensed \$18,750 and \$25,000 for the nine months ended September 30, 2008 and 2007, respectively. During 2007, 2006 and 2005, the Company expensed \$25,000, \$25,000 and \$0, respectively and has expensed \$68,750 from Inception through September 30, 2008. In addition, the Company will owe royalties based upon its commercial sales (other than Gencaro) and other milestones, if any. In August 2007 the Company executed an amendment to the license agreement to acquire additional patent rights and paid \$15,000 for those rights. All payments have been recorded as research and development expenses.



**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

As part of its licensing arrangement, the Company has granted ULEHI at total of 302,785 shares of common stock. Pursuant to an anti-dilution provision in the license agreement (see Note 8 to ARCA s Financial Statements), the Company issued 69,882 shares, 142,903 shares, 0 shares, and 212,785 shares in 2007, 2006, 2005 and Inception through September 30, 2008, respectively. For the nine month ending September 30, 2008 and 2007, the Company issued 0 shares, and 69,882 shares, respectively. The estimated fair value of shares granted in 2007 was \$0.29 per share. The Company recorded the estimated fair value of the shares as research and development expense because the rights granted under the agreement have no alternate use other than the Company s research and development efforts. The anti-dilution provision was fully satisfied in May 2007 with the Company s Series B Preferred Stock financing.

**(7) Preferred Stock**

***(a) Series A Redeemable Convertible Preferred Stock***

In February 2006, the Company issued 6,148,171 shares of Series A Redeemable Convertible Preferred Stock, or Series A, at a price of \$1.6265 per share. In December 2006, the Company issued 3,074,086 shares in the second tranche of Series A at a price of \$1.6265 per share. Each share is initially convertible into one share of common stock. Each holder of Series A is entitled to receive, if and when declared, payment of an equivalent per-share dividend based on the number of common shares into which each share of Series A is convertible, as of the date of declaration. The rate of conversion of Series A into common stock shall be adjusted in the event the Company issues dilutive shares of common stock according to a formula defined in the Restated Certificate of Incorporation. Holders of Series A are entitled to vote as though the Series A were converted into common stock.

***(b) Series B Redeemable Convertible Preferred Stock***

In May 2007, the Company issued 3,688,902 shares of Series B Redeemable Convertible Preferred Stock, or Series B, at a price of \$2.439 per share. In December 2007, the Company issued 2,766,677 shares in the second tranche of Series B at a price of \$3.253 per share. Each share is initially convertible into one share of common stock. Each holder of Series B is entitled to receive, if and when declared, payment of an equivalent per-share dividend based on the number of common shares into which each share of Series B is convertible, as of the date of declaration. The rate of conversion of Series B into common stock shall be adjusted in the event the Company issues dilutive shares of common stock according to a formula defined in the Restated Certificate of Incorporation. Holders of Series B are entitled to vote as though the Series B were converted into common stock.

Collectively, the Series A and Series B Preferred stock issuances are referred to as Preferred Stock.

Holders of Preferred Stock possess the following preferential rights:

**i) Liquidation Rights**

Upon any liquidation, dissolution, or winding up of the Company, including a sale of the Company, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of common stock, holders of Preferred Stock shall be entitled to receive an amount per

## Edgar Filing: NUVELO INC - Form S-4/A

share equal to the original issue price of the respective Preferred Stock Series (as adjusted for any stock dividends, combinations, splits, recapitalizations, unpaid declared, and unpaid dividends). After the payment of this amount, payments shall be made ratably to the holders of common stock and Preferred Stock on an as-if-converted basis until such holders of Preferred Stock have received an aggregate amount per share of Preferred Stock equal to three times the original issue price of

F-62



**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and  
for the period from Inception to September 30, 2008 is unaudited)**

the respective Preferred Stock Series; thereafter, the remaining payments shall be distributed ratably to the holders of the common stock. Preferred Stock may, at the option of the holder, be converted at any time into fully paid and nonassessable shares of common stock and receive distributions as common holders.

**ii) Redemption**

A majority of the Preferred Stockholders may require the Company to redeem all of the outstanding Preferred Stock in three annual installments beginning not prior to May 2011 and ending on the date two years from such first redemption date. The Company shall effect such redemptions on each redemption date by paying in cash in exchange for the shares of Preferred Stock to be redeemed on such redemption date a sum equal to the original issue price per share of Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations, and the like) plus declared and unpaid dividends, if any, with respect to such shares. At December 31, 2007 and September 30, 2008, the Company had no declared and unpaid dividends.

**iii) Voting**

Preferred Stock stockholders are entitled to vote together with common stockholders as one class based on the number of common stock into which each share of Preferred Stock is then convertible. Preferred Stock stockholders, voting as a separate class, shall have the exclusive right to elect four members of the board of directors. Common stockholders are entitled to elect one board member. Holders of common stock and Preferred Stock, voting together as a single class on an as-if-converted basis, shall then be entitled to elect all remaining members of the Board. For so long as at least 20% of the originally issued shares of Preferred Stock (subject to adjustment for any stock split, reverse stock split or other similar event affecting the Preferred Stock) remain outstanding, consent of the holders of at least a majority of the outstanding Series Preferred shall be necessary for effecting or validating any material change in the Company's business.

**iv) Conversion**

Preferred Stock may, at the option of the holder, be converted at any time into fully paid and nonassessable shares of common stock. The number of shares of common stock to which a holder of Preferred Stock shall be entitled upon conversion shall be the product obtained by multiplying the Series Preferred Conversion Rate by the number of shares of Preferred Stock being converted. At December 31, 2007 and September 30, 2008, the conversion price equals the original purchase price, and each share of Preferred Stock was convertible into one share of common stock. The terms of the Preferred Stock provide for adjustments to the conversion rates in specified circumstances primarily to provide the holder protection against dilution.

Each share of Preferred Stock shall automatically be converted into shares of common stock, based on the then effective Preferred Stock conversion price, (A) at any time upon the affirmative election of a majority of the Series Preferred Stockholders, or (B) immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of common stock for the account of the Company in which (i) the per share price is at least two times the then effective Series Preferred Conversion Price for the second tranche of Series B Preferred and (ii) the gross cash proceeds to the Company (before underwriting discounts, commissions, and fees) are at least \$30 million. At December 31, 2007, the Company had 15,677,836 shares of common stock reserved for the conversion of Preferred Stock. At September 30, 2008, the Company had 15,734,218 shares of common stock reserved for the conversion of Preferred Stock. In connection with the proposed merger (Note 12), the terms of the Preferred Stock were modified to provide

for automatic conversion upon the close of the transaction.

F-63

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and  
for the period from Inception to September 30, 2008 is unaudited)**

***(c) Warrants for Series B Redeemable Preferred***

On July 17, 2007, the Company issued warrants to purchase 31,790 shares of Series B Redeemable Preferred Stock to a financial institution in connection with a credit facility (see Note 5 to ARCA s Financial Statements). The warrants have an exercise price of \$2.43975 per share, a 10 year life, and were fully vested and exercisable at the time of grant. In accordance with FSP 150-5, the warrants were recorded as a long-term liability at their estimated fair value at the time of issuance. At each reporting period the Company updates the estimated fair value of the warrants based upon current market conditions, and the change in the estimated fair value is reported in the statement of operations. At December 31, 2007, the fair value estimate was updated using the Black-Scholes model and the following assumptions: dividend yield of 0%; estimated volatility of 75%; risk-free interest rate of 4.03%, and a remaining contract life of 9.5 years. The change in the estimated fair value was recorded as interest expense.

**(8) Common Stock**

The Company has 26.0 million shares of common stock authorized, of which 4,416,648 and 5,713,818 were issued and outstanding at December 31, 2007 and September 30, 2008, respectively with 15,734,218 shares reserved for conversion of Redeemable Convertible Preferred Stock. The dividend and preference rights of the common stock are junior to those of the Preferred Stock. Each holder of common stock is entitled to one vote per share of common stock.

Under the terms of its agreements with ULEHI, the Company agreed to issue shares of common stock such that ULEHI maintains, on an as-if-converted basis, ownership of 1.5% of the Company s issued and outstanding stock. ULEHI s rights terminated on the earliest of (a) immediately prior to a sale of all or substantially all of the assets of the Company, or (b) immediately prior to any issuance or exchange of stock in connection with a change in control, or, once the Company has raised its first \$20.0 million in equity funding. With the first issuance of its Series B Preferred Stock in May 2007, the Company surpassed the \$20.0 million in equity funding and the final shares were issued to ULEHI in June 2007.

**(9) 2004 Incentive Stock Options Plan**

Under the terms of the 2004 Stock Option Plan, or the Plan, options to purchase an aggregate of 6,356,550 shares of the Company s common stock are authorized for awards to employees, officers, directors, agents, consultants, and independent contractors of the Company. Under the terms of the Plan, the purchase price per share of a nonqualified stock option cannot be less than 85% of the estimated fair value of the Company s common stock at the time of grant. The purchase price per share of an incentive stock option cannot be less than 100% of the estimated fair value per share of the Company s common stock at the time of grant. In no case is the option price of any option less than the par value per share of ARCA common stock. Options granted under the Plan are exercisable for a period up to 10 years from date of grant. Options typically vest over four years at a rate of 25% after 12 months from the date of grant, and ratably per quarter thereafter, conditioned upon continued employment. Upon adoption of the Plan in 2004, the board of directors authorized 700,000 shares for the plan. This was the only option activity for the 2004 year. The board of directors authorized an increase in the number of shares in the plan of 2,433,645, 2,164,361, and 1,090,333, during 2007, 2006, and 2005, respectively. During the nine months ended September 30, 2008 the board of directors reallocated shares from the Plan to Series B Redeemable Preferred Stock related to the Company s issuance of Series B Redeemable Preferred Stock Warrants. This reallocation resulted in a reduction of 31,789 shares available for issuance under the plan. To the extent required by law, the exercise price of a nonqualified stock option may not be less than the fair market value of the underlying stock on the date of grant.



**Table of Contents****ARCA BIOPHARMA, INC.**

(a development stage enterprise)

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)

The following summarizes the activity of the Plan including the number of options and weighted average exercise prices:

	For the Nine Months ended September 30, 2008		2007	For the Years Ended December 31, 2006		2005		
	Options (unaudited)	Weighted- Average Exercise Price (unaudited)		Options	Weighted- Average Exercise Price	Options	Weighted- Average Exercise Price	Options
Options outstanding beginning of period	3,178,847	\$ 0.13	3,269,246	\$ 0.10	1,715,646	\$ 0.01		\$
Granted	1,701,800	0.38	506,321	0.29	1,988,600[1]	0.15	1,715,646	0.01
Exercised	(1,297,170)	0.04	(580,001)[1]	0.16	(288,125)	0.01		
Forfeited and cancelled	(202,125)	0.24	(16,719)	0.10	(146,875)	0.01		
Options outstanding end of period	3,381,352	0.27	3,178,847	0.13	3,269,246	0.10	1,715,646	0.01
Exercisable at end of period	1,422,642	\$ 0.18	2,129,779	\$ 0.09	1,645,523	\$ 0.10	306,020	\$ 0.01

[1] Includes 500,000 shares allocated from the Plan in 2006 for a restricted stock grant which was issued in 2007.

**Table of Contents****ARCA BIOPHARMA, INC.**

(a development stage enterprise)

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)

The following tables summarize information about the Company's outstanding stock options as of December 31, 2007 and September 30, 2008:

Exercise Price	Options Outstanding		Options Exercisable
	Number Outstanding as of December 31, 2007	Weighted Average Remaining Contractual Life (in years)	Number Exercisable as of December 31, 2007
\$0.01	1,206,580	7.01	904,935
0.10	61,566	7.44	37,026
0.15	1,450,201	8.80	1,135,193
0.28	240,000	9.10	2,625
0.30	126,500	9.35	50,000
0.31	94,000	9.84	0
	3,178,847	8.17	2,129,779

Exercise Price	Options Outstanding		Options Exercisable
	Number Outstanding as of September 30, 2008	Weighted Average Remaining Contractual Life (in years)	Number Exercisable as of September 30, 2008
\$0.01	75,410	6.26	0
0.10	61,566	6.23	48,569
0.15	1,254,575	8.08	1,101,104
0.28	237,750	8.35	88,406
0.30	101,500	8.59	66,188
0.31	911,050	9.38	34,375
0.45	739,500	9.89	84,000
	3,381,352	8.79	1,422,642

At December 31, 2007, the Company had \$131,000 of total unrecognized compensation expense (net of estimated forfeitures) on unvested options. This compensation expense is expected to be recognized over a weighted average remaining period of approximately 1.44 years. At September 30, 2008, the Company had \$329,000 of unrecognized compensation expense (net of estimated forfeitures) on unvested options. This compensation expense is expected to be recognized over a weighted average remaining period of approximately 1.47 years.

## Edgar Filing: NUVELO INC - Form S-4/A

For the unaudited interim periods ended September 30, 2008 and 2007, the intrinsic value of options exercised was \$450,759 and \$6,601, respectively. For the years ended December 31, 2007 and 2006 and from Inception through September 30, 2008, the total intrinsic value of options exercised was \$6,601, \$28,813 and \$497,698, respectively.

The Company selected the Black-Scholes option pricing model as the most appropriate valuation method for its share-based awards. This valuation model was developed for use in estimating the fair value of traded options

F-66

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

which have no vesting restriction and are fully transferable. Consequently, the Company's estimate of fair value may differ from other valuation models.

The Black-Scholes valuation model requires the Company to make assumptions and judgments about the variables used in the calculation. These variables and assumptions include the fair value of ARCA's common stock, expected term, the expected volatility, the risk-free interest rate, and expected dividends. The Company used the following assumptions when determining the fair value of its stock options:

- i. *Expected Term* The expected term represents the period that the Company's share-based awards are expected to be outstanding. The Company elected to use the simplified method described in SEC Staff Accounting Bulletin No. 107 to compute the expected term.
- ii. *Expected Volatility* Management estimates volatility for option grants by evaluating the average historical volatility of a peer group of public companies. Management believes historical volatility of the identified peer group to be a reasonable proxy for estimating future volatility.
- iii. *Risk-Free Interest Rate* The risk-free interest rate used in the Black-Scholes valuation model is based on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.
- iv. *Expected Dividend* The Company has not issued dividends to date and does not anticipate issuing dividends.

The fair value of each award for the nine months ended September 30, 2008 and 2007 (unaudited) and the years ended December 31, 2007 and 2006 was estimated at the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions:

	September 30, 2008		December 31, 2007	
	(unaudited)	(unaudited)	2007	2006
Volatility factor	62%	71%	66%	76%
Expected term of options in years	5.98 years	4.70 years	5.88 years	6.25 years
Risk-free interest rate	3.15%	4.61%	4.18%	3.88%
Dividend yield	0%	0%	0%	0%
Weighted average grant date fair value	\$0.19	\$0.15	\$0.18	\$0.10

For the unaudited interim periods ended September 30, 2008 and 2007 and the years ended December 31, 2007 and 2006, the Company recognized the following non-cash, share-based compensation expense:

September 30,

December 31,



Edgar Filing: NUVELO INC - Form S-4/A

	2008 (unaudited)	2007 (unaudited)	2007	2006
Research and development	\$ 71,124	\$ 9,097	\$ 13,281	\$ 2,957
General and administrative	49,112	27,211	36,281	36,525
<b>Total</b>	<b>\$ 120,236</b>	<b>\$ 36,308</b>	<b>\$ 49,562</b>	<b>\$ 39,482</b>

The amounts in the table were allocated to the same expense categories as the base compensation for the participants in the plan. The table includes share-based compensation expense for awards granted to non-employees, including independent consultants. The compensation expense of these awards was recognized

F-67

**Table of Contents**

**ARCA BIOPHARMA, INC.**

**(a development stage enterprise)**

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and  
for the period from Inception to September 30, 2008 is unaudited)**

in accordance with the provisions of SFAS No. 123(R) (subsequent to January 1, 2006), SFAS No. 123 prior to that date and Emerging Issues Task Force, or EITF, No. 96-18, *Accounting for Equity Instruments that Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services*, which require valuing the stock options using a Black-Scholes option pricing model and remeasuring such stock options to the current estimated fair value until the performance date has been reached. The performance date had been reached for all awards granted to non-employees as of December 31, 2007, therefore, no remeasurement of the awards was needed. Awards were granted to non-employees during the nine month period ending September 30, 2008. Portions of these awards have not yet reached their performance criteria and are therefore subject to remeasurement until the criteria is reached.

During 2006, certain option grants were made that provided for accelerated vesting under certain circumstances, including a change in control of the Company. During 2008, certain options were modified to provide for accelerated vesting under certain conditions related to a change in control.

In November 2006, the Company granted stock options to its President and CEO for 992,000 shares. The grant was exercisable immediately, but if exercised, is subject to certain repurchase rights that lapse over four years: (i) 25% upon grant and until the first anniversary of the vesting start date and ratably per quarter thereafter, or (ii) if the Company has a corporate transaction resulting in a change of control.

In November 2006, the Company entered into a restricted stock agreement with its President and CEO for 500,000 shares, whereby the President and CEO could purchase the shares at their estimated fair value of \$0.15 per share. The Company retains certain repurchase rights (allowing the Company to repurchase the shares at the price paid by this individual) on 250,000 shares that lapse on the date that the trading value of Company's common stock, listed on a national exchange, results in market capitalization of the Company, as reported by such exchange over the immediately preceding ten business days, of at least \$250.0 million, or a corporate transaction results in consideration paid by the acquirer is at least \$250.0 million. Repurchase rights on the remaining 250,000 shares will lapse on the same terms as the first 250,000 if the two conditions above are met with values of at least \$500.0 million. Should these criteria not be met within 10 years from the grant date, the Company's repurchase option will be exercised automatically. These shares will vest upon closing of the merger.

In February 2007, the Company amended the purchase terms of the restricted stock agreement to provide that the purchase price for 250,000 shares was deemed to be satisfied in consideration for services rendered to the Company, with an estimated fair value of \$37,250. The estimated fair value of the services were expensed, and the total consideration received of \$75,000 has been reflected as a long-term liability until the criteria for vesting are achieved or ten years, when the repurchase right is exercised automatically. The shares will vest upon the closing of the merger.

**(10) Income Taxes**

Effective June 1, 2005, the Company changed from an S-Corporation to a C-Corporation. As an S-Corporation, the net operating loss carryforwards were distributed to the Company's stockholders. Since June 2005 through December 31, 2007, for federal income tax purposes, the Company has net operating loss carryforwards of approximately \$19.8 million, which will expire beginning 2025 through 2027. The Tax Reform Act of 1986 contains provisions that may limit the net operating loss carryforwards available to be used in any given year in the event of a significant change in ownership interest. As such, a portion of the Company's net operating loss carryforwards may be limited.

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to the Company's history of operating losses, management is unable to conclude that it is more likely than not that the Company will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax asset of approximately \$8.0 million at December 31, 2007, reflecting a change of approximately \$5.5 million for 2007. Similarly, the Company's entire net deferred tax asset is fully reserved at September 30, 2008. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards.

The differences between the provision for income taxes and the amounts computed by applying the U.S. federal statutory income tax rate to the loss before provision for income taxes is as follows:

	Year ended December 31,		
	2007	2006	2005
	(in thousands)		
U.S. federal income tax benefit at statutory rates	\$ (4,898)	\$ (1,834)	\$ (511)
State income tax benefit, net of federal expense (benefit)	(421)	(158)	(44)
Research and experimentation credits	(182)	(21)	
Other	44	20	49
Change in valuation allowance	5,457	1,993	506
	\$	\$	\$

The Company has had no provision for income taxes since inception due to its S-corporation status and its net operating losses.

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA'S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

Deferred income taxes reflect the net tax effects of timing differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of the Company's net deferred tax assets are as follows:

	<b>December 31,</b>	
	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>	
Deferred tax assets:		
Current deferred tax assets:		
Cash to accrual adjustment	\$ 14	\$ 257
Total current deferred tax assets	14	257
Valuation allowance	(14)	(257)
Net current deferred tax assets		
Noncurrent deferred tax assets:		
Net operating loss carryforwards	7,516	2,151
Charitable contribution carryforwards	122	59
Research and experimentation credits	203	21
Capitalized intangibles	92	
Stock based compensation	8	15
Depreciation and amortization	2	
Total noncurrent deferred tax assets	7,943	2,246
Valuation allowance	(7,943)	(2,244)
Net noncurrent deferred tax assets		2
Deferred tax liabilities:		
Noncurrent deferred tax liabilities:		
Depreciation and amortization		2
Total noncurrent deferred tax liabilities		2
Net deferred tax assets	\$	\$

SFAS No. 109 requires that valuation allowance be provided if it is more likely than not that some portion or all deferred tax assets will not be realized. The Company's ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income through profitable operations. Due to the Company's history of losses and the uncertainty of future profitable operations, the Company has recorded a full valuation allowance against its deferred tax assets. The valuation allowance for deferred tax assets increased by \$5.5 million in 2007. At

## Edgar Filing: NUVELO INC - Form S-4/A

December 31, 2007, the Company has approximately \$19.8 million of net operating loss carryforwards and approximately \$203,000 of research and experimentation credits which may be used to offset future taxable income. The carryforwards will expire in 2025 through 2027.

Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operation losses and credits before utilization.

F-70

**Table of Contents****ARCA BIOPHARMA, INC.****(a development stage enterprise)****NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

**(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)**

In July 2006, the FASB issued FASB Interpretation No. 48 *Accounting of Uncertainty in Tax Positions - an Interpretation of FASB Statement No. 109*, or FIN 48. The purpose of FIN 48 is to clarify certain aspects of the recognition and measurement related to accounting for income tax uncertainties. Under FIN 48 the impact of uncertain tax positions must be recognized in the financial statements if that position is more likely than not of being sustained upon audit by a relevant taxing authority.

The Company adopted FIN 48 effective January 1, 2007. Upon adoption of FIN 48 and through September 30, 2008 (unaudited), the Company had no tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months from the date of adoption of FIN 48 or from September 30, 2008 (unaudited). In the event the Company concludes it is subject to interest or penalties arising from uncertain tax positions, the Company will record interest and penalties as a component of other income and expense. No amounts of interest or penalties were recognized in ARCA s financial statements for the nine months ended September 30, 2008 (unaudited).

Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. Thus, upon adoption of FIN 48, the Company s open tax years extend back to 2005. The Company believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on the Company s financial condition, result of operations, or cash flow. Therefore, no reserve for uncertain income tax positions has been recorded pursuant to FIN 48.

**(11) Selected Quarterly Financial Data (Unaudited)**

	Net Loss	Net Loss to Common Stockholders	Basic and Diluted Net Loss Attributable to Common Stockholders per Share
	(in thousands, except per share data)		
Year ended December 31, 2006:			
First quarter	\$ (1,573)	\$ (1,575)	\$ (0.60)
Second quarter	(633)	(638)	(0.19)
Third quarter	(1,340)	(1,345)	(0.40)
Fourth quarter	(1,695)	(1,700)	(0.46)
Year ended December 31, 2007:			
First quarter	\$ (2,869)	\$ (2,874)	\$ (0.77)
Second quarter	(3,683)	(3,687)	(0.98)
Third quarter	(3,694)	(3,712)	(0.97)
Fourth quarter	(3,748)	(3,758)	(0.98)

Basic and diluted net loss attributable to common stockholders per share are identical since common equivalent shares are excluded from the calculation as their effect is anti-dilutive.



**Table of Contents****ARCA BIOPHARMA, INC.**

(a development stage enterprise)

**NOTES TO ARCA S FINANCIAL STATEMENTS (Continued)**

(Information as of September 30, 2008, for the nine months ended September 30, 2008 and 2007, and for the period from Inception to September 30, 2008 is unaudited)

**(12) Events Subsequent to December 31, 2007****(a) New Business Office Lease**

On February 8, 2008 the Company entered into a lease agreement for approximately 15,000 square feet of newly constructed office facilities in Broomfield, Colorado, which serves as the Company's primary business offices. The lease has a term of 5 years and the Company relocated to the new facility upon its completion in July 2008. The Company paid a security deposit of \$57,800. Below is a summary of the future minimum lease payments committed under this lease:

<b>Years ended December 31:</b>	
2008	\$ 134,866
2009	235,287
2010	242,385
2011	249,632
2012	257,115
2013	108,452
	<b>\$ 1,227,737</b>

**(b) CPEC Milestone Payment**

In August 2008, the Company paid CPEC \$500,000 for a milestone royalty due based on the July 31, 2008 submission of the Company's NDA with the FDA.

**(c) Credit Facility**

In August 2008, the Company drew the full \$4.0 million balance of its Credit Facility. The loan requires monthly interest only payments through December 2008 and then monthly principal and interest payments beginning in January 2009 for 24 months. In accordance with the loan agreement, the Company issued 24,592 warrants for its Series B-2 preferred stock. The warrants have an exercise price of \$3.253 per share, a 10-year life, and were fully vested and exercisable at the time of grant. The estimated fair value of the warrants was accounted for as a debt discount, and will be reflected as additional interest expense over the term of the Credit Facility.

**(d) Proposed Merger With Nuvelo, Inc.**

In September 2008, the Company entered into a definitive merger agreement whereby it proposes to merge with Nuvelo, Inc. Based on the terms of the transaction, the Company's shareholders are expected to control the combined company, and as such, the Company is considered to be the acquirer for accounting purposes. The merger is subject to shareholder approval, and is expected to be consummated in the first quarter of 2009.



*(e) Issuance of Convertible Note*

In October 2008, the Company issued convertible notes in exchange for \$8.75 million of cash from existing investors. If the proposed merger closes prior to March 31, 2009, the maturity date of the notes, the notes automatically convert to common stock. The Company also issued warrants to the noteholders which allow them to purchase common stock at an exercise price which is dependent upon the value of the stock indicated by the proposed merger transaction. The issuance of the notes and warrants results in adjustments to the conversion prices for Series B in accordance with the anti-dilution provisions in effect at such time.

F-72

**Table of Contents**

**ANNEX A**

**AGREEMENT AND PLAN OF MERGER AND REORGANIZATION**

among:

**NUVELO, INC.,**

a Delaware corporation;

**DAWN ACQUISITION SUB, INC.,**

a Delaware corporation; and

**ARCA BIOPHARMA, INC.,**

a Delaware corporation

Dated as of September 24, 2008

**Table of Contents****Table of Contents**

	<b>Page</b>
<b><u>SECTION 1. DESCRIPTION OF TRANSACTION</u></b>	A-1
1.1 <u>The Merger</u>	A-1
1.2 <u>Effects of the Merger</u>	A-1
1.3 <u>Closing; Effective Times of the Merger</u>	A-1
1.4 <u>Certificate of Incorporation and Bylaws; Directors and Officers</u>	A-2
1.5 <u>Conversion of Shares; Treatment of Warrants</u>	A-2
1.6 <u>Closing of the Company's Transfer Books</u>	A-3
1.7 <u>Exchange of Certificates</u>	A-4
1.8 <u>Tax Consequences</u>	A-5
1.9 <u>Appraisal Rights</u>	A-5
1.10 <u>Further Action</u>	A-5
<b><u>SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY</u></b>	A-6
2.1 <u>Subsidiaries; Due Organization; Etc</u>	A-6
2.2 <u>Certificate of Incorporation and Bylaws</u>	A-6
2.3 <u>Capitalization; Etc</u>	A-6
2.4 <u>Financial Statements; Financial Controls</u>	A-8
2.5 <u>Absence of Changes</u>	A-9
2.6 <u>Title to Assets</u>	A-9
2.7 <u>Receivables; Customers</u>	A-9
2.8 <u>Equipment; Leasehold</u>	A-10
2.9 <u>Intellectual Property</u>	A-10
2.10 <u>Contracts</u>	A-11
2.11 <u>Liabilities</u>	A-13
2.12 <u>Compliance with Legal Requirements</u>	A-13
2.13 <u>Tax Matters</u>	A-15
2.14 <u>Employee and Labor Matters; Benefit Plans</u>	A-16
2.15 <u>Environmental Matters</u>	A-19
2.16 <u>Insurance</u>	A-19
2.17 <u>Related Party Transactions</u>	A-20
2.18 <u>Legal Proceedings; Orders</u>	A-20
2.19 <u>Authority; Binding Nature of Agreement</u>	A-20
2.20 <u>Inapplicability of Anti-takeover Statutes</u>	A-20
2.21 <u>Vote Required</u>	A-20
2.22 <u>Non-Contravention; Consents</u>	A-21
2.23 <u>Financial Advisor</u>	A-21
2.24 <u>Full Disclosure</u>	A-22
<b><u>SECTION 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</u></b>	A-22
3.1 <u>Due Organization</u>	A-22
3.2 <u>Certificate of Incorporation and Bylaws</u>	A-23
3.3 <u>Capitalization; Etc</u>	A-23
3.4 <u>SEC Filings; Financial Statements</u>	A-24
3.5 <u>Absence of Changes</u>	A-24
3.6 <u>Title to Assets</u>	A-25
3.7 <u>Equipment; Leasehold</u>	A-25
3.8 <u>Intellectual Property</u>	A-25
3.9 <u>Material Contracts</u>	A-26
3.10 <u>Liabilities</u>	A-26

**Table of Contents****Table of Contents**

(continued)

	<b>Page</b>
3.11 <u>Compliance with Legal Requirements</u>	A-26
3.12 <u>Tax Matters</u>	A-28
3.13 <u>Employee and Labor Matters: Benefit Plans</u>	A-29
3.14 <u>Environmental Matters</u>	A-32
3.15 <u>Insurance</u>	A-32
3.16 <u>Legal Proceedings: Orders</u>	A-33
3.17 <u>Authority: Binding Nature of Agreement</u>	A-33
3.18 <u>Inapplicability of Anti-takeover Statutes</u>	A-33
3.19 <u>Vote Required</u>	A-33
3.20 <u>Non-Contravention: Consents</u>	A-33
3.21 <u>Fairness Opinion</u>	A-34
3.22 <u>Financial Advisor</u>	A-34
3.23 <u>Valid Issuance</u>	A-34
3.24 <u>Full Disclosure</u>	A-34
<b><u>SECTION 4. CERTAIN COVENANTS OF THE PARTIES</u></b>	<b>A-35</b>
4.1 <u>Access and Investigation</u>	A-35
4.2 <u>Operations Prior to Closing</u>	A-35
4.3 <u>Budget</u>	A-37
4.4 <u>No Solicitation</u>	A-38
<b><u>SECTION 5. ADDITIONAL COVENANTS OF THE PARTIES</u></b>	<b>A-39</b>
5.1 <u>Registration Statement; Proxy Statement/Prospectus</u>	A-39
5.2 <u>Company Stockholder Approval</u>	A-40
5.3 <u>Parent Stockholders Meeting</u>	A-41
5.4 <u>Stock Options</u>	A-42
5.5 <u>Regulatory Approvals and Related Matters</u>	A-43
5.6 <u>Disclosure</u>	A-44
5.7 <u>[Reserved.]</u>	A-44
5.8 <u>Tax Matters</u>	A-44
5.9 <u>Letter of the Company's Accountants</u>	A-44
5.10 <u>Listing</u>	A-44
5.11 <u>Board of Directors; Officers</u>	A-45
5.12 <u>Charter Amendments</u>	A-45
5.13 <u>Termination of Company Stockholder and Other Related Agreements</u>	A-45
5.14 <u>Section 16b</u>	A-45
<b><u>SECTION 6. CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</u></b>	<b>A-45</b>
6.1 <u>Accuracy of Company Representations</u>	A-45
6.2 <u>Performance of Covenants</u>	A-46
6.3 <u>Effectiveness of Registration Statement</u>	A-46
6.4 <u>Company Stockholder Approval</u>	A-46
6.5 <u>Parent Stockholder Approval</u>	A-46
6.6 <u>Consents</u>	A-46
6.7 <u>Documents</u>	A-46
6.8 <u>No Company Material Adverse Effect</u>	A-47
6.9 <u>Other Governmental Approvals</u>	A-47
6.10 <u>Listing</u>	A-47
6.11 <u>No Restraints</u>	A-47
6.12 <u>No Governmental Litigation</u>	A-47
6.13 <u>Termination of Company Stockholder and Other Related Agreements</u>	A-48



**Table of Contents**

**Table of Contents**

(continued)

	<b>Page</b>
<b><u>SECTION 7. CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</u></b>	A-48
7.1 <u>Accuracy of Parent Representations</u>	A-48
7.2 <u>Performance of Covenants</u>	A-48
7.3 <u>Effectiveness of Registration Statement</u>	A-48
7.4 <u>Company Stockholder Approval</u>	A-48
7.5 <u>Parent Stockholder Approval</u>	A-48
7.6 <u>Documents</u>	A-48
7.7 <u>No Parent Material Adverse Effect</u>	A-49
7.8 <u>Other Governmental Approvals</u>	A-49
7.9 <u>Listing</u>	A-49
7.10 <u>No Restraints</u>	A-49
7.11 <u>No Governmental Litigation</u>	A-49
<b><u>SECTION 8. TERMINATION</u></b>	A-49
8.1 <u>Termination</u>	A-49
8.2 <u>Effect of Termination</u>	A-51
8.3 <u>Expenses; Termination Fees</u>	A-51
<b><u>SECTION 9. MISCELLANEOUS PROVISIONS</u></b>	A-52
9.1 <u>Amendment</u>	A-52
9.2 <u>Waiver</u>	A-52
9.3 <u>No Survival of Representations and Warranties</u>	A-52
9.4 <u>Entire Agreement; Counterparts; Exchanges by Facsimile or Electronic Delivery</u>	A-52
9.5 <u>Applicable Law; Jurisdiction</u>	A-53
9.6 <u>Disclosure Schedules</u>	A-53
9.7 <u>Attorneys Fees</u>	A-53
9.8 <u>Assignability; No Third Party Rights</u>	A-53
9.9 <u>Notices</u>	A-53
9.10 <u>Cooperation</u>	A-54
9.11 <u>Severability</u>	A-54
9.12 <u>Construction</u>	A-54

**Table of Contents**

EXECUTION VERSION

**AGREEMENT AND PLAN OF MERGER AND REORGANIZATION**

**THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION ( Agreement )** is made and entered into as of September 24, 2008 (the **Execution Date** ), by and among: **NUVELO, INC.**, a Delaware corporation ( **Parent** ); **DAWN ACQUISITION SUB, INC.**, a Delaware corporation and a wholly-owned subsidiary of Parent ( **Merger Sub** ); and **ARCA BIOPHARMA, INC.**, a Delaware corporation (the **Company** ). Certain capitalized terms used in this Agreement are defined in **Exhibit A**.

**RECITALS**

**A.** Parent, Merger Sub and the Company intend to effect a merger of Merger Sub into the Company in accordance with this Agreement and the DGCL (the **Merger** ). Upon consummation of the Merger, Merger Sub will cease to exist, and the Company (as the Surviving Corporation) will become a wholly-owned subsidiary of Parent.

**B.** It is intended that, for United States federal income tax purposes, the Merger shall qualify as a reorganization within the meaning of Section 368(a) of the Code.

**C.** The respective boards of directors of Parent, Merger Sub and the Company have approved this Agreement and the Merger and contemporaneously with the execution of this Agreement certain stockholders of the Company have executed voting agreements pursuant to which such stockholders have agreed to vote in favor of the Merger through the Company Written Consent (the **Company Voting Agreements** ) and certain stockholders of Parent have executed voting agreements pursuant to which such stockholders have agreed to vote in favor of the issuance of Parent Common Stock in the Merger and the Charter Amendment at the Parent Stockholders Meeting.

**AGREEMENT**

The parties to this Agreement, intending to be legally bound, agree as follows:

**SECTION 1. DESCRIPTION OF TRANSACTION**

**1.1 The Merger.** Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time (as defined in Section 1.3), Merger Sub shall be merged with and into the Company. By virtue of the Merger, at the Effective Time, the separate existence of Merger Sub shall cease and the Company shall continue as the surviving corporation in the Merger (the **Surviving Corporation** ).

**1.2 Effects of the Merger.** The Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL.

**1.3 Closing; Effective Times of the Merger.**

**(a)** The consummation of the Contemplated Transactions (the **Closing** ) shall take place at the offices of Cooley Godward Kronish LLP, 3175 Hanover Street, Palo Alto, California, on a date to be designated by Parent, which shall be no later than the fifth business day after the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in Sections 6 and 7 (other than conditions which by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions). The date on which the Closing actually takes place is referred to as the **Closing Date**.

**(b)** Subject to the provisions of this Agreement, in order to effect the Merger, a certificate of merger satisfying the applicable requirements of the DGCL shall be duly executed by the Company and

---

**Table of Contents**

concurrently with or as soon as practicable following the Closing shall be filed with the Secretary of State of the State of Delaware. The Merger shall become effective at the time of the filing of such certificate of merger with the Secretary of State of the State of Delaware or at such later time as may be designated by Parent and specified in such certificate of merger (the time as of which the Merger becomes effective being referred to as the **Effective Time** ).

**1.4 Certificate of Incorporation and Bylaws; Directors and Officers.** Unless otherwise determined by Parent prior to the Effective Time:

(a) the Certificate of Incorporation of the Surviving Corporation shall be amended and restated immediately after the Effective Time to conform to **Exhibit B**;

(b) the Bylaws of the Surviving Corporation shall be amended and restated as of the Effective Time to conform to the Bylaws of Merger Sub as in effect immediately prior to the Effective Time; and

(c) the directors and officers of the Surviving Corporation immediately after the Effective Time shall be the respective individuals who are listed as directors and officers of the Company on Schedule 1.4(c).

**1.5 Conversion of Shares; Treatment of Warrants.**

(a) At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any stockholder of the Company:

(i) any shares of Company Capital Stock held by any wholly-owned Subsidiary of the Company immediately prior to the Effective Time (or held in the Company's treasury) shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor;

(ii) any shares of Company Capital Stock held by Parent, Merger Sub or any other wholly-owned Subsidiary of Parent immediately prior to the Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor;

(iii) except as provided in Section 1.5(a)(i) and (ii) above and subject to Sections 1.5(b), 1.5(c), 1.6, 1.7 and 1.9, each share of Company Capital Stock outstanding immediately prior to the Effective Time shall be converted into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio (as defined below and as determined in accordance with the methodology reflected in the spreadsheet attached hereto as Schedule 1.5(a)(iii) (the **Spreadsheet** )).

(1) The **Company Share Value** shall equal the product of (x) Parent Trading Price multiplied by (y) the Exchange Ratio.

(2) The **Exchange Ratio** shall be determined as of immediately prior to the Effective Time and shall equal (x) 109,009,278 divided by (y) the sum of (A) the number of shares of Company Common Stock issued and outstanding immediately prior to the Effective Time, (B) the number of shares of Company Common Stock issuable upon the conversion of each share of Company Preferred Stock issued and outstanding immediately prior to the Effective Time (as calculated in accordance with the Company's certificate of incorporation in effect immediately prior to the Effective Time), (C) the number of Treasury Method Shares of Company Common Stock Outstanding (as defined below) (which it is agreed shall be calculated to at least five decimal places), and (D) the number of shares of Company Common Stock issuable pursuant to or upon conversion of any convertible notes or other rights outstanding as of immediately prior to the Effective Time (whether or not currently exercisable) to acquire shares of Company Capital Stock, *including* the notes issued pursuant to the Note Purchase Agreement (as defined below) and the Company Warrants issued pursuant to the Note Purchase Agreement but *excluding* other Company Warrants and Company Options, or issuable upon conversion of any Company Preferred Stock issuable pursuant to or upon conversion of any convertible notes or other rights outstanding as of immediately prior to Effective Time (as calculated in accordance with the Company's certificate of incorporation in effect immediately prior to the Effective Time).



---

**Table of Contents**

(3) The **Parent Trading Price** shall equal the average closing price of the Parent Common Stock on the Nasdaq Market for the five consecutive trading days immediately preceding (but not including) the date that includes the Effective Time.

(4) The **Treasury Method Shares of Company Common Stock Outstanding** shall equal (x) the product of the number of shares of Company Common Stock underlying each Company Option and Company Warrant (other than Company Warrants issued in connection with the Note Purchase Agreement (as defined below)) that is outstanding and unexercised as of immediately prior to the Effective Time multiplied by the difference between (A) the Company Share Value and (B) the per share exercise price for each such Company Option and Company Warrant that is outstanding and unexercised as of immediately prior to the Effective Time; divided by (y) the Company Share Value, *provided, however* that for purposes of greater certainty each Company Option and Company Warrant that has a per share exercise price that is greater than or equal to the Company Share Value as of the Effective Time shall be ignored for purposes of calculating the Treasury Method Shares of Company Common Stock Outstanding.

(5) The Exchange Ratio is sometimes also referred to herein as the **Merger Consideration**.

(iv) each share of the Common Stock, \$0.001 par value per share, of Merger Sub outstanding immediately prior to the Effective Time shall be converted into one share of common stock of the Surviving Corporation.

(b) If, during the period from the date of this Agreement through the Effective Time, the outstanding shares of Parent Common Stock are changed into a different number or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, or if a stock dividend is declared by Parent during such period, or a record date with respect to any such event shall occur during such period, then appropriate adjustments shall be made to the formula used to calculate the Exchange Ratio, including, but not limited to, the number 109,009,278 in Section 1.5(a)(iii)(2).

(c) No fractional shares of Parent Common Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Capital Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall, in lieu of such fraction of a share and upon surrender of such holder's Company Stock Certificate(s) (as defined in Section 1.6) be paid in cash the dollar amount (rounded to the nearest whole cent), without interest, determined by multiplying such fraction by the closing price of a share of Parent Common Stock on the Nasdaq Market on the date the Merger becomes effective.

(d) Each Company Warrant outstanding at the Effective Time shall be assumed by Parent to the extent not exercised prior to the Closing. At the Effective Time, each Company Warrant shall be converted into a warrant to acquire that number of shares of Parent Common Stock equal to the product of (x) the number of shares of Company Capital Stock subject to such Company Warrant by (y) Exchange Ratio, rounded down to the nearest whole share of Parent Common Stock. Each Company Warrant shall have a purchase price per share of Parent Common Stock equal to the quotient obtained by dividing (x) the per share purchase price of Company Capital Stock subject to such Company Warrant by (y) the Exchange Ratio rounded up to the nearest whole cent. Each Company Warrant shall otherwise be subject to the same terms and conditions (including as to vesting and exercisability) as were applicable under the respective Company Warrant immediately prior to the Effective Time.

**1.6 Closing of the Company's Transfer Books.** At the Effective Time: (a) all shares of Company Capital Stock outstanding immediately prior to the Effective Time shall automatically be canceled and retired and shall cease to exist, and all holders of certificates representing shares of Company Capital Stock that were outstanding immediately prior to the Effective Time shall cease to have any rights as stockholders of the Company; and

---

**Table of Contents**

(b) the stock transfer books of the Company shall be closed with respect to all shares of Company Capital Stock outstanding immediately prior to the Effective Time. No further transfer of any such shares of Company Capital Stock shall be made on such stock transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any shares of Company Capital Stock outstanding immediately prior to the Effective Time (a **Company Stock Certificate**) is presented to the Exchange Agent (as defined in Section 1.7) or to the Surviving Corporation or Parent, such Company Stock Certificate shall be canceled and shall be exchanged as provided in Section 1.7.

**1.7 Exchange of Certificates.**

(a) On or prior to the Closing Date, Parent shall select a reputable bank or trust company reasonably acceptable to the Company to act as payment and exchange agent in the Merger (the **Exchange Agent**). As promptly as practicable after the Effective Time, Parent shall deposit with the Exchange Agent: (i) certificates representing the shares of Parent Common Stock issuable pursuant to Section 1.5(a)(iii); and (ii) cash sufficient to make payments in lieu of fractional shares in accordance with Section 1.5(c). The shares of Parent Common Stock and cash amounts so deposited with the Exchange Agent, together with any dividends or distributions received by the Exchange Agent with respect to such shares of Parent Common Stock, are referred to collectively as the **Exchange Fund**.

(b) As promptly as practicable after the Effective Time, the Exchange Agent will mail to the Persons who were record holders of Company Stock Certificates immediately prior to the Effective Time: (i) a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of Company Stock Certificates shall be effected, and risk of loss and title to Company Stock Certificates shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent); and (ii) instructions for use in effecting the surrender of Company Stock Certificates in exchange for cash and certificates representing Parent Common Stock. Upon surrender of a Company Stock Certificate to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A) the holder of such Company Stock Certificate shall be entitled to receive in exchange therefor, a certificate representing the number of whole shares of Parent Common Stock that such holder has the right to receive pursuant to the provisions of Section 1.5(a)(iii) (and cash in lieu of any fractional share of Parent Common Stock pursuant to Section 1.5(c)); and (B) the Company Stock Certificate so surrendered shall be canceled. Until surrendered as contemplated by this Section 1.7(b), each Company Stock Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive cash and shares of Parent Common Stock pursuant to the provisions of Section 1.5(a)(iii) and cash in lieu of any fractional share of Parent Common Stock pursuant to Section 1.5(c). If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition to the payment of any cash or the issuance of any certificate representing Parent Common Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an appropriate affidavit and to deliver a bond (in such sum as Parent may reasonably direct) as indemnity against any claim that may be made against the Exchange Agent, Parent or the Surviving Corporation with respect to such Company Stock Certificate.

(c) No dividends or other distributions declared or made with respect to Parent Common Stock with a record date after the Effective Time shall be paid or otherwise delivered to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Common Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate in accordance with this Section 1.7 (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar laws, to receive all such dividends and distributions, without interest).

(d) Any portion of the Exchange Fund that remains undistributed to holders of Company Stock Certificates as of the date 180 days after the date on which the Merger becomes effective shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates in accordance with this Section 1.7 shall thereafter look only to Parent for satisfaction of their claims for shares of Parent Common Stock pursuant to the provisions of

---

**Table of Contents**

Section 1.5(a)(iii), cash in lieu of fractional shares of Parent Common Stock pursuant to Section 1.5(c) and any dividends or distributions with respect to shares of Parent Common Stock.

(e) Each of the Exchange Agent, Parent and the Surviving Corporation shall be entitled to deduct and withhold from any consideration payable or otherwise deliverable pursuant to this Agreement to any holder or former holder of Company Common Stock such amounts as may be required to be deducted or withheld from such consideration under the Code or any provision of state, local or foreign tax law or under any other applicable Legal Requirement. To the extent such amounts are so deducted or withheld, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid.

(f) Neither Parent nor the Surviving Corporation shall be liable to any holder or former holder of Company Common Stock or to any other Person with respect to any shares of Parent Common Stock (or dividends or distributions with respect thereto), or for any cash amounts, delivered to any public official pursuant to any applicable abandoned property law, escheat law or other similar Legal Requirement.

**1.8 Tax Consequences.** For federal income tax purposes, the Merger is intended to constitute a reorganization within the meaning of Section 368 of the Code, and the parties will report the Merger as such for federal, state and local income tax purposes. None of the parties will knowingly take any action, or fail to take any action, which action or failure to act would cause the Merger to fail to qualify as a reorganization within the meaning of Section 368 of the Code or the Treasury Regulations promulgated thereunder. The parties to this Agreement adopt this Agreement as a plan of reorganization within the meaning of Sections 1.368-2(g) and 1.368-3(a) of the United States Treasury Regulations.

**1.9 Appraisal Rights.**

(a) Notwithstanding anything to the contrary contained in this Agreement, any shares of Company Capital Stock that, as of immediately prior to the Effective Time, are held by holders who have as of such time preserved appraisal rights under Section 262 of the DGCL with respect to such shares shall not be converted into or represent the right to receive shares of Parent Common Stock in accordance with Section 1.5(a)(iii), or cash in lieu of fractional shares in accordance with Section 1.5(c), and the holder or holders of such shares shall be entitled only to such rights as may be granted to such holder or holders pursuant to Section 262 of the DGCL; *provided, however*, that if such appraisal rights shall not be perfected or the holders of such shares shall otherwise lose their appraisal rights with respect to such shares, then, as of the later of the Effective Time or the time of the failure to perfect such status or the loss of such rights, such shares shall automatically be converted into and shall represent only the right to receive (upon the surrender of such holder's Company Stock Certificate(s) in accordance with Section 1.7) shares of Parent Common Stock in accordance with Section 1.5(a)(iii) and cash in lieu of fractional shares in accordance with Section 1.5(c).

(b) The Company shall give Parent: (i) prompt notice of any written demand received by the Company prior to the Effective Time to require the Company to purchase shares of Company Common Stock pursuant to Section 262 of the DGCL and of any other demand, notice or instrument delivered to the Company prior to the Effective Time pursuant to the DGCL; and (ii) the opportunity to participate in all negotiations and proceedings with respect to any such demand, notice or instrument. The Company shall not make any payment or settlement offer prior to the Effective Time with respect to any such demand unless Parent shall have consented in writing to such payment or settlement offer.

**1.10 Further Action.** If, at any time after the Effective Time, any further action is determined by Parent or the Surviving Corporation to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of Merger Sub and the Company, the officers and directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Merger Sub, in the name of the Company and otherwise) to take such action.

---

**Table of Contents****SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY**

The Company represents and warrants to Parent and Merger Sub as follows (it being understood that each representation and warranty contained in this Section 2 is subject to: (a) the exceptions and disclosures set forth in the part or subpart of the Company Disclosure Schedule corresponding to the particular Section or subsection in this Section 2 in which such representation and warranty appears; (b) any exceptions or disclosures explicitly cross-referenced in such part or subpart of the Company Disclosure Schedule by reference to another part or subpart of the Company Disclosure Schedule; and (c) any exception or disclosure set forth in any other part or subpart of the Company Disclosure Schedule to the extent it is readily apparent from the wording of such exception or disclosure that such exception or disclosure is intended to qualify such representation and warranty):

**2.1 Subsidiaries; Due Organization; Etc.**

(a) Part 2.1(a) of the Company Disclosure Schedule identifies each Subsidiary of the Company and indicates its jurisdiction of organization. Neither the Company nor any of the Entities identified in Part 2.1(a) of the Company Disclosure Schedule owns any capital stock of, or any equity interest of any nature in, any other Entity, other than the Entities identified in Part 2.1(a) of the Company Disclosure Schedule. None of the Acquired Corporations has agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity.

(b) Each of the Acquired Corporations is a corporation duly organized, validly existing and, in jurisdictions that recognize the concept, is in good standing under the laws of the jurisdiction of its incorporation and has all necessary power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii) to own and use its assets in the manner in which its assets are currently owned and used; and (iii) to perform its obligations under all Contracts by which it is bound.

(c) Each of the Acquired Corporations (in jurisdictions that recognize the following concepts) is qualified to do business as a foreign corporation, and is in good standing, under the laws of all jurisdictions where the nature of its business requires such qualification, except as would not have and would not reasonably be expected to have or result in a Company Material Adverse Effect.

**2.2 Certificate of Incorporation and Bylaws.** The Company has delivered to Parent accurate and complete copies of: (a) the certificate of incorporation, bylaws and other charter and organizational documents of each Acquired Corporation, including all amendments thereto; (b) the stock records of each Acquired Corporation; and (c) the minutes and other records of the meetings and other proceedings (including any actions taken by written consent or otherwise without a meeting) of the stockholders of each Acquired Corporation, the board of directors of each Acquired Corporation and all committees of the board of directors of each Acquired Corporation. The books of account, stock records, minute books and other records of the Acquired Corporations are accurate, up-to-date and complete in all material respects, and have been maintained in accordance with prudent business practices.

**2.3 Capitalization, Etc.**

(a) The authorized capital stock of the Company consists of 26,000,000 shares of Company Common Stock, of which 5,713,818 shares have been issued and are outstanding as of the date of this Agreement, 9,222,257 shares of Series A Preferred Stock, all of which have been issued and are outstanding as of the date of this Agreement, and 3,720,692 shares of Series B-1 Preferred Stock, of which 3,688,902 shares have been issued and are outstanding as of the date of this Agreement and 2,791,269 shares of Series B-2 Preferred Stock, of which 2,766,677 have been issued and are outstanding as of the date of this Agreement. Except as set forth in Part 2.3(a)(i) of the Company Disclosure Schedule, the Company does not hold any shares of its capital stock in its treasury. All of the outstanding shares of Company Capital Stock have been duly authorized and validly issued, and are fully paid and nonassessable. Except as set forth in Part 2.3(a)(ii) of the Company Disclosure Schedule: (i) none of the outstanding shares of Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right;

---

**Table of Contents**

(ii) none of the outstanding shares of Company Capital Stock is subject to any right of first refusal or similar right in favor of the Company or any other Person; and (iii) there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Company Capital Stock. None of the Acquired Corporations is under any obligation, or is bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Company Capital Stock or any other securities. Part 2.3(a)(iii) of the Company Disclosure Schedule provides an accurate and complete description of the terms of each repurchase option which is held by the Company and to which any of the shares of Company Capital Stock is subject. Each share of Company Preferred Stock is convertible into one share of Company Common Stock.

(b) As of the date of this Agreement, 3,385,351 shares of Company Common Stock are subject to issuance pursuant to outstanding Company Options. Part 2.3(b)(i) of the Company Disclosure Schedule sets forth accurate and complete information with respect to the holder, the vesting, the exercise price, the expiration date, the shares underlying, the applicable Company Option Plan, and the tax status of each Company Option outstanding as of the date of this Agreement. No Company Option is held by a Person residing or domiciled outside of the United States. All outstanding Company Options were granted pursuant to the terms of one of the Company Option Plans. The Company has delivered to Parent accurate and complete copies of all stock option plans pursuant to which any of the Acquired Corporations has ever granted stock options, and the forms of all stock option agreements evidencing such options. The Company Option Plans are binding upon and enforceable by the Company against all holders of Company Options, subject to (i) laws of general application relating to bankruptcy, insolvency, reorganization, moratorium and the enforcement of creditors' rights generally, and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. As of the date of this Agreement, 56,382 shares of Company Preferred Stock are subject to issuance pursuant to outstanding warrants ( **Company Warrants** ). Part 2.3(b)(ii) of the Company Disclosure Schedule sets forth accurate and complete information with respect to the holder, the vesting, the exercise price, the expiration date and the shares underlying each Company Warrant outstanding as of the date of this Agreement. The Company has delivered to Parent accurate and complete copies of all Company Warrants.

(c) Except as set forth in Part 2.3(b) of the Company Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of any of the Acquired Corporations; (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of any of the Acquired Corporations; (iii) Contract under which any of the Acquired Corporations is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities; or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive (A) any shares of capital stock or other securities of any of the Acquired Corporations, or (B) any portion of any Merger Consideration or other consideration payable in connection with the Merger (other than in respect of outstanding shares of Company Capital Stock as set forth in Section 2.3(a)).

(d) All outstanding shares of capital stock, and all options, warrants and other securities of the Acquired Corporations have been issued and granted in compliance with (i) all applicable securities laws and other applicable Legal Requirements, and (ii) all requirements set forth in applicable Contracts.

(e) All of the outstanding shares of capital stock of each of the Company's Subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and free of preemptive rights, with no personal liability attaching to the ownership thereof, and are owned beneficially and of record by the Company, free and clear of any Encumbrances.

(f) Except as set forth in Part 2.3(f) of the Company Disclosure Schedule, none of the Acquired Corporations has ever repurchased, redeemed or otherwise reacquired any shares of Company Capital Stock or other securities of any Acquired Corporation, other than Company Options forfeited by Company

---

**Table of Contents**

Employees in connection with the termination of a Company Employee's employment with an Acquired Corporation. All securities so reacquired by the Company or any other Acquired Corporation were reacquired in compliance with (i) all applicable Legal Requirements, and (ii) all requirements set forth in applicable restricted stock purchase agreements and other applicable Contracts.

**2.4 Financial Statements; Financial Controls.**

(a) The Company has delivered to Parent the following financial statements and notes (collectively, the **Company Financial Statements**): (i) the audited consolidated balance sheets of the Company and its consolidated Subsidiaries as of December 31, 2005, 2006 and 2007 and the related audited consolidated statements of operations, statements of stockholders' equity and statements of cash flows of the Company and its consolidated Subsidiaries for the years then ended, together with the independent auditor's report therefor and notes thereto; and (ii) the unaudited consolidated balance sheet of the Company and its consolidated Subsidiaries as of June 30, 2008 (the **Most Recent Balance Sheet**), and the related unaudited statement of income, statement of stockholders' equity and statement of cash flows of the Company and its consolidated Subsidiaries for the six months then ended. The Acquired Corporations' Net Cash as of August 31, 2008 was \$ 4,180,069.

(b) The Company Financial Statements are accurate and complete in all material respects and fairly present the financial position of the Company and its consolidated Subsidiaries as of the respective dates thereof and the results of operations and cash flows of the Company and its consolidated Subsidiaries for the periods covered thereby. The Company Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except that the financial statements referred to in Section 2.4(a)(ii) do not contain footnotes and are subject to normal and recurring year end adjustments, which will not, individually or in the aggregate, be material in magnitude).

(c) Each of the Acquired Corporations maintains accurate books and records reflecting its assets and liabilities and maintains proper and adequate internal accounting controls which provide assurance that: (i) transactions are executed with management's authorization; (ii) transactions are recorded as necessary to permit preparation of the consolidated financial statements of the Company and its consolidated Subsidiaries and to maintain accountability for the assets of the Acquired Corporations; (iii) access to the assets of the Acquired Corporations is permitted only in accordance with management's authorization; (iv) the reporting of the assets of the Acquired Corporations is compared with existing assets at regular intervals; and (v) accounts, notes and other receivables are recorded accurately, and proper and adequate procedures are implemented to effect the collection thereof on a current and timely basis.

(d) The Company and each of the parties (other than Parent) to that convertible note purchase agreement dated of even date herewith and provided to Parent (the **Note Purchase Agreement**) have duly authorized, executed and delivered the Note Purchase Agreement. The Note Purchase Agreement constitutes the legal, valid and binding obligation of the Company and each of the other parties to the Note Purchase Agreement (other than Parent), enforceable against such parties in accordance with its terms, subject to: (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. The Company has exercised all of its rights under the Note Purchase Agreement to obligate the parties (other than the Company and Parent) to purchase not less than \$8,750,000 in principal amount of convertible notes pursuant to the Note Purchase Agreement (for consideration equal to the principal amount of such notes) subject solely to the closing conditions set forth in the Note Purchase Agreement. The board of directors of the Company (at a meeting duly called and held) has unanimously approved the Charter Amendment as such term is defined in the Note Purchase Agreement (the **Company NPA Charter Amendment**), holders of a requisite number of shares of the Company's capital stock have approved the Company NPA Charter Amendment such that it has been adopted and approved, all in accordance with the DGCL, and the officers of the Company have been authorized and instructed to file the Company NPA Charter Amendment with the Secretary of State of the State of Delaware.

---

**Table of Contents**

**2.5 Absence of Changes.** Except as set forth in Part 2.5 of the Company Disclosure Schedule, between December 31, 2007 and the date of this Agreement: (a) there has not been any Company Material Adverse Effect, and no event has occurred or circumstance has arisen that, in combination with any other events or circumstances, would reasonably be expected to have or result in a Company Material Adverse Effect; (b) there has not been any material loss, damage or destruction to, or any material interruption in the use of, any of the assets of any of the Acquired Corporations (whether or not covered by insurance); (c) none of the Acquired Corporations has received any inquiry, proposal or offer relating to a possible Acquisition Transaction; (d) none of the Acquired Corporations has made any capital expenditure which, when added to all other capital expenditures made on behalf of the Acquired Corporations since December 31, 2007, exceeds \$100,000 in the aggregate; (e) none of the Acquired Corporations has written off as uncollectible, or established any extraordinary reserve with respect to, any account receivable or other indebtedness; (f) none of the Acquired Corporations has entered into any material transaction or taken any other material action outside the ordinary course of business or inconsistent with past practices; (g) none of the Acquired Corporations has taken any action of the type referred to in Section 4.2(b); and (h) none of the Acquired Corporations has agreed or committed to take any of the actions referred to in clauses (c) through (g) of this sentence.

**2.6 Title to Assets.** The Acquired Corporations own, and have good, valid and marketable title to, all assets purported to be owned by them, including: (a) all assets reflected on the Most Recent Balance Sheet (except for inventory sold or otherwise disposed of in the ordinary course of business since the date of the Most Recent Balance Sheet); and (b) all other assets reflected in the books and records of the Acquired Corporations as being owned by the Acquired Corporations. All of said assets are owned by the Acquired Corporations free and clear of any Encumbrances, except for (i) any lien for current taxes not yet due and payable, (ii) minor liens that have arisen in the ordinary course of business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of any Acquired Corporation, and (iii) liens described in Part 2.6 of the Company Disclosure Schedule. The Acquired Corporations are the lessees of, and hold valid leasehold interests in, all assets purported to have been leased by them, including: (A) all assets reflected as leased on the Most Recent Balance Sheet; and (B) all other assets reflected in the books and records of the Acquired Corporations as being leased to the Acquired Corporations, and the Acquired Corporations enjoy undisturbed possession of such leased assets.

**2.7 Receivables; Customers.**

(a) Part 2.7(a) of the Company Disclosure Schedule contains an accurate and complete list as of the date of this Agreement of all outstanding loans and advances made by any of the Acquired Corporations to any Company Associate, other than routine travel advances made to directors or officers or other employees in the ordinary course of business.

(b) Part 2.7(b)(i) of the Company Disclosure Schedule accurately identifies, and provides an accurate and complete breakdown of the revenues received from, each customer or other Person that accounted for revenues of at least \$100,000 in the fiscal year ended December 31, 2006 or the fiscal year ended December 31, 2007. The Company has not received any notice or other communication, and has not received any other information, indicating that any customer or other Person identified or required to be identified in Part 2.7(b) of the Company Disclosure Schedule may cease dealing with any of the Acquired Corporations. Part 2.7(b)(ii) of the Company Disclosure Schedule identifies, as of the date of this Agreement, each Person that, pursuant to any Company Contract, is required to pay to an Acquired Corporation after the date of this Agreement \$100,000 or more in cash if any payments under such Contract have not been recognized as revenue by any Acquired Corporation on or prior to the date of this Agreement. The Company has delivered to Parent information setting forth: (A) the amount of cash that the Acquired Corporations expect to receive from each Person referred to in the immediately preceding sentence; and (B) the fiscal quarter in which the Acquired Corporations expect to receive such cash (it being understood that no representation or warranty is being made pursuant to this sentence as to whether or when such amounts will actually be received by the Acquired Corporations).

## Table of Contents

**2.8 Equipment; Leasehold.** All material items of equipment and other tangible assets owned by or leased to the Acquired Corporations are adequate for the uses to which they are being put, are in good condition and repair (ordinary wear and tear excepted) and are adequate for the conduct of the business of the Acquired Corporations in the manner in which such business is currently being conducted. No Acquired Corporation owns any real property or any interest in real property, except for the leaseholds created under the real property leases identified in Part 2.8 of the Company Disclosure Schedule.

## **2.9 Intellectual Property.**

(a) Part 2.9(a) of the Company Disclosure Schedule sets forth a complete and accurate list as of the date of this Agreement of: (i) all Registered Intellectual Property (as defined below) in which any of the Acquired Corporations has any ownership interest (collectively, the **Owned Intellectual Property**); and (ii) all IP Contracts (as defined below) relating to the Company Intellectual Property; provided that such list need not include shrink-wrap and similar licenses for off-the-shelf retail-available software used solely on the computers of the Company or its Subsidiaries (collectively, **Shrink Wrap Licenses**). For purposes of this Agreement the terms (A) **Intellectual Property** shall mean any and all of the following, and rights in, arising out of, or associated therewith: U.S. and non-U.S. (i) non-expired patents, utility models, supplementary protection certificates and applications therefor (including provisional applications, invention disclosures, certificates of invention and applications for certificates of invention) and divisionals, continuations, continuations-in-part, patents of addition, reissues, renewals, extensions, re-examinations, and equivalents thereof throughout the world (**Patents**), (ii) trade secrets, know-how, proprietary information, inventions, discoveries, improvements, technology, technical data and research and development, whether patentable or not (collectively, **Trade Secrets**), (iii) trademarks, service marks, trade dress, trade names and Internet domain names and registrations and applications therefor, and equivalents thereof throughout the world, (iv) copyrights, mask works, registrations and applications therefor, and equivalents thereof throughout the world, (v) computer software and firmware, including all source code, object code, specifications, databases, designs and documentation (collectively, **Software**) and (vi) other intellectual property, industrial property and proprietary rights and all applications, registrations and grants related thereto; (B) **IP Contracts** shall mean, collectively, any and all agreements pursuant to which rights to any material Intellectual Property are in any manner transferred, conveyed, licensed, granted, restricted or waived; (C) **Registered Intellectual Property** shall mean all registered copyrights and trademarks and all issued Patents; and (D) **Company Intellectual Property** shall mean the Owned Intellectual Property and all other Intellectual Property that is used by or licensed to the Acquired Corporations.

(b) An Acquired Corporation is the owner or joint owner of each item of Intellectual Property in which it has an ownership interest (collectively, the **Company Owned Intellectual Property**), and has the right to use all other Company Intellectual Property, in each case free and clear of all Encumbrances. An Acquired Corporation is listed in the records of the appropriate U.S. and/or non-U.S. Governmental Body as the sole and exclusive owner of record for each registration, grant and application included in the Company Owned Intellectual Property, except as otherwise disclosed in Part 2.9(b) of the Company Disclosure Schedule.

(c) To the Company's Knowledge, the Company Intellectual Property and all of the Acquired Corporations' rights therein, is and are valid and enforceable. To the Company's Knowledge, there are no facts, proceedings, claims or challenges that cause or would cause any Company Intellectual Property to be invalid or unenforceable, or challenging the Acquired Corporations' rights in any Company Intellectual Property, and no Acquired Corporation has received any notice from any Person bringing or threatening to bring such proceedings, claims or challenges. No act has been done or omitted to be done by the Acquired Corporations, which has, had or could have the effect of impairing or dedicating to the public, or entitling any Person to cancel, forfeit, modify or consider abandoned, any Company Owned Intellectual Property, or, except with respect to IP Contracts listed in Part 2.9(a) of the Company Disclosure Schedule, give any Person any rights with respect thereto. All necessary registration, maintenance and renewal fees in respect



**Table of Contents**

of the Company Owned Intellectual Property have been paid and all necessary documents and certificates have been filed with the relevant Governmental Authorities for the purpose of maintaining such Company Owned Intellectual Property. The Acquired Corporations have not divulged, furnished to or made accessible any of their Trade Secrets to any Person who is not subject to an enforceable written agreement to maintain the confidentiality of such Trade Secrets, and the Acquired Corporations otherwise take and have taken reasonable measures to maintain the confidentiality of their Trade Secrets.

(d) To the Company's Knowledge, none of the Acquired Corporations or any of their respective current or contemplated activities, or products misappropriates, violates or otherwise conflicts with, or has infringed, misappropriated or violated, or will infringe, misappropriate or violate any Intellectual Property of any Person, and no Acquired Corporation has received any notice nor are any of them subject to any actual or threatened proceedings claiming or alleging any of the foregoing. No proceedings or claims in which an Acquired Corporation alleges that any Person is infringing, misappropriating or otherwise violating any Owned Intellectual Property are pending, and none have been served by, instituted or asserted by the Acquired Corporations, nor are the Acquired Corporations aware of any such infringement, misappropriation or violation. To the Company's Knowledge, there are no breaches or defaults of, or any disputes or threatened disputes concerning, any of the IP Contracts.

(e) The consummation of the transactions contemplated by this Agreement will not (i) result in the loss of, or otherwise adversely affect, any material rights of the Acquired Corporations in any Company Intellectual Property, or (ii) grant or require any Acquired Corporation to grant to any Person any rights with respect to any Company Intellectual Property, (iii) subject the Acquired Corporations to any increase in royalties or other payments in respect of any Company Intellectual Property, (iv) diminish any royalties or other payments the Company or its Subsidiaries would otherwise be entitled to in respect of any Company Intellectual Property, or (v) result in the material breach or, by the terms of such contract, termination of any Company Contract.

**2.10 Contracts.**

(a) Part 2.10 of the Company Disclosure Schedule identifies each Company Contract that constitutes a Company Material Contract. For purposes of this Agreement, each of the following shall be deemed to constitute a **Company Material Contract** :

(i) any Company Contract: (A) constituting a Company Employee Agreement; (B) pursuant to which any of the Acquired Corporations or Company Affiliates is or may become obligated to make any severance, termination, deferred compensation or similar payment, or provide any post-termination employee benefits (whether cash, equity or otherwise), to any Company Associate or any spouse, heir or Representative of any Company Associate; (C) pursuant to which any of the Acquired Corporations or Company Affiliates is or may become obligated to pay any bonus (including any retention bonus or success bonus) or similar payment (other than payments constituting base salary or commissions paid in the ordinary course of business) in excess of \$100,000 to any Company Associate; (D) pursuant to which any of the Acquired Corporations or Company Affiliates is or may become obligated to accelerate the vesting, exercisability or issuance of, or otherwise modify, any stock option, restricted stock, stock appreciation right or other equity interest in any of the Acquired Corporations; (E) pursuant to which any of the Acquired Corporations or Company Affiliates is or may become obligated to pay or accelerate the vesting or payment of any bonus, tax reimbursement or other payment (whether cash, equity, or otherwise) to any Company Associate as a result of the Merger or any of the other Contemplated Transactions, alone or in combination with any other event; or (F) with any works council, labor union or similar organization or body;

(ii) any Company Contract identified or required to be identified in Part 2.9 of the Company Disclosure Schedule;

(iii) any Company Contract with any distributor and any Company Contract with any other reseller or sales representative that includes any provision with respect to exclusivity;

---

**Table of Contents**

(iv) any Company Contract with any manufacturer, vendor, foundry, or other supplier, including any Company Contract for the performance of services by a third party relating to any Company Intellectual Property or Company Product;

(v) any Company Contract that provides for: (A) reimbursement of any Company Associate for, or advancement to any Company Associate of, legal fees or other expenses associated with any Legal Proceeding or the defense thereof; or (B) indemnification of any Company Associate;

(vi) any Company Contract imposing any restriction on the right or ability of any Acquired Corporation: (A) to compete with any other Person; (B) to acquire any product or other asset or any services from any other Person; (C) to solicit, hire or retain any Person as a director, an officer or other employee, a consultant or an independent contractor; (D) to develop, sell, supply, distribute, offer, support or service any product or any technology or other asset to or for any other Person; (E) to perform services for any other Person; or (F) to transact business with any other Person;

(vii) any Company Contract incorporating or relating to any guaranty, any warranty, any sharing of liabilities or any indemnity (including any indemnity with respect to Intellectual Property) or similar obligation;

(viii) any Company Contract relating to any currency hedging;

(ix) any Company Contract requiring that any of the Acquired Corporations give any notice or provide any information to any Person prior to considering or accepting any Acquisition Proposal or similar proposal, or prior to entering into any discussions, agreement, arrangement or understanding relating to any Acquisition Transaction or similar transaction;

(x) any Company Contract relating to the ownership, lease or sublease of any property that is leased to or controlled, owned or used by any of the Acquired Corporations;

(xi) any Company Contract constituting or relating to a Government Contract or Government Bid that contemplates or involves the payment or delivery of cash or other consideration in an amount or having a value in excess of \$100,000 in the aggregate, or contemplates or involves the performance of services having a value in excess of \$100,000 in the aggregate;

(xii) any Company Contract that contemplates or involves the payment or delivery of cash or other consideration in an amount or having a value in excess of \$100,000 in the aggregate, or contemplates or involves the performance of services having a value in excess of \$100,000 in the aggregate;

(xiii) any Company Contract that has a term of more than one year and that may not be terminated by an Acquired Corporation (without penalty in excess of \$100,000) within 60 days after the delivery of a termination notice by such Acquired Corporation (other than confidentiality or nondisclosure agreements entered into by any Acquired Corporation in the ordinary course of business);

(xiv) any Company Contract that would reasonably be expected to have a material effect on the ability of the Company to perform any of its obligations under this Agreement, or to consummate any of the Contemplated Transactions;

(xv) any Company Contract that provides for: (A) any right of first refusal, right of first negotiation, right of first notification or similar right with respect to any securities or assets of any Acquired Corporation; or (B) any no shop provision or similar exclusivity provision with respect to any securities or assets of any Acquired Corporation; and

(xvi) any other Company Contract that is material to any Acquired Corporation.

The Company has delivered to Parent an accurate and complete copy of each Company Contract that constitutes a Company Material Contract.

(b) Each Company Contract is valid and in full force and effect, and is enforceable in accordance with its terms, subject to: (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.

**Table of Contents**

(c) Except as set forth in Part 2.10(c) of the Company Disclosure Schedule: (i) none of the Acquired Corporations has violated or breached in any material respect, or committed any default in any material respect under, any Company Contract; (ii) to the Knowledge of the Company, no other Person has violated or breached in any material respect, or committed any default in any material respect under, any Company Contract; (iii) to the Knowledge of the Company, no event has occurred, and no circumstance or condition exists, that (with or without notice or lapse of time) would reasonably be expected to: (A) result in a violation or breach in any material respect of any of the provisions of any Company Contract; (B) give any Person the right to declare a default in any material respect under any Company Contract; (C) give any Person the right to receive or require a rebate, chargeback, penalty or change in delivery schedule under any Company Contract; (D) give any Person the right to accelerate the maturity or performance of any Company Contract that constitutes a Company Material Contract; (E) result in the disclosure, release or delivery of any Company Source Code; or (F) give any Person the right to cancel, terminate or modify any Company Contract that constitutes a Company Material Contract; and (iv) since December 31, 2004, none of the Acquired Corporations has received any notice or other communication regarding any actual or possible violation or breach of, or default under, any Company Material Contract.

**2.11 Liabilities.** None of the Acquired Corporations has any accrued, contingent or other liabilities required by GAAP to be set forth on a consolidated balance sheet of the Company or in the notes thereto, except for: (a) liabilities identified as such, or specifically reserved against, in the Most Recent Balance Sheet; (b) normal and recurring current liabilities that have been incurred by the Acquired Corporations since the date of the Most Recent Balance Sheet in the ordinary course of business and consistent with past practices; (c) liabilities for performance of obligations of the Acquired Corporations pursuant to the express terms of Company Contracts; and (d) liabilities described in Part 2.11 of the Company Disclosure Schedule.

**2.12 Compliance with Legal Requirements.**

(a) The Acquired Corporations and Persons acting in concert with or on behalf of the Acquired Corporations are not, nor has any of them since December 31, 2004 been, in violation of any Legal Requirement applicable to the Acquired Corporations or by which any of their respective properties are bound or any regulation issued under any of the foregoing or has been notified in writing by any Governmental Body of any violation, or any investigation with respect to any such Legal Requirement, including Legal Requirements enforced by the United States Food and Drug Administration (the **FDA**), the European Medicines Agency (**EMA**) and other comparable Governmental Authorities (collectively, **Drug Law**), except for any such violation that would not, or would not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect.

(b) The Acquired Corporations have all material registrations, applications, licenses, requests for approvals, exemptions, permits and other regulatory authorizations (**Authorizations**) from Governmental Authorities required to conduct their respective businesses as now being conducted. Such Authorizations are valid and in full force and effect, and the Acquired Corporations and Persons acting in concert with and on behalf of the Acquired Corporations are in compliance in all material respects with all such Authorizations. The Company has provided to Parent all material Authorizations from the FDA and the EMA.

(c) To the Knowledge of the Company, the Acquired Corporations and Persons acting in concert with and on behalf of the Company:

(i) have not used in any capacity the services of any individual or entity debarred, excluded, or disqualified under 21 U.S.C. Section 335a, 42 U.S.C. Section 1320a-7, 21 C.F.R. Section 312.70, or any similar laws, rules or regulations; and

(ii) have not been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment, exclusion, or disqualification under 21 U.S.C. Section 335a, 42 U.S.C. Section 1320a-7, 21 C.F.R. Section 312.70, or any similar laws, rules or regulations.

---

**Table of Contents**

(d) None of the Acquired Corporations, and (to the Knowledge of the Company) no Representative of any of the Acquired Corporations with respect to any matter relating to any of the Acquired Corporations, has: (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (ii) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns or violated any provision of the Foreign Corrupt Practices Act of 1977, as amended; or (iii) made any other unlawful payment.

(e) No product or product candidate manufactured, tested, distributed, held or marketed by or on behalf of any of the Acquired Corporations has been recalled, withdrawn, suspended or discontinued (whether voluntarily or otherwise) since December 31, 2004. At no time since December 31, 2004, has any of the Acquired Corporations received notice that any Governmental Body or institutional review board or comparable body has commenced, or threatened to initiate, any proceeding seeking the recall, market withdrawal, suspension or withdrawal of approval, or seizure of any such product or product candidate; the imposition of material sales, marketing or production restriction on any product or product candidate; or the suspension, termination or other restriction of preclinical or clinical research by or on behalf of any of the Acquired Corporations, including any action regarding any investigator participating in any such research, nor is any such proceeding pending. The Company has, prior to the execution of this Agreement, provided to Parent all information about serious adverse drug experiences since December 31, 2004 obtained or otherwise received by any of the Acquired Corporations from any source, in the United States or outside the United States, including information derived from clinical investigations prior to any market authorization approvals, commercial marketing experience, postmarketing clinical investigations, postmarketing epidemiological/surveillance studies or registries, reports in the scientific literature, and unpublished scientific papers relating to any product or product candidate manufactured, tested, distributed, held or marketed by any of the Acquired Corporations or any of their licensors or licensees in the possession of any of the Acquired Corporations (or to which any of them has access), except for any adverse drug experiences that would not, or would not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect.

(f) None of the Acquired Corporations, or Persons acting in concert with or on behalf of the Acquired Corporations, or any officers, employees or agents of the same has with respect to any product that is manufactured, tested, distributed, held or marketed by or on behalf of any of the Acquired Corporations made an untrue statement of a material fact or fraudulent statement to the FDA, the EMEA or any other Governmental Body, failed to disclose a material fact required to be disclosed to the FDA, the EMEA or any other Governmental Body, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for the EMEA or any other Governmental Body to invoke any similar policy.

(g) All pre-clinical and clinical studies relating to product or product candidates, conducted by or on behalf of the Acquired Corporations have been, or are being, conducted in compliance with the applicable requirements of the FDA's Good Laboratory Practice and Good Clinical Practice requirements, including regulations under 21 C.F.R. Parts 50, 54, 56, 58, 312 and applicable guidance documents, as amended from time to time, the Animal Welfare Act, and all applicable similar requirements in other jurisdictions, and all requirements relating to protection of human subjects.

(h) The Acquired Corporations has filed with the FDA, any other Governmental Authority, and any institutional review board or comparable body, all required notices, supplemental applications, and annual or other reports, including adverse experience reports, with respect to each investigational new drug application or any comparable foreign regulatory application, related to the manufacture, testing, study, or sale of any product or product candidate, as applicable, except as would not reasonably be expected to have a Company Material Adverse Effect.

---

**Table of Contents**

**2.13 Tax Matters.**

(a) Each of the Tax Returns required to be filed by or on behalf of the respective Acquired Corporations with any Governmental Body with respect to any taxable period ending on or before the Closing Date (the **Company Returns**): (i) has been or will be filed on or before the applicable due date (including any extensions of such due date); and (ii) has been, or will be when filed, prepared in all material respects in compliance with all applicable Legal Requirements. All Taxes of all Acquired Corporations, whether or not shown on the Company Returns, due on or before the Closing Date, have been or will be paid on or before the Closing Date.

(b) The Most Recent Balance Sheet fully accrues all actual and contingent liabilities for Taxes with respect to all periods through the date of this Agreement in accordance with GAAP, except for liabilities for Taxes incurred since the date of the Most Recent Balance Sheet in the operation of the business of the Acquired Corporations. The Company will establish, prior to the Closing Date, in the ordinary course of business and consistent with its past practices, reserves adequate for the payment of all Taxes for the period from the date of the Most Recent Balance Sheet through the Closing Date.

(c) No Acquired Corporation and no Company Return is currently being (or since December 31, 2004 has been) audited by any Governmental Body. No extension or waiver of the limitation period applicable to any of the Company Returns has been granted (by the Company or any other Person), and no such extension or waiver has been requested from any Acquired Corporation.

(d) No claim or Legal Proceeding is pending or, to the Knowledge of the Company, has been threatened against or with respect to any Acquired Corporation in respect of any material Tax. There are no unsatisfied liabilities for material Taxes (including liabilities for interest, additions to tax and penalties thereon and related expenses) with respect to any notice of deficiency or similar document received by any Acquired Corporation with respect to any material Tax (other than liabilities for Taxes asserted under any such notice of deficiency or similar document which are being contested in good faith by the Acquired Corporations and with respect to which adequate reserves for payment have been established on the Most Recent Balance Sheet). There are no liens for material Taxes upon any of the assets of any Acquired Corporation except liens for current Taxes not yet due and payable. None of the Acquired Corporations has been, and none of the Acquired Corporations will be, required to include any adjustment in taxable income for any tax period (or portion thereof) pursuant to Section 481 or 263A of the Code (or any comparable provision of state or foreign Tax laws) as a result of transactions or events occurring, or accounting methods employed, prior to the Closing.

(e) No claim has ever been received by an Acquired Corporation from any Governmental Body in a jurisdiction where an Acquired Corporation does not file a Tax Return that an Acquired Corporation is or may be subject to taxation by that jurisdiction which has resulted or would reasonably be expected to result in an obligation by an Acquired Corporation to pay material Taxes.

(f) There are no Company Contracts relating to allocating or sharing of Taxes. None of the Acquired Corporations is liable for Taxes of any other Person, or is currently under any contractual obligation to indemnify any Person with respect to any amounts of such Person's Taxes nor is there any Company Contract providing for payments by an Acquired Corporation with respect to any amount of Taxes of any other Person. For the purposes of this Section 2.13(f), the following Company Contracts shall be disregarded: (i) commercially reasonable Company Contracts providing for the allocation or payment of real property Taxes attributable to real property leased or occupied by any Acquired Corporation and (ii) commercially reasonable Company Contracts for the allocation or payment of personal property Taxes, sales or use Taxes or value added Taxes with respect to personal property leased, used, owned or sold in the ordinary course of business.

(g) No Acquired Corporation has constituted either a distributing corporation or a controlled corporation within the meaning of Section 355(a)(1)(A) of the Code. No Acquired Corporation is or has been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code.

---

**Table of Contents**

(h) No Acquired Corporation has been a member of an affiliated group of corporations within the meaning of Section 1504 of the Code or within the meaning of any similar Legal Requirement to which an Acquired Corporation may be subject, other than the affiliated group of which the Company is the common parent.

(i) The Company has delivered to Parent accurate and complete copies of all Tax Returns of the Acquired Corporations for all Tax years that remain open or are otherwise subject to audit, and all other material Tax Returns of the Acquired Corporations filed since December 31, 2001.

(j) No Acquired Corporation has taken any position on its federal income Tax Returns (whether or not such position has been disclosed on such federal income Tax Returns) that would reasonably be expected to give rise to a material understatement penalty within the meaning of Section 6662 of the Code or any similar Legal Requirement.

(k) No Acquired Corporation has participated in, or is currently participating in, a Listed Transaction or a Reportable Transaction within the meaning of Treasury Regulation Section 1.6011-4(b) or similar transaction under any corresponding or similar Legal Requirement.

**2.14 Employee and Labor Matters; Benefit Plans.**

(a) Except as set forth in Part 2.14(a) of the Company Disclosure Schedule, none of the Acquired Corporations is a party to or bound by, and none of the Acquired Corporations has ever been a party to or bound by, any union contract, collective bargaining agreement or similar Contract.

(b) None of the Acquired Corporations is or has ever been engaged, in any unfair labor practice of any nature. There has never been any slowdown, work stoppage, labor dispute or union organizing activity, or any similar activity or dispute, affecting any of the Acquired Corporations or any of their employees. There is not now pending, and no Person has threatened to commence, any such slowdown, work stoppage, labor dispute or union organizing activity or any similar activity or dispute. No event has occurred, and no condition or circumstance exists, that might directly or indirectly give rise to or provide a basis for the commencement of any such slowdown, work stoppage, labor dispute or union organizing activity or any similar activity or dispute. There are no actions, suits, claims, labor disputes or grievances pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any labor, safety or discrimination matters involving any Company Associate, including charges of unfair labor practices or discrimination complaints.

(c) Part 2.14(c) of the Company Disclosure Schedule contains an accurate and complete list as of the date hereof of each Company Employee Plan and each Company Employee Agreement. None of the Acquired Corporations intends or has agreed or committed to (i) establish or enter into any new Company Employee Plan or Company Employee Agreement, or (ii) modify or terminate any Company Employee Plan or Company Employee Agreement (except to conform any such Company Employee Plan or Company Employee Agreement to the requirements of any applicable Legal Requirements, in each case as previously disclosed to Parent in writing).

(d) The Company has delivered to Parent accurate and complete copies of: (i) all documents embodying or setting forth the terms of each Company Employee Plan and each Company Employee Agreement, including all amendments thereto and all related trust documents; (ii) the three most recent annual reports (Form Series 5500 and all schedules and financial statements attached thereto), if any, required under ERISA, the Code or any other applicable Legal Requirement in connection with each Company Employee Plan; (iii) for each Company Employee Plan that is subject to the minimum funding standards of Section 302 of ERISA, the most recent annual and periodic accounting of Company Employee Plan assets; (iv) the most recent summary plan description together with the summaries of material modifications thereto, if any, required under ERISA with respect to each Company Employee Plan; (v) all material written Contracts relating to each Company Employee Plan, including administrative service agreements and group insurance contracts; (vi) all written materials provided to any Company Associate relating to any Company Employee Plan and any proposed Company Employee Plan, in each case, relating

---

**Table of Contents**

to any amendments, terminations, establishments, increases or decreases in benefits, acceleration of payments or vesting schedules or other events that would result in any liability to any of the Acquired Corporations or any Company Affiliate; (vii) all correspondence to or from any Governmental Body relating to any Company Employee Plan; (viii) all COBRA forms and related notices; (ix) all insurance policies pertaining to fiduciary liability insurance covering the fiduciaries for each Company Employee Plan; (x) all non-discrimination test reports and summaries for each Company Employee Plan for the three most recent plan years; and (xi) the most recent IRS determination or opinion letter issued with respect to each Company Employee Plan intended to be qualified under Section 401(a) of the Code.

(e) Each of the Acquired Corporations and Company Affiliates has performed all material obligations required to be performed by it under each Company Employee Plan and Company Employee Agreement. No Acquired Corporation or Company Affiliate is in default or violation of, and the Company has no Knowledge of any default or violation by any other party to, the terms of any Company Employee Plan or Company Employee Agreement. Each Company Employee Plan and Company Employee Agreement has been established and maintained substantially in accordance with its terms and in substantial compliance with all applicable Legal Requirements, including ERISA and the Code. Any Company Employee Plan intended to be qualified under Section 401(a) of the Code has obtained a favorable determination letter (or opinion letter, if applicable) as to its qualified status under the Code and incorporates or has been amended to incorporate all provisions required to comply with the Tax Reform Act of 1986 and all subsequent legislation. For each Company Employee Plan that is intended to be qualified under Section 401(a) of the Code, there has been no event, condition or circumstance that has adversely affected or is likely to adversely affect its tax-qualified status. No prohibited transaction, within the meaning of Section 4975 of the Code or Sections 406 and 407 of ERISA, that is not otherwise exempt under Section 408 of ERISA, has occurred with respect to any Company Employee Plan. There are no claims or Legal Proceedings pending, or, to the Knowledge of the Company, threatened or reasonably anticipated (other than routine claims for benefits), against any Company Employee Plan or against the assets of any Company Employee Plan. Each Company Employee Plan can be amended, terminated or otherwise discontinued after the Closing in accordance with its terms, without liability to Parent, any of the Acquired Corporations or any Company Affiliate (other than ordinary administration expenses), subject to applicable Legal Requirements. There are no audits, inquiries or Legal Proceedings pending or, to the Knowledge of the Company, threatened by the IRS, the DOL, or any other Governmental Body with respect to any Company Employee Plan or Company Employee Agreement. No Acquired Corporation, and no Company Affiliate, has ever incurred any penalty or tax with respect to any Company Employee Plan under Section 502(i) of ERISA, under Sections 4975 through 4980 of the Code or under any other applicable Legal Requirement. Each of the Acquired Corporations and Company Affiliates has timely made all contributions and other payments required by and due under the terms of each Company Employee Plan and Company Employee Agreement.

(f) Each Company Contract that is a nonqualified deferred compensation plan subject to Section 409A of the Code has been operated since January 1, 2005 in good faith compliance with Section 409A of the Code. No stock right (as defined in U.S. Treasury Department regulation 1.409A-1(l)) has been granted to any Company Associate that (i) has an exercise price that has been or may be less than the fair market value of the underlying equity as of the date such option or right was granted, as determined by the board of directors of the Company in good faith, (ii) has any feature for the deferral of compensation other than the deferral of recognition of income until the later of exercise or disposition of such option or rights, or (iii) has been granted after December 31, 2004, with respect to any class of stock that is not service recipient stock (within the meaning of applicable regulations under Section 409A of the Code). No compensation payable by any of the Acquired Corporations or any of the Company Affiliates shall be or has been reportable as nonqualified deferred compensation in the gross income of any individual or entity as a result of the operation of Section 409A of the Code.

(g) No Acquired Corporation, and no Company Affiliate, has ever maintained, established, sponsored, participated in, or contributed to any:  
(i) Company Pension Plan, including but not limited to, a plan which is subject to Part 3 of Subtitle B of Title I of ERISA, Title IV of ERISA or Section 412 of the Code;

---

**Table of Contents**

(ii) multiemployer plan within the meaning of Section (3)(37) of ERISA; (iii) Company Pension Plan in which stock of any of the Acquired Corporations or any Company Affiliate is or was held as a plan asset, (iv) multiple employer plan or to any plan described in Section 413 of the Code; or (vi) self-insured plan that provides benefits to employees (including any such plan pursuant to which a stop-loss policy or contract applies).

(h) Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby (either alone or in connection with any other event, including any termination of employment or service) will (i) result in any payment (including severance, golden parachute, bonus or otherwise), becoming due to any Company Associate under any Company Employee Plan or Company Employee Agreement, (ii) result in any forgiveness of indebtedness, (iii) materially increase any benefits otherwise payable by the Company under any Company Employee Plan or Company Employee Agreement, (iv) result in the acceleration of the time of payment or vesting of any such benefits except as required under Section 411(d)(3) of the Code or (v) be reasonably likely to result in any payment to any Company Associate being non-deductible by virtue of Section 280G or Section 4999 of the Code. Part 2.14(h) of the Company Disclosure Schedule sets forth the Company Employee Plans and Company Employee Agreements giving rise to the potential excess parachute payments (within the meaning of Section 280G of the Code) payable by the Company or any of its Subsidiaries in connection with the transactions contemplated by this Agreement, either as a result of the transactions contemplated by this Agreement or in conjunction with any other event.

(i) No Company Employee Plan provides (except at no cost to the Acquired Corporations or any Company Affiliate), or reflects or represents any liability of any of the Acquired Corporations or any Company Affiliate to provide, retiree life insurance, retiree health benefits or other retiree employee welfare benefits to any Person for any reason, except as may be required by COBRA or other applicable Legal Requirements. Other than commitments made that involve no future costs to any of the Acquired Corporations or any Company Affiliate, no Acquired Corporation, and no Company Affiliate, has ever represented, promised or contracted (whether in oral or written form) to any Company Employee (either individually or to Company Employees as a group) or any other Person that any such Company Employee or other Person would be provided with retiree life insurance, retiree health benefits or other retiree employee welfare benefits, except to the extent required by applicable Legal Requirements.

(j) Except as set forth in Part 2.14(j) of the Company Disclosure Schedule, and except as expressly required or provided by this Agreement, neither the execution or delivery of this Agreement nor the consummation of any of the Contemplated Transactions will (either alone or upon the occurrence of any additional or subsequent events) constitute an event under any Company Employee Plan, Company Employee Agreement, trust or loan that will or may result (either alone or in connection with any other circumstance or event) in any payment (whether of severance pay or otherwise), acceleration of any right, obligation or benefit, forgiveness of indebtedness, vesting, distribution, increase in benefits or obligation to fund benefits with respect to any Company Employee.

(k) Except as set forth in Part 2.14(k) of the Company Disclosure Schedule, no Acquired Corporation, and no Company Affiliate: (i) has violated or otherwise failed to comply with any Legal Requirement respecting employment, employment practices, terms and conditions of employment or wages and hours, including the health care continuation requirements of COBRA, the requirements of FMLA, the requirements of HIPAA and the provisions of any similar Legal Requirement; (ii) has failed to withhold or report any amounts required by applicable Legal Requirements or by Contract to be withheld or reported with respect to wages, salaries and other payments to Company Employees; (iii) is liable for any arrears of wages or any taxes or any penalty for failure to comply with the Legal Requirements applicable to any of the foregoing; and (iv) is liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body with respect to unemployment compensation benefits, social security or other benefits or obligations for Company Employees (other than routine payments to be made in the normal course of business and consistent with past practice). There are no pending or, to the Knowledge of the Company, threatened or reasonably anticipated claims or Legal Proceedings against any of the Acquired Corporations or any Company Affiliate under any worker's compensation policy or long-term disability policy.



---

**Table of Contents**

(l) To the Knowledge of the Company, no stockholder of the Company, and no current Company Associate, is obligated under any Contract or subject to any Order that would interfere with such Person's efforts to promote the interests of the Acquired Corporations or that would interfere with the businesses of the Acquired Corporations or any Company Affiliate. Neither the execution nor the delivery of this Agreement, nor the carrying on of the business of any of the Acquired Corporations or any Company Affiliate as presently conducted nor any activity of such stockholder or current Company Associate in connection with the carrying on of the business of the Acquired Corporations or any Company Affiliate as presently conducted will, to the Knowledge of the Company, conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default under, any Contract under which any of such stockholders or current Company Associate has any rights or obligations.

**2.15 Environmental Matters.**

(a) Since December 31, 2005, none of the Acquired Corporations has received any notice or other communication, whether from a Governmental Body, citizens group, Company Associate or otherwise, that alleges that any of the Acquired Corporations is not or might not be in compliance with any Environmental Law, and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the compliance by any of the Acquired Corporations with any Environmental Law in the future.

(b) To the Knowledge of the Company, and except as would not reasonably be expected to have or result in a Company Material Adverse Effect: (i) all property that is or was leased to or controlled, owned or used by any of the Acquired Corporations, and all surface water, groundwater, soil and soil vapors associated with or adjacent to such property, is free of any Materials of Environmental Concern (as defined in Section 2.15(d)) or material environmental contamination of any nature; (ii) none of the property that is or was leased to or controlled, owned or used by any of the Acquired Corporations contains any above ground or underground storage tanks, waste treatment systems, asbestos, equipment using PCBs or underground injection wells; and (iii) none of the property that is or was leased to or controlled, owned or used by any of the Acquired Corporations contains any tanks or sumps in which process wastewater or any Materials of Environmental Concern have been Released (as defined in Section 2.15(d)).

(c) No Acquired Corporation has ever sent or transported, or arranged to send or transport, any Materials of Environmental Concern to a site that, pursuant to any applicable Environmental Law: (i) has been placed on the National Priorities List of hazardous waste sites or any similar state list; (ii) is otherwise designated or identified as a potential site for remediation, cleanup, closure or other environmental remedial activity; or (iii) is subject to a Legal Requirement to take removal or remedial action as detailed in any applicable Environmental Law or to make payment for the cost of investigating or conducting any removal or remedial actions at such site.

(d) For purposes of this Agreement: (i) **Environmental Law** means any federal, state, local or foreign Legal Requirement relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface), including any Legal Requirement relating to emissions, discharges, releases or threatened releases of Materials of Environmental Concern, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Materials of Environmental Concern; (ii) **Materials of Environmental Concern** include chemicals, pollutants, contaminants, wastes, toxic substances, petroleum and petroleum products and any other substance that is now or hereafter regulated by any Environmental Law or that is otherwise a danger to health, reproduction or the environment; and (iii) **Release** means any spilling, leaking, emitting, discharging, depositing, escaping, leaching, dumping or other releasing into the environment, whether intentional or unintentional.

**2.16 Insurance.** All fire and casualty, general liability, business interruption, product liability, sprinkler and water damage insurance policies and other forms of insurance maintained by any of the Acquired Corporations have been provided or made available to Parent. To the Knowledge of the Company, each such policy is in full force and effect. All premiums due thereon have been paid in full.

---

**Table of Contents**

**2.17 Related Party Transactions.** Except as set forth in Part 2.17 of the Company Disclosure Schedule: (a) no Related Party has, and no Related Party has had, any direct or indirect interest in any material asset used in or otherwise relating to the business of any of the Acquired Corporations; (b) no Related Party is, or has been, indebted to any of the Acquired Corporations; (c) no Related Party has entered into, or has had any direct or indirect financial interest in, any Company Material Contract, transaction or business dealing involving any of the Acquired Corporations; (d) no Related Party is competing, or has competed, directly or indirectly, with any of the Acquired Corporations; and (e) no Related Party has any claim or right against any of the Acquired Corporations (other than rights under Company Options and rights to receive compensation for services performed as an employee of the Company). (For purposes of this Agreement, each of the following shall be deemed to be a **Related Party** : (i) each individual who is, or who has at any time been, an officer or director of any of the Acquired Corporations; (ii) each member of the immediate family of each of the Persons referred to in clause (i) above; and (iii) any trust or other Entity (other than the Company) in which any one of the Persons referred to in clauses (i) and (ii) above holds (or in which more than one of such individuals collectively hold), beneficially or otherwise, a material voting, proprietary or equity interest).

**2.18 Legal Proceedings; Orders.**

(a) Except as set forth in Part 2.18(a) of the Company Disclosure Schedule, there is no pending Legal Proceeding, and (to the Knowledge of the Company) no Person has threatened to commence any Legal Proceeding: (i) that involves any of the Acquired Corporations, any business of any of the Acquired Corporations or any of the assets owned, leased or used by any of the Acquired Corporations; or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Merger or any of the other Contemplated Transactions. None of the Legal Proceedings identified in Part 2.18(a) of the Company Disclosure Schedule has had or, if adversely determined, would reasonably be expected to have or result in a Company Material Adverse Effect. To the Knowledge of the Company, no event has occurred, and no claim, dispute or other condition or circumstance exists, that would reasonably be expected to give rise to or serve as a basis for the commencement of any Legal Proceeding of the type described in clause (i) or clause (ii) of the first sentence of this Section 2.18(a) .

(b) There is no Order to which any of the Acquired Corporations, or any of the assets owned or used by any of the Acquired Corporations, is subject. To the Knowledge of the Company, no officer or other key employee of any of the Acquired Corporations is subject to any Order that prohibits such officer or other employee from engaging in or continuing any conduct, activity or practice relating to the business of any of the Acquired Corporations.

**2.19 Authority; Binding Nature of Agreement.** The Company has the corporate right, power and authority to enter into and, subject to obtaining the Required Company Stockholder Vote (as defined in Section 2.21), to perform its obligations under this Agreement. The board of directors of the Company (at a meeting duly called and held) has: (a) unanimously determined that the Merger is advisable and fair to, and in the best interests of, the Company and its stockholders; (b) unanimously authorized and approved the execution, delivery and performance of this Agreement by the Company and unanimously approved the Merger; and (c) unanimously recommended the adoption of this Agreement by the holders of Company Capital Stock. This Agreement constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to: (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.

**2.20 Inapplicability of Anti-takeover Statutes.** No state takeover statute or similar Legal Requirement applies or purports to apply to the Merger, this Agreement or any of the Contemplated Transactions.

**2.21 Vote Required.** The affirmative vote of a majority of its outstanding capital stock and the affirmative vote of a majority of the four entities listed on Schedule 2.21 attached hereto (collectively, the **Required Company Stockholder Vote** ) are the only votes of the holders of any class or series of the Company's capital

---

**Table of Contents**

stock necessary to adopt this Agreement. The stockholders of the Company that have entered into and delivered Company Voting Agreements with and in favor of the Parent together hold sufficient shares of Company Capital Stock to deliver the Required Company Stockholder Vote in accordance with such Company Voting Agreements.

**2.22 Non-Contravention; Consents.** Except as set forth in Part 2.22 of the Company Disclosure Schedule, neither (1) the execution, delivery or performance of this Agreement or any of the other Contracts referred to in this Agreement, nor (2) the consummation of the Merger or any of the other Contemplated Transactions will directly or indirectly (with or without notice or lapse of time):

(a) contravene, conflict with or result in a violation of (i) any of the provisions of the certificate of incorporation, bylaws or other charter or organizational documents of any of the Acquired Corporations, or (ii) any resolution adopted by the stockholders, the board of directors or any committee of the board of directors of any of the Acquired Corporations;

(b) contravene, conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge the Merger or any of the other Contemplated Transactions or to exercise any remedy or obtain any relief under, any Legal Requirement or any Order to which any of the Acquired Corporations, or any of the assets owned or used by any of the Acquired Corporations, is subject;

(c) contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by any of the Acquired Corporations or that otherwise relates to the business of any of the Acquired Corporations or to any of the assets owned or used by any of the Acquired Corporations;

(d) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Contract that constitutes a Company Material Contract, or give any Person the right to (i) declare a default or exercise any remedy under any such Company Contract, (ii) a rebate, chargeback, penalty or change in delivery schedule under any such Company Contract, (iii) accelerate the maturity or performance of any obligation under any such Company Contract, or (iv) cancel, terminate or modify any term of any such Company Contract; or

(e) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by any of the Acquired Corporations (except for minor liens that will not, in any case or in the aggregate, materially detract from the value of the assets subject thereto or materially impair the operations of any of the Acquired Corporations).

Except as may be required by the DGCL and except as set forth in Part 2.22 of the Company Disclosure Schedule, none of the Acquired Corporations was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or any of the other Contemplated Transactions, or (y) the consummation of the Merger or any of the other Contemplated Transactions. (For purposes of this Agreement, an Acquired Corporation will be deemed to be or to have been required to obtain a Consent if the failure to obtain such Consent (1) could result in the imposition of any liability or obligation on, or the expansion of any liability or obligation of, any of the Acquired Corporations, (2) could result in the termination, modification or limitation of any contractual or other right of any of the Acquired Corporations, or (3) could otherwise have an adverse effect on the business, condition, capitalization, assets, Intellectual Property, liabilities, results of operations, financial performance or prospects of any of the Acquired Corporations.

**2.23 Financial Advisor.** Except for J.P. Morgan and Cowen and Company, LLC, no broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the Merger or any of the other Contemplated Transactions based upon arrangements made by or on behalf of any of the Acquired Corporations. The Company has furnished to Parent accurate and complete copies of all agreements under which any such fees, commissions or other amounts have been paid or may become payable and all indemnification and other agreements related to the engagement of J.P. Morgan and Cowen and Company, LLC.

---

**Table of Contents**

**2.24 Full Disclosure.**

(a) To the Company's Knowledge, this Agreement (including the Company Disclosure Schedule) does not, and the certificate referred to in Section 6.7 will not: (i) contain any representation, warranty or information that is false, misleading or incomplete with respect to any material fact; or (ii) omit to state any material fact necessary in order to make the representations, warranties and information contained and to be contained herein and therein (in the light of the circumstances under which such representations, warranties and information were or will be made or provided) not false or misleading.

(b) None of the information supplied or to be supplied by or on behalf of the Company for inclusion or incorporation by reference in the Form S-4 Registration Statement will, at the time the Form S-4 Registration Statement is filed with the SEC or at the time it becomes effective under the Securities Act, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading. None of the information supplied or to be supplied by or on behalf of the Company for inclusion or incorporation by reference in the Proxy Statement/Prospectus will, at the time the Proxy Statement/Prospectus is mailed to the stockholders of Parent or at the time the Company Written Consent is executed by Company stockholders sufficient to provide the Required Company Stockholder Vote) or at the time of the Parent Stockholders Meeting (or any adjournment or postponement thereof), contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading.

**Section 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB**

Parent and Merger Sub represent and warrant to the Company as follows (it being understood that each representation and warranty contained in this Section 3 is subject to: (a) the exceptions and disclosures set forth in the part or subpart of the Parent Disclosure Schedule corresponding to the particular Section or subsection in this Section 3 in which such representation and warranty appears; (b) any exceptions or disclosures explicitly cross-referenced in such part or subpart of the Parent Disclosure Schedule by reference to another part or subpart of the Parent Disclosure Schedule; and (c) any exception or disclosure set forth in any of the Parent SEC Documents or other part or subpart of the Parent Disclosure Schedule to the extent it is readily apparent from the wording of such exception or disclosure that such exception or disclosure is intended to qualify such representation and warranty):

**3.1 Due Organization.**

(a) Part 3.1(a) of the Parent Disclosure Schedule identifies each Subsidiary of Parent and indicates its jurisdiction of organization. Neither Parent nor any of the Entities identified in Part 3.1(a) of the Parent Disclosure Schedule owns any capital stock of, or any equity interest of any nature in, any other Entity, other than the Entities identified in Part 3.1(a) of the Parent Disclosure Schedule. None of the Acquiring Corporations has agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity.

(b) Parent is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, Merger Sub is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and Parent and Merger Sub have all necessary power and authority: (i) to conduct their businesses in the manner in which their businesses are currently being conducted; (ii) to own and use their assets in the manner in which their assets are currently owned and used; and (iii) to perform their obligations under all Contracts by which they are bound.

(c) Each of Parent and Merger Sub (in jurisdictions that recognize the following concepts) is qualified to do business as a foreign corporation, and is in good standing, under the laws of all jurisdictions where the nature of its business requires such qualification, except as would not have and would not reasonably be expected to have or result in a Parent Material Adverse Effect.

---

**Table of Contents**

**3.2 Certificate of Incorporation and Bylaws.** The copies of the certificate of incorporation and bylaws of Parent which are incorporated by reference as exhibits to the Parent's Annual Report on Form 10-K for the year ended December 31, 2007 are complete and correct copies of such documents and contain all amendments thereto as in effect on the date of this Agreement. Parent has delivered to the Company accurate and complete copies of: (a) the certificate of incorporation, bylaws and other charter and organizational documents of each Acquiring Corporation, including all amendments thereto; and (b) the minutes and other records of the meetings and other proceedings (including any actions taken by written consent or otherwise without a meeting) of the stockholders of each Acquiring Corporation, the board of directors of each Acquiring Corporation and all committees of the board of directors of each Acquiring Corporation.

**3.3 Capitalization, Etc.**

(a) The authorized capital stock of Parent consists of (i) 100,000,000 shares of Parent Common Stock and (ii) 5,000,000 shares of Parent Preferred Stock. As of the close of business on September 15, 2008: (A) 53,663,805 shares of Parent Common Stock were issued and outstanding; (B) no shares of Parent Preferred Stock were issued or outstanding; (C) no shares of Parent Common Stock were held by Parent in its treasury; (D) there were outstanding Parent Options to purchase 5,594,298 shares of Parent Common Stock, outstanding restricted stock units pursuant to which 27,332 shares of Parent Common Stock are issuable, and 6,806,216 shares of Parent Common Stock were reserved for issuance under the Parent Stock Plans (not including shares issuable pursuant to Parent Options and restricted stock units); and (E) there were outstanding warrants ( **Parent Warrants** ) exercisable for 850,224 shares of Parent Common Stock and such number of shares of Parent Common Stock were reserved for issuance upon conversion of such Parent Warrants. Such issued and outstanding shares of Parent Common Stock have been duly authorized and validly issued, are fully paid and nonassessable, and are free of preemptive rights. During the period from September 15, 2008 to the date of this Agreement, (i) there have been no issuances by Parent of shares of capital stock of Parent other than issuances of capital stock of Parent pursuant to the exercise of Parent Options outstanding on such date and (ii) there have been no issuances of Parent Options or other options, warrants or other rights to acquire capital stock of Parent. Parent has not, subsequent to September 15, 2008, declared or paid any dividend, or declared or made any distribution on, or authorized the creation or issuance of, or issued, or authorized or effected any split-up or any other recapitalization of, any of its capital stock, or directly or indirectly redeemed, purchased or otherwise acquired any of its outstanding capital stock. Parent has not heretofore agreed to take any such action, and there are no outstanding contractual obligations of Parent of any kind to redeem, purchase or otherwise acquire any outstanding shares of capital stock of Parent. Other than the Parent Common Stock, there are no outstanding bonds, debentures, notes or other indebtedness or securities of Parent having the right to vote (or, other than the outstanding Parent Options and warrants, convertible into, or exchangeable for, securities having the right to vote) on any matters on which stockholders of Parent may vote.

(b) Except as set forth in Section 3.3(a), (i) as of September 15, 2008, no shares of capital stock or other voting securities of Parent are issued, reserved for issuance or outstanding, and (ii) there are no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind to which Parent or any of Parent Subsidiaries is a party or by which any of them is bound obligating Parent or any of the Parent Subsidiaries to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other voting securities of Parent or of any of the Parent Subsidiaries or obligating Parent or any of the Parent Subsidiaries to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement or undertaking.

(c) All outstanding shares of Parent Common Stock, and all options and other securities of Parent have been issued and granted in compliance with: (i) all applicable securities laws and other applicable Legal Requirement applicable to Parent; and (ii) all material requirements set forth in applicable Contracts.

---

**Table of Contents****3.4 SEC Filings; Financial Statements.**

(a) Parent has delivered (or made available on the SEC website) to the Company accurate and complete copies of all registration statements, proxy statements and other statements, reports, schedules, forms and other documents filed by Parent with, and all Parent Certifications (as defined below) filed or furnished by Parent with or to, the SEC since December 31, 2005, including all amendments thereto (collectively, the **Parent SEC Documents**). All statements, reports, schedules, forms and other documents required to have been filed or furnished by Parent with or to the SEC since December 31, 2005 have been so filed or furnished on a timely basis. None of Parent's Subsidiaries is required to file or furnish any documents with or to the SEC. As of the time it was filed with or furnished to the SEC: (i) each of the Parent SEC Documents complied as to form in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be); and (ii) none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, except to the extent corrected by the filing or furnishing of the applicable amending or superseding Parent SEC Document. Each of the certifications and statements relating to Parent SEC Documents required by: (1) the SEC's Order dated June 27, 2002 pursuant to Section 21(a)(1) of the Exchange Act (File No. 4-460); (2) Rule 13a-14 or 15d-14 under the Exchange Act; or (3) 18 U.S.C. §1350 (Section 906 of the Sarbanes-Oxley Act) (collectively, the **Parent Certifications**) is accurate and complete, and complied as to form and content with all applicable Legal Requirements in effect at the time such Parent Certification was filed with or furnished to the SEC.

(b) Parent and its Subsidiaries maintain disclosure controls and procedures required by Rule 13a-15 or 15d-15 under the Exchange Act. Such disclosure controls and procedures are designed to ensure that all material information concerning Parent required to be disclosed by Parent in the reports that it is required to file, submit or furnish under the Exchange Act is recorded, processed, summarized and reported on a timely basis to the individuals responsible for the preparation of such reports.

(c) The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii) were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q, Form 8-K or any successor form under the Exchange Act, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that will not, individually or in the aggregate, be material in amount), and (iii) fairly present in all material respects the consolidated financial position of Parent and its Subsidiaries as of the respective dates thereof and the consolidated results of operations and cash flows of Parent and its Subsidiaries for the periods covered thereby. The Acquiring Corporations' Net Cash as of August 31, 2008 was \$64,800,000.

(d) To the Knowledge of Parent, Parent's auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) independent with respect to Parent within the meaning of Regulation S-X under the Exchange Act; and (iii) in compliance with subsections (g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder. All non-audit services (as defined in Section 2(a)(8) of the Sarbanes-Oxley Act) performed by Parent's auditors for Parent or any of its Subsidiaries were approved as required by Section 202 of the Sarbanes-Oxley Act.

**3.5 Absence of Changes.** Except as set forth in Part 3.5 of the Parent Disclosure Schedule, between December 31, 2007 and the date of this Agreement: (a) there has not been any Parent Material Adverse Effect, and no event has occurred or circumstance has arisen that, in combination with any other events or circumstances, would reasonably be expected to have or result in a Parent Material Adverse Effect; (b) there has not been any material loss, damage or destruction to, or any material interruption in the use of, any of the assets

## Table of Contents

of the Acquiring Corporations (whether or not covered by insurance); (c) none of the Acquiring Corporations has made any capital expenditure which, when added to all other capital expenditures made on behalf of the Acquiring Corporations since December 31, 2007, exceeds \$500,000 in the aggregate; (d) none of the Acquiring Corporations has written off as uncollectible, or established any extraordinary reserve with respect to, any account receivable or other indebtedness; (e) none the Acquiring Corporations has entered into any material transaction or taken any other material action outside the ordinary course of business or inconsistent with past practices; (f) none of the Acquiring Corporations has taken any action of the type referred to in Section 4.2(b); and (g) none of the Acquiring Corporations has agreed or committed to take any of the actions referred to in clauses (c) through (f) of this sentence.

**3.6 Title to Assets.** The Acquiring Corporations own, and have good, valid and marketable title to, all assets purported to be owned by them, including: (a) all assets reflected on the unaudited consolidated balance sheet included in Parent's quarterly report on Form 10-Q for the quarter ending on June 30, 2008 as filed with the SEC on July 24, 2008 (the **Parent June 2008 Balance Sheet**), (except for inventory sold or otherwise disposed of in the ordinary course of business since the date of the Parent June 2008 Balance Sheet); and (b) all other assets reflected in the books and records of the Acquiring Corporations as being owned by them. All of said assets are owned by the Acquiring Corporations free and clear of any Encumbrances, except for (i) any lien for current taxes not yet due and payable, (ii) minor liens that have arisen in the ordinary course of business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of the Acquiring Corporations, and (iii) liens described in Part 3.6 of the Parent Disclosure Schedule. The Acquiring Corporations are the lessees of, and hold valid leasehold interests in, all assets purported to have been leased by them, including: (A) all assets reflected as leased on the Parent June 2008 Balance Sheet; and (B) all other assets reflected in the books and records of Parent as being leased to Parent, and Parent enjoys undisturbed possession of such leased assets.

**3.7 Equipment; Leasehold.** All material items of equipment and other tangible assets owned by or leased to the Acquiring Corporations are adequate for the uses to which they are being put, are in good condition and repair (ordinary wear and tear excepted) and are adequate for the conduct of the business of the Acquiring Corporations in the manner in which such businesses are currently being conducted. The Acquiring Corporations do not own any real property or any interest in real property, except for the leaseholds created under the real property leases identified in Part 3.7 of the Parent Disclosure Schedule.

### **3.8 Intellectual Property**

(a) Part 3.8(a) of the Parent Disclosure Schedule sets forth a complete and accurate list as of the date of this Agreement of: (i) all Registered Intellectual Property in which any of the Acquiring Corporations has an ownership interest; and (ii) all IP Contracts relating to Parent Intellectual Property; provided that such list need not include Shrink Wrap Licenses. For purposes of this Agreement the term **Parent Intellectual Property** shall mean all Registered Intellectual Property in which any Acquiring Corporations has an ownership interest and all other Intellectual Property that is used by or licensed to the Acquiring Corporations .

(b) An Acquiring Corporation is the owner or joint owner of each item of Intellectual Property in which it has an ownership interest (collectively, the **Parent Owned Intellectual Property**), and has the right to use all other Parent Intellectual Property, in each case free and clear of all Encumbrances. An Acquiring Corporation is listed in the records of the appropriate U.S. and/or non-U.S. Governmental Body as the sole and exclusive owner of record for each registration, grant and application included in the Parent Owned Intellectual Property, except as otherwise disclosed in Part 3.8(b) of the Parent Disclosure Schedule.

(c) To the Parent's Knowledge, the Parent Intellectual Property and all of the Acquiring Corporations' rights therein, is and are valid and enforceable. To the Parent's Knowledge, there are no facts, proceedings, claims or challenges that cause or would cause any Parent Intellectual Property to be invalid or unenforceable, or challenging the Acquiring Corporations' rights in any Parent Intellectual Property, and no

**Table of Contents**

Acquiring Corporation has received any notice from any Person bringing or threatening to bring such proceedings, claims or challenges. No act has been done or omitted to be done by an Acquiring Corporation, which has, had or could have the effect of impairing or dedicating to the public, or entitling any Person to cancel, forfeit, modify or consider abandoned, any Parent Owned Intellectual Property, or, except with respect to IP Contracts, give any Person any rights with respect thereto. All necessary registration, maintenance and renewal fees in respect of the Parent Owned Intellectual Property have been paid and all necessary documents and certificates have been filed with the relevant Governmental Authorities for the purpose of maintaining such Parent Owned Intellectual Property. No Acquiring Corporation has divulged, furnished to or made accessible any of its Trade Secrets to any Person who is not subject to a written agreement to maintain the confidentiality of such Trade Secrets, and the Acquiring Corporations otherwise take and have taken reasonable measures to maintain the confidentiality of their Trade Secrets.

(d) To the Parent's Knowledge, none of the Acquiring Corporations or any of their respective current or contemplated activities, or products misappropriates, violates or otherwise conflicts with, or has infringed, misappropriated, violated or otherwise conflicted with, or will infringe, misappropriate, violate or otherwise conflict with, any Intellectual Property of any Person, and no Acquiring Corporation has received any notice nor is any of them subject to any actual or threatened proceedings claiming or alleging any of the foregoing. No proceedings or claims in which an the Acquiring Corporation alleges that any Person is infringing, misappropriating or otherwise violating any Parent Owned Intellectual Property are pending, and none have been served by, instituted or asserted by an Acquiring Corporation, nor are the Acquiring Corporations aware of any such infringement, misappropriation or violation. To Parent's Knowledge, there are no breaches or defaults of, or any disputes or threatened disputes concerning, any of the Parent IP Contracts.

(e) The consummation of the transactions contemplated by this Agreement will not (i) result in the loss of, or otherwise adversely affect, any material rights of an Acquiring Corporations in any Parent Intellectual Property, or (ii) grant or require the any Acquiring Corporation to grant to any Person any rights with respect to any Parent Intellectual Property, (iii) subject any the Acquiring Corporation to any increase in royalties or other payments in respect of any Parent Intellectual Property, (iv) diminish any royalties or other payments the Acquiring Corporations would otherwise be entitled to in respect of any Parent Intellectual Property, or (v) result in the material breach or, by the terms of such contract, termination of any IP Contract to which an Acquiring Corporation is a party or is otherwise bound.

**3.9 Material Contracts.** Except for this Agreement, as of the date of this Agreement, Parent is not a party to or bound by any material contract (as such term is defined in Item 601(b)(10) of Regulation S-K promulgated by the SEC) (each a **Parent Material Contract**) that is not filed as an exhibit to a Parent SEC Document.

**3.10 Liabilities.** None of the Acquiring Corporations has any accrued, contingent or other liabilities required by GAAP to be set forth on a consolidated balance sheet of Parent or in the notes thereto, except for: (a) liabilities identified as such, or specifically reserved against, in the Parent June 2008 Balance Sheet; (b) normal and recurring current liabilities that have been incurred by Parent since the date of the Parent June 2008 Balance Sheet in the ordinary course of business and consistent with past practices; (c) liabilities for performance of obligations of the Acquiring Corporations pursuant to the express terms of Contracts to which an Acquiring Corporation is a party or is otherwise bound; and (d) liabilities described in Part 3.10 of the Parent Disclosure Schedule.

**3.11 Compliance with Legal Requirements.**

(a) The Acquiring Corporations and Persons acting in concert with or on behalf of the Acquiring Corporations are not, nor has any of them since December 31, 2004 been, in violation of any Legal Requirement applicable to the Acquiring Corporations or by which any of their respective properties are bound or any regulation issued under any of the foregoing or has been notified in writing by any



---

**Table of Contents**

Governmental Body of any violation, or any investigation with respect to any such Legal Requirement, including Drug Law, except for any such violation that would not, or would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect.

**(b)** The Acquiring Corporations have all material Authorizations from Governmental Authorities required to conduct their business as now being conducted. Such Authorizations are valid and in full force and effect, and the Acquiring Corporations and Persons acting in concert with and on their behalf are in compliance in all material respects with all such Authorizations. Parent has provided to the Company all material Authorizations from the FDA and the EMEA.

**(c)** To the Knowledge of Parent, the Acquiring Corporations and Persons acting in concert with and on behalf of the Acquiring Corporations:

**(i)** have not used in any capacity the services of any individual or entity debarred, excluded, or disqualified under 21 U.S.C. Section 335a, 42 U.S.C. Section 1320a-7, 21 C.F.R. Section 312.70, or any similar laws, rules or regulations; and

**(ii)** have not been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment, exclusion, or disqualification under 21 U.S.C. Section 335a, 42 U.S.C. Section 1320a-7, 21 C.F.R. Section 312.70, or any similar laws, rules regulations.

**(d)** None of the Acquiring Corporations has, and (to the Knowledge of Parent) no Representative of any of the Acquiring Corporations with respect to any matter relating to any of the Acquiring Corporations, has: (a) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns or violated any provision of the Foreign Corrupt Practices Act of 1977, as amended; or (c) made any other unlawful payment.

**(e)** Except as disclosed in the Parent SEC Documents, no product or product candidate manufactured, tested, distributed, held or marketed by or on behalf of the Acquiring Corporations has been recalled, withdrawn, suspended or discontinued (whether voluntarily or otherwise) since December 31, 2004. At no time since December 31, 2004, has any of the Acquiring Corporations received notice that any Governmental Body or institutional review board or comparable body has commenced, or threatened to initiate, any proceeding seeking the recall, market withdrawal, suspension or withdrawal of approval, or seizure of any such product or product candidate; the imposition of material sales, marketing or production restriction on any product or product candidate; or the suspension, termination or other restriction of preclinical or clinical research by or on behalf of any of the Acquiring Corporations, including any action regarding any investigator participating in any such research, nor is any such proceeding pending. Parent has, prior to the execution of this Agreement, provided to Company all information about serious adverse drug experiences since December 31, 2004 obtained or otherwise received by any of the Acquiring Corporations from any source, in the United States or outside the United States, including information derived from clinical investigations prior to any market authorization approvals, commercial marketing experience, postmarketing clinical investigations, postmarketing epidemiological/surveillance studies or registries, reports in the scientific literature, and unpublished scientific papers relating to any product or product candidate manufactured, tested, distributed, held or marketed by any of the Acquiring Corporations or any of their licensors or licensees in the possession of any of the Acquiring Corporations (or to which any of them has access), except for any adverse drug experiences that would not, or would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect.

**(f)** None of the Acquiring Corporations, or Persons acting in concert with or on behalf of the Acquiring Corporations, or any officers, employees or agents of the same has with respect to any product that is manufactured, tested, distributed, held or marketed by or on behalf of any of the Acquiring Corporations made an untrue statement of a material fact or fraudulent statement to the FDA, the EMEA or any other Governmental Body, failed to disclose a material fact required to be disclosed to the FDA, the EMEA or any

---

**Table of Contents**

other Governmental Body, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for the EMEA or any other Governmental Body to invoke any similar policy.

(g) All pre-clinical and clinical studies relating to product or product candidates, conducted by or on behalf of the Acquiring Corporations have been, or are being, conducted in compliance with the applicable requirements of the FDA's Good Laboratory Practice and Good Clinical Practice requirements, including regulations under 21 C.F.R. Parts 50, 54, 56, 58, 312 and applicable guidance documents, as amended from time to time, the Animal Welfare Act, and all applicable similar requirements in other jurisdictions, and all requirements relating to protection of human subjects.

(h) The Acquiring Corporations have filed with the FDA, any other Governmental Authority, and any institutional review board or comparable body, all required notices, supplemental applications, and annual or other reports, including adverse experience reports, with respect to each investigational new drug application or any comparable foreign regulatory application, related to the manufacture, testing, study, or sale of any product or product candidate, as applicable, except as would not reasonably be expected to have a Parent Material Adverse Effect.

**3.12 Tax Matters.**

(a) Each of the Tax Returns required to be filed by or on behalf of the respective Acquiring Corporations with any Governmental Body with respect to any taxable period ending on or before the Closing Date (the **Parent Returns**): (i) has been or will be filed on or before the applicable due date (including any extensions of such due date); and (ii) has been, or will be when filed, prepared in all material respects in compliance with all applicable Legal Requirements. All Taxes of all Acquiring Corporations, whether or not shown on the Parent Returns, due on or before the Closing Date, have been or will be paid on or before the Closing Date.

(b) The Parent June 2008 Balance Sheet fully accrues all actual and contingent liabilities for Taxes with respect to all periods through the date of this Agreement in accordance with GAAP, except for liabilities for Taxes incurred since the date of the Parent June 2008 Balance Sheet in the operation of the business of the Acquiring Corporations. Parent will establish, prior to the Closing Date, in the ordinary course of business and consistent with its past practices, reserves adequate for the payment of all Taxes for the period from the date of the Parent June 2008 Balance Sheet through the Closing Date.

(c) No Acquiring Corporation and no Parent Return is currently being (or since December 31, 2004 has been) audited by any Governmental Body. No extension or waiver of the limitation period applicable to any of the Parent Returns has been granted (by Parent or any other Person), and no such extension or waiver has been requested from any Acquiring Corporation.

(d) No claim or Legal Proceeding is pending or, to the Knowledge of Parent, has been threatened against or with respect to any Acquiring Corporation in respect of any material Tax. There are no unsatisfied liabilities for material Taxes (including liabilities for interest, additions to tax and penalties thereon and related expenses) with respect to any notice of deficiency or similar document received by any Acquiring Corporation with respect to any material Tax (other than liabilities for Taxes asserted under any such notice of deficiency or similar document which are being contested in good faith by an Acquiring Corporations and with respect to which adequate reserves for payment have been established on the Parent June 2008 Balance Sheet). There are no liens for material Taxes upon any of the assets of any Acquiring Corporation except liens for current Taxes not yet due and payable. None of the Acquiring Corporations has been, and none will be, required to include any adjustment in taxable income for any tax period (or portion thereof) pursuant to Section 481 or 263A of the Code (or any comparable provision of state or foreign Tax laws) as a result of transactions or events occurring, or accounting methods employed, prior to the Closing.

---

**Table of Contents**

(e) No claim has ever been received by an Acquiring Corporation from any Governmental Body in a jurisdiction where an Acquiring Corporation does not file a Tax Return that an Acquiring Corporation is or may be subject to taxation by that jurisdiction which has resulted or would reasonably be expected to result in an obligation by an Acquiring Corporation to pay material Taxes.

(f) There are no Contracts relating to allocating or sharing of Taxes to which an Acquiring Corporation is a party or is otherwise bound. None of the Acquiring Corporations is liable for Taxes of any other Person, or is currently under any contractual obligation to indemnify any Person with respect to any amounts of such Person's Taxes or is a party to any Contract providing for payments by an Acquiring Corporation with respect to any amount of Taxes of any other Person. For the purposes of this Section 3.12(f), the following Contracts shall be disregarded: (i) commercially reasonable Contracts providing for the allocation or payment of real property Taxes attributable to real property leased or occupied by an Acquiring Corporation and (ii) commercially reasonable Contracts for the allocation or payment of personal property Taxes, sales or use Taxes or value added Taxes with respect to personal property leased, used, owned or sold in the ordinary course of business.

(g) No Acquiring Corporation has constituted either a distributing corporation or a controlled corporation within the meaning of Section 355(a)(1)(A) of the Code. No Acquiring Corporation is, and no Acquiring Corporation has been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code.

(h) No Acquiring Corporation has been a member of an affiliated group of corporations within the meaning of Section 1504 of the Code or within the meaning of any similar Legal Requirement to which an Acquiring Corporation may be subject, other than the affiliated group of which Parent is the common parent.

(i) Parent has delivered to the Company accurate and complete copies of all Tax Returns of the Acquiring Corporations for all Tax years from and including the tax year ended December 31, 2001.

(j) No Acquiring Corporation has taken any position on its federal income Tax Returns (whether or not such position has been disclosed on such federal income Tax Returns) that would reasonably be expected to give rise to a material understatement penalty within the meaning of Section 6662 of the Code or any similar Legal Requirement.

(k) No Acquiring Corporations has participated in, or is currently participating in, a Listed Transaction or a Reportable Transaction within the meaning of Treasury Regulation Section 1.6011-4(b) or similar transaction under any corresponding or similar Legal Requirement.

**3.13 Employee and Labor Matters; Benefit Plans.**

(a) Except as set forth in Part 3.13(a) of the Parent Disclosure Schedule, no Acquiring Corporation is a party to or bound by, and no Acquiring Corporation has ever been a party to or bound by, any union contract, collective bargaining agreement or similar Contract.

(b) No Acquiring Corporation is, or has ever been engaged in any unfair labor practice of any nature. There has never been any slowdown, work stoppage, labor dispute or union organizing activity, or any similar activity or dispute, affecting the Acquiring Corporations or any of their employees. There is not now pending, and no Person has threatened to commence, any such slowdown, work stoppage, labor dispute or union organizing activity or any similar activity or dispute. No event has occurred, and no condition or circumstance exists, that might directly or indirectly give rise to or provide a basis for the commencement of any such slowdown, work stoppage, labor dispute or union organizing activity or any similar activity or dispute. There are no actions, suits, claims, labor disputes or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any labor, safety or discrimination matters involving any employee of an the Acquiring Corporation, including charges of unfair labor practices or discrimination complaints.

---

**Table of Contents**

(c) Part 3.13(c) of the Parent Disclosure Schedule contains an accurate and complete list as of the date hereof of each Parent Employee Plan and each Parent Employee Agreement. None of the Acquiring Corporations intends or has agreed or committed to (i) establish or enter into any new Parent Employee Plan or Parent Employee Agreement, or (ii) modify or terminate any Parent Employee Plan or Parent Employee Agreement (except to conform any such Parent Employee Plan or Parent Employee Agreement to the requirements of any applicable Legal Requirements, in each case as previously disclosed to the Company in writing).

(d) Parent has made available to the Company accurate and complete copies of: (i) all documents embodying or setting forth the terms of each Parent Employee Plan and each Parent Employee Agreement, including all amendments thereto and all related trust documents; (ii) the three most recent annual reports (Form Series 5500 and all schedules and financial statements attached thereto), if any, required under ERISA, the Code or any other applicable Legal Requirement in connection with each Parent Employee Plan; (iii) for each Parent Employee Plan that is subject to the minimum funding standards of Section 302 of ERISA, the most recent annual and periodic accounting of Parent Employee Plan assets; (iv) the most recent summary plan description together with the summaries of material modifications thereto, if any, required under ERISA with respect to each Parent Employee Plan; (v) all material written Contracts relating to each Parent Employee Plan, including administrative service agreements and group insurance contracts; (vi) all written materials provided to any Parent Associate relating to any Parent Employee Plan and any proposed Parent Employee Plan, in each case, relating to any amendments, terminations, establishments, increases or decreases in benefits, acceleration of payments or vesting schedules or other events that would result in any liability to any of the Acquiring Corporations or any Parent Affiliate; (vii) all correspondence to or from any Governmental Body relating to any Parent Employee Plan; (viii) all COBRA forms and related notices; (ix) all insurance policies pertaining to fiduciary liability insurance covering the fiduciaries for each Parent Employee Plan; (x) all non-discrimination test reports and summaries for each Parent Employee Plan for the three most recent plan years; and (xi) the most recent IRS determination or opinion letter issued with respect to each Parent Employee Plan intended to be qualified under Section 401(a) of the Code.

(e) Each of the Acquiring Corporations and Parent Affiliates has performed all material obligations required to be performed by it under each Parent Employee Plan and Parent Employee Agreement. No Acquiring Corporation or Parent Affiliate is in default or violation of, and Parent has no Knowledge of any default or violation by any other party to, the terms of any Parent Employee Plan or Parent Employee Agreement. Each Parent Employee Plan and Parent Employee Agreement has been established and maintained substantially in accordance with its terms and in substantial compliance with all applicable Legal Requirements, including ERISA and the Code. Any Parent Employee Plan intended to be qualified under Section 401(a) of the Code has obtained a favorable determination letter (or opinion letter, if applicable) as to its qualified status under the Code and incorporates or has been amended to incorporate all provisions required to comply with the Tax Reform Act of 1986 and all subsequent legislation. For each Parent Employee Plan that is intended to be qualified under Section 401(a) of the Code, there has been no event, condition or circumstance that has adversely affected or is likely to adversely affect its tax-qualified status. No prohibited transaction, within the meaning of Section 4975 of the Code or Sections 406 and 407 of ERISA, that is not otherwise exempt under Section 408 of ERISA, has occurred with respect to any Parent Employee Plan. There are no claims or Legal Proceedings pending, or, to the Knowledge of Parent, threatened or reasonably anticipated (other than routine claims for benefits), against any Parent Employee Plan or against the assets of any Parent Employee Plan. Each Parent Employee Plan can be amended, terminated or otherwise discontinued after the Closing in accordance with its terms, without liability to the Company, any of the Acquiring Corporations or any Parent Affiliate (other than ordinary administration expenses), subject to applicable Legal Requirements. There are no audits, inquiries or Legal Proceedings pending or, to the Knowledge of Parent, threatened by the IRS, the DOL, or any other Governmental Body with respect to any Parent Employee Plan or Parent Employee Agreement. No Acquiring Corporation, and no Parent Affiliate, has ever incurred any penalty or tax with respect to any Parent Employee Plan under Section 502(i) of ERISA, under Sections 4975 through 4980 of the Code or under any other applicable Legal Requirement. Each of the Acquiring Corporations and Parent Affiliates have timely made all contributions and other payments required by and due under the terms of each Parent Employee Plan and Parent Employee Agreement.

---

**Table of Contents**

**(f)** Each Contract to which an Acquiring Corporation is a party or is otherwise bound with any individual or entity that is a nonqualified deferred compensation plan subject to Section 409A of the Code has been operated since January 1, 2005 in good faith compliance with Section 409A of the Code. No stock right (as defined in U.S. Treasury Department regulation 1.409A-1(l)) has been granted to any Parent Associate that (i) has an exercise price that has been or may be less than the fair market value of the underlying equity as of the date such option or right was granted, as determined by the board of directors of Parent in good faith, (ii) has any feature for the deferral of compensation other than the deferral of recognition of income until the later of exercise or disposition of such option or rights, or (iii) has been granted after December 31, 2004, with respect to any class of stock that is not service recipient stock (within the meaning of applicable regulations under Section 409A of the Code). No compensation payable by any of the Acquiring Corporations or any of the Parent Affiliates shall be or has been reportable as nonqualified deferred compensation in the gross income of any individual or entity as a result of the operation of Section 409A of the Code.

**(g)** No Acquiring Corporation, and no Parent Affiliate, has ever maintained, established, sponsored, participated in, or contributed to any: (i) Parent Pension Plan, including but not limited to, a plan which is subject to Part 3 of Subtitle B of Title I of ERISA, Title IV of ERISA or Section 412 of the Code; (ii) multiemployer plan within the meaning of Section (3)(37) of ERISA; (iii) Parent Pension Plan in which stock of any of the Acquiring Corporations or any Parent Affiliate is or was held as a plan asset, (iv) multiple employer plan or to any plan described in Section 413 of the Code; or (vi) self-insured plan that provides benefits to employees (including any such plan pursuant to which a stop-loss policy or contract applies).

**(h)** Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby (either alone or in connection with any other event, including any termination of employment or service) will (i) result in any payment (including severance, golden parachute, bonus or otherwise), becoming due to any Parent Associate under any Parent Employee Plan or Parent Employee Agreement, (ii) result in any forgiveness of indebtedness, (iii) materially increase any benefits otherwise payable by Parent under any Parent Employee Plan or Parent Employee Agreement, (iv) result in the acceleration of the time of payment or vesting of any such benefits except as required under Section 411(d)(3) of the Code or (v) be reasonably likely to result in any payment to any Parent Associate being non-deductible by virtue of Section 280G or Section 4999 of the Code. Part 3.13(h) of the Company Disclosure Schedule sets forth the Parent Employee Plans and Parent Employee Agreement giving rise to the potential excess parachute payments (within the meaning of Section 280G of the Code) payable by an Acquiring Corporation in connection with the transactions contemplated by this Agreement, either as a result of the transactions contemplated by this Agreement or in conjunction with any other event.

**(i)** No Parent Employee Plan provides (except at no cost to the Acquiring Corporations or any Parent Affiliate), or reflects or represents any liability of any of the Acquiring Corporations or any Parent Affiliate to provide, retiree life insurance, retiree health benefits or other retiree employee welfare benefits to any Person for any reason, except as may be required by COBRA or other applicable Legal Requirements. Other than commitments made that involve no future costs to any of the Acquiring Corporations or any Parent Affiliate, no Acquiring Corporation, and no Parent Affiliate, has ever represented, promised or contracted (whether in oral or written form) to any Parent Employee (either individually or to Parent Employees as a group) or any other Person that any such Parent Employee or other Person would be provided with retiree life insurance, retiree health benefits or other retiree employee welfare benefits, except to the extent required by applicable Legal Requirements.

**(j)** Except as set forth in Part 3.13(j) of the Parent Disclosure Schedule, and except as expressly required or provided by this Agreement, neither the execution or delivery of this Agreement nor the consummation of any of the Contemplated Transactions will (either alone or upon the occurrence of any additional or subsequent events) constitute an event under any Parent Employee Plan, Parent Employee Agreement, trust or loan that will or may result (either alone or in connection with any other circumstance or event) in any payment (whether of severance pay or otherwise), acceleration of any right, obligation or benefit, forgiveness of indebtedness, vesting, distribution, increase in benefits or obligation to fund benefits with respect to any Parent Employee.

---

**Table of Contents**

(k) Except as set forth in Part 3.13(k) of the Parent Disclosure Schedule, no Acquiring Corporation, and no Parent Affiliate: (i) has violated or otherwise failed to comply with any Legal Requirement respecting employment, employment practices, terms and conditions of employment or wages and hours, including the health care continuation requirements of COBRA, the requirements of FMLA, the requirements of HIPAA and the provisions of any similar Legal Requirement; (ii) has failed to withhold or report any amounts required by applicable Legal Requirements or by Contract to be withheld or reported with respect to wages, salaries and other payments to Parent Employees; (iii) is liable for any arrears of wages or any taxes or any penalty for failure to comply with the Legal Requirements applicable to any of the foregoing; and (iv) is liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body with respect to unemployment compensation benefits, social security or other benefits or obligations for Parent Employees (other than routine payments to be made in the normal course of business and consistent with past practice). There are no pending or, to the Knowledge of Parent, threatened or reasonably anticipated claims or Legal Proceedings against any of the Acquiring Corporations or any Parent Affiliate under any worker's compensation policy or long-term disability policy.

(l) To the Knowledge of Parent, no stockholder of Parent, and no current Parent Associate, is obligated under any Contract or subject to any Order that would interfere with such Person's efforts to promote the interests of the Acquiring Corporations or that would interfere with the businesses of the Acquiring Corporations or any Parent Affiliate. Neither the execution nor the delivery of this Agreement, nor the carrying on of the business of any of the Acquiring Corporations or any Parent Affiliate as presently conducted nor any activity of such stockholder or current Parent Associate in connection with the carrying on of the business of the Acquiring Corporations or any Parent Affiliate as presently conducted will, to the Knowledge of Parent, conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default under, any Contract under which any of such stockholders or current Parent Associate has any rights or obligations.

**3.14 Environmental Matters.**

(a) Since December 31, 2005, no Acquiring Corporation has received any notice or other communication, whether from a Governmental Body, citizens group or otherwise, that alleges that an Acquiring Corporation is not or might not be in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with the compliance by the Acquiring Corporations with any Environmental Law in the future.

(b) To the Knowledge of Parent, and except as would not reasonably be expected to have or result in a Parent Material Adverse Effect: (i) all property that is or was leased to or controlled, owned or used by the Acquiring Corporations, and all surface water, groundwater, soil and soil vapors associated with or adjacent to such property, is free of any Materials of Environmental Concern or material environmental contamination of any nature; (ii) none of the property that is or was leased to or controlled, owned or used by the Acquiring Corporations contains any above ground or underground storage tanks, waste treatment systems, asbestos, equipment using PCBs or underground injection wells; and (iii) none of the property that is or was leased to or controlled, owned or used by the Acquiring Corporations contains any tanks or sumps in which process wastewater or any Materials of Environmental Concern have been Released.

(c) No Acquiring Corporation has ever sent or transported, or arranged to send or transport, any Materials of Environmental Concern to a site that, pursuant to any applicable Environmental Law: (i) has been placed on the National Priorities List of hazardous waste sites or any similar state list; (ii) is otherwise designated or identified as a potential site for remediation, cleanup, closure or other environmental remedial activity; or (iii) is subject to a Legal Requirement to take removal or remedial action as detailed in any applicable Environmental Law or to make payment for the cost of investigating or conducting any removal or remedial actions at such site.

**3.15 Insurance.** All fire and casualty, general liability, business interruption, product liability, sprinkler and water damage insurance policies and other forms of insurance maintained by the Acquiring Corporations have been provided or made available to the Company. To the Knowledge of Parent, each such policy is in full force and effect. All premiums due thereon have been paid in full.

**Table of Contents**

**3.16 Legal Proceedings; Orders.**

(a) Except as set forth in Part 3.16(a) of the Parent Disclosure Schedule or in the Parent SEC Documents, there is no pending Legal Proceeding, and (to the Knowledge of Parent) no Person has threatened to commence any Legal Proceeding: (i) that involves an Acquiring Corporation, any business of an Acquiring Corporation or any of the assets owned, leased or used by an Acquiring Corporation; or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Merger or any of the other Contemplated Transactions. None of the Legal Proceedings identified in Part 3.16(a) of the Parent Disclosure Schedule has had or, if adversely determined, would reasonably be expected to have or result in a Parent Material Adverse Effect. To the Knowledge of Parent, no event has occurred, and no claim, dispute or other condition or circumstance exists, that would reasonably be expected to give rise to or serve as a basis for the commencement of any Legal Proceeding of the type described in clause (i) or clause (ii) of the first sentence of this Section 3.16(a).

(b) There is no Order to which Parent, or any of the assets owned or used by Parent, is subject. To the Knowledge of Parent, no officer or other key employee of an Acquiring Corporation is subject to any Order that prohibits such officer or other employee from engaging in or continuing any conduct, activity or practice relating to the business of the Acquiring Corporations.

**3.17 Authority; Binding Nature of Agreement.** Subject to obtaining the Required Parent Stockholder Vote (as defined in Section 3.19) and the vote of Parent as the sole stockholder of Merger Sub with respect to the Merger, each of Parent and Merger Sub has the corporate right, power and authority to enter into and to perform its obligations under this Agreement. The board of directors of Parent (at a meeting duly called and held or acting by written consent) as of the date of this Agreement has: (a) unanimously determined that the issuance of Parent Common Stock in the Merger and the Charter Amendment are advisable and fair to, and in the best interests of, Parent and its stockholders; (b) unanimously authorized and approved the execution, delivery and performance of this Agreement by Parent and unanimously approved the Merger and the Charter Amendment; and (c) unanimously recommended the approval of the issuance of Parent Common Stock in the Merger and the Charter Amendment by the holders of Parent Common Stock and directed that the issuance of Parent Common Stock in the Merger be submitted for consideration by Parent's stockholders at the Parent Stockholders Meeting. The board of directors of Merger Sub (by unanimous written consent) has: (i) unanimously determined that the Merger is advisable and fair to, and in the best interests of, Merger Sub and its stockholder; (ii) unanimously authorized and approved the execution, delivery and performance of this Agreement by Merger Sub and unanimously approved the Merger; and (iii) unanimously recommended the adoption of this Agreement by the stockholder of Merger Sub and directed that this Agreement and the Merger be submitted for consideration by the stockholder of Merger Sub. This Agreement constitutes the legal, valid and binding obligation of Parent and Merger Sub, enforceable against them in accordance with its terms, subject to: (A) laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (B) rules of law governing specific performance, injunctive relief and other equitable remedies.

**3.18 Inapplicability of Anti-takeover Statutes.** The board of directors of each Acquiring Corporation (at a meeting duly called and held) has, to the extent necessary, adopted a resolution having the effect of causing such Acquiring Corporation not to be subject to any state takeover law or similar Legal Requirement that might otherwise apply to the Merger or any of the other Contemplated Transactions. No state takeover statute or similar Legal Requirement applies or purports to apply to the Merger, this Agreement or any of the Contemplated Transactions.

**3.19 Vote Required.** The only vote of Parent's stockholders required to approve the issuance of Parent Common Stock in the Merger and to approve the Charter Amendment is the affirmative vote of a majority of the outstanding shares of Common Stock of Parent (collectively, the **Required Parent Stockholder Vote** ).

**3.20 Non-Contravention; Consents.** Except as set forth in Part 3.20 of the Parent Disclosure Schedule, neither (1) the execution, delivery or performance of this Agreement or any of the other Contracts referred to in

---

**Table of Contents**

this Agreement, nor (2) the consummation of the Merger or any of the other Contemplated Transactions will directly or indirectly (with or without notice or lapse of time):

(a) contravene, conflict with or result in a violation of: (i) any of the provisions of the certificate of incorporation or bylaws of Parent or Merger Sub; or (ii) any resolution adopted by the stockholders, the board of directors or any committee of the board of directors of Parent or Merger Sub;

(b) contravene, conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge the Merger or any of the other Contemplated Transactions or to exercise any remedy or obtain any relief under, any Legal Requirement or any Order to which the Acquiring Corporations, or any of the assets owned or used by the Acquiring Corporations, is subject;

(c) contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by any of the Acquiring Corporations or that otherwise relates to the business of any of the Acquiring Corporations or to any of the assets owned or used by any of the Acquiring Corporations;

(d) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any such Contract; (ii) a rebate, chargeback, penalty or change in delivery schedule under any such Contract; (iii) accelerate the maturity or performance of any such Parent Material Contract; or (iv) cancel, terminate or modify any right, benefit, obligation or other term of such Parent Material Contract; or

(e) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by any of the Acquiring Corporations (except for minor liens that will not, in any case or in the aggregate, materially detract from the value of the assets subject thereto or materially impair the operations of any of the Acquiring Corporations).

Except as may be required by the Securities Act, Exchange Act, the DGCL and the rules and regulations of Nasdaq, neither Parent nor Merger Sub was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with:

(x) the execution, delivery or performance of this Agreement; or (y) the consummation of the Merger or any of the other Contemplated Transactions.

**3.21 Fairness Opinion.** Parent's board of directors has received the written opinion of Jefferies & Co., Inc., financial advisor to Parent, dated September 24, 2008, to the effect that the Merger Consideration is fair, from a financial point of view, to Parent.

**3.22 Financial Advisor.** Except for Jefferies & Co., Inc., no broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the Merger or any of the other Contemplated Transactions based upon arrangements made by or on behalf of the Acquiring Corporations. Parent has furnished to Company accurate and complete copies of all agreements under which any such fees, commissions or other amounts have been paid or may become payable and all indemnification and other agreements related to the engagement of Jefferies & Co., Inc.

**3.23 Valid Issuance.** The Parent Common Stock to be issued in the Merger, including the Parent Common Stock to be issued upon the exercise of assumed and converted Company Options and Company Warrants, has been duly authorized and will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable and will not be subject to any restriction on resale under the Securities Act, other than restrictions imposed on affiliates of Parent by Rule 144 under the Securities Act.

**3.24 Full Disclosure.**

(a) To Parent's Knowledge, this Agreement (including the Parent Disclosure Schedule) does not, and the certificate referred to in Section 7.6 will not: (i) contain any representation, warranty or information that



---

**Table of Contents**

is false, misleading or incomplete with respect to any material fact; or (ii) omit to state any material fact necessary in order to make the representations, warranties and information contained and to be contained herein and therein (in the light of the circumstances under which such representations, warranties and information were or will be made or provided) not false or misleading.

(b) None of the information to be supplied by or on behalf of Parent for inclusion in the Form S-4 Registration Statement will, at the time the Form S-4 Registration Statement becomes effective under the Securities Act, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading. The Proxy Statement/Prospectus will, at the time the Proxy Statement/Prospectus is mailed to the stockholders of Parent or at the time the Company Written Consent is executed by Company stockholders sufficient to provide the Required Company Stockholder Vote or at the time of the Parent Stockholders Meeting (or any adjournment or postponement thereof), contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading, except that no representation or warranty is made by Parent with respect to statements made or incorporated by reference therein based on information supplied by or on behalf of the Company for inclusion or incorporation by reference in the Proxy Statement/Prospectus. The Proxy Statement/Prospectus will comply as to form in all material respects with the provisions of the Exchange Act and the rules and regulations promulgated by the SEC thereunder.

**SECTION 4. CERTAIN COVENANTS OF THE PARTIES**

**4.1 Access and Investigation.** During the period commencing on the date of this Agreement and ending as of the earlier of the Effective Time or the termination of this Agreement (the **Pre-Closing Period**), each of the Company and Parent shall, and shall cause the respective Representatives of the other party to: (a) provide the other party's Representatives with reasonable access during normal business hours to the Representatives, personnel and assets of such party and its Subsidiaries and to all existing books, records, Tax Returns, work papers and other documents and information relating to such party and its Subsidiaries; and (b) provide the other party's Representatives with such copies of the existing books, records, Tax Returns, work papers and other documents and information relating to such party and its Subsidiaries as the other party may reasonably request.

**4.2 Operations Prior to Closing.**

(a) Except (i) as expressly contemplated or permitted by this Agreement, (ii) as set forth in Section 4.2 of the Company Disclosure Schedule or the Parent Disclosure Schedule, (iii) as required by applicable Legal Requirement; or (iv) as approved in advance by the other party hereto in writing, at all times during the period commencing with the execution and delivery of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to Section 8 and the Effective Time, each of the Company and Parent shall, and each of them shall cause its Subsidiaries to (w) carry on its business in the usual, regular and ordinary course in substantially the same manner as heretofore conducted and in compliance with all applicable Legal Requirements, (x) pay its debts and Taxes when due, in each case subject to good faith disputes over such debts or Taxes, (y) pay or perform all material obligations when due, and (z) use reasonable best efforts, consistent with past practices and policies, to (A) preserve intact its present business organization, (B) keep available the services of its present officers and employees and (C) preserve its relationships with customers, suppliers, distributors, licensors, licensees and others with which it has significant business dealings.

(b) Except (A) as expressly contemplated or permitted by this Agreement, (B) as set forth in Section 4.2 of the Company Disclosure Schedule or the Parent Disclosure Schedule, as the case may be, (C) with respect to the obligations under clauses (viii), (xiii), (xvii), (xviii), and (xxi) below, as contemplated in the Parent Operating Budget or Company Operating Budget, as applicable, but without regard to timing, or (D) with the prior written consent by the other party hereto, which shall not be

---

**Table of Contents**

unreasonably withheld, delayed or conditioned, at all times during the period commencing with the execution and delivery of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to Section 8 and the Effective Time, neither the Company nor Parent shall, nor shall either of them cause or permit any of their respective Subsidiaries to, do any of the following:

(i) propose to adopt any amendments to or amend its certificate of incorporation or bylaws or comparable organizational documents;

(ii) authorize for issuance, issue, sell, deliver or agree or commit to issue, sell or deliver (whether through the issuance or granting of options, warrants, other equity-based (whether payable in cash, securities or other property or any combination of the foregoing) commitments, subscriptions, rights to purchase or otherwise) any of its securities or any securities of any of its Subsidiaries, except for (A) the issuance and sale of shares of common stock pursuant to stock options or restricted stock units outstanding prior to the date hereof, and (B) grants of purchase rights under the Parent's employee stock purchase plan for the three month offering periods commencing September 1, 2008 and December 1, 2008 pursuant to terms substantially similar with respect to the determination of offering price and participation limits as in effect for the offering period commenced September 1, 2008;

(iii) amend any of its securities (including options, warrants and similar rights) or any securities of any of its Subsidiaries; *provided, however*, that nothing in this paragraph (iii) shall prohibit the Company or Parent from dissolving and/or merging into any of its Subsidiaries certain other Subsidiaries that are not material to it and its Subsidiaries, taken as a whole;

(iv) incur any indebtedness or guarantee any indebtedness for borrowed money or issue or sell any debt securities or guarantee any debt securities or other obligations of others or create a Encumbrance over any of its assets;

(v) declare, set aside or pay any dividend or other distribution of property in respect of any shares of capital stock, make any other actual, constructive or deemed distribution of property in respect of the shares of capital stock or effect or commit to any stock repurchase or redemption of its capital stock;

(vi) propose or adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of it or any of its Subsidiaries (other than the transactions contemplated hereby); *provided, however*, that nothing in this paragraph (vi) shall prohibit the Company or Parent from dissolving and/or merging into any of its Subsidiaries certain other Subsidiaries that are not material to it and its Subsidiaries, taken as a whole;

(vii) forgive any loans of any party, including its employees, officers or directors or any employees, officers or directors of any of its Subsidiaries, or any of its Affiliates;

(viii) increase the compensation payable or to become payable to its officers, employees or consultants, or grant any severance or termination pay to, or enter into any severance agreement with any director, officer, consultant or other employee, or establish, adopt, enter into or amend any collective bargaining, bonus, profit sharing, thrift, compensation, stock option, restricted stock, pension, retirement, deferred compensation, employment, termination, severance or other plan, agreement, trust, fund, policy or arrangement for the benefit of any such director, officer, consultant or employee, except the parties may make any amendments to existing employee benefit plans to the extent necessary to maintain their compliance with applicable Legal Requirements (including any amendments necessary or desirable to comply with Section 409A of the Code so as to avoid the imposition of additional Tax with respect thereto) and the parties may make grants of equity awards as provided in Section 4.2(b)(ii) above;

(ix) acquire, sell, lease, license or dispose of any material property or assets in any single transaction or series of related transactions, except for (i) transactions pursuant to existing Contracts, or (ii) transactions in the ordinary course of business consistent with past practice;

(x) except as may be required by applicable Legal Requirements or GAAP, make any change in any of the accounting principles or practices used by it;

---

**Table of Contents**

(xi) make or change any material Tax election, adopt or change any Tax accounting method, settle or compromise any material Tax liability, or consent to the extension or waiver of the limitations period applicable to a material Tax claim or assessment;

(xii) enter into any Company Material Contract or Parent Material Contract, as the case may be;

(xiii) amend in any material respect (other than an amendment where the only material amendment is to the amount to be paid or received by the Company or Parent, as applicable, and does not increase the amount to be so paid, or decrease the amount to be so received, by more than \$100,000) any Company Material Contract or Parent Material Contract, as the case may be, or grant any release or relinquishment of any material rights under any Company Material Contract or Parent Material Contract, as the case may be;

(xiv) sell, assign, transfer, license or sublicense, pledge or otherwise encumber any Company Intellectual Property or Parent Intellectual Property, as applicable (other than non-exclusive licenses in the ordinary course of business consistent with past practice);

(xv) acquire (by merger, consolidation or acquisition of stock or assets) any other Person or any equity interest therein;

(xvi) mortgage, pledge or subject to Encumbrance, any of its assets or properties;

(xvii) authorize, incur or commit to incur any new capital expenditure(s) which in the aggregate exceed \$100,000; *provided, however*, that the foregoing shall not limit any maintenance capital expenditures or capital expenditures required pursuant to existing Contracts;

(xviii) settle or compromise any pending or threatened Legal Proceeding or pay, discharge or satisfy or agree to pay, discharge or satisfy any Liability;

(xix) initiation of any material Legal Proceeding;

(xx) except as required by applicable Legal Requirements or GAAP, revalue in any material respect any of its properties or assets, including writing-off notes or accounts receivable other than in the ordinary course of business consistent with past practice;

(xxi) authorize, incur or commit to any clinical trial or other action that would trigger obligations to make milestone or other payments or commitments which in the aggregate exceed \$100,000; or

(xxii) enter into a Contract to do any of the foregoing or knowingly take any action which is reasonably expected to result in any of the conditions to the consummation of the transactions contemplated hereby not being satisfied, or knowingly take any action which would make any of its representations or warranties set forth in this Agreement untrue or incorrect in any material respect, or that would materially impair its ability to consummate the transactions contemplated by this Agreement in accordance with the terms hereof or materially delay such consummation.

**4.3 Budget.**

(a) Schedule 4.3(a) sets forth a monthly operating budget of the Acquiring Corporations including a budgeted consolidated balance sheet, consolidated statement of operations and consolidated statement of cash flows (the **Parent Operating Budget**) for each month-end through February 28, 2009. Prior to the Closing Date and except with the prior written consent of the Company, Parent will use its reasonable best efforts, and will use its reasonable best efforts to cause the Acquiring Corporations to, control their expenditures and revenues to operate their businesses within the Parent Operating Budget. Within 10 business days of the end of each month Parent shall provide to the Company an unaudited consolidated balance sheet, consolidated statement of operations and consolidated statement of cash flows for the Acquiring Corporations setting forth the actual results for the preceding month, including a comparison to the Parent Operating Budget. The Acquiring Corporations' Net Cash as of the end of each fiscal quarter shall not be less than 95 percent of the Acquiring Corporations' Net Cash amount forecast in the Parent

---

**Table of Contents**

Operating Budget for such time, except with the prior written consent of the Company. If the Closing shall occur more than 45 days after the end of a fiscal quarter, then prior to the Closing, Parent shall provide to the Company an unaudited consolidated balance sheet, consolidated statement of operations and consolidated statement of cash flows for the Acquiring Corporations setting forth the actual results for the period spanning from the start of the current fiscal quarter to the last day of the calendar month ending no less than 10 business days before the Closing (the **Stub Period** ), including a comparison to the Parent Operating Budget. The Acquiring Corporations Net Cash as of the end of the Stub Period shall not be less than 95 percent of the Acquiring Corporations Net Cash amount forecast in the Parent Operating Budget for the Stub Period, except with the prior written consent of the Company.

(b) Schedule 4.3(b) sets forth a monthly operating budget of the Acquired Corporations including a budgeted consolidated balance sheet, consolidated statement of operations and consolidated statement of cash flows (the **Company Operating Budget** ) for each month-end through February 28, 2009. Prior to the Closing Date and except with the prior written consent of Parent, the Company will use its reasonable best efforts, and will use its reasonable best efforts to cause the Acquired Corporations to, control their expenditures and revenues to operate their businesses within the Company Operating Budget. Within 10 business days of the end of each month the Company shall provide to Parent an unaudited consolidated balance sheet, consolidated statement of operations and consolidated statement of cash flows for the Acquired Corporations setting forth the actual results for the preceding month, including a comparison to the Company s Operating Budget. The Acquired Corporations Net Cash as of the end of each fiscal quarter shall be greater than or equal to the Acquired Corporations Net Cash amount forecast in the Company Operating Budget for such time minus \$500,000, except with the prior written consent of Parent. If the Closing shall occur more than 45 days after the end of a fiscal quarter, then prior to the Closing, the Company shall provide to Parent an unaudited consolidated balance sheet, consolidated statement of operations and consolidated statement of cash flows for the Acquired Corporations setting forth the actual results for the Stub Period, including a comparison to the Company Operating Budget. The Acquired Corporations Net Cash as of the end of the Stub Period shall be greater than or equal to the Acquired Corporations Net Cash amount forecast in the Company Operating Budget for the Stub Period minus \$500,000, except with the prior written consent of Parent.

**4.4 No Solicitation.**

(a) During the Pre-Closing Period, neither the Company nor Parent shall, directly or indirectly, and each of the Company and Parent shall ensure that its respective Subsidiaries and the respective Representatives of their respective Subsidiaries do not, directly or indirectly:

(i) solicit, initiate, knowingly encourage, induce or facilitate the making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that would reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry;

(ii) furnish any nonpublic information regarding the Company or Parent, as the case may be, or any of its Subsidiaries, to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;

(iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry;

(iv) approve, endorse or recommend any Acquisition Proposal or Acquisition Inquiry; or

(v) enter into any letter of intent or similar document or any Contract contemplating or otherwise relating to any Acquisition Transaction;

*provided, however*, that prior to the Parent Stockholders Meeting, this Section 4.4(a) shall not prohibit Parent from furnishing nonpublic information regarding the Acquiring Corporations to, or entering into discussions and negotiations with, any Person in response to an Acquisition Proposal made by such Person (and not withdrawn) that constitutes, or would reasonably be expected to result in the submission by such

**Table of Contents**

Person to Parent of, a Parent Superior Offer if: (A) neither Parent nor any Representative of Parent shall have breached any of the provisions set forth in this Section 4.34(a); (B) at least two business days prior to furnishing any such nonpublic information to, or entering into discussions or negotiations with, such Person, Parent gives the Company written notice of the identity of such Person and of Parent's intention to furnish nonpublic information to, or enter into discussions or negotiations with, such Person, and Parent receives from such Person an executed confidentiality agreement; and (C) at least two business days prior to furnishing any such nonpublic information to such Person, Parent furnishes such nonpublic information to the Company (to the extent such nonpublic information has not been previously furnished by Parent to the Company), *and provided, however*, that prior to the receipt of the Company Stockholder Approval, this Section 4.4(a) shall not prohibit the Company from furnishing nonpublic information regarding the Acquired Corporations to, or entering into discussions and negotiations with, any Person in response to an Acquisition Proposal made by such Person (and not withdrawn) that constitutes, or would reasonably be expected to result in the submission by such Person to the Company of, a Company Superior Offer if: (A) neither the Company nor any Representative of Company shall have breached any of the provisions set forth in this Section 4.4(a); (B) at least two days prior to furnishing any such nonpublic information to, or entering into discussions or negotiations with, such Person, the Company gives Parent written notice of the identity of such Person and of the Company's intention to furnish nonpublic information to, or enter into discussions or negotiations with, such Person, and the Company receives from such Person an executed confidentiality agreement; and (C) at least two days prior to furnishing any such nonpublic information to such Person, the Company furnishes such nonpublic information to Parent (to the extent such nonpublic information has not been previously furnished by the Company to Parent).

(b) Each of the Company and Parent shall promptly (and in no event later than 48 hours after receipt of any Acquisition Proposal or Acquisition Inquiry) advise the other party orally and in writing of any Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof) that is made or submitted by any Person during the Pre-Closing Period. Such party shall keep the other party informed with respect to: (i) the status of any such Acquisition Proposal or Acquisition Inquiry; and (ii) the status and terms of any modification or proposed modification thereto.

(c) Each of the Company and Parent shall immediately cease and cause to be terminated any existing discussions with any Person that relate to any Acquisition Proposal or Acquisition Inquiry.

**SECTION 5. ADDITIONAL COVENANTS OF THE PARTIES**

**5.1 Registration Statement; Proxy Statement/Prospectus.**

(a) As promptly as practicable after the date of this Agreement, Parent and the Company shall prepare the Proxy Statement/Prospectus and Parent shall prepare and cause to be filed with the SEC the Proxy Statement/Prospectus and the Form S-4 Registration Statement, in which the Proxy Statement/Prospectus will be included as a prospectus, providing Company (and its counsel) with a reasonable opportunity to review and comment on the Form S-4 Registration Statement prior to it being filed with the SEC. Parent shall use commercially reasonable efforts and the Company shall cooperate with Parent as reasonably requested by Parent: (i) to cause the Form S-4 Registration Statement and the Proxy Statement/Prospectus to comply with the applicable rules and regulations promulgated by the SEC; (ii) to promptly notify the Company of, cooperate with the Company with respect to and respond promptly to any comments of the SEC or its staff; (iii) to have the Form S-4 Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC; and (iv) to keep the Form S-4 Registration Statement effective through the Closing in order to permit the consummation of the Merger. Parent shall use commercially reasonable efforts to cause the Proxy Statement/Prospectus to be mailed to Parent's stockholders, and the Company shall use commercially reasonable efforts to cause the Proxy Statement/Prospectus to be mailed to the Company's stockholders, as promptly as practicable after the Form S-4 Registration Statement is declared effective under the Securities Act. Each of Parent and the Company shall promptly furnish to the other all information concerning such party and its Subsidiaries and stockholders

**Table of Contents**

that may be required or reasonably requested in connection with any action contemplated by this Section 5.1. Notwithstanding the generality of the foregoing, the Company shall provide Parent with all information relating to the Company required to be included in the Form S-4 Registration Statement and the Proxy Statement/Prospectus as soon as is reasonably practicable, but in any event, on or before October 13, 2008, provided that such date shall be extended on a day for day basis based upon any delays by Parent or its advisors in providing Parent valuations or other information required to be included in materials to be furnished by the Company. If either Parent or the Company becomes aware of any information that should be disclosed in an amendment or supplement to the Form S-4 Registration Statement or the Proxy Statement/Prospectus, then such party: (i) shall promptly inform the other party thereof; (ii) shall provide the other party (and its counsel) with a reasonable opportunity to review and comment on any amendment or supplement to the Form S-4 Registration Statement or the Proxy Statement/Prospectus prior to it being filed with the SEC; (iii) shall provide the other party with a copy of such amendment or supplement promptly after it is filed with the SEC; and (iv) shall cooperate, if appropriate, in mailing such amendment or supplement to the stockholders of the Company or the stockholders of Parent.

(b) Prior to the Effective Time, Parent shall use commercially reasonable efforts to obtain all regulatory approvals needed to ensure that the Parent Common Stock to be issued in the Merger will (to the extent required) be registered or qualified or exempt from registration or qualification under the securities law of every state of the United States in which any registered holder of Company Capital Stock has an address of record on the record date for determining the stockholders entitled to consent pursuant to the Company Written Consent; *provided, however*, that Parent shall not be required: (i) to qualify to do business as a foreign corporation in any jurisdiction in which it is not now qualified; or (ii) to file a general consent to service of process in any jurisdiction.

**5.2 Company Stockholder Approval.**

(a) Within 72 hours after Parent has provided the Company notice that the Form S-4 Registration Statement is declared effective, the Company shall solicit and obtain, by written consent (the **Company Written Consent**) of the Company Stockholders in lieu of a meeting pursuant to Section 228 of the DGCL, the Required Company Stockholder Vote for purposes of, (i) adopting this Agreement and approving the Merger, and all other transactions contemplated hereby, (ii) acknowledging that the approval given thereby is irrevocable and that such Company Stockholder is aware of its rights to demand appraisal for its shares pursuant to Section 262 of the DGCL, a copy of which was attached thereto, and that such Company Stockholder has received and read a copy of Section 262 of the DGCL and (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its Company Capital Stock under the DGCL.

(b) Subject to Section 5.2(c): (i) the Proxy Statement/Prospectus shall include a statement to the effect that the board of directors of the Company recommends that the Company's stockholders vote to approve the Merger (the recommendation of the Company's board of directors that the Company's stockholders vote to approve the Merger being referred to as the **Company Board Recommendation**); and (ii) the Company Board Recommendation shall not be withdrawn or modified in a manner adverse to Parent, and no resolution by the board of directors of the Company or any committee thereof to withdraw the Company Board Recommendation or modify the Company Board Recommendation in a manner adverse to Parent shall be adopted. Nothing in this Section 5.2(b) shall preclude the Company from making any accurate and complete public disclosure of any material facts if: (1) the Company's board of directors determines in good faith, after taking into account the advice of the Company's outside legal counsel, that such disclosure is required by the fiduciary duties of the board of directors of the Company or by any Legal Requirement; and (2) the Company shall have provided Parent with reasonable advance notice of the content of such disclosure.

(c) Notwithstanding anything to the contrary contained in Section 5.2(b), at any time prior to the approval of the Merger by the Required Company Stockholder Vote, the Company Board Recommendation may be withdrawn or modified in a manner adverse to Parent if: (i) the Company shall have provided to

---

**Table of Contents**

Parent, at least five business days prior to each meeting of the Company's board of directors at which such board of directors considers the possibility of withdrawing the Company Board Recommendation or modifying the Company Board Recommendation in a manner adverse to Parent, written notice of such meeting together with reasonably detailed information regarding the circumstances giving rise to the consideration of such possibility; and (ii) the Company's board of directors determines in good faith, after taking into account the advice of the Company's outside legal counsel, that the withdrawal or modification of the Company Board Recommendation is required in order for the Company's board of directors to comply with its fiduciary obligations to the Company's stockholders under applicable law. The Company shall notify Parent promptly (and in any event within two hours) of: (A) any withdrawal of or modification to the Company Board Recommendation; and (B) the circumstances surrounding such withdrawal or modification. Subject to Section 8.1(h), if the Company does withdraw or modify the Company Board Recommendation pursuant to this Section 5.2(c), if requested by Parent, the Company shall nonetheless proceed with soliciting the Company Written Consent.

**5.3 Parent Stockholders Meeting.**

(a) Parent shall take all action necessary to call, give notice of and hold a meeting of the holders of Parent Common Stock to vote on the issuance of Parent Common Stock in the Merger and the Charter Amendment (collectively, the **Parent Stockholders Meeting**). The Parent Stockholders Meeting shall be held on a date selected by Parent but no later than 25 business days after the Form S-4 Registration Statement is declared effective. Parent shall ensure that all proxies solicited in connection with the Parent Stockholders Meeting are solicited in compliance with all applicable Legal Requirements.

(b) Subject to Section 5.3(c): (i) the Proxy Statement/Prospectus shall include a statement to the effect that the board of directors of Parent recommends that Parent's stockholders vote to approve the issuance of Parent Common Stock in the Merger and the Charter Amendment (the recommendation of Parent's board of directors that Parent's stockholders vote to approve the issuance of Parent Common Stock in the Merger and the Charter Amendment being referred to as the **Parent Board Recommendation**); and (ii) the Parent Board Recommendation shall not be withdrawn or modified in a manner adverse to the Company, and no resolution by the board of directors of Parent or any committee thereof to withdraw the Parent Board Recommendation or modify the Parent Board Recommendation in a manner adverse to the Company shall be adopted. Nothing in this Section 5.3(b) shall preclude Parent from making any accurate and complete public disclosure of any material facts if: (1) Parent's board of directors determines in good faith, after taking into account the advice of Parent's outside legal counsel, that such disclosure is required by the fiduciary duties of the board of directors of Parent or by any Legal Requirement; and (2) Parent shall have provided the Company with reasonable advance notice of the content of such disclosure.

(c) Notwithstanding anything to the contrary contained in Section 5.3(b), at any time prior to the approval of the issuance of Parent Common Stock in the Merger by the Required Parent Stockholder Vote, the Parent Board Recommendation may be withdrawn or modified in a manner adverse to the Company if: (i) Parent shall have provided to the Company, at least five business days prior to each meeting of Parent's board of directors at which such board of directors considers the possibility of withdrawing the Parent Board Recommendation or modifying the Parent Board Recommendation in a manner adverse to the Company, written notice of such meeting together with reasonably detailed information regarding the circumstances giving rise to the consideration of such possibility; and (ii) Parent's board of directors determines in good faith, after taking into account the advice of Parent's outside legal counsel, that the withdrawal or modification of the Parent Board Recommendation is required in order for Parent's board of directors to comply with its fiduciary obligations to Parent's stockholders under applicable law. Parent shall notify the Company promptly (and in any event within two hours) of: (A) any withdrawal of or modification to the Parent Board Recommendation; and (B) the circumstances surrounding such withdrawal or modification. Subject to Section 8.1(g), if Parent does withdraw or modify the Parent Board Recommendation pursuant to this Section 5.3(c), if requested by the Company, Parent shall nonetheless proceed with the Parent Stockholder meeting to vote on the issuance of Parent Company Stock in the Merger and the Charter Amendment.

---

**Table of Contents****5.4 Stock Options.**

(a) At the Effective Time, without any action on the part of Parent, the Company or the holders of Company Options, except as otherwise required by applicable Legal Requirements, Parent shall assume each Company Option that is then outstanding and unexercised (an **Assumed Company Option**) in accordance with the terms of the Company Option Plan, and Parent's board of directors or a duly authorized committee thereof shall succeed to the authority and responsibility of the Company's board of directors or any committee thereof with respect to each Assumed Company Option. Each Assumed Company Option will continue to have, and be subject to the same terms and conditions of such Company Option (including the terms and conditions of any applicable stock option agreement or other document evidencing such Company Option, if any) immediately prior to the Effective Time (including any repurchase rights or vesting provisions, if applicable), except that (i) each Assumed Company Option will be exercisable (or will become exercisable in accordance with its terms) solely for a number of whole shares of Parent Common Stock equal to the product of (x) the number of shares of Company Common Stock that would be issuable upon exercise of the Assumed Company Option immediately prior to the Effective Time multiplied by the Exchange Ratio, rounded down to the nearest whole number of shares of Parent Common Stock, and (ii) the per share exercise price for the Parent Common Stock issuable upon exercise of such Assumed Company Option will be equal to the quotient equal to (x) the per share exercise price for such Assumed Company Option immediately prior to the Effective Time divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. Each Assumed Company Option shall be vested immediately following the Effective Time as to the same percentage of the total number of shares subject thereto as it was vested as to immediately prior to the Effective Time, except to the extent such Assumed Company Option (either by its terms or by the terms of another Contract) provides for acceleration of vesting thereof. Each Assumed Company Option shall, in accordance with its terms, be subject to further adjustment as determined in the reasonable discretion of Parent's board of directors to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction subsequent to the Effective Time. The exercise price under each Assumed Company Option, the number of shares for which such Assumed Company Option is exercisable and the terms and conditions of exercise of such Assumed Company Option shall be determined in such manner so as to comply to the greatest extent possible with Section 424(a) of the Code and Section 409A of the Code.

(b) Prior to the Effective Time, the Company shall provide notice to each holder of outstanding Company Options describing the treatment of such Company Options in accordance with this Section 5.4. As soon as reasonably practicable following the date hereof and conditional upon the Effective Time, the board of directors of the Company shall make all determinations reasonably necessary under the Company Option Plan to accomplish the transactions contemplated by this Section 5.4 and, to the extent necessary and practicable, to reflect the transactions contemplated by this Agreement, including the Merger. As soon as reasonably practicable following the Effective Time (and in no event later than five business days after the Effective Time), Parent shall issue to each holder of an Assumed Company Option a document evidencing the assumption of the applicable Company Option by Parent as contemplated by this Section 5.4. Subject to the occurrence of the Effective Time, Parent shall take all corporate action reasonably necessary to reserve for issuance a sufficient number of shares of Parent Common Stock for delivery upon exercise of the Assumed Company Options pursuant to the terms set forth in this Section 5.4 and shall, from and after the Effective Time, honor the obligations of the Company to the holders of Assumed Company Options under the Company Option Plan.

(c) Provided that the Company shall first provide to Parent the names of its stockholders and the number of shares of Company Capital Stock or Company Options which may be subject to Section 16b of the Exchange Act and any other information reasonably requested by Parent and relating to the same, the board of directors of Parent shall, prior to the Effective Time, take appropriate action to approve, for purposes of Section 16b of the Exchange Act, the deemed grant of options to purchase Parent Common Stock under the Company Options (as assumed pursuant hereto).



---

**Table of Contents**

(d) Parent shall file with the SEC no later than 10 business days after the Effective Time a registration statement on Form S-8 (or any successor form or other appropriate forms) relating to Parent Common Stock issuable pursuant to the Assumed Company Options and shall use all reasonable efforts to maintain the effectiveness of such registration statement (and maintain the current status of the prospectus or prospectuses contained therein) for so long as such Assumed Company Options remain outstanding. Parent shall use all reasonable efforts to cause shares of Parent Common Stock, when issued upon exercise of Assumed Company Options, to be approved for quotation on Nasdaq Market.

(e) Prior to the Effective Time, the Company shall take all actions that may be necessary (under the Company Option Plan and otherwise) to effectuate the provisions of this Section 5.4 and to ensure that, from and after the Effective Time, holders of Company Options have no rights with respect thereto other than those specifically provided in this Section 5.4.

(f) Prior to the initial filing of the Form S-4 Registration Statement, Parent and the Company, shall each consider in good faith any proposal by the other party to solicit the approval of Parent's stockholders to increase the number of shares issuable pursuant to Parent's 2004 Equity Incentive Plan in connection with the Parent Stockholder Meeting, provided that the failure to mutually agree upon whether to solicit such approval shall not be deemed a breach of any covenant or obligation pursuant to this Agreement or give rise to any party's rights or remedies hereunder.

**5.5 Regulatory Approvals and Related Matters.**

(a) Except as otherwise provided in this Agreement, each party shall use commercially reasonable efforts to file, as soon as practicable after the date of this Agreement, all notices, reports and other documents required to be filed by such party with any Governmental Body with respect to the Merger and the other Contemplated Transactions. Without limiting the generality of the foregoing, the Company and Parent shall, promptly after the date of this Agreement, prepare and file the notifications required under any Legal Requirement that is designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade (collectively, **Antitrust Laws**) in connection with the Contemplated Transactions. The Company and Parent shall use commercially reasonable efforts to respond as promptly as practicable to: (i) any inquiries or requests (including any second request) received from the Federal Trade Commission or the U.S. Department of Justice (**FTC/DOJ**) for additional information or documentation; and (ii) any inquiries or requests received from any state attorney general, foreign antitrust authority or other Governmental Body in connection with antitrust or related matters.

(b) Subject to compliance with applicable Legal Requirements, Parent shall use commercially reasonable efforts to provide to the Company, and the Company shall use commercially reasonable efforts to provide to Parent, as promptly as practicable any information that is required in order to effectuate any filings or applications by Parent or the Company, as the case may be, pursuant to Section 5.5(a). Except where prohibited by applicable Legal Requirements, and subject to the Confidentiality Agreement, each of the Company and Parent shall use commercially reasonable efforts to: (i) consult with and consider the views of the other party regarding material positions being taken in material filings to be made under Antitrust Laws in connection with the Merger; (ii) provide the other (and its counsel) as promptly as practicable with copies of all material filings and material written submissions made by such party with any Governmental Body under any Antitrust Law in connection with the Merger.

(c) Subject to Section 5.5(d), Parent and the Company shall use commercially reasonable efforts to take, or cause to be taken, all actions necessary to consummate the Merger and make effective the other Contemplated Transactions. Without limiting the generality of the foregoing, but subject to Section 5.5(d), each party to this Agreement: (i) shall make all filings (if any) and give all notices (if any) required to be made and given by such party in connection with the Merger and the other Contemplated Transactions; (ii) shall use commercially reasonable efforts to obtain each Consent (if any) required to be obtained (pursuant to any applicable Legal Requirement or Contract, or otherwise) by such party in connection with the Merger; and (iii) shall use commercially reasonable efforts to lift any restraint, injunction or other legal bar to the Merger.

---

**Table of Contents**

(d) Notwithstanding anything to the contrary contained in this Section 5.5 or elsewhere in this Agreement, neither Parent nor Merger Sub shall have any obligation under this Agreement: (i) to divest or agree to divest (or cause any of its Subsidiaries or any of the Acquired Corporations to divest or agree to divest) any of its respective businesses, product lines or assets, or to take or agree to take (or cause any of its Subsidiaries or any of the Acquired Corporations to take or agree to take) any other action or agree (or cause any of its Subsidiaries or any of the Acquired Corporations to agree) to any limitation or restriction on any of its respective businesses, product lines or assets; (ii) to license or otherwise make available (or cause any of its Subsidiaries or any of the Acquired Corporations to license or otherwise make available) to any Person, any Intellectual Property, or to commit to cause any of the Acquired Corporations to license or otherwise make available to any Person any Intellectual Property; or (iii) to contest any Legal Proceeding relating to the Merger or any of the other Contemplated Transactions.

**5.6 Disclosure.** Parent and the Company shall consult with each other before issuing any press release or otherwise making any public statement, and the Company shall consult with Parent and consider the views and comments of Parent before any of the Acquired Corporations or any of their Representatives sends any emails or other documents to Company Associates generally or otherwise communicates with Company Associates generally, with respect to the Merger or any of the other Contemplated Transactions; *provided, however*, that Parent and the Company shall agree on the contents of the press release announcing the execution of this Agreement. Notwithstanding anything to the contrary contained in this Section 5.6, the obligations of Parent and the Company set forth in this Section 5.6 shall not apply with respect to any public statement relating to the withdrawal or modification of the Parent Board Recommendation pursuant to Section 5.3(c).

**5.7 [Reserved.]**

**5.8 Tax Matters.** Prior to the effectiveness of the Form S-4 Registration Statement: (a) the Company shall execute and deliver to Cooley Godward Kronish LLP and to Hogan & Hartson LLP a tax representation letter in a customary form to be mutually agreed to by the parties; and (b) Parent and Merger Sub shall execute and deliver to Cooley Godward Kronish LLP and to Hogan & Hartson LLP a tax representation letter in a customary form to be mutually agreed to by the parties. To the extent requested by Parent or the Company, each of Parent, Merger Sub and the Company shall confirm to Cooley Godward Kronish LLP and to Hogan & Hartson LLP the accuracy and completeness as of the Effective Time of the tax representation letters delivered pursuant to the immediately preceding sentence. Following the delivery of the tax representation letters pursuant to the first sentence of this Section 5.8: (a) Parent shall use commercially reasonable efforts to cause Cooley Godward Kronish LLP to deliver to it a tax opinion satisfying the requirements of Item 601 of Regulation S-K under the Securities Act; and (b) the Company shall use commercially reasonable efforts to cause Hogan & Hartson LLP to deliver to it a tax opinion satisfying the requirements of Item 601 of Regulation S-K under the Securities Act. In rendering such opinion, each of such counsel shall be entitled to rely on the tax representation letters referred to in this Section 5.8.

**5.9 Letter of the Company's Accountants.** The Company shall use commercially reasonable efforts to cause to be delivered to Parent a letter of KPMG LLP, dated no more than two business days before the date on which the Form S-4 Registration Statement becomes effective (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for letters delivered by independent public accountants in connection with registration statements similar to the Form S-4 Registration Statement.

**5.10 Listing.** Parent shall promptly (i) to the extent required by the rules and regulations of the Nasdaq Stock Market LLC ( **Nasdaq** ), prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in the Merger and use its reasonable best efforts to cause such shares to be approved for listing (subject to notice of issuance), and (ii) to the extent required by Nasdaq Marketplace Rule 4340, file an initial listing for the Parent Common Stock on the Nasdaq Market (the **Nasdaq Listing Application** ) and use its reasonable best efforts to cause such Nasdaq Listing Application to be conditionally approved prior to the Effective Time, including without limitation, seeking stockholder approval and committing

**Table of Contents**

to Nasdaq to effect a reverse stock split (the **Reverse Stock Split** ), if necessary, with respect to the then-outstanding shares of Parent Common Stock. In addition to the foregoing, during the Pre-Closing Period, Parent and the Company shall jointly determine (i) a course of action to approach Nasdaq with the objective of obtaining an extension of time (the **Listing Extension** ) for Parent to regain compliance with Marketplace Rule 4450(a)(5) and (ii) the magnitude of the Reverse Stock Split. The Company shall cooperate with Parent as reasonably requested by Parent to cause the Nasdaq Listing Application to be approved and the shares of Parent Common Stock to be issued in the Merger to be approved for listing on the Nasdaq Market and shall promptly furnish to Parent all information concerning the Acquired Corporations and their stockholders that may be required or reasonably requested in connection with any action contemplated by this Section 5.10. Parent shall provide the Company with the opportunity to review, comment on and approve any filings or submissions to be made to Nasdaq and to participate in any proceeding before Nasdaq in connection with any action contemplated by this Section 5.10.

**5.11 Board of Directors; Officers.** Prior to the Parent Stockholders Meeting, Parent shall have taken or caused to be taken all necessary corporate action such that immediately after the Effective Time the board of directors of Parent shall be composed of the persons listed as directors on Schedule 5.11 hereto. Parent and the Company agree that promptly after the Effective Time the senior officers of Parent shall be those persons named as such on Schedule 5.11.

**5.12 Charter Amendments.**

(a) Immediately prior to the Effective Time, Parent shall file an amendment to its amended and restated certificate of incorporation in the form of **Exhibit C** (the **Charter Amendment** ) with the Secretary of State of the State of Delaware to become effective immediately prior to the Effective Time.

(b) On the first business day immediately following the date of this Agreement, Company shall file the Company NPA Charter Amendment with the Secretary of State of the State of Delaware to become effective immediately upon filing.

**5.13 Termination of Company Stockholder and Other Related Agreements.** Prior to the Closing Date, the Company will obtain the necessary written consent of its stockholders to, effective upon the Closing Date, terminate the following agreements: (a) Amended and Restated Shareholders Agreement, (b) Amended and Restated Investor Rights Agreement, (c) Amended and Restated Right of First Refusal and Co-Sale Agreement, and (d) Amended and Restated Voting Agreement.

**5.14 Section 16b.** Prior to the Closing Date and pursuant to Rule 16b-3(d) of the Exchange Act, the board of directors of Parent will adopt a resolution approving the issuance pursuant to the Merger of Parent Common Stock to parties that are or will become officers and directors of Parent and their affiliates so that such issuances are exempt from application of Section 16b of the Exchange Act.

**SECTION 6. CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB**

The obligations of Parent and Merger Sub to cause the Merger to be effected and otherwise cause the Contemplated Transactions to be consummated are subject to the satisfaction, at or prior to the Closing, of each of the following conditions:

**6.1 Accuracy of Company Representations.** Each of the representations and warranties of the Company contained in this Agreement shall have been accurate in all respects as of the date of this Agreement and shall be accurate in all respects as of the Closing Date as if made on and as of the Closing Date (except for any representation or warranty made as of a specific date, which shall have been accurate in all respects as of such date); *provided, however*, that: (a) for purposes of determining accuracy as of the foregoing dates (and for purposes of determining accuracy for purposes of clause (b) of this proviso): (i) all Company Material Adverse Effect qualifications and other materiality qualifications limiting the scope of the representations and warranties of the Company contained in this Agreement shall be disregarded; (ii) all Company Material Adverse

## **Table of Contents**

Effect qualifications and other materiality qualifications limiting the scope of the defined terms used in the representations and warranties of the Company contained in this Agreement shall be disregarded; and (iii) any update of or modification to the Company Disclosure Schedule made or purported to have been made after the execution of this Agreement shall be disregarded; and (b) any inaccuracies in the representations and warranties of the Company contained in this Agreement will be disregarded if such inaccuracies (considered collectively) do not constitute, and would not reasonably be expected to have or result in, a Company Material Adverse Effect.

**6.2 Performance of Covenants.** All of the covenants and obligations in this Agreement that the Company is required to comply with or to perform at or prior to the Closing shall have been complied with and performed in all material respects.

**6.3 Effectiveness of Registration Statement.** The Form S-4 Registration Statement shall have become effective in accordance with the provisions of the Securities Act; no stop order shall have been issued by the SEC and shall remain in effect with respect to the Form S-4 Registration Statement; and no proceeding seeking such a stop order shall have been initiated by the SEC and remain pending or shall be threatened in writing by the SEC.

**6.4 Company Stockholder Approval.** This Agreement shall have been duly adopted and the Merger shall have been duly approved by the Required Company Stockholder Vote.

**6.5 Parent Stockholder Approval.** The issuance of Parent Common Stock in the Merger and the Charter Amendment shall have been duly approved by the Required Parent Stockholder Vote, and the Charter Amendment shall have been accepted for filing by the Secretary of State of the State of Delaware.

**6.6 Consents.** The Consents identified in Part 6 of the Company Disclosure Schedule shall have been obtained and shall be in full force and effect; and all other Consents required to be obtained in connection with the Merger and the other Contemplated Transactions shall have been obtained and shall be in full force and effect, except where the failure to obtain such Consents would not reasonably be expected to have or result in a Company Material Adverse Effect.

**6.7 Documents.** Parent shall have received the following documents, each of which shall be in full force and effect:

(a) a legal opinion of Cooley Godward Kronish LLP, dated as of the Closing Date and addressed to Parent, to the effect that the Merger will constitute a reorganization within the meaning of Section 368 of the Code (it being understood that: (i) in rendering such opinion, Cooley Godward Kronish LLP may rely upon the tax representation letters referred to in Section 5.8; and (ii) if Cooley Godward Kronish LLP does not render such opinion or withdraws or modifies such opinion, this condition shall nonetheless be deemed to be satisfied if Hogan & Hartson LLP renders such opinion to Parent); and

(b) a certificate executed by the Chief Executive Officer and Chief Financial Officer of the Company, in their capacities as such (which certificate shall be in full force and effect), confirming that the conditions set forth in Sections 6.1 (Accuracy of Company Representations), 6.2 (Performance of Covenants), 6.4 (Company Stockholder Approval), 6.6 (Consents) and 6.8 (No Company Material Adverse Effect) have been duly satisfied and certifying, as of immediately prior to the Effective Time, (i) the number of shares of Company Common Stock issued and outstanding immediately prior to the Effective Time, (ii) the number of shares of Company Common Stock issuable upon the conversion of each share of Company Preferred Stock issued and outstanding immediately prior to the Effective Time and that such number of shares has been determined in accordance with provisions of the Company's certificate of incorporation in effect immediately prior to the Effective Time, (iii) the number of Treasury Method Shares of Company Common Stock Outstanding, (iv) the number of shares of Company Common Stock issuable pursuant to or upon conversion of any convertible notes or other rights outstanding as of immediately prior to the Effective Time (whether or not currently exercisable) to acquire shares of Company Capital Stock, *including* the notes issued pursuant to the Note Purchase Agreement and the Company Warrants issued pursuant to the Note

---

**Table of Contents**

Purchase Agreement but *excluding* other Company Warrants and Company Options, or upon conversion of any Company Preferred Stock issuable pursuant to or upon conversion of any such convertible notes or other rights outstanding as of the Effective Time and that such number of shares has been determined in accordance with provisions of the Company's certificate of incorporation in effect immediately prior to the Effective Time, (v) the Exchange Ratio (as determined in accordance with the methodology as set forth in the Spreadsheet), and (vi) the following information with respect to each holder of the securities and rights described in clauses (i) through (iv) of this sentence: (A) such holder's record address, (B) the number of each of such securities and rights held by such holder and, if applicable, the certificate numbers related thereto, (C) the exercise price(s) of each of such holder's Company Options and Company Warrants, (D) the number of shares of Parent Common Stock such holder is entitled to receive pursuant to Section 1.5(a)(iii), (E) the amount of cash such holder is entitled to receive pursuant to Section 1.5(c), and (F) the number of shares of Parent Common Stock into which each of such holder's Company Options and Company Warrants are convertible pursuant to Sections 5.4 and 1.5(d) together with the adjusted exercise price with respect thereto.

**6.8 No Company Material Adverse Effect.** Since the date of this Agreement, there shall not have occurred and be continuing any Company Material Adverse Effect, and no event shall have occurred or circumstance shall exist that, in combination with any other events or circumstances, would reasonably be expected to have or result in a Company Material Adverse Effect.

**6.9 Other Governmental Approvals.** Any Governmental Authorization or other Consent required to be obtained with respect to the Merger under any applicable Antitrust Law shall have been obtained and shall remain in full force and effect, and no such Governmental Authorization or other Consent so obtained shall require or contain any term, limitation, condition or restriction that would reasonably be expected to result in material harm to: (a) Parent or the Company or any Subsidiary of Parent or the Company; (b) any business or material asset of Parent or the Company or any Subsidiary of Parent or the Company; or (c) the future ability or authority of Parent or the Company or any Subsidiary of Parent or the Company to conduct business or to own, operate or retain exclusive rights to any material asset.

**6.10 Listing.** The Nasdaq Listing Application shall have been conditionally approved, and the shares of Parent Common Stock to be issued in the Merger shall be conditionally approved for listing on the Nasdaq Market, both subject only to completion of the Closing and completion by Parent of any reverse stock split required by Nasdaq.

**6.11 No Restraints.** No temporary restraining order, preliminary or permanent injunction or other Order preventing the consummation of the Merger shall have been issued by any court of competent jurisdiction or other Governmental Body and remain in effect, and there shall not be any Legal Requirement enacted or deemed applicable to the Merger that makes consummation of the Merger illegal.

**6.12 No Governmental Litigation.** There shall not be pending or threatened any Legal Proceeding in which a Governmental Body is or is threatened to become a party: (a) challenging or seeking to restrain, prohibit, rescind or unwind the consummation of the Merger or any of the other Contemplated Transactions; (b) relating to the Merger or any of the other Contemplated Transactions and seeking to obtain from Parent or any of the Acquired Corporations any damages or other relief that would reasonably be expected to be material to Parent or the Acquired Corporations; (c) seeking to prohibit or limit in any material respect Parent's ability to vote, transfer, receive dividends with respect to or otherwise exercise ownership rights with respect to the stock of the Surviving Corporation; (d) that could materially and adversely affect the right or ability of Parent or any of the Acquired Corporations to own any of the material assets or operate the business of any of the Acquired Corporations; (e) seeking to compel any of the Acquired Corporations or Acquiring Corporations to dispose of or hold separate any material assets or business as a result of the Merger or any of the other Contemplated Transactions; or (f) seeking to impose (or that could result in the imposition of) any criminal sanctions or liability on Parent or any of the Acquired Corporations.

---

## **Table of Contents**

**6.13 Termination of Company Stockholder and Other Related Agreements.** Prior to the Closing Date, the Company will obtain the necessary written consent of its stockholders to, effective upon the Closing Date, terminate the following agreements: (a) Amended and Restated Shareholders Agreement, (b) Amended and Restated Investor Rights Agreement, (c) Amended and Restated Right of First Refusal and Co-Sale Agreement, and (d) Amended and Restated Voting Agreement.

### **SECTION 7. CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY**

The obligation of the Company to cause the Merger to be effected and otherwise cause the Contemplated Transactions to be consummated is subject to the satisfaction, at or prior to the Closing, of the following conditions:

**7.1 Accuracy of Parent Representations.** Each of the representations and warranties of Parent contained in this Agreement shall have been accurate in all respects as of the date of this Agreement and shall be accurate in all respects as of the Closing Date as if made on and as of the Closing Date (except for any representations and warranties of Parent contained in this Agreement made as of a specific date, which shall have been accurate in all respects as of such date); *provided, however*, that: (a) for purposes of determining the accuracy of the representations and warranties of Parent contained in this Agreement as of the foregoing dates (and for purposes of determining the accuracy of the representations and warranties of Parent contained in this Agreement for purposes of clause (b) of this proviso): (i) all Parent Material Adverse Effect qualifications and other materiality qualifications limiting the scope of the representations and warranties of Parent contained in this Agreement shall be disregarded; (ii) all Parent Material Adverse Effect qualifications and other materiality qualifications limiting the scope of the defined terms used in the representations and warranties of Parent contained in this Agreement shall be disregarded; and (iii) any update of or modification to the Parent Disclosure Schedule made or purported to have been made after the execution of this Agreement shall be disregarded; and (b) any inaccuracies in the representations and warranties of Parent contained in this Agreement will be disregarded if such inaccuracies (considered collectively) do not constitute, and would not reasonably be expected to have or result in, a Parent Material Adverse Effect.

**7.2 Performance of Covenants.** All of the covenants and obligations in this Agreement that Parent and Merger Sub are required to comply with or to perform at or prior to the Closing shall have been complied with and performed in all material respects.

**7.3 Effectiveness of Registration Statement.** The Form S-4 Registration Statement shall have become effective in accordance with the provisions of the Securities Act; no stop order shall have been issued by the SEC and shall remain in effect with respect to the Form S-4 Registration Statement; and no proceeding seeking such a stop order shall have been initiated by the SEC and remain pending or shall be threatened in writing by the SEC.

**7.4 Company Stockholder Approval.** This Agreement shall have been duly adopted and the Merger shall have been duly approved by the Required Company Stockholder Vote.

**7.5 Parent Stockholder Approval.** The issuance of Parent Common Stock in the Merger and the Charter Amendment shall have been duly approved by the Required Parent Stockholder Vote, and the Charter Amendment shall have been accepted for filing by the Secretary of State of the State of Delaware.

**7.6 Documents.** The Company shall have received the following documents:

(a) a legal opinion of Hogan & Hartson LLP, dated as of the Closing Date, to the effect that the Merger will constitute a reorganization within the meaning of Section 368 of the Code (it being understood that: (i) in rendering such opinion, Hogan & Hartson LLP may rely upon the tax representation letters referred to in Section 5.8; and (ii) if Hogan & Hartson LLP does not render such opinion or withdraws or modifies such opinion, this condition shall nonetheless be deemed to be satisfied if Cooley Godward Kronish LLP renders such opinion to the Company); and

---

**Table of Contents**

(b) a certificate executed by an executive officer of Parent, in his or her capacity as such (which certificate shall be in full force and effect), confirming that the conditions set forth in Sections 7.1 (Accuracy of Parent Representations), 7.2 (Performance of Covenants), 7.5 (Parent Stockholder Approval) and 7.7 (No Parent Material Adverse Effect) have been duly satisfied.

**7.7 No Parent Material Adverse Effect.** Since the date of this Agreement, there shall not have occurred and be continuing any Parent Material Adverse Effect, and no event shall have occurred or circumstance shall exist that, in combination with any other events or circumstances, would reasonably be expected to have or result in a Parent Material Adverse Effect.

**7.8 Other Governmental Approvals.** Any Governmental Authorization or other Consent required to be obtained with respect to the Merger under any applicable Antitrust Law shall have been obtained and shall remain in full force and effect, and no such Governmental Authorization or other Consent so obtained shall require or contain any term, limitation, condition or restriction that would reasonably be expected to result in material harm to: (a) Parent or the Company or any Subsidiary of Parent or the Company; (b) any business or material asset of an Acquiring Corporation or an Acquired Corporation; or (c) the future ability or authority of an Acquiring Corporation or an Acquired Corporation to conduct business or to own, operate or retain exclusive rights to any material asset.

**7.9 Listing.** The Nasdaq Listing Application shall have been conditionally approved, and the shares of Parent Common Stock to be issued in the Merger shall be conditionally approved for listing on the Nasdaq Market, both subject only to completion of the Closing and completion by Parent of any reverse stock split required by Nasdaq.

**7.10 No Restraints.** No temporary restraining order, preliminary or permanent injunction or other Order preventing the consummation of the Merger shall have been issued by any court of competent jurisdiction or other Governmental Body and remain in effect, and there shall not be any Legal Requirement enacted or deemed applicable to the Merger that makes consummation of the Merger illegal.

**7.11 No Governmental Litigation.** There shall not be pending or threatened any Legal Proceeding in which a Governmental Body is or is threatened to become a party: (a) challenging or seeking to restrain, prohibit, rescind or unwind the consummation of the Merger or any of the other Contemplated Transactions; (b) relating to the Merger or any of the other Contemplated Transactions and seeking to obtain from Parent or any of the Acquired Corporations any damages or other relief that would reasonably be expected to be material to Parent or the Acquired Corporations; (c) seeking to prohibit or limit in any material respect Parent's ability to vote, transfer, receive dividends with respect to or otherwise exercise ownership rights with respect to the stock of the Surviving Corporation; (d) that could materially and adversely affect the right or ability of Parent or any of the Acquired Corporations to own any of the material assets or operate the business of any of the Acquired Corporations; (e) seeking to compel any of the Acquired Corporations or Acquiring Corporations to dispose of or hold separate any material assets or business as a result of the Merger or any of the other Contemplated Transactions; or (f) seeking to impose (or that could result in the imposition of) any criminal sanctions or liability on Parent or any of the Acquired Corporations.

**SECTION 8. TERMINATION**

**8.1 Termination.** This Agreement may be terminated prior to the Effective Time (whether before or after adoption of this Agreement by the Company's stockholders and whether before or after approval of the issuance of Parent Common Stock in the Merger by Parent's stockholders):

(a) by mutual written consent of Parent and the Company, duly authorized by their respective boards of directors;

(b) by either Parent or the Company if the Merger shall not have been consummated by the End Date (as defined below); *provided, however*, that a party shall not be permitted to terminate this Agreement

**Table of Contents**

pursuant to this Section 8.1(b) if the failure to consummate the Merger by the End Date is attributable to a failure on the part of such party to perform any covenant or obligation in this Agreement required to be performed by such party at or prior to the Effective Time;

(e) by either Parent or the Company if a court of competent jurisdiction or other Governmental Body shall have issued a final and nonappealable Order, or shall have taken any other final and nonappealable action, having the effect of permanently restraining, enjoining or otherwise prohibiting the consummation of the Merger;

(d) by either Parent or the Company if: (i) the Parent Stockholders Meeting (including any adjournments and postponements thereof) shall have been held and Parent's stockholders shall have taken a final vote on the issuance of shares of Parent Common Stock in the Merger; and (ii) the issuance of Parent Common Stock in the Merger shall not have been approved at the Parent Stockholders Meeting (and shall not have been approved at any adjournment or postponement thereof) by the Required Parent Stockholder Vote;

(e) by Parent if: (i) any of the representations and warranties of the Company contained in this Agreement shall have been inaccurate as of the date of this Agreement or shall have become inaccurate as of a date subsequent to the date of this Agreement (as if made on such subsequent date), in each case giving effect to clause (b) of the proviso to Section 6.1, such that the condition set forth in Section 6.1 would not be satisfied (it being understood that, for purposes of determining the accuracy of the representations and warranties of the Company contained in this Agreement as of the date of this Agreement or as of any subsequent date, and for purposes of determining the accuracy of the representations and warranties of the Company contained in this Agreement for purposes of clause (b) of the proviso to Section 6.1; (A) all Company Material Adverse Effect qualifications and other materiality qualifications limiting the scope of the representations and warranties of the Company contained in this Agreement shall be disregarded; (B) all Company Material Adverse Effect qualifications and other materiality qualifications limiting the scope of the defined terms used in the representations and warranties of the Company contained in this Agreement shall be disregarded; and (C) any update of or modification to the Company Disclosure Schedule made or purported to have been made after the execution of this Agreement shall be disregarded); or (ii) any of the Company's covenants or obligations contained in this Agreement shall have been breached such that the condition set forth in Section 6.2 would not be satisfied; *provided, however*, that if an inaccuracy in any of the Company's representations and warranties as of a date subsequent to the date of this Agreement or breach of a covenant or obligation by the Company is curable by the Company, and the Company is continuing to exercise commercially reasonable efforts to cure such inaccuracy or breach, then Parent may not terminate this Agreement under this Section 8.1(f) on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of 30 days commencing on the date that Parent gives the Company notice of such inaccuracy or breach;

(f) by the Company if: (i) any of the representations and warranties of Parent or Merger Sub contained in this Agreement shall have been inaccurate as of the date of this Agreement or shall have become inaccurate as of a date subsequent to the date of this Agreement (as if made on such subsequent date), in each case giving effect to clause (b) of the proviso to Section 7.1, such that the condition set forth in Section 7.1 would not be satisfied (it being understood that, for purposes of determining the accuracy of the representations and warranties of Parent or Merger Sub contained in this Agreement as of the date of this Agreement or as of any subsequent date, and for purposes of determining the accuracy of the representations and warranties of Parent or Merger Sub contained in this Agreement for purposes of clause (b) of the proviso to Section 7.1; (A) all Parent Material Adverse Effect qualifications and other materiality qualifications limiting the scope of the representations and warranties of Parent contained in this Agreement shall be disregarded; (B) all Parent Material Adverse Effect qualifications and other materiality qualifications limiting the scope of the defined terms used in the representations and warranties of Parent contained in this Agreement shall be disregarded; and (C) any update of or modification to the Parent Disclosure Schedule made or purported to have been made after the execution of this Agreement shall be disregarded); or (ii) any of Parent's or Merger Sub's covenants or obligations contained in this Agreement



---

**Table of Contents**

shall have been breached such that the condition set forth in Section 7.2 would not be satisfied; *provided, however*, that if an inaccuracy in any of Parent's or Merger Sub's representations and warranties as of a date subsequent to the date of this Agreement or breach of a covenant or obligation by Parent or Merger Sub is curable by Parent or Merger Sub, and Parent or Merger Sub is continuing to exercise commercially reasonable efforts to cure such inaccuracy or breach, then the Company may not terminate this Agreement under this Section 8.1(g) on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of 30 days commencing on the date that the Company gives Parent notice of such inaccuracy or breach; or

(g) by Parent immediately prior to entering into a definitive agreement with respect to a Parent Superior Offer, provided that (A) subject to the terms of this Agreement, the board of directors of Parent has withdrawn or modified the Parent Board Recommendation in accordance with Section 5.3(c) and authorized Parent to enter into a definitive agreement for a transaction that constitutes a Parent Superior Offer, (B) immediately prior to the termination of this Agreement, Parent pays to the Company the amount payable pursuant to Section 8.3(b) and (C) immediately following such termination Parent enters into a definitive agreement to effect such Parent Superior Offer.

(h) by Company immediately prior to entering into a definitive agreement with respect to a Company Superior Offer, provided that (A) subject to the terms of this Agreement, the board of directors of the Company has withdrawn or modified the Company Board Recommendation in accordance with Section 5.2(c) and authorized the Company to enter into a definitive agreement for a transaction that constitutes a Company Superior Offer, (B) immediately prior to the termination of this Agreement, the Company pays to Parent the amount payable pursuant to Section 8.3(b), and (C) immediately following such termination of the Company enters into a definitive agreement to effect such Company Superior Offer.

(i) by Parent if the Company has not completed the sale and issuance of at least \$8,750,000 in principal amount of convertible notes (for consideration to the Company equal to the principal amount of such notes) pursuant to the terms of the Note Purchase Agreement on or prior to October 14, 2008.

The **End Date** shall be February 28, 2009.

**8.2 Effect of Termination.** In the event of the termination of this Agreement as provided in Section 8.1, this Agreement shall be of no further force or effect; *provided, however*, that: (i) this Section 8.2, Section 8.3 and Section 9 shall survive the termination of this Agreement and shall remain in full force and effect; (ii) the Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force and effect in accordance with their terms; and (iii) the termination of this Agreement shall not relieve any party from any liability for any material breach of any covenant or obligation contained in this Agreement or for any intentional and material breach of any representation or warranty contained in this Agreement.

**8.3 Expenses; Termination Fees.**

(a) Except as set forth in this Section 8.3, all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the party incurring such expenses, whether or not the Merger is consummated; *provided, however*, that Parent and the Company shall share equally all fees and expenses, other than attorneys' fees, incurred in connection with: (i) the filing, printing and mailing of the Form S-4 Registration Statement and the Proxy Statement/Prospectus and any amendments or supplements thereto; and (ii) the filing of any notice or other document under any applicable foreign Antitrust Law.

(b) (i) If this Agreement is terminated by Parent pursuant to Section 8.1(g) or (ii) if: (A) this Agreement is terminated by the Company or Parent pursuant to Section 8.1(d); (B) prior to the Parent Stockholders Meeting an Acquisition Proposal with respect to Parent shall have been publicly made and not withdrawn prior to the Parent Stockholders Meeting; (C) within nine (9) months following such termination, Parent enters into a definitive agreement to consummate an Acquisition Transaction with a party other than

---

**Table of Contents**

the Company; and (D) such Acquisition Transaction is consummated pursuant to such definitive agreement, then Parent shall pay to the Company a nonrefundable fee in the amount of \$947,112 in cash and shall reimburse the Company for up to \$500,000 of actual out of pocket legal, accounting and investment advisory fees paid or payable in connection with the Contemplated Transactions. In the case of clause (ii) of the preceding sentence, such payment shall be made within 24 hours of the consummation referred to in subclause (ii)(D) of the preceding sentence. If this Agreement is terminated by the Company pursuant to Section 8.1(h) or Parent pursuant to Section 8.1(i), then the Company shall pay to Parent a nonrefundable fee in the amount of \$1,922,924 in cash and shall reimburse Parent for up to \$500,000 of actual out of pocket legal, accounting and investment advisory fees paid or payable in connection with the Contemplated Transactions. The total of such payments shall be made within 24 hours of a termination by Parent pursuant to Section 8.1(i).

**SECTION 9. MISCELLANEOUS PROVISIONS**

**9.1 Amendment.** This Agreement may be amended with the approval of the respective boards of directors of the Company and Parent at any time (whether before or after the adoption of this Agreement by the Company's stockholders and whether before or after approval of the issuance of Parent Common Stock in the Merger by Parent's stockholders); *provided, however*, that: (a) after any such adoption of this Agreement by the Company's stockholders, no amendment shall be made which by law requires further approval of the stockholders of the Company without the further approval of such stockholders; and (b) after any such approval of the issuance of Parent Common Stock in the Merger by Parent's stockholders, no amendment shall be made which by law or any rule or regulation of Nasdaq requires further approval of Parent's stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties hereto.

**9.2 Waiver.**

(a) Subject to Sections 9.2(b) and 9.2(c), at any time prior to the Effective Time, any party hereto may: (i) extend the time for the performance of any of the obligations or other acts of the other parties to this Agreement; (ii) waive any inaccuracy in or breach of any representation, warranty, covenant or obligation of the other party in this Agreement or in any document delivered pursuant to this Agreement; and (iii) waive compliance with any covenant, obligation or condition for the benefit of such party contained in this Agreement.

(b) No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

(c) No party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

**9.3 No Survival of Representations and Warranties.** None of the representations and warranties contained in this Agreement or in any certificate delivered pursuant to this Agreement shall survive the Merger.

**9.4 Entire Agreement; Counterparts; Exchanges by Facsimile or Electronic Delivery.** This Agreement and the other agreements, exhibits and disclosure schedules referred to herein constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof; *provided, however*, that the Confidentiality Agreement shall

## **Table of Contents**

not be superseded and shall remain in full force and effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by facsimile or by electronic delivery shall be sufficient to bind the parties to the terms and conditions of this Agreement.

**9.5 Applicable Law; Jurisdiction.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. In any action between any of the parties arising out of or relating to this Agreement or any of the Contemplated Transactions: (a) each of the parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware; and (b) each of the parties irrevocably waives the right to trial by jury.

**9.6 Disclosure Schedules.** The Company Disclosure Schedule shall be arranged in separate parts corresponding to the numbered and lettered sections contained in Section 2. The Parent Disclosure Schedule shall be arranged in separate parts corresponding to the numbered and lettered sections contained in Section 3. For purposes of this Agreement: (a) each statement or other item of information set forth in the Company Disclosure Schedule or in any update to the Company Disclosure Schedule shall be deemed to be a representation and warranty made by the Company in Section 2; and (b) each statement or other item of information set forth in the Parent Disclosure Schedule or in any update to the Parent Disclosure Schedule shall be deemed to be a representation and warranty made by Parent and Merger Sub in Section 3.

**9.7 Attorneys Fees.** In any action at law or suit in equity to enforce this Agreement or the rights of any of the parties hereunder, the prevailing party in such action or suit shall be entitled to receive a reasonable sum for its attorneys fees and all other reasonable costs and expenses incurred in such action or suit.

**9.8 Assignability; No Third Party Rights.** This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties hereto and their respective successors and assigns; *provided, however*, that neither this Agreement nor any party's rights or obligations hereunder may be assigned or delegated by such party without the prior written consent of the other parties, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by any party without the prior written consent of the other parties shall be void and of no effect. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

**9.9 Notices.** All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given or made as follows: (a) if sent by registered or certified mail in the United States return receipt requested, upon receipt; (b) if sent by nationally recognized overnight air courier (such as DHL or Federal Express), two business days after sending; (c) if sent by facsimile transmission before 5:00 p.m., when transmitted and receipt is confirmed; (d) if sent by facsimile transmission after 5:00 p.m. and receipt is confirmed, on the following business day; and (e) if otherwise actually personally delivered, when delivered, provided that such notices, requests, demands and other communications are delivered to the address set forth below, or to such other address as any party shall provide by like notice to the other parties to this Agreement:

if to Parent or Merger Sub:

Nuvelo, Inc.

201 Industrial Road, Suite 310

San Carlos, CA 94070-6211

Attention: Lee Bendekgey

Facsimile: (650) 517-8001

**Table of Contents**

with a copy (which shall not constitute notice) to:

Cooley Godward Kronish LLP

5 Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306

Attention: John Geschke, Esq.

Facsimile: (650) 849-7400

if to the Company:

ARCA biopharma, Inc.

8001 Arista Place, Suite 200

Broomfield, CO 80021

Attention: Chief Executive Officer

Facsimile: (720) 208-9261

with a copy (which shall not constitute notice) to:

Hogan & Hartson LLP

1470 Walnut Street, Suite 200

Boulder, CO 80302

Attention: William R. Roberts, Esq.

Facsimile: (720) 406-5301

**9.10 Cooperation.** Each Party agrees to cooperate fully with Parent and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.

**9.11 Severability.** Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.

**9.12 Construction.**

## Edgar Filing: NUVELO INC - Form S-4/A

(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.

(b) The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.

(c) As used in this Agreement, the words *include* and *including*, and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words *without limitation*.

A-54

**Table of Contents**

(d) Except as otherwise indicated, all references in this Agreement to Sections, Exhibits and Schedules are intended to refer to Sections of this Agreement and Exhibits or Schedules to this Agreement.

(e) The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

*[Remainder of page intentionally left blank]*

A-55

**Table of Contents**

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first above written.

**NUVELO, INC.**

By: /s/ TED W. LOVE  
Name: Ted W. Love  
Title: Chairman of the Board and Chief Executive Officer

**DAWN ACQUISITION SUB, INC.**

By: /s/ LEE BENDEKGEY  
Name: Lee Bendekgey  
Title: Chief Executive Officer

**ARCA BIOPHARMA, INC.**

By: /s/ RICHARD B. BREWER  
Name: Richard B. Brewer  
Title: President and Chief Executive Officer

*Merger Agreement Signature Page*

A-56

---

**Table of Contents**

**EXHIBIT A**

**CERTAIN DEFINITIONS**

For purposes of the Agreement (including this Exhibit A):

**Acquired Corporations.** Acquired Corporations shall mean: (a) the Company; (b) each of the Company's Subsidiaries; and (c) any other Entity that has been merged with or into, or that is a predecessor to, any of the Entities identified in clauses (a) or (b) above.

**Acquiring Corporations.** Acquiring Corporations shall mean (a) Parent; (b) each of Parent's Subsidiaries; and (c) any other Entity that has been merged with or into, or that is a predecessor to, any of the Entities identified in clauses (a) or (b) above.

**Acquired Corporations Net Cash.** Acquired Corporations Net Cash shall mean the Acquired Corporations' cash and cash-equivalents, marketable securities, restricted cash, collaboration receivables and other current assets minus the sum of the Acquired Corporations' accounts payable, accrued compensation and employee benefits, accrued clinical trial and drug manufacturing costs and other current accrued liabilities, including accrued audit, tax, legal and research fees and use tax, all determined in a manner consistent with the manner in which such items were determined for the Most Recent Balance Sheet.

**Acquiring Corporations Net Cash.** Acquiring Corporations Net Cash shall mean the Acquiring Corporations' cash and cash-equivalents, marketable securities, restricted cash, collaboration receivables and other current assets minus the sum of the Acquiring Corporations' accounts payable, accrued compensation and employee benefits, accrued clinical trial and drug manufacturing costs and other current accrued liabilities, including accrued audit, tax, legal and research fees and use tax, all determined in a manner consistent with the manner in which such items were determined for the Parent June 2008 Balance Sheet.

**Acquisition Inquiry.** Acquisition Inquiry shall mean an inquiry, indication of interest or request for nonpublic information (other than an inquiry, indication of interest or request for information made or submitted by Parent or the Company, as the case may be) that would reasonably be expected to lead to an Acquisition Proposal.

**Acquisition Proposal.** Acquisition Proposal shall mean any offer or proposal (other than an offer or proposal made or submitted by Parent or the Company, as the case may be) contemplating or otherwise relating to any Acquisition Transaction.

**Acquisition Transaction.** Acquisition Transaction shall mean any transaction or series of transactions involving:

(a) any merger, exchange, consolidation, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, takeover offer, tender offer, exchange offer or other similar transaction: (i) in which the Company or Parent, as the case may be or any material Subsidiary of the Company or Parent, as the case may be is a constituent corporation or is otherwise involved; (ii) in which a Person or group (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding voting securities of the Company or Parent, as the case may be or any material Subsidiary of the Company or Parent, as the case may be; or (iii) in which the Company or Parent, as the case may be, or any of its material Subsidiaries issues securities representing more than 20% of the outstanding voting securities of the Company or such material Subsidiary of the Company;

(b) any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated net revenues, consolidated net income or consolidated assets of the Company and its Subsidiaries or Parent and its Subsidiaries, as the case may be; or



**Table of Contents**

(c) any liquidation or dissolution of the Company or any of its material Subsidiaries or Parent or any of its material Subsidiaries, as the case may be.

For purposes of the preceding sentence, a **material Subsidiary** shall mean any Subsidiary of the applicable party that, together with all Subsidiaries of such Subsidiary on a consolidated basis, accounts for 20% or more of the consolidated net revenues, consolidated net income or consolidated assets of such party and its Subsidiaries, taken together as a whole.

**Agreement.** Agreement shall mean the Agreement and Plan of Merger and Reorganization to which this Exhibit A is attached, as it may be amended from time to time.

**COBRA.** COBRA shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

**Code.** Code shall mean the United States Internal Revenue Code of 1986, as amended.

**Company Affiliate.** Company Affiliate shall mean any Person under common control with any of the Acquired Corporations or required to be aggregated with any of the Acquired Corporations within the meaning of Section 414(b), Section 414(c), Section 414(m) or Section 414(o) of the Code, and the regulations issued thereunder.

**Company Associate.** Company Associate shall mean any current or former officer or other employee, or current or former independent contractor, consultant or director, of or to any of the Acquired Corporations or any Company Affiliate.

**Company Capital Stock.** Company Capital Stock shall mean the Company Common Stock and the Company Preferred Stock.

**Company Common Stock.** Company Common Stock shall mean the Common Stock, \$0.001 par value per share, of the Company.

**Company Contract.** Company Contract shall mean any Contract: (a) to which any of the Acquired Corporations is a party; (b) by which any of the Acquired Corporations or any Company Intellectual Property or any other asset of any of the Acquired Corporations is or may become bound or under which any of the Acquired Corporations has, or may become subject to, any obligation; or (c) under which any of the Acquired Corporations has or may acquire any right or interest.

**Company Disclosure Schedule.** Company Disclosure Schedule shall mean the Company Disclosure Schedule and exhibits thereto that have been prepared by the Company in accordance with the requirements of Section 9.6 of the Agreement and that has been delivered by the Company to Parent upon the execution of the Agreement.

**Company Employee.** Company Employee shall mean any director or any officer or other employee of any of the Acquired Corporations.

**Company Employee Agreement.** Company Employee Agreement shall mean any management, employment, severance, retention, transaction bonus, change in control, consulting, relocation, repatriation or expatriation agreement or other similar Contract between: (a) any of the Acquired Corporations or any Company Affiliate; and (b) any Company Associate, other than any such Contract that is terminable at will (or following a notice period imposed by applicable law) without any obligation on the part of any Acquired Corporation or any Company Affiliate to make any severance, termination, change in control or similar payment or to provide any benefit, other than severance payments required to be made by any Acquired Corporation under applicable foreign law.

---

**Table of Contents**

**Company Employee Plan.** Company Employee Plan shall mean any plan, program, policy, practice or Contract providing for compensation, severance, termination pay, deferred compensation, performance awards, stock or stock-related awards, fringe benefits, retirement benefits or other benefits or remuneration of any kind, whether or not in writing and whether or not funded, including each employee benefit plan, within the meaning of Section 3(3) of ERISA (whether or not ERISA is applicable to such plan): (a) that is or has been maintained or contributed to, or required to be maintained or contributed to, by any of the Acquired Corporations or any Company Affiliate for the benefit of any Company Associate; or (b) with respect to which any of the Acquired Corporations or any Company Affiliate has or may incur or become subject to any liability or obligation; *provided, however*, that a Company Employee Agreement shall not be considered a Company Employee Plan.

**Company Material Adverse Effect.** Company Material Adverse Effect shall mean any effect, change, event or circumstance (each, an **Effect**) that, considered together with all other Effects, has a material adverse effect on: (a) the business, financial condition, operations or results of operations of the Acquired Corporations taken as a whole; *provided, however*, that, in no event shall any of the following, alone or in combination, be deemed to constitute, nor shall any of the following be taken into account in determining whether there has occurred, a Company Material Adverse Effect: Effects resulting from (i) conditions generally affecting the industries in which the Acquired Corporations participate or the U.S. or global economy or capital markets as a whole, to the extent that such conditions do not have a disproportionate impact on the Acquired Corporations taken as a whole; (ii) any failure by the Company or any of its Subsidiaries to meet internal projections or forecasts or third party revenue or earnings predictions for any period ending (or for which revenues or earnings are released) on or after the date of the Agreement (it being understood, however, that any Effect causing or contributing to such failures to meet projections or predictions may constitute a Company Material Adverse Effect and may be taken into account in determining whether a Company Material Adverse Effect has occurred); (iii) the execution, delivery, announcement or performance of the obligations under this Agreement or the announcement, pendency or anticipated consummation of the Merger; (iv) any natural disaster or any acts of terrorism, sabotage, military action or war or any escalation or worsening thereof; (v) any changes (after the date of this Agreement) in GAAP or applicable Legal Requirements; (vi) the taking of any action required by this Agreement; (vii) the FDA's failure to file the Company's NDA for Gencaro (provided that the NDA is promptly re-submitted and accepted for filing by the FDA within 30 days); and (viii) the FDA's failure to determine the approvability of the NDA by the Closing; (b) the ability of the Company to consummate the Merger or to perform any of its covenants or obligations under the Agreement; or (c) Parent's ability to vote, transfer, receive dividends with respect to or otherwise exercise ownership rights with respect to the stock of the Surviving Corporation.

**Company Option Plans.** Company Option Plans shall mean the Company 2004 Stock Incentive Plan, as amended to date.

**Company Options.** Company Options shall mean options to purchase shares of Company Common Stock from the Company (whether granted by the Company pursuant to the Company Option Plans, assumed by the Company or otherwise).

**Company Pension Plan.** Company Pension Plan shall mean each: (a) Company Employee Plan that is an employee pension benefit plan, within the meaning of Section 3(2) of ERISA; or (b) other occupational pension plan, including any final salary or money purchase plan.

**Company Preferred Stock.** Company Preferred Stock shall mean the Preferred Stock, \$0.001 par value per share, of the Company.

**Company Stockholder Approval.** Company Stockholder Approval shall mean the receipt by the Company, by the Company Written Consent, of the Required Company Stockholders' Vote.

**Company Superior Offer.** Company Superior Offer shall mean an unsolicited bona fide written offer by an unaffiliated third party to acquire pursuant to a tender offer, exchange offer, merger, consolidation or other business combination: (a) all or substantially all of the assets of Company; or (b) more than 50% of the

---

**Table of Contents**

outstanding voting securities of Company and as a result of which the stockholders of Company immediately preceding such transaction would cease to hold at least 50% of the equity interests in the surviving or resulting Entity of such transaction or any direct or indirect Parent thereof, in exchange for consideration that is determined by the board of directors of Company, in its good faith judgment, after obtaining and taking into account the advice of an independent financial advisor of nationally recognized reputation, and after taking into account the likelihood and anticipated timing of consummation, to be more favorable from a financial point of view to the Company's stockholders than the Merger determined on a basis of long-term value, taking into account the strategic value of the Merger.

**Confidentiality Agreement.** Confidentiality Agreement shall mean that certain letter with respect to the non-use and non-disclosure of certain confidential information of the Company and Parent dated as of January 15, 2007, between the Company and Parent.

**Consent.** Consent shall mean any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).

**Contemplated Transactions.** Contemplated Transactions shall mean the Merger and the other transactions contemplated by the Agreement.

**Contract.** Contract shall mean any written, oral or other agreement, contract, subcontract, lease, understanding, arrangement, instrument, note, option, warranty, purchase order, license, sublicense, insurance policy, benefit plan or legally binding commitment or undertaking of any nature.

**DGCL.** DGCL shall mean the Delaware General Corporation Law.

**DOL.** DOL shall mean the United States Department of Labor.

**Encumbrance.** Encumbrance shall mean any lien, pledge, hypothecation, charge, mortgage, easement, encroachment, imperfection of title, title exception, title defect, right of possession, lease, tenancy license, security interest, encumbrance, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).

**Entity.** Entity shall mean any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity.

**ERISA.** ERISA shall mean the Employee Retirement Income Security Act of 1974, as amended.

**Exchange Act.** Exchange Act shall mean the Securities Exchange Act of 1934, as amended.

**Form S-4 Registration Statement.** Form S-4 Registration Statement shall mean the registration statement on Form S-4 to be filed with the SEC by Parent in connection with the issuance of Parent Common Stock in the Merger, as said registration statement may be amended.

**GAAP.** GAAP shall mean generally accepted accounting principles in the United States.

**Government Bid.** Government Bid shall mean any quotation, bid or proposal submitted to any Governmental Body or any proposed prime contractor or higher-tier subcontractor of any Governmental Body.

## **Table of Contents**

**Government Contract.** Government Contract shall mean any prime contract, subcontract, letter contract, purchase order or delivery order executed or submitted to or on behalf of any Governmental Body or any prime contractor or higher-tier subcontractor, or under which any Governmental Body or any such prime contractor or subcontractor otherwise has or may acquire any right or interest.

**Governmental Authorization.** Governmental Authorization shall mean any: (a) permit, license, certificate, franchise, permission, variance, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Legal Requirement; or (b) right under any Contract with any Governmental Body.

**Governmental Body.** Governmental Body shall mean any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal); or (d) self-regulatory organization (including Nasdaq).

**IRS.** IRS shall mean the United States Internal Revenue Service.

**Knowledge.** Knowledge shall mean, with respect to any particular matter: (a) with respect to the Company, the actual knowledge of the Company's Chief Executive Officer, Chief Financial Officer, Vice President of Finance, Vice President Regulatory Affairs, Chief Medical Officer, General Counsel and the Chairman of the board of directors of the Company regarding such matter; and (b) with respect to Parent, the actual knowledge of Parent's Chief Executive Officer, Chief Financial Officer, Vice President - Regulatory Affairs, General Counsel and the Chairman of the board of directors of the Parent regarding such matter.

**Legal Proceeding.** Legal Proceeding shall mean any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.

**Legal Requirement.** Legal Requirement shall mean any federal, state, local, municipal, foreign or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, order, award, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of Nasdaq).

**Nasdaq Market.** Nasdaq Market shall mean any one of the Nasdaq Global Select Market, the Nasdaq Global Market or Nasdaq Capital Market.

**Order.** Order shall mean any order, writ, injunction, judgment or decree.

**Parent Affiliate.** Parent Affiliate shall mean any Person under common control with any of the Acquiring Corporations or required to be aggregated with any of the Acquiring Corporations within the meaning of Section 414(b), Section 414(c), Section 414(m) or Section 414(o) of the Code, and the regulations issued thereunder.

**Parent Associate.** Parent Associate shall mean any current or former officer or other employee, or current or former independent contractor, consultant or director, of or to any of the Acquiring Corporations or any Parent Affiliate.

**Parent Common Stock.** Parent Common Stock shall mean the Common Stock, \$0.001 par value per share, of Parent.

---

**Table of Contents**

**Parent Disclosure Schedule.** Parent Disclosure Schedule shall mean the Parent Disclosure Schedule that has been prepared by Parent in accordance with the requirements of Section 9.6 of the Agreement and that has been delivered by Parent to the Company on the date of the Agreement.

**Parent Employee.** Parent Employee shall mean any director or any officer or other employee of any of the Acquiring Corporations.

**Parent Employee Agreement.** Parent Employee Agreement shall mean any management, employment, severance, retention, transaction bonus, change in control, consulting, relocation, repatriation or expatriation agreement or other similar Contract between: (a) any of the Acquiring Corporations or any Parent Affiliate; and (b) any Parent Associate, other than any such Contract that is terminable at will (or following a notice period imposed by applicable law) without any obligation on the part of any Acquiring Corporation or any Parent Affiliate to make any severance, termination, change in control or similar payment or to provide any benefit, other than severance payments required to be made by any Acquiring Corporation under applicable foreign law.

**Parent Employee Plan.** Parent Employee Plan shall mean any plan, program, policy, practice or Contract providing for compensation, severance, termination pay, deferred compensation, performance awards, stock or stock-related awards, fringe benefits, retirement benefits or other benefits or remuneration of any kind, whether or not in writing and whether or not funded, including each employee benefit plan, within the meaning of Section 3(3) of ERISA (whether or not ERISA is applicable to such plan): (a) that is or has been maintained or contributed to, or required to be maintained or contributed to, by any of the Acquiring Corporations or any Parent Affiliate for the benefit of any Parent Associate; or (b) with respect to which any of the Acquiring Corporations or any Parent Affiliate has or may incur or become subject to any liability or obligation; *provided, however*, that a Parent Employee Agreement shall not be considered a Parent Employee Plan.

**Parent Material Adverse Effect.** Parent Material Adverse Effect shall mean any Effect that, considered together with all other Effects, has a material adverse effect on: (a) the business, financial condition, operations or results of operations of Parent and its Subsidiaries taken as a whole; *provided, however*, that, in no event shall any of the following, alone or in combination, be deemed to constitute, nor shall any of the following be taken into account in determining whether there has occurred, a Parent Material Adverse Effect: Effects resulting (i) from conditions generally affecting the industries in which Parent participates or the U.S. or global economy or capital markets as a whole, to the extent that such conditions do not have a disproportionate impact on Parent and its Subsidiaries taken as a whole; (ii) changes in the trading price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to such changes in the trading price or trading volume of Parent Common Stock may constitute a Parent Material Adverse Effect and may be taken into account in determining whether a Parent Material Adverse Effect has occurred); (iii) any failure by Parent or any of its Subsidiaries to meet internal projections or forecasts or third party revenue or earnings predictions for any period ending (or for which revenues or earnings are released) on or after the date of the Agreement (it being understood, however, that any Effect causing or contributing to such failures to meet projections or predictions may constitute a Parent Material Adverse Effect and may be taken into account in determining whether a Parent Material Adverse Effect has occurred); (iv) the execution, delivery, announcement or performance of the obligations under this Agreement or the announcement, pendency or anticipated consummation of the Merger; (v) any natural disaster or any acts of terrorism, sabotage, military action or war or any escalation or worsening thereof; (vi) any changes (after the date of this Agreement) in GAAP or applicable Legal Requirements; (vii) the taking of any action required by this Agreement; and (viii) the matters, or events arising from the matters, set forth in Parts 3.8(d) and 3.16 of the Parent Disclosure Schedule; or (b) the ability of Parent or Merger Sub to consummate the Merger or to perform any of its covenants or obligations under the Agreement.

**Parent Options.** Parent Options shall mean options to purchase shares of Parent Common Stock from Parent (whether granted by Parent pursuant to Parent's stock option plans, assumed by Parent or otherwise).

**Parent Pension Plan.** Parent Pension Plan shall mean each: (a) Parent Employee Plan that is an employee pension benefit plan, within the meaning of Section 3(2) of ERISA; or (b) other occupational pension plan, including any final salary or money purchase plan.

---

**Table of Contents**

**Parent Preferred Stock.** Parent Preferred Stock shall mean Preferred Stock, \$0.001 par value per share, of Parent.

**Parent Stock Plans.** Parent Stock Plans shall mean Parent's 1995 Stock Option Plan, 2002 Equity Incentive Plan, 2004 Equity Incentive Plan, Non-Employee Director Stock Option Plan, Scientific Advisory Board/Consultant Stock Option Plan, Employee Stock Purchase Plan and Non-Qualified Employee Stock Purchase Plan.

**Parent Superior Offer.** Parent Superior Offer shall mean an unsolicited bona fide written offer by an unaffiliated third party to acquire pursuant to a tender offer, exchange offer, merger, consolidation or other business combination: (a) all or substantially all of the assets of Parent; or (b) more than 50% of the outstanding voting securities of Parent and as a result of which the stockholders of Parent immediately preceding such transaction would cease to hold at least 50% of the equity interests in the surviving or resulting Entity of such transaction or any direct or indirect payment thereof, in exchange for consideration that is determined by the board of directors of Parent, in its good faith judgment, after obtaining and taking into account the advice of an independent financial advisor or nationally recognized reputation, and after taking into account the likelihood and anticipated timing of consummation, to be more favorable from a financial point of view to Parent's stockholders than the Merger.

**Person.** Person shall mean any individual, Entity or Governmental Body.

**Proxy Statement/Prospectus.** Proxy Statement/Prospectus shall mean the proxy statement/prospectus to be sent to the Company's stockholders in connection with the issuance of the Parent Common Stock in the Merger and to Parent's stockholders in connection with the Parent Stockholders Meeting.

**Representatives.** Representatives shall mean directors, officers, other employees, agents, attorneys, accountants, advisors and representatives.

**Sarbanes-Oxley Act.** Sarbanes-Oxley Act shall mean the Sarbanes-Oxley Act of 2002, as it may be amended from time to time.

**SEC.** SEC shall mean the United States Securities and Exchange Commission.

**Securities Act.** Securities Act shall mean the Securities Act of 1933, as amended.

**Subsidiary.** An Entity shall be deemed to be a Subsidiary of another Person if such Person directly or indirectly owns or purports to own, beneficially or of record: (a) an amount of voting securities of or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity's board of directors or other governing body; or (b) at least 50% of the outstanding equity, voting or financial interests in such Entity.

**Tax.** Tax shall mean any federal, state, local, foreign or other tax (including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, unemployment tax, national health insurance tax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax or payroll tax), levy, assessment, tariff, duty (including any customs duty), deficiency or fee, and any related charge or amount (including any fine, penalty or interest), imposed, assessed or collected by or under the authority of any Governmental Body.

**Tax Return.** Tax Return shall mean any return (including any information return), report, statement, declaration, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Legal Requirement relating to any Tax.

**Table of Contents**

**EXHIBIT B**

**CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION**

**THIRD AMENDED AND RESTATED**

**CERTIFICATE OF INCORPORATION**

**OF**

**ARCA BIOPHARMA, INC.**

Richard Brewer hereby certifies that:

**ONE:** The original name of this Corporation is ARCA Discovery, Inc. The date of filing the original Certificate of Incorporation of this Corporation with the Secretary of State of the State of Delaware was September 22, 2004, the date of filing the Amended and Restated Certificate of Incorporation of this Corporation with the Secretary of State of the State of Delaware was February 21, 2006, and the date of filing of the Second Amended and Restated Certificate of Incorporation of this Corporation with the Secretary of State of the State of Delaware was May 31, 2007.

**TWO:** He is the duly elected and acting President of this company.

**THREE:** The Second Amended and Restated Certificate of Incorporation of this Corporation is hereby amended and restated to read as follows:

**ARTICLE I.**

The name of this corporation is ARCA biopharma, Inc. (the Corporation ).

**ARTICLE II.**

The registered office of the Corporation shall be located at 1209 Orange Street, in the City of Wilmington, Delaware 19801 in the County of New Castle. The registered agent of the Corporation at such address shall be The Corporation Trust Company.

**ARTICLE III.**

The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

**ARTICLE IV.**

This Corporation is authorized to issue one class of stock to be designated Common Stock. The total number of shares that the Corporation is authorized to issue is One Thousand (1,000) shares, all of which shall be Common Stock, par value \$0.001 per share.

**ARTICLE V.**

A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability: (i) for any breach of the

**Table of Contents**

director's duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the General Corporation Law of the State of Delaware; or (iv) for any transaction from which the director derived any improper personal benefit. If the General Corporation Law of the State of Delaware is amended after approval by the stockholders of this Article to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware as so amended.

Any repeal or modification of the foregoing provisions of this Article V by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or modification.

**ARTICLE VI.**

The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred on stockholders herein are granted subject to this reservation.

**ARTICLE VII.**

Election of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

**ARTICLE VIII.**

The number of directors which shall constitute the whole Board of Directors of the Corporation shall be fixed from time to time by, or in the manner provided in, the Bylaws of the Corporation or in an amendment thereof duly adopted by the Board of Directors of the Corporation or by the stockholders of the Corporation.

**ARTICLE IX.**

Meetings of stockholders of the Corporation may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors of the Corporation or in the Bylaws of the Corporation.

**ARTICLE X.**

Except as otherwise provided in this Certificate of Incorporation, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors of the Corporation is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.

\* \* \* \*

**FOUR:** This Third Amended and Restated Certificate of Incorporation has been duly approved by the Board of Directors of this Corporation.

**FIVE:** This Third Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of shares of this Corporation in accordance with Section 228 of the General Corporation Law of



**Table of Contents**

the State of Delaware. This Third Amended and Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware by the stockholders of this Corporation.

**IN WITNESS WHEREOF, ARCA biopharma, Inc.** has caused this Third Amended and Restated Certificate of Incorporation to be signed by its President this     day of     , 200     .

**ARCA biopharma, Inc.**

By:  
Richard Brewer, President

A-66

**Table of Contents**

**EXHIBIT C**

**CHARTER AMENDMENT**

**CERTIFICATE OF AMENDMENT TO THE  
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION  
OF  
NUVELO, INC.**

NUVELO, INC., a corporation organized and existing under the General Corporation law of the State of Delaware does hereby certify:

**ONE:** The date of filing the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was March 16, 2004 as amended and restated on March 18, 2004.

**TWO:** The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows:

Article IV shall be amended and restated to read in its entirety as follows:

Effective at 5:00 p.m. Eastern time, on the date of filing of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the Effective Time), the shares of the Corporation's Common Stock, par value \$0.001 per share, issued and outstanding immediately prior to the Effective Time and the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time shall be combined into a smaller number of shares such that each shares of issued Common Stock immediately prior to the Effective Time are combined into one validly issued, fully paid and nonassessable share of Common Stock, par value \$0.001 per share. Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the combination, following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder), shall be entitled to receive a cash payment equal to the fraction to which such holder would otherwise be entitled multiplied by the then fair value of the Common Stock as determined by the Board of Directors. <sup>1</sup>

Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time), provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined.

The total number of shares of all classes of stock this Corporation shall have authority to issue following the Effective Time is 255,000,000 consisting of 250,000,000 shares of Common Stock, par value \$0.001 per share, and 5,000,000 shares of Preferred Stock, par value \$0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.

<sup>1</sup> Shall be a number greater than one and equal to or less than 50, the exact number within the range to be determined by the board of directors of the Corporation prior to the Effective Time and publicly announced by the Corporation.

**Table of Contents**

The Board of Directors of the Corporation is hereby authorized to fix or alter the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions, if any), the redemption price or prices, the liquidation preferences, any other designations, preferences and relative, participating, optional or other special rights, and any qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, and the number of shares constituting any such unissued series and the designation thereof, or any of them; and to increase or decrease the number of shares of any series subsequent to the issue of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be so decreased, the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series.

**THREE:** Thereafter, pursuant to a resolution by the Board of Directors of the Corporation, this Certificate of Amendment was submitted to the stockholders of the corporation for their consideration and was duly adopted and approved in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware at a special meeting of the stockholders.

**IN WITNESS WHEREOF**, Nuvelo, Inc. has caused this **CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION** to be signed by its Chairman of the Board of Directors and Chief Executive Officer this    day of                    ,                    .

**NUVELO, INC.**

By:

Ted. W. Love, M.D.  
Chairman of the Board of Directors and Chief  
Executive Officer

A-68

**Table of Contents**

**ANNEX B**

**AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION**

This Amendment No. 1 to Agreement and Plan of Merger and Reorganization (this **Amendment** ) is entered into as of October , 2008, by and among **NUVELO, INC.**, a Delaware corporation ( **Parent** ), **DAWN ACQUISITION SUB, INC.**, a Delaware corporation and wholly-owned subsidiary of Parent ( **Merger Sub** ), and **ARCA BIOPHARMA, INC.**, a Delaware corporation (the **Company** ). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement and Plan of Merger and Reorganization, dated as of September 24, 2008, by and among Parent, Merger Sub and the Company (the **Merger Agreement** ).

**RECITALS**

**A.** The parties desire to amend the Merger Agreement so as to, among other things, modify the agreed upon composition of the Board of Directors of Parent following the Effective Time and clarify the covenants of Parent to seek amendments to its amended and restated certificate of incorporation.

**B.** The respective boards of directors of Parent and the Company have each approved this Amendment.

**AGREEMENT**

The parties to this Amendment, intending to be legally bound agree as follows:

**1. Certificate of Incorporation.** Exhibit B to the Merger Agreement is hereby deleted and shall have no operative effect. Section 1.4(a) of the Merger Agreement is hereby amended and restated in its entirety to read as follows:

(a) the Certificate of Incorporation of the Surviving Corporation shall be the amended and restated certificate of incorporation of the Company as of the Execution Date, as amended by the Company NPA Charter Amendment (as defined below);

**2. Charter Amendments.** Section 5.12 of the Merger Agreement is hereby amended and restated in its entirety to read as follows:

**5.12 Charter Amendments.**

(a) Immediately prior to the Effective Time, Parent shall file an amendment to its amended and restated certificate of incorporation in the form of **Exhibit C** (the **Charter Amendment** ) with the Secretary of State of the State of Delaware to become effective immediately prior to the Effective Time.

(b) On or prior to September 25, 2008, Company shall file the Company NPA Charter Amendment with the Secretary of State of the State of Delaware to become effective immediately upon filing.

(c) In connection with the Parent Stockholder Meeting, Parent shall use commercially reasonable efforts to solicit the consent of its stockholders to approve an amendment to Parent's amended and restated certificate of incorporation to increase the number of authorized shares of Parent common stock to 250 million, it being understood that such amendment, notwithstanding the provisions of Section 4.2, is expressly authorized under this Agreement.

B-1

**Table of Contents**

**3. Exhibit C.** Exhibit C to the Merger Agreement is hereby amended and restated in its entirety in the form attached to this Amendment as **Exhibit C**.

**4. Schedule 5.11.** Schedule 5.11 to the Merger Agreement is hereby amended and restated in its entirety in the form attached hereto as Schedule 5.11. The execution of this Agreement by the Company shall constitute the consent of the Company to Nuvelo taking such action is necessary to amend its bylaws and increase the authorized size of its board of directors to ten (10) members to satisfy its obligations pursuant to Section 5.11 of the Merger Agreement.

**5. Parent Stockholders Meeting.** Section 5.3(a) of the Merger Agreement is hereby amended and restated in its entirety to read as follows:

**5.3 Parent Stockholders Meeting.**

(a) Parent shall take all action necessary to call, give notice of and hold a meeting of the holders of Parent Common Stock to vote on the issuance of Parent Common Stock in the Merger and the Charter Amendment (collectively, the **Parent Stockholders Meeting** ). The Parent Stockholders Meeting shall be held on a date selected by Parent, in consultation with the Company, but such date shall be no later than 42 calendar days after the Form S-4 Registration Statement is declared effective. Parent shall ensure that all proxies solicited in connection with the Parent Stockholders Meeting are solicited in compliance with all applicable Legal Requirements.

**6. References to the Merger Agreement.** Subject to paragraph 6 of this Amendment, after giving effect to this Amendment, each reference in the Merger Agreement to Agreement , hereof , hereunder or words of like import referring to the Merger Agreement shall refer to the Merger Agreement as amended by this Amendment and all references in the Company Disclosure Schedule and Parent Disclosure Schedule to the Agreement shall refer to the Merger Agreement as amended by this Amendment.

**7. Date References.** All references in the Merger Agreement, the Company Disclosure Schedule and the Parent Disclosure Schedule to the Execution Date, the date hereof , the date of this Agreement or words of like import shall remain as references to September 24, 2008.

**8. Other Miscellaneous Terms.** The provisions of Section 9 (Miscellaneous Provisions) of the Merger Agreement shall apply *mutatis mutandis* to this Amendment, and to the Merger Agreement as modified by this Amendment, taken together as a single agreement, reflecting the terms therein as modified hereby.

**9. No Further Amendment.** Except as amended hereby, the Merger Agreement and each of the provisions contained therein shall remain in full force and effect. Nothing herein shall affect, modify or limit any waiver or consent granted by any party pursuant to the Merger Agreement. Each such waiver or consent granted prior to the date hereof remains in full force and effect.

[Signature Page follows]

**Table of Contents**

Parent, Merger Sub and the Company have caused this Amendment to the Agreement and Plan of Merger and Reorganization to be executed as of the date first written above.

**NUVELO, INC.**

By: /s/ Ted W. Love

Name: Ted W. Love

Title: Chairman of the Board and Chief Executive Officer

**DAWN ACQUISITION SUB, INC.**

By: /s/ Lee Bendkgey

Name: Lee Bendkgey

Title: Chief Executive Officer

**ARCA BIOPHARMA, INC.**

By: /s/ Richard B. Brewer

Name: Richard B. Brewer

Title: President and Chief Executive Officer

B-3

---

**Table of Contents**

**EXHIBIT C**

**CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVELO, INC.**

NUVELO, INC., a corporation organized and existing under the General Corporation law of the State of Delaware does hereby certify:

**ONE:** The date of filing the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was March 16, 2004 as amended and restated on March 18, 2004.

**TWO:** The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows:

Article IV shall be amended to add the following provisions in their entirety to the existing provisions of Article IV:

Effective at 5:00 p.m. Eastern time, on the date of filing of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the Effective Time ), the shares of the Corporation's Common Stock, par value \$0.001 per share, issued and outstanding immediately prior to the Effective Time and the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time shall be combined into a smaller number of shares such that each<sup>1</sup> shares of issued Common Stock immediately prior to the Effective Time are combined into one validly issued, fully paid and nonassessable share of Common Stock, par value \$0.001 per share. Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the combination, following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder), shall be entitled to receive a cash payment equal to the fraction to which such holder would otherwise be entitled multiplied by the then fair value of the Common Stock as determined by the Board of Directors.

Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time), provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined.

**THREE:** Thereafter, pursuant to a resolution by the Board of Directors of the Corporation, this Certificate of Amendment was submitted to the stockholders of the corporation for their consideration and was duly adopted and approved in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware at a special meeting of the stockholders.

<sup>1</sup> Shall be a number greater than one and equal to or less than 50, the exact number within the range to be determined by the board of directors of the Corporation prior to the Effective Time and publicly announced by the Corporation.

**Table of Contents**

IN WITNESS WHEREOF, Nuvelo, Inc. has caused this CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION to be signed by its Chairman of the Board of Directors and Chief Executive Officer this            day of            ,            .

NUVELO, INC.

By:

Ted. W. Love, M.D.  
Chairman of the Board of Directors and Chief  
Executive Officer

B-5



**Table of Contents**

**SCHEDULE 5.11**

**DIRECTORS**

Dr. Ted Love, Mary K. Pendergrast, Dr. Burton E. Sobel, Richard B. Brewer, Michael R. Bristow M.D., PhD, Dr. John Zabriskie, Dr. William Freytag, Dr. John-Francois Formela, David G. Lowe PhD, Linda Grais M.D.

**EXECUTIVE OFFICERS**

Richard B. Brewer	Chief Executive Officer
Michael R. Bristow, M.D., PhD	Chief Science and Medical Officer
Lee Bendekgey	Chief Financial Officer
Christopher Ozeroff	Executive Vice President of Business Development and General Counsel

B-6

**Table of Contents**

ANNEX C

**VOTING AGREEMENT**

THIS VOTING AGREEMENT ( *Agreement* ) is entered into as of September 24, 2008, by and between Nuvelo, Inc., a Delaware corporation ( *Parent* ), and ( *Stockholder* ).

**RECITALS**

**A.** Stockholder is a holder of record and the beneficial owner (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934) of certain shares of capital stock of ARCA biopharma, Inc., a Delaware corporation (the *Company* ).

**B.** Parent, Dawn Acquisition Sub, Inc., a Delaware corporation ( *Merger Sub* ), and the Company are entering into an Agreement and Plan of Merger and Reorganization of even date herewith (the *Merger Agreement* ) which provides (subject to the conditions set forth therein) for the merger of the Merger Sub with and into the Company (the *Merger* ).

**C.** In the Merger, the outstanding shares of capital stock of the Company are to be converted into the right to receive shares of common stock of Parent.

**D.** In order to induce Parent to enter into the Merger Agreement, Stockholder is entering into this Agreement.

**AGREEMENT**

The parties to this Agreement, intending to be legally bound, agree as follows:

**SECTION 1. CERTAIN DEFINITIONS**

**1.1 Specified Terms.** For purposes of this Agreement:

(a) Stockholder shall be deemed to *Own* or to have acquired *Ownership* of a security if Stockholder: (i) is the record owner of such security; or (ii) is the beneficial owner (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934) of such security.

(b) *Subject Securities* shall mean: (i) all securities of the Company (including all shares of Company Capital Stock and all options, warrants and other rights to acquire shares of Company Capital Stock) Owned by Stockholder as of the date of this Agreement; and (ii) all additional securities of the Company (including all additional shares of Company Capital Stock and all additional options, warrants and other rights to acquire shares of Company Capital Stock) of which Stockholder acquires Ownership during the period from the date of this Agreement through the Voting Covenant Expiration Date.

(c) A Person shall be deemed to have effected a *Transfer* of a security if such Person directly or indirectly: (i) sells, pledges, encumbers, grants an option with respect to, transfers or disposes of such security or any interest in such security to any Person other than Parent; (ii) enters into an agreement or commitment contemplating the possible sale of, pledge of, encumbrance of, grant of an option with respect to, transfer of or disposition of such security or any interest therein to any Person other than Parent; or (iii) reduces such Person's beneficial ownership of, interest in or risk relating to such security.

(d) *Voting Covenant Expiration Date* shall mean the earlier of the date upon which the Merger Agreement is terminated, or the date upon which the Merger is consummated; provided that the Voting Covenant Expiration Date shall not be later than March 31, 2009 (unless the failure of the Merger to occur is a result of a breach of this Agreement by the Stockholder).

---

**Table of Contents**

**1.2 Other Terms.** Capitalized terms used herein and not defined shall have the meanings set forth in the Merger Agreement.

**SECTION 2. TRANSFER OF SUBJECT SECURITIES AND VOTING RIGHTS**

**2.1 Restriction on Transfer of Subject Securities.** Subject to Section 2.3, during the period from the date of this Agreement through the Voting Covenant Expiration Date, Stockholder shall not, directly or indirectly, cause or permit any Transfer of any of the Subject Securities to be effected.

**2.2 Restriction on Transfer of Voting Rights.** During the period from the date of this Agreement through the Voting Covenant Expiration Date, Stockholder shall ensure that: (a) none of the Subject Securities is deposited into a voting trust; and (b) no proxy is granted, and no voting agreement or similar agreement is entered into, with respect to any of the Subject Securities, other than a proxy granted to Parent.

**2.3 Permitted Transfers.** Section 2.1 shall not prohibit a transfer of Company Common Stock by Stockholder (i) to any member of his immediate family, or to a trust for the benefit of Stockholder or any member of his immediate family, (ii) upon the death of Stockholder, or (iii) if Stockholder is a partnership or limited liability company, to one or more partners or members of Stockholder or to an affiliated corporation under common control with Stockholder; *provided, however*, that a transfer referred to in this sentence shall be permitted only if, as a precondition to such transfer, the transferee agrees in a writing, reasonably satisfactory in form and substance to Parent, to be bound by the terms of this Agreement.

**SECTION 3. VOTING OF SHARES**

**3.1 Voting Covenant.** Stockholder hereby agrees that, prior to the Voting Covenant Expiration Date, at any meeting of the stockholders of the Company, however called, and in any written action by consent of stockholders of the Company (a ***Stockholder Consent*** ), unless otherwise directed in writing by Parent, Stockholder shall cause the Subject Securities to be voted:

(a) in favor of the Merger, the execution and delivery by the Company of the Merger Agreement and the adoption and approval of the Merger Agreement and the terms thereof, in favor of each of the other actions contemplated by the Merger Agreement and in favor of any action in furtherance of any of the foregoing; and

(b) against any action or agreement that would result in a breach of any representation, warranty, covenant or obligation of the Company in the Merger Agreement; and

(c) against the following actions (other than the Merger and the transactions contemplated by the Merger Agreement, such actions set forth in Section 4.2 of the Company Disclosure Schedule, or such actions consented to in writing by Parent): (A) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving the Company or any subsidiary of the Company; (B) any sale, lease or transfer of a material amount of assets of the Company or any subsidiary of the Company; (C) any reorganization, recapitalization, dissolution or liquidation of the Company or any subsidiary of the Company; (D) any change in a majority of the board of directors of the Company; (E) any amendment to the Company's certificate of incorporation or bylaws, which amendment would in any manner frustrate, prevent or nullify the Merger, the Merger Agreement or any transactions contemplated by the Merger Agreement or change in any manner the voting rights of any class of Company Capital Stock; (F) any material change in the capitalization of the Company or the Company's corporate structure; and (G) any other action which is intended, or could reasonably be expected, to impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement or this Agreement.

Prior to the Voting Covenant Expiration Date Stockholder shall not enter into any agreement or understanding with any Person to vote or give instructions in any manner inconsistent with clause (a) , (b) , or (c) of the preceding sentence.

---

**Table of Contents**

**3.2 Proxy; Further Assurances.**

(a) Contemporaneously with the execution of this Agreement: (i) Stockholder shall deliver to Parent a proxy in the form attached to this Agreement as Exhibit A, which shall be irrevocable to the fullest extent permitted by law (at all times prior to the Voting Covenant Expiration Date) with respect to the securities referred to therein (the **Proxy**); and (ii) Stockholder shall cause to be delivered to Parent an additional proxy (in the form attached hereto as **Exhibit A**) executed on behalf of the record owner of any outstanding shares of Company Capital Stock that are owned beneficially (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934), but not of record, by Stockholder.

(b) Stockholder shall, at his or its own expense, perform such further acts and execute such further proxies and other documents and instruments as may reasonably be required to vest in Parent the power to carry out and give effect to the provisions of this Agreement.

(c) In the event that the Company shall solicit a Stockholder Consent, Stockholder shall take all actions required of it pursuant to this Agreement, including without limitation Section 3.1, as soon as reasonably practicable following receipt of any such solicitation and in no event later than the later of (i) seventy-two (72) hours after the Form S-4 Registration is declared effective; or (ii) twenty-four (24) hours after the receipt of such solicitation (the *Consent Deadline*); *provided, however*, that Stockholder's failure to take all actions required of it pursuant to this Agreement prior to the Consent Deadline shall not be deemed a breach of this Agreement in the event that the Company shall have obtained the Required Company Stockholder Vote within the time period specified in Section 5.2(a) of the Merger Agreement; and *provided, further* that the foregoing limitation shall in no way be deemed to limit Stockholder obligations under this Section 3.2 to take all actions required of it pursuant to this Agreement as soon as reasonably practicable following receipt of any such solicitation or Stockholder's liability for breach of such obligation or any other obligation pursuant to this Agreement.

**SECTION 4. WAIVER OF APPRAISAL RIGHTS**

Stockholder hereby irrevocably and unconditionally waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters' rights and any similar rights relating to the Merger or any related transaction that Stockholder may have by virtue of any outstanding shares of Company Capital Stock Owned by Stockholder.

**SECTION 5. No SOLICITATION**

Stockholder agrees that, during the period from the date of this Agreement through the Voting Covenant Expiration Date, Stockholder shall not, directly or indirectly, and Stockholder shall ensure that his or its Representatives do not, directly or indirectly: (i) solicit, initiate, knowingly encourage, induce or facilitate the making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnish any nonpublic information regarding the Company or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or an Acquisition Inquiry; (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any Acquisition Proposal or Acquisition Inquiry; or (v) enter into any letter of intent or similar document or any Contract contemplating or otherwise relating to any Acquisition Transaction. Stockholder shall immediately cease and discontinue, and Stockholder shall ensure that his or its Representatives immediately cease and discontinue, any existing discussions with any Person that relate to any Acquisition Proposal or Acquisition Inquiry. Notwithstanding the foregoing, if the Stockholder is an officer of the Company, nothing in this Section 5 shall be interpreted to prohibit the Stockholder from acting in accordance with instructions given by the Board of Directors of the Company so long as such actions comply with the Merger Agreement.

---

**Table of Contents**

**SECTION 6. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER**

Stockholder hereby represents and warrants to Parent as follows:

**6.1 Authorization, etc.** Stockholder has the absolute and unrestricted right, power, authority and capacity to execute and deliver this Agreement and the Proxy and to perform his or its obligations hereunder and thereunder. This Agreement and the Proxy have been duly executed and delivered by Stockholder and constitute legal, valid and binding obligations of Stockholder, enforceable against Stockholder in accordance with their terms, subject to (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. [If Stockholder is a general or limited partnership, then Stockholder is a partnership duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was organized. If Stockholder is a limited liability company, then Stockholder is a limited liability company duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was organized.]

**6.2 No Conflicts or Consents.**

(a) The execution and delivery of this Agreement and the Proxy by Stockholder do not, and the performance of this Agreement and the Proxy by Stockholder will not: (i) conflict with or violate any law, rule, regulation, order, decree or judgment applicable to Stockholder or by which he or it or any of his or its properties is or may be bound or affected; or (ii) result in or constitute (with or without notice or lapse of time) any breach of or default under, or give to any other Person (with or without notice or lapse of time) any right of termination, amendment, acceleration or cancellation of, or result (with or without notice or lapse of time) in the creation of any encumbrance or restriction on any of the Subject Securities pursuant to, any Contract to which Stockholder is a party or by which Stockholder or any of his or its affiliates or properties is or may be bound or affected.

(b) The execution and delivery of this Agreement and the Proxy by Stockholder do not, and the performance of this Agreement and the Proxy by Stockholder will not, require any consent or approval of any Person [pursuant to, any Contract to which Stockholder is a party or by which Stockholder or any of his or its affiliates or properties is or may be bound or affected].

**6.3 Title to Securities.** As of the date of this Agreement: (a) Stockholder holds of record (free and clear of any encumbrances or restrictions) the number and type of outstanding shares of Company Capital Stock set forth under the heading **Shares Held of Record** on the signature page hereof; (b) Stockholder holds (free and clear of any encumbrances or restrictions) the options, warrants and other rights to acquire shares of Company Capital Stock set forth under the heading **Options and Other Rights** on the signature page hereof; (c) Stockholder Owns the additional securities of the Company set forth under the heading **Additional Securities Beneficially Owned** on the signature page hereof; and (d) Stockholder does not directly or indirectly Own any shares of capital stock or other securities of the Company, or any option, warrant or other right to acquire (by purchase, conversion or otherwise) any shares of capital stock or other securities of the Company, other than the shares and options, warrants and other rights set forth on the signature page hereof.

**6.4 Accuracy of Representations.** The representations and warranties contained in this Agreement are accurate in all respects as of the date of this Agreement, will be accurate in all respects at all times through the Voting Covenant Expiration Date and will be accurate in all respects as of the date of the consummation of the Merger as if made on that date.

**SECTION 7. ADDITIONAL COVENANTS OF STOCKHOLDER**

**7.1 Further Assurances.** From time to time and without additional consideration, Stockholder shall (at Stockholder's sole expense) execute and deliver, or cause to be executed and delivered, such additional transfers, assignments, endorsements, proxies, consents and other instruments, and shall (at Stockholder's sole expense) take such further actions, as Parent may request for the purpose of carrying out and furthering the intent of this Agreement.

---

**Table of Contents**

**7.2 Legends.** If requested by Parent, immediately after the execution of this Agreement (and from time to time upon the acquisition by Stockholder of Ownership of any shares of Company Capital Stock prior to the Voting Covenant Expiration Date), Stockholder shall cause each certificate evidencing any outstanding shares of Company Capital Stock or other securities of the Company Owned by Stockholder to be surrendered so that the transfer agent for such securities may affix thereto a legend in the following form:

THE SECURITY OR SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, EXCHANGED OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT IN COMPLIANCE WITH THE TERMS AND PROVISIONS OF A VOTING AGREEMENT DATED AS OF SEPTEMBER 24, 2008, AS IT MAY BE AMENDED, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER.

**SECTION 8. MISCELLANEOUS**

**8.1 Survival of Representations, Warranties and Agreements.** All representations, warranties, covenants and agreements made by Stockholder in this Agreement shall survive (i) the consummation of the Merger and (ii) any termination of the Merger Agreement, provided that Sections 2, 3[, 5] and 7 of this Agreement shall not survive the Voting Covenant Termination Date.

**8.2 Expenses.** All costs and expenses incurred in connection with the transactions contemplated by this Agreement shall be paid by the party incurring such costs and expenses.

**8.3 Notices.** Any notice or other communication required or permitted to be delivered to either party under this Agreement shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by facsimile) to the address or facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice given to the other party):

if to Stockholder:

at the address set forth on the signature page hereof; and

if to Parent:

Nuvelo, Inc.

201 Industrial Road, Suite 310

San Carlos, CA

Attn: Chief Executive Officer

Fax: (650) 517-8023

**8.4 Severability.** Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

**8.5 Entire Agreement.** This Agreement, the Proxy and any other documents delivered by the parties in connection herewith constitute the entire agreement between the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings between the parties with respect thereto. No addition to or modification of any provision of this Agreement shall be binding upon either party unless made in writing and signed by both parties.



---

**Table of Contents**

**8.6 Assignment; Binding Effect.** Except as provided herein, neither this Agreement nor any of the interests or obligations hereunder may be assigned or delegated by Stockholder, and any attempted or purported assignment or delegation of any of such interests or obligations shall be void. Subject to the preceding sentence, this Agreement shall be binding upon Stockholder and his heirs, estate, executors and personal representatives and his or its successors and assigns, and shall inure to the benefit of Parent and its successors and assigns. Without limiting any of the restrictions set forth in Section 2 or Section 7.1 or elsewhere in this Agreement, this Agreement shall be binding upon any Person to whom any Subject Securities are transferred. Nothing in this Agreement is intended to confer on any Person (other than Parent and its successors and assigns) any rights or remedies of any nature.

**8.7 Specific Performance.** The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement or the Proxy were not performed in accordance with its specific terms or were otherwise breached. Stockholder agrees that, in the event of any breach or threatened breach by Stockholder of any covenant or obligation contained in this Agreement or in the Proxy, Parent shall be entitled (in addition to any other remedy that may be available to it, including monetary damages) to seek and obtain (a) a decree or order of specific performance to enforce the observance and performance of such covenant or obligation, and (b) an injunction restraining such breach or threatened breach. Stockholder further agrees that neither Parent nor any other Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this Section 8.7, and Stockholder irrevocably waives any right he or it may have to require the obtaining, furnishing or posting of any such bond or similar instrument.

**8.8 Non-Exclusivity.** The rights and remedies of Parent under this Agreement are not exclusive of or limited by any other rights or remedies which it may have, whether at law, in equity, by contract or otherwise, all of which shall be cumulative (and not alternative). Without limiting the generality of the foregoing, the rights and remedies of Parent under this Agreement, and the obligations and liabilities of Stockholder under this Agreement, are in addition to their respective rights, remedies, obligations and liabilities under common law requirements and under all applicable statutes, rules and regulations.

**8.9 Governing Law; Venue.**

(a) This Agreement and the Proxy shall be construed in accordance with, and governed in all respects by, the laws of the State of Delaware (without giving effect to principles of conflicts of laws).

(b) Any legal action or other legal proceeding relating to this Agreement or the Proxy or the enforcement of any provision of this Agreement or the Proxy may be brought or otherwise commenced in any state or federal court located in the State of Delaware. Stockholder:

(i) expressly and irrevocably consents and submits to the jurisdiction of each state and federal court located in the State of Delaware in connection with any such legal proceeding;

(ii) agrees that service of any process, summons, notice or document by U.S. mail addressed to him or it at the address set forth on the signature page hereof shall constitute effective service of such process, summons, notice or document for purposes of any such legal proceeding;

(iii) agrees that each state and federal court located in the State of Delaware shall be deemed to be a convenient forum; and

(iv) agrees not to assert (by way of motion, as a defense or otherwise), in any such legal proceeding commenced in any state or federal court located in the State of Delaware, any claim that Stockholder is not subject personally to the jurisdiction of such court, that such legal proceeding has been brought in an inconvenient forum, that the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced in or by such court.

Nothing contained in this Section 8.9 shall be deemed to limit or otherwise affect the right of Parent to commence any legal proceeding or otherwise proceed against Stockholder in any other forum or jurisdiction.



## **Table of Contents**

(c) STOCKHOLDER IRREVOCABLY WAIVES THE RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LEGAL PROCEEDING RELATING TO THIS AGREEMENT OR THE PROXY OR THE ENFORCEMENT OF ANY PROVISION OF THIS AGREEMENT OR THE PROXY.

**8.10 Counterparts.** This Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument.

**8.11 Captions.** The captions contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

**8.12 Attorneys Fees.** If any legal action or other legal proceeding relating to this Agreement or the enforcement of any provision of this Agreement is brought against Stockholder, the prevailing party shall be entitled to recover reasonable attorneys fees, costs and disbursements (in addition to any other relief to which the prevailing party may be entitled).

**8.13 Waiver.** No failure on the part of Parent to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of Parent in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. Parent shall not be deemed to have waived any claim available to Parent arising out of this Agreement, or any power, right, privilege or remedy of Parent under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of Parent; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

### **8.14 Construction.**

(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.

(b) The parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.

(c) As used in this Agreement, the words include and including, and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words without limitation.

(d) Except as otherwise indicated, all references in this Agreement to Sections and Exhibits are intended to refer to Sections of this Agreement and Exhibits to this Agreement.

**8.15 No Limitation on Actions of Stockholder as Director.** [In the event Stockholder is a member of the Board of Directors of the Company, notwithstanding] [Notwithstanding] anything to the contrary in this Agreement, nothing in this Agreement is intended or shall be construed to require the Stockholder [or any representative or designee of such Stockholder] to take any action, or limit any action the Stockholder [or any representative or designee of such Stockholder] may take, to the extent that doing so would be inconsistent with [Stockholder s] fiduciary duties [of the Stockholder or any representative or designee of such Stockholder] as a director of the Company.

**Table of Contents**

IN WITNESS WHEREOF, Parent and Stockholder have caused this Agreement to be executed as of the date first written above.

NUVELO, INC.

By:

STOCKHOLDER

Name:

Address:

Facsimile:

Shares Held of Record

Options and Other Rights

Additional Securities Beneficially Owned

C-8

**Table of Contents**

**EXHIBIT A**

**FORM OF IRREVOCABLE PROXY**

The undersigned stockholder (the *Stockholder*) of **ARCA BIOPHARMA, INC.**, a Delaware corporation (the *Company*), hereby irrevocably (to the fullest extent permitted by law) appoints and constitutes **TED W. LOVE, M.D., LEE BENDEKGEY and NUVELO, INC.**, a Delaware corporation (*Parent*), and each of them, the attorneys and proxies of the Stockholder with full power of substitution and resubstitution, to the full extent of the Stockholder's rights with respect to (i) the outstanding shares of capital stock of the Company owned of record by the Stockholder as of the date of this proxy, which shares are specified on the final page of this proxy, and (ii) any and all other shares of capital stock of the Company which the Stockholder may acquire on or after the date hereof. (The shares of the capital stock of the Company referred to in clauses (i) and (ii) of the immediately preceding sentence are collectively referred to as the *Shares*.) Upon the execution hereof, all prior proxies given by the Stockholder with respect to any of the Shares are hereby revoked, and the Stockholder agrees that no subsequent proxies will be given with respect to any of the Shares.

This proxy is irrevocable, is coupled with an interest and is granted in connection with the Voting Agreement, dated as of the date hereof, between Parent and the Stockholder (the *Voting Agreement*), and is granted in consideration of Parent entering into the Agreement and Plan of Merger and Reorganization, dated as of the date hereof, among Parent, Merger Sub and the Company (the *Merger Agreement*). This proxy will terminate on the Voting Covenant Expiration Date (as defined in the Voting Agreement).

The attorneys and proxies named above will be empowered, and may exercise this proxy, to vote the Shares at any time until the Voting Covenant Expiration Date (the *Merger*) at any meeting of the stockholders of the Company, however called, and in connection with any written action by consent of stockholders of the Company:

(i) in favor of the Merger, the execution and delivery by the Company of the Merger Agreement and the adoption and approval of the Merger Agreement and the terms thereof, in favor of each of the other actions contemplated by the Merger Agreement and in favor of any action in furtherance of any of the foregoing; and

(ii) against any action or agreement that would result in a breach of any representation, warranty, covenant or obligation of the Company in the Merger Agreement; and

(iii) against the following actions (other than the Merger and the transactions contemplated by the Merger Agreement, such actions set forth in Section 4.2 of the Company Disclosure Schedule, or such actions consented to in writing by Parent): (A) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving the Company or any subsidiary of the Company; (B) any sale, lease or transfer of a material amount of assets of the Company or any subsidiary of the Company; (C) any reorganization, recapitalization, dissolution or liquidation of the Company or any subsidiary of the Company; (D) any change in a majority of the board of directors of the Company; (E) any amendment to the Company's certificate of incorporation or bylaws, which amendment would in any manner frustrate, prevent or nullify the Merger, the Merger Agreement or any transactions contemplated by the Merger Agreement or change in any manner the voting rights of any class of Company Capital Stock; (F) any material change in the capitalization of the Company or the Company's corporate structure; and (G) any other action which is intended, or could reasonably be expected, to impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement or this Agreement.

The Stockholder may vote the Shares on all other matters not referred to in this proxy, and the attorneys and proxies named above may not exercise this proxy with respect to such other matters.

This proxy shall be binding upon the heirs, estate, executors, personal representatives, successors and assigns of the Stockholder (including any transferee of any of the Shares).

**Table of Contents**

Any term or provision of this proxy that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the Stockholder agrees that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this proxy shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Stockholder agrees to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

Dated: September 24, 2008

Name

Shares of capital stock of the Company owned of record  
as of the date of this proxy:

C-10

**Table of Contents**

**ANNEX D**

**VOTING AGREEMENT**

THIS VOTING AGREEMENT ( *Agreement* ) is entered into as of September 24, 2008, by and between **AREOPHARMA, INC.**, a Delaware corporation (the *Company* ), and ( *Stockholder* ).

**RECITALS**

**A.** Stockholder is a holder of record and the beneficial owner (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934) of certain shares of common stock of **NUVELO, INC.**, a Delaware corporation (the *Parent* ).

**B.** Parent, Dawn Acquisition Sub, Inc., a Delaware corporation ( *Merger Sub* ), and the Company are entering into an Agreement and Plan of Merger and Reorganization of even date herewith (the *Merger Agreement* ) which provides (subject to the conditions set forth therein) for the merger of the Merger Sub with and into the Company (the *Merger* ).

**C.** In the Merger, the outstanding shares of capital stock of the Company are to be converted into the right to receive shares of common stock of Parent.

**D.** In order to induce Company to enter into the Merger Agreement, Stockholder is entering into this Agreement.

**AGREEMENT**

The parties to this Agreement, intending to be legally bound, agree as follows:

**SECTION 1. CERTAIN DEFINITIONS**

**1.1 Specified Terms.** For purposes of this Agreement:

(a) Stockholder shall be deemed to *Own* or to have acquired *Ownership* of a security if Stockholder: (i) is the record owner of such security; or (ii) is the beneficial owner (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934) of such security.

(b) *Subject Securities* shall mean: (i) all securities of Parent (including all shares of Parent Common Stock and all options, warrants and other rights to acquire shares of Parent Common Stock) Owned by Stockholder as of the date of this Agreement; and (ii) all additional securities of Parent (including all additional shares of Parent Common Stock and all additional options, warrants and other rights to acquire shares of Parent Common Stock) of which Stockholder acquires Ownership during the period from the date of this Agreement through the Voting Covenant Expiration Date.

(c) A Person shall be deemed to have effected a *Transfer* of a security if such Person directly or indirectly: (i) sells, pledges, encumbers, grants an option with respect to, transfers or disposes of such security or any interest in such security to any Person; (ii) enters into an agreement or commitment contemplating the possible sale of, pledge of, encumbrance of, grant of an option with respect to, transfer of or disposition of such security or any interest therein to any Person; or (iii) reduces such Person's beneficial ownership of, interest in or risk relating to such security.

(d) *Voting Covenant Expiration Date* shall mean the earlier of the date upon which the Merger Agreement is terminated, or the date upon which the Merger is consummated.

---

**Table of Contents**

**1.2 Other Terms.** Capitalized terms used herein and not defined shall have the meanings set forth in the Merger Agreement.

**SECTION 2. TRANSFER OF SUBJECT SECURITIES AND VOTING RIGHTS**

**2.1 Restriction on Transfer of Subject Securities.** Subject to Section 2.3, during the period from the date of this Agreement through the Voting Covenant Expiration Date, Stockholder shall not, directly or indirectly, cause or permit any Transfer of any of the Subject Securities to be effected.

**2.2 Restriction on Transfer of Voting Rights.** Subject to Section 2.3, during the period from the date of this Agreement through the Voting Covenant Expiration Date, Stockholder shall ensure that: (a) none of the Subject Securities is deposited into a voting trust; and (b) no proxy is granted, and no voting agreement or similar agreement is entered into, with respect to any of the Subject Securities, other than a proxy granted to the Company.

**2.3 Permitted Transfers.** Sections 2.1 and 2.2 shall not prohibit a Transfer of Parent Common Stock by Stockholder (i) pursuant to Rule 144 promulgated under the Securities Act; (ii) to any member of his immediate family, or to a trust for the benefit of Stockholder or any member of his immediate family, or (iii) upon the death of Stockholder, or (iv) if Stockholder is a partnership or limited liability company, to one or more partners or members of Stockholder or to an affiliated corporation under common control with Stockholder; *provided, however*, that a Transfer referred to in clauses (ii), (iii) or (iv) of this Section 2.3 shall be permitted only if, as a precondition to such transfer, the transferee agrees in a writing, reasonably satisfactory in form and substance to the Company, to be bound by the terms of this Agreement.

**SECTION 3. VOTING OF SHARES**

**3.1 Voting Covenant.** Stockholder hereby agrees that, prior to the Voting Covenant Expiration Date, at any meeting of the stockholders of Parent, unless otherwise directed in writing by the Company, Stockholder shall cause the Subject Securities to be voted:

(a) in favor of the issuance of the shares of Parent Common Stock in the Merger; and

(b) in favor of the Charter Amendment; and

(c) against any action or agreement that would result in a breach of any representation, warranty, covenant or obligation of Parent in the Merger Agreement; and

(d) against the following actions (other than the Merger, actions contemplated by the Merger Agreement, such actions set forth in Section 4.2 of Parent Disclosure Schedule, or such actions consented to in writing by the Company): (A) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving Parent or any subsidiary of the Parent; (B) any sale, lease or transfer of a material amount of assets of Parent or any subsidiary of Parent; (C) any reorganization, recapitalization, dissolution or liquidation of Parent or any subsidiary of Parent; (D) any change in a majority of the board of directors of Parent; (E) any amendment to Parent's certificate of incorporation or bylaws other than the Charter Amendment; (F) any material change in the capitalization of Parent or the Parent's corporate structure; and (G) any other action which is intended, or could reasonably be expected, to impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement or this Agreement.

Prior to the Voting Covenant Expiration Date Stockholder shall not enter into any agreement or understanding with any Person to vote or give instructions in any manner inconsistent with clause (a), (b), (c) or (d) of the preceding sentence.

---

## **Table of Contents**

### **3.2 Proxy; Further Assurances.**

(a) Contemporaneously with the execution of this Agreement: (i) Stockholder shall deliver to the Company a proxy in the form attached to this Agreement as **Exhibit A**, which shall be irrevocable to the fullest extent permitted by law (at all times prior to the Voting Covenant Expiration Date) with respect to the securities referred to therein (the **Proxy**); and (ii) Stockholder shall cause to be delivered to the Company an additional proxy (in the form attached hereto as **Exhibit A**) executed on behalf of the record owner of any outstanding shares of Parent Common Stock that are owned beneficially (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934), but not of record, by Stockholder.

(b) Stockholder shall, at his or its own expense, perform such further acts and execute such further proxies and other documents and instruments as may reasonably be required to vest in the Company the power to carry out and give effect to the provisions of this Agreement.

### **SECTION 4. NO SOLICITATION**

Stockholder agrees that, during the period from the date of this Agreement through the Voting Covenant Expiration Date, Stockholder shall not, directly or indirectly, and Stockholder shall ensure that his or its Representatives do not, directly or indirectly: (i) solicit, initiate, knowingly encourage, induce or facilitate the making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnish any nonpublic information regarding Parent or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or an Acquisition Inquiry; (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any Acquisition Proposal or Acquisition Inquiry; or (v) enter into any letter of intent or similar document or any Contract contemplating or otherwise relating to any Acquisition Transaction. Stockholder shall immediately cease and discontinue, and Stockholder shall ensure that his or its Representatives immediately cease and discontinue, any existing discussions with any Person that relate to any Acquisition Proposal or Acquisition Inquiry. Notwithstanding the foregoing, if the Stockholder is an officer of Parent, nothing in this Section 4 shall be interpreted to prohibit the Stockholder from acting in accordance with instructions given by the Board of Directors of Parent so long as such actions comply with the Merger Agreement.

### **SECTION 5. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER**

Stockholder hereby represents and warrants to the Company as follows:

**5.1 Authorization, etc.** Stockholder has the absolute and unrestricted right, power, authority and capacity to execute and deliver this Agreement and the Proxy and to perform his or its obligations hereunder and thereunder. This Agreement and the Proxy have been duly executed and delivered by Stockholder and constitute legal, valid and binding obligations of Stockholder, enforceable against Stockholder in accordance with their terms, subject to (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. If Stockholder is a general or limited partnership, then Stockholder is a partnership duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was organized. If Stockholder is a limited liability company, then Stockholder is a limited liability company duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was organized.

### **5.2 No Conflicts or Consents.**

(a) The execution and delivery of this Agreement and the Proxy by Stockholder do not, and the performance of this Agreement and the Proxy by Stockholder will not: (i) conflict with or violate any law, rule, regulation, order, decree or judgment applicable to Stockholder or by which he or it or any of his or its properties is or may be bound or affected; or (ii) result in or constitute (with or without notice or lapse of

---

**Table of Contents**

time) any breach of or default under, or give to any other Person (with or without notice or lapse of time) any right of termination, amendment, acceleration or cancellation of, or result (with or without notice or lapse of time) in the creation of any encumbrance or restriction on any of the Subject Securities pursuant to, any Contract to which Stockholder is a party or by which Stockholder or any of his or its affiliates or properties is or may be bound or affected.

(b) The execution and delivery of this Agreement and the Proxy by Stockholder do not, and the performance of this Agreement and the Proxy by Stockholder will not, require any consent or approval of any Person.

**5.3 Title to Securities.** As of the date of this Agreement: (a) Stockholder holds of record (free and clear of any encumbrances or restrictions) the number and type of outstanding shares of Parent Common Stock set forth under the heading **Shares Held of Record** on the signature page hereof; (b) Stockholder holds (free and clear of any encumbrances or restrictions) the options, warrants and other rights to acquire shares of Parent Common Stock set forth under the heading **Options and Other Rights** on the signature page hereof; (c) Stockholder Owns the additional securities of Parent set forth under the heading **Additional Securities Beneficially Owned** on the signature page hereof; and (d) Stockholder does not directly or indirectly Own any shares of capital stock or other securities of Parent, or any option, warrant or other right to acquire (by purchase, conversion or otherwise) any shares of capital stock or other securities of Parent, other than the shares and options, warrants and other rights set forth on the signature page hereof.

**5.4 Accuracy of Representations.** The representations and warranties contained in this Agreement are accurate in all respects as of the date of this Agreement, will be accurate in all respects at all times through the Voting Covenant Expiration Date and will be accurate in all respects as of the date of the consummation of the Merger as if made on that date.

**SECTION 6. ADDITIONAL COVENANTS OF STOCKHOLDER**

**6.1 Further Assurances.** From time to time and without additional consideration, Stockholder shall (at Stockholder's sole expense) execute and deliver, or cause to be executed and delivered, such additional transfers, assignments, endorsements, proxies, consents and other instruments, and shall (at Stockholder's sole expense) take such further actions, as the Company may request for the purpose of carrying out and furthering the intent of this Agreement.

**6.2 Legends.** If requested by the Company, immediately after the execution of this Agreement (and from time to time upon the acquisition by Stockholder of Ownership of any shares of Parent Common Stock prior to the Voting Covenant Expiration Date), Stockholder shall cause each certificate evidencing any outstanding shares of Parent Common Stock or other securities of the Parent Owned by Stockholder to be surrendered so that the transfer agent for such securities may affix thereto a legend in the following form:

THE SECURITY OR SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, EXCHANGED OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT IN COMPLIANCE WITH THE TERMS AND PROVISIONS OF A VOTING AGREEMENT DATED AS OF SEPTEMBER 24, 2008, AS IT MAY BE AMENDED, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER.

**SECTION 7. MISCELLANEOUS**

**7.1 Survival of Representations, Warranties and Agreements.** All representations, warranties, covenants and agreements made by Stockholder in this Agreement shall survive (i) the consummation of the Merger and (ii) any termination of the Merger Agreement, provided that Sections 2, 3, 4 and 6 of this Agreement shall not survive the Voting Covenant Termination Date.



## **Table of Contents**

**7.2 Expenses.** All costs and expenses incurred in connection with the transactions contemplated by this Agreement shall be paid by the party incurring such costs and expenses.

**7.3 Notices.** Any notice or other communication required or permitted to be delivered to either party under this Agreement shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by facsimile) to the address or facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice given to the other party):

if to Stockholder:

at the address set forth on the signature page hereof; and

if to the Company:

Arca biopharma, Inc.

8001 Arista Place, Suite 200

Broomfield, CO 80021

Attn: Chief Executive Officer

Fax: (650) 517-8023

**7.4 Severability.** Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

**7.5 Entire Agreement.** This Agreement, the Proxy and any other documents delivered by the parties in connection herewith constitute the entire agreement between the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings between the parties with respect thereto. No addition to or modification of any provision of this Agreement shall be binding upon either party unless made in writing and signed by both parties.

**7.6 Assignment; Binding Effect.** Except as provided herein, neither this Agreement nor any of the interests or obligations hereunder may be assigned or delegated by Stockholder, and any attempted or purported assignment or delegation of any of such interests or obligations shall be void. Subject to the preceding sentence, this Agreement shall be binding upon Stockholder and his heirs, estate, executors and personal representatives and his or its successors and assigns, and shall inure to the benefit of the Company and its successors and assigns. Without limiting any of the restrictions set forth in Section 2 or Section 6.1 or elsewhere in this Agreement, this Agreement shall be binding upon any Person to whom any Subject Securities are transferred. Nothing in this Agreement is intended to confer on any Person (other than the Company and its successors and assigns) any rights or remedies of any nature.

**7.7 Specific Performance.** The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement or the Proxy were not performed in accordance with its specific terms or were otherwise breached. Stockholder agrees that, in the event of any breach or threatened breach by Stockholder of any covenant or obligation contained in this Agreement or in the Proxy, the Company shall be entitled (in addition to any other remedy that may be available to it, including monetary damages) to seek and obtain (a) a

---

**Table of Contents**

decree or order of specific performance to enforce the observance and performance of such covenant or obligation, and (b) an injunction restraining such breach or threatened breach. Stockholder further agrees that neither the Company nor any other Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this Section 7.7, and Stockholder irrevocably waives any right he or it may have to require the obtaining, furnishing or posting of any such bond or similar instrument.

**7.8 Non-Exclusivity.** The rights and remedies of the Company under this Agreement are not exclusive of or limited by any other rights or remedies which it may have, whether at law, in equity, by contract or otherwise, all of which shall be cumulative (and not alternative). Without limiting the generality of the foregoing, the rights and remedies of the Company under this Agreement, and the obligations and liabilities of Stockholder under this Agreement, are in addition to their respective rights, remedies, obligations and liabilities under common law requirements and under all applicable statutes, rules and regulations.

**7.9 Governing Law; Venue.**

(a) This Agreement and the Proxy shall be construed in accordance with, and governed in all respects by, the laws of the State of Delaware (without giving effect to principles of conflicts of laws).

(b) Any legal action or other legal proceeding relating to this Agreement or the Proxy or the enforcement of any provision of this Agreement or the Proxy may be brought or otherwise commenced in any state or federal court located in the State of Delaware. Stockholder:

(i) expressly and irrevocably consents and submits to the jurisdiction of each state and federal court located in the State of Delaware in connection with any such legal proceeding;

(ii) agrees that service of any process, summons, notice or document by U.S. mail addressed to him or it at the address set forth on the signature page hereof shall constitute effective service of such process, summons, notice or document for purposes of any such legal proceeding;

(iii) agrees that each state and federal court located in the State of Delaware shall be deemed to be a convenient forum; and

(iv) agrees not to assert (by way of motion, as a defense or otherwise), in any such legal proceeding commenced in any state or federal court located in the State of Delaware, any claim that Stockholder is not subject personally to the jurisdiction of such court, that such legal proceeding has been brought in an inconvenient forum, that the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced in or by such court.

Nothing contained in this Section 7.9 shall be deemed to limit or otherwise affect the right of the Company to commence any legal proceeding or otherwise proceed against Stockholder in any other forum or jurisdiction.

(c) STOCKHOLDER IRREVOCABLY WAIVES THE RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LEGAL PROCEEDING RELATING TO THIS AGREEMENT OR THE PROXY OR THE ENFORCEMENT OF ANY PROVISION OF THIS AGREEMENT OR THE PROXY.

**7.10 Counterparts.** This Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument.

**7.11 Captions.** The captions contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

## **Table of Contents**

**7.12 Attorneys Fees.** If any legal action or other legal proceeding relating to this Agreement or the enforcement of any provision of this Agreement is brought against Stockholder, the prevailing party shall be entitled to recover reasonable attorneys' fees, costs and disbursements (in addition to any other relief to which the prevailing party may be entitled).

**7.13 Waiver.** No failure on the part of the Company to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of the Company in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. The Company shall not be deemed to have waived any claim available to the Company arising out of this Agreement, or any power, right, privilege or remedy of the Company under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of the Company; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

### **7.14 Construction.**

(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.

(b) The parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.

(c) As used in this Agreement, the words "include" and "including," and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words "without limitation."

(d) Except as otherwise indicated, all references in this Agreement to "Sections" and "Exhibits" are intended to refer to Sections of this Agreement and Exhibits to this Agreement.

**7.15 No Limitation on Actions of Stockholder as Director.** In the event Stockholder is a member of the Board of Directors of Parent, notwithstanding anything to the contrary in this Agreement, nothing in this Agreement is intended or shall be construed to require the Stockholder to take any action, or limit any action the Stockholder may take, to the extent that doing so would be inconsistent with Stockholder's fiduciary duties as a director of Parent.

**Table of Contents**

IN WITNESS WHEREOF, the Company and Stockholder have caused this Agreement to be executed as of the date first written above.

ARCA BIOPHARMA, INC.

By:

STOCKHOLDER

Name:

Address:

Facsimile:

Shares Held of Record

Options and Other Rights

Additional Securities Beneficially Owned

D-8

**Table of Contents**

**EXHIBIT A**

**FORM OF IRREVOCABLE PROXY**

The undersigned stockholder (the **Stockholder**) of NUVELO, INC., a Delaware corporation ( **Parent** ), hereby irrevocably (to the fullest extent permitted by law) appoints and constitutes \_\_\_\_\_, \_\_\_\_\_, and ARCA BIOPHARMA, INC., a Delaware corporation (the **Company** ), and each of them, the attorneys and proxies of the Stockholder with full power of substitution and resubstitution, to the full extent of the Stockholder's rights with respect to (i) the outstanding shares of common stock of Parent owned of record by the Stockholder as of the date of this proxy, which shares are specified on the final page of this proxy, and (ii) any and all other shares of common stock of Parent which the Stockholder may acquire on or after the date hereof. (The shares of common stock of Parent referred to in clauses (i) and (ii) of the immediately preceding sentence are collectively referred to as the **Shares**.) Upon the execution hereof, all prior proxies given by the Stockholder with respect to any of the Shares are hereby revoked, and the Stockholder agrees that no subsequent proxies will be given with respect to any of the Shares.

Subject to the terms herein, this proxy is irrevocable, is coupled with an interest and is granted in connection with the Voting Agreement, dated as of the date hereof, between the Company and the Stockholder (the **Voting Agreement** ), and is granted in consideration of the Company entering into the Agreement and Plan of Merger and Reorganization, dated as of the date hereof, among Parent, Merger Sub and the Company (the **Merger Agreement** ). This proxy will terminate on the earlier of (i) Voting Covenant Expiration Date (as defined in the Voting Agreement), or (ii) with respect to any Shares which Stockholder may Transfer (as defined in the Voting Agreement) pursuant to Section 2.3(i) of the Voting Agreement, on the date of such Transfer.

The attorneys and proxies named above will be empowered, and may exercise this proxy, to vote the Shares subject to this Proxy at any time until the Voting Covenant Expiration Date (the **Merger** ) at any meeting of the stockholders of Parent:

(i) in favor of the issuance of the shares of Parent Common Stock in the Merger; and

(ii) in favor of the Charter Amendment; and

(iii) against any action or agreement that would result in a breach of any representation, warranty, covenant or obligation of Parent in the Merger Agreement; and

(iv) against the following actions (other than the Merger, actions contemplated by the Merger Agreement, such actions set forth in Section 4.2 of Parent Disclosure Schedule, or such actions consented to in writing by Company): (A) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving Parent or any subsidiary of the Parent; (B) any sale, lease or transfer of a material amount of assets of Parent or any subsidiary of Parent; (C) any reorganization, recapitalization, dissolution or liquidation of Parent or any subsidiary of Parent; (D) any change in a majority of the board of directors of Parent; (E) any amendment to Parent's certificate of incorporation or bylaws other than the Charter Amendment; (F) any material change in the capitalization of Parent or the Parent's corporate structure; and (G) any other action which is intended, or could reasonably be expected, to impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement or the Voting Agreement.

The Stockholder may vote the Shares on all other matters not referred to in this proxy, and the attorneys and proxies named above may not exercise this proxy with respect to such other matters.

This proxy shall be binding upon the heirs, estate, executors, personal representatives, successors and assigns of the Stockholder, and any transferee of any of the Shares who acquires such Shares pursuant to a Transfer made pursuant to Sections 2.3(ii), (iii) or (iv) of the Voting Agreement.

**Table of Contents**

Any term or provision of this proxy that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the Stockholder agrees that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this proxy shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Stockholder agrees to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

Dated: September 24, 2008

Name

Shares of common stock of Parent owned of record as of the date of this proxy:

D-10

**Table of Contents**

ANNEX E

**Jefferies & Company, Inc.**

**520 Madison Avenue, 12th Floor**

**New York, NY 10022**

**[www.jefferies.com](http://www.jefferies.com)**

**PRIVILEGED AND CONFIDENTIAL**

September 24, 2008

Board of Directors

Nuvelo, Inc.

201 Industrial Road

Suite 310

San Carlos, CA 94070

Members of the Board of Directors:

We understand that Nuvelo, Inc., a Delaware corporation ( Nuvelo ), Dawn Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Nuvelo ( Merger Sub ), and ARCA biopharma, Inc., a Delaware corporation ( ARCA ), propose to enter into an Agreement and Plan of Merger and Reorganization (the Merger Agreement ), pursuant to which Merger Sub will merge with and into ARCA, with ARCA continuing as the surviving corporation (the Merger ). Pursuant to the Merger, each outstanding share of common stock, par value \$0.001 per share, of ARCA ( ARCA Common Stock ) and each outstanding share of preferred stock, par value \$0.001 per share, of ARCA ( ARCA Preferred Stock ) and collectively with the ARCA Common Stock, the ARCA Capital Stock ) (other than shares of ARCA Capital Stock that are owned by ARCA as treasury stock or by any wholly-owned subsidiary of ARCA and shares of ARCA Capital Stock owned by Nuvelo or Merger Sub or any other wholly-owned subsidiary of Nuvelo, all of which shares shall be canceled and shall cease to exist, and other than shares of ARCA Capital Stock as to which appraisal rights have been properly exercised) will be converted into the right to receive a number of shares of common stock, par value \$0.001 per share, of Nuvelo ( Nuvelo Common Stock ) determined as set forth in Section 1.5 of the Merger Agreement (the shares of Nuvelo Common Stock to be exchanged are referred to as the Exchange Ratio ). The terms and conditions of the Merger are more fully set forth in the Merger Agreement.

We have assumed, with your consent, for purposes of our opinion that (i) the capitalization of ARCA immediately prior to the effective time of the Merger shall be as set forth in Section 2.3 of the Merger Agreement, but after giving effect to the issuance of \$8,750,000 in principal amount of 6% convertible promissory notes of ARCA (the Notes ) and related warrants to purchase ARCA Common Stock providing for 20% warrant coverage (the Note Warrants ) issued in connection with that certain Note and Warrant Purchase Agreement dated September 24, 2008 (the Note and Warrant Purchase Agreement ), and (ii) the Exchange Ratio will always result in the conversion of all outstanding shares of ARCA Capital Stock (including the shares of ARCA Common Stock issuable upon exercise of the Note Warrants) and all outstanding ARCA securities that are convertible or exchangeable into ARCA Capital Stock (other than out-of-the-money ARCA options and warrants) into not more than, in the aggregate, 67% of the outstanding Nuvelo Common Stock, on a fully diluted basis using the treasury stock method, at the effective time of the Merger. For purposes of our opinion, we have ignored, with your consent, the value of ARCA options and warrants that will be out-of-the-money when converted into Nuvelo securities at the effective time of the Merger.





---

**Table of Contents**

You have asked for our opinion as to whether the Exchange Ratio is fair, from a financial point of view, to Nuvelo.

In arriving at our opinion, we have, among other things:

- (i) reviewed a draft of the Merger Agreement, dated September 24, 2008, and the exhibits thereto;
- (ii) reviewed certain publicly available financial and other information about Nuvelo and ARCA;
- (iii) reviewed certain information furnished to us by Nuvelo and ARCA, respectively, including financial forecasts and analyses, relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Nuvelo and ARCA, respectively;
- (iv) held discussions with members of senior management of Nuvelo and ARCA concerning the matters described in clauses (ii) and (iii) above;
- (v) reviewed certain publicly available information, including share trading price history and valuation multiples, of Nuvelo and certain publicly traded companies that we deemed comparable to Nuvelo;
- (vi) performed a liquidation analysis for Nuvelo based on information furnished to us by Nuvelo's management;
- (vii) compared the proposed financial terms of the Merger with the financial terms of certain other transactions that we deemed relevant;
- (viii) performed a discounted cash flow analysis for Nuvelo and ARCA, utilizing pro forma financial information prepared by, and furnished to us by, the management of Nuvelo and ARCA, respectively;
- (ix) considered the pro forma impact of the Merger, taking into account, among other things, product pipeline and ability to raise capital; and
- (x) conducted such other financial studies, analyses and investigations as we deemed appropriate including our assessment of general economic, market and monetary conditions.

In our review and analysis and in rendering this opinion, we have assumed and relied upon, but have not made (and have not assumed any responsibility for) any independent investigation or verification of, the accuracy and completeness of the financial and other information that was supplied or otherwise made available by Nuvelo or ARCA or that was publicly available to us (including, without limitation, the information described above), or that was otherwise reviewed by us. In our review, we did not make any independent evaluation or appraisal of any of the assets or liabilities of, nor did we conduct a physical inspection of any of the properties or facilities of, Nuvelo or ARCA. In addition, we have not been furnished with, nor do we assume any responsibility to obtain, any such evaluations or appraisals. We have not evaluated the solvency or fair value of Nuvelo or ARCA under any state or federal laws relating to bankruptcy, insolvency or similar matters. We also have undertaken no independent analysis of any pending or threatened litigation, regulatory action, possible unasserted claims or other contingent liabilities, to which Nuvelo, ARCA or any of their affiliates is a party, or may be subject, and with your consent, our opinion makes no assumption concerning, and therefore does not consider, the possible assertion of claims, outcomes or damages arising out of such matters.

## Edgar Filing: NUVELO INC - Form S-4/A

With respect to the financial forecasts provided to and examined by us, we note that projecting future results of any company is inherently subject to uncertainty. Nuvelo and ARCA have informed us, however, and we have assumed, that such financial forecasts were reasonably prepared on bases reflecting the best currently available estimates and good faith judgments of the management of Nuvelo as to the future financial performance of Nuvelo, and ARCA as to the future financial performance of ARCA. We have assumed, with your consent, that the financial results (including the anticipated pro forma financial effects) reflected in such forecasts will be realized at the times and in the amounts projected by Nuvelo and ARCA. In addition, we have assumed, with

E-2

---

**Table of Contents**

your consent, that the information provided to us by Nuvelo in connection with our liquidation analysis for Nuvelo was accurate and complete and based on reasonable assumptions reflecting the good faith judgment of management. We express no opinion as to such financial forecasts, the information provided to us in connection with our liquidation analysis or the assumptions on which the foregoing are made. We also express no opinion as to the viability of the combined company following the Merger, including the potential for or timing of commercialization of any product or service, the nature and extent of the combined company's financing needs or the ability of the combined company to satisfy any such financing needs.

Our opinion is based on economic, monetary, regulatory, market and other conditions existing and which can be evaluated as of the date hereof. We have assumed, with your consent, for purposes of computing the Exchange Ratio that the Parent Trading Price (as defined in the Merger Agreement) is \$0.39, the five day average closing share price of Nuvelo as of September 19, 2008. We express no opinion as to the price at which the shares of Nuvelo Common Stock will trade at any future time. We assume no responsibility to update or revise our opinion based on circumstances or events occurring after the date hereof and disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our opinion of which we become aware after the date hereof.

We have made no independent investigation of any legal or accounting matters affecting Nuvelo or ARCA, and we have assumed the correctness in all respects material to our analysis of all legal and accounting advice given to Nuvelo and its Board of Directors, including, without limitation, advice as to the legal, accounting and tax consequences of the terms of, and transactions contemplated by, the Merger Agreement to Nuvelo and its stockholders. In addition, in preparing this opinion, we have not taken into account any tax consequences of the transaction to Nuvelo or ARCA. We have assumed that the final form of the Merger Agreement will be substantially similar to, and will not differ in any material respect from, the last draft reviewed by us. In addition, we have assumed that the Merger will be consummated in accordance with the terms of the Merger Agreement, without waiver, modification or amendment of any material term, condition or agreement and that, in the course of obtaining the necessary regulatory or third party approvals, consents, and releases (contractual or otherwise) for the Merger, no delay, limitations, restrictions or conditions, including any divestiture requirements or amendments or modifications, will be imposed that would have an adverse effect on Nuvelo, ARCA or the contemplated benefits of the Merger. We have further assumed, with your consent, for purposes of our opinion that ARCA shall have received prior to the Merger aggregate proceeds of at least \$8,750,000 from the sale and issuance of the Notes and Note Warrants pursuant to the Note and Warrant Purchase Agreement. We have also assumed that the shares of Nuvelo Common Stock to be issued in the Merger to the stockholders of ARCA will be listed on the Nasdaq Global Market.

It is understood that our opinion is furnished solely for the use and benefit of the Board of Directors of Nuvelo in its consideration of the Merger and is not intended to, and does not, confer rights and remedies on any other person, and is not intended to be used, and may not be used, for any other purpose without our written consent. Our opinion does not address the relative merits of the transactions contemplated by the Merger Agreement as compared to any alternative transaction or opportunity that might be available to Nuvelo, nor does it address the underlying business decision by Nuvelo to engage in the Merger or the terms of the Merger Agreement or the documents referred to therein. Furthermore, our opinion does not constitute a recommendation as to how any holder of Nuvelo Common Stock should vote on the Merger or any matter related thereto. In addition, you have not asked us to address, and this opinion does not address, the fairness to, or any other consideration of, the holders of any class of securities or the creditors or other constituencies of Nuvelo or ARCA. You have also not asked us to address, and this opinion does not address, the fairness of the amount or nature of, or any other aspects relating to, any compensation to be received by any officers, directors or employees of any parties to the Merger or any class of such persons, relative to the Exchange Ratio or otherwise.

We have been engaged by Nuvelo to act as its financial advisor in connection with the Merger and to deliver this opinion. We have received and will receive certain fees in connection with our engagement, including a fee which was paid upon our engagement by Nuvelo, a fee payable upon delivery of this opinion and a transaction

**Table of Contents**

fee contingent upon consummation of the Merger. We also will be reimbursed for expenses incurred in connection with our engagement. Nuvelo has agreed to indemnify us against liabilities arising out of or in connection with the services rendered and to be rendered by us under our engagement with Nuvelo. In the ordinary course of our business, we and our affiliates may trade or hold securities of Nuvelo and/or its affiliates for our own account and for the accounts of our customers and, accordingly, may at any time hold long or short positions in those securities. During the two years preceding the date of this opinion, we provided financial advisory services to Nuvelo in connection with an unrelated matter and received a customary retainer fee and reimbursement for our out-of-pocket expenses in connection therewith. In addition, we may seek to, in the future, provide financial advisory and financial services to Nuvelo, ARCA, and/or their respective affiliates, for which we would expect to receive compensation.

Except as otherwise expressly provided in our engagement letter with Nuvelo, our opinion may not be published, reproduced, summarized, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent; *provided, however*, that this opinion may be included in its entirety in the English language in any disclosure document required by applicable law to be distributed to the holders of Nuvelo Common Stock in connection with the Merger. Nuvelo and its affiliates may not make any public references to Jefferies & Company, Inc. (Jefferies) or any of its affiliates without the prior written consent of Jefferies. This opinion has been approved for issuance by the fairness committee of Jefferies.

Based upon and subject to the assumptions made, procedures followed, matters considered and limitations described herein, we are of the opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to Nuvelo.

Very truly yours,

/s/ Jefferies & Company, Inc.

JEFFERIES & COMPANY, INC.

**Table of Contents**

ANNEX F

**CERTIFICATE OF AMENDMENT TO THE  
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION  
OF NUVELO, INC.**

NUVELO, INC., a corporation organized and existing under the General Corporation law of the State of Delaware does hereby certify:

**ONE:** The date of filing the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was March 16, 2004 as amended and restated on March 18, 2004.

**TWO:** The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows:

Article IV shall be amended to add the following provisions in their entirety to the existing provisions of Article IV:

Effective at 5:00 p.m. Eastern time, on the date of filing of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the Effective Time ), the shares of the Corporation's Common Stock, par value \$0.001 per share, issued and outstanding immediately prior to the Effective Time and the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time shall be combined into a smaller number of shares such that each<sup>1</sup> shares of issued Common Stock immediately prior to the Effective Time are combined into one validly issued, fully paid and nonassessable share of Common Stock, par value \$0.001 per share. Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the combination, following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder), shall be entitled to receive a cash payment equal to the fraction to which such holder would otherwise be entitled multiplied by the then fair value of the Common Stock as determined by the Board of Directors.

Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time), provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined.

**THREE:** Thereafter, pursuant to a resolution by the Board of Directors of the Corporation, this Certificate of Amendment was submitted to the stockholders of the corporation for their consideration and was duly adopted and approved in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware at a special meeting of the stockholders.

<sup>1</sup> Shall be a number greater than one and equal to or less than 50, the exact number within the range to be determined by the board of directors of the Corporation prior to the Effective Time and publicly announced by the Corporation.

**Table of Contents**

IN WITNESS WHEREOF, Nuvelo, Inc. has caused this CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION to be signed by its Chairman of the Board of Directors and Chief Executive Officer this     day of             ,     .

NUVELO, INC.

By:

Ted. W. Love, M.D.  
Chairman of the Board of Directors and

Chief Executive Officer

F-2

Table of Contents

ANNEX G

**CERTIFICATE OF AMENDMENT TO THE  
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION  
OF NUVELO, INC.**

NUVELO, INC., a corporation organized and existing under the General Corporation law of the State of Delaware does hereby certify:

**ONE:** The date of filing the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was March 16, 2004 as amended and restated on March 18, 2004.

**TWO:** The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows:

Article IV shall be amended to remove the following provisions in their entirety:

The total number of shares of all classes of stock this Corporation shall have authority to issue is 105,000,000, consisting of 100,000,000 shares of Common Stock, par value \$0.001 per share, and 5,000,000 shares of Preferred Stock, par value \$0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.

Article IV shall be amended to add the following provisions in their entirety to the existing provisions of Article IV:

The total number of shares of all classes of stock this Corporation shall have authority to issue following the Effective Time is 255,000,000 consisting of 250,000,000 shares of Common Stock, par value \$0.001 per share, and 5,000,000 shares of Preferred Stock, par value \$0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.

**THREE:** Thereafter, pursuant to a resolution by the Board of Directors of the Corporation, this Certificate of Amendment was submitted to the stockholders of the corporation for their consideration and was duly adopted and approved in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware at a special meeting of the stockholders.

**IN WITNESS WHEREOF**, Nuvelo, Inc. has caused this **CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION** to be signed by its Chairman of the Board of Directors and Chief Executive Officer this    day of    ,    .

NUVELO, INC.

By:

Ted. W. Love, M.D.  
Chairman of the Board of Directors and

Chief Executive Officer

**Table of Contents**

**ANNEX H**

**SECTION 262 of THE DELAWARE GENERAL CORPORATION LAW**

**§ 262. Appraisal rights.**

(a) Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d) of this Section with respect to such shares, who continuously holds such shares through the effective date of the merger or consolidation, who has otherwise complied with subsection (d) of this Section and who has neither voted in favor of the merger or consolidation nor consented thereto in writing pursuant to Section 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder's shares of stock under the circumstances described in subsections (b) and (c) of this section. As used in this section, the word "stockholder" means a holder of record of stock in a stock corporation and also a member of record of a non-stock corporation; the words "stock" and "share" mean and include what is ordinarily meant by those words and also membership or membership interest of a member of a non-stock corporation; and the words "depository receipt" mean a receipt or other instrument issued by a depository representing an interest in one or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository.

(b) Appraisal rights shall be available for the shares of any class or series of stock of a constituent corporation in a merger or consolidation to be effected pursuant to § 251 (other than a merger effected pursuant to § 251(g) of this title), § 252, § 254, § 257, § 258, § 263 or § 264 of this title:

(1) Provided, however, that no appraisal rights under this Section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of and to vote at the meeting of stockholders to act upon the agreement of merger or consolidation, were either (i) listed on a national securities exchange or (ii) held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in subsection (f) of Section 251 of this title.

(2) Notwithstanding paragraph (1) of this subsection, appraisal rights under this Section shall be available for the shares of any class or series of stock of a constituent corporation if the holders thereof are required by the terms of an agreement of merger or consolidation pursuant to §§ 251, 252, 254, 257, 258, 263 and 264 of this title to accept for such stock anything except:

- a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or depository receipts in respect thereof;
- b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger or consolidation will be either listed on a national securities exchange or held of record by more than 2,000 holders;
- c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing subparagraphs a. and b. of this paragraph; or
- d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing subparagraphs a., b. and c. of this paragraph.

(3) In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under § 253 of this title is not owned by the parent corporation immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.



---

**Table of Contents**

(c) Any corporation may provide in its certificate of incorporation that appraisal rights under this Section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation or the sale of all or substantially all of the assets of the corporation. If the certificate of incorporation contains such a provision, the procedures of this section, including those set forth in subsections (d) and (e) of this section, shall apply as nearly as is practicable.

(d) Appraisal rights shall be perfected as follows:

(1) If a proposed merger or consolidation for which appraisal rights are provided under this Section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for such meeting with respect to shares for which appraisal rights are available pursuant to subsection (b) or (c) hereof that appraisal rights are available for any or all of the shares of the constituent corporations, and shall include in such notice a copy of this section. Each stockholder electing to demand the appraisal of such stockholder's shares shall deliver to the corporation, before the taking of the vote on the merger or consolidation, a written demand for appraisal of such stockholder's shares. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder's shares. A proxy or vote against the merger or consolidation shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger or consolidation, the surviving or resulting corporation shall notify each stockholder of each constituent corporation who has complied with this subsection and has not voted in favor of or consented to the merger or consolidation of the date that the merger or consolidation has become effective; or

(2) If the merger or consolidation was approved pursuant to § 228 or § 253 of this title, then either a constituent corporation before the effective date of the merger or consolidation or the surviving or resulting corporation within 10 days thereafter shall notify each of the holders of any class or series of stock of such constituent corporation who are entitled to appraisal rights of the approval of the merger or consolidation and that appraisal rights are available for any or all shares of such class or series of stock of such constituent corporation, and shall include in such notice a copy of this section. Such notice may, and, if given on or after the effective date of the merger or consolidation, shall, also notify such stockholders of the effective date of the merger or consolidation. Any stockholder entitled to appraisal rights may, within 20 days after the date of mailing of such notice, demand in writing from the surviving or resulting corporation the appraisal of such holder's shares. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder's shares. If such notice did not notify stockholders of the effective date of the merger or consolidation, either (i) each such constituent corporation shall send a second notice before the effective date of the merger or consolidation notifying each of the holders of any class or series of stock of such constituent corporation that are entitled to appraisal rights of the effective date of the merger or consolidation or (ii) the surviving or resulting corporation shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder's shares in accordance with this subsection. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger or consolidation, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given.

---

**Table of Contents**

(e) Within 120 days after the effective date of the merger or consolidation, the surviving or resulting corporation or any stockholder who has complied with subsections (a) and (d) of this Section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger or consolidation, any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such stockholder's demand for appraisal and to accept the terms offered upon the merger or consolidation. Within 120 days after the effective date of the merger or consolidation, any stockholder who has complied with the requirements of subsections (a) and (d) of this Section hereof, upon written request, shall be entitled to receive from the corporation surviving the merger or resulting from the consolidation a statement setting forth the aggregate number of shares not voted in favor of the merger or consolidation and with respect to which demands for appraisal have been received and the aggregate number of holders of such shares. Such written statement shall be mailed to the stockholder within 10 days after such stockholder's written request for such a statement is received by the surviving or resulting corporation or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d) of this Section hereof, whichever is later. Notwithstanding subsection (a) of this section, a person who is the beneficial owner of shares of such stock held either in a voting trust or by a nominee on behalf of such person may, in such person's own name, file a petition or request from the corporation the statement described in this subsection.

(f) Upon the filing of any such petition by a stockholder, service of a copy thereof shall be made upon the surviving or resulting corporation, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all stockholders who have demanded payment for their shares and with whom agreements as to the value of their shares have not been reached by the surviving or resulting corporation. If the petition shall be filed by the surviving or resulting corporation, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving or resulting corporation and to the stockholders shown on the list at the addresses therein stated. Such notice shall also be given by 1 or more publications at least 1 week before the day of the hearing, in a newspaper of general circulation published in the City of Wilmington, Delaware or such publication as the Court deems advisable. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving or resulting corporation.

(g) At the hearing on such petition, the Court shall determine the stockholders who have complied with this Section and who have become entitled to appraisal rights. The Court may require the stockholders who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with such direction, the Court may dismiss the proceedings as to such stockholder.

(h) After the Court determines the stockholders entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger or consolidation, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, interest from the effective date of the merger through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger and the date of payment of the judgment. Upon application by the surviving or resulting corporation or by any stockholder entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any stockholder whose name appears on the list filed by the surviving or resulting corporation pursuant to subsection (f) of this Section and who has submitted such stockholder's certificates of stock to the Register in Chancery, if such is

**Table of Contents**

required, may participate fully in all proceedings until it is finally determined that such stockholder is not entitled to appraisal rights under this section.

(i) The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving or resulting corporation to the stockholders entitled thereto. Payment shall be so made to each such stockholder, in the case of holders of uncertificated stock forthwith, and the case of holders of shares represented by certificates upon the surrender to the corporation of the certificates representing such stock. The Court's decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving or resulting corporation be a corporation of this State or of any state.

(j) The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a stockholder, the Court may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorney's fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal.

(k) From and after the effective date of the merger or consolidation, no stockholder who has demanded appraisal rights as provided in subsection (d) of this Section shall be entitled to vote such stock for any purpose or to receive payment of dividends or other distributions on the stock (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger or consolidation); provided, however, that if no petition for an appraisal shall be filed within the time provided in subsection (e) of this section, or if such stockholder shall deliver to the surviving or resulting corporation a written withdrawal of such stockholder's demand for an appraisal and an acceptance of the merger or consolidation, either within 60 days after the effective date of the merger or consolidation as provided in subsection (e) of this Section or thereafter with the written approval of the corporation, then the right of such stockholder to an appraisal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any stockholder without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just; provided, however that this provision shall not affect the right of any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder's demand for appraisal and to accept the terms offered upon the merger or consolidation within 60 days after the effective date of the merger or consolidation, as set forth in subsection (e) of this section.

(l) The shares of the surviving or resulting corporation to which the shares of such objecting stockholders would have been converted had they assented to the merger or consolidation shall have the status of authorized and unissued shares of the surviving or resulting corporation.

---

**Table of Contents**

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 20. *Indemnification of Directors and Officers***

As permitted by Section 102 of the Delaware General Corporation Law, Nuvelo has adopted provisions in its amended and restated certificate of incorporation and amended and restated bylaws that limit or eliminate the personal liability of its directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to Nuvelo or its stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

any breach of the director's duty of loyalty to Nuvelo or its stockholders;

any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

any transaction from which the director derived an improper personal benefit.

These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Nuvelo's amended and restated certificate of incorporation also authorizes us to indemnify its officers, directors and other agents to the fullest extent permitted under Delaware law.

As permitted by Section 145 of the Delaware General Corporation Law, Nuvelo's amended and restated bylaws provide that:

Nuvelo may indemnify its directors, officers, and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;

Nuvelo may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

the rights provided in Nuvelo's amended and restated bylaws are not exclusive.

Nuvelo's amended and restated certificate of incorporation and its amended and restated bylaws provide for the indemnification provisions described above and elsewhere herein. In addition, Nuvelo has entered into separate indemnification agreements with its directors and officers which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements may require Nuvelo, among other things, to indemnify its officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also may require Nuvelo to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they are indemnified. In addition, Nuvelo has purchased a policy of directors' and officers' liability insurance that insures its directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of its officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended.



**Table of Contents**

**Item 21. Exhibits and Financial Statement Schedules Exhibits.**

The exhibit index immediately following the signature page to this proxy statement/prospectus/consent solicitation is incorporated herein by reference as the list of exhibits required as part of this registration statement.

**Item 22. Undertakings**

The undersigned Registrant hereby undertakes:

- (1) That, prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other Items of the applicable form;
- (2) That every prospectus (i) that is filed pursuant to paragraph (1) immediately preceding, or (ii) that purports to meet the requirements of Section 10(a)(3) of the Securities Act of 1933 and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;
- (3) To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective;
- (4) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue; and
- (5) The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item 4 of this form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No.1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Carlos, State of California, on November 21, 2008.

**NUVELO, INC.**

By: /s/ LEE BENDEKGEY  
Lee Bendekgey

Senior Vice President, Chief Financial Officer and  
General Counsel

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No.1 to the registration statement on Form S-4 has been signed by the following persons in the capacities and on the dates indicated.

<b>Signatures</b>	<b>Title</b>	<b>Date</b>
/s/ TED W. LOVE	President, Chief Executive Officer and Director	November 21, 2008
<b>Ted W. Love</b>	(Principal Executive Officer)	
/s/ LEE BENDEKGEY	Chief Financial Officer	November 21, 2008
<b>Lee Bendekgey</b>	(Principal Financial and Accounting Officer)	
*	Director	November 21, 2008
<b>James R. Gavin</b>		
*	Director	November 21, 2008
<b>Mary K. Pendergast</b>		
*	Director	November 21, 2008
<b>Mark L. Perry</b>		
*	Director	November 21, 2008
<b>Kimberly Popovits</b>		
*	Director	November 21, 2008
<b>Burton E. Sobel</b>		

\* By: /s/ LEE BENDEKGEY  
**Lee Bendekgey**  
**Attorney-in-fact**





**Table of Contents**

**Exhibit Index**

**Exhibit**

<b>Number</b>	<b>Description</b>
2.1	Agreement and Plan of Merger between Hyseq, Inc., Vertical Merger Corp. and Variagenics, Inc. dated November 9, 2002.(10)
2.2	Agreement and Plan of Merger between Nuvelo, Inc. and Nuvelo, Inc., a Nevada corporation and Nuvelo, Inc. s predecessor in interest dated March 19, 2004.(14)
2.3	Stock Purchase Agreement between SBH Genomics, Inc., Radoje Drmanac, Snezana Drmanac, Nuvelo, Inc., and Affymetrix, Inc. dated December 3, 2004.(17)
2.4	Agreement and Plan of Merger and Reorganization, dated as of September 24, 2008, among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.(31)
2.5	Amendment No. 1 to Agreement and Plan of Merger and Reorganization dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.(32)
2.6*	Form of Voting Agreement between Nuvelo, Inc. and certain officers, directors and stockholders of ARCA biopharma, Inc. dated September 24, 2008.
2.7*	Form of Voting Agreement between ARCA biopharma, Inc. and certain officers, directors and stockholders of Nuvelo, Inc. dated September 24, 2008.
3.1	Amended and Restated Certificate of Incorporation of Nuvelo, Inc.(14)
3.2	Amended and Restated By-Laws of Nuvelo, Inc.(28)
4.1	Form of Nuvelo, Inc. Common Stock Certificate.(14)
4.2	Certificate of Designations of Series A Junior Participating Preferred Stock.(14)
4.3	Warrant to purchase 1,491,544 shares of Common Stock of Hyseq, Inc. dated January 8, 2002.(7)
4.4	Warrant to purchase 350,000 shares of Common Stock of Nuvelo, Inc. dated August 4, 2005.(21)
4.5	Registration Rights Agreement by and between Nuvelo, Inc. and Kingsbridge Capital Limited dated August 4, 2005.(21)
4.6	Reference is made to Exhibits 3.1 and 3.2.
5.1**	Opinion of Cooley Godward Kronish LLP.
8.1**	Opinion of Cooley Godward Kronish LLP regarding tax matters.
8.2**	Opinion of Hogan & Hartson LLP regarding tax matters.
10.1	Form of Indemnification Agreement between Hyseq, Inc. and each of its directors and officers.(1)
10.2	Stock Option Plan, as amended.(2)
10.3	Employee Stock Purchase Plan, as amended and restated on May 31, 2007.(23)
10.4	Non-Employee Director Stock Option Plan, as amended.(3)
10.5	Employment and Confidential Information Agreement dated January 11, 2001 between Hyseq, Inc. and Dr. Ted W. Love.(4)
10.6	Lease dated April 30, 2001 between The Irvine Company and Hyseq, Inc.(5)
10.7	Form of Non-Stockholder Approved Stock Option Agreement for Officers.(6)
10.8	Collaboration Agreement dated of January 8, 2002 between Hyseq, Inc. and Amgen Inc.(8)

**Table of Contents**

**Exhibit**

<b>Number</b>	<b>Description</b>
10.9	First Amendment to Lease Agreement dated August 1, 2002 between Hyseq, Inc. and The Irvine Company.(9)
10.10	Form of Warrant Purchase Agreement, entered into January 8, 2002 between Hyseq, Inc. and Amgen Inc.(7)
10.11	Nuvelo, Inc. 2002 Equity Incentive Plan.(11)
10.12	Second Amendment to Lease dated October 21, 2003 by and between the Irvine Company and Nuvelo, Inc.(12)
10.13	Collaboration Agreement dated January 12, 2004 between Nuvelo, Inc. and Archemix Corp.(13)
10.14	License Agreement dated February 4, 2004, among Dendreon San Diego LLC, Dendreon Corporation and Nuvelo, Inc.(13)
10.15	Amended and Restated Nuvelo, Inc. 2004 Equity Incentive Plan.(23)
10.16	Form of Notice of Grant of Stock Option under Nuvelo, Inc. 2004 Equity Incentive Plan.(15)
10.17	Form of Nuvelo, Inc. Stock Option Agreement (Single Trigger Acceleration) under Nuvelo, Inc. 2004 Equity Incentive Plan.(15)
10.18	Form of Nuvelo, Inc. Stock Option Agreement (Double Trigger Acceleration) under Nuvelo, Inc. 2004 Equity Incentive Plan.(16)
10.19	Nuvelo, Inc. Amended Executive Change in Control and Severance Benefit Plan.(27)
10.20§	Opt-Out, Termination, Settlement and Release Agreement dated October 29, 2004 between Nuvelo, Inc. and Amgen Inc.(18)
10.21§	License Agreement dated November 3, 2004 between Nuvelo, Inc. and Amgen Inc.(18)
10.22	Lease Agreement dated January 11, 2005 between Nuvelo, Inc. and BMR-201 Industrial Road LLC.(18)
10.23§	Collaboration Agreement dated March 31, 2005 between Kirin Brewery Company and Nuvelo, Inc.(19)
10.24	First Amendment to Lease dated May 10, 2005 between BMR-2001 Industrial Road LLC and Nuvelo, Inc.(20)
10.25	Common Stock Purchase Agreement dated August 4, 2005 by and between Kingsbridge Capital Limited and Nuvelo, Inc.(21)
10.26	Third Amendment to Lease dated September 15, 2005 between The Irvine Company and Nuvelo, Inc.(22)
10.27§	Amended and Restated Collaboration and License Agreement dated July 31, 2006 between Nuvelo, Inc. and Archemix Corp.(24)
10.28	Letter Agreement dated June 26, 2007 between Bayer Healthcare AG and Nuvelo, Inc.(25)
10.29	Base Salary for Named Executive Officer, effective August 1, 2007.(26)
10.30	Amended and Restated Addendum to Employment Agreement between Nuvelo, Inc. and Ted W. Love dated January 1, 2008.(30)
10.31	Bonuses for Named Executive Officers Approved on January 25, 2008.(30)
10.32	Separation Agreement between Nuvelo, Inc. and Michael D. Levy dated March 20, 2008.(30)

**Table of Contents**

**Exhibit**

<b>Number</b>	<b>Description</b>
21.1	Subsidiaries of Nuvelo, Inc. as of December 31, 2007.(29)
23.1**	Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
23.2**	Consent of KPMG LLP, Independent Registered Public Accounting Firm.
23.3**	Consent of KPMG LLP, Independent Registered Public Accounting Firm.
23.4**	Consent of Cooley Godward Kronish LLP (included in Exhibit 5.1 hereto).
23.5**	Consent of Cooley Godward Kronish LLP (included in Exhibit 8.1 hereto).
23.6**	Consent of Hogan & Hartson, LLP (included in Exhibit 8.2 hereto).
24.1*	Power of Attorney (included in the signature page to the initial filing hereof).
99.1**	Form of Proxy Card for Nuvelo Special Meeting of Stockholders.
99.2*	Consent of Richard B. Brewer to be named as a director of the combined company.
99.3*	Consent of Michael R. Bristow, M.D., Ph.D., to be named as a director of the combined company.
99.4*	Consent of John L. Zabriskie, Ph.D., to be named as a director of the combined company.
99.5*	Consent of J. William Freytag, Ph.D., to be named as a director of the combined company.
99.6**	Consent of Jean-François Formela, M.D., to be named as a director of the combined company.
99.7*	Consent of David. G. Lowe, Ph.D., to be named as a director of the combined company.
99.8**	Consent of Linda Grais, M.D., to be named as a director of the combined company.
99.9**	Consent of Jefferies & Company, Inc.

\* Previously filed.

\*\* Filed herewith.

Compensatory plan or agreement.

§ Confidential treatment has been requested for portions of this document, which are omitted and filed separately with the SEC.

- (1) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form S-1, as amended, File No. 333-29091.
- (2) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form S-8, filed on May 20, 1998, File No. 333-08978.
- (3) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form S-8, filed on May 20, 1998, File No. 333-53089.

## Edgar Filing: NUVELO INC - Form S-4/A

- (4) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form 10-K filed April 2, 2001, File No. 000-22873.
- (5) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form 8-K, filed on May 21, 2001, File No. 000-22873.
- (6) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form 10-K/A, filed on May 9, 2002, File No. 000-22873.

**Table of Contents**

- (7) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form 10-Q, filed on May 15, 2002, File No. 000-22873.
- (8) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form 10-Q/A, filed on July 22, 2002, File No. 000-22873.
- (9) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form 10-Q, filed on November 8, 2002, File No. 000-22873.
- (10) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Hyseq, Inc. s Form 8-K, filed on November 12, 2002, File No. 000-22873.
- (11) Previously filed with the SEC as an Appendix to and incorporated herein by reference from Nuvelo, Inc. s Proxy Statement on Schedule 14A, filed on June 13, 2002, File No. 000-22873.
- (12) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-Q, filed on November 14, 2003, File No. 000-22873.
- (13) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed on February 19, 2004, File No. 000-22873.
- (14) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed March 26, 2004, File No. 000-22873.
- (15) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed September 20, 2004, File No. 000-22873.
- (16) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-Q, filed on November 9, 2004, File No. 000-22873.
- (17) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed December 9, 2004, File No. 000-22873.
- (18) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-K, filed on March 16, 2005, File No. 000-22873.
- (19) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-Q, filed on May 10, 2005, File No. 000-22873.

## Edgar Filing: NUVELO INC - Form S-4/A

- (20) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed May 13, 2005, File No. 000-22873.
- (21) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed August 5, 2005, File No. 000-22873.
- (22) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed September 20, 2005, File No. 000-22873.
- (23) Previously filed with the SEC as an Appendix to and incorporated herein by reference from Nuvelo, Inc. s Proxy Statement on Schedule 14A, filed on April 18, 2007, File No. 000-22873.
- (24) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-Q, filed November 8, 2006, File No. 000-22873.
- (25) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed June 26, 2007, File No. 000-22873.
- (26) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed September 19, 2007, File No. 000-22873.
- (27) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-Q, filed November 7, 2007, File No. 000-22873.

**Table of Contents**

- (28) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed December 12, 2007, File No. 000-22873.
  
- (29) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-K, filed March 12, 2008, File No. 000-22873.
  
- (30) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 10-Q, filed May 9, 2008, File No. 000-22873.
  
- (31) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed September 25, 2008, File No. 000-22873.
  
- (32) Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc. s Form 8-K, filed October 29, 2008, File No. 000-22873.